Also O
during O
last O
administration O
, O
PMN O
count O
in O
filtered O
blood O
cardioplegic O
solution O
was O
decreased O
compared O
to O
samples O
collected O
before O
filter O
passage O
( O
0.66 O
? O
[]

A O
total O
of O
120 O
healthy O
postmenopausal O
women O
were O
enrolled O
, O
and O
doses O
of O
10 O
to O
600 O
mg O
once O
daily O
and O
50 O
and O
300 O
mg O
twice O
daily O
were O
evaluated O
in O
15- O
and O
28-day O
multiple-dosing O
cohorts O
. O
[]

Serotonergic O
( O
5-HT O
) O
abnormalities O
have O
been O
documented O
in O
autism O
. O
[]

CP O
13.0 O
months O
+/- O
7.0 O
( O
P O
less O
than O
0.05 O
) O
. O
[]

No O
other O
marine O
food O
products O
significantly O
predicted O
RBC O
EPA O
+ O
DHA O
concentration O
. O
[]

CONCLUSIONS O
Slower O
than O
anticipated O
recruitment O
resulted O
in O
considerably O
fewer O
patients O
than O
planned O
being O
studied O
. O
[]

Sixty O
patients O
with O
peptic O
ulcer O
( O
gastric O
, O
32 O
patients O
; O
duodenal O
, O
28 O
patients O
) O
who O
had O
a O
history O
of O
ulcer O
recurrence O
were O
randomly O
assigned O
to O
dual O
therapy O
with O
amoxycillin O
( O
500 O
mg O
three O
times O
daily O
for O
2 O
weeks O
) O
and O
omeprazole O
( O
20 O
mg O
once O
daily O
for O
8 O
weeks O
) O
or O
to O
triple O
therapy O
with O
metronidazole O
( O
500 O
mg O
twice O
daily O
for O
2 O
weeks O
) O
plus O
amoxycillin O
and O
omeprazole O
, O
given O
in O
the O
same O
dosages O
as O
dual O
therapy O
. O
[]

Oxytocin O
infusion O
reduces O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
adults O
with O
autistic O
and O
Asperger O
's O
disorders O
. O
['Life-Impact']

In O
prospective O
face-to-face O
interviews O
, O
data O
were O
obtained O
on O
socio-demographic O
and O
lifestyle O
characteristics O
, O
psychosocial O
factors O
and O
clinic-related O
variables O
. O
[]

Seven O
were O
allocated O
to O
labetalol O
treatment O
( O
Group O
A O
) O
, O
eight O
to O
hydralazine O
treatment O
( O
Group O
B O
) O
and O
seven O
women O
received O
both O
drugs O
due O
to O
poor O
blood O
pressure O
control O
with O
a O
single O
drug O
therapy O
( O
Group O
C O
) O
. O
[]

There O
were O
3 O
and O
1 O
couplets O
and O
0.2 O
and O
0.2 O
runs O
of O
ventricular B-outcome ['Physiological-Clinical']
tachycardia I-outcome ['Physiological-Clinical']
per O
patient O
per O
hour O
, O
respectively O
. O
['Physiological-Clinical']

Journal-Name:Revista O
de O
la O
Facultad O
de O
Ciencias O
Medicas O
(Cordoba, O
Argentina) O
[]

of O
ectopic B-outcome ['Physiological-Clinical']
supraventricular I-outcome ['Physiological-Clinical']
beats I-outcome ['Physiological-Clinical']
was O
26.1 O
+/- O
61.9 O
after O
ibopamine O
and O
21.7 O
+/- O
35.8 O
after O
placebo O
( O
p O
= O
ns O
) O
. O
['Physiological-Clinical']

METHODS O
Six O
hundred O
fifty-five O
patients O
with O
chronic O
AF O
underwent O
maximal O
exercise O
testing O
at O
baseline O
and O
8 O
weeks O
, O
6 O
months O
, O
and O
1 O
year O
after O
randomization O
to O
sotalol O
, O
amiodarone O
, O
or O
placebo O
therapy O
and O
attempted O
direct O
current O
cardioversion O
. O
[]

Palo O
Alto, O
CA, O
USA. O
[]

In O
many O
previous O
studies O
NTG O
has O
been O
found O
to O
be O
effective O
in O
controlling O
hypertension B-outcome ['Physiological-Clinical']
; O
ISDN O
offers O
and O
alternative O
approach O
in O
reducing O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
component O
required O
revision O
, O
and O
no O
revisions O
were O
pending O
. O
[]

Nurses O
took O
156 O
s O
to O
start O
infusions O
when O
using O
pre-filled O
syringes O
compared O
with O
276 O
s O
when O
preparing O
them O
de O
novo O
, O
a O
mean O
delay O
of O
106 O
s O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
73-140 O
s O
, O
P O
< O
0.0001 O
] O
. O
[]

OBJECTIVE: O
to O
measure O
the O
effect O
of O
an O
infant O
stimulation O
therapy O
(auditory, O
tactile, O
visual O
and O
vestibular) O
on O
the O
adaptation B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
postnatal I-outcome ['Physiological-Clinical']
life I-outcome ['Physiological-Clinical']
of O
the O
mother-child O
dyad. O
[['Physiological-Clinical']]

Interobserver O
variation O
was O
analyzed O
using O
the O
kappa O
statistic O
. O
[]

INTERVENTION O
Stabilization O
of O
tibial O
fractures O
either O
with O
a O
slotted O
, O
stainless O
steel O
reamed O
nail O
or O
a O
solid O
, O
titanium O
unreamed O
nail O
. O
[]

Gastric O
ulcer O
treatment O
with O
intravenous O
human O
epidermal O
growth O
factor O
: O
a O
double-blind O
controlled O
clinical O
study O
. O
[]

Eighty-three O
patients O
with O
pulmonary O
bullae O
(American O
Society O
of O
Anesthesiologists O
(ASA) O
I-III) O
undergoing O
lobectomy, O
with O
general O
anaesthesia, O
were O
included. O
[]

Complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
platelet O
recovery O
(CRp) O
, O
complete B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
with O
incomplete O
haematological O
recovery O
(CRi) O
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
did O
not O
differ O
between O
groups O
when O
stratified O
by O
cytogenetics, O
de-novo O
versus O
secondary O
or O
therapy-related O
acute O
myeloid O
leukaemia, O
or O
TP53(mut) O
status. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality']]

OBJECTIVE O
To O
determine O
the O
clinical B-outcome ['Physiological-Clinical']
benefit O
of O
oral O
dexamethasone O
in O
children O
admitted O
to O
the O
hospital O
with O
bronchiolitis O
treated O
with O
nebulized O
salbutamol O
. O
['Physiological-Clinical']

Both O
drugs O
increase O
platelet B-outcome ['Physiological-Clinical']
5-HT I-outcome ['Physiological-Clinical']
in O
the O
first O
phase O
of O
treatment O
. O
['Physiological-Clinical']

This O
study O
investigated O
acute O
effects O
of O
caffeine O
ingestion O
on O
signal-averaged B-outcome ['Physiological-Clinical']
P-wave I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
QRS I-outcome ['Physiological-Clinical']
complexes I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
Intravenous O
nicorandil O
, O
a O
hybrid O
compound O
of O
ATP-sensitive O
potassium O
channel O
opener O
and O
nitric O
oxide O
donor O
, O
has O
been O
reported O
to O
ameliorate O
early O
functional O
and O
clinical O
problems O
in O
patients O
with O
acute O
myocardial O
infarction O
. O
[]

TRIAL O
REGISTRATION: O
The O
trial O
was O
registered O
prospectively O
with O
the O
national O
database O
at O
the O
Clinical O
Research O
Network O
(UKCRN O
Portfolio O
9366). O
[]

Most O
external O
defibrillation O
paddles O
are O
rectangular O
in O
shape O
and O
can O
, O
therefore O
, O
be O
placed O
in O
a O
transverse O
or O
longitudinal O
orientation O
. O
[]

FUNDING: O
Seattle O
Genetics O
Inc, O
Millennium O
Pharmaceuticals O
Inc, O
a O
wholly O
owned O
subsidiary O
of O
Takeda O
Pharmacuetical O
Company O
Limited, O
and O
National O
Institutes O
of O
Health O
National O
Cancer O
Institute O
Cancer O
Center. O
[]

P O
= O
0.001 O
and O
P O
= O
0.048 O
, O
respectively O
. O
[]

In O
hypertensive O
patients O
, O
beta-endorphin O
decreased O
systemic B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
and O
plasma B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
and O
endothelin-1 B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
and O
raised O
circulating O
atrial O
natriuretic B-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
GH B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
, O
and O
IGF-I B-outcome ['Physiological-Clinical']
( O
P O
< O
0.0001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Participants O
will O
be O
randomized O
in O
a O
1:1 O
ratio O
between O
Arm O
1 O
( O
RT O
? O
[]

Overall O
, O
side-effects B-outcome ['Adverse-effects']
were O
fewer O
with O
ketoprofen B-outcome ['Resource-use']
than O
with O
indomethacin B-outcome ['Resource-use']
. O
['Adverse-effects', 'Resource-use', 'Resource-use']

A O
significant O
fall O
in O
86rubidium B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
was O
observed O
. O
['Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

The O
primary O
end O
point O
was O
time O
from O
randomization O
to O
relapse O
. O
[]

PURPOSE O
To O
verify O
the O
influence O
of O
cavity O
access O
diameter O
on O
demineralized B-outcome ['Physiological-Clinical']
dentin I-outcome ['Physiological-Clinical']
removal I-outcome ['Physiological-Clinical']
in O
the O
ART O
approach O
. O
['Physiological-Clinical']

Group O
B O
patients O
were O
pretreated O
with O
lidocaine O
0.5 O
mg/kg O
followed O
by O
propofol O
2.0 O
mg/kg O
at O
3.3 O
mg/sec O
. O
[]

Acute O
effects O
of O
caffeine O
ingestion O
on O
signal-averaged B-outcome ['Physiological-Clinical']
electrocardiograms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
the O
subsequent O
dose O
reduction O
, O
the O
mean O
pH B-outcome ['Physiological-Clinical']
decreased O
to O
6.1-6.2 O
. O
['Physiological-Clinical']

There O
were O
no O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
CONCLUSIONS: O
There O
is O
no O
evidence O
that O
the O
use O
of O
resin O
modified O
glass O
ionomer O
cement O
over O
light-cured O
composite O
for O
bonding O
brackets O
reduces O
the O
incidence O
of O
new O
demineralized B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
or O
bond B-outcome ['Physiological-Clinical']
failures I-outcome ['Physiological-Clinical']
. O
There O
might O
be O
other O
reasons O
for O
using O
resin O
modified O
glass O
ionomer O
cement. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Plasma B-outcome ['Physiological-Clinical']
FVIII I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
determined O
using O
a O
validated O
chromogenic O
substrate O
assay O
. O
['Physiological-Clinical']

The O
most O
beneficial O
timing O
for O
autologous O
reinfusion O
of O
predonated O
blood O
remains O
unknown O
. O
[]

5 O
. O
[]

STEPP O
analyses O
showed O
little O
effect O
of O
chemotherapy O
for O
tumors O
with O
high O
levels O
of O
ER B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
( O
P O
= O
0.07 O
) O
, O
or O
for O
the O
cohort O
with O
one O
positive O
node O
( O
P O
= O
0.03 O
) O
. O
['Physiological-Clinical']

d O
) O
. O
[]

Root O
cause O
analysis O
( O
RCA O
) O
has O
been O
implemented O
to O
prevent O
such O
errors O
. O
[]

Statistically O
significant O
differences O
between O
groups O
indicated O
that O
the O
sensory O
integration O
therapy O
program O
positively O
affected O
treated O
children O
. O
[]

Secondary O
outcome O
measures O
are O
remission B-outcome ['Physiological-Clinical']
as O
measured O
with O
the O
PHQ9 O
and O
the O
IDS-SR O
, O
and O
cost-effectiveness O
measured O
with O
the O
TiC-P O
, O
the O
EQ-5D O
and O
the O
SF-36 O
. O
['Physiological-Clinical', 'Resource-use']

In O
counterbalanced O
order O
, O
25 O
couples O
were O
exposed O
to O
couple-responsible O
and O
therapist-responsible O
episodes O
during O
one O
therapy O
session O
. O
[]

Induction O
deaths B-outcome ['Mortality']
were O
comparable O
at O
9 O
% O
( O
ALL-2 O
) O
versus O
7 O
% O
( O
L-20 O
) O
. O
['Mortality']

In O
group O
2 O
( O
control O
group O
; O
n O
= O
20 O
) O
patients O
received O
only O
oral O
calcium O
( O
1,000 O
mg/day O
) O
and O
vitamin O
D O
( O
400 O
IU/day O
) O
. O
[]

The O
training O
focused O
on O
stimulating O
joint O
attention O
and O
language O
skills O
and O
was O
based O
on O
the O
intervention O
described O
by O
Drew O
et O
al O
. O
( O
[]

The O
European O
and O
Australian O
Stroke O
Prevention O
in O
Reversible O
Ischaemia O
Trial O
( O
ESPRIT O
) O
is O
a O
randomised O
clinical O
trial O
in O
which O
patients O
with O
cerebral O
ischaemia O
of O
arterial O
origin O
will O
be O
randomised O
between O
oral O
anticoagulation O
( O
international O
normalized O
ratio O
( O
INR O
) O
: O
2.0-3.0 O
) O
, O
the O
combination O
of O
acetylsalicylic O
acid O
( O
in O
any O
dose O
between O
30 O
and O
325 O
mg O
per O
day O
) O
plus O
dipyridamole O
( O
400 O
mg O
daily O
) O
and O
acetylsalicylic O
acid O
only O
( O
in O
any O
dose O
between O
30 O
and O
325 O
mg O
per O
day O
) O
. O
[]

Quantifying O
the O
extent O
of O
osteonecrosis O
of O
the O
femoral O
head O
. O
[]

Cephalic O
venous O
biomarkers O
of O
free O
radical-mediated O
lipid O
peroxidation O
( O
lipid O
hydroperoxides O
, O
LOOH O
) O
, O
nitrite O
( O
NO2- O
) O
and O
lipid O
soluble O
antioxidants O
were O
also O
obtained O
at O
rest O
. O
[]

HBOT O
may O
possibly O
have O
a O
broad-spectrum O
antimicrobial O
effect O
worthy O
of O
further O
study O
. O
[]

Carious O
tissue O
was O
removed O
by O
hand B-outcome ['Life-Impact']
excavation I-outcome ['Life-Impact']
, O
bur B-outcome ['Resource-use']
excavation I-outcome ['Resource-use']
, O
air-abrasion O
, O
laser B-outcome ['Resource-use']
ablation I-outcome ['Resource-use']
, O
chemomechanical B-outcome ['Resource-use']
methods I-outcome ['Resource-use']
and O
sono-abrasion B-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Resource-use', 'Resource-use', 'Resource-use', 'Physiological-Clinical']

This O
study O
compared O
operative O
gastrostomy O
( O
OG O
) O
( O
by O
surgeons O
) O
with O
endoscopic O
gastrostomy O
( O
PEG O
) O
( O
by O
physicians O
) O
in O
a O
prospective O
randomized O
fashion O
to O
determine O
whether O
one O
technique O
was O
superior O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
access O
the O
effects O
of O
pentoxifylline O
plus O
risperidone O
in O
the O
treatment O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
. O
['Life-Impact']

Twenty-three O
subjects O
were O
given O
a O
plasma-derived O
vaccine O
( O
Hevac O
B O
) O
and O
27 O
received O
a O
recombinant O
HBsAg O
vaccine O
( O
yeast-derived O
; O
Engerix-B O
) O
. O
[]

Side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
(all O
mild) O
occurred O
in O
4.2% O
of O
the O
participants. O
[['Adverse-effects']]

Title: O
Phase O
1 O
Trial O
of O
an O
RNA O
Interference O
Therapy O
for O
Acute O
Intermittent O
Porphyria. O
[]

An O
indirect O
response O
model O
was O
developed O
to O
describe O
the O
pharmacodynamic B-outcome ['Physiological-Clinical']
relationships O
between O
flare O
or O
wheal O
areas O
and O
bilastine O
plasma O
concentrations O
. O
['Physiological-Clinical']

Additionally O
40 O
euthyroid O
controls O
were O
studied O
. O
[]

The O
aim O
of O
this O
open O
, O
prospective O
, O
randomised O
study O
was O
to O
estimate O
the O
eventual O
benefits O
from O
the O
inclusion O
of O
high-dose O
cytarabine O
in O
the O
cisplatin-5-fluorouracil O
( O
5-FU O
) O
regimen O
as O
first-line O
treatment O
of O
patients O
with O
advanced O
head O
and O
neck O
cancer O
. O
[]

Participants O
were O
randomly O
allocated O
to O
the O
intervention O
( O
n=9 O
) O
or O
control O
( O
n=8 O
) O
group O
using O
a O
concealed O
method O
. O
[]

This O
risk O
was O
also O
significantly O
reduced O
in O
subgroups O
consisting O
of O
women O
and O
patients O
of O
both O
sexes O
aged O
> O
or O
= O
60 O
years O
. O
[]

The O
present O
study O
evaluated O
the O
effect O
of O
adjuvant O
immunochemotherapy O
with O
the O
use O
of O
BCG O
( O
bacille O
Calmette-Guerin O
) O
and O
FAM O
( O
5-fluorouracil O
, O
adriamycin O
, O
mitomycin O
C O
) O
chemotherapy O
on O
the O
survival B-outcome ['Mortality']
of I-outcome ['Mortality']
patients I-outcome ['Mortality']
with O
locally O
advanced O
resectable O
gastric O
cancer O
. O
['Mortality']

Mean O
arterial B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
were O
recorded O
at O
baseline O
, O
after O
induction O
, O
immediately O
after O
intubation O
and O
every O
minute O
for O
five O
minutes O
after O
intubation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
decline O
in O
performance O
occurred O
with O
risperidone O
. O
[]

In O
the O
high-dose O
therapy O
arm O
the O
overall O
response O
rate O
was O
83 O
% O
with O
64 O
% O
in O
CR O
( O
difference O
between O
arms O
not O
significant O
) O
. O
[]

The O
sessions O
did O
not O
differ O
significant O
in O
terms O
of O
the O
Tsk O
time-course O
response B-outcome ['Life-Impact']
. O
['Life-Impact']

OBJECTIVES O
The O
aim O
of O
this O
study O
was O
to O
examine O
if O
an O
acute O
nicotine O
infusion O
alters O
insulin O
sensitivity O
to O
a O
similar O
degree O
in O
type O
2 O
diabetic O
patients O
as O
in O
healthy O
control O
subjects O
. O
[]

No O
significant O
complications B-outcome ['Resource-use']
were O
noticed O
regarding O
sildenafil O
use O
. O
['Resource-use']

Parents O
of O
381 O
girls O
and O
375 O
boys O
age O
8-12 O
y O
completed O
family O
history O
questionnaires O
. O
[]

Twenty O
patients O
were O
treated O
with O
intranasal O
Bdp O
and O
twenty O
patients O
received O
no O
treatment O
after O
polypectomy O
. O
[]

The O
one-year O
survival B-outcome ['Mortality']
was O
37 O
% O
for O
group O
A O
and O
44 O
% O
for O
group O
B O
( O
P O
= O
0.35 O
) O
. O
['Mortality']

Load O
theory O
of O
selective O
attention O
and O
cognitive O
control O
. O
[]

The O
presence O
of O
group-B O
streptococci O
in O
the O
urine O
of O
pregnant O
women O
seems O
to O
be O
associated O
with O
preterm O
labour O
. O
[]

CONTEXT O
Experimental O
and O
epidemiological O
data O
suggest O
that O
vitamin O
E O
supplementation O
may O
prevent O
cancer O
and O
cardiovascular O
events O
. O
[]

METHODS O
The O
main O
goal O
of O
this O
study O
was O
to O
determine O
whether O
PCI O
and O
thrombolytic O
therapy O
achieve O
comparable O
reperfusion O
rates O
, O
as O
evidenced O
by O
ST-segment O
resolution O
. O
[]

but O
moist O
desquamation O
developed O
in O
42 O
% O
of O
patients O
in O
the O
b.i.d O
. O
[]

Secondary O
endpoints O
include O
post-intervention O
complications B-outcome ['Adverse-effects']
, O
late O
recurrence B-outcome ['Physiological-Clinical']
of O
acute O
appendicitis O
after O
one O
year, O
duration B-outcome ['Resource-use']
of I-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
pain B-outcome ['Physiological-Clinical']
, O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
and O
treatment B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
Primary O
endpoint O
will O
be O
evaluated O
in O
two O
stages: O
point O
estimates O
with O
95% O
confidence O
interval O
(CI) O
will O
be O
calculated O
for O
both O
groups O
and O
proportion O
difference O
between O
groups O
with O
95% O
CI O
will O
be O
calculated O
and O
evaluated O
based O
on O
6 O
percentage O
point O
non-inferiority O
margin. O
[['Adverse-effects'], ['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact'], ['Resource-use']]

Compared O
to O
the O
control O
group O
, O
the O
intervention O
group O
showed O
a O
significant O
and O
larger O
reduction O
in O
GI O
score O
by O
8 O
% O
at O
6 O
months O
( O
p=0.0007 O
) O
. O
[]

Vilazodone O
lacks O
proarrhythmogenic O
potential O
in O
healthy O
participants O
: O
a O
thorough O
ECG O
study O
. O
[]

The O
tension-free O
hernioplasty O
in O
a O
randomized O
trial O
. O
[]

CONCLUSIONS O
When O
using O
the O
bispectral O
index O
for O
monitoring O
sedation O
during O
catheterization O
in O
children O
, O
we O
noted O
decreased O
need O
for O
doses O
of O
midazolam B-outcome ['Resource-use']
and O
ketamine B-outcome ['Physiological-Clinical']
, O
a O
lower O
need O
for O
respiratory B-outcome ['Resource-use']
support I-outcome ['Resource-use']
and O
less O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Resource-use', 'Physiological-Clinical', 'Resource-use', 'Adverse-effects']

MATERIALS O
AND O
METHODS O
One O
hundred O
and O
six O
consecutive O
patients O
with O
ureteric O
calculi O
at O
different O
levels O
were O
treated O
by O
ESWL O
using O
Siemens O
Lithostar O
2 O
machine O
. O
[]

In O
a O
double-blind O
, O
randomised O
study O
of O
thromboprophylaxis O
in O
patients O
undergoing O
total O
hip O
replacement O
, O
we O
compared O
a O
low-molecular-weight O
heparin O
with O
a O
placebo O
. O
[]

We O
also O
report O
an O
analysis O
comparing O
the O
proportion O
of O
eyes O
that O
developed O
one O
or O
more O
key O
events O
to O
the O
cumulative O
number O
of O
injections O
. O
[]

CONCLUSIONS O
Exercise O
therapy O
for O
patients O
with O
acute O
low O
back O
pain O
does O
not O
reduce O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
. O
['Life-Impact']

On O
the O
contrary O
, O
naltrexone O
increased O
the O
incidence O
of O
stereotypic B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
on O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
, O
and O
the O
care O
staff O
evaluated O
the O
effect O
of O
the O
50-mg/d O
treatment O
as O
being O
significantly O
worse O
than O
that O
of O
the O
placebo O
treatment O
as O
measured O
by O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

CONCLUSION O
No O
difference O
in O
the O
leak O
rate O
could O
be O
revealed O
. O
[]

Potentiation O
of O
bradykinin-induced O
tissue O
plasminogen O
activator O
release O
by O
angiotensin-converting O
enzyme O
inhibition O
. O
[]

The O
comparison O
acupuncture O
treatment O
group O
had O
no O
significant O
change O
in O
severity O
from O
baseline O
over O
the O
treatment O
phase O
. O
[]

We O
used O
logistic O
regression O
analyses O
to O
study O
the O
interaction O
between O
the O
user O
characteristics O
and O
the O
delivery O
mode O
in O
the O
prediction O
of O
dropout O
rate O
within O
the O
intervention O
period O
. O
[]

Metabolic B-outcome ['Physiological-Clinical']
pathways O
involving O
lysine B-outcome ['Physiological-Clinical']
, O
and O
phytochemicals B-outcome ['Physiological-Clinical']
were O
also O
modulated O
by O
navy O
bean O
intake O
in O
CRC O
survivors. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Analyses O
of O
predictors O
of O
relapse O
and O
response O
are O
now O
needed O
to O
improve O
the O
therapeutic O
value O
of O
this O
modality O
. O
[]

Misoprostol O
versus O
oxytocin O
for O
the O
reduction O
of O
postpartum B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
Interstitial B-outcome ['Physiological-Clinical']
Cystitis I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Index O
and O
Interstitial B-outcome ['Physiological-Clinical']
Cystitis I-outcome ['Physiological-Clinical']
Problem B-outcome ['Physiological-Clinical']
Index O
mean O
scores O
improved O
by O
71 O
% O
and O
69 O
% O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
percentage O
of O
patients O
with O
adverse B-outcome ['Adverse-effects']
drug I-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
lowest O
among O
those O
receiving O
sotalol O
. O
['Adverse-effects']

INTRODUCTION O
Estimating O
the O
cost O
utility O
of O
hemiarthroplasty O
compared O
to O
internal O
fixation O
in O
the O
treatment O
of O
displaced O
femoral O
neck O
fractures O
in O
the O
elderly O
. O
[]

The O
primary O
outcomes O
is O
the O
mortality B-outcome ['Mortality']
rate O
at O
6 O
months O
follow-up O
. O
['Mortality']

Lessons O
learnt O
in O
conducting O
a O
clinical O
drug O
trial O
in O
children O
with O
Asperger O
Syndrome O
. O
[]

The O
median O
volume B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
specimens I-outcome ['Physiological-Clinical']
in O
the O
NETZ O
arm O
was O
739 O
mm O
( O
3 O
) O
larger O
( O
P= O
0.33 O
) O
and O
they O
were O
less O
likely O
to O
be O
removed O
in O
multiple O
pieces O
( O
2.5 O
% O
vs O
29.5 O
% O
, O
RR O
0.09 O
, O
95 O
% O
CI O
0.04 O
to O
0.20 O
) O
. O
['Physiological-Clinical']

There O
was O
a O
positive O
relationship O
between O
GH B-outcome ['Physiological-Clinical']
AUC I-outcome ['Physiological-Clinical']
and O
minimum B-outcome ['Physiological-Clinical']
BG I-outcome ['Physiological-Clinical']
in O
patients O
with O
PHD O
on O
treatment O
( O
r O
( O
2 O
) O
= O
0.45 O
, O
P O
= O
0.012 O
) O
with O
increased O
insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
off O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
degree O
of O
ventilatory B-outcome ['Physiological-Clinical']
limitation I-outcome ['Physiological-Clinical']
, O
as O
expressed O
by O
the O
Ve/maximum B-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
ventilation I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
was O
similar O
in O
both O
conditions O
in O
patients O
with O
COPD O
. O
['Physiological-Clinical', 'Physiological-Clinical']

World O
Health O
Organization O
performance O
status O
( O
WHO O
PS O
) O
for O
CLIP O
or O
alpha-fetoprotein O
for O
BCLC O
allowed O
a O
significant O
improvement O
of O
prognostic O
information O
. O
[]

The O
proportions O
of O
eicosapentaenoic B-outcome ['Physiological-Clinical']
and O
docosahexaenoic B-outcome ['Physiological-Clinical']
acids I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
serum B-outcome ['Physiological-Clinical']
lipids I-outcome ['Physiological-Clinical']
increased O
in O
the O
fatty O
fish O
group O
only O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
efficacy O
measures O
were O
response O
latencies O
to O
visually O
presented O
stimuli O
requiring O
two O
different O
types O
of O
attention-controlled B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
, O
i.e. O
, O
focused B-outcome ['Life-Impact']
and O
divided B-outcome ['Life-Impact']
attention B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Effect O
of O
Orlistat O
in O
obese O
patients O
with O
heart O
failure O
: O
a O
pilot O
study O
. O
[]

In O
conclusion O
, O
this O
long-term O
study O
did O
not O
show O
any O
serious O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
comparison O
of O
the O
analgesic B-outcome ['Resource-use']
efficacy O
, O
onset B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
, O
and O
tolerability B-outcome ['Life-Impact']
of O
ibuprofen O
arginate O
and O
ibuprofen O
in O
postoperative O
dental O
pain O
. O
['Resource-use', 'Physiological-Clinical', 'Life-Impact']

MSL-109 O
adjuvant O
therapy O
for O
cytomegalovirus O
retinitis O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
: O
the O
Monoclonal O
Antibody O
Cytomegalovirus O
Retinitis O
Trial O
. O
[]

All O
patients O
treated O
with O
verapamil O
( O
17 O
AF O
, O
3 O
AFI O
) O
showed O
lower B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
after O
1 O
hour O
; O
however O
, O
only O
1 O
( O
6 O
% O
) O
with O
AF O
converted O
to O
sinus O
rhythm O
and O
1 O
( O
6 O
% O
) O
converted O
to O
AFI O
. O
['Physiological-Clinical']

51 O
patients O
were O
divided O
into O
two O
groups O
: O
one O
in O
acupuncture O
treatment O
and O
the O
other O
without O
any O
treatment O
. O
[]

Comparison O
of O
amantadine O
and O
desipramine O
combined O
with O
psychotherapy O
for O
treatment O
of O
cocaine O
dependence O
. O
[]

Simultaneously O
, O
this O
intervention O
increased O
interferon-? O
( O
IFN-? O
) O
level O
and O
unchanged O
interleukin-4 O
level O
, O
as O
well O
as O
, O
decreased O
myeloperoxidase O
( O
MPO O
) O
and O
interleukin-6 O
levels O
in O
plasma O
. O
[]

All O
relevant O
prognostic O
factors O
were O
balanced O
, O
with O
the O
exception O
that O
there O
were O
significantly O
more O
progesterone O
receptor O
positive O
patients O
in O
the O
doxorubicin-treated O
group O
. O
[]

Identification O
of O
predictors O
of O
clinical O
improvement O
has O
been O
limited O
by O
the O
power O
of O
the O
study O
. O
[]

SC O
was O
more O
often O
not O
used O
or O
successfully O
deployed O
. O
[]

Patients O
were O
randomly O
allocated O
to O
the O
splinting O
group O
( O
n O
= O
17 O
) O
or O
the O
control O
group O
( O
n O
= O
16 O
) O
. O
[]

Histopathologic B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
eyelid I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
following O
trichloroacetic O
acid O
chemical O
peel O
. O
['Physiological-Clinical']

Overall B-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
both O
treatments O
was O
similar O
to O
placebo O
, O
and O
there O
were O
no O
clinically O
relevant O
effects O
on O
cardiac B-outcome ['Physiological-Clinical']
repolarisation I-outcome ['Physiological-Clinical']
with O
either O
mizolastine O
or O
loratadine O
. O
['Life-Impact', 'Physiological-Clinical']

Of O
169 O
evaluable O
IFN/HU-treated O
patients O
( O
75 O
% O
) O
, O
104 O
patients O
( O
62 O
% O
) O
achieved O
a O
cytogenetic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
that O
was O
complete O
in O
12 O
% O
( O
n=21 O
) O
, O
major O
in O
14 O
% O
( O
n=24 O
) O
, O
and O
at O
least O
minimal O
in O
35 O
% O
( O
n=59 O
) O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
Weight O
changes O
. O
[]

Risperidone O
has O
shown O
safety O
and O
efficacy O
for O
aggressive O
and O
destructive O
behaviors O
in O
short-term O
studies O
. O
[]

4.6 O
kg/m O
( O
2 O
) O
) O
with O
normal O
lipid O
and O
inflammatory O
markers O
. O
[]

In O
experiment O
2 O
, O
observers O
aimed O
a O
laser O
gun O
at O
targets O
while O
fixating O
either O
the O
rear O
or O
the O
front O
gunsight O
monocularly O
, O
or O
the O
target O
either O
monocularly O
or O
binocularly O
. O
[]

Arginine O
vasopressin O
dissociates O
the O
diuresis B-outcome ['Physiological-Clinical']
and O
natriuresis B-outcome ['Physiological-Clinical']
due O
to O
atrial O
natriuretic O
factor O
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
aim O
of O
the O
trial O
is O
to O
evaluate O
the O
treatment O
of O
depressive O
disorder O
in O
primary O
care O
in O
the O
Netherlands O
by O
means O
of O
an O
adapted O
collaborative O
care O
framework O
, O
including O
contracting O
and O
adherence-improving O
strategies O
, O
combined O
with O
Problem O
Solving O
Treatment O
and O
antidepressant O
medication O
according O
to O
a O
treatment O
algorithm O
. O
[]

Our O
task O
was O
divided O
into O
three O
phases O
: O
movement O
selection O
and O
initiation O
( O
initiate O
) O
, O
synchronisation O
of O
finger O
tapping O
with O
an O
external O
auditory O
cue O
( O
synchronise O
) O
, O
and O
continued O
tapping O
in O
absence O
of O
the O
auditory O
pacer O
( O
continue O
) O
. O
[]

The O
capsules O
of O
the O
test O
formulation O
were O
opened O
and O
administered O
on O
a O
tablespoonful O
of O
apple O
sauce O
. O
[]

Renal O
biopsy O
studies O
showed O
no O
differences O
between O
the O
two O
groups O
in O
terms O
of O
incidence O
and O
severity O
of O
the O
histologic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
antimycotic O
antibiotic O
griseofulvin O
inhibits O
the O
MA-sensitive O
PMN O
chemotaxis O
in O
vitro O
in O
concentrations O
far O
below O
those O
obtained O
in O
serum O
during O
antimycotic O
therapy O
. O
[]

To O
test O
this O
assumption O
, O
54 O
PTSD O
patients O
were O
randomized O
to O
prolonged O
exposure O
therapy O
or O
prolonged O
exposure O
therapy O
plus O
cognitive O
restructuring O
. O
[]

12.2 O
vs. O
22.8 O
? O
[]

The O
outcome O
of O
both O
treatment O
arms O
, O
as O
well O
as O
a O
comparison O
of O
the O
LAG O
group O
, O
to O
that O
of O
the O
SL O
group O
, O
are O
updated O
. O
[]

RESULTS O
Delivered O
energy B-outcome ['Physiological-Clinical']
at O
the O
defibrillation B-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
was O
10.1+/-5.0 O
J O
for O
the O
single-coil O
configuration O
and O
8.7+/-4.0 O
J O
for O
the O
dual-coil O
configuration O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

No O
difference O
in O
species B-outcome ['Physiological-Clinical']
number O
was O
noted O
in O
controls O
. O
['Physiological-Clinical']

Our O
ongoing O
work O
is O
directed O
at O
further O
defining O
force O
interactions O
. O
[]

A O
masked O
evaluator O
assessed O
parent O
performance B-outcome ['Life-Impact']
, O
and O
parents O
rated O
instructional B-outcome ['Life-Impact']
effectiveness. O
[['Life-Impact'], ['Life-Impact']]

Calcium O
hydroxide O
, O
a O
material O
widely O
used O
for O
the O
treatment O
of O
permanent O
teeth O
has O
not O
been O
used O
frequently O
for O
pulpectomy O
in O
primary O
teeth O
. O
[]

RESULTS O
Although O
differences O
between O
the O
treatment O
groups O
were O
found O
in O
both O
the O
maxillary O
and O
mandibular O
arches O
after O
phase O
1 O
, O
these O
differences O
were O
no O
longer O
evident O
by O
the O
end O
of O
full O
orthodontic O
treatment O
or O
after O
posttreatment O
retention O
. O
[]

Additionally O
, O
children O
in O
the O
experimental O
group O
, O
whose O
GSR B-outcome ['Life-Impact']
measures O
decreased O
, O
on O
average O
, O
after O
deep O
pressure O
, O
were O
somewhat O
more O
likely O
to O
have O
higher O
GSR B-outcome ['Life-Impact']
arousal I-outcome ['Life-Impact']
a O
priori O
. O
['Life-Impact', 'Life-Impact']

The O
greatest O
benefit O
was O
observed O
in O
patients O
who O
had O
previously O
received O
chemotherapy O
. O
[]

An O
albendazole O
course O
at O
30 O
mg/kg/day O
combined O
with O
corticosteroids O
is O
safe O
and O
more O
effective O
than O
the O
usual O
dose O
. O
[]

The O
primary O
outcome O
measure O
was O
the O
change O
from O
baseline O
in O
the O
RDAI B-outcome ['Physiological-Clinical']
score O
at O
24 O
hours O
. O
['Physiological-Clinical']

Some O
question O
whether O
they O
do O
not O
remove O
too O
much O
tooth O
substance O
. O
[]

OBJECTIVE O
The O
aim O
of O
the O
study O
was O
to O
compare O
safety O
, O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
with O
haloperidol O
in O
the O
treatment O
of O
Autistic O
Disorder O
( O
AD O
) O
. O
['Life-Impact']

RESULTS O
There O
were O
no O
group O
differences O
on O
formal B-outcome ['Life-Impact']
measures I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
, O
cognition B-outcome ['Life-Impact']
, O
or O
['Life-Impact', 'Life-Impact']

One O
involved O
the O
use O
of O
examples O
of O
common O
errors O
( O
error O
) O
and O
the O
other O
demonstrated O
the O
skill O
being O
performed O
correctly O
( O
correct O
) O
. O
[]

The O
'number O
needed O
to O
telephone O
' O
was O
17 O
. O
[]

Assessment O
of O
the O
pain O
of O
blood-sugar O
testing O
: O
a O
randomised O
controlled O
trial O
. O
[]

Follow O
up O
was O
incomplete O
in O
3.3 O
% O
and O
4.7 O
% O
patients O
in O
standard O
and O
sequential O
therapy O
groups O
, O
respectively O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Efficacy O
, O
safety O
, O
predictability O
, O
stability B-outcome ['Physiological-Clinical']
, O
HOAs B-outcome ['Physiological-Clinical']
, O
and O
CS O
were O
evaluated O
before O
and O
after O
enhancement O
at O
6 O
months O
' O
follow-up O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
mice O
, O
methotrimeprazine O
only O
possessed O
antinociceptive B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
doses O
which O
caused O
marked B-outcome ['Physiological-Clinical']
sedation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
72 O
months O
no O
significant O
difference O
between O
the O
patients O
and O
the O
healthy O
controls O
could O
be O
detected O
. O
[]

Consecutive O
2-s O
epochs O
of O
a O
10-min O
EEG O
record O
( O
resting O
conditions O
) O
of O
F3/C3-F4/C4-P3/01-P4/02 O
were O
subjected O
to O
FFT O
( O
Fast O
Fourier O
Transform O
) O
. O
[]

Complications B-outcome ['Adverse-effects']
occurred O
in O
26 O
% O
of O
OG O
patients O
and O
9 O
% O
died B-outcome ['Mortality']
. O
['Adverse-effects', 'Mortality']

This O
study O
was O
performed O
in O
a O
double-blind, O
randomized O
crossover O
fashion O
consisting O
of O
two O
exhaustive O
exercise O
protocols. O
[]

Modifications O
of O
the O
patch O
system O
may O
perhaps O
make O
it O
possible O
to O
achieve O
higher O
[]

METHODS O
A O
pragmatic O
, O
cluster O
randomised O
trial O
with O
an O
intervention O
( O
an O
interactive O
seminar O
) O
delivered O
at O
practice O
level O
( O
n=13 O
practices O
; O
6=intervention O
, O
7=control O
) O
. O
[]

Only O
49.3 O
% O
( O
37/77 O
) O
of O
surviving O
patients O
consented O
to O
follow-up O
at O
4 O
months O
and O
89 O
% O
( O
33/37 O
) O
completed O
the O
assessment O
. O
[]

The O
students O
taught O
on O
an O
integrated O
course O
showed O
a O
much O
greater O
range O
of O
results O
. O
[]

A O
risk O
score O
incorporating O
routine O
practice O
data O
was O
used O
to O
identify O
people O
aged O
40-69 O
years O
at O
high-risk O
of O
undiagnosed O
diabetes O
. O
[]

Four O
hundred O
sixty-seven O
members O
of O
an O
occupational O
cohort O
( O
total O
N O
= O
573 O
) O
were O
examined O
via O
questionnaires O
and O
B-mode O
ultrasound O
. O
[]

Two O
hundred O
patients O
with O
similar O
demographics O
undergoing O
elective O
LC O
were O
randomized O
to O
one O
of O
four O
groups O
of O
50 O
patients O
each O
, O
including O
Group O
A O
placebo O
control O
, O
Group O
B O
with O
isotonic O
saline O
irrigation O
, O
Group O
C O
with O
bupivacaine O
irrigation O
, O
and O
Group O
D O
with O
lignocaine O
irrigation O
. O
[]

RESULTS O
Patients O
who O
registered O
in O
a O
screened O
area O
felt O
significantly O
more O
able O
to O
[]

RESULTS O
Both O
groups O
showed O
a O
significant O
improvement O
during O
observation O
[ O
ISGA O
27.1 O
% O
( O
C/BPO O
) O
and O
24.6 O
% O
( O
C/BPO O
+ O
laser O
) O
, O
total O
lesion B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
9.2 O
% O
and O
9.0 O
% O
, O
['Physiological-Clinical']

AIM O
To O
see O
whether O
laparoscopy O
improves O
the O
accuracy O
of O
a O
clinical O
diagnosis O
of O
acute O
appendicitis O
in O
women O
of O
reproductive O
age O
, O
and O
to O
determine O
what O
the O
long-term O
sequelae O
are O
of O
not O
removing O
an O
appendix O
deemed O
at O
laparoscopy O
to O
be O
normal O
. O
[]

Fifty O
alcoholic O
inpatients O
were O
randomly O
assigned O
to O
the O
PALS O
program O
( O
n O
= O
25 O
) O
or O
to O
the O
library O
for O
free O
reading O
time O
( O
n O
= O
25 O
) O
. O
[]

Therapeutic O
recommendations B-outcome ['Life-Impact']
in O
polycythemia O
vera O
based O
on O
Polycythemia O
Vera O
Study O
Group O
protocols O
. O
['Life-Impact']

An O
additional O
26 O
patients O
were O
treated O
in O
an O
identical O
fashion O
, O
but O
were O
not O
part O
of O
the O
randomized O
trial O
because O
of O
contraindications O
to O
chemotherapy O
, O
refusal O
to O
enter O
the O
randomized O
trial O
, O
or O
because O
they O
were O
treated O
before O
1977 O
in O
a O
trial O
in O
which O
all O
patients O
received O
chemotherapy O
. O
[]

BACKGROUND O
Non-adherence O
in O
hypertension O
is O
a O
global O
problem O
and O
promoting O
adherence O
is O
necessary O
to O
decrease O
cardiovascular O
mortality O
. O
[]

Analyses O
of O
baseline O
determinants O
of O
exercise O
capacity O
, O
predictors O
of O
change O
in O
exercise O
capacity O
at O
6 O
months O
and O
1 O
year O
, O
and O
the O
short- O
and O
long-term O
effects O
of O
cardioversion O
on O
exercise O
capacity O
were O
made O
. O
[]

Effects O
of O
inhaled O
treprostinil O
on O
exercise O
capacity O
, O
functional O
class O
, O
and O
echocardiographic O
and O
hemodynamic O
data O
were O
evaluated O
. O
[]

Data O
on O
the O
effect O
of O
hormone O
replacement O
therapy O
on O
hemostasis O
are O
inconsistent O
, O
and O
there O
are O
few O
data O
in O
women O
with O
coronary O
artery O
disease O
. O
[]

OBJECTIVE O
To O
find O
the O
optimal O
dose O
of O
a O
new O
hypoallergenic O
folding O
variant O
of O
recombinant O
Bet O
v O
1 O
( O
rBet O
v O
1-FV O
) O
as O
SIT O
for O
patients O
with O
birch O
pollen O
allergy O
. O
[]

0.4 O
to O
2.8 O
? O
[]

Comparing O
the O
mean O
individual O
daily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
scores O
for O
each O
phase O
of O
study O
, O
5 O
patients O
( O
31 O
% O
) O
had O
significantly O
less O
pain B-outcome ['Physiological-Clinical']
while O
receiving O
mexiletine O
compared O
with O
their O
response O
to O
placebo O
, O
5 O
patients O
( O
31 O
% O
) O
had O
significantly O
less O
pain O
while O
receiving O
placebo O
, O
and O
no O
difference O
was O
noted O
in O
6 O
patients O
( O
38 O
% O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Data O
for O
high O
grade O
PIN O
and O
LSPC O
were O
gathered O
from O
each O
ERSPC O
centre O
. O
[]

Plasma O
malondialdehyde B-outcome ['Physiological-Clinical']
did O
not O
change O
after O
exercise O
in O
placebo O
but O
was O
significantly O
decreased O
in O
AA O
(p O
< O
0.05). O
[['Physiological-Clinical']]

The O
results O
of O
these O
cultures O
demonstrated O
a O
significant O
bioburden B-outcome ['Physiological-Clinical']
( O
greater O
than O
10 O
( O
5 O
) O
) O
in O
the O
majority O
of O
cases O
, O
despite O
a O
lack O
of O
clinical O
signs O
of O
infection O
. O
['Physiological-Clinical']

Effective O
surgical B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
costing O
$ O
40,000 O
would O
be O
cost-effective O
compared O
with O
unsuccessful O
medical O
treatment O
. O
['Resource-use', 'Resource-use']

Prophylaxis O
was O
discontinued O
if O
the O
patient O
experienced O
a O
possible O
or O
proven O
fungal O
infection O
or O
a O
serious O
toxicity O
. O
[]

Self-reported O
late O
toxicity O
was O
scored O
according O
to O
the O
LENT O
SOMA O
criteria O
in O
a O
structured O
telephone O
interview O
and O
with O
questionnaires O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
International O
Index O
of O
Erectile O
Function O
( O
IIEF O
) O
, O
and O
sexual O
function-vaginal O
changes O
questionnaire O
( O
SVQ O
) O
. O
[]

BACKGROUND O
Seborrhoeic O
dermatitis O
is O
a O
chronic O
inflammatory O
disease O
with O
remissions O
and O
exacerbations O
, O
characterized O
by O
erythema O
, O
scaling O
and O
pruritus O
primarily O
on O
the O
face O
, O
scalp O
and O
chest O
. O
[]

The O
patients O
were O
divided O
into O
two O
groups O
by O
random O
allocation O
using O
Ti-Ti O
rods O
(n O
= O
29) O
and O
CrCo-Ti O
rods O
(n O
= O
30) O
and O
the O
alone O
difference O
among O
them O
in O
the O
surgical O
procedure O
was O
rod O
material O
(Ti-Ti O
or O
CrCo-Ti O
rods) O
and O
finally, O
radiological B-outcome ['Physiological-Clinical']
outcomes O
were O
compared O
preoperatively, O
postoperatively O
and O
at O
last O
follow-up O
for O
12 O
months. O
[['Physiological-Clinical']]

METHODS O
Eight O
normal O
male O
volunteers O
undergoing O
UGIE O
with O
sedation O
( O
0.1 O
mg/kg O
of O
midazolam O
) O
and O
without O
it O
( O
two O
endoscopies O
per O
volunteer O
in O
random O
order O
) O
were O
monitored O
throughout O
the O
procedure O
by O
means O
of O
electrocardiogram B-outcome ['Resource-use']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
peripheral O
oxygen O
saturation O
( O
SpO2 O
) O
. O
['Resource-use', 'Physiological-Clinical']

RESULTS O
In O
the O
analyses O
of O
time O
to O
PPMD O
recurrence O
, O
poor O
sleep O
quality O
, O
but O
none O
of O
the O
hormones O
, O
was O
associated O
with O
PPMD O
recurrence O
( O
p O
< O
.05 O
) O
after O
controlling O
for O
medication O
assignment O
. O
[]

All O
patients O
received O
the O
Spectron O
EF O
stem O
. O
[]

After O
fenfluramine O
treatment O
blood O
serotonin O
levels O
fell O
, O
urinary O
catecholamine O
levels O
fell O
and O
the O
HVA/DA O
ratio O
rose O
. O
[]

Analysis O
of O
variance O
was O
used O
to O
analyze O
mean O
differences O
on O
demographic O
variables O
and O
mean O
number O
of O
weeks O
in O
study O
. O
[]

This O
study O
compared O
measurements O
taken O
by O
a O
new O
portable O
Fleisch O
pneumotachograph O
spirometer O
( O
known O
as O
the O
Escort O
) O
with O
those O
of O
the O
commonly O
used O
mini-Wright O
peak O
flow O
meter O
and O
the O
Micromed O
Pocket O
turbine O
spirometer O
. O
[]

Guar O
led O
to O
an O
additional O
lowering O
of O
the O
total O
cholesterol B-outcome ['Physiological-Clinical']
in O
the O
plasma O
by O
7 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.05 O
) O
associated O
with O
a O
fall O
of O
the O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LDL-cholesterol I-outcome ['Physiological-Clinical']
( O
LDL-cholesterol O
) O
by O
13 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.01 O
) O
without O
any O
changes O
in O
the O
very O
low O
density O
lipoprotein O
( O
VLDL O
) O
and O
high O
density O
lipoprotein O
( O
HDL O
) O
cholesterols O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Median O
within-practice O
[]

RESULTS O
The O
incidence O
of O
AF B-outcome ['Physiological-Clinical']
was O
24 O
% O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
a O
classroom-based O
activity O
break O
on O
in-school B-outcome ['Life-Impact']
step I-outcome ['Life-Impact']
counts I-outcome ['Life-Impact']
of O
primary O
school O
children O
. O
['Life-Impact']

METHODS O
& O
DESIGN O
This O
paper O
describes O
the O
development O
and O
evaluation O
protocol O
of O
a O
web-based O
out-of-school O
smoking O
prevention O
programme O
for O
primary O
school O
children O
( O
age O
10-13 O
years O
) O
entitled O
'Fun O
without O
Smokes O
' O
. O
[]

After O
4 O
min O
the O
full O
anesthetic O
dose O
, O
based O
on O
body O
size O
, O
was O
injected O
with O
the O
patient O
supine O
. O
[]

Toothbrush O
heads O
were O
vortexed O
and O
cultured O
for O
Prevotella O
species O
( O
Ps O
) O
, O
Porphyromonas O
gingivalis O
( O
Pg O
) O
, O
Actinobacillus O
actinomycetemcomitans O
( O
Aa O
) O
, O
and O
non-specific O
colony-forming O
units O
( O
NS O
) O
. O
[]

These O
estimates O
, O
however O
, O
are O
influenced O
by O
the O
degree O
to O
which O
the O
dose O
of O
exogenous O
insulin O
is O
greater O
than O
the O
physiologic O
response O
to O
a O
glucose O
load O
. O
[]

Reduced O
albuminuria O
with O
sarpogrelate O
is O
accompanied O
by O
a O
decrease O
in O
monocyte O
chemoattractant O
protein-1 O
levels O
in O
type O
2 O
diabetes O
. O
[]

Title: O
A O
Double-Blind O
Placebo-Controlled O
Randomized O
Trial O
Evaluating O
the O
Effect O
of O
Polyphenol-Rich O
Herbal O
Congee O
on O
Bone B-outcome ['Physiological-Clinical']
Turnover I-outcome ['Physiological-Clinical']
Markers O
of O
the O
Perimenopausal O
and O
Menopausal O
Women. O
[['Physiological-Clinical']]

Chi2 O
and O
Kruskal-Wallis O
tests O
were O
used O
for O
the O
statistical O
analysis O
. O
[]

The O
changes O
at O
the O
endpoint O
compared O
with O
baseline O
were O
: O
-11.90 O
+/- O
3.79 O
( O
mean O
+/- O
SD O
) O
and O
-5.15 O
+/- O
3.04 O
for O
group O
A O
and O
B O
respectively O
. O
[]

Married O
women O
( O
n O
= O
125,257 O
) O
underwent O
5-week O
surveillance O
for O
pregnancy O
, O
ascertained O
by O
a O
history O
of O
amenorrhea O
and O
confirmed O
by O
urine O
test O
. O
[]

Chemotherapy O
for O
patients O
with O
non-small O
cell O
lung O
cancer O
: O
the O
surgical O
setting O
of O
the O
Big O
Lung O
Trial O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
was O
noted O
only O
once O
. O
['Physiological-Clinical']

The O
prevalence O
of O
halitosis O
in O
the O
population O
is O
approximately O
30%, O
of O
which O
80 O
to O
90% O
of O
the O
cases O
originate O
in O
the O
oral O
cavity O
resulting O
from O
proteolytic O
degradation O
by O
gram O
negative O
anaerobic O
bacteria. O
[]

Prediction O
of O
the O
response O
to O
citalopram O
and O
reboxetine O
in O
post-stroke O
depressed O
patients O
. O
[]

The O
primary O
objective O
of O
the O
present O
randomized O
phase O
III O
trial O
was O
to O
compare O
the O
3-yr O
survival B-outcome ['Mortality']
rate O
of O
patients O
treated O
with O
standard O
fractionated O
radiotherapy O
( O
RT O
) O
alone O
or O
with O
the O
same O
RT O
concomitantly O
with O
cisplatin O
( O
DDP O
) O
or O
carboplatin O
( O
Cb O
) O
. O
['Mortality']

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

Echo-Doppler O
of O
renal O
arteries O
was O
performed O
to O
verify O
the O
anatomic O
patency O
and O
flow O
velocities O
of O
the O
reperfused O
artery O
. O
[]

Other O
studies O
found O
that O
there O
is O
an O
aerobic O
( O
in O
the O
gastrointestinal O
tract O
) O
oxidation O
of O
ferrous O
ion O
to O
ferric O
ion O
caused O
in O
iron-paracetamol O
in O
vivo O
reactions O
. O
[]

The O
primary O
endpoint O
was O
the O
incidence O
of O
grade O
2+ B-outcome ['Physiological-Clinical']
sensory I-outcome ['Physiological-Clinical']
neuropathy I-outcome ['Physiological-Clinical']
( O
SN B-outcome ['Physiological-Clinical']
) O
toxicity B-outcome ['Adverse-effects']
( O
CTCAE O
v O
3.0 O
) O
in O
each O
treatment O
arm O
, O
analyzed O
by O
chi-square O
testing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Zolmitriptan O
( O
Zomig O
, O
formerly O
311C90 O
) O
is O
a O
selective O
5-hydroxytryptamine O
( O
5-HT O
) O
1B/1D-receptor O
agonist O
with O
central O
and O
peripheral O
activity O
for O
the O
acute O
treatment O
of O
migraine O
. O
[]

METHODS O
We O
included O
patients O
older O
than O
18 O
years O
, O
expected O
to O
be O
in O
ICU O
for O
more O
than O
72 O
hours O
, O
with O
a O
glucose O
value O
of O
more O
than O
10 O
mmol/L O
within O
48 O
hours O
of O
ICU O
admission O
. O
[]

OBJECTIVE O
To O
examine O
the O
psychometric O
properties O
of O
the O
Children O
's O
Yale-Brown O
Obsessive O
Compulsive O
Scales O
( O
CYBOCS O
) O
modified O
for O
pervasive O
developmental O
disorders O
( O
PDDs O
) O
. O
[]

Of O
the O
total O
number O
of O
cases O
, O
59 O
% O
were O
aged O
60 O
to O
89 O
years O
, O
and O
55 O
% O
were O
men O
. O
[]

i.v O
. O
[]

METHODS: O
The O
prospective, O
randomized, O
single-center O
study O
was O
conducted O
at O
the O
Medical O
Department O
of O
University O
Hospital O
Dubrava, O
Zagreb, O
between O
April O
and O
June O
2018. O
[]

METHODS O
We O
measured O
plasma O
norepinephrine O
content O
during O
ischemic O
events O
from O
blood O
obtained O
from O
automatic O
pump O
withdrawal O
with O
the O
assistance O
of O
a O
real-time O
ST O
segment O
depression O
monitor O
. O
[]

Prolonged O
critical O
illness O
is O
characterized O
by O
feeding-resistant O
wasting O
of O
protein O
, O
whereas O
reesterification O
, O
instead O
of O
oxidation O
of O
fatty O
acids O
, O
allows O
fat O
stores O
to O
accrue O
and O
associate O
with O
a O
low-activity O
status O
of O
the O
somatotropic O
and O
thyrotropic O
axis O
, O
which O
seems O
to O
be O
partly O
of O
hypothalamic O
origin O
. O
[]

In O
conclusion O
, O
PLP O
is O
a O
promising O
safe O
and O
effective O
procedure O
for O
treatment O
of O
benign O
thyroid O
nodules O
in O
patients O
at O
high O
surgical O
risk O
. O
[]

Up O
to O
50% O
of O
reproductive-age O
women O
suffer O
from O
pelvic O
pain. O
[]

Treatment O
groups O
were O
comparable O
with O
respect O
to O
age O
and O
baseline O
granulocyte O
counts O
. O
[]

Effectiveness O
of O
hygienic-dietary O
recommendations O
as O
enhancers O
of O
antidepressant O
treatment O
in O
patients O
with O
depression O
: O
study O
protocol O
of O
a O
randomized O
controlled O
trial O
. O
[]

Radiation-induced O
brachial O
plexopathy O
occurs O
mainly O
as O
diffuse O
damage O
to O
the O
brachial O
plexus O
. O
[]

Postthrombotic B-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
also O
occurred O
with O
less O
frequency O
in O
systemically O
treated O
patients O
versus O
controls O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Satisfaction O
was O
associated O
with O
meeting O
participants O
' O
information O
needs O
and O
reduced O
belief O
in O
the O
necessity O
for O
investigations O
for O
low O
back O
pain O
, O
including O
X-rays O
and O
blood O
tests O
. O
[]

METHODS: O
Sixty-nine O
patients O
receiving O
VATS O
lobectomy O
in O
Department O
of O
Thoracic O
Surgery, O
West O
China O
Hospital, O
Sichuan O
University O
from O
September O
15, O
2017 O
to O
January O
15, O
2018 O
were O
randomly O
divided O
into O
the O
acapella O
group O
(AG) O
or O
the O
control O
group O
(CG). O
[]

The O
interaction O
of O
eptifibatide O
with O
CrCl O
had O
borderline O
significance O
for O
the O
30-day O
outcome O
( O
p O
= O
0.109 O
) O
. O
[]

Hemiarthroplasty O
was O
thus O
cost O
effective O
. O
[]

Pharmacokinetic O
properties O
of O
YM17E O
, O
an O
inhibitor O
of O
acyl O
coenzyme O
A O
: O
cholesterol O
acyl O
transferase O
, O
and O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

The O
results O
showed O
a O
highly O
significant O
diagnosisxdrugxtime B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
on O
repeated O
measure O
analysis O
covaried O
for O
baseline O
. O
['Physiological-Clinical']

Fifty-two O
patients O
with O
Fredrickson O
Type O
IIb O
or O
Type O
IV O
hyperlipidaemia O
, O
in O
whom O
diet O
had O
not O
achieved O
satisfactory O
lipid O
levels O
, O
completed O
a O
double O
blind O
randomised O
study O
of O
acipimox O
versus O
placebo O
. O
[]

For O
two O
matched O
chemotherapy O
treatments O
, O
one O
pre-test O
and O
two O
post-test O
measures O
were O
employed O
. O
[]

Success B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
valvotomy I-outcome ['Physiological-Clinical']
, O
procedure-related B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
, O
and O
follow-up O
events B-outcome ['Physiological-Clinical']
of O
the O
2 O
techniques O
were O
compared O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

infusion O
at O
90 O
mg/h O
for O
24 O
h. O
The O
placebo O
group O
( O
n O
= O
14 O
) O
received O
corresponding O
volumes O
of O
isotonic O
saline O
. O
[]

Effects O
of O
nutritional O
supplementation O
on O
IQ B-outcome ['Life-Impact']
and O
certain O
other O
variables O
associated O
with O
Down O
syndrome O
. O
['Life-Impact']

Ciclesonide O
is O
an O
intranasal O
corticosteroid O
approved O
for O
the O
treatment O
of O
allergic O
rhinitis O
. O
[]

OBJECTIVE O
We O
evaluated O
the O
ability O
of O
topical O
pimecrolimus O
to O
reduce O
the O
severity O
of O
cetuximab-related O
facial O
rash O
. O
[]

The O
pain-free B-outcome ['Physiological-Clinical']
and O
the O
absolute O
walking B-outcome ['Life-Impact']
distance O
( O
ACD O
) O
were O
monitored O
by O
standardized O
treadmill O
test O
at O
baseline O
and O
at O
4 O
, O
12 O
and O
24 O
weeks O
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
Patients O
were O
treated O
with O
weekly O
bolus O
5-fluorouracil O
( O
5-FU O
) O
and O
leucovorin O
( O
FL O
; O
Roswell O
Park O
Regimen O
) O
or O
the O
same O
regimen O
plus O
oxaliplatin O
( O
FLOX O
) O
. O
[]

Contour B-outcome ['Physiological-Clinical']
detectability I-outcome ['Physiological-Clinical']
was O
found O
to O
be O
a O
function O
not O
only O
of O
the O
relative O
spacing O
of O
contour O
elements O
with O
respect O
to O
the O
noise O
elements O
but O
also O
of O
the O
average O
density O
of O
the O
overall O
pattern O
. O
['Physiological-Clinical']

Effect O
of O
n-3 O
polyunsaturated O
fatty O
acid O
intake O
on O
phospholipid O
fatty O
acid O
composition O
in O
plasma O
and O
erythrocytes O
. O
[]

Nine O
normal O
volunteers O
and O
15 O
patients O
with O
pituitary O
disorders O
were O
given O
a O
combined O
test O
of O
anterior O
pituitary O
function O
using O
four O
hypothalamic O
releasing O
factors O
and O
arginine O
vasopressin O
. O
[]

Further O
studies O
are O
needed O
to O
demonstrate O
whether O
beta-carotene O
has O
a O
role O
as O
adjunct O
therapy O
in O
treatment O
of O
HIV-infected B-outcome ['Physiological-Clinical']
patients O
. O
['Physiological-Clinical']

Twenty-one O
women O
died B-outcome ['Mortality']
of O
their O
disease O
. O
['Mortality']

In O
this O
initial O
study O
, O
two O
villages O
were O
randomly O
assigned O
a O
nutritious O
supplement O
( O
atole O
) O
for O
all O
children O
and O
two O
villages O
a O
less O
nutritious O
one O
( O
fresco O
) O
. O
[]

The O
occlusal O
surface O
was O
ground O
flat O
and O
the O
teeth O
were O
sectioned O
mesio-distally O
. O
[]

Drug O
effects O
were O
monitored O
with O
behavior O
checklists O
rated O
by O
parents O
and O
teachers O
, O
and O
ethological O
playroom O
observations O
. O
[]

From O
May O
, O
2006 O
, O
we O
conducted O
a O
quasi-randomized O
trial O
to O
determine O
if O
an O
in-home O
education O
and O
invitation O
intervention O
would O
increase O
uptake O
of O
cervical O
cancer O
screening O
. O
[]

Cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers O
were O
measured O
before O
, O
after O
cycle O
1 O
, O
3 O
and O
6 O
and O
at O
4 O
weeks O
post-treatment O
. O
['Physiological-Clinical']

Large O
individual O
differences O
characterize O
the O
changes O
induced O
by O
sleep O
deprivation O
on O
neurobehavioral O
functions O
and O
rhythmic O
brain O
activity O
. O
[]

RESULTS O
Patients O
placed O
on O
indomethacin O
obtained O
relief B-outcome ['Physiological-Clinical']
more O
consistently O
and O
more O
completely O
. O
['Physiological-Clinical']

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
parameters O
used O
for O
the O
bioequivalence O
assessment O
( O
AUClast O
, O
AUCinf O
and O
Cmax B-outcome ['Physiological-Clinical']
) O
were O
determined O
from O
the O
terbinafine O
concentration O
data O
using O
non-compartmental O
analysis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
mean O
change O
in O
lag O
time O
was O
-7 O
+/- O
14 O
min O
( O
-7.2 O
% O
) O
in O
the O
PUFA-diet O
group O
and O
+4 O
+/- O
16 O
min O
( O
+4.0 O
% O
) O
in O
the O
MUFA-diet O
group O
( O
P O
= O
0.029 O
, O
PUFA-diet O
group O
vs O
MUFA-diet O
group O
) O
. O
[]

Eye O
movements O
affirm O
: O
automatic B-outcome ['Physiological-Clinical']
overt I-outcome ['Physiological-Clinical']
gaze I-outcome ['Physiological-Clinical']
and O
arrow B-outcome ['Life-Impact']
cueing I-outcome ['Life-Impact']
for O
typical O
adults O
and O
adults O
with O
autism O
spectrum O
disorder O
. O
['Physiological-Clinical', 'Life-Impact']

Few O
studies O
have O
evaluated O
the O
impact O
of O
maintenance O
immunosuppression O
on O
blood O
humoral O
parameters O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Before O
crossover, O
the O
objective O
response B-outcome ['Physiological-Clinical']
rate O
was O
33% O
(95% O
CI, O
20 O
to O
48) O
in O
the O
sorafenib O
group O
and O
20% O
(95% O
CI, O
8 O
to O
38) O
in O
the O
placebo O
group. O
[['Physiological-Clinical']]

These O
algorithms O
provided O
accurate O
estimates O
of O
GAI O
in O
the O
WAIS-III O
standardization O
sample O
. O
[]

Continuous O
chemotherapy O
in O
responsive O
metastatic O
breast O
cancer O
: O
a O
role O
for O
tumour O
markers O
? O
[]

Outcomes O
were O
assessed O
over O
a O
6-year O
period O
of O
program O
implementation O
for O
a O
cohort O
of O
youth O
in O
each O
school O
, O
followed O
from O
grades O
3 O
to O
8 O
. O
[]

UNLABELLED O
It O
has O
been O
shown O
that O
the O
stress O
response O
to O
lower O
abdominal O
surgery O
can O
be O
inhibited O
by O
epidural O
analgesia O
( O
EA O
) O
. O
[]

The O
patients O
received O
20 O
mg/day O
atorvastatin O
and O
3 O
g/day O
colestimide O
or O
40 O
mg/day O
atorvastatin O
. O
[]

METHODS O
This O
prospective O
, O
comparative O
study O
was O
conducted O
with O
healthy O
males O
and O
females O
between O
the O
ages O
of O
19 O
and O
24 O
. O
[]

However O
, O
the O
patients O
treated O
with O
aminophylline O
had O
significantly O
more O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
( O
p O
< O
0.05 O
) O
. O
['Adverse-effects']

MAIN O
OUTCOME O
MEASURES O
Preoperative B-outcome ['Physiological-Clinical']
cervical I-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
, O
acceptability B-outcome ['Life-Impact']
and O
complications B-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Life-Impact', 'Adverse-effects']

RESULTS O
A O
dose-dependent O
duration O
of O
pulpal O
and O
soft O
tissue O
anesthesia O
was O
obtained O
only O
by O
the O
ISA O
. O
[]

By O
contrast O
, O
no O
difference O
in O
FFS O
was O
observed O
when O
patients O
were O
stratified O
by O
EBER-ISH O
. O
[]

CONCLUSIONS O
The O
use O
of O
distraction O
techniques O
is O
effective O
in O
reducing O
situational O
anxiety O
in O
older O
children O
and O
lowering O
parental O
perception O
of O
pain O
distress O
in O
younger O
children O
. O
[]

RESULTS O
Compared O
with O
sixteen O
control O
participants O
, O
patients O
with O
CSX O
had O
significantly O
higher O
activity B-outcome ['Life-Impact']
of O
MPO B-outcome ['Physiological-Clinical']
and O
levels O
of O
MDA B-outcome ['Physiological-Clinical']
, O
but O
significantly O
lower B-outcome ['Physiological-Clinical']
SOD I-outcome ['Physiological-Clinical']
activity B-outcome ['Life-Impact']
and O
levels O
of O
NOx B-outcome ['Physiological-Clinical']
before O
treatment O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

This O
randomized O
controlled O
clinical O
trial O
compares O
the O
effectiveness O
of O
a O
biopsychosocial O
treatment O
with O
a O
solely O
conventional O
biomedical O
therapy O
in O
patients O
with O
subacute B-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
using O
parameters O
for O
pain O
intensity O
, O
functional O
status O
, O
depressive O
dysfunction O
and O
work O
performance O
. O
['Physiological-Clinical']

RESULTS O
Regarding O
chemical B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

0.004 O
) O
because O
salt O
or O
CES O
ingestion O
did O
not O
affect O
fluid B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
( O
W O
68 O
% O
, O
SW O
72 O
% O
, O
CES-L O
68 O
% O
, O
CES O
76 O
% O
) O
. O
['Physiological-Clinical']

Recatheterization B-outcome ['Resource-use']
was O
necessary O
in O
3 O
cases O
( O
6.1 O
% O
) O
cases O
in O
the O
PlasmaKinetic O
group O
and O
in O
1 O
( O
2.1 O
% O
) O
in O
the O
TURP O
group O
. O
['Resource-use']

Bacteriuria O
in O
post-biopsy B-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
was O
significantly O
more O
common O
in O
the O
anesthesia O
group O
. O
['Physiological-Clinical']

Skin O
incision O
in O
the O
control O
group O
began O
at O
the O
distal O
border O
of O
the O
carpal O
ligament O
, O
followed O
the O
longitudinal O
crease O
of O
the O
palm O
, O
and O
crossed O
the O
base O
of O
the O
palm O
in O
a O
zigzag O
fashion O
. O
[]

Funded O
by O
GlaxoSmithKline O
and O
Medicines O
for O
Malaria O
Venture; O
GATHER O
ClinicalTrials.gov O
number, O
NCT02216123 O
.). O
[]

In O
phase O
1 O
, O
the O
control O
group O
had O
no O
weights O
placed O
. O
[]

For O
a O
subset O
of O
the O
participants O
( O
53 O
children O
ages O
5-16 O
) O
pre O
and O
post O
measurements O
of O
nutritional O
and O
metabolic O
status O
were O
also O
conducted O
. O
[]

Students O
( O
n=2453 O
) O
in O
the O
seven O
middle O
schools O
in O
one O
school O
district O
were O
assessed O
at O
school O
at O
the O
beginning O
and O
end O
of O
the O
sixth O
, O
seventh O
, O
eighth O
grade O
and O
beginning O
of O
the O
9th O
grade O
. O
[]

7.6 O
years O
and O
with O
a O
mean O
BMI O
of O
32.8 O
? O
[]

Endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
brachial I-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
flow-mediated I-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
FMD I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline O
, O
after O
fat O
gain O
( O
8 O
weeks O
) O
, O
and O
after O
weight O
loss O
( O
16 O
weeks O
) O
for O
fat O
gainers O
and O
at O
baseline O
and O
follow-up O
( O
8 O
weeks O
) O
for O
weight O
maintainers O
. O
['Physiological-Clinical']

The O
growth O
of O
fibroblasts O
and O
keratinocytes O
may O
be O
enhanced O
by O
pulsed O
low-intensity O
direct O
current O
due O
to O
changes O
in O
calcium B-outcome ['Physiological-Clinical']
homeostasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
this O
study O
, O
participants O
were O
required O
to O
locomote O
in O
the O
dark O
to O
a O
lit O
target O
in O
three O
different O
conditions O
: O
monocular O
vision/target O
with O
image O
size O
, O
binocular O
vision/target O
with O
image O
size O
, O
and O
binocular O
vision/point-light O
target O
( O
without O
image O
size O
) O
. O
[]

These O
pregnancies O
were O
randomly O
allocated O
to O
a O
treatment O
group O
( O
AD O
and O
estimated O
weight O
reported O
) O
or O
to O
a O
control O
group O
( O
AD O
and O
estimated O
weight O
withheld O
) O
. O
[]

In O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
of O
minocycline O
in O
60 O
HD O
patients O
, O
the O
authors O
determined O
that O
over O
8 O
weeks O
, O
minocycline O
at O
100 O
and O
200 O
mg/day O
was O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
and O
safe O
in O
HD O
patients O
. O
['Life-Impact']

[ O
Neoton O
and O
thrombolytic O
therapy O
of O
myocardial O
infarction O
] O
. O
[]

[ O
The O
comparison O
of O
the O
effect O
of O
enalapril O
and O
indapamide O
on O
the O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
central B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
through O
pulse O
wave O
analysis O
] O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:American O
journal O
of O
orthodontics O
and O
dentofacial O
orthopedics O
: O
official O
publication O
of O
the O
American O
Association O
of O
Orthodontists, O
its O
constituent O
societies, O
and O
the O
American O
Board O
of O
Orthodontics O
[]

TLC O
clinical O
sites O
were O
in O
Baltimore O
, O
Cincinnati O
and O
Columbus O
, O
Newark O
and O
Philadelphia O
. O
[]

OBJECTIVE O
Our O
aim O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
the O
two O
types O
of O
TVT-S O
for O
female O
stress O
urinary O
incontinence O
( O
SUI O
) O
. O
[]

The O
effects O
of O
adult O
intervention O
on O
infants O
' O
level O
of O
attention B-outcome ['Life-Impact']
to O
objects O
were O
studied O
with O
10-month-old O
infants O
. O
['Life-Impact']

There O
was O
a O
concomitant O
significant O
decrease O
in O
depression B-outcome ['Life-Impact']
rating O
from O
HDS O
8.9 O
to O
5.3 O
( O
p O
< O
0.005 O
, O
Wilcoxon O
's O
test O
) O
. O
['Life-Impact']

High O
ECOG O
scores, O
cancer O
localization O
to O
the O
right O
side O
of O
colon O
and O
lymph O
node O
metastasis O
were O
associated O
with O
increased O
risk O
of O
death B-outcome ['Mortality']
and O
all O
remained O
independent O
factors O
affecting O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
. O
The O
most O
common O
grade O
3/4 O
treatment-related O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
hypertension B-outcome ['Physiological-Clinical']
and O
hand-foot B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
. O
Apatinib O
treatment O
for O
patients O
with O
advanced O
colorectal O
cancer O
who O
had O
failed O
chemotherapy O
achieved O
better O
disease B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
prolonged O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
relative O
to O
untreated O
controls. O
[['Mortality'], ['Mortality'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality']]

We O
estimated O
annual O
income O
, O
hours O
worked O
, O
and O
average O
hourly O
wages O
from O
all O
economic O
activities O
. O
[]

In O
this O
study O
the O
human O
glyceryltrinitrate O
( O
GTN O
) O
model O
of O
migraine O
was O
for O
the O
first O
time O
used O
to O
test O
the O
effect O
of O
a O
prophylactic O
drug O
. O
[]

Reperfusion B-outcome ['Physiological-Clinical']
arrhythmias I-outcome ['Physiological-Clinical']
, O
CK B-outcome ['Physiological-Clinical']
and O
CKMB B-outcome ['Physiological-Clinical']
, O
corrected O
TIMI O
frame O
count O
( O
CTFC B-outcome ['Physiological-Clinical']
) O
, O
wall B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
score O
index O
( O
WMSI O
) O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
by O
echocardiography O
were O
compared O
between O
the O
two O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pharmacokinetics B-outcome ['Physiological-Clinical']
and O
relative B-outcome ['Physiological-Clinical']
bioavailability I-outcome ['Physiological-Clinical']
of O
prajmalium O
bitartrate O
after O
single O
oral O
dosing O
. O
['Physiological-Clinical']

In O
30 O
patients O
with O
follow-up O
data O
the O
rate O
of O
change O
in O
hip B-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
over O
a O
year O
was O
also O
determined O
by O
both O
methods O
. O
['Physiological-Clinical']

In O
the O
sequential O
arm O
, O
29 O
of O
53 O
evaluable O
patients O
( O
55 O
% O
; O
95 O
% O
confidence O
interval O
, O
41 O
% O
-68 O
% O
) O
had O
a O
complete O
response O
. O
[]

DESIGN O
This O
was O
a O
16-week O
prospective O
, O
double O
blinded O
, O
randomized O
controlled O
trial O
of O
40 O
women O
with O
laparoscopically O
confirmed O
endometriosis O
. O
[]

Patients O
with O
diminutive O
polyps O
in O
the O
rectum O
or O
sigmoid O
colon O
were O
randomized O
to O
hot O
biopsy O
treatment O
for O
either O
1 O
) O
electrocautery O
for O
2 O
s O
( O
fixed O
duration O
cautery O
) O
or O
2 O
) O
cautery O
until O
visible O
necrosis O
of O
the O
polyp O
base O
was O
evident O
( O
variable O
duration O
cautery O
) O
. O
[]

Randomisation O
was O
done O
centrally O
with O
a O
computer-generated O
randomisation O
schedule O
and O
was O
stratified O
by O
baseline O
platelet O
count O
( O
? O
[]

Wound O
infections O
were O
diagnosed O
by O
blinded O
investigators O
using O
Centers O
for O
Disease O
Control O
and O
Prevention O
criteria O
. O
[]

Tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
is O
thought O
to O
induce O
cachexia O
in O
subjects O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
, O
and O
it O
has O
been O
suggested O
that O
HIV-seropositive O
patients O
would O
benefit O
from O
treatment O
with O
pentoxifylline O
, O
a O
known O
suppressor O
of O
TNF-alpha O
production O
. O
[]

While O
the O
EG O
took O
part O
in O
an O
endurance O
and O
activity O
of O
daily O
living-training O
twice O
a O
day O
, O
the O
CG O
received O
the O
clinic O
's O
standard O
physiotherapy O
program O
once O
a O
day O
. O
[]

The O
AUC O
and O
Cmax B-outcome ['Physiological-Clinical']
after O
fasting O
were O
closely O
similar O
to O
those O
after O
a O
meal O
, O
showing O
that O
bioavailability O
was O
not O
affected O
by O
food O
intake O
. O
['Physiological-Clinical']

Parameters O
discriminating O
the O
development O
of O
ESUL B-outcome ['Physiological-Clinical']
in O
a O
specific O
patient O
were O
type O
of O
AF B-outcome ['Physiological-Clinical']
, O
maximum B-outcome ['Physiological-Clinical']
energy I-outcome ['Physiological-Clinical']
delivered I-outcome ['Physiological-Clinical']
, O
usage O
of O
a O
nasogastric O
tube O
, O
and O
additional O
left O
atrial O
lines O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pilot O
results O
agreed O
with O
other O
trials O
published O
in O
the O
literature O
and O
demonstrated O
tamsulone-FS O
efficacy O
and O
safety O
for O
management O
of O
lower O
urinary B-outcome ['Physiological-Clinical']
tract I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
caused O
by O
prostatic O
adenoma O
. O
['Physiological-Clinical']

Outcome O
measures O
were O
the O
Childhood B-outcome ['Life-Impact']
Autism B-outcome ['Life-Impact']
Rating O
Scale O
, O
the O
Gilliam O
Autism B-outcome ['Life-Impact']
Rating O
Scale O
, O
the O
Expressive B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
Receptive I-outcome ['Life-Impact']
One-Word I-outcome ['Life-Impact']
Picture I-outcome ['Life-Impact']
Vocabulary I-outcome ['Life-Impact']
tests O
, O
and O
Clinical O
Global O
Impressions O
of O
Change O
. O
['Life-Impact']

Rates O
were O
not O
significantly O
different O
between O
the O
arms O
. O
[]

Measurements O
were O
performed O
at O
baseline O
and O
after O
4 O
weeks O
. O
[]

Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
levels O
were O
measured O
at O
the O
beginning O
of O
the O
study. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact']]

RESULTS O
Mean O
weight O
and O
length B-outcome ['Physiological-Clinical']
gains I-outcome ['Physiological-Clinical']
in O
the O
LP O
, O
FS50 O
, O
and O
FS25 O
groups O
were O
2.37 O
, O
2.47 O
, O
and O
2.37 O
kg O
( O
P O
= O
.66 O
) O
and O
12.7 O
, O
13.5 O
, O
and O
13.2 O
cm O
( O
P O
= O
.23 O
) O
, O
respectively O
. O
['Physiological-Clinical']

RESULTS O
Dapsone O
gel-treated O
patients O
achieved O
superior O
results O
in O
terms O
of O
the O
investigator O
's O
global O
acne O
assessment O
( O
P O
< O
.001 O
) O
and O
the O
mean O
percentage O
reduction O
in O
inflammatory B-outcome ['Physiological-Clinical']
, O
noninflammatory B-outcome ['Physiological-Clinical']
, O
and O
total O
['Physiological-Clinical', 'Physiological-Clinical']

PFS B-outcome ['Mortality']
was O
significantly O
prolonged O
with O
pazopanib O
compared O
with O
placebo O
in O
the O
overall O
study O
population O
( O
median O
, O
PFS O
9.2 O
v O
4.2 O
months O
; O
hazard O
ratio O
[ O
HR O
] O
, O
0.46 O
; O
95 O
% O
CI O
, O
0.34 O
to O
0.62 O
; O
P O
< O
.0001 O
) O
, O
the O
treatment-naive O
subpopulation O
( O
median O
PFS O
11.1 O
v O
2.8 O
months O
; O
HR O
, O
0.40 O
; O
95 O
% O
CI O
, O
0.27 O
to O
0.60 O
; O
P O
< O
.0001 O
) O
, O
and O
the O
cytokine-pretreated O
subpopulation O
( O
median O
PFS O
, O
7.4 O
v O
4.2 O
months O
; O
HR O
, O
0.54 O
; O
95 O
% O
CI O
, O
0.35 O
to O
0.84 O
; O
P O
< O
.001 O
) O
. O
['Mortality']

The O
initial O
dose O
of O
bupivacaine O
in O
the O
2 O
groups O
was O
4 O
mg, O
and O
the O
subsequent O
dose O
for O
the O
following O
patient O
was O
depended O
on O
the O
probability O
of O
the O
current O
dose. O
[]

The O
Japanese O
Children O
's O
Cancer O
and O
Leukemia O
Study O
Group O
. O
[]

The O
aim O
of O
this O
randomized O
, O
controlled O
, O
double-blind O
, O
split O
mouth O
, O
clinical O
study O
was O
to O
evaluate O
and O
compare O
the O
desensitizing O
effects O
of O
erbium O
, O
chromium-doped O
: O
yttrium O
, O
scandium O
, O
gallium O
and O
garnet O
( O
Er O
, O
Cr O
: O
YSGG O
) O
to O
galium-aluminium-arsenide O
( O
GaAlAs O
) O
laser O
on O
DH O
. O
[]

doses O
resulting O
in O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
up O
to O
100 O
times O
those O
measured O
after O
therapeutic O
doses O
( O
6 O
mg O
b.i.d O
. O
) O
['Physiological-Clinical']

INTRODUCTION O
In O
young O
adults O
with O
childhood-onset O
growth O
hormone O
deficiency O
( O
CO O
GHD O
) O
, O
GH O
treatment O
after O
final O
height O
is O
reached O
has O
been O
shown O
to O
have O
beneficial O
effects O
on O
spine O
and O
hip O
bone O
mineral O
density O
. O
[]

von B-outcome ['Physiological-Clinical']
Willebrand I-outcome ['Physiological-Clinical']
factor O
antigen B-outcome ['Physiological-Clinical']
levels O
declined O
significantly O
under O
the O
influence O
of O
pegvisomant O
alone O
( O
1.1 O
+/- O
0.07 O
vs. O
0.8 O
+/- O
0.06 O
U/ml O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Beneficial O
effects O
of O
a O
soy-based O
dietary O
supplement O
on O
lipid B-outcome ['Physiological-Clinical']
levels O
and O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
markers B-outcome ['Physiological-Clinical']
in O
type O
2 O
diabetic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Procalcitonin O
is O
a O
good O
tool O
to O
guide O
duration O
of O
antibiotic O
therapy O
in O
patients O
with O
severe O
acute O
pancreatitis O
. O
[]

Prostanoid B-outcome ['Physiological-Clinical']
biosynthesis I-outcome ['Physiological-Clinical']
was O
not O
inhibited O
. O
['Physiological-Clinical']

After O
debriefing O
, O
53.1 O
% O
chose O
public B-outcome ['Physiological-Clinical']
data O
release B-outcome ['Physiological-Clinical']
, O
33.1 O
% O
chose O
restricted B-outcome ['Physiological-Clinical']
( O
controlled B-outcome ['Physiological-Clinical']
access I-outcome ['Physiological-Clinical']
database O
) O
release B-outcome ['Physiological-Clinical']
, O
and O
13.7 O
% O
opted B-outcome ['Life-Impact']
out I-outcome ['Life-Impact']
of O
data O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Based O
on O
these O
studies O
, O
we O
decided O
to O
assess O
the O
effectiveness O
of O
Ginkgo O
biloba O
extract O
( O
Ginko O
T.D. O
, O
Tolidaru O
, O
Iran O
) O
as O
an O
adjunctive O
agent O
to O
risperidone O
in O
the O
treatment O
of O
autism O
. O
[]

One O
patient O
(4%) O
died B-outcome ['Mortality']
from O
sepsis B-outcome ['Physiological-Clinical']
in O
the O
context O
of O
neutropenic B-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
, O
infection B-outcome ['Physiological-Clinical']
, O
and O
haemorrhage B-outcome ['Physiological-Clinical']
in O
the O
5-day O
group, O
and O
in O
the O
10-day O
group O
six O
patients O
(14%) O
died B-outcome ['Mortality']
from O
infection B-outcome ['Physiological-Clinical']
. O
Early O
mortality B-outcome ['Mortality']
was O
similar O
in O
the O
two O
groups. O
[['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality'], ['Physiological-Clinical'], ['Mortality']]

ICT O
patients O
required O
analgesic B-outcome ['Resource-use']
drugs I-outcome ['Resource-use']
during O
76.8 O
+/- O
31 O
hours O
and O
VATS O
patients O
38.4 O
+/- O
13 O
hours O
( O
p O
< O
.05 O
) O
. O
['Resource-use']

METHODS/DESIGN O
The O
study O
will O
employ O
a O
cluster O
randomised O
controlled O
trial O
design O
. O
[]

BACKGROUND: O
Mental O
health O
disorders O
among O
adolescents O
have O
emerged O
as O
a O
major O
public O
health O
issue O
in O
many O
low O
and O
middle-income O
countries, O
including O
India. O
[]

Clinical O
outcomes O
and O
complications B-outcome ['Adverse-effects']
were O
compared O
for O
1 O
year O
of O
follow-up O
. O
['Adverse-effects']

After O
each O
study O
phase O
the O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
GFR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
RPF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
describe O
the O
development O
of O
a O
behavioral O
intervention O
designed O
to O
decrease O
sexual O
and O
injection B-outcome ['Resource-use']
risk O
behaviors B-outcome ['Life-Impact']
among O
young O
IDUs O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

Over O
a O
24-month O
observation O
period O
the O
immunized O
group O
always O
had O
higher O
levels O
of O
peripheral B-outcome ['Physiological-Clinical']
leukocytes I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
peripheral B-outcome ['Physiological-Clinical']
lymphocytes I-outcome ['Physiological-Clinical']
; O
this O
difference O
was O
significant O
for O
the O
first O
21 O
months O
. O
['Physiological-Clinical']

Fluorescein B-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
classic I-outcome ['Physiological-Clinical']
and O
occult B-outcome ['Physiological-Clinical']
CNV I-outcome ['Physiological-Clinical']
could O
not O
be O
halted O
by O
10 O
Gy O
, O
while O
a O
temporary B-outcome ['Physiological-Clinical']
growth I-outcome ['Physiological-Clinical']
retardation I-outcome ['Physiological-Clinical']
was O
observed O
in O
cases O
irradiated O
with O
36 O
Gy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
used O
a O
randomized O
clinical O
trial O
with O
133 O
incontinent O
elderly O
in O
seven O
nursing O
homes O
to O
evaluate O
the O
effectiveness O
of O
a O
behavioral O
training O
therapy O
and O
its O
cost O
implications O
. O
[]

Infliximab B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
2 O
hours O
after O
each O
infusion O
and O
at O
1 O
, O
3 O
, O
4 O
, O
5 O
, O
8 O
, O
10 O
, O
14 O
and O
18 O
weeks O
. O
['Physiological-Clinical']

CONCLUSIONS O
Hydration O
with O
sodium O
bicarbonate O
provides O
better O
protection O
against O
[]

Recruitment O
was O
from O
January O
2015 O
to O
May O
2018, O
with O
follow-up O
until O
July O
2018. O
[]

Epirubicin O
and O
cyclophosphamide O
versus O
epirubicin O
and O
docetaxel O
as O
first-line O
therapy O
for O
women O
with O
metastatic O
breast O
cancer O
: O
final O
results O
of O
a O
randomised O
phase O
III O
trial O
. O
[]

Also O
, O
the O
immunological O
measures O
did O
not O
appear O
relevant O
to O
the O
significantly O
favourable O
effect O
of O
levamisole O
on O
the O
prognosis O
. O
[]

[ O
Intravesical O
electrostimulation O
and O
magnetophoresis O
in O
overactive O
bladder O
in O
females O
: O
efficacy O
of O
Amus-01-Intramag O
device O
with O
Intrastim O
attachment O
] O
. O
[]

METHODS O
Patients O
with O
inoperable O
carcinoma O
of O
the O
oesophagus O
were O
randomised O
to O
receive O
either O
endoscopic O
Nd O
: O
YAG O
laser O
therapy O
alone O
, O
or O
laser O
followed O
by O
brachytherapy O
. O
[]

However O
, O
in O
the O
D53-treated O
group O
, O
but O
not O
in O
the O
placebo O
group O
, O
IL-1 B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
induced O
by O
low O
LPS B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
( O
5 O
mg/L O
) O
was O
significantly O
higher O
( O
mean O
+/- O
SEM O
: O
1,238 O
+/- O
287 O
U/10 O
( O
6 O
) O
AM O
) O
on O
day O
15 O
in O
comparison O
with O
day O
1 O
( O
577 O
+/- O
113 O
U/10 O
( O
6 O
) O
AM O
; O
p O
less O
than O
0.05 O
, O
Wilcoxon O
W O
test O
) O
and O
in O
comparison O
with O
the O
control O
group O
( O
day O
15 O
IL-1 B-outcome ['Physiological-Clinical']
production O
induced O
by O
5 O
mg/L O
LPS O
, O
758 O
+/- O
175 O
U/10 O
( O
6 O
) O
AM O
; O
p O
less O
than O
0.05 O
, O
Mann-Whitney O
U O
test O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

No O
significant O
difference O
was O
recorded O
between O
the O
sucrose O
and O
sterile O
water O
groups O
in O
the O
magnitude O
or O
latency O
of O
the O
spinal O
nociceptive O
reflex O
withdrawal O
recorded O
from O
the O
biceps O
femoris O
of O
the O
stimulated O
leg O
. O
[]

Both O
drugs O
induced O
a O
reduction O
in O
the O
albumin B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
AER I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PDE5 O
inhibition O
, O
by O
blocking O
degradation O
of O
nitric O
oxide O
second-messenger O
cyclic O
guanosine O
monophosphate O
, O
might O
be O
beneficial O
. O
[]

The O
impact O
of O
emotional O
distress O
on O
HIV B-outcome ['Physiological-Clinical']
risk O
reduction O
among O
women O
. O
['Physiological-Clinical']

Enclosed O
were O
eyes O
with O
visual O
acuity O
of O
> O
or O
= O
0.1 O
and O
< O
or O
= O
0.6 O
revealing O
a O
juxta-subfoveal O
CNV O
either O
of O
the O
occult O
type O
( O
type O
1 O
) O
or O
the O
classic O
type O
( O
isolated O
or O
as O
part O
of O
a O
predominantly O
occult O
lesion O
) O
. O
[]

Mild B-outcome ['Physiological-Clinical']
genital I-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
were O
reported O
in O
42 O
% O
of O
CS O
users O
( O
itching B-outcome ['Physiological-Clinical']
, O
burning B-outcome ['Physiological-Clinical']
, O
tingling B-outcome ['Physiological-Clinical']
, O
testicular B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
dysuria B-outcome ['Physiological-Clinical']
, O
and O
warm B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
cold I-outcome ['Physiological-Clinical']
feeling I-outcome ['Physiological-Clinical']
) O
and O
8 O
% O
of O
KY O
Jelly O
users O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
evaluate O
the O
efficacy O
of O
diltiazem O
versus O
placebo O
in O
patients O
with O
stable O
angina O
. O
[]

From O
this O
study O
, O
a O
low-dose O
test O
( O
MEG-X O
concentration O
30 O
minutes O
after O
50 O
mg O
lidocaine O
intravenously O
[ O
MEG-X30min O
] O
normalized O
to O
standard O
MEG-X O
test O
results O
) O
was O
developed O
. O
[]

Compliance O
with O
the O
recommended O
treatment O
, O
of O
at O
least O
four O
hours O
daily O
, O
is O
unknown O
. O
[]

METHOD O
Survivors O
of O
out-of-hospital O
ventricular O
fibrillation O
or O
asystole O
( O
N O
= O
129 O
) O
, O
documented O
by O
electrocardiograms O
from O
registries O
of O
a O
citywide O
Medic O
One O
unit O
and O
two O
countywide O
emergency O
units O
, O
were O
randomized O
into O
a O
two O
group O
, O
experimental O
, O
longitudinal O
design O
. O
[]

At O
5 O
years O
, O
we O
evaluated O
the O
cumulative O
incidence O
of O
allergic B-outcome ['Physiological-Clinical']
diseases I-outcome ['Physiological-Clinical']
( O
eczema B-outcome ['Physiological-Clinical']
, O
food B-outcome ['Physiological-Clinical']
allergy I-outcome ['Physiological-Clinical']
, O
allergic B-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

One O
other O
possible O
factor O
contributing O
to O
pruritus O
is O
the O
pattern O
of O
immune O
dysregulation O
. O
[]

Thus O
succinylcholine O
may O
be O
used O
as O
the O
sole O
paralytic O
agent O
in O
rapid-sequence O
intubation O
of O
head O
trauma O
patients O
. O
[]

We O
explored O
characteristics O
of O
NSCLC O
that O
could O
predict O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(DFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
using O
Cox O
regression O
models. O
[['Physiological-Clinical', 'Mortality'], ['Mortality']]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
a O
subhypnotic O
dose O
of O
propofol O
with O
the O
conventional O
antiemetics O
droperidol O
and O
metoclopramide O
for O
the O
prophylaxis O
of O
PONV O
after O
breast O
cancer O
surgery O
in O
Japanese O
patients O
. O
[]

CONCLUSION: O
The O
use O
of O
colorings O
in O
eye O
drops O
can O
help O
distinguishing O
the O
vials O
and O
preventing O
misidentification B-outcome ['Life-Impact']
. O
[['Life-Impact']]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

One O
explanation O
might O
be O
that O
in O
some O
patients O
an O
early O
spread O
of O
tumor O
cells O
has O
occurred O
which O
might O
not O
be O
curable O
by O
surgical O
means O
. O
[]

Estradiol B-outcome ['Physiological-Clinical']
, O
prolactin B-outcome ['Physiological-Clinical']
and O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
a O
single O
measure O
of O
IL-6 B-outcome ['Physiological-Clinical']
were O
assayed O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
plasma B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
after O
administration O
of O
450 O
mg O
were O
almost O
the O
same O
as O
after O
300 O
mg O
. O
['Physiological-Clinical']

To O
test O
the O
effects O
of O
paromomycin O
, O
10 O
patients O
with O
AIDS O
and O
cryptosporidiosis O
were O
randomized O
to O
paromomycin O
or O
placebo O
in O
a O
double-blind O
trial O
. O
[]

Effluent B-outcome ['Physiological-Clinical']
carcinogen I-outcome ['Physiological-Clinical']
antigen-125 I-outcome ['Physiological-Clinical']
levels O
were O
inversely O
correlated O
with O
peritoneal O
glucose O
exposure O
during O
lactate O
but O
not O
bicarbonate O
APD O
, O
indicating O
improved O
in O
vivo O
mesothelial O
cell O
tolerance O
of O
high-dose O
glucose O
with O
the O
neutral-pH O
PD O
fluid O
with O
reduced O
glucose O
degradation O
product O
content O
. O
['Physiological-Clinical']

A O
complete B-outcome ['Physiological-Clinical']
response O
, O
defined O
as O
no B-outcome ['Physiological-Clinical']
emesis I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
no B-outcome ['Physiological-Clinical']
need I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
another I-outcome ['Physiological-Clinical']
rescue I-outcome ['Physiological-Clinical']
antiemetic I-outcome ['Physiological-Clinical']
, O
during O
the O
first O
3 O
h O
( O
0-3 O
h O
) O
after O
anesthesia B-outcome ['Resource-use']
was O
87 O
% O
with O
granisetron O
and O
78 O
% O
with O
perphenazine O
( O
P O
= O
0.204 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

METHODS O
We O
investigated O
the O
impact O
of O
dose O
and O
duration O
of O
parenteral O
amino O
acids O
, O
with O
cysteine O
, O
on O
acid-base O
parameters O
in O
122 O
low-birth-weight O
infants O
. O
[]

CONCLUSION O
AND O
CLINICAL O
RELEVANCE O
When O
methadone O
was O
administered O
by O
the O
SC O
route O
, O
the O
half-life O
was O
longer O
, O
but O
the O
individual O
variation O
in O
[]

Blood O
samples O
were O
obtained O
from O
the O
antecubital O
vein O
before O
each O
exercise O
test, O
1 O
min O
after O
completing O
the O
test, O
and O
after O
a O
24-h O
recovery. O
[]

1 O
, O
2 O
and O
Table O
2 O
) O
. O
( O
[]

Overall O
survival B-outcome ['Mortality']
was O
similar O
( O
21 O
and O
22 O
months O
for O
PLD O
and O
doxorubicin O
, O
respectively O
; O
HR=0.94 O
; O
95 O
% O
CI O
0.74-1.19 O
) O
. O
['Mortality']

PATIENTS O
AND O
METHODS O
Study O
group O
consisted O
of O
56,653 O
screened O
men O
in O
the O
ERSPC O
centres O
of O
Finland O
, O
Italy O
, O
Netherlands O
, O
Sweden O
and O
Switzerland O
, O
who O
underwent O
3-7 O
screening O
rounds O
at O
2-4 O
year O
interval O
. O
[]

In O
group O
2 O
, O
37 O
embryo O
transfers O
resulted O
in O
eight O
implantations B-outcome ['Physiological-Clinical']
( O
21.6 O
% O
) O
. O
['Physiological-Clinical']

Process O
evaluation O
of O
Healthy O
Bodies O
, O
Healthy O
Souls O
: O
a O
church-based O
health O
intervention O
program O
in O
Baltimore O
City O
. O
[]

DESIGN O
Randomized O
controlled O
trial O
. O
[]

Most O
effective O
regimen O
of O
tranexamic O
acid O
in O
knee O
arthroplasty O
: O
a O
prospective O
randomized O
controlled O
study O
in O
240 O
patients O
. O
[]

Plasma O
PCSK9 O
levels O
were O
higher O
in O
double-dose O
statin O
than O
in O
ezetimibe-plus-statin O
at O
12 O
weeks O
, O
but O
similar O
at O
52 O
weeks O
. O
[]

Patients O
were O
randomized O
to O
receive O
MF-DPI O
400 O
microg O
once-daily O
in O
the O
evening O
or O
MF-DPI O
200 O
microg O
twice-daily O
. O
[]

Initial O
studies O
have O
demonstrated O
that O
persons O
performing O
Nordic O
Walking O
are O
able O
to O
exercise O
longer O
and O
harder O
compared O
to O
normal O
walking O
thereby O
increasing O
their O
cardiovascular O
metabolism O
. O
[]

After O
that O
the O
total O
daily O
doses O
was O
adjusted O
to O
240 O
mg O
and O
160 O
mg O
, O
respectively O
, O
until O
the O
7th O
day O
. O
[]

Clinical O
reactions O
and O
neutralizing O
antibody O
responses O
to O
six O
pre-exposure O
regimens O
of O
purified O
chick O
embryo O
cell O
culture O
rabies O
vaccine O
( O
PCECV O
) O
and O
human O
diploid O
cell O
strain O
rabies O
vaccine O
( O
HDCSV O
) O
were O
studied O
in O
177 O
volunteers O
. O
[]

The O
intervention O
group O
received O
family O
education O
, O
and O
data O
on O
their O
knowledge O
about O
schizophrenia B-outcome ['Life-Impact']
, O
symptoms B-outcome ['Life-Impact']
, O
functioning B-outcome ['Life-Impact']
, O
psychosocial B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
, O
relapse B-outcome ['Life-Impact']
and O
medication B-outcome ['Life-Impact']
adherence I-outcome ['Life-Impact']
were O
collected O
and O
compared O
with O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

We O
analysed O
event-free B-outcome ['Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
on O
an O
intention-to-treat O
basis O
. O
['Mortality', 'Mortality']

RESULTS O
From O
May O
1989 O
through O
March O
1993 O
, O
171 O
patients O
were O
randomized O
( O
84 O
to O
VP O
and O
87 O
to O
VIP O
) O
. O
[]

4 O
months O
after O
the O
end O
of O
treatment O
a O
standardised O
examination O
was O
done O
. O
[]

A O
total O
of O
269 O
patients O
, O
who O
presented O
with O
symptoms O
and O
electrocardiographic O
signs O
suggesting O
acute O
myocardial O
infarction O
were O
randomized O
to O
acute O
intravenous O
and O
subsequent O
oral O
therapy O
with O
propranolol O
( O
n O
= O
134 O
) O
or O
placebo O
( O
n O
= O
135 O
) O
. O
[]

RESULTS O
The O
characteristics O
of O
the O
population O
studied O
were O
similar O
to O
those O
reported O
in O
previous O
trials O
of O
beta-blockers O
. O
[]

2 O
. O
[]

Randomly O
selected O
households O
( O
N O
= O
452 O
) O
were O
divided O
into O
three O
interventions O
implemented O
by O
community O
workers O
: O
1 O
) O
fee-based O
As O
testing O
with O
household O
education O
( O
HE O
) O
; O
2 O
) O
fee-based O
As O
testing O
with O
household O
education O
and O
a O
local O
media O
campaign O
( O
HELM O
) O
; O
and O
3 O
) O
fee-based O
As O
testing O
alone O
( O
Control O
) O
. O
[]

All O
six O
with O
no O
difference O
received O
aspirin O
plus O
omeprazole O
in O
the O
first O
treatment O
period O
. O
[]

Both O
the O
drug O
and O
the O
transdermal O
system O
were O
generally O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
under O
the O
study O
conditions O
. O
['Life-Impact']

However O
, O
this O
finding O
must O
be O
interpreted O
with O
caution O
, O
since O
it O
is O
a O
secondary O
end O
point O
and O
was O
found O
only O
after O
multiple O
analyses O
of O
the O
data O
. O
[]

RESULTS O
The O
average O
ridge B-outcome ['Physiological-Clinical']
width I-outcome ['Physiological-Clinical']
decreased O
by O
0.50 O
mm O
for O
both O
groups O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
counselor O
enhancement O
produced O
increased O
cessation B-outcome ['Life-Impact']
at O
12 O
months O
but O
not O
at O
18 O
months O
. O
['Life-Impact']

The O
probability O
of O
patients O
remaining O
in O
the O
study O
over O
time O
without O
developing O
signs O
of O
exacerbating B-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
fluticasone O
propionate O
groups O
than O
in O
the O
placebo O
group O
( O
P O
= O
.001 O
) O
. O
['Physiological-Clinical']

Treatment O
of O
bladder O
cancer O
with O
intravesical O
instillation O
of O
adriamycin O
. O
[]

[ O
Pilot O
results O
of O
using O
tamsulone-FS O
in O
patients O
with O
prostatic O
adenoma O
according O
to O
the O
results O
of O
a O
randomized O
multicenter O
comparative O
trial O
] O
. O
[]

BACKGROUND O
Although O
collaborative O
care O
is O
effective O
for O
treating O
depression O
and O
other O
mental O
disorders O
in O
primary O
care O
, O
there O
have O
been O
no O
randomized O
trials O
of O
collaborative O
care O
specifically O
for O
patients O
with O
Posttraumatic O
stress O
disorder O
( O
PTSD O
) O
. O
[]

Oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
, O
antioxidant B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
muscle B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
were O
assessed O
at O
baseline O
and O
after O
30 O
days O
of O
chocolate O
intake. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Total O
anthelmintic O
failure O
to O
control O
nematode O
parasites O
of O
small O
ruminants O
on O
government O
breeding O
farms O
in O
Sabah O
, O
East O
Malaysia O
. O
[]

Skeletal O
muscle O
total O
creatine O
content O
and O
creatine O
transporter O
gene O
expression O
in O
vegetarians O
prior O
to O
and O
following O
creatine O
supplementation O
. O
[]

Is O
a O
2-week O
duration O
sufficient O
for O
stenting O
in O
endopyelotomy O
? O
[]

BACKGROUND O
Pruritus O
in O
HIV-1+ O
patients O
is O
common O
and O
increases O
with O
disease O
progression O
. O
[]

Twenty-one O
attention O
deficit O
disorder O
with O
hyperactivity O
and O
seven O
autistic O
children O
were O
randomly O
exposed O
to O
negatively O
ionized O
and O
ambient O
atmospheres O
under O
rigorously O
controlled O
experimental O
conditions O
. O
[]

Conclusion O
Intra-articular O
injection O
of O
Triamcinolone O
acetenoid O
is O
effective O
in O
symptoms B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
and O
improving O
functional B-outcome ['Life-Impact']
outcome O
in O
clinically O
diagnosed O
osteoarthritis O
of O
knees O
in O
community O
set O
up O
during O
health O
camps. O
[['Physiological-Clinical'], ['Life-Impact']]

After O
intravenous O
dosing O
, O
C O
( O
max O
) O
and O
T O
( O
max O
) O
were O
4.53 O
? O
[]

INTERVENTIONS O
IP O
was O
induced O
by O
occluding O
the O
LAD O
twice O
for O
a O
2-min O
period O
followed O
by O
3-min O
LAD O
reperfusion O
before O
bypass O
grafting O
of O
the O
first O
coronary O
vessel O
. O
[]

Durability B-outcome ['Life-Impact']
of O
central O
venous O
catheters O
. O
['Life-Impact']

Disopyramide-pyridostigmine O
interaction O
: O
selective O
reversal O
of O
anticholinergic O
symptoms O
with O
preservation O
of O
antiarrhythmic O
effect O
. O
[]

To O
detect O
trends O
in O
confidence O
, O
confidence O
scores O
were O
plotted O
over O
time O
, O
and O
multiple O
linear O
regression O
analysis O
was O
performed O
. O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

In O
these O
patients O
DBP B-outcome ['Physiological-Clinical']
decreased O
throughout O
the O
following O
eight O
weeks O
. O
['Physiological-Clinical']

Effectiveness O
of O
norgestimate O
and O
ethinyl O
estradiol O
in O
treating O
moderate O
acne O
vulgaris O
. O
[]

RESULTS: O
In O
the O
LASIK O
group, O
central B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increased O
from O
52.38 O
+/- O
2.57 O
mum O
to O
57.00 O
+/- O
4.23 O
mum O
and O
remained O
almost O
stable O
at O
this O
level O
for O
up O
to O
24 O
months. O
[['Physiological-Clinical']]

Title: O
Repeated O
doses O
of O
Praziquantel O
in O
Schistosomiasis O
Treatment O
(RePST) O
- O
single O
versus O
multiple O
praziquantel O
treatments O
in O
school-aged O
children O
in O
Cote O
d'Ivoire: O
a O
study O
protocol O
for O
an O
open-label, O
randomised O
controlled O
trial. O
[]

The O
results O
show O
that O
4 O
months O
after O
treatment O
, O
the O
intensive O
multidisciplinary O
program O
is O
superior O
to O
the O
less O
intensive O
programs O
in O
terms O
of O
return-to-work O
rate O
, O
health-care O
contacts O
, O
pain O
and O
disability O
scores O
, O
and O
staying O
physically O
active O
. O
( O
[]

Mean O
pupil B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
in O
group O
0 O
was O
8.57 O
and O
8.73 O
in O
group O
1 O
. O
['Physiological-Clinical']

All O
patients O
were O
followed O
up O
for O
24 O
months O
. O
[]

Publication O
date: O
2018/12/12 O
00:00 O
[accepted] O
[]

Title: O
Citrus O
Aurantium O
and O
caffeine O
complex O
versus O
placebo O
on O
biomarkers O
of O
metabolism B-outcome ['Physiological-Clinical']
: O
a O
double O
blind O
crossover O
design. O
[['Physiological-Clinical']]

Clinical O
and O
endoscopic O
controls O
were O
performed O
4 O
, O
6 O
and O
8 O
weeks O
after O
the O
onset O
of O
the O
treatment O
. O
[]

METHOD O
Sixteen O
dyads O
( O
preschoolers O
with O
ASD O
and O
the O
public O
school O
teachers O
who O
worked O
in O
the O
child O
's O
classroom O
) O
were O
randomly O
assigned O
to O
the O
6-week O
JASP/ER O
intervention O
or O
a O
control O
group O
. O
[]

In O
the O
pindolol O
monotherapy O
group O
, O
a O
significant O
reduction O
of O
triglycerides B-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.01 O
) O
and O
a O
significant O
increase O
of O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( O
p O
less O
than O
0.05 O
) O
were O
recorded O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE: O
Compare O
the O
outcome O
of O
spinal B-outcome ['Physiological-Clinical']
deformity I-outcome ['Physiological-Clinical']
correction I-outcome ['Physiological-Clinical']
between O
Ti-Ti O
and O
CrCo-Ti O
rods O
for O
the O
treatment O
of O
spinal O
Adolescent O
Idiopathic O
Scoliosis O
(AIS) O
using O
rods O
mentioned O
with O
all O
pedicle O
screws O
and O
translation O
technique. O
[['Physiological-Clinical']]

Students O
in O
an O
equal O
sign O
group O
learned O
about O
the O
equal O
sign O
only O
. O
[]

Compared O
with O
ASC O
alone O
, O
we O
noted O
a O
small O
, O
non-significant O
survival B-outcome ['Mortality']
benefit O
for O
ASC O
plus O
chemotherapy O
( O
hazard O
ratio O
[ O
HR O
] O
0.89 O
[ O
95 O
% O
CI O
0.72-1.10 O
] O
; O
p=0.29 O
) O
. O
['Mortality']

BMI O
explained O
27 O
% O
of O
inter-individual O
butyrate O
variation O
, O
whereas O
protein O
, O
starch O
, O
carbohydrate O
, O
fiber O
, O
and O
fat O
intake O
explained O
up O
to O
16 O
, O
6 O
, O
2 O
, O
4 O
, O
and O
2 O
% O
of O
butyrate O
variation O
, O
respectively O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
ST I-outcome ['Physiological-Clinical']
segment B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
increased O
to O
341 O
+/- O
148 O
from O
296 O
+/- O
154 O
seconds O
( O
p O
= O
0.005 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
significant O
differences O
favoring O
acetaminophen O
vs O
placebo O
for O
3 O
prespecified O
secondary O
outcomes: O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
duration I-outcome ['Physiological-Clinical', 'Life-Impact']
(median, O
1 O
vs O
2 O
days; O
difference, O
-1 O
[95% O
CI, O
-2 O
to O
0]), O
ICU B-outcome ['Resource-use']
length I-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
(median, O
29.5 O
vs O
46.7 O
hours; O
difference, O
-16.7 O
[95% O
CI, O
-20.3 O
to O
-0.8]), O
and O
breakthrough O
analgesia B-outcome ['Resource-use']
(median, O
322.5 O
vs O
405.3 O
microg O
morphine O
equivalents; O
difference, O
-83 O
[95% O
CI, O
-154 O
to O
-14]). O
[['Physiological-Clinical', 'Life-Impact'], ['Resource-use'], ['Resource-use']]

Treatment O
of O
children O
with O
autism O
: O
a O
randomized O
controlled O
trial O
to O
evaluate O
a O
caregiver-based O
intervention O
program O
in O
community O
day-care O
centers O
. O
[]

BACKGROUND: O
Observational O
data O
have O
shown O
that O
slow O
advancement O
of O
enteral O
feeding O
volumes O
in O
preterm O
infants O
is O
associated O
with O
a O
reduced O
risk O
of O
necrotizing O
enterocolitis O
but O
an O
increased O
risk O
of O
late-onset O
sepsis. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
Bispectral I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
(BIS) I-outcome ['Physiological-Clinical']
60 I-outcome ['Physiological-Clinical']
and O
rocuronium B-outcome ['Life-Impact']
onset I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
were O
longer O
in O
the O
Group O
R O
(P O
< O
.01 O
and O
P O
< O
.01, O
respectively). O
[['Physiological-Clinical'], ['Life-Impact']]

Speech O
audiometry O
was O
performed O
under O
four O
different O
conditions O
: O
headset O
only O
, O
and O
three O
different O
ear O
plugs O
worn O
under O
the O
headset O
. O
[]

However O
, O
substantial O
residual O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
drinking B-outcome ['Life-Impact']
persisted O
at O
the O
end O
of O
the O
trial O
. O
['Life-Impact']

The O
changes O
in O
RBC B-outcome ['Physiological-Clinical']
EPA I-outcome ['Physiological-Clinical']
content I-outcome ['Physiological-Clinical']
were O
inversely O
correlated O
with O
the O
changes O
in O
SBP B-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
and O
directly O
correlated O
with O
the O
increases O
in O
HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
non-HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
pilot O
study O
attempted O
to O
make O
a O
comparison O
between O
the O
human O
radius O
and O
the O
sheep O
tibia O
for O
experimental O
purposes O
. O
[]

In O
total, O
27 O
participants, O
inexperienced O
in O
spinal O
ultrasonography, O
were O
enrolled O
and O
allocated O
to O
1 O
of O
2 O
groups O
(training O
group, O
n O
= O
18; O
control O
group, O
n O
= O
9). O
[]

The O
lead O
system O
evaluated O
was O
a O
dual-coil O
transvenous O
defibrillation O
lead O
with O
a O
left O
pectoral O
pulse O
generator O
emulator O
. O
[]

Effects O
of O
formoterol O
, O
salmeterol O
or O
oxitropium O
bromide O
on O
airway B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
salbutamol I-outcome ['Physiological-Clinical']
in O
COPD O
. O
['Physiological-Clinical']

Direct O
comparison O
between O
both O
interventions O
revealed O
that O
the O
reduction O
in O
subcutaneous B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
was O
statistically O
significantly O
larger O
in O
the O
group O
that O
combined O
exercise O
with O
diet: O
an O
additional O
10.6 O
cm(2) O
(95%CI O
-18.7; O
- O
2.4) O
was O
lost O
compared O
to O
the O
diet-only O
group. O
[['Physiological-Clinical']]

Repeated-measures O
analysis O
of O
variance O
was O
used O
to O
evaluate O
treatment O
and O
time O
effects O
on O
mood O
and O
quality O
of O
life O
. O
[]

Imitation O
is O
an O
early O
skill O
thought O
to O
play O
a O
role O
in O
social O
development O
, O
leading O
some O
to O
suggest O
that O
teaching O
imitation O
to O
children O
with O
autism O
should O
lead O
to O
improvements O
in O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact']

The O
correlations O
remained O
when O
the O
data O
set O
was O
limited O
to O
patients O
with O
TSH O
in O
the O
range O
0.3-4.0 O
mIU/liter O
. O
[]

The O
two O
preparations O
were O
considered O
bioequivalent O
if O
the O
90 O
% O
confidence O
intervals O
for O
the O
ratio O
of O
geometric B-outcome ['Physiological-Clinical']
means O
['Physiological-Clinical']

In O
the O
H. O
pylori-infected O
group O
, O
increase O
in O
GA B-outcome ['Physiological-Clinical']
was O
seen O
in O
the O
corpus O
( O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

VARIABLES O
Pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
, O
numbers O
of O
other O
symptoms B-outcome ['Physiological-Clinical']
, O
and O
physical B-outcome ['Life-Impact']
role I-outcome ['Life-Impact']
impact I-outcome ['Life-Impact']
and O
social-functioning B-outcome ['Life-Impact']
subscales O
from O
the O
Medical O
Outcomes O
Study O
36 O
Short O
Form O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

METHODS O
A O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
on O
26 O
asthma O
patients O
who O
randomly O
received O
vaccination O
or O
placebo O
for O
1 O
year O
. O
[]

Of O
the O
patients O
treated O
with O
photons O
45.7 O
% O
had O
severe O
reactions B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
compared O
with O
10.6 O
% O
after O
neutron O
therapy O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

Signal-averaged B-outcome ['Physiological-Clinical']
electrocardiograms I-outcome ['Physiological-Clinical']
were O
recorded O
in O
a O
subgroup O
of O
24 O
patients O
. O
['Physiological-Clinical']

The O
causes O
of O
pruritus O
are O
numerous O
including O
xerosis O
, O
drug O
and O
photoeruptions O
, O
follicular O
and O
papular O
eruptions O
as O
well O
as O
infestations O
and O
infections O
by O
a O
wide O
range O
of O
organisms O
. O
[]

In O
each O
school O
one O
class O
was O
randomly O
assigned O
as O
the O
intervention O
group O
and O
another O
as O
controls O
. O
[]

AIM: O
To O
assess O
the O
effectiveness O
of O
a O
self-administered O
rehabilitation O
program O
in O
adults O
with O
shoulder O
pain O
syndrome O
in O
primary O
care. O
[]

Twelve O
(9.5%) O
and O
10 O
(7.9%) O
subjects O
experienced O
>30% O
endothelial B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
loss O
(ECL) O
at O
12 O
and O
24 O
months, O
respectively. O
[['Physiological-Clinical']]

Eleven O
of O
60 O
( O
18.3 O
% O
) O
patients O
in O
the O
prophylactic O
epidural O
blood O
patch O
group O
developed O
a O
post-dural B-outcome ['Physiological-Clinical']
puncture I-outcome ['Physiological-Clinical']
headache I-outcome ['Physiological-Clinical']
compared O
with O
39 O
of O
49 O
( O
79.6 O
% O
) O
in O
the O
therapeutic O
epidural O
blood O
patch O
group O
( O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

To O
re-evaluate O
the O
effect O
of O
metformin O
on O
fasting O
triglyceride O
concentration O
and O
on O
blood O
pressure O
, O
the O
BIGPRO O
1.2 O
trial O
included O
non-diabetic O
men O
( O
n=168 O
) O
with O
a O
fasting O
plasma O
triglyceride O
concentration O
> O
or O
=1.7 O
and O
< O
or O
=6.5 O
mmol/l O
, O
high O
blood O
pressure O
( O
systolic O
> O
or O
=140 O
and O
< O
or O
=180 O
and/or O
diastolic O
> O
or O
=90 O
and O
< O
or O
=105 O
mmHg O
, O
or O
treatment O
for O
hypertension O
) O
and O
a O
waist-to-hip O
ratio O
> O
or O
=0.95 O
. O
[]

A O
randomised O
group O
comparison O
controlled O
trial O
of O
'preschoolers O
with O
autism O
' O
: O
a O
parent O
education O
and O
skills O
training O
intervention O
for O
young O
children O
with O
autistic O
disorder O
. O
[]

Additionally O
, O
knee-specific B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
and O
functional B-outcome ['Life-Impact']
limitations I-outcome ['Life-Impact']
were O
assessed O
using O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
( O
WOMAC O
) O
and O
the O
Activities O
of O
Daily O
Living O
Scale O
( O
ADLS O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Group O
TF O
( O
48 O
infants O
) O
received O
trophic O
feeding O
from O
day O
3 O
( O
0.5-1 O
ml/h O
) O
along O
with O
parenteral O
nutrition O
until O
ventilatory O
support O
finished O
. O
[]

These O
results O
support O
recent O
approaches O
to O
apply O
OT O
as O
a O
pharmacological O
treatment O
of O
ASD O
symptoms O
. O
[]

Twenty-four O
NC O
smokers O
and O
20 O
smokers O
with O
SZ O
matched O
on O
nicotine O
addiction O
severity O
participated O
in O
a O
resting O
state O
fMRI O
study O
and O
were O
scanned O
during O
two O
separate O
sessions O
while O
receiving O
a O
placebo O
or O
nicotine O
patch O
, O
in O
a O
randomized O
, O
cross-over O
design O
. O
[]

Matched-pair O
analysis O
of O
all-polyethylene O
versus O
metal-backed O
tibial O
components O
. O
[]

Pantoprazole O
did O
not O
influence O
the O
characteristic O
ECG O
modifications O
( O
T-wave O
) O
caused O
by O
digoxin O
. O
[]

BACKGROUND O
AND O
PURPOSE O
Elevated O
serum O
uric O
acid O
level O
is O
associated O
with O
poor O
outcome O
and O
increased O
risk O
of O
recurrent O
events O
after O
stroke O
. O
[]

However O
, O
there O
was O
a O
significantly O
higher O
incidence O
of O
varus O
angulation O
by O
10 O
degrees O
or O
more O
by O
the O
completion O
of O
healing O
among O
fractures O
treated O
with O
the O
sliding O
hip O
screw O
( O
p O
= O
0.04 O
) O
. O
[]

Median O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
PFS B-outcome ['Physiological-Clinical']
, O
months O
) O
was O
similar O
in O
both O
treatment O
arms O
( O
pemetrexed-cisplatin O
, O
3.6 O
; O
placebo-cisplatin O
, O
2.8 O
; O
HR O
, O
0.88 O
; O
95 O
% O
CI O
, O
0.76-1.03 O
; O
P O
= O
.166 O
) O
. O
['Mortality', 'Physiological-Clinical']

In O
123 O
patients O
( O
per O
protocol O
set O
) O
, O
those O
remaining O
free O
from O
PAF/PAFL B-outcome ['Physiological-Clinical']
after O
the O
treatment O
were O
3.1 O
% O
on O
placebo O
, O
7.7 O
% O
on O
25 O
mg/BID O
, O
9.4 O
% O
on O
50 O
mg/BID O
, O
and O
39.4 O
% O
on O
100 O
mg/BID O
of O
flecainide O
. O
['Physiological-Clinical']

Twenty-eight O
nurses O
participated O
in O
the O
study O
, O
9 O
first-generation O
and O
19 O
second-generation O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

A O
decrease O
in O
collagen-induced B-outcome ['Physiological-Clinical']
aggregation I-outcome ['Physiological-Clinical']
by O
using O
washed O
platelet O
suspensions O
was O
found O
in O
both O
groups O
after O
nutritional O
supplementation O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
determine O
the O
level O
of O
occupational O
exposure O
to O
anesthetic O
gases O
in O
the O
absence O
of O
an O
extractor O
during O
pediatric O
anesthesia O
and O
to O
assess O
the O
efficacy O
of O
a O
purpose-built O
extraction O
system O
. O
[]

CONCLUSIONS O
The O
sample O
of O
children O
with O
AS O
in O
this O
study O
presented O
with O
a O
profile O
of O
anxiety O
similar O
to O
a O
sample O
of O
clinically O
diagnosed O
anxious O
children O
. O
[]

Hematopoietic O
progenitors O
collected O
during O
each O
cycle O
were O
reinfused O
on O
day O
3 O
of O
the O
next O
cycle O
. O
[]

Proportions O
of O
all O
TLV O
categories O
were O
higher O
in O
the O
CRM-training O
group O
( O
p O
< O
0.001 O
) O
. O
[]

After O
6 O
months, O
RA B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
RV B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
area E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
RV B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
tricuspid I-outcome ['Physiological-Clinical']
regurgitation I-outcome ['Physiological-Clinical']
velocity I-outcome ['Physiological-Clinical']
showed O
a O
significant O
reduction. O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Two O
groups O
of O
patients O
were O
randomly O
categorized O
according O
to O
the O
route O
of O
administration O
of O
scorpion O
antivenom; O
intramuscular O
and O
intravenous O
with O
50 O
patients O
in O
each O
group. O
[]

The O
extent O
of O
defects B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
MCE I-outcome ['Physiological-Clinical']
was O
less O
than O
the O
extent O
of O
either O
abnormal O
wall O
motion O
or O
SPECT O
abnormalities O
. O
['Physiological-Clinical']

Major B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
occurred O
in O
3/75 O
( O
4 O
% O
) O
patients O
of O
the O
V O
group O
and O
in O
1/75 O
( O
1.3 O
% O
) O
patient O
of O
the O
H O
group O
( O
p O
< O
0.05 O
) O
. O
['Adverse-effects']

Duration O
of O
effect O
was O
dose O
dependent O
. O
[]

Results O
showed O
a O
significant O
reduction O
in O
depression B-outcome ['Life-Impact']
, O
anxiety B-outcome ['Life-Impact']
and O
rumination B-outcome ['Life-Impact']
in O
the O
intervention O
group O
, O
as O
opposed O
to O
the O
control O
group O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Radioiodine O
WBS O
and O
serum O
Tg O
measurements O
were O
performed O
after O
administration O
of O
recombinant O
human O
TSH O
and O
again O
after O
thyroid O
hormone O
withdrawal O
in O
each O
patient O
. O
[]

The O
participants O
also O
performed O
a O
visual O
task O
, O
in O
which O
they O
rated O
the O
intensity O
of O
pleasure B-outcome ['Life-Impact']
they O
experienced O
in O
response O
to O
emotionally B-outcome ['Life-Impact']
positive O
and O
neutral B-outcome ['Life-Impact']
pictures I-outcome ['Life-Impact']
differing O
in O
luminance B-outcome ['Physiological-Clinical']
contrast I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
Previously O
, O
we O
showed O
that O
acute O
respiratory O
distress O
syndrome O
patients O
fed O
an O
enteral O
diet O
containing O
eicosapentaenoic O
acid O
and O
gamma-linolenic O
acid O
and O
elevated O
antioxidants O
( O
EPA+GLA O
; O
Oxepa O
) O
had O
significantly O
reduced O
pulmonary O
inflammation O
, O
increased O
oxygenation O
, O
and O
improved O
clinical O
outcomes O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
if O
tHcy O
lowering O
vitamins O
decrease O
the O
circulating O
levels O
of O
A-beta O
protein O
1-40 O
( O
A O
beta O
40 O
) O
. O
[]

The O
RCT O
evaluated O
the O
effects O
of O
the O
parent-delivered O
component O
of O
the O
intervention O
. O
[]

For O
histological O
grade O
, O
there O
was O
no O
obvious O
difference O
in O
treatment O
response O
between O
the O
groups O
. O
[]

CONTEXT O
The O
Diabetic O
Control O
and O
Complications O
Trial O
( O
DCCT O
) O
researchers O
kept O
careful O
records O
of O
the O
food O
consumption O
and O
tobacco O
using O
habits O
of O
type O
1 O
diabetic O
subjects O
. O
[]

METHODS: O
The O
study O
generated O
five O
data O
sets. O
[]

Children O
with O
autistic O
spectrum O
disorders O
. O
[]

CONCLUSION O
These O
results O
suggest O
that O
an O
acute O
bout O
( O
4 O
min O
) O
of O
static O
stretching O
of O
the O
lower O
limbs O
during O
recovery O
periods O
between O
efforts O
may O
compromise O
RSA B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
but O
has O
less O
effect O
on O
CODS O
performance O
. O
['Physiological-Clinical']

A O
randomized O
, O
open-label O
, O
multicenter O
study O
was O
undertaken O
to O
compare O
the O
effects O
of O
oral O
contraceptives O
( O
OC O
) O
containing O
100 O
micrograms O
levonorgestrel O
( O
LNG O
) O
/20 O
micrograms O
ethinyl O
estradiol O
( O
EE O
) O
( O
Aless/Loette O
) O
and O
1000 O
micrograms O
norethindrone O
acetate O
( O
NETA O
) O
/20 O
micrograms O
EE O
( O
Loestrin O
Fe O
1/20 O
) O
on O
menstrual O
cycle O
control O
over O
four O
cycles O
of O
use O
. O
[]

No O
significant O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
any O
patient O
. O
['Adverse-effects']

We O
have O
compared O
the O
efficacy O
of O
0.25 O
% O
S O
( O
- O
) O
-bupivacaine O
with O
0.25 O
% O
RS-bupivacaine O
in O
providing O
epidural B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
for O
labour O
in O
a O
randomized O
, O
multicentre O
, O
double-blind O
study O
. O
['Resource-use']

Forty-three O
subjects O
were O
randomized O
to O
one O
of O
three O
groups O
( O
proximal O
tibiofibular O
manipulation O
, O
distal O
tibiofibular O
manipulation O
, O
or O
control O
) O
. O
[]

The O
primary O
end O
point O
was O
the O
proportion O
of O
vaccine B-outcome ['Resource-use']
high O
responders O
at O
9 O
months O
, O
defined O
as O
a O
2-fold O
increase O
in O
IgG O
levels O
to O
> O
or O
= O
1 O
microg/mL O
for O
at O
least O
5 O
of O
7 O
of O
the O
7vPnC O
serotypes O
. O
['Resource-use']

Participants O
in O
the O
patient O
preference O
group O
achieved O
marginally O
better O
outcomes O
than O
those O
randomised O
to O
a O
treatment O
group O
, O
but O
the O
clinical O
significance O
of O
these O
differences O
is O
unclear O
. O
[]

Analysis O
of O
prevention O
program O
effectiveness O
with O
clustered O
data O
using O
generalized O
estimating O
equations O
. O
[]

Simultaneously O
there O
was O
a O
significant O
( O
P O
< O
0.001 O
) O
increase O
in O
glutathione B-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
and O
total O
antioxidant B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
and O
significant O
decrease O
( O
P O
< O
0.05 O
) O
in O
malondialdehyde B-outcome ['Physiological-Clinical']
and O
glutathion B-outcome ['Physiological-Clinical']
reductase I-outcome ['Physiological-Clinical']
levels O
in O
the O
serum O
of O
patients O
treated O
with O
chemotherapy O
compared O
to O
the O
patients O
treated O
with O
radiotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Title: O
Intrathecal O
dexmedetomidine O
can O
decrease O
the O
95% O
effective O
dose O
of O
bupivacaine O
in O
spinal O
anesthesia O
for O
cesarean O
section: O
A O
prospective, O
double-blinded, O
randomized O
study. O
[]

The O
primary O
end O
point O
was O
the O
frequency O
of O
residual O
tumor O
. O
[]

Tailored O
group O
participants O
demonstrated O
significantly O
greater O
positive O
changes O
in O
prevention B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
after O
the O
intervention O
, O
including O
['Life-Impact']

Drug O
therapy O
of O
ventricular O
tachycardia O
: O
a O
cost O
comparison O
of O
randomized O
noninvasive O
and O
invasive O
approaches O
. O
[]

Metronidazole O
is O
particularly O
effective O
in O
vitro O
against O
spirochetes O
, O
and O
this O
efficacy O
was O
investigated O
as O
a O
means O
of O
measuring O
patient O
compliance O
with O
metronidazole O
usage O
. O
[]

In O
3 O
out O
of O
8 O
patients O
who O
underwent O
a O
further O
bronchoscopy B-outcome ['Physiological-Clinical']
after O
18 O
months O
of O
treatment O
, O
disappearance O
of O
nodules B-outcome ['Physiological-Clinical']
was O
noted O
at O
the O
later O
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
The O
r-HuEPO O
dose O
of O
400 O
U/kg O
appears O
significantly O
more O
effective O
than O
the O
200 O
U/kg O
to O
stimulate O
erythropoiesis O
in O
anemic O
sideropenic O
cancer O
patients O
. O
[]

Tetrahydrobiopterin O
in O
the O
treatment O
of O
children O
with O
autistic O
disorder O
: O
a O
double-blind O
placebo-controlled O
crossover O
study O
. O
[]

Metoclopramide O
increased O
LOSP B-outcome ['Physiological-Clinical']
significantly O
at O
3 O
min O
after O
administration O
i.v O
. O
( O
['Physiological-Clinical']

There O
was O
some O
evidence O
of O
therapeutic O
carry-over O
effects O
in O
both O
clinical O
and O
biochemical O
measures O
in O
those O
children O
who O
received O
NTX O
before O
PLC O
. O
[]

Cellular O
markers O
were O
chosen O
to O
assess O
general B-outcome ['Physiological-Clinical']
pediatric I-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
emphasizing B-outcome ['Physiological-Clinical']
maturation I-outcome ['Physiological-Clinical']
and O
activation O
of O
B O
, O
T B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
median O
number O
of O
aflibercept B-outcome ['Physiological-Clinical']
cycles I-outcome ['Physiological-Clinical']
was O
16 O
( O
range O
1-44 O
) O
, O
12 O
patients O
received O
?20 O
cycles O
. O
['Physiological-Clinical']

Indoor O
exposure O
to O
asthma O
triggers O
has O
emerged O
as O
an O
important O
cause O
of O
asthma O
exacerbations O
. O
[]

No O
statistical O
differences O
were O
seen O
in O
the O
demographic O
and O
baseline O
data O
among O
both O
groups O
. O
[]

A O
generalized B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
intense I-outcome ['Physiological-Clinical']
erythema I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
cervix I-outcome ['Physiological-Clinical']
was O
observed O
in O
10 O
of O
12 O
Acidform/N-9 O
users O
and O
abrasion O
occurred O
in O
nine O
of O
them O
. O
['Physiological-Clinical']

Efficacy O
and O
safety O
of O
recombinant O
human O
nerve O
growth O
factor O
in O
patients O
with O
diabetic O
polyneuropathy O
: O
A O
randomized O
controlled O
trial O
. O
[]

This O
group O
was O
randomly O
subdivided O
into O
3 O
groups O
: O
1 O
) O
Intradermal O
group O
( O
ID O
Group O
) O
, O
42 O
patients O
given O
an O
intradermal O
injections O
of O
OK-432 O
. O
[]

Right O
colon O
adenomas O
were O
missed O
more O
often O
( O
27 O
% O
) O
than O
left O
colon O
adenomas O
( O
21 O
% O
) O
, O
but O
the O
difference O
was O
not O
significant O
. O
[]

All O
patients O
received O
methylprednisolon O
for O
14 O
days O
, O
thereafter O
a O
double-blinded O
medication O
containing O
either O
placebo O
( O
n O
= O
56 O
) O
or O
methylprednisolon O
( O
n O
= O
54 O
) O
for O
6 O
months O
, O
which O
was O
completely O
stopped O
thereafter O
. O
[]

Small-diameter O
hysteroscopy O
with O
Versapoint O
versus O
resectoscopy O
with O
a O
unipolar O
knife O
for O
the O
treatment O
of O
septate O
uterus O
: O
a O
prospective O
randomized O
study O
. O
[]

Publication O
date: O
2019/01/22 O
06:00 O
[medline] O
[]

Dexamethasone O
for O
the O
treatment O
of O
depression O
: O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
trial O
. O
[]

Results O
of O
the O
two O
experiments O
suggest O
that O
manipulation B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
words I-outcome ['Life-Impact']
is O
retrieved O
without O
conscious O
effort O
and O
that O
manipulation B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
constitutes O
a O
part O
of O
the O
lexical-semantic O
representation O
of O
objects O
. O
['Life-Impact', 'Life-Impact']

By O
the O
evaluation O
of O
the O
individual O
data O
, O
it O
became O
apparent O
that O
, O
the O
pains B-outcome ['Physiological-Clinical']
increase O
with O
increasing O
gas O
consumption O
, O
a O
fact O
which O
led O
to O
assumption O
that O
the O
pains B-outcome ['Physiological-Clinical']
are O
caused O
by O
a O
physical O
effect O
such O
as O
the O
cooling O
of O
the O
peritoneum O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Homozygotic O
risk O
allele O
carriers O
showed O
slower O
reaction O
times O
( O
RT O
) O
and O
higher O
activation O
of O
left B-outcome ['Physiological-Clinical']
fusiform I-outcome ['Physiological-Clinical']
gyrus I-outcome ['Physiological-Clinical']
during O
visual O
processing O
of O
social B-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

The O
efficacy O
of O
early O
continuous O
positive O
airway O
pressure O
therapy O
in O
patients O
with O
acute O
cardiogenic O
pulmonary O
edema O
. O
[]

[ O
Clinical O
diagnosis O
of O
deep O
venous O
thrombosis O
after O
hip O
replacement O
surgery O
] O
. O
[]

Effective O
strategies O
included O
( O
a O
) O
the O
use O
of O
choral O
responding O
; O
( O
b O
) O
the O
use O
of O
student-to-student O
responding O
; O
( O
c O
) O
the O
rotation O
of O
materials O
every O
5 O
minutes O
during O
the O
30-minute O
group O
while O
teaching O
2 O
to O
3 O
concepts O
; O
and O
( O
d O
) O
the O
use O
of O
random O
, O
unpredictable O
trials O
for O
student O
responding O
. O
[]

Therefore O
, O
home O
visit O
education O
and O
invitation O
intervention O
produced O
only O
a O
nominal O
effect O
on O
increasing O
Pap O
smear O
coverage O
within O
a O
4-month O
study O
period O
. O
[]

Dietary B-outcome ['Life-Impact']
iron I-outcome ['Life-Impact']
exposures I-outcome ['Life-Impact']
were O
not O
associated O
with O
either O
subsite O
. O
['Life-Impact']

This O
randomized O
clinical O
trial O
included O
obese O
patients O
with O
ejection O
fractions O
< O
or O
=40 O
% O
. O
[]

This O
study O
details O
retrospective O
and O
prospective O
comparison O
of O
electrocautery O
division O
of O
the O
isthmus O
with O
older O
techniques O
. O
[]

CONCLUSIONS O
This O
study O
shows O
that O
ketorolac O
30 O
mg O
suppositories O
are O
effective O
in O
clinical O
conditions O
, O
such O
as O
after O
surgery O
, O
in O
which O
pain O
control O
must O
be O
achieved O
within O
the O
shortest O
time O
interval O
and O
maintained O
or O
improved O
by O
means O
of O
a O
single O
route O
of O
administration O
. O
[]

Adjusted O
mean O
differences O
between O
desvenlafaxine O
and O
placebo O
were O
2.1 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.78-3.46 O
; O
P O
= O
0.002 O
) O
on O
the O
HAM-D?? O
and O
1.3 O
( O
95 O
% O
CI O
, O
-0.09 O
to O
2.76 O
; O
P O
= O
0.067 O
) O
on O
the O
SDS O
. O
[]

RESULTS O
Difference O
between O
the O
two O
protocols O
was O
significant O
as O
the O
group O
that O
received O
topiramate O
had O
a O
greater O
reduction O
in O
ABC-C O
subscale O
scores O
for O
irritability O
, O
stereotypic B-outcome ['Physiological-Clinical']
behavior I-outcome ['Physiological-Clinical']
and O
hyperactivity/noncompliance B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

15 O
of O
29 O
patients O
rated O
themselves O
as O
better O
after O
completing O
exercise O
treatment O
compared O
with O
eight O
of O
30 O
patients O
who O
completed O
flexibility O
treatment O
. O
[]

Data O
were O
analysed O
using O
Systematic O
Text O
Condensation. O
[]

BMS-181101 O
was O
well O
tolerated B-outcome ['Life-Impact']
both O
with O
and O
without O
ingestion O
of O
food O
. O
['Life-Impact']

The O
participants O
were O
followed O
for O
a O
median O
of O
17.4 O
months O
. O
[]

The O
eye-lens O
dosemeters O
were O
placed O
near O
the O
eye O
closest O
to O
the O
radiation O
source O
(Carinou, O
E., O
Ferrari, O
P., O
Bjelac, O
O. O
C., O
Gingaume, O
M., O
Merce, O
M. O
S. O
and O
O'Connor, O
U. O
Eye O
lens O
monitoring O
for O
interventional O
radiology O
personnel: O
dosemeters, O
calibration O
and O
practical O
aspects O
of O
H O
p O
(3) O
monitoring. O
[]

No O
differences O
were O
found O
in O
side O
effects O
or O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
. O
['Life-Impact']

Two O
experiments O
investigated O
sensory/motor-based B-outcome ['Life-Impact']
functional I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
of O
man-made O
objects O
: O
manipulation O
features O
associated O
with O
the O
actual O
usage O
of O
objects O
. O
['Life-Impact']

21 O
out O
of O
30 O
patients O
( O
70 O
% O
) O
profited O
from O
such O
a O
treatment O
, O
showing O
a O
drop O
from O
5 O
-- O
30 O
attacks O
to O
0 O
-- O
1 O
attack B-outcome ['Physiological-Clinical']
per O
month O
and O
normalization O
of O
high B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
serotonin I-outcome ['Physiological-Clinical']
, O
5-HIAA B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
histamine I-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Median O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
times O
were O
60 O
weeks O
for O
PLD O
and O
56.7 O
weeks O
for O
topotecan O
. O
['Mortality']

The O
Pakistanis O
also O
had O
a O
lower O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
vitamin I-outcome ['Life-Impact']
D O
than O
that O
of O
the O
Norwegians O
( O
median O
2.2 O
vs O
3.3 O
micrograms/day O
, O
P O
< O
0.05 O
) O
, O
and O
a O
lower O
total O
intake O
, O
including O
supplements O
( O
median O
2.9 O
vs O
7.0 O
micrograms/day O
, O
P O
< O
0.001 O
) O
. O
['Life-Impact']

BACKGROUND O
AND O
AIM O
Endothelial O
dysfunction O
in O
hypertensive O
type-2 O
diabetic O
patients O
is O
associated O
with O
increased O
levels O
of O
circulating O
soluble B-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecules I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Mann-Whitney O
U-test O
was O
used O
to O
compare O
relative O
increase O
between O
the O
measured O
cardiac B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
for O
the O
two O
groups O
. O
['Physiological-Clinical']

Forty-three O
patients O
were O
selected O
for O
the O
experimental O
group O
, O
and O
31 O
control O
subjects O
used O
the O
sham O
instrument O
( O
placebo O
group O
) O
. O
[]

Their O
diet O
and O
serum O
phospholipid O
fatty O
acid O
profiles O
were O
monitored O
. O
[]

The O
two O
groups O
were O
comparable O
in O
terms O
of O
baseline O
characteristics O
. O
[]

Vancomycin O
added O
to O
empirical O
combination O
antibiotic O
therapy O
for O
fever O
in O
granulocytopenic O
cancer O
patients O
. O
[]

Open O
or O
uncontrolled O
studies O
have O
suggested O
that O
providing O
cancer O
patients O
with O
audiotapes O
of O
their O
clinical O
interviews O
can O
improve O
information O
recall B-outcome ['Life-Impact']
and O
reduce O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Bacteria O
were O
identified O
in O
23 O
patients O
, O
11 O
of O
83 O
undergoing O
cholecystectomy O
alone O
and O
12 O
of O
28 O
undergoing O
exploration O
of O
the O
common O
bile O
duct O
( O
P O
less O
than O
0.01 O
) O
. O
[]

METHODS O
The O
374 O
patients O
evaluated O
in O
this O
study O
were O
a O
subgroup O
of O
a O
larger O
multicenter O
, O
cross-sectional O
, O
randomized O
study O
that O
was O
carried O
out O
in O
1996 O
. O
[]

Subfoveal O
and O
pulsatile O
choroidal B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow O
were O
measured O
with O
laser O
Doppler O
flowmetry O
and O
laser O
interferometry O
, O
respectively O
. O
['Physiological-Clinical']

Four-year O
survival B-outcome ['Mortality']
was O
73.0 O
% O
for O
279 O
high-risk O
patients O
( O
any O
Stage O
IV O
, O
all O
UH O
) O
who O
received O
postoperative O
radiation O
therapy O
( O
RT O
) O
and O
AMD O
+ O
VCR O
+ O
ADR O
+/- O
cyclophosphamide O
( O
CPM O
) O
. O
['Mortality']

Forty-two O
patients O
with O
migraine O
without O
aura O
underwent O
the O
test O
before O
and O
2 O
months O
after O
antimigraine O
therapy O
. O
[]

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

OBJECTIVE O
The O
objective O
was O
to O
determine O
whether O
there O
is O
a O
threshold O
beyond O
which O
increasing O
doses O
of O
vitamin O
D O
, O
or O
concentrations O
of O
serum O
25-hydroxyvitamin O
D O
[ O
25 O
( O
OH O
) O
D O
] O
, O
no O
longer O
increase O
calcium B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Teachers O
assigned O
to O
the O
waitlist O
control O
condition O
will O
receive O
an O
alternative O
training O
on O
how O
to O
monitor O
physical O
functional O
capacity O
in O
children O
with O
special O
needs. O
[]

There O
was O
no O
significant O
pharmacokinetic B-outcome ['Physiological-Clinical']
and O
pharmacodynamic B-outcome ['Physiological-Clinical']
difference O
between O
plain O
bupivacaine O
and O
ropivacaine O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Tube O
feeding O
was O
initiated O
in O
both O
groups O
within O
a O
mean O
of O
29 O
( O
24 O
to O
72 O
) O
hours O
of O
the O
gastrostomy O
placement O
. O
[]

However O
, O
this O
could O
not O
be O
confirmed O
using O
estimates O
from O
the O
Bergman O
Minimal O
Model O
, O
perhaps O
because O
of O
our O
small O
sample O
size O
. O
[]

Title: O
Foot O
and O
ankle O
characteristics O
and O
dynamic O
knee O
valgus O
in O
individuals O
with O
patellofemoral O
osteoarthritis. O
[]

To O
study O
the O
acute O
effects O
of O
acid O
fog O
on O
the O
lung O
, O
the O
authors O
generated O
a O
monodisperse O
10 O
microM O
MMAD O
aerosol O
of O
H2SO4 O
with O
a O
pH O
of O
2.0 O
and O
a O
nominal O
concentration O
of O
500 O
micrograms/m3 O
. O
[]

CONCLUSIONS O
Finasteride O
improves O
urodynamic O
measures O
of O
obstruction O
in O
men O
with O
BPE O
and O
LUTS O
, O
with O
continued O
improvement O
during O
the O
second O
12 O
months O
of O
therapy O
. O
[]

Within O
each O
risk O
group O
, O
mortality B-outcome ['Mortality']
during O
the O
initial O
hospitalization O
and O
median O
long-term O
survival B-outcome ['Mortality']
were O
similar O
among O
patients O
receiving O
either O
treatment O
. O
['Mortality', 'Mortality']

Furthermore O
, O
a O
higher O
percentage O
of O
patients O
in O
the O
azithromycin O
group O
rated O
overall B-outcome ['Physiological-Clinical']
symptomatic I-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
as O
excellent O
or O
good O
. O
['Physiological-Clinical']

CONCLUSION O
Yoga O
may O
improve O
mood O
status O
and O
quality O
of O
life O
for O
women O
undergoing O
detoxification O
for O
heroin O
dependence O
. O
[]

INTERPRETATION: O
Enteral O
supplementation O
with O
bovine O
lactoferrin O
does O
not O
reduce O
the O
risk O
of O
late-onset O
infection B-outcome ['Physiological-Clinical']
in O
very O
preterm O
infants. O
[['Physiological-Clinical']]

The O
overall O
incidence O
of O
PONV O
was O
low O
and O
was O
not O
significantly O
different O
between O
the O
two O
groups O
. O
[]

Ganitumab O
is O
a O
monoclonal O
IgG1 O
antibody O
that O
blocks O
IGF-1R O
. O
[]

RESULTS O
After O
controlling O
for O
body O
weight O
, O
there O
was O
a O
significant O
effect O
of O
time O
on O
fasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
P O
= O
0.0177 O
) O
and O
total O
cholesterol B-outcome ['Physiological-Clinical']
( O
P O
= O
0.0386 O
) O
concentrations O
, O
and O
on O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( O
P O
= O
0.0413 O
) O
, O
with O
reductions O
in O
these O
variables O
occurring O
over O
time O
; O
there O
was O
no O
time-by-diet O
interaction O
for O
any O
of O
the O
parameters O
studied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
an O
objective O
response O
to O
chemotherapy O
on O
either O
treatment O
arm O
survived B-outcome ['Mortality']
twice O
as O
long O
as O
the O
nonresponders O
. O
['Mortality']

Median O
total O
direct O
cost O
outcomes O
were O
similar O
between O
groups O
( O
EL O
= O
$ O
9,696 O
and O
ES O
= O
$ O
13,197 O
; O
P O
=.46 O
) O
. O
[]

Lorazepam O
was O
liked O
better O
than O
were O
other O
drugs O
only O
at O
1 O
hour O
and O
only O
compared O
with O
buspirone O
20 O
and O
placebo O
. O
[]

Mosquitoes O
were O
collected O
in O
these O
communities O
by O
the O
all-night O
landing O
catch O
method O
and O
were O
individually O
dissected O
to O
identify O
rates O
of O
infection O
and O
infectiveness O
. O
[]

METHOD O
The O
Identifying O
Depression O
As O
a O
Comorbid O
Condition O
( O
IDACC O
) O
study O
employed O
a O
hybrid O
design O
, O
incorporating O
a O
randomized O
controlled O
trial O
nested O
within O
a O
prospective O
cohort O
study O
. O
[]

Secondary O
outcomes O
included O
ratings O
of O
pain O
and O
sleep O
quality O
as O
well O
as O
the O
ability O
to O
perform O
daily O
activities O
( O
Ambulatory O
Post O
Acute O
Care O
Daily O
Activities O
Short O
Form O
) O
, O
quality O
of O
life O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
) O
, O
and O
fatigue O
( O
Functional O
Assessment O
of O
Cancer O
Therapy-Fatigue O
) O
. O
[]

Most O
responses O
returned O
to O
the O
baseline O
values O
within O
24 O
h. O
[]

METHODS O
Between O
October O
15 O
, O
1996 O
, O
and O
March O
24 O
, O
1999 O
, O
104 O
patients O
at O
13 O
centers O
were O
prospectively O
randomized O
to O
undergo O
embolization O
using O
an O
n-BCA/Tantalum O
Powder/Ethiodol O
mixture O
or O
Trufill O
PVA O
. O
[]

During O
the O
postpartum O
period O
, O
information O
was O
collected O
via O
a O
questionnaire O
about O
participants O
' O
levels O
of O
satisfaction O
with O
a O
variety O
of O
aspects O
of O
care O
provided O
during O
the O
antenatal O
, O
delivery O
and O
postpartum O
periods O
. O
[]

Ca B-outcome ['Physiological-Clinical']
x I-outcome ['Physiological-Clinical']
P I-outcome ['Physiological-Clinical']
product I-outcome ['Physiological-Clinical']
levels O
were O
also O
significantly O
lower O
in O
the O
lanthanum O
carbonate O
group O
at O
the O
end O
of O
randomized O
treatment O
( O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Psychological O
treatment O
may O
treat O
effectively O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
, O
pain B-outcome ['Physiological-Clinical']
, O
and O
fatigue B-outcome ['Physiological-Clinical']
among O
cancer O
patients O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
primary O
outcome O
was O
the O
recovery B-outcome ['Physiological-Clinical']
perceived O
by O
the O
patient. O
[['Physiological-Clinical']]

The O
effects O
of O
acute O
administration O
per O
os O
of O
30 O
mg O
camazepam O
and O
the O
same O
dose O
of O
temazepam O
, O
were O
compared O
with O
placebo O
in O
8 O
young O
male O
volunteers O
, O
fully O
adapted O
to O
the O
laboratory O
environment O
by O
6 O
nights O
of O
adaptation O
. O
[]

However O
, O
the O
protocols O
used O
and O
the O
results O
found O
in O
the O
3 O
RCTs O
were O
diverse O
. O
[]

Maximal O
plasma B-outcome ['Physiological-Clinical']
concentration O
and O
area O
under O
the O
plasma O
concentration-time O
curve O
increased O
and O
oral O
clearance O
decreased O
disproportionately O
with O
dose O
. O
['Physiological-Clinical']

In O
both O
duodenal O
ulcer O
treatment O
groups O
, O
and O
with O
both O
drugs O
, O
healing B-outcome ['Physiological-Clinical']
was O
negatively O
influenced O
by O
ulcer B-outcome ['Physiological-Clinical']
size O
, O
ulcer B-outcome ['Physiological-Clinical']
number I-outcome ['Physiological-Clinical']
, O
smoking B-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
and O
a O
disease B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
of O
5 O
years O
or O
more O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

STUDY O
OBJECTIVE O
Comparison O
of O
tamoxifen O
and O
mastectomy O
in O
treatment O
of O
breast O
cancer O
in O
elderly O
patients O
. O
[]

One O
surgeon O
rated O
breast O
Steri-Strip O
S O
scars O
worse O
than O
suture O
scars O
( O
4.3 O
versus O
3.7 O
; O
p O
= O
0.014 O
) O
. O
[]

Although O
social B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
improved O
significantly O
as O
a O
result O
of O
watching O
The O
Transporters O
, O
a O
significant O
improvement O
in O
social B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
was O
however O
, O
also O
observed O
in O
the O
Thomas O
the O
Tank O
Engine O
condition O
suggesting O
the O
unique O
content O
of O
The O
Transporters O
DVD O
was O
not O
pivotal O
to O
the O
improvement O
of O
social B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
in O
general O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Journal O
ID: O
8216186 O
[]

After O
a O
minimum O
of O
4 O
yr O
of O
GH O
treatment O
, O
at O
a O
mean O
age O
of O
12.7 O
+/- O
0.7 O
yr O
, O
low O
dose O
micronized O
17beta-estradiol O
was O
given O
orally O
. O
[]

The O
exercise O
group O
performed O
40 O
min O
of O
resistance O
exercises O
on O
machines O
followed O
by O
30 O
min O
of O
aerobic O
training O
on O
a O
treadmill O
3x/wk. O
[]

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
longer-term O
effects O
of O
combined O
medical O
and O
surgical O
therapy O
for O
CRS O
on O
overall O
health O
status O
and O
QOL O
. O
[]

OBJECTIVES O
To O
compare O
the O
tolerance O
, O
adherence O
and O
effectiveness O
of O
two O
approaches O
for O
the O
treatment O
of O
latent O
tuberculosis O
infection O
( O
LTBI O
) O
: O
6 O
months O
of O
isoniazid O
( O
6H O
) O
vs. O
3 O
months O
of O
isoniazid O
plus O
rifampicin O
( O
3RH O
) O
. O
[]

5mU/l O
vs O
median O
Controls O
, O
37.4mU/l O
; O
P O
< O
0.01 O
) O
and O
1.0 O
microg/kg O
( O
median O
peak O
Irradiated O
, O
4.8mU/l O
vs O
median O
Controls O
, O
15.2mU/l O
; O
P O
< O
0 O
. O
[]

[ O
Comparison O
between O
anterior O
rhinomanometry O
and O
impulse-oscillometric O
rhinometry O
found O
within O
nasal B-outcome ['Physiological-Clinical']
allergen I-outcome ['Physiological-Clinical']
provocation I-outcome ['Physiological-Clinical']
] O
. O
['Physiological-Clinical']

The O
primary O
end O
point O
was O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
OS O
) O
; O
secondary O
end O
points O
included O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
. O
['Mortality', 'Mortality']

Participants O
of O
the O
Web-based O
intervention O
were O
significantly O
younger O
( O
P O
< O
.001 O
) O
, O
more O
often O
men O
( O
P=.01 O
) O
, O
had O
a O
higher O
body O
mass O
index O
( O
BMI O
) O
( O
P=.001 O
) O
and O
a O
lower O
intention O
to O
be O
physically O
active O
( O
P=.03 O
) O
than O
participants O
of O
the O
printed O
intervention O
. O
[]

TRIAL O
REGISTRATION: O
Registration O
name: O
Virtual O
Task O
in O
Amyotrophic O
Lateral O
Sclerosis; O
Registration O
number: O
NCT03113630 O
; O
retrospectively O
registered O
on O
04/13/2017. O
[]

Plasma O
A? O
increased O
with O
dose O
, O
and O
CSF O
A? O
increased O
at O
the O
highest O
dose O
, O
suggesting O
that O
intravenous O
ponezumab O
alters O
central O
A? O
levels O
. O
[]

In O
Study O
3 O
( O
a O
daily O
event O
sampling O
study O
) O
, O
the O
authors O
showed O
that O
the O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
8 O
hours O
of O
continuous O
low-level O
heatwrap O
therapy O
for O
the O
treatment O
of O
acute O
nonspecific O
low O
back O
pain O
( O
LBP O
) O
. O
[]

Comparable O
electrocardiographic B-outcome ['Physiological-Clinical']
results I-outcome ['Physiological-Clinical']
were O
obtained O
during O
placebo O
and O
tegaserod O
treatment O
. O
['Physiological-Clinical']

ClinicalTrials.gov O
number O
, O
NCT00100230 O
. O
) O
. O
[]

18 O
) O
F-FDG B-outcome ['Physiological-Clinical']
PET/CT I-outcome ['Physiological-Clinical']
metabolic I-outcome ['Physiological-Clinical']
response O
['Physiological-Clinical']

Orally O
delivered O
, O
inactivated O
whole-cell O
vaccines O
are O
safe O
methods O
of O
inducing O
local O
and O
systemic O
immunity O
. O
[]

METHODS O
AND O
RESULTS O
We O
performed O
the O
following O
studies O
: O
( O
1 O
) O
a O
cross-sectional O
comparison O
of O
smokers O
and O
control O
subjects O
, O
( O
2 O
) O
an O
examination O
of O
the O
dose-response O
relationship O
, O
( O
3 O
) O
an O
exploration O
of O
the O
effect O
of O
smoking O
cessation O
( O
3 O
weeks O
) O
and O
nicotine O
patch O
supplementation O
, O
( O
4 O
) O
the O
effect O
of O
aspirin O
consumption O
, O
and O
( O
5 O
) O
the O
effects O
of O
5 O
days O
' O
dosing O
with O
vitamin O
E O
( O
100 O
and O
800 O
U O
) O
, O
vitamin O
C O
( O
2 O
g O
) O
, O
and O
their O
combination O
. O
[]

After O
six O
weeks O
, O
biopsies B-outcome ['Resource-use']
were O
taken O
from O
EGCG O
and O
vehicle O
treated O
sites O
. O
['Resource-use']

The O
calorific B-outcome ['Life-Impact']
value I-outcome ['Life-Impact']
of O
the O
absorbed O
osmotic O
agent O
was O
lower O
, O
by O
19 O
% O
with O
isotonic O
and O
22 O
% O
with O
hypertonic O
solutions O
, O
when O
glycerol O
was O
used O
in O
place O
of O
glucose O
. O
['Life-Impact']

Nine O
healthy O
volunteers O
( O
age O
, O
23.4 O
+/- O
0.2 O
years O
; O
body O
mas O
index O
[ O
BMI O
] O
, O
23.5 O
+/- O
1.6 O
kg/m O
( O
2 O
) O
) O
were O
fed O
, O
in O
random O
order O
, O
with O
a O
high-fat O
diet O
( O
HFD O
) O
( O
65 O
% O
of O
energy O
content O
fat O
, O
15 O
% O
protein O
, O
20 O
% O
carbohydrate O
) O
or O
a O
high-carbohydrate O
diet O
( O
HCD O
) O
( O
70 O
% O
carbohydrate O
, O
15 O
% O
protein O
, O
15 O
% O
fat O
) O
for O
5 O
days O
, O
with O
a O
washout O
period O
of O
10 O
days O
between O
the O
diets O
. O
[]

METHODS O
Our O
study O
population O
consisted O
of O
242 O
individuals O
recruited O
by O
advertisements O
and O
mailing O
lists O
( O
mean O
[ O
+/- O
SD O
] O
age O
, O
77 O
+/- O
4 O
years O
) O
. O
[]

METHODS O
Data O
were O
collected O
in O
a O
combined O
crossover O
multiple O
baseline O
design O
across O
participants O
. O
[]

Mean O
pain B-outcome ['Physiological-Clinical']
assessment O
by O
subjects O
was O
3.6 O
for O
HA+lidocaine O
and O
5.8 O
for O
HA O
alone O
( O
p O
< O
.001 O
) O
. O
['Physiological-Clinical']

PATIENTS O
Adult O
( O
age O
> O
or=18 O
years O
) O
critically O
ill O
patients O
with O
hemoglobin O
< O
or=12 O
g/dL O
, O
expected O
hospitalization O
of O
> O
or=7 O
days O
, O
with O
no O
ongoing O
acute O
blood O
loss O
. O
[]

It O
is O
important O
that O
new O
types O
of O
spirometer O
for O
widespread O
clinical O
use O
are O
pragmatically O
evaluated O
in O
primary O
care O
. O
[]

Weight O
and O
leptin B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
among O
risperidone-treated O
youths O
with O
autism O
: O
6-month O
prospective O
data O
. O
['Physiological-Clinical']

Pain O
scores O
were O
higher O
in O
the O
surgical O
treatment O
group O
compared O
with O
the O
triamcinolone O
injection O
group O
( O
P O
< O
0.003 O
) O
. O
['Physiological-Clinical']

After O
6 O
months O
of O
hearing-aid O
use O
, O
individuals O
experienced O
more O
physical B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
pleasure I-outcome ['Life-Impact']
, O
whereas O
individuals O
using O
hearing O
aids O
for O
long O
periods O
of O
time O
reported O
similar O
levels O
of O
pleasure O
at O
the O
beginning O
and O
at O
the O
end O
of O
a O
6-month O
interval O
. O
['Life-Impact']

INTERPRETATION O
This O
is O
a O
post O
hoc O
subgroup O
analysis O
of O
an O
outcome O
variable O
, O
which O
was O
not O
in O
the O
official O
protocol O
. O
[]

When O
histologic O
changes O
were O
compared O
between O
the O
2 O
groups O
, O
decrease O
in O
acute B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
gastritis I-outcome ['Physiological-Clinical']
was O
more O
frequent O
after O
H. O
pylori O
eradication O
( O
P O
< O
0.001 O
) O
but O
changes O
in O
IM B-outcome ['Physiological-Clinical']
were O
similar O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

The O
Social O
Communication O
Assessment O
for O
Toddlers O
with O
Autism O
( O
SCATA O
) O
: O
an O
instrument O
to O
measure O
the O
frequency O
, O
form O
and O
function B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
in O
toddlers O
with O
autism O
spectrum O
disorder O
. O
['Life-Impact']

A O
total O
of O
40 O
eligible O
patients O
were O
randomly O
allocated O
to O
a O
treatment O
group O
(received O
BZSF O
and O
ceftriaxone) O
or O
a O
control O
group O
(received O
ceftriaxone O
alone). O
[]

Psychological B-outcome ['Life-Impact']
measures O
included O
['Life-Impact']

RESULTS O
TLT O
failed O
to O
arrest O
progression O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
dilation I-outcome ['Physiological-Clinical']
by O
the O
end O
of O
the O
hospital O
stay O
. O
['Physiological-Clinical']

METHODS O
Eighty O
patients O
in O
whom O
ultrasonography O
revealed O
unilateral O
, O
mobile O
, O
unilocular O
, O
thin-walled O
ovarian O
cysts O
without O
internal O
echoes O
and O
greater O
than O
30 O
mm O
but O
not O
exceeding O
60 O
mm O
in O
diameter O
were O
enrolled O
into O
the O
study O
. O
[]

Effect O
of O
flurbiprofen O
sodium O
on O
pupillary B-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
during O
scleral O
buckling O
surgery O
. O
['Physiological-Clinical']

BACKGROUND O
Children O
who O
show O
disproportionate O
difficulty O
with O
the O
pragmatic O
as O
compared O
with O
the O
structural O
aspects O
of O
language O
are O
described O
as O
having O
pragmatic O
language O
impairment O
( O
PLI O
) O
or O
social O
communication O
disorder O
( O
SCD O
) O
. O
[]

The O
Fluorouracil O
Filtering O
Surgery O
Study O
Group O
. O
[]

A O
comparison O
of O
dorsal O
and O
volar O
resting O
hand O
splints O
in O
the O
reduction O
of O
hypertonus O
. O
[]

The O
data O
reported O
in O
this O
study O
were O
collected O
at O
baseline O
before O
any O
intervention O
activities O
was O
initiated O
. O
[]

Twelve O
nonsmoking O
healthy O
subjects O
took O
part O
in O
a O
prospective O
double-blind O
placebo O
control O
study O
. O
[]

Lung O
function O
and O
respiratory O
symptoms O
in O
a O
1-year O
randomized O
smoking O
cessation O
trial O
of O
varenicline O
in O
COPD O
patients O
. O
[]

Dose O
distribution O
curves O
in O
cross-section O
and O
midsagittal O
planes O
are O
shown O
and O
calculations O
or O
equivalent O
doses O
at O
various O
selected O
points O
using O
Ellis O
's O
nominal O
single-dose O
formula O
are O
tabulated O
. O
[]

Its O
leakage B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
was O
lower O
and O
quality O
of O
life O
was O
better O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
, O
open-label O
, O
dose-escalating O
phase O
I O
study O
. O
[]

In O
addition O
, O
analysis O
of O
brachial B-outcome ['Physiological-Clinical']
artery I-outcome ['Physiological-Clinical']
flow-mediated I-outcome ['Physiological-Clinical']
vasodilatation I-outcome ['Physiological-Clinical']
and O
24-hour B-outcome ['Physiological-Clinical']
ambulatory I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitoring I-outcome ['Physiological-Clinical']
were O
performed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
median O
total O
sum O
of O
vitagram O
points O
was O
28.1 O
for O
radiotherapy O
, O
20.7 O
for O
cyclophosphamide O
and O
6.8 O
for O
placebo O
. O
[]

After O
20 O
minutes O
( O
approximate O
time O
to O
peak O
nicotine O
levels O
) O
, O
echocardiograms O
and O
signal-averaged O
electrocardiograms O
( O
SAECG O
) O
were O
obtained O
. O
[]

Subgroup O
analysis O
of O
children O
( O
5-12 O
years O
) O
with O
autism O
enrolled O
in O
an O
8-week O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
risperidone O
for O
pervasive O
developmental O
disorders O
. O
[]

DESIGN O
Prospective O
, O
randomized O
, O
partly O
blinded O
study O
. O
[]

Parents O
' O
checklist O
ratings O
( O
ABC O
) O
as O
well O
as O
clinicians O
' O
ratings O
( O
CGI O
) O
pointed O
to O
significant O
improvements O
after O
the O
course O
of O
treatment O
; O
improvements O
were O
clearest O
on O
the O
ABC O
social B-outcome ['Life-Impact']
withdrawal I-outcome ['Life-Impact']
subscale O
. O
['Life-Impact']

Publication O
date: O
2018/12/22 O
06:00 O
[entrez] O
[]

In O
the O
C O
group O
, O
13 O
% O
received O
no O
chemotherapy O
, O
21 O
% O
one O
or O
two O
cycles O
, O
and O
64 O
% O
all O
three O
cycles O
of O
their O
prescribed O
chemotherapy O
( O
60 O
% O
of O
the O
latter O
with O
no O
delays O
or O
modification O
) O
. O
[]

Immunologic B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
after O
laparoscopic O
colon O
cancer O
operation O
within O
an O
enhanced O
recovery O
program O
. O
['Physiological-Clinical']

Baseline O
CRP O
was O
significantly O
inversely O
associated O
with O
the O
baseline O
25 O
[]

However, O
the O
effect O
of O
PICSI O
on O
livebirth O
rates O
is O
uncertain. O
[]

Three O
hundred O
forty-one O
Tanzanian O
preschool O
children O
were O
randomly O
assigned O
to O
levamisole O
or O
placebo O
treatment O
given O
at O
three-month O
intervals O
. O
[]

Pain B-outcome ['Physiological-Clinical']
, O
global B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(GQoL) I-outcome ['Life-Impact']
and O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
specific O
for O
CD O
(QoLCD) O
were O
assessed O
before O
and O
after O
the O
intervention. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

However O
, O
this O
redistribution O
was O
not O
observed O
in O
patients O
who O
presented O
a O
worsening O
of O
right O
ventricular O
function O
( O
right O
ventricular O
end-diastolic O
area/left O
ventricular O
end-diastolic O
area O
increase O
> O
40 O
% O
) O
at O
high-frequency O
oscillatory O
ventilation+15 O
. O
[]

Continuous O
clodronate O
treatment O
resulted O
in O
a O
clear O
fall O
in O
biochemical O
indices O
of O
bone B-outcome ['Physiological-Clinical']
resorption I-outcome ['Physiological-Clinical']
, O
together O
with O
a O
consequent O
decrease O
in O
osteocalcin O
at O
6 O
( O
P O
< O
.02 O
) O
and O
12 O
months O
( O
P O
< O
.003 O
) O
and O
a O
significant O
increase O
in O
parathyroid B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
after O
12 O
months O
( O
P O
< O
.001 O
) O
of O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Etomidate O
with O
or O
without O
flumazenil O
anesthesia O
for O
stem O
cell O
transplantation O
in O
autistic O
children O
. O
[]

RESULTS O
There O
was O
a O
high O
rate O
of O
dropout B-outcome ['Life-Impact']
( O
51 O
% O
) O
from O
the O
study O
, O
and O
the O
rates O
were O
significantly O
higher O
among O
smokers O
( O
64 O
% O
) O
than O
non-smokers O
( O
36 O
% O
) O
. O
['Life-Impact']

Pooled O
Multiple O
Sleep O
Latency O
Test O
( O
MSLT O
) O
data O
from O
2 O
randomized O
, O
double-blind O
, O
placebo-controlled O
trials O
in O
463 O
patients O
with O
SWD O
, O
1 O
with O
armodafinil O
150 O
mg/d O
and O
1 O
with O
modafinil O
200 O
mg/d O
( O
both O
administered O
around O
2200 O
h O
before O
night O
shifts O
) O
, O
were O
used O
to O
build O
a O
pharmacokinetic/pharmacodynamic B-outcome ['Physiological-Clinical']
model O
. O
['Physiological-Clinical']

Title: O
Prevalence O
and O
correlates O
of O
psychological O
distress O
among O
13-14 O
year O
old O
adolescent O
girls O
in O
North O
Karnataka, O
South O
India: O
a O
cross-sectional O
study. O
[]

BACKGROUND O
Mirror O
therapy O
( O
MT O
) O
and O
mesh O
glove O
( O
MG O
) O
afferent O
stimulation O
may O
be O
effective O
in O
reducing O
motor O
impairment O
after O
stroke O
. O
[]

Both O
restorations B-outcome ['Physiological-Clinical']
had O
to O
be O
replaced O
. O
['Physiological-Clinical']

FINDINGS O
Of O
the O
120 O
patients O
initially O
enrolled O
, O
one O
withdrew O
after O
signing O
consent O
and O
one O
patient O
's O
baseline O
bone O
marrow O
was O
not O
available O
. O
[]

Efficacy O
of O
prophylactic O
ondansetron O
in O
a O
patient-controlled O
analgesia O
environment O
. O
[]

However O
, O
the O
time O
of O
recovery O
showed O
a O
significant O
decrease O
only O
in O
the O
LED O
group O
( O
p O
= O
0.003 O
) O
. O
[]

METHODS O
AND O
MATERIALS O
Patients O
( O
N O
= O
207 O
) O
with O
nonresectable O
rectal O
cancer O
were O
randomized O
to O
preoperative O
CRT O
or O
RT O
( O
2 O
Gy O
? O
[]

PURPOSE O
To O
compare O
once-daily O
radiation O
therapy O
( O
qdRT O
) O
with O
hyperfractionated O
accelerated O
radiation O
therapy O
( O
HART O
) O
after O
two O
cycles O
of O
induction O
chemotherapy O
. O
[]

Journal O
ID: O
101566341 O
[]

RESULTS O
KGQG O
group O
showed O
better O
efficacy O
over O
control O
group O
in O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
, O
decrease O
of O
serum B-outcome ['Physiological-Clinical']
PCIII I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
CIV I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
HA I-outcome ['Physiological-Clinical']
levels O
and O
liver B-outcome ['Physiological-Clinical']
pathologic I-outcome ['Physiological-Clinical']
grades I-outcome ['Physiological-Clinical']
( O
P O
0.05 O
or O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Relapse B-outcome ['Physiological-Clinical']
is O
less O
frequent O
when O
a O
combination O
of O
bismuth O
and O
an O
antimicrobial O
agent O
is O
used O
; O
such O
a O
combination O
is O
characterized O
by O
local B-outcome ['Physiological-Clinical']
and O
systemic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
, O
stability O
at O
low B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
, O
and O
good B-outcome ['Physiological-Clinical']
penetration I-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucus I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Ambulatory B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
of O
children O
with O
cerebral O
palsy O
: O
which O
characteristics O
are O
important O
? O
['Life-Impact']

CONCLUSION O
Interpersonal O
communication O
can O
have O
a O
powerful O
effect O
on O
recruitment O
. O
[]

SUBJECTS O
AND O
METHODS O
The O
study O
included O
149 O
patients O
, O
among O
whom O
36 O
patients O
with O
hypervascular O
hepatocellular O
carcinoma O
were O
identified O
. O
[]

The O
incidence O
of O
initial B-outcome ['Physiological-Clinical']
RAO I-outcome ['Physiological-Clinical']
was O
5.9 O
% O
in O
the O
2,000-IU O
group O
and O
2.9 O
% O
in O
the O
5,000-IU O
group O
( O
p O
= O
0.17 O
) O
, O
with O
a O
compression O
time O
of O
2.10 O
? O
['Physiological-Clinical']

3 O
. O
[]

DISCUSSION O
This O
trial O
will O
identify O
whether O
home-based O
pulmonary O
rehabilitation O
can O
deliver O
equivalent O
benefits O
to O
centre-based O
pulmonary O
rehabilitation O
in O
a O
cost O
effective O
manner O
. O
[]

Terazosin O
was O
effective O
in O
lowering O
blood O
pressure O
when O
administered O
alone O
( O
in O
dosages O
of O
1 O
to O
80 O
mg/day O
) O
and O
when O
prescribed O
( O
in O
dosages O
of O
1 O
to O
20 O
mg/day O
) O
in O
combination O
with O
other O
antihypertensive O
agents O
. O
[]

OBJECT O
Stable O
hemodynamics O
, O
normocapnia O
, O
and O
adequate O
pain O
relief O
are O
considered O
important O
factors O
in O
the O
reduction O
of O
neurological O
complications O
in O
pediatric O
patients O
undergoing O
encephaloduroarteriomyosynangiosis O
( O
EDAMS O
) O
operations O
for O
the O
treatment O
of O
moyamoya O
disease O
. O
[]

METHODS O
Eighty-four O
cases O
were O
randomly O
divided O
into O
3 O
groups O
, O
28 O
cases O
in O
each O
group O
. O
[]

Patients O
who O
sustained O
an O
accidental O
dural O
puncture O
during O
establishment O
of O
epidural O
analgesia O
during O
labour O
or O
at O
caesarean O
delivery O
were O
randomly O
assigned O
to O
receive O
a O
prophylactic O
epidural O
blood O
patch O
or O
conservative O
treatment O
with O
a O
therapeutic O
epidural O
blood O
patch O
if O
required O
. O
[]

There O
is O
a O
strong O
association O
between O
premature B-outcome ['Mortality']
coronary I-outcome ['Mortality']
heart I-outcome ['Mortality']
disease I-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
men O
and O
the O
mean O
levels O
of O
8-oxo-dG O
for O
the O
five O
countries O
( O
r O
= O
0.95 O
, O
P O
< O
0.01 O
) O
. O
['Mortality']

Postoperative O
response O
to O
treatment O
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
( O
ALT B-outcome ['Physiological-Clinical']
) O
, O
AFP B-outcome ['Physiological-Clinical']
, O
imaging B-outcome ['Resource-use']
examination I-outcome ['Resource-use']
of I-outcome ['Resource-use']
the I-outcome ['Resource-use']
tumor I-outcome ['Resource-use']
, O
patient O
's O
survival B-outcome ['Mortality']
were O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Mortality']

Antibiotic-associated B-outcome ['Physiological-Clinical']
nephrotoxicity I-outcome ['Physiological-Clinical']
was O
more O
frequent O
in O
patients O
treated O
with O
vancomycin O
( O
6 O
% O
vs. O
2 O
% O
, O
P O
= O
.02 O
) O
. O
['Physiological-Clinical']

RESULTS O
The O
score O
of O
symptoms B-outcome ['Physiological-Clinical']
and O
signs B-outcome ['Physiological-Clinical']
markedly O
decreased O
after O
treatment O
, O
in O
treatment O
group O
: O
vertigo B-outcome ['Physiological-Clinical']
had O
( O
2.75 O
+/- O
1.01 O
) O
scores O
, O
neck-shoulder B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
1.58 O
+/- O
0.36 O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
0.39 O
+/- O
0.09 O
) O
, O
nausea-vomiting B-outcome ['Physiological-Clinical']
( O
1.58 O
+/- O
1.30 O
) O
, O
ear B-outcome ['Physiological-Clinical']
noises I-outcome ['Physiological-Clinical']
( O
0.48 O
+/- O
0.32 O
) O
, O
positive O
neck B-outcome ['Physiological-Clinical']
rotation O
test O
( O
0.59 O
+/- O
0.21 O
) O
; O
and O
in O
control O
group O
: O
vertigo B-outcome ['Physiological-Clinical']
had O
( O
5.68 O
+/- O
2.02 O
) O
scores O
, O
neck-shoulder B-outcome ['Physiological-Clinical']
pain B-outcome ['Physiological-Clinical']
( O
3.12 O
+/- O
1.82 O
) O
, O
headache B-outcome ['Physiological-Clinical']
( O
1.86 O
+/- O
0.65 O
) O
, O
nausea-vomiting B-outcome ['Physiological-Clinical']
( O
3.25 O
+/- O
0.69 O
) O
, O
ear B-outcome ['Physiological-Clinical']
noises I-outcome ['Physiological-Clinical']
( O
1.64 O
+/- O
0.61 O
) O
, O
positive O
neck B-outcome ['Physiological-Clinical']
rotation O
test O
( O
1.79 O
+/- O
0.67 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Nightblind O
pregnant O
women O
were O
randomly O
assigned O
to O
receive O
, O
6 O
d/wk O
under O
supervision O
for O
6 O
wk O
, O
a O
vitamin O
A-fortified O
rice O
curry O
dish O
providing O
850 O
microg O
retinal O
activity O
equivalents/d O
with O
either O
a O
30-mg O
Fe O
and O
6-mg O
riboflavin O
( O
FeR O
+ O
VA O
) O
capsule O
or O
a O
placebo O
control O
( O
VA O
only O
) O
capsule O
. O
[]

To O
assess O
the O
effect O
of O
DUP O
on O
the O
neuropsychological O
status O
of O
the O
patients O
, O
a O
linear O
mixed-effect O
model O
was O
fitted O
to O
each O
neuropsychological O
dimension O
. O
[]

Diarrhea B-outcome ['Physiological-Clinical']
and O
diaper-area B-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
were O
more O
common O
among O
children O
who O
received O
amoxicillin-clavulanate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

T O
Yale-Brown O
Obsessive B-outcome ['Physiological-Clinical', 'Life-Impact']
Compulsive I-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(Y-BOCS)], O
Hamilton O
Anxiety B-outcome ['Physiological-Clinical', 'Life-Impact']
Scale O
(HAMA) O
were O
used O
to O
assess O
the O
efficacy, O
Pittsburgh O
Sleep B-outcome ['Physiological-Clinical']
Quality I-outcome ['Physiological-Clinical']
Index O
(PSQI) O
was O
used O
to O
evaluate O
the O
sleep B-outcome ['Physiological-Clinical']
quality I-outcome ['Physiological-Clinical']
, O
and O
Treatment O
Emergent O
Symptom O
Scale O
(TESS) O
was O
used O
to O
evaluate O
the O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
Data O
were O
analyzed O
in O
the O
intention-to-treat O
sample. O
[['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects']]

Serum O
amylase O
and O
lipase O
levels O
were O
determined O
1 O
day O
before O
and O
within O
24 O
hours O
after O
ERCP O
. O
[]

47 O
received O
treatment O
without O
TLT O
and O
neoton O
, O
30 O
patients O
received O
TLT O
with O
streptokinase O
preparations O
, O
29 O
patients O
were O
given O
streptokinase O
preparations O
and O
neoton O
. O
[]

Patients O
and O
their O
physicians O
selected O
either O
definitive O
radiotherapy O
or O
precystectomy O
radiotherapy O
; O
patients O
were O
then O
randomly O
allocated O
to O
receive O
intravenous O
cisplatin O
100 O
mg/m2 O
at O
2-week O
intervals O
for O
three O
cycles O
concurrent O
with O
pelvic O
radiation O
, O
or O
to O
receive O
radiation O
without O
chemotherapy O
. O
[]

SETTING O
Clinical O
assisted O
conception O
program O
. O
[]

The O
groups O
' O
diagnostic O
accuracy O
, O
however O
, O
did O
not O
differ O
significantly O
on O
the O
post-test O
, O
retention O
test O
or O
transfer O
test O
items O
( O
p O
> O
0.12 O
) O
. O
[]

In O
a O
phase O
II O
study O
119 O
patients O
with O
disseminated O
malignant O
melanoma O
were O
randomized O
to O
receive O
treatment O
with O
dacarbazine O
alone O
or O
in O
combination O
with O
vindesine O
. O
[]

We O
evaluated O
the O
effects O
of O
extended-release O
alfuzosin O
HCl O
10 O
mg O
once O
daily O
( O
q.d O
. O
) O
[]

The O
main O
beneficial O
effect O
of O
exercise B-outcome ['Life-Impact']
occurred O
in O
the O
first O
4 O
weeks O
of O
the O
intervention O
. O
['Life-Impact']

Mothers O
in O
the O
special O
care O
program O
who O
continued O
to O
attend O
clinic O
used O
the O
emergency O
room O
less O
than O
the O
mothers O
who O
continued O
to O
attend O
in O
the O
control O
group O
. O
[]

The O
AF O
frequency O
decreased O
similarly O
in O
both O
groups O
, O
and O
there O
was O
no O
significant O
difference O
in O
the O
primary O
endpoint O
between O
the O
two O
groups O
. O
[]

The O
PFS O
technique O
was O
standardized O
, O
and O
all O
tracings O
were O
read O
by O
a O
single O
reader O
unaware O
of O
the O
treatment O
group O
. O
[]

In O
the O
placebo O
group O
, O
245 O
patients O
remained O
H. O
pylori O
infected O
. O
[]

The O
control O
group O
did O
not O
perform O
a O
training O
program O
. O
[]

In O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
and O
crossover O
design O
, O
nine O
female O
and O
three O
male O
healthy O
subjects O
( O
age O
34 O
( O
sd O
11 O
) O
years O
, O
BMI O
24.5 O
( O
sd O
2.5 O
) O
kg/m O
( O
2 O
) O
) O
with O
a O
preference O
for O
a O
high-fat O
diet O
ingested O
ENT O
( O
3 O
x O
15 O
mg/d O
) O
or O
placebo O
( O
PLA O
) O
while O
consuming O
a O
high-fat O
diet O
ad O
libitum O
for O
4 O
d. O
Eight O
subjects O
ended O
each O
intervention O
with O
a O
36 O
h O
stay O
in O
the O
respiration O
chamber O
, O
continuing O
the O
diet O
and O
treatment O
. O
[]

Rett O
syndrome O
is O
a O
severe O
neurodevelopmental O
disorder O
of O
unknown O
etiology O
, O
occurring O
almost O
exclusively O
in O
female O
patients O
. O
[]

Basing O
on O
50 O
posttraumatic O
intensive-care O
patients O
with O
medium O
grade O
lesions O
( O
ISS O
criteria O
) O
, O
the O
prophylactic O
effect O
of O
an O
intravenously O
applicable O
IgM O
preparation O
( O
Pentaglobin O
) O
against O
nosocomial O
infections B-outcome ['Physiological-Clinical']
was O
investigated O
. O
['Physiological-Clinical']

Small O
choroidal O
melanomas O
were O
defined O
as O
1.0 O
to O
3.0 O
mm O
in O
apical O
height O
and O
at O
least O
5.0 O
mm O
in O
basal O
diameter O
. O
[]

These O
results O
demonstrated O
that O
both O
drugs O
were O
safe O
and O
well O
tolerated O
in O
the O
treatment O
of O
AD O
. O
[]

Brief O
, O
high-impact O
exercise O
increases O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
but O
the O
optimal O
frequency O
of O
such O
exercise O
and O
the O
location O
of O
bone O
accrual O
is O
unknown O
. O
['Physiological-Clinical']

SETTING O
Norwegian O
university O
teaching O
hospital O
. O
[]

h(- O
1) O
followed O
by O
a O
maintenance O
dose O
with O
continuous O
infusion O
of O
3 O
mg.kg(- O
1). O
[]

We O
found O
that O
superficial B-outcome ['Physiological-Clinical']
peels I-outcome ['Physiological-Clinical']
with I-outcome ['Physiological-Clinical']
necrosis I-outcome ['Physiological-Clinical']
involving O
30 O
% O
of O
the O
epidermis O
were O
produced O
by O
the O
lowest-concentration O
combination O
of O
TCA O
applied B-outcome ['Life-Impact']
( O
20 O
% O
followed O
by O
0 O
% O
) O
. O
['Physiological-Clinical', 'Life-Impact']

2-D O
gel O
electrophoresis O
of O
delipidated O
plasmas O
established O
successful O
conversion O
of O
alphaHDL O
to O
prebeta-like O
HDL O
. O
[]

DESIGN O
Following O
a O
2-week O
, O
single-blind O
placebo O
washout O
phase O
, O
12 O
autistic O
subjects O
completed O
a O
10-week O
, O
double-blind O
, O
crossover O
comparison O
of O
clomipramine O
and O
placebo O
, O
and O
12 O
different O
subjects O
completed O
a O
similar O
comparison O
of O
clomipramine O
and O
desipramine O
. O
[]

The O
freshly O
extracted O
juice O
of O
50 O
g O
of O
garlic O
or O
onion O
, O
as O
well O
as O
an O
equivalent O
amount O
of O
their O
ether-extracted O
essential O
oils O
, O
was O
administered O
randomly O
on O
four O
different O
days O
during O
a O
one-week O
period O
. O
[]

Febuxostat O
is O
potentially O
a O
safe O
and O
efficacious O
alternative O
. O
[]

This O
difference O
was O
statistically O
significant O
. O
[]

RESULTS O
Results O
showed O
no O
effect O
of O
aroma O
on O
galvanic B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
during O
relaxation O
. O
['Physiological-Clinical']

The O
present O
study O
investigated O
the O
effects O
of O
a O
Neurologic O
Music O
Therapy O
( O
NMT O
) O
sensory-motor O
rehabilitation O
technique O
, O
Therapeutic O
Instrumental O
Music O
Performance O
( O
TIMP O
) O
as O
compared O
to O
Traditional O
Occupational O
Therapy O
( O
TOT O
) O
, O
on O
endurance B-outcome ['Physiological-Clinical']
, O
self-perceived B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Little O
evidence O
exists O
to O
indicate O
whether O
community O
psychiatric O
nurses O
can O
achieve O
the O
results O
reported O
by O
expert O
cognitive-behavioural O
therapists O
in O
patients O
with O
schizophrenia O
. O
[]

Age, O
sex, O
type O
of O
femoral O
prosthesis, O
and O
the O
injection O
method O
of O
TXA O
were O
risk O
factors O
for O
HBL O
of O
patients O
after O
receiving O
TKA. O
[]

OBJECTIVE O
This O
study O
aimed O
to O
compare O
the O
haemorrhagic O
complications O
and O
efficacy O
of O
enoxaparin O
, O
a O
low O
molecular O
weight O
heparin O
( O
LMWH O
) O
, O
and O
conventional O
standard O
heparin O
( O
SH O
) O
in O
gynaecological O
oncologic O
surgery O
. O
[]

The O
prophylactic O
antiemetic O
efficacy O
of O
intravenous O
( O
i.v O
. O
) O
[]

Journal-Name:Nutrients O
[]

Participants O
fixated B-outcome ['Physiological-Clinical']
an O
object O
picture O
( O
e.g O
. O
['Physiological-Clinical']

Nine O
patients O
( O
7 O
% O
) O
could O
not O
be O
monitored O
at O
1 O
or O
2 O
years O
, O
but O
4 O
of O
these O
9 O
nevertheless O
filled O
in O
the O
1-year O
questionnaire O
. O
[]

[ O
Results O
of O
a O
cooperative O
prospective O
study O
of O
treatment O
of O
primary O
digestive O
localizations O
of O
non-Hodgkin O
's O
lymphoma O
] O
. O
[]

Eight O
incidents O
of O
PCP O
and O
19 O
deaths B-outcome ['Mortality']
were O
observed O
in O
the O
treatment O
group O
during O
a O
median O
follow-up O
of O
16.4 O
months O
( O
range O
, O
2.3-32.4 O
months O
) O
. O
['Mortality']

Title: O
Comparison O
Of O
Simultaneous O
Versus O
Delayed O
Ventriculoperitoneal O
Shunting O
In O
Patients O
Undergoing O
Meningocoele O
Repair O
In O
Terms O
Of O
Infection B-outcome ['Physiological-Clinical']
. O
[['Physiological-Clinical']]

CONCLUSIONS O
The O
Junior O
Detective O
Training O
Program O
appeared O
to O
be O
effective O
in O
enhancing O
the O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
and O
emotional B-outcome ['Life-Impact']
understanding I-outcome ['Life-Impact']
of O
children O
with O
AS O
. O
['Life-Impact', 'Life-Impact']

The O
patients O
in O
the O
stapled O
group O
returned B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
or I-outcome ['Life-Impact']
routine I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
earlier O
( O
ie O
, O
within O
8.12 O
days O
[ O
2.48 O
] O
) O
as O
compared O
with O
17.62 O
( O
5.59 O
) O
in O
the O
open O
group O
. O
['Life-Impact']

The O
Phase O
III O
trial O
therefore O
consists O
of O
two O
sub-protocols O
: O
one O
for O
patients O
with O
malignant O
conditions O
( O
four O
week O
protocol O
) O
and O
one O
for O
patients O
with O
non-malignant O
conditions O
( O
eight O
week O
protocol O
) O
. O
[]

CONCLUSIONS O
The O
LD O
( O
50 O
) O
for O
acute B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
mallard O
ducks O
was O
60 O
% O
of O
their O
total O
blood O
volume O
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

61 O
inpatients O
with O
the O
diagnosis O
Rhinitis O
following O
nasal O
operation O
were O
included O
in O
this O
study O
and O
30 O
patients O
were O
treated O
with O
verum O
and O
placebo O
each O
. O
[]

The O
pregnancy B-outcome ['Physiological-Clinical']
rate O
and O
cervical B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
were O
also O
higher O
in O
that O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
This O
study O
was O
designed O
to O
compare O
with O
placebo O
the O
dose-response O
effect O
of O
cyclical O
doses O
of O
the O
C21 O
progestogen O
, O
medroxyprogesterone O
acetate O
( O
MPA O
) O
on O
blood O
pressure O
( O
BP O
) O
when O
administered O
to O
normotensive O
postmenopausal O
women O
receiving O
a O
fixed O
mid-range O
daily O
dose O
of O
conjugated O
equine O
oestrogen O
( O
CEE O
) O
. O
[]

CONCLUSION O
Compared O
with O
cryotherapy O
, O
the O
diode O
laser O
was O
more O
convenient O
, O
technically O
easier O
to O
administer O
, O
and O
better O
tolerated O
by O
the O
patient O
. O
[]

RESULTS O
Subjects O
' O
mean O
age O
was O
43.6 O
years O
; O
all O
were O
women O
. O
[]

This O
manuscript O
presents O
the O
results O
of O
a O
randomized O
controlled O
trial O
testing O
the O
efficacy O
of O
interactive O
voice O
response O
( O
IVR O
) O
in O
recycling O
low O
income O
smokers O
who O
had O
previously O
used O
quitline O
( O
QL O
) O
support O
back O
to O
QL O
support O
for O
a O
new O
quit O
attempt O
. O
[]

These O
data O
provide O
novel O
evidence O
for O
the O
unique O
association O
between O
AS O
of O
the O
development O
of O
anxiety O
symptoms O
. O
[]

Patients O
were O
randomly O
assigned O
to O
receive O
or O
not O
to O
receive O
ifosfamide O
and/or O
MTP O
in O
a O
2 O
x O
2 O
factorial O
design O
. O
[]

Grade O
3 O
burns O
with O
a O
200-mum O
spot O
size O
were O
placed O
with O
both O
modalities O
. O
[]

Evaluation O
of O
umbilical O
cord O
serum O
therapy O
for O
persistent O
corneal O
epithelial O
defects O
. O
[]

A O
total O
of O
159 O
American O
Society O
of O
Anesthesiologists O
(ASA) O
physical O
status O
I O
to O
III O
patients O
scheduled O
for O
primary O
TKA O
were O
randomized O
to O
one O
of O
three O
study O
groups. O
[]

A O
prespecified O
interim O
analysis O
at O
week O
8 O
showed O
a O
greater O
than O
expected O
change O
in O
the O
primary O
outcome O
and O
supported O
early O
closing O
of O
patient O
enrolment, O
since O
this O
analysis O
indicated O
that O
the O
full O
planned O
sample O
size O
was O
not O
needed. O
[]

Moreover O
, O
the O
parietal O
P300 O
source O
strength O
increased O
after O
acute O
, O
subacute O
and O
superimposed O
infusion O
of O
Actovegin O
as O
compared O
to O
placebo O
. O
[]

The O
prevention O
of O
nausea O
, O
vomiting O
and O
appetite O
loss O
induced O
by O
remission O
induction O
chemotherapy O
for O
acute O
myeloid O
leukemia O
was O
compared O
by O
randomization O
between O
granisetron O
alone O
and O
combination O
with O
granisetron O
plus O
methylprednisolone O
. O
[]

CONCLUSION O
We O
introduced O
and O
evaluated O
an O
optimized O
patient O
care O
program O
for O
patients O
undergoing O
open O
infrarenal O
aortic O
aneurysm O
repair O
which O
showed O
a O
significant O
advantage O
for O
fast-track O
patients O
in O
terms O
of O
postoperative B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
ORR B-outcome ['Physiological-Clinical']
was O
better O
with O
the O
longer O
regimens O
( O
arm O
A O
, O
56.9 O
% O
; O
B O
, O
64 O
% O
; O
and O
C O
, O
47.6 O
% O
; O
P O
: O
=.06 O
) O
and O
was O
41 O
% O
after O
second-line O
FEC O
100 O
. O
['Physiological-Clinical']

Locomoting-to-reach O
is O
a O
basic O
perception/action O
behavior O
that O
requires O
visual O
information O
for O
the O
control O
of O
both O
locomotion O
and O
reaching O
components O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
response O
and O
safety O
were O
assessed O
on O
Days O
1 O
, O
2 O
, O
3 O
, O
4 O
to O
5 O
and O
21 O
+/- O
5 O
. O
['Physiological-Clinical']

It O
would O
be O
needed O
to O
investigate O
whether O
the O
differences O
may O
be O
distinct O
or O
not O
the O
same O
when O
other O
dosages O
are O
used O
. O
[]

[ O
Aortofemoral O
bifurcation O
bypass O
. O
[]

The O
aim O
was O
to O
evaluate O
the O
efficacy O
and O
tolerability O
of O
a O
short-term O
parenteral O
prophylaxis O
with O
Teicoplanin O
and O
the O
end-point O
of O
the O
study O
was O
the O
evaluation O
of O
wound O
contamination O
assessed O
by O
means O
of O
microbiologic O
culture O
of O
drainage O
fluid O
. O
[]

Femoral-artery O
blood O
samples O
were O
taken O
for O
assay O
of O
adrenaline O
and O
noradrenaline O
. O
[]

Representative O
samples O
of O
fractured O
specimens O
were O
observed O
by O
SEM O
( O
scanning O
electron O
microscopy O
) O
. O
[]

Efficacy O
of O
prepackaged O
, O
low O
residual O
test O
meals O
with O
4L O
polyethylene O
glycol O
versus O
a O
clear O
liquid O
diet O
with O
4L O
polyethylene O
glycol O
bowel O
preparation O
: O
a O
randomized O
trial O
. O
[]

There O
was O
also O
some O
evidence O
that O
cumulative O
time O
to O
perform O
the O
three O
100-m O
swims O
was O
decreased O
in O
the O
Cr O
group O
. O
[]

In O
the O
labetalol-treated O
patients O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
17 O
instances O
fell O
from O
198 O
+/- O
5/104 O
+/- O
4 O
mmHg O
to O
143 O
+/- O
7/89 O
+/- O
5 O
mmHg O
180 O
min O
following O
injection O
of O
labetalol O
50 O
mg O
. O
['Physiological-Clinical']

G-CSF O
was O
given O
after O
each O
course O
, O
and O
the O
next O
scheduled O
course O
was O
started O
as O
soon O
as O
neutrophil O
count O
was O
> O
1 O
x O
10 O
( O
9 O
) O
/L O
and O
platelet O
count O
was O
> O
100 O
x O
10 O
( O
9 O
) O
/L O
. O
[]

Objective:To O
investigate O
the O
efficacy O
and O
safety O
of O
LOPasparaginase O
+ O
vincristine O
+ O
dexamethasone O
chemotherapy O
combined O
with O
radiotherapy O
in O
patients O
with O
nasal O
NK/T O
cell O
lymphoma. O
[]

Participants O
were O
randomly O
assigned O
to O
fitting O
with O
NLFC O
( O
Phonak O
Naida O
V O
SP O
or O
UP O
) O
or O
with O
conventional O
processing O
in O
hearing O
aids O
, O
prescribed O
by O
using O
either O
the O
NAL O
or O
the O
DSL O
formula O
. O
[]

With O
Dimerex O
the O
mixing O
of O
the O
contrast O
medium O
with O
the O
synovial B-outcome ['Physiological-Clinical']
fluid I-outcome ['Physiological-Clinical']
was O
slower O
than O
with O
Conray O
Meglumin O
, O
and O
a O
good O
or O
fair O
image B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
as O
evaluated O
subjectively O
, O
lasted O
longer O
. O
['Physiological-Clinical', 'Life-Impact']

13.0? O
) O
. O
[]

During O
each O
period O
all O
subjects O
were O
given O
a O
15-g O
supplement O
of O
fish O
oil O
and O
either O
0 O
( O
placebo O
) O
, O
100 O
, O
200 O
, O
or O
400 O
mg O
alpha-tocopheryl O
acetate O
daily O
. O
[]

The O
most O
effective O
treatment O
regimen O
was O
VAC O
plus O
ADR O
; O
74 O
% O
of O
the O
patients O
were O
free O
of O
disease O
at O
2 O
years O
. O
[]

Children B-outcome ['Physiological-Clinical']
's O
IQs B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
comprehension I-outcome ['Life-Impact']
did O
not O
increase O
, O
but O
adaptive/social B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
scores O
and O
expressive B-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
quotients O
decreased O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

H. O
pylori O
infection O
was O
confirmed O
by O
histology O
. O
[]

Episodes O
of O
fever B-outcome ['Physiological-Clinical']
and O
neutropenia B-outcome ['Physiological-Clinical']
were O
not O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Simvastatin O
blunts O
endotoxin-induced O
tissue O
factor O
in O
vivo O
. O
[]

For O
this O
reason O
, O
the O
direction O
of O
the O
IJV O
was O
classified O
as O
typical O
in O
80 O
% O
of O
group O
I O
, O
in O
85 O
% O
of O
group O
II O
, O
but O
in O
only O
45 O
% O
of O
group O
III O
. O
[]

Visit-to-visit O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
in O
the O
European O
Lacidipine O
Study O
on O
Atherosclerosis O
: O
methodological O
aspects O
and O
effects O
of O
antihypertensive O
treatment O
. O
['Physiological-Clinical']

There O
were O
30 O
statistically O
significant O
metabolite B-outcome ['Physiological-Clinical']
differences O
in O
the O
stool O
of O
participants O
that O
consumed O
navy O
bean O
at O
day O
28 O
compared O
to O
the O
participants' O
baseline O
(p O
</= O
0.05) O
and O
26 O
significantly O
different O
metabolites B-outcome ['Physiological-Clinical']
when O
compared O
to O
the O
control O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Pre-treatment O
disease B-outcome ['Physiological-Clinical']
scores O
were O
significantly O
higher O
in O
the O
meloxicam O
group O
for O
owner B-outcome ['Physiological-Clinical']
mobility I-outcome ['Physiological-Clinical']
( O
p=0.01 O
) O
and O
veterinary B-outcome ['Physiological-Clinical']
lameness I-outcome ['Physiological-Clinical']
( O
p=0.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Safety O
and O
immunogenicity B-outcome ['Physiological-Clinical']
of O
a O
cluster O
specific O
immunotherapy O
in O
children O
with O
bronchial O
asthma O
and O
mite O
allergy O
. O
['Physiological-Clinical']

This O
may O
have O
applicability O
to O
the O
clinical O
strategy O
of O
permissive O
hypercapnia O
and O
allow O
the O
benefit O
of O
decreased O
airway B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
to O
be O
realized O
while O
minimizing O
the O
adverse O
hemodynamic O
effects O
of O
hypercapnic O
acidosis O
. O
['Physiological-Clinical']

Total O
sleep B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
was O
8.05 O
h O
( O
95 O
% O
CI O
7.65-8.44 O
) O
baseline O
, O
8.75 O
h O
( O
95 O
% O
CI O
8.56-8.98 O
) O
with O
placebo O
and O
9.84 O
h O
( O
95 O
% O
CI O
9.68-9.99 O
) O
with O
melatonin O
. O
['Physiological-Clinical']

Subjects O
randomized O
to O
NAC O
were O
initiated O
at O
900 O
mg O
daily O
for O
4 O
weeks O
, O
then O
900 O
mg O
twice O
daily O
for O
4 O
weeks O
and O
900 O
mg O
three O
times O
daily O
for O
4 O
weeks O
. O
[]

CONCLUSION O
Use O
of O
weekly O
vitamin O
A O
or O
beta O
carotene O
in O
pregnant O
women O
in O
Bangladesh O
, O
compared O
with O
placebo O
, O
did O
not O
reduce O
all-cause O
maternal O
, O
fetal O
, O
or O
infant O
mortality O
. O
[]

In O
stratum O
2 O
( O
n O
= O
84 O
) O
, O
CBRs O
were O
29.2 O
% O
with O
gefitinib O
and O
31.4 O
% O
with O
placebo O
. O
[]

METHODS O
A O
total O
of O
47 O
MONW O
individuals O
with O
hypomagnesemia O
were O
enrolled O
in O
clinical O
a O
randomized O
double-blind O
placebo-controlled O
trial O
. O
[]

RESULTS O
In O
nine O
control O
patients O
, O
there O
were O
no O
significant O
changes O
in O
the O
severity O
of O
OSA B-outcome ['Physiological-Clinical']
, O
MSNA B-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
, O
or O
HR B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Cumulative O
amount O
of O
i.v O
. O
[]

Each O
patient O
received O
up O
to O
2 O
doses O
of O
analgesic O
medication O
when O
necessary O
. O
[]

Forty-two O
diabetic O
patients O
were O
asked O
to O
access O
a O
Web O
site O
by O
using O
a O
cellular O
phone O
or O
wire O
Internet O
and O
input O
their O
blood B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
levels O
every O
day O
. O
['Physiological-Clinical']

RESULTS O
At O
month O
12 O
, O
biopsy-confirmed B-outcome ['Physiological-Clinical']
acute I-outcome ['Physiological-Clinical']
rejections I-outcome ['Physiological-Clinical']
were O
reported O
for O
15.2 O
% O
( O
induction O
) O
and O
30.4 O
% O
( O
noninduction O
) O
of O
patients O
( O
P=0.001 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
Central O
nervous O
system O
adverse O
effects O
, O
such O
as O
sedation B-outcome ['Physiological-Clinical']
, O
often O
accompany O
the O
use O
of O
first-generation O
antihistamines O
. O
['Physiological-Clinical']

49.2 O
mg/L O
, O
63.0 O
? O
[]

CONCLUSION O
Fexofenadine O
did O
not O
affect O
recovery O
to O
a O
fixed O
dose O
of O
AMP O
challenge O
or O
any O
other O
surrogate O
inflammatory O
markers O
when O
given O
as O
add-on O
therapy O
to O
corticosteroid-treatedatopic O
asthmatic O
patients O
. O
[]

DISCUSSION O
If O
ROMEO O
confirms O
that O
group O
care O
can O
be O
successfully O
implemented O
in O
different O
clinics O
, O
a O
novel O
clinico-pedagogic O
tool O
will O
have O
been O
acquired O
to O
support O
patient-centred O
education O
, O
improve O
lifestyle B-outcome ['Life-Impact']
and O
outcomes O
, O
support O
team B-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
, O
enhance O
providers O
' O
attitudes B-outcome ['Life-Impact']
and O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
was O
a O
dose O
related O
reduction O
in O
symptoms B-outcome ['Physiological-Clinical']
, O
plasma B-outcome ['Physiological-Clinical']
follicle I-outcome ['Physiological-Clinical']
stimulating I-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
, O
and O
urinary B-outcome ['Physiological-Clinical']
calcium I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
hydroxyproline I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twelve O
patients O
were O
randomized O
to O
receive O
5/microg/kg/day O
G-CSF O
and O
14 O
patients O
to O
receive O
5 O
microg/kg/day O
GM-CSF O
, O
both O
administered O
subcutaneously O
starting O
on O
day O
1 O
after O
the O
end O
of O
Dexa-BEAM O
. O
[]

Among O
the O
31 O
patients O
, O
17 O
patients O
who O
received O
pirarubicin O
instillation O
had O
fewer O
recurrences B-outcome ['Physiological-Clinical']
when O
compared O
with O
14 O
patients O
who O
received O
control O
treatment O
( O
P O
= O
0.0001 O
) O
. O
['Physiological-Clinical']

TRIAL O
REGISTRATION O
Clinicaltrials.gov O
Identifier O
: O
NCT00626587 O
. O
[]

Statistical O
analyses O
were O
conducted O
using O
Fisher O
exact O
test O
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
analyzed O
using O
Cox O
modeling O
. O
['Mortality']

The O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fracture I-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
was O
significantly O
longer O
with O
unreamed O
nails O
. O
['Physiological-Clinical']

Many O
etiologic O
factors O
cause O
a O
femoral O
head O
necrosis O
such O
as O
, O
for O
example O
, O
high-dose O
steroids O
, O
abuse O
of O
alcohol O
, O
defect O
of O
bone O
marrow O
and O
trauma O
of O
the O
hip O
. O
[]

The O
associations O
between O
the O
SNP O
and O
acute B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
were O
indicated O
by O
odds O
ratios O
( O
ORs O
) O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
, O
which O
were O
computed O
with O
logistic O
regression O
model O
. O
['Adverse-effects']

BACKGROUND O
In O
patients O
with O
ventricular O
tachycardia O
( O
VT O
) O
and O
a O
history O
of O
myocardial O
infarction O
, O
intervention O
with O
an O
implantable O
cardioverter O
defibrillator O
( O
ICD O
) O
can O
prevent O
sudden O
cardiac O
death O
and O
thereby O
reduce O
total O
mortality O
. O
[]

Scores O
for O
cleansing B-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
entire I-outcome ['Physiological-Clinical']
colon I-outcome ['Physiological-Clinical']
as O
determined O
by O
endoscopists O
who O
were O
blinded O
to O
the O
cathartic O
agent O
were O
highest O
in O
patients O
receiving O
sodium O
phosphate O
( O
p O
< O
0.02 O
) O
. O
['Physiological-Clinical']

CONCLUSION O
CM O
administered O
for O
2 O
wk O
significantly O
improved O
clinical O
measurements O
of O
autism O
severity O
and O
decreased O
serum O
level O
of O
TARC O
in O
autistic O
children O
, O
but O
subsequent O
studies O
are O
recommended O
. O
[]

These O
results O
led O
to O
the O
termination O
of O
the O
study O
based O
on O
the O
raised O
criteria O
since O
we O
anticipated O
the O
actual O
cause O
of O
the O
shoulder O
pain O
to O
be O
due O
to O
an O
unknown O
factor O
. O
[]

However, O
limited O
studies O
to O
investigate O
the O
association O
of O
health O
education O
via O
Wechat O
platform O
on O
increased O
the O
basic O
self-care O
skills O
and O
glycemic O
control O
rate O
in O
patients O
with O
type O
2 O
diabetes. O
[]

Fifty O
of O
the O
60 O
girls O
( O
83 O
% O
) O
had O
reached O
a O
normal B-outcome ['Physiological-Clinical']
FH I-outcome ['Physiological-Clinical']
( O
FH O
SD O
score O
, O
more O
than O
-2 O
) O
. O
['Physiological-Clinical']

RESULTS O
Both O
topical O
therapies O
were O
equally O
effective O
with O
initial O
response O
rates O
of O
86 O
% O
( O
18/21 O
) O
for O
BCG O
and O
81 O
% O
( O
17/21 O
) O
for O
mitomycin O
C O
plus O
doxorubicin O
, O
irrespective O
of O
the O
tumor O
grade O
. O
[]

In O
the O
current O
article O
, O
we O
address O
the O
existing O
assumption O
in O
the O
literature O
on O
cognitive O
behavioral O
treatment O
of O
PTSD O
that O
patients O
with O
severe O
negative O
trauma-related O
cognitions O
would O
benefit O
more O
from O
a O
treatment O
package O
that O
includes O
exposure O
and O
cognitive O
techniques O
compared O
with O
a O
treatment O
that O
includes O
exposure O
only O
. O
[]

Effects O
of O
a O
long-term O
vitamin O
D O
and O
calcium O
supplementation O
on O
falls B-outcome ['Life-Impact']
and O
parameters O
of O
muscle B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
community-dwelling O
older O
individuals O
. O
['Life-Impact', 'Physiological-Clinical']

Clinical O
data O
comparing O
the O
renal O
effects O
of O
ACEIs O
and O
ARBs O
, O
either O
singly O
or O
in O
combination O
, O
are O
scarce O
and O
usually O
concern O
the O
use O
of O
standard O
or O
high O
doses O
. O
[]

AIM O
To O
compare O
the O
efficacy O
of O
human O
recombinant O
FSH O
( O
r-hFSH O
) O
plus O
human O
recombinant O
LH O
( O
r-hLH O
) O
in O
a O
2:1 O
ratio O
with O
highly O
purified O
human O
menopausal O
gonadotropin O
( O
hMG-HP O
) O
urinary O
extract O
, O
containing O
LH-like O
activity O
, O
in O
women O
with O
HH O
. O
[]

The O
primary O
endpoint O
is O
treatment O
discontinuation B-outcome ['Life-Impact']
rate O
for I-outcome ['Life-Impact']
any I-outcome ['Life-Impact']
causes I-outcome ['Life-Impact']
. O
['Life-Impact']

It O
was O
used O
the O
Autism B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
to O
interview O
the O
mothers O
, O
and O
the O
Sample O
of O
Vocal B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
( O
SVB O
) O
, O
in O
three O
occasions O
: O
at O
the O
beginning O
of O
the O
intervention O
process O
( O
time O
0 O
) O
, O
six O
months O
later O
( O
time O
1 O
) O
and O
12 O
months O
later O
( O
time O
2 O
) O
. O
['Life-Impact', 'Life-Impact']

The O
drug O
and O
placebo O
were O
administered O
in O
a O
double-blind O
crossover O
design O
over O
17 O
weeks O
. O
[]

PROCEDURE O
After O
tooth O
scaling O
and O
root O
planing O
, O
2 O
treatment O
, O
1 O
placebo O
, O
and O
1 O
control O
site O
were O
selected O
for O
each O
dog O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Highly O
distressed B-outcome ['Life-Impact']
women O
did O
not O
derive O
a O
['Life-Impact']

DESIGN O
We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Based O
on O
this O
study O
, O
a O
second O
study O
was O
implemented O
using O
both O
the O
estrogen-receptor O
( O
ER O
) O
content O
of O
the O
primary O
tumor O
and O
axillary O
nodal O
status O
to O
select O
therapy O
. O
[]

The O
probiotic O
approach O
may O
thus O
offer O
a O
new O
direction O
in O
the O
search O
for O
future O
foods O
for O
allergy O
treatment O
and O
prevention O
strategies O
. O
[]

This O
study O
was O
therefore O
designed O
to O
compare O
the O
effectiveness O
of O
0.4 O
% O
Dexamethasone O
sodium O
phosphate O
( O
DEX-P O
) O
phonophoresis O
( O
PH O
) O
with O
0.4 O
% O
DEX-P O
iontophoresis O
( O
ION O
) O
therapy O
in O
the O
management O
of O
patients O
with O
knee O
joint O
OA O
. O
[]

The O
following O
were O
measured O
before O
and O
after O
intervention O
: O
strength B-outcome ['Physiological-Clinical']
by O
one O
repetition O
maximum O
, O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
by O
the O
7-d O
accelerometry O
and O
the O
3-d O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
recall O
, O
dietary B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
by O
3-d O
records O
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
by O
dual-energy O
x-ray O
absorptiometry O
( O
DEXA O
) O
, O
glucose/insulin B-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
by O
oral O
glucose O
tolerance O
test O
, O
and O
intravenous O
glucose O
tolerance O
test O
with O
minimal O
modeling O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Polymorphisms O
of O
ADORA2A O
modulate O
psychomotor O
vigilance O
and O
the O
effects O
of O
caffeine O
on O
neurobehavioural B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
sleep B-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
after O
sleep O
deprivation O
. O
['Life-Impact', 'Physiological-Clinical']

Functional O
performance O
was O
assessed O
using O
timed O
up O
and O
go O
, O
chair O
stand O
, O
single O
leg O
stand O
, O
and O
step O
test O
. O
[]

We O
then O
related O
the O
norepinephrine O
content O
to O
ischemic O
episodes O
assessed O
by O
48-h O
Holter O
recording O
, O
blood O
pressure O
reading O
by O
ambulatory O
blood O
pressure O
monitoring O
and O
patients O
' O
diaries O
. O
[]

RESULTS O
One-hundred O
and O
sixty-six O
patients O
were O
recruited O
. O
[]

Trimetazidine O
: O
a O
new O
concept O
in O
the O
treatment O
of O
angina O
. O
[]

The O
majority O
of O
retrospective O
studies O
and O
subjective O
experiences O
favor O
PTFE O
grafts O
over O
BCAHs O
. O
[]

The O
overall O
rate O
of O
post-operative B-outcome ['Physiological-Clinical']
deep I-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
including I-outcome ['Physiological-Clinical']
meningitis I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
abscesses I-outcome ['Physiological-Clinical']
was O
also O
significantly O
( O
p O
less O
than O
0.005 O
) O
different O
with O
3.1 O
% O
in O
the O
cefotiam O
versus O
9.0 O
% O
in O
the O
control O
group O
. O
['Physiological-Clinical']

In O
our O
recent O
randomized O
trial O
in O
HF O
, O
abolition O
of O
OSA O
by O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
increased O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LVEF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
lowered O
morning B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Updated O
analysis O
of O
E1684 O
, O
E1690 O
, O
and O
E1694 O
confirmed O
their O
original O
conclusions O
, O
now O
at O
median O
follow-up O
intervals O
of O
2.1-12.6 O
years O
. O
[]

Furthermore O
, O
the O
HR O
, O
double O
product O
and O
Borg O
score O
at O
isotime O
were O
significantly O
lower O
in O
the O
LED O
group O
and O
in O
the O
exercise O
group O
( O
p O
< O
0.05 O
) O
. O
[]

Caregiver-mediated O
intervention O
for O
low-resourced O
preschoolers O
with O
autism O
: O
an O
RCT O
. O
[]

Introduction: O
Videoconferencing O
has O
been O
employed O
in O
numerous O
medical O
education O
settings O
ranging O
from O
remote O
supervision O
of O
medical O
trainees O
to O
conducting O
residency O
interviews. O
[]

Each O
treatment O
was O
given O
for O
3 O
months O
. O
[]

The O
?TBS O
values O
of O
Groups O
1 O
and O
4 O
were O
similar O
and O
higher O
than O
those O
of O
Group O
2 O
. O
[]

Publication O
date: O
2019/01/08 O
06:00 O
[entrez] O
[]

Methods: O
A O
random O
cluster O
sampling O
method O
has O
been O
used, O
including O
300 O
rural O
residents O
aged O
above O
18 O
years O
old O
from O
three O
villages O
(184 O
in O
control O
group, O
116 O
in O
intervention O
group), O
in O
order O
to O
proceed O
the O
physical O
check-up O
and O
health O
education O
programs. O
[]

Doses O
were O
titrated O
to O
the O
optimum O
. O
[]

CONCLUSIONS O
All O
patients O
in O
both O
groups O
had O
an O
increasing O
tendency O
to O
free O
radical O
production O
during O
early O
reperfusion O
. O
[]

No O
additional O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
observed O
in O
the O
EBUS-TBNA O
plus O
CDPs O
group O
. O
['Adverse-effects']

Gastrointestinal B-outcome ['Physiological-Clinical']
toxicity I-outcome ['Physiological-Clinical']
was O
severe O
in O
both O
groups O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
109 O
patients O
with O
HBV O
were O
randomized O
into O
FK506 O
group O
( O
52 O
cases O
) O
and O
CsA O
group O
( O
57 O
cases O
) O
after O
KT O
, O
and O
a O
2-year-long O
follow-up O
of O
the O
patients O
was O
conducted O
to O
record O
the O
patient O
and O
graft B-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
, O
incidence O
of O
acute B-outcome ['Physiological-Clinical']
graft I-outcome ['Physiological-Clinical']
rejection I-outcome ['Physiological-Clinical']
and O
postoperative B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

CLINICAL O
TRIAL O
REGISTRATION O
URL O
: O
http O
: O
//www.clinicaltrials.gov O
. O
[]

BACKGROUND O
Mineralocorticoid-receptor O
antagonists O
improve O
the O
prognosis O
for O
patients O
with O
heart O
failure O
and O
a O
reduced O
left O
ventricular O
ejection O
fraction O
. O
[]

The O
order O
of O
the O
experiments O
was O
randomized O
between O
sham O
( O
60 O
min O
of O
seated O
upright O
rest O
) O
and O
exercise O
( O
60 O
min O
of O
upright O
cycling O
at O
60 O
% O
peak O
aerobic O
capacity O
) O
. O
[]

BACKGROUND O
We O
report O
the O
10-year O
results O
of O
the O
EORTC O
trial O
24891 O
comparing O
a O
larynx-preservation O
approach O
to O
immediate O
surgery O
in O
hypopharynx O
and O
lateral O
epilarynx O
squamous O
cell O
carcinoma O
. O
[]

Their O
persistent O
sleeplessness O
was O
tentatively O
attributed O
to O
an O
undiagnosed O
intolerance O
to O
cow O
's O
milk O
. O
[]

An O
increased O
erythrocyte O
membrane O
polyunsaturated O
fatty O
acid O
content O
might O
correct O
the O
lower O
erythrocyte O
deformability O
in O
cyclosporin O
treated O
patients O
. O
[]

RESULTS O
The O
study O
enrolled O
195 O
patients O
, O
of O
whom O
188 O
were O
eligible O
for O
analysis O
. O
[]

Artificial O
tear O
instillation O
alone O
or O
CC O
combined O
with O
ATs O
or O
EH O
significantly O
reduced O
the O
temperature O
( O
P O
< O
0.05 O
) O
. O
[]

These O
parameters O
are O
the O
net O
result O
of O
combinations O
of O
genetic O
alterations O
effecting O
tumour O
behaviour O
and O
could O
potentially O
reflect O
subtypes O
that O
respond O
differently O
to O
endocrine O
treatment O
. O
[]

0.3 O
, O
4.3 O
? O
[]

This O
finding O
would O
indicate O
that O
the O
chance O
of O
developing O
cicatricial O
ectropion O
with O
any O
of O
the O
tested O
combinations O
of O
TCA O
should O
be O
very O
remote O
. O
[]

At O
9-12 O
months O
after O
AMI O
, O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
remained O
significantly O
higher O
than O
at O
baseline O
in O
both O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
investigate O
etomidate O
administration O
with O
or O
without O
flumazenil O
in O
autistic O
children O
who O
underwent O
intrathecal O
transplantation O
of O
stem O
cells O
by O
lumbar O
puncture O
. O
[]

Breast O
Cancer O
Education O
Intervention O
modules O
and O
interventions O
are O
organized O
within O
a O
QOL O
framework O
. O
[]

Having O
health B-outcome ['Life-Impact']
insurance I-outcome ['Life-Impact']
( O
odds O
ratio O
= O
7.20 O
, O
P O
= O
.00 O
) O
and O
a O
negative O
urine B-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
screen I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
= O
.56 O
, O
P O
= O
.04 O
) O
were O
significant O
predictors O
of O
being O
in O
HBP O
care O
. O
['Life-Impact', 'Physiological-Clinical']

The O
results O
in O
diabetic O
patients O
were O
similar O
to O
those O
in O
nondiabetic O
patients O
. O
[]

Atrial O
flutter O
cycle O
length O
and O
atrial O
monophasic O
action O
potential O
duration O
recorded O
from O
the O
right O
atrium O
during O
atrial O
flutter O
were O
measured O
at O
baseline O
and O
following O
infusion O
of O
ibutilide O
, O
procainamide O
, O
or O
placebo O
. O
[]

METHODS O
Multicenter O
, O
randomized O
, O
controlled O
, O
two O
arm-parallel O
, O
clinical O
trial O
. O
[]

Operating B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
, O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
functional B-outcome ['Life-Impact']
index I-outcome ['Life-Impact']
( O
1 O
week O
postoperatively O
) O
, O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
, O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
full I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
were O
documented O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Prothrombin O
fragments O
1+2 O
and O
urinary O
11-dehydro-thromboxane O
B2 O
( O
TXB2 O
) O
were O
additionally O
measured O
in O
60 O
of O
100 O
patients O
( O
30 O
of O
whom O
were O
smokers O
) O
and O
in O
24 O
healthy O
controls O
. O
[]

The O
6 O
minute O
walk O
in O
idiopathic O
pulmonary O
fibrosis O
: O
longitudinal O
changes O
and O
minimum O
important O
difference O
. O
[]

rHu O
EPO O
treatment O
affects O
the O
T O
lymphocyte O
subsets O
inducing O
a O
deep O
decrease O
of O
CD8 B-outcome ['Physiological-Clinical']
and O
CD16 B-outcome ['Physiological-Clinical']
cell O
percentage O
leading O
to O
normalisation O
of O
the O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
duration O
of O
treatment O
lasted O
for O
8 O
weeks. O
[]

The O
study O
duration O
was O
3 O
years O
; O
however O
, O
the O
2.5 O
mg O
group O
was O
discontinued O
by O
protocol O
amendment O
after O
2 O
years O
. O
[]

Survival O
analyses O
were O
performed O
via O
the O
Kaplan-Meier O
method. O
[]

In O
part O
B O
, O
cediranib O
30 O
mg/day O
appeared O
to O
be O
the O
most O
sustainable O
for O
chronic O
dosing O
. O
[]

CONCLUSION O
The O
findings O
of O
this O
study O
showed O
that O
the O
diode O
laser O
can O
perform O
a O
significant O
reduction O
in O
the O
hair B-outcome ['Physiological-Clinical']
amount I-outcome ['Physiological-Clinical']
without O
significant O
epidermal O
damage O
, O
at O
least O
for O
a O
short O
period O
. O
['Physiological-Clinical']

Body O
mass O
index O
( O
BMI O
) O
and O
waist B-outcome ['Physiological-Clinical']
circumference I-outcome ['Physiological-Clinical']
did O
not O
change O
in O
any O
groups O
except O
for O
the O
NETE-8 O
in O
which O
BMI O
increased O
significantly O
( O
p O
= O
0.02 O
) O
at O
the O
end O
of O
the O
treatment O
period O
. O
['Physiological-Clinical']

One O
group O
had O
open O
appendicectomy O
, O
as O
planned O
. O
[]

Participants O
responded O
to O
the O
presence O
of O
a O
green O
K O
in O
an O
array O
of O
two O
, O
five O
, O
or O
nine O
distractor O
stimuli O
during O
a O
40-min O
vigil O
. O
[]

The O
main O
outcomes O
were O
mean O
change O
of O
visual O
analog O
rating O
scale O
( O
VARS O
) O
and O
index O
scores O
measured O
through O
a O
quality-of-life O
questionnaire O
( O
EQ-5D O
) O
, O
and O
changes O
in O
the O
visual O
analog O
scale O
( O
VAS O
) O
, O
all O
of O
which O
were O
assessed O
at O
each O
visit O
. O
[]

CONCLUSIONS O
A O
program O
of O
cooperation O
between O
physician O
and O
pharmacist O
was O
successful O
in O
reducing O
cardiovascular O
risk O
factors O
in O
patients O
with O
mild O
to O
moderate O
hypertension O
by O
promoting O
better O
blood O
pressure O
( O
BP O
) O
control O
, O
appropriate O
changes O
in O
antihypertensive O
medications O
, O
and O
beneficial O
changes O
in O
lifestyle O
. O
[]

Few O
randomized O
controlled O
trials O
have O
been O
aimed O
specifically O
at O
lifestyle O
issues O
among O
persons O
with O
a O
psychiatric O
disability O
. O
[]

It O
has O
proven O
properties O
like O
anti-inflammatory, O
antioxidant, O
antimicrobial, O
hepatoprotective, O
immunostimulant, O
antiseptic, O
antimutagenic, O
and O
it O
also O
accelerates O
wound O
healing. O
[]

Participants O
will O
be O
randomly O
allocated O
to O
hospital-based O
or O
home-based O
pulmonary O
rehabilitation O
. O
[]

CONCLUSION O
The O
effect O
of O
acupuncture O
combined O
with O
drug O
for O
treatment O
of O
male O
osteoporosis O
is O
good O
with O
little O
adverse O
reaction O
. O
[]

Complete O
diet O
collections O
were O
analyzed O
for O
nitrogen O
(for O
protein), O
fat, O
energy, O
and O
carbohydrate O
by O
difference. O
[]

Twenty O
subjects O
, O
who O
have O
TMJ O
pain O
, O
were O
included O
for O
this O
study O
and O
randomly O
assigned O
to O
either O
the O
experimental O
group O
( O
n O
= O
10 O
) O
or O
the O
control O
group O
( O
n O
= O
10 O
) O
. O
[]

All O
outcomes O
were O
assessed O
by O
a O
blinded O
outcomes O
researcher O
using O
a O
standardised O
outcomes O
measurement O
tool O
developed O
specifically O
for O
this O
population O
. O
[]

Grade O
? O
[]

All O
participants O
completed O
a O
22-item O
test O
3 O
weeks O
later O
. O
[]

Eligible O
patients O
at O
National O
Cholesterol O
Education O
Program-Adult O
Treatment O
Panel O
III O
LDL-C B-outcome ['Physiological-Clinical']
treatment O
goal O
on O
a O
statin O
, O
with O
or O
without O
other O
lipid-modifying O
medications O
, O
are O
treated O
with O
anacetrapib O
, O
100 O
mg O
, O
or O
placebo O
for O
18 O
months O
, O
followed O
by O
a O
3-month O
, O
poststudy O
follow-up O
. O
['Physiological-Clinical']

First-intron O
polymorphisms O
with O
greater O
numbers O
of O
CA O
dinucleotide O
repeats O
tend O
to O
downregulate O
EGFR O
expression O
, O
which O
suggests O
that O
this O
polymorphism O
may O
modulate O
susceptibility O
to O
lung O
cancer O
. O
[]

Clinical O
trial O
: O
exposure O
to O
ribavirin O
predicts O
EVR O
and O
SVR O
in O
patients O
with O
HCV O
genotype O
1 O
infection O
treated O
with O
peginterferon O
alpha-2a O
plus O
ribavirin O
. O
[]

OBJECTIVE O
To O
determine O
the O
effect O
of O
patient O
position O
on O
the O
reproducibility O
of O
cardiac O
output O
measurements O
. O
[]

Journal-Name:JAMA O
[]

Phase O
I O
compared O
the O
new O
spirometer O
with O
the O
mini-Wright O
peak O
flow O
meter O
and O
Phase O
2 O
compared O
the O
new O
spirometer O
and O
the O
turbine O
spirometer O
. O
[]

29.88 O
) O
pg/ml O
, O
t O
= O
4.67 O
- O
14.23 O
, O
P O
< O
0.01 O
) O
, O
also O
lower O
than O
those O
of O
control O
group O
20 O
days O
after O
the O
treatment O
( O
PRA O
( O
2.02 O
? O
[]

This O
study O
investigates O
the O
effect O
of O
systemic O
lidocaine O
on O
experimental-induced B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
in O
25 O
volunteers O
. O
['Physiological-Clinical']

[ O
Administration O
of O
tobramycin O
aerosols O
in O
patients O
with O
nosocomial O
pneumonia O
: O
a O
preliminary O
study O
] O
. O
[]

The O
primary O
efficacy O
end O
point O
was O
the O
skeletal-related O
event O
( O
SRE O
) O
rate O
ratio O
between O
treatment O
groups O
. O
[]

METHODS O
One O
hundred O
eighty-three O
older O
adults O
( O
age O
72.7 O
+/- O
6 O
years O
, O
range O
56-93 O
; O
body O
mass O
index O
28.2 O
+/- O
4.9 O
, O
range O
16.6-46.0 O
) O
were O
recruited O
from O
a O
New O
Zealand O
falls O
prevention O
intervention O
trial O
. O
[]

The O
hormonal O
receptor O
status O
was O
determined O
in O
30 O
patients O
of O
the O
group O
I O
and O
23 O
patients O
of O
the O
group O
II O
. O
[]

SETTING O
Needle O
exchange O
program-Providence O
, O
Rhode O
Island O
, O
USA O
. O
[]

Although O
long-term O
follow-up O
studies O
are O
needed O
to O
confirm O
the O
results O
, O
this O
study O
suggests O
that O
cyproheptadine O
augmentation O
may O
be O
effective O
in O
treating O
chronic O
schizophrenic B-outcome ['Physiological-Clinical']
patients O
who O
are O
intolerant O
of O
extrapyramidal B-outcome ['Physiological-Clinical']
side I-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
of O
conventional O
antipsychotics O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Available O
data O
are O
not O
sufficient O
to O
serve O
as O
a O
basis O
for O
firm O
dietary O
advice O
. O
[]

RESULTS O
There O
were O
no O
significant O
differences O
with O
respect O
to O
overall O
mood B-outcome ['Life-Impact']
impact O
between O
the O
medication O
arms O
. O
['Life-Impact']

Median O
post-hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
1.7 O
days O
for O
group O
A O
while O
it O
was O
longer O
( O
2.9 O
days O
) O
for O
group O
B O
. O
['Resource-use']

After O
six O
months O
of O
NHT O
therapy O
the O
proportion O
of O
patients O
with O
pathological B-outcome ['Physiological-Clinical']
stage I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
( O
67 O
% O
vs. O
36 O
% O
, O
respectively O
) O
and O
negative O
margins B-outcome ['Physiological-Clinical']
was O
greater O
than O
after O
3 O
months O
( O
92 O
% O
vs. O
42 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
both O
social O
and O
non-social O
cues O
shifted O
attention B-outcome ['Life-Impact']
to O
the O
cued O
location O
in O
children O
with O
autism O
. O
['Life-Impact']

TEN O
versus O
TPN O
following O
major O
abdominal O
trauma O
-- O
reduced O
septic O
morbidity O
. O
[]

The O
findings O
revealed O
that O
women O
were O
more O
likely O
than O
men O
to O
attend B-outcome ['Resource-use']
aftercare I-outcome ['Resource-use']
. O
['Resource-use']

Patients O
were O
randomised O
to O
six O
cycles O
of O
FEC O
( O
75 O
) O
or O
FEC O
( O
90 O
) O
, O
with O
all O
three O
drugs O
given O
on O
day O
1 O
of O
each O
14-day O
cycle O
. O
[]

METHODS O
Patients O
with O
a O
diagnosis O
of O
HP O
gastritis O
or O
peptic O
ulcer O
disease O
confirmed O
using O
endoscopy O
and O
stool O
antigen O
testing O
were O
eligible O
for O
inclusion O
in O
this O
study O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
below-knee O
amputation O
on O
the O
hip O
isometric O
muscle O
strength O
and O
effect O
of O
rehabilitation O
on O
improvement O
of O
hip O
muscle O
strength O
in O
below-knee O
amputees O
, O
secondary O
to O
war O
wounding O
. O
[]

All O
children O
returned O
to O
full B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
Similar O
results O
were O
obtained O
in O
patients O
in O
2nd O
group, O
where O
MPFL O
was O
reconstructed O
with O
ipsilateral O
gracilis O
tendon. O
[ O
[['Life-Impact']]

A O
further O
4 O
weeks O
of O
combined O
therapy O
enhanced O
most O
anticoagulant B-outcome ['Physiological-Clinical']
effects I-outcome ['Physiological-Clinical']
only O
when O
atorvastatin O
was O
added O
to O
quinapril O
. O
['Physiological-Clinical']

DESIGN O
Reanalysis O
of O
the O
baseline O
prediction O
model O
for O
the O
development O
of O
POAG O
from O
the O
Ocular O
Hypertension O
Treatment O
Study O
( O
OHTS O
) O
substituting O
IOP O
adjusted O
for O
CCT O
using O
5 O
different O
correction O
formulae O
for O
unadjusted O
IOP O
. O
[]

These O
are O
the O
branching O
case O
pathways O
( O
present O
or O
absent O
) O
and O
structured O
clinical O
reasoning O
feedback O
( O
present O
or O
absent O
) O
. O
[]

Several O
studies O
demonstrated O
that O
polyphenols O
are O
able O
to O
inhibit O
the O
growth O
of O
TMA-producing O
bacterial O
strains, O
and O
resveratrol O
(RSV) O
reduced O
TMAO O
levels O
in O
mice. O
[]

BACKGROUND O
Insulin-like O
growth O
factors O
( O
IGF-1 O
and O
IGF-2 O
) O
bind O
to O
the O
IGF-1 O
receptor O
( O
IGF-1R O
) O
, O
increasing O
cell B-outcome ['Physiological-Clinical']
proliferation I-outcome ['Physiological-Clinical']
and O
survival B-outcome ['Mortality']
. O
['Physiological-Clinical', 'Mortality']

Neutrophil O
C3bi O
receptor O
expression O
was O
measured O
at O
0 O
and O
24 O
hours O
. O
[]

The O
use O
of O
the O
transition O
zone O
volume O
for O
this O
correction O
results O
in O
a O
higher O
discriminatory O
potential O
when O
compared O
to O
the O
use O
of O
the O
total O
prostate O
volume O
; O
however O
, O
the O
observed O
difference O
was O
not O
statistically O
significant O
. O
[]

The O
main O
factors O
were O
two O
sources O
of O
dietary O
CP O
and O
four O
levels O
of O
RPLM O
. O
[]

There O
were O
no O
statistically O
significant O
differences O
between O
groups O
in O
the O
amount O
of O
hydrocodone O
bitartrate O
consumption O
. O
[]

Significantly O
fewer O
patients O
in O
the O
paracetamol O
group O
received O
rescue O
analgesics O
compared O
to O
the O
placebo O
group O
( O
9.5 O
% O
vs. O
65.6 O
% O
, O
respectively O
) O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
after O
2 O
years O
was O
89 O
% O
after O
stenting O
and O
70 O
% O
after O
angioplasty O
. O
['Physiological-Clinical']

Fifteen O
subjects O
participated O
in O
the O
experiment O
. O
[]

For O
the O
208 O
patients O
evaluable O
for O
safety O
, O
the O
most O
common O
grade O
3/4 O
toxicity B-outcome ['Adverse-effects']
for O
each O
regimen O
was O
neutropaenia B-outcome ['Physiological-Clinical']
, O
with O
64 O
% O
, O
57 O
% O
, O
and O
68 O
% O
for O
GP1 O
, O
GP2 O
, O
and O
GD O
, O
respectively O
. O
['Adverse-effects', 'Physiological-Clinical']

Patients O
randomized O
to O
V.A.C O
. O
( O
[]

Recatheterization O
and O
submaximal O
exercise O
thallium-201 O
single O
photon O
emission O
computed O
tomography O
were O
performed O
before O
hospital O
discharge O
. O
[]

Despite O
its O
high O
prevalence O
, O
medical O
teams O
often O
overlook O
malnutrition O
, O
and O
screening O
of O
these O
patients O
is O
not O
routine O
. O
[]

METHODS O
Data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
'The O
Body O
& O
Cancer O
Trial O
' O
. O
[]

Of O
children O
who O
were O
using O
spoken O
language O
at O
age O
8 O
years O
, O
several O
baseline O
behaviors O
predicted O
their O
later O
ability O
, O
including O
earlier O
age O
of O
entry O
into O
the O
study O
, O
initiating O
joint B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
skill I-outcome ['Life-Impact']
, O
['Life-Impact']

Dietary O
outcome O
measures O
in O
the O
areas O
of O
saturated B-outcome ['Life-Impact']
fat I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
( O
g O
) O
, O
and O
the O
intake O
of O
fruit B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
serves I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
vegetables B-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
serves I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
, O
grain B-outcome ['Life-Impact']
and O
cereals B-outcome ['Life-Impact']
as O
total O
and O
wholegrain B-outcome ['Life-Impact']
( O
serves O
) O
were O
collected O
using O
7-day O
estimated O
dietary O
records O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
Wind-up O
occurred O
only O
with O
the O
2 O
Hz O
train O
in O
the O
UO O
and O
hand O
( O
both O
p=0.01 O
) O
. O
[]

Vinorelbine O
is O
an O
important O
chemotherapy O
option O
for O
MBC O
. O
[]

CONCLUSION O
TGF-beta O
1 O
had O
no O
beneficial O
effects O
on O
wound B-outcome ['Physiological-Clinical']
healing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
patients O
were O
dialyzed O
against O
the O
same O
calcium O
dialyzate O
( O
1.62 O
mmol/l O
) O
. O
[]

The O
effect O
of O
the O
micronutrients O
on O
the O
outcome O
variables O
growth O
, O
biochemical O
status O
, O
mental B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
and O
bone B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
were O
assessed O
. O
['Life-Impact', 'Physiological-Clinical']

RESULTS O
A O
total O
of O
200 O
patients O
were O
enrolled O
. O
[]

The O
preparation O
of O
the O
bis O
( O
D3-methyloxime O
) O
, O
bis-methyl O
ester O
of O
PGE-M O
containing O
a O
tritium O
tracer O
in O
position O
2 O
which O
was O
used O
as O
internal O
standard O
for O
the O
SIM O
method O
is O
described O
. O
[]

Our O
data O
suggest O
that O
enhanced O
activation O
of O
the O
mTOR O
signaling O
pathway O
is O
playing O
a O
role O
in O
the O
greater O
synthesis O
of O
muscle O
proteins O
when O
resistance O
exercise O
is O
followed O
by O
EAA+CHO O
ingestion O
. O
[]

Group O
5 O
received O
placebo O
plus O
G-CSF O
5 O
microg/kg/day O
. O
[]

CONCLUSION O
We O
conclude O
that O
chronic O
allergen O
exposure O
induces O
inflammatory O
changes O
in O
the O
bronchial O
mucosa O
. O
[]

Dental O
bacteremia O
in O
children O
. O
[]

Suppression O
of O
immediate O
and O
late O
anti-IgE-induced B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
by O
topically O
applied O
alcohol/onion O
extract O
. O
['Physiological-Clinical']

The O
treated O
area O
was O
sampled O
by O
the O
scrub-wash O
method O
immediately O
before O
treatment O
began O
and O
after O
2 O
and O
4 O
weeks O
, O
and O
microorganisms O
were O
enumerated O
and O
identified O
. O
[]

The O
intervention O
subjects O
are O
individually O
guided O
to O
increase O
their O
level O
of O
physical O
activity O
. O
[]

Theorists O
have O
long O
debated O
the O
wisdom O
of O
therapists O
disclosing B-outcome ['Life-Impact']
personal I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
during O
psychotherapy O
. O
['Life-Impact']

Although O
midazolam O
failed O
to O
produce O
anaesthesia B-outcome ['Resource-use']
in O
the O
dose O
range O
used O
, O
the O
dose O
of O
propofol O
['Resource-use']

Journal-Name:BMC O
public O
health O
[]

Plasma O
A? O
( O
1-x O
) O
and O
A? O
( O
1-40 O
) O
increased O
dose O
dependently O
, O
and O
mean O
CSF O
A? O
( O
1-x O
) O
increased O
38 O
% O
from O
baseline O
with O
10 O
mg/kg O
( O
P O
= O
0.002 O
vs O
placebo O
) O
. O
[]

There O
was O
also O
no O
significant O
difference O
in O
outcome O
after O
PDT O
. O
[]

During O
delayed O
intensification O
, O
all O
patients O
received O
a O
dexamethasone O
dosage O
of O
10 O
mg/m O
( O
2 O
) O
/d O
for O
21 O
days O
, O
with O
taper O
. O
[]

During O
the O
first O
week O
of O
treatment O
, O
the O
goal O
of O
diastolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
of O
less O
than O
90 O
mmHg O
was O
reached O
by O
40 O
% O
of O
the O
enalapril O
group O
and O
62 O
% O
of O
the O
lisinopril O
group O
; O
by O
the O
end O
of O
the O
titration O
period O
, O
98 O
% O
and O
96 O
% O
, O
respectively O
, O
had O
achieved O
the O
BP B-outcome ['Physiological-Clinical']
goal O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
sample O
of O
2985 O
previous O
QL O
callers O
were O
randomized O
to O
either O
receive O
IVR O
screening O
for O
current O
smoking O
( O
control O
group O
) O
or O
IVR O
screening O
plus O
an O
IVR O
intervention O
. O
[]

The O
results O
show O
that O
the O
experimental O
group O
demonstrated O
significantly O
greater O
improvement O
in O
self-control B-outcome ['Life-Impact']
than O
the O
control O
group O
, O
which O
concurs O
with O
the O
parental O
reports O
of O
reduced O
autistic B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
and O
increased O
control O
of O
temper B-outcome ['Life-Impact']
and O
behaviors B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Measures O
included O
a O
composite O
strength B-outcome ['Life-Impact']
score O
(bench O
press O
+ O
squat). O
[['Life-Impact']]

Electromyography-measured O
eyestrain B-outcome ['Physiological-Clinical']
was O
less O
with O
toric O
versus O
spherical O
contact O
lenses O
at O
fitting O
(least-square O
ratio O
of O
toric O
over O
spherical=0.72; O
P=0.0019) O
but O
not O
at O
follow-up O
(ratio=0.86; O
P=0.11). O
[['Physiological-Clinical']]

The O
Delta O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
and O
Delta O
cardiac B-outcome ['Physiological-Clinical']
output O
values O
were O
lower O
in O
the O
Group O
R O
(P O
= O
.02 O
and O
P O
= O
.04, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

The O
results O
of O
our O
manikin O
study O
suggest O
that O
for O
personnel O
not O
experienced O
in O
tracheal O
intubation O
, O
the O
LTS-D O
offers O
a O
good O
alternative O
to O
ET O
and O
BMV O
to O
manage O
the O
airway O
during O
resuscitation O
, O
and O
to O
avoid O
the O
failure O
to O
achieve O
tracheal O
intubation O
with O
the O
ET O
, O
and O
the O
failure O
to O
achieve O
adequate O
ventilation O
with O
the O
BMV O
. O
[]

The O
healing B-outcome ['Physiological-Clinical']
rate O
did O
not O
differ O
significantly O
between O
the O
two O
treatment O
groups O
. O
['Physiological-Clinical']

The O
treated O
skin O
removed O
at O
the O
time O
of O
blepharoplasty O
was O
reviewed O
in O
a O
masked O
fashion O
by O
a O
dermatopathologist O
to O
determine O
the O
depth O
of O
necrosis O
. O
[]

Five O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
documented O
during O
the O
clinical O
investigation O
, O
none O
of O
which O
was O
considered O
by O
the O
investigators O
to O
be O
related O
to O
the O
study O
medication O
. O
['Adverse-effects']

In O
the O
BAL O
, O
there O
were O
no O
NO2-induced O
changes O
in O
either O
cell B-outcome ['Physiological-Clinical']
numbers I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
soluble I-outcome ['Physiological-Clinical']
mediators I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
IO O
group O
had O
the O
greatest O
drain B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
the O
IOPO O
group O
the O
greatest O
total O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:BMC O
psychology O
[]

The O
effectiveness O
of O
nifedipine O
as O
first-line O
monotherapy O
for O
mild O
diastolic B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
( O
range O
: O
95 O
to O
105 O
mm O
Hg O
) O
was O
tested O
in O
this O
placebo-controlled O
, O
double-blind O
, O
randomized O
trial O
. O
['Physiological-Clinical']

This O
randomized O
, O
double-blind O
, O
phase O
II O
study O
was O
conducted O
to O
assess O
the O
efficacy O
and O
safety O
of O
two O
doses O
of O
pemetrexed O
in O
a O
homogeneous O
population O
. O
[]

The O
effects O
of O
esmolol O
, O
an O
ultrashort-acting O
beta O
blocker O
, O
and O
verapamil O
were O
compared O
in O
controlling O
ventricular B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
in O
45 O
patients O
with O
atrial O
fibrillation O
or O
atrial O
flutter O
, O
in O
a O
randomized O
, O
parallel O
, O
open-label O
study O
. O
['Physiological-Clinical']

Comparison O
between O
intermittent O
mandatory O
ventilation O
and O
synchronized O
intermittent O
mandatory O
ventilation O
with O
pressure O
support O
in O
children O
. O
[]

RESULTS O
Among O
patients O
who O
received O
rhNGF O
, O
418 O
( O
83 O
% O
) O
completed O
the O
regimen O
compared O
with O
461 O
( O
90 O
% O
) O
who O
received O
placebo O
. O
[]

PERSPECTIVE O
This O
study O
showed O
that O
KC O
has O
a O
significant O
effect O
on O
reducing O
autonomic O
pain O
responses O
in O
preterm O
infants O
. O
[]

Journal O
ID: O
101234168 O
[]

To O
identify O
patients O
with O
type O
II O
diabetes O
mellitus O
for O
whom O
insulin O
therapy O
is O
most O
beneficial O
, O
we O
conducted O
a O
randomized O
controlled O
trial O
in O
the O
general O
medicine O
clinic O
of O
a O
university O
hospital O
. O
[]

Other O
clinical O
outcomes O
, O
such O
as O
frequency O
and O
severity B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
, O
development O
of O
pneumonia B-outcome ['Physiological-Clinical']
or O
infection B-outcome ['Physiological-Clinical']
, O
in-hospital B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
and O
response O
rate O
were O
similar O
in O
the O
two O
groups O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

A O
pilot O
study O
to O
improve O
venipuncture B-outcome ['Life-Impact']
compliance I-outcome ['Life-Impact']
in O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

The O
Home B-outcome ['Life-Impact']
Situations I-outcome ['Life-Impact']
Questionnaire O
( O
HSQ O
) O
and O
the O
Hyperactivity/Noncompliance O
subscale O
of O
the O
Aberrant O
Behavior B-outcome ['Life-Impact']
Checklist O
were O
used O
as O
outcome O
measures O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

13 O
patients O
( O
22 O
% O
) O
[ O
8 O
of O
31 O
( O
26 O
% O
) O
controls O
, O
5 O
of O
28 O
( O
18 O
% O
) O
in O
the O
interferon O
arm O
] O
received O
single O
hemi-body O
irradiation O
alone O
due O
to O
progressive O
disease O
and/or O
persistent O
cytopoenias O
following O
the O
initial O
procedure O
. O
[]

Only O
modest O
associations O
existed O
between O
total O
folate B-outcome ['Life-Impact']
intakes I-outcome ['Life-Impact']
and O
plasma B-outcome ['Physiological-Clinical']
( O
r O
= O
0.46 O
, O
P O
< O
0.001 O
) O
and O
RBC O
( O
r O
= O
0.36 O
, O
P O
< O
0.01 O
) O
folate B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
16-wk O
postpartum O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
validity O
of O
cardiotocography O
for O
the O
detection O
of O
cord B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
average O
age O
was O
30 O
; O
subjects O
were O
predominantly O
female O
, O
and O
mostly O
wore O
frequent-replacement O
contact O
lenses O
. O
[]

OBJECTIVE O
The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
tolerability O
of O
amlodipine O
maleate O
with O
those O
of O
amlodipine O
besylate O
in O
Korean O
patients O
with O
mild O
to O
moderate O
hypertension O
. O
[]

In O
45 O
patients O
with O
type O
2 O
diabetes O
mellitus O
( O
DM O
) O
, O
we O
prospectively O
analyzed O
urinary O
excretion O
of O
N-acetyl-beta-glucosaminidase O
( O
NAG O
) O
, O
a O
marker O
of O
tubular O
renal O
damage O
; O
the O
potential O
relationship O
with O
urinary O
protein O
excretion O
; O
and O
effects O
of O
pentoxifylline O
( O
PTF O
) O
administration O
. O
[]

Risk O
comprehension B-outcome ['Life-Impact']
was O
assessed O
as O
the O
concordance O
between O
perceived O
subjective O
lifetime O
breast O
cancer O
risk O
and O
estimated O
objective O
lifetime O
risk O
. O
['Life-Impact']

The O
risk O
for O
falls B-outcome ['Life-Impact']
decreased O
for O
exercise O
participants O
with O
low O
baseline O
physical O
functioning O
( O
hazard O
ratio O
, O
.51 O
) O
but O
increased O
for O
exercise O
participants O
with O
high O
baseline O
physical O
functioning O
( O
hazard O
ratio O
, O
3.51 O
) O
. O
['Life-Impact']

Alendronate O
daily O
, O
weekly O
in O
conventional O
tablets O
and O
weekly O
in O
enteric O
tablets O
: O
preliminary O
study O
on O
the O
effects O
in O
bone B-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
and O
incidence O
of O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Doctors O
focused O
on O
the O
importance O
of O
improving O
patients O
' O
compliance O
and O
use O
of O
services O
. O
[]

Attempts O
have O
been O
made O
to O
remove O
endotoxin O
, O
the O
main O
cause O
of O
sepsis O
, O
from O
the O
circulation O
using O
polymyxin O
B O
immobilized O
fiber O
, O
charcoal O
hemoperfusion O
, O
and O
plasma O
or O
whole O
blood O
exchange O
. O
[]

Valid O
and O
reliable O
self-report O
measures O
of O
withdrawal B-outcome ['Life-Impact']
did O
not O
reveal O
gender O
differences O
in O
response O
['Life-Impact']

By O
end O
of O
follow O
up O
142 O
patients O
had O
died B-outcome ['Mortality']
, O
42 O
of O
aneurysm-related O
factors O
; O
overall B-outcome ['Mortality']
mortality I-outcome ['Mortality']
after O
4 O
years O
was O
64 O
% O
. O
['Mortality', 'Mortality']

if O
the O
C O
( O
2 O
) O
level O
was O
?60 O
ng/mL O
( O
T2 O
group O
) O
. O
[]

Complication O
rates O
did O
not O
differ O
between O
closure O
types O
. O
['Adverse-effects']

Leucocyte O
depletion O
of O
perioperative O
blood O
transfusion O
does O
not O
affect O
long-term O
survival B-outcome ['Mortality']
and O
recurrence O
in O
patients O
with O
gastrointestinal O
cancer O
. O
['Mortality']

Analysis O
was O
by O
intention O
to O
treat O
( O
ITT O
) O
. O
[]

Adverse O
effects O
were O
more O
frequent O
. O
[]

For O
the O
majority O
of O
the O
patients O
, O
sufficient O
pain O
relief O
can O
be O
obtained O
if O
adequate O
treatment O
is O
provided O
. O
[]

Porfimer O
sodium O
exhibited O
a O
longer O
elimination O
half-life B-outcome ['Physiological-Clinical']
( O
175.3 O
hr O
) O
, O
slower O
clearance O
( O
0.0028 O
L/kg/hr O
) O
, O
and O
a O
larger O
area O
under O
the O
curve O
( O
1075 O
microg/g/hr O
) O
in O
tumors O
than O
did O
tin O
ethyl O
etiopurpurin O
or O
aluminum O
chlorophthalocyanine O
. O
['Physiological-Clinical']

INTRODUCTION: O
Halitosis O
is O
the O
term O
used O
to O
describe O
any O
unpleasant O
odor O
relative O
to O
expired O
air O
regardless O
of O
its O
source. O
[]

Decompression O
could O
be O
cost-effective O
in O
the O
longer-term, O
but O
results O
of O
this O
analysis O
are O
sensitive O
to O
the O
assumptions O
made O
about O
how O
costs O
and O
QALYs O
are O
extrapolated O
beyond O
the O
follow-up O
of O
the O
trial. O
[]

SAMPLE O
Thirty-one O
children O
with O
DCD O
aged O
7 O
to O
9 O
years O
participated O
in O
the O
study O
. O
[]

Additional O
outcomes O
included O
the O
change O
in O
other O
sputum O
markers O
of O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
airway B-outcome ['Physiological-Clinical']
responsiveness I-outcome ['Physiological-Clinical']
, O
symptom B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
, O
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Randomized O
, O
controlled O
, O
split-face O
comparison O
of O
anesthesia O
was O
performed O
on O
12 O
volunteers O
. O
[]

Subsequent O
HF O
was O
preceded O
by O
a O
decrease O
in O
eGFR B-outcome ['Physiological-Clinical']
over O
1 O
year O
compared O
to O
modest O
improvement O
in O
those O
without O
subsequent O
HF O
( O
-0.09 O
? O
['Physiological-Clinical']

Primary O
outcomes O
are O
performance O
for O
each O
case O
design O
in O
a O
standardized O
fifteen O
item O
clinical B-outcome ['Life-Impact']
reasoning I-outcome ['Life-Impact']
assessment O
, O
integrated O
into O
each O
VP O
, O
which O
is O
identical O
for O
each O
topic O
. O
['Life-Impact']

Overall O
, O
patients O
reported O
that O
sodium O
phosphate O
and O
castor O
oil O
were O
easier O
to O
complete O
( O
p O
< O
0.05 O
) O
. O
[]

The O
blastocysts O
were O
collected O
from O
gilts O
and O
vitrified O
using O
the O
new O
device O
( O
MVAC O
) O
or O
a O
Cryotop O
( O
CT O
) O
. O
[]

Treatment O
consisted O
of O
5 O
iCBT-based O
lessons O
, O
homework O
tasks O
, O
additional O
resources O
, O
weekly O
e-mail O
or O
telephone O
contact O
from O
a O
Clinical O
Psychologist O
, O
and O
automated O
e-mails O
. O
[]

Although O
laser O
has O
definite O
advantages O
, O
cryotherapy O
can O
be O
considered O
as O
an O
alternative O
modality O
of O
treatment O
in O
developing O
countries O
due O
to O
economic O
reasons O
. O
[]

Median O
survival B-outcome ['Mortality']
was O
7.6 O
months O
in O
the O
ASC O
alone O
group O
and O
8.5 O
months O
in O
the O
ASC O
plus O
chemotherapy O
group O
. O
['Mortality']

Journal O
ID: O
101599229 O
[]

Isoniazid O
prophylaxis O
for O
tuberculosis O
in O
HIV O
infection O
: O
a O
meta-analysis O
of O
randomized O
controlled O
trials O
. O
[]

Subjective O
indicators O
of O
image O
quality O
indicated O
a O
reduction O
in O
[]

CONCLUSION: O
The O
results O
of O
the O
present O
study O
and O
other O
experimental O
and O
clinical O
trials O
confirmed O
that O
the O
administration O
of O
the O
scorpion O
antivenom O
by O
intravenous O
route O
has O
a O
lower O
incidence O
of O
systemic O
toxicity B-outcome ['Adverse-effects']
, O
a O
better O
outcome O
of O
fatal B-outcome ['Mortality']
complication O
resulted O
from O
envenomation O
especially O
cardiogenic B-outcome ['Physiological-Clinical']
shock I-outcome ['Physiological-Clinical']
, O
decreased O
need B-outcome ['Resource-use']
for O
ICU O
facilities O
and O
mechanical B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
shorter O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
better O
overall O
outcome O
than O
the O
intramuscular O
route. O
[['Adverse-effects'], ['Mortality'], ['Physiological-Clinical'], ['Resource-use'], ['Resource-use'], ['Resource-use']]

METHOD O
159 O
periodontally O
healthy O
subjects O
abstained O
from O
oral O
hygiene O
procedures O
and O
self-administered O
either O
0.005 O
% O
, O
0.01 O
% O
, O
0.05 O
% O
P-113 O
or O
placebo O
mouthrinse O
formulations O
twice O
daily O
over O
a O
four O
week O
treatment O
period O
. O
[]

1-year O
results O
. O
[]

To O
investigate O
whether O
L-carnitine O
might O
be O
of O
benefit O
in O
Rett O
syndrome O
, O
a O
randomized O
, O
placebo-controlled O
, O
double-blind O
crossover O
trial O
of O
L-carnitine O
has O
been O
completed O
in O
35 O
subjects O
. O
[]

However O
, O
after O
30 O
min O
, O
diltiazem O
affords O
better O
myocardial B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
and O
more O
effective O
control O
of O
hypertension B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
these O
data O
call O
for O
continuous O
surveillance O
for O
these O
events O
and O
efforts O
beyond O
the O
acute O
phase O
at O
increasing O
adherence O
to O
evidence-based O
therapies O
to O
improve O
the O
outcomes O
of O
these O
patients O
. O
[]

Measured O
serum B-outcome ['Physiological-Clinical']
propofol I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
equilibrium I-outcome ['Physiological-Clinical']
with O
the O
effect-site O
at O
which O
50 O
% O
of O
the O
patients O
did O
not O
respond O
to O
verbal O
commands O
( O
EC50 O
for O
loss O
of O
consciousness O
) O
were O
determined O
by O
logistic O
regression O
. O
['Physiological-Clinical']

Children O
in O
the O
community O
treatment O
group O
received O
a O
variety O
of O
services O
averaging O
3.9 O
hours O
per O
week O
. O
[]

INTERVENTION O
The O
MgSO4 O
group O
received O
0.2 O
ml/kg O
of O
50 O
% O
MgSO4 O
as O
intravenous O
( O
i.v O
. O
) O
[]

Suitable O
embryos O
( O
maximum O
two O
embryos O
) O
were O
transferred O
on O
day O
3 O
after O
ICSI O
. O
[]

Tumour O
necrosis O
factor-? O
was O
significantly O
higher O
in O
the O
RFA O
group O
( O
p O
< O
0.05 O
) O
. O
[]

Two O
hundred O
and O
twenty-eight O
patients O
were O
treated O
with O
concurrent O
capecitabine O
and O
radiotherapy O
( O
Cap-CRT O
) O
, O
and O
172 O
patients O
were O
treated O
with O
capecitabine O
and O
oxaliplatin O
plus O
radiotherapy O
( O
Cap-Oxa-CRT O
) O
. O
[]

On O
day O
3 O
, O
17 O
beta-estradiol B-outcome ['Resource-use']
, O
follicle-stimulating B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
luteinizing B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
, O
and O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

After O
adding O
exposure O
however O
, O
these O
parameters O
were O
clearly O
and O
significantly O
reduced O
. O
[]

A O
single O
oral O
dose O
of O
1500 O
mg O
mefloquine O
hydrochloride O
was O
administered O
to O
11 O
patients O
and O
5 O
volunteers O
and O
750 O
mg O
was O
given O
to O
16 O
patients O
and O
5 O
volunteers O
. O
[]

Among O
uteri O
weighing O
> O
500 O
g O
LAVH O
showed O
a O
shorter O
recovery O
, O
but O
longer O
operating O
time O
than O
TAH O
and O
a O
27 O
% O
rate O
of O
conversion B-outcome ['Resource-use']
to I-outcome ['Resource-use']
laparotomy I-outcome ['Resource-use']
. O
['Resource-use']

The O
measurement O
and O
quantification O
of O
saccadic O
eye O
movements O
is O
a O
powerful O
tool O
for O
assessing O
sensory O
, O
motor O
, O
and O
cognitive O
function O
. O
[]

[ O
Carbohydrate O
substitutes O
: O
comparative O
study O
of O
intestinal O
absorption O
of O
fructose O
, O
sorbitol O
and O
xylitol O
] O
. O
[]

With O
the O
addition O
of O
cholestyramine O
, O
there O
was O
a O
41 O
per O
cent O
total O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
from O
the O
control O
value O
and O
a O
50 O
percent O
decrease O
in O
low B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
parallel O
with O
the O
decrease O
in O
LDL-cholesterol B-outcome ['Physiological-Clinical']
, O
the O
apoprotein B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
also O
was O
diminished O
by O
20 O
% O
( O
P O
less O
than O
or O
equal O
to O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

However O
, O
we O
found O
that O
there O
were O
significant O
differences O
among O
the O
groups O
in O
terms O
of O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
( O
75 O
% O
for O
clarithromycin O
, O
64 O
% O
for O
roxithromycin O
, O
and O
41 O
% O
for O
erythromycin O
stearate O
, O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

Inhibition O
of O
increased O
central O
sympathetic O
vasoconstrictor O
outflow O
is O
one O
mechanism O
by O
which O
nocturnal O
CPAP O
reduces O
awake O
BP B-outcome ['Physiological-Clinical']
in O
HF O
patients O
with O
moderate O
to O
severe O
OSA O
. O
['Physiological-Clinical']

Eleven O
of O
the O
24 O
children O
improved O
in O
two O
or O
more O
settings O
. O
[]

We O
studied O
the O
nocturnal B-outcome ['Physiological-Clinical']
melatonin I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
8 O
healthy O
volunteers O
, O
and O
6 O
women O
with O
untreated O
primary O
hypothyroidism O
, O
a O
disease O
state O
that O
is O
associated O
with O
increased O
nocturnal O
secretion O
of O
melatonin O
. O
['Physiological-Clinical']

The O
incidence O
of O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
was O
not O
different O
from O
placebo O
. O
['Adverse-effects']

Haemodynamic O
profile O
of O
angiotensin O
II O
antagonism O
in O
essential O
hypertensive O
patients O
. O
[]

Immunologic O
and O
hemodynamic O
effects O
of O
low-dose O
hydrocortisone O
in O
septic O
shock O
: O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
. O
[]

Journal-Name:Complementary O
therapies O
in O
clinical O
practice O
[]

Using O
this O
technique O
, O
vasculature B-outcome ['Physiological-Clinical']
and O
red B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
are O
separated O
from O
the O
background O
of O
the O
image O
. O
['Physiological-Clinical']

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

Patients O
who O
enrolled O
in O
the O
study O
were O
significantly O
younger O
than O
those O
who O
did O
not O
( O
p O
< O
0.001 O
) O
. O
[]

2003 O
) O
. O
[]

Failure O
of O
lithium O
to O
reduce O
period O
of O
neutropenia O
during O
induction O
therapy O
of O
acute O
myeloid O
leukemia O
. O
[]

Neither O
basal O
values O
nor O
changes O
of O
renin O
and O
aldosterone B-outcome ['Physiological-Clinical']
were O
related O
to O
the O
hypotensive O
effect O
of O
labetalol O
. O
['Physiological-Clinical']

Intra-articular O
hyaluronic O
acid O
compared O
to O
intra-articular O
triamcinolone O
hexacetonide O
in O
inflammatory O
knee O
osteoarthritis O
. O
[]

Levels O
of O
many B-outcome ['Physiological-Clinical']
vitamins I-outcome ['Physiological-Clinical']
, O
minerals B-outcome ['Physiological-Clinical']
, O
and O
biomarkers B-outcome ['Physiological-Clinical']
improved/increased O
showing O
good O
compliance B-outcome ['Life-Impact']
and O
absorption B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

BACKGROUND: O
Heartburn O
that O
persists O
despite O
proton-pump O
inhibitor O
(PPI) O
treatment O
is O
a O
frequent O
clinical O
problem O
with O
multiple O
potential O
causes. O
[]

The O
risk O
of O
death B-outcome ['Mortality']
in O
the O
group O
treated O
with O
vitamin O
A O
was O
less O
than O
half O
that O
in O
the O
control O
group O
( O
relative O
risk O
, O
0.46 O
; O
95 O
percent O
confidence O
interval O
, O
0.30 O
to O
0.71 O
) O
. O
['Mortality']

OBJECTIVE O
We O
sought O
to O
investigate O
the O
effects O
of O
levocetirizine O
( O
5 O
mg O
) O
, O
diphenhydramine O
( O
50 O
mg O
) O
, O
and O
placebo O
on O
memory B-outcome ['Life-Impact']
and O
psychomotor B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
after O
acute O
( O
day O
1 O
) O
and O
subchronic O
( O
day O
4 O
) O
daily O
administration O
in O
48 O
healthy O
volunteers O
( O
24 O
men O
and O
24 O
women O
) O
. O
['Life-Impact', 'Life-Impact']

After O
a O
2-wk O
run-in O
period O
, O
the O
doses O
of O
BDI O
were O
halved O
, O
while O
the O
patients O
were O
assigned O
to O
receive O
orally O
ONO-1078 O
, O
450 O
mg O
twice O
daily O
, O
or O
placebo O
. O
[]

At O
the O
highest O
thermal O
burden O
, O
the O
effect O
of O
nifedipine B-outcome ['Physiological-Clinical']
was O
inconsistent O
and O
not O
significantly O
different O
from O
that O
of O
placebo O
. O
['Physiological-Clinical']

The O
best O
response O
to O
GH O
was O
obtained O
in O
younger O
patients O
with O
low O
GHBP O
levels O
. O
[]

Journal-Name: O
The O
journal O
of O
contemporary O
dental O
practice O
[]

RESULTS O
Physician B-outcome ['Life-Impact']
prompting I-outcome ['Life-Impact']
, O
dependent B-outcome ['Life-Impact']
drinking I-outcome ['Life-Impact']
, O
and O
recent B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
were O
significant O
correlates O
of O
physician O
counseling O
( O
P O
< O
.05 O
) O
, O
while O
male O
gender O
was O
a O
marginally O
significant O
correlate O
( O
P O
= O
.08 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

A O
pair O
of O
defibrillator O
paddles O
were O
instrumented O
to O
measure O
paddle B-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
results O
are O
discussed O
in O
terms O
of O
their O
implication O
for O
hypotheses O
linking O
laterality O
and O
training O
. O
[]

Both O
arms O
exceeded O
the O
intervention O
goal O
, O
but O
there O
was O
not O
a O
significant O
difference O
between O
arms O
at O
follow-up O
. O
[]

CONCLUSIONS O
Results O
support O
the O
use O
of O
adaptive O
devices O
and O
orofacial O
exercise O
to O
improve O
[]

The O
effect O
of O
topical O
nasal O
fluticasone O
on O
objective B-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
and O
the O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
, O
sleep B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Thirty-two O
eyes B-outcome ['Physiological-Clinical']
were O
rescued O
in O
treatment O
group O
with O
the O
cure O
rate O
of O
65.3 O
% O
. O
['Physiological-Clinical']

A O
randomized O
controlled O
trial O
was O
conducted O
to O
compare O
the O
efficacy O
of O
clinical O
hypnosis O
versus O
cognitive O
behavioral O
( O
CB O
) O
coping O
skills O
training O
in O
alleviating O
the O
pain B-outcome ['Physiological-Clinical']
and O
distress B-outcome ['Life-Impact']
of O
30 O
pediatric O
cancer O
patients O
( O
age O
5 O
to O
15 O
years O
) O
undergoing O
bone O
marrow O
aspirations O
. O
['Physiological-Clinical', 'Life-Impact']

At O
baseline O
, O
daily B-outcome ['Life-Impact']
dietary I-outcome ['Life-Impact']
fiber I-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
correlated O
negatively O
with O
PAI-1 O
activity O
. O
['Life-Impact']

Effect O
of O
zoledronic O
acid O
on O
disseminated O
tumour O
cells O
in O
women O
with O
locally O
advanced O
breast O
cancer O
: O
an O
open O
label O
, O
randomised O
, O
phase O
2 O
trial O
. O
[]

Antibiotic-use B-outcome ['Resource-use']
rates O
at O
baseline O
were O
2.8 O
, O
1.7 O
, O
and O
1.4 O
antibiotics O
per O
person-year O
among O
those O
aged O
3 O
to O
< O
24 O
, O
24 O
to O
< O
48 O
, O
and O
48 O
to O
< O
72 O
months O
, O
respectively O
. O
['Resource-use']

There O
were O
no O
significant O
differences O
in O
the O
implant B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
rate O
as O
determined O
by O
radiographic O
['Physiological-Clinical']

No O
adverse O
effects O
on O
CD4 B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
or O
organ B-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
occurred O
in O
either O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Blood-impregnated O
filter O
papers O
( O
Guthrie O
cards O
) O
from O
603 O
randomly O
chosen O
New O
Zealand O
neonates O
were O
genotyped O
blind O
to O
17-hydroxyprogesterone O
( O
17-OHP O
) O
levels O
. O
[]

School O
physical O
education O
(PE) O
is O
an O
important O
existing O
network O
in O
which O
participation O
in O
physical O
activity O
beyond O
school O
can O
be O
promoted O
to O
the O
captive O
young O
people. O
[]

Moreover O
, O
BW O
decreased O
both O
linearly O
( O
P O
< O
0.01 O
) O
and O
quadratically O
( O
P O
< O
0.05 O
) O
as O
choline O
increased O
from O
0 O
to O
6,800 O
mg/kg O
. O
[]

Statistical O
analysis O
was O
performed O
using O
repeated O
measures O
ANOVA O
and O
Fisher O
's O
pairwise O
comparisons O
. O
[]

RESULTS O
Eighty-five O
( O
56 O
% O
) O
men O
participated O
. O
[]

This O
double-blind O
, O
randomized O
, O
phase O
III O
clinical O
trial O
was O
carried O
out O
in O
two O
parallel O
groups O
to O
assess O
the O
efficacy O
of O
ebrotidine O
( O
N- O
[ O
( O
E O
) O
- O
[ O
[ O
2- O
[ O
[ O
[ O
2- O
[ O
( O
diaminomethylene O
) O
amino O
] O
-4-thiazolyl O
] O
methyl O
] O
thio O
] O
ethyl O
] O
amino O
] O
methylene O
] O
-4-bromo-benzenesulfonamide O
, O
CAS O
100981-43-9 O
, O
FI-3542 O
) O
400 O
mg O
and O
ranitidine O
300 O
mg O
given O
in O
single O
evening O
dose O
, O
combined O
with O
amoxicillin O
750 O
mg O
and O
metronidazole O
500 O
mg O
three O
times O
daily O
for O
14 O
days O
, O
in O
the O
eradication B-outcome ['Physiological-Clinical']
of O
Helicobacter O
pylori O
in O
patients O
with O
duodenal O
ulcer O
. O
['Physiological-Clinical']

METHODS O
In O
a O
double-blind O
study O
, O
20 O
patients O
undergoing O
lateral O
thoracotomy O
for O
lung O
resection O
were O
randomized O
to O
receive O
0.5 O
mg O
SM O
preoperatively O
and O
INB O
with O
bupivacaine O
( O
INB+ O
) O
prior O
to O
wound O
closure O
or O
0.5 O
mg O
SM O
with O
INB O
using O
saline O
( O
INB- O
) O
. O
[]

RESULTS O
Clomipramine O
was O
superior O
to O
desipramine O
and O
placebo O
, O
as O
indicated O
by O
standardized O
ratings O
of O
autism B-outcome ['Life-Impact']
and O
anger B-outcome ['Life-Impact']
as O
well O
as O
ratings O
of O
repetitive B-outcome ['Life-Impact']
and O
compulsive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

No O
further O
group O
differences O
were O
found. O
[]

In O
one O
patient O
this O
was O
incapacitating B-outcome ['Physiological-Clinical']
after O
10 O
mg O
and O
precluded O
exposure O
to O
20 O
mg O
. O
['Physiological-Clinical']

Journal-Name:Medicine O
[]

Other O
end O
points O
included O
changes O
in O
fasting B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
weight O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
safety O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

Although O
corticosteroid O
therapy O
might O
be O
clinically O
beneficial O
for O
bronchiectasis O
, O
very O
little O
is O
known O
of O
its O
effects O
on O
the O
inflammatory B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
infective I-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
in O
bronchiectasis O
. O
['Physiological-Clinical']

Six O
subjects O
withdrew O
because O
of O
adverse O
effects O
, O
and O
1 O
was O
unavailable O
for O
follow-up O
. O
[]

At O
present O
no O
study O
of O
gastric O
dysrhythmia O
, O
measured O
with O
epigastric B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
, O
has O
been O
presented O
, O
and O
the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
gastric O
rhythms O
by O
means O
of O
impedance O
gastrography O
in O
control O
infants O
, O
compared O
to O
infants O
with O
different O
gastrointestinal O
diseases O
, O
before O
and O
after O
treatment O
of O
their O
disease O
. O
['Physiological-Clinical']

BACKGROUND O
Improved O
endothelial O
function O
may O
contribute O
to O
the O
beneficial O
effects O
of O
cholesterol O
lowering O
therapy O
in O
patients O
with O
coronary O
artery O
disease O
( O
CAD O
) O
, O
but O
results O
of O
the O
effect O
of O
statin O
therapy O
on O
endothelial O
function O
are O
disparate O
in O
these O
patients O
. O
[]

Future O
studies O
are O
still O
needed O
to O
warrant O
these O
results. O
[]

24 O
( O
18 O
% O
) O
patients O
receiving O
eltrombopag O
needed O
rescue B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
compared O
with O
25 O
( O
40 O
% O
) O
patients O
receiving O
placebo O
( O
p=0?001 O
) O
. O
['Resource-use']

Publication O
Type: O
Journal O
Article O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Mean O
airway B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
18?3 O
cm O
H2O O
during O
conventional O
mechanical O
ventilation O
and O
was O
increased O
until O
33?3 O
cm O
H2O O
at O
high-frequency O
oscillatory O
ventilation+15 O
. O
['Physiological-Clinical']

Results O
showed O
parents O
reporting O
fewer O
and O
lower O
intensity O
of O
problem B-outcome ['Life-Impact']
behaviours I-outcome ['Life-Impact']
and O
increased O
social B-outcome ['Life-Impact']
interactions I-outcome ['Life-Impact']
at O
4 O
weeks O
and O
3 O
months O
. O
['Life-Impact', 'Life-Impact']

The O
difference O
of O
the O
reduction O
of O
the O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
between O
enalapril O
and O
timolol O
group O
at O
the O
end O
of O
the O
combined O
treatment O
was O
statistically O
significant O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

Participants O
with O
a O
CVD O
relative O
risk O
of O
1.5 O
assessed O
by O
risk O
scores O
were O
randomly O
assigned O
to O
one O
of O
the O
3 O
groups O
: O
habitual O
( O
control O
, O
CT O
) O
, O
high-flavonoid O
( O
HF O
) O
or O
low-flavonoid O
( O
LF O
) O
diets O
. O
[]

In O
the O
case O
of O
RAO O
as O
assessed O
by O
duplex O
ultrasonography O
3 O
to O
4 O
hours O
after O
hemostasis O
, O
immediate O
1-hour O
ulnar O
artery O
compression O
was O
applied O
. O
[]

Similarly O
, O
there O
was O
no O
DFS B-outcome ['Mortality']
( O
HR O
, O
1.84 O
; O
95 O
% O
CI O
, O
0.44 O
to O
7.73 O
; O
P O
= O
.395 O
) O
or O
OS B-outcome ['Mortality']
benefit O
( O
HR O
, O
3.16 O
; O
95 O
% O
CI O
, O
0.61 O
to O
16.45 O
; O
P O
= O
.15 O
) O
from O
gefitinib O
for O
the O
15 O
patients O
with O
EGFR O
mutation-positive O
tumors O
. O
['Mortality', 'Mortality']

In O
addition, O
for O
the O
upper O
50th O
percentile O
group, O
the O
adjusted O
mean O
post-supplementation O
baseline O
hydroxyproline B-outcome ['Physiological-Clinical']
(HYP) I-outcome ['Physiological-Clinical']
for O
the O
high O
dose O
group O
(1.5 O
+/- O
0.3 O
mug.mL(- O
1)) O
was O
significantly O
less O
than O
both O
the O
low O
dose O
(2.4 O
+/- O
0.3 O
mug.mL(- O
1); O
p O
= O
0.034) O
and O
placebo O
(2.4 O
+/- O
0.3 O
mug.mL(- O
1), O
p O
= O
0.024) O
groups. O
[['Physiological-Clinical']]

The O
primary O
outcome O
measures O
were O
the O
proportions O
of O
patients O
achieving O
BP B-outcome ['Physiological-Clinical']
, O
TC B-outcome ['Physiological-Clinical']
, O
and O
BP/TC B-outcome ['Physiological-Clinical']
therapeutic I-outcome ['Physiological-Clinical']
goals I-outcome ['Physiological-Clinical']
( O
BP O
lower O
than O
140/90 O
mm O
Hg O
for O
patients O
with O
uncomplicated O
hypertension O
and O
lower O
than O
130/80 O
mm O
Hg O
for O
patients O
with O
diabetes O
, O
chronic O
kidney O
disease O
, O
or O
history O
of O
myocardial O
infarction O
or O
stroke O
; O
TC O
lower O
than O
200 O
mg O
per O
dL O
for O
patients O
without O
CVD O
and O
lower O
than O
175 O
mg O
per O
dL O
for O
patients O
with O
CVD O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

UNLABELLED O
Propofol O
causes O
pain O
on O
IV B-outcome ['Resource-use']
injection I-outcome ['Resource-use']
in O
28 O
% O
-90 O
% O
of O
patients O
. O
['Resource-use']

Remission B-outcome ['Physiological-Clinical']
duration O
and O
survival B-outcome ['Mortality']
were O
similar O
when O
induction O
regimens O
were O
compared O
. O
['Physiological-Clinical', 'Mortality']

Patients O
were O
allocated O
at O
random O
to O
receive O
a O
daily O
bedtime O
dose O
of O
either O
1 O
ketoprofen O
tablet O
or O
1 O
indomethacin O
suppository O
plus O
the O
dummy O
of O
the O
other O
formulation O
for O
a O
period O
of O
3 O
weeks O
. O
[]

Altered O
peripheral B-outcome ['Physiological-Clinical']
vasodilator I-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
of O
nitroglycerin O
during O
long-term O
infusion O
of O
N-acetylcysteine O
. O
['Physiological-Clinical']

NCE O
decreased O
linearly O
( O
P O
< O
0.05 O
) O
as O
the O
level O
of O
RDN O
increased O
. O
[]

This O
study O
has O
high O
potential O
to O
have O
a O
major O
impact O
on O
clinical O
management O
and O
outcomes O
after O
a O
breast O
cancer O
diagnosis O
. O
[]

Journal-Name: O
JAMA O
[]

More O
patients O
sensitized O
at O
baseline O
became O
non-sensitized O
at O
M12 O
with O
Tac/MMF O
than O
with O
CsA/AZA O
. O
[]

CONCLUSIONS: O
The O
application O
of O
OPEP O
device O
during O
the O
perioperative O
period O
was O
valuable O
in O
decreasing O
pulmonary B-outcome ['Physiological-Clinical']
complications I-outcome ['Physiological-Clinical']
and O
enhancing O
recovery B-outcome ['Physiological-Clinical']
for O
lung O
cancer O
patients O
receiving O
VATS O
lobectomy. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

5 O
) O
Total O
tract O
digestibility O
of O
protein O
decreased O
from O
4 O
to O
8 O
weeks O
of O
age O
for O
soybean O
meal O
and O
rapeseed O
meal O
but O
increased O
for O
soybean O
cake O
and O
rapeseed O
cake O
. O
[]

Nausea/vomiting B-outcome ['Physiological-Clinical']
and O
stomatitis B-outcome ['Physiological-Clinical']
were O
significantly O
less O
frequent O
in O
arm O
A O
as O
was O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
decrease O
in O
arm O
C O
( O
A O
= O
six O
patients O
, O
B O
= O
five O
patients O
, O
and O
C O
= O
one O
patient O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Risedronate O
significantly O
increased O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
at O
the O
spine O
and O
hip O
within O
6 O
months O
. O
['Physiological-Clinical']

Cognitive O
behavioral O
therapies O
( O
CBT O
) O
are O
frequently O
used O
with O
success O
for O
children O
with O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Physical O
activity O
level O
and O
energy O
expenditure O
were O
assessed O
with O
a O
1-day O
activity O
diary O
. O
[]

A O
second O
objective O
is O
to O
determine O
which O
subgroups O
within O
the O
autism O
spectrum O
profit O
most O
from O
the O
intervention O
. O
[]

Low-dose O
MTX O
significantly O
reduced O
the O
steroid B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
in O
this O
group O
of O
subjects O
with O
steroid-dependent O
asthma O
. O
['Resource-use']

ANIMALS O
Five O
male O
Holstein-Friesian O
calves O
( O
8-15 O
days O
of O
age O
) O
. O
[]

In O
the O
various O
subgroups O
formed O
for O
different O
primary O
diagnoses O
, O
concomitant O
steroidal O
therapy O
and O
concomitant O
severe O
internal O
medical O
diseases O
cefotiam O
treated O
patients O
and O
controls O
were O
comparable O
as O
well O
. O
[]

In O
contrast O
, O
plasma O
lysozyme O
level O
in O
coronary O
sinus O
blood O
samples O
at O
the O
end O
of O
reperfusion O
in O
Group O
II O
was O
significantly O
higher O
compared O
to O
that O
in O
pre-clamping O
samples O
( O
p O
< O
0.014 O
) O
. O
[]

The O
suppressive O
activity O
of O
the O
patient O
plasma O
was O
assayed O
by O
measurement O
of O
normal O
PMN O
superoxide O
production O
relative O
to O
normal O
control O
plasma O
( O
ratio O
P O
: O
C O
) O
. O
[]

The O
most O
relevant O
combination O
was O
good O
quality O
implementation O
of O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
breaks I-outcome ['Life-Impact']
, O
implemented O
by O
teachers O
with O
a O
high O
self-efficacy B-outcome ['Life-Impact']
, O
and O
a O
good O
previous O
knowledge B-outcome ['Life-Impact']
about O
the O
intervention. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Oat O
powder O
, O
containing O
a O
low O
amount O
of O
total O
fibre O
and O
a O
high O
amount O
of O
carbohydrates O
in O
liquid O
matrix O
, O
gave O
a O
higher O
incremental B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
peak O
concentration B-outcome ['Physiological-Clinical']
compared O
to O
rye O
bran O
and O
sugar O
beet O
fibre O
and O
higher O
insulin B-outcome ['Physiological-Clinical']
incremental I-outcome ['Physiological-Clinical']
area O
under O
curve O
compared O
to O
control O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
sample O
was O
composed O
of O
11 O
children O
diagnosed O
with O
Autism O
( O
n=6 O
) O
and O
Asperger O
syndrome O
( O
n=5 O
) O
by O
a O
multidisciplinary O
team O
, O
that O
attended O
specialized O
speech-language O
pathology O
therapy O
at O
the O
institution O
were O
the O
study O
was O
carried O
out O
. O
[]

The O
day-to-day O
variability O
in O
morning O
USG O
( O
coefficient O
of O
variation O
= O
0.2 O
? O
[]

RESULTS O
Pioglitazone-treated O
patients O
demonstrated O
greater O
increases O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
HDL-C I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
reductions O
in O
glycated O
hemoglobin B-outcome ['Physiological-Clinical']
, O
triglycerides B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

71.9 O
mm O
( O
3 O
) O
vs. O
133.9 O
? O
[]

The O
median O
follow-up O
period O
was O
6.1 O
months O
( O
range O
1 O
day O
to O
20 O
months O
) O
. O
[]

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
increased O
13 O
% O
with O
sodium O
nitroprusside O
, O
remained O
unchanged O
with O
isoflurane O
, O
and O
decreased O
23 O
% O
with O
esmolol O
. O
['Physiological-Clinical']

METHODS O
AND O
MATERIALS O
Sixty-four O
patients O
were O
randomly O
assigned O
to O
receive O
either O
a O
clinical O
intervention O
including O
an O
information O
session O
, O
the O
use O
of O
a O
pain O
diary O
, O
and O
the O
possibility O
to O
contact O
a O
physician O
to O
adjust O
the O
pain O
medication O
, O
or O
the O
usual O
treatment O
of O
pain O
by O
the O
staff O
radiation O
oncologist O
. O
[]

Each O
patient O
received O
6 O
cycles O
of O
chemotherapy O
with O
intravenous O
administration O
of O
paclitaxel O
( O
175 O
mg/m2 O
, O
on O
D3 O
) O
and O
epirubicin O
( O
60 O
mg/m2 O
, O
on O
Dl O
and O
D2 O
) O
. O
[]

CONCLUSIONS: O
This O
study O
concluded O
that O
if O
targeting O
the O
increasing O
worldwide O
obesity O
problem O
through O
workplace O
initiated O
weight O
loss O
programs, O
the O
sales O
pitch O
to O
managements O
and O
employers O
have O
to O
be O
tailored O
in O
order O
to O
increase O
the O
participation O
and O
the O
motivation O
for O
the O
initiative. O
[]

Intra-articular O
hyaluronic O
acid O
compared O
to O
exercise O
therapy O
in O
osteoarthritis O
of O
the O
ankle O
. O
[]

The O
most O
common O
treatment O
emergent O
[]

The O
ABC-C O
Rating O
Scale O
scores O
improved O
with O
piracetam O
. O
[]

FINANCIAL O
DISCLOSURE O
( O
S O
) O
Proprietary O
or O
commercial O
disclosure O
may O
be O
found O
after O
the O
references O
. O
[]

The O
results O
were O
classified O
as O
unsuccessful B-outcome ['Physiological-Clinical']
, O
improvement O
and O
cure B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

PATIENTS O
AND O
METHODS: O
Initially, O
56 O
patients O
were O
randomized O
into O
four O
groups; O
control O
group O
(n=12), O
single-dose O
(n=16), O
repeated-dose O
(n=12) O
and O
continuous O
infusion O
(n=16) O
RSB O
analgesia O
groups. O
[]

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
2 O
in-season O
short-term O
sprint O
and O
power O
training O
protocols O
on O
vertical O
countermovement O
jump O
height O
( O
with O
or O
without O
arms O
) O
, O
sprint O
( O
Sprint-15m O
) O
speed O
, O
and O
agility O
( O
Agility-15m O
) O
speed O
in O
male O
elite O
junior O
soccer O
players O
. O
[]

We O
conclude O
that O
, O
at O
infusion O
rates O
in O
the O
low- O
to O
mid-antiarrhythmic O
range O
, O
lidocaine O
has O
no O
effect O
on O
acute B-outcome ['Physiological-Clinical']
nociceptive I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
but O
does O
have O
a O
limited O
and O
selective O
effect O
on O
secondary B-outcome ['Physiological-Clinical']
hyperalgesia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Divalproex O
has O
been O
shown O
to O
have O
efficacy O
in O
treating O
epilepsy O
, O
bipolar O
disorder O
, O
mood O
lability O
, O
and O
impulsive O
aggression O
. O
[]

Title: O
Corneal B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Endothelial I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Cell I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
Density I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
Morphology S3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
After O
Phacoemulsification O
in O
Patients O
With O
Primary O
Open-Angle O
Glaucoma O
and O
Cataracts: O
2-Year O
Results O
of O
a O
Randomized O
Multicenter O
Trial. O
[['Physiological-Clinical', 'Physiological-Clinical']]

The O
fed O
trials O
resulted O
in O
lower O
plasma O
PSE O
concentrations O
at O
all O
time O
points O
compared O
with O
the O
nonfed O
trials O
. O
[]

Although O
there O
was O
a O
general O
trend O
of O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
reduction, O
the O
numbers O
of O
participants O
who O
may O
be O
classified O
as O
pre-diabetes O
and O
diabetes O
groups O
( O
fasting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
sugar I-outcome ['Physiological-Clinical']
(FBS) I-outcome ['Physiological-Clinical']
100 O
mg/dl) O
in O
the O
amla O
group O
were O
only O
8. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Blood O
samples O
were O
obtained O
from O
participants O
in O
32 O
sectors O
( O
5 O
% O
) O
for O
biochemical O
studies O
. O
[]

The O
purposes O
include O
also O
analysing O
the O
potential O
effects O
of O
changes O
in O
physical O
activity O
on O
productivity B-outcome ['Life-Impact']
at I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
and O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
and O
healthcare B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Life-Impact', 'Life-Impact', 'Resource-use']

CONCLUSION: O
Training O
using O
a O
gelatin-based O
cervical O
spine O
phantom O
helps O
novices O
acquire O
the O
skills B-outcome ['Life-Impact']
necessary O
to O
perform O
ultrasound-guided O
cervical O
medial O
branch O
blocks. O
[['Life-Impact']]

The O
group O
was O
made O
up O
of O
men O
and O
women O
aged O
between O
48 O
and O
73 O
years O
in O
chronic O
treatment O
with O
digitalis O
and O
diuretics O
for O
at O
least O
3 O
months O
and O
who O
still O
displayed O
symptoms O
. O
[]

BACKGROUND: O
Sperm O
selection O
strategies O
aimed O
at O
improving O
success O
rates O
of O
intracytoplasmic O
sperm O
injection O
(ICSI) O
include O
binding O
to O
hyaluronic O
acid O
(herein O
termed O
hyaluronan). O
[]

Safety O
of O
the O
combination O
of O
valsartan O
and O
benazepril O
in O
patients O
with O
chronic O
renal O
disease O
. O
[]

Significant O
improvements O
in O
serum O
Ca B-outcome ['Physiological-Clinical']
, O
P B-outcome ['Physiological-Clinical']
and O
iPTH B-outcome ['Physiological-Clinical']
levels O
were O
observed O
at O
4, O
8, O
and O
12 O
weeks O
in O
the O
treatment O
group O
(P O
&lt; O
0.05) O
but O
only O
at O
12 O
weeks O
in O
the O
control O
group O
(P O
&lt; O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
conclusion O
, O
a O
substantial O
number O
of O
patients O
revealed O
evidence O
of O
cognitive O
deficits O
a O
long O
time O
after O
HSCT O
. O
[]

Treatment O
included O
4 O
sessions O
of O
manual O
therapy O
and O
stabilizing O
exercises O
aimed O
at O
correcting O
the O
lumbopelvic O
rhythm O
. O
[]

Randomized O
controlled O
trials O
are O
needed O
. O
[]

In O
the O
G-CSF O
group O
, O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neutropenia I-outcome ['Physiological-Clinical']
was O
significantly O
shorter O
and O
the O
frequency O
of O
documented O
infection O
was O
significantly O
decreased O
. O
['Physiological-Clinical']

Markers O
of O
systemic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
predict O
survival O
in O
patients O
with O
advanced O
renal O
cell O
cancer O
. O
['Physiological-Clinical']

RESULTS O
The O
epidural O
group O
had O
significantly O
lower O
pain B-outcome ['Physiological-Clinical']
scores O
at O
3 O
evaluation O
times O
through O
postoperative O
day O
number O
4 O
( O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

INTRODUCTION O
Biventricular O
pacing O
system O
implantation O
is O
a O
time-consuming O
and O
challenging O
procedure O
. O
[]

Whether O
somatostatin O
has O
regulatory O
influence O
on O
melatonin B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
man O
has O
never O
been O
unequivocally O
shown O
. O
['Physiological-Clinical']

CONCLUSIONS O
Combined O
cardiac O
stem O
cell O
delivery O
induces O
a O
moderate O
but O
significant O
improvement O
in O
myocardial B-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
size I-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical']

Pimecrolimus O
cream O
1 O
% O
vs. O
betamethasone O
17-valerate O
0.1 O
% O
cream O
in O
the O
treatment O
of O
seborrhoeic O
dermatitis O
. O
[]

We O
investigated O
whether O
VK2 O
could O
reduce O
incidence O
of O
tumor O
recurrence O
after O
treatment O
of O
HCC O
. O
[]

Protocol-directed O
angiography O
has O
been O
performed O
at O
randomly O
assigned O
intervals O
, O
weighted O
toward O
the O
end O
of O
the O
study O
period O
. O
[]

OBJECTIVE O
This O
study O
set O
out O
to O
investigate O
the O
potential O
for O
pharmacodynamic B-outcome ['Physiological-Clinical']
interaction I-outcome ['Physiological-Clinical']
between O
low-dose O
ASA O
and O
esomeprazole O
in O
healthy O
volunteers O
, O
by O
measuring O
ASA O
antiplatelet B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Clinical O
and O
radiographic O
evaluation O
of O
guided O
tissue O
regeneration O
in O
the O
treatment O
of O
class O
II O
furcation O
defects O
. O
[]

It O
is O
not O
, O
however O
, O
clear O
whether O
the O
treatment O
should O
be O
started O
with O
a O
high O
or O
a O
low O
dose O
of O
the O
inhaled O
steroid O
. O
[]

Furthermore, O
trends O
for O
sex O
differences O
were O
discovered O
in O
urinary, O
but O
not O
salivary, O
hydration B-outcome ['Physiological-Clinical']
markers, O
with O
discrepancies O
in O
kinetics O
between O
fluid O
compartments O
both O
warranting O
further O
study. O
[['Physiological-Clinical']]

Double-blind O
placebo-controlled O
trial O
of O
aprindine O
and O
digoxin O
for O
the O
prevention O
of O
symptomatic B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
study O
compared O
sub-Tenon O
's O
and O
retrobulbar O
anesthesia O
. O
[]

Participants O
in O
both O
groups O
made O
anticipatory O
judgements B-outcome ['Life-Impact']
regarding O
movement B-outcome ['Life-Impact']
initiation I-outcome ['Life-Impact']
( O
approximately O
100 O
ms O
) O
. O
['Life-Impact', 'Life-Impact']

Fasting B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
was O
13 O
+/- O
3 O
and O
10 O
+/- O
2 O
mU/l O
and O
fasting O
glucose O
5.3 O
+/- O
0.2 O
and O
5.1 O
+/- O
0.1 O
mmol/l O
after O
placebo O
and O
metformin O
treatment O
, O
respectively O
( O
ns O
) O
. O
['Physiological-Clinical']

The O
intervention O
period O
lasted O
30 O
days O
(1 O
session O
every O
10 O
days). O
[]

It O
is O
generally O
agreed O
that O
absolute-direction O
judgments O
require O
information O
about O
eye O
position O
, O
whereas O
relative-direction O
judgments O
do O
not O
. O
[]

The O
home O
TEACCHing O
program O
for O
toddlers O
with O
autism O
. O
[]

Therefore, O
it O
can O
be O
concluded O
that O
MBCT O
is O
effective O
on O
illness B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
syndrome I-outcome ['Life-Impact']
and O
can O
be O
used O
as O
an O
MBI O
method O
to O
reduce O
the O
illness B-outcome ['Life-Impact']
perceptions I-outcome ['Life-Impact']
in O
people O
with O
RA. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

FUNDING: O
National O
Institute O
for O
Health O
Research O
Efficacy O
and O
Mechanism O
Evaluation O
Programme. O
[]

Participants O
then O
completed O
the O
Reading O
the O
Mind O
in O
the O
Eyes O
Task O
, O
a O
widely O
used O
and O
reliable O
test O
of O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
. O
['Life-Impact']

Poylmerized O
whole O
ragweed O
: O
an O
improved O
method O
of O
immunotherapy O
. O
[]

Trial O
Registration: O
ClinicalTrials.gov O
Identifier: O
NCT02571361. O
[]

After O
that O
, O
additional O
3 O
cycles O
of O
EP O
consolidation O
were O
administered O
. O
[]

The O
scores O
on O
awakening O
and O
after O
10 O
minutes O
were O
significantly O
lower O
in O
the O
bupivacaine O
group O
( O
P O
< O
0.05 O
, O
Mann-Whitney O
U O
test O
) O
. O
[]

Zidovudine O
was O
discontinued O
in O
group O
A O
patients O
before O
instituting O
GM-CSF O
treatment O
and O
was O
restarted O
in O
a O
graduated O
fashion O
over O
4 O
weeks O
. O
[]

Here O
, O
we O
investigated O
whether O
a O
3-week O
administration O
of O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
expected O
to O
increase O
brain O
5-HT O
levels O
, O
is O
associated O
with O
a O
decline O
in O
brain O
5-HT4R O
binding O
. O
[]

Birth O
weight O
for O
infants B-outcome ['Physiological-Clinical']
born I-outcome ['Physiological-Clinical']
to O
women O
who O
quit O
smoking O
averaged O
7.2 O
lb O
versus O
6.8 O
and O
6.3 O
lb O
for O
mothers O
smoking O
one O
to O
six O
and O
more O
than O
six O
cigarettes O
per O
day O
at O
delivery O
( O
P O
< O
.01 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
addition O
of O
concurrent O
cisplatin O
to O
radiotherapy O
resulted O
in O
a O
[]

METHODS O
We O
performed O
a O
cohort O
analysis O
of O
data O
from O
a O
randomized O
controlled O
trial O
of O
episiotomy O
conducted O
in O
3 O
Montreal O
hospitals O
in O
1990-1991 O
. O
[]

Our O
findings O
show O
that O
the O
influenza O
vaccine O
alone O
as O
well O
as O
the O
combination O
of O
the O
influenza O
and O
pneumococcal O
vaccine O
increases O
CRP-levels O
with O
a O
peak O
2 O
days O
after O
vaccination O
. O
['Physiological-Clinical']

These O
findings O
are O
compatible O
with O
the O
lack O
of O
efficacy O
of O
enoxaparin O
in O
reducing O
ischemic O
deficit O
after O
SAH O
. O
[]

Journal O
ID: O
101125284 O
[]

At O
6 O
months O
, O
the O
UC O
group O
showed O
QoL O
improvement O
and O
less O
anxiety B-outcome ['Life-Impact']
compared O
to O
the O
CER O
group O
. O
['Life-Impact', 'Life-Impact']

The O
data O
collected O
included O
heart O
rate O
, O
mean O
arterial O
pressure O
, O
respiratory O
rate O
, O
saturation O
of O
oxygen O
, O
amount O
of O
sedatives O
, O
awakening O
time O
and O
adverse O
effects O
. O
[]

RESULTS O
Subjects O
displayed O
a O
strong O
implicit O
preference O
for O
whites O
over O
blacks O
( O
P O
< O
.0001 O
) O
and O
associated O
medically B-outcome ['Life-Impact']
cooperative I-outcome ['Life-Impact']
with O
whites O
over O
blacks O
( O
P O
< O
.0001 O
) O
. O
['Life-Impact']

Title: O
Open-labeled O
randomized O
controlled O
trial O
to O
evaluate O
the O
1-year O
clinical O
outcomes O
of O
polymer-free O
sirolimus-eluting O
coronary O
stents O
as O
compared O
with O
biodegradable O
polymer-based O
sirolimus-eluting O
coronary O
stents. O
[]

on O
day O
1 O
, O
and O
prednisone O
( O
50 O
mg/m O
( O
2 O
) O
) O
on O
days O
1-5 O
. O
[]

Adjudication O
of O
type-4a B-outcome ['Physiological-Clinical']
MI I-outcome ['Physiological-Clinical']
in O
patients O
with O
an O
ACS O
was O
problematic O
with O
< O
10 O
% O
of O
the O
potential O
type-4a O
MI O
being O
confirmed O
as O
an O
event O
, O
as O
compared O
with O
approximately O
95 O
% O
in O
stable O
patients O
undergoing O
elective O
PCI O
. O
['Physiological-Clinical']

RESULTS O
Two O
hundred O
ninety-four O
patients O
who O
did O
not O
have O
brain O
metastases O
at O
the O
time O
of O
random O
assignment O
were O
analyzed O
. O
[]

The O
2nd O
dose O
was O
administered O
after O
an O
interval O
of O
6 O
months. O
[]

The O
treatment O
group O
had O
temperatures B-outcome ['Physiological-Clinical']
that O
were O
significantly O
higher O
than O
those O
of O
the O
control O
group O
30 O
minutes O
after O
arrival O
in O
the O
PACU O
, O
and O
the O
treatment O
group O
experienced O
a O
greater O
['Physiological-Clinical']

The O
larger O
and O
small O
forceps O
were O
used O
in O
a O
random O
sequence O
to O
avoid O
a O
reduction O
in O
diagnostic O
yield O
of O
the O
second O
series O
of O
biopsies O
related O
to O
possible O
bleeding O
by O
first O
series O
of O
biopsies O
. O
[]

Insertion B-outcome ['Life-Impact']
was O
more O
frequently O
successful O
( O
50/50 O
vs O
15/50 O
, O
P=0.0002 O
) O
and O
faster O
( O
35+/-17 O
s O
vs O
54+/-45 O
s O
, O
mean+/-SD O
, O
P=0.006 O
) O
with O
the O
bougie-guided O
technique O
. O
['Life-Impact']

7.6 O
% O
vs. O
29.0 O
? O
[]

PARTICIPANTS O
Forty-nine O
volunteers O
who O
passed O
the O
initial O
assessment O
for O
recurrent O
aphthous O
stomatitis O
entered O
a O
pretrial O
phase O
in O
which O
their O
eligibility O
for O
the O
trial O
phase O
of O
the O
study O
was O
assessed O
. O
[]

After O
interventions, O
the O
exercise O
group O
had O
lower O
percentage O
body B-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
(%BF) O
and O
cardiometabolic B-outcome ['Physiological-Clinical']
risk O
markers, O
and O
higher O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
(LM) I-outcome ['Physiological-Clinical']
and O
leg B-outcome ['Life-Impact']
muscle I-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
compared O
to O
the O
usual O
care O
group. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

A O
2015 O
review. O
[]

CONCLUSION O
These O
results O
suggest O
that O
hCG O
administered O
when O
the O
largest O
follicle O
size O
reaches O
16.0-16.9 O
mm O
leads O
to O
similar O
clinical O
and O
ongoing O
pregnancy O
rates O
as O
when O
it O
reaches O
18.0-18.9 O
mm O
in O
IUI O
cycles O
. O
[]

Effects O
of O
weight-bearing O
versus O
nonweight-bearing O
exercise O
on O
function B-outcome ['Life-Impact']
, O
walking B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
, O
and O
position O
sense B-outcome ['Physiological-Clinical']
in O
participants O
with O
knee O
osteoarthritis O
: O
a O
randomized O
controlled O
trial O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Several O
investigators O
have O
reported O
a O
significantly O
reduced O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
as O
defined O
by O
monoclonal O
antibodies O
, O
in O
the O
peripheral O
blood O
of O
Caucasian O
patients O
with O
chronic O
active O
hepatitis O
B O
( O
CAHB O
) O
. O
['Physiological-Clinical']

Based O
on O
serial O
electrocardiographic O
data O
, O
115 O
of O
the O
246 O
patients O
with O
angina O
had O
transient O
ST-T B-outcome ['Physiological-Clinical']
changes O
and O
131 O
did O
not O
. O
['Physiological-Clinical']

The O
probability O
that O
phenytoin O
has O
any O
prophylactic B-outcome ['Resource-use']
efficacy O
is O
0.383 O
. O
['Resource-use']

BACKGROUND O
The O
effectiveness O
of O
heart O
failure O
disease O
management O
programs O
in O
patients O
under O
cardiologists O
' O
care O
over O
long-term O
follow-up O
is O
not O
established O
. O
[]

We O
chose O
to O
test O
valproate O
due O
to O
its O
well O
documented O
effect O
as O
a O
migraine O
prophylactic O
drug O
. O
[]

The O
effect O
of O
vitamin O
D3 O
( O
cholecalciferol O
) O
supplementation O
on O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
is O
uncertain O
. O
['Physiological-Clinical']

Design, O
Setting, O
and O
Participants: O
Randomized, O
placebo-controlled, O
factorial O
clinical O
trial O
among O
120 O
patients O
aged O
60 O
years O
or O
older O
undergoing O
on-pump O
coronary O
artery O
bypass O
graft O
(CABG) O
surgery O
or O
combined O
CABG/valve O
surgeries O
at O
a O
US O
center. O
[]

Patients O
with O
solid O
malignancies O
( O
n O
= O
23 O
) O
received O
AUTO O
. O
[]

Twenty O
typical O
and O
19 O
autistic O
adults O
donated O
to O
charity O
and O
to O
a O
person O
, O
both O
when O
alone O
and O
when O
observed O
. O
[]

METHODS O
Eighty-six O
patients O
consented O
and O
were O
randomly O
assigned O
intraoperatively O
to O
one O
of O
two O
study O
groups O
, O
and O
sixty-eight O
of O
them O
completed O
the O
study O
. O
[]

The O
usefulness O
of O
OK-432 O
was O
studied O
using O
the O
sealed O
envelope O
method O
. O
[]

METHODS O
In O
this O
prospective O
, O
controlled O
trial O
, O
121 O
gastric O
cancer O
patients O
attending O
inpatient O
rehabilitation O
after O
surgical O
treatment O
received O
either O
the O
interactive O
intervention O
or O
lectures O
providing O
information O
. O
[]

Treatment O
did O
not O
affect O
the O
proportion O
of O
cows O
exhibiting O
ovarian B-outcome ['Physiological-Clinical']
luteal I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
before O
the O
start O
of O
the O
breeding O
season O
( O
67 O
% O
) O
or O
pregnancy O
rate O
( O
91 O
% O
) O
. O
['Physiological-Clinical']

Journal-Name:The O
New O
England O
journal O
of O
medicine O
[]

Only O
245 O
patients O
( O
100 O
% O
of O
patients O
with O
prior O
variceal O
hemorrhage O
, O
61 O
% O
of O
patients O
without O
prior O
hemorrhage O
) O
were O
receiving O
some O
form O
of O
prophylactic O
therapy O
. O
[]

Tunnelling O
of O
the O
catheter O
subcutaneously O
for O
a O
distance O
of O
5 O
cm O
reduced O
the O
incidence O
of O
inward O
migration O
of O
1 O
cm O
or O
more O
( O
p O
< O
0.01 O
) O
compared O
to O
a O
standard O
method B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
fixation I-outcome ['Physiological-Clinical']
with O
a O
transparent B-outcome ['Physiological-Clinical']
adhesive I-outcome ['Physiological-Clinical']
dressing I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
total O
of O
2961 O
eligible O
patients O
were O
identified O
from O
September O
2015 O
to O
January O
2017. O
[]

Onset O
and O
complete B-outcome ['Physiological-Clinical']
spread O
of O
sensory B-outcome ['Resource-use']
blockade I-outcome ['Resource-use']
were O
similar O
in O
all O
five O
groups O
. O
['Physiological-Clinical', 'Resource-use']

AIM O
To O
investigate O
the O
role O
of O
exogenous O
bile O
acid O
therapy O
in O
patients O
with O
poor O
pouch O
function O
after O
restorative O
proctocolectomy O
for O
ulcerative O
colitis O
. O
[]

Twenty-seven O
adolescent O
basketball O
players O
( O
14.7+/-0.5 O
years O
; O
Tanner O
stage O
: O
3.5+/-0.5 O
) O
were O
randomly O
divided O
into O
a O
specialized O
basketball O
training O
group O
( O
SP O
, O
n=10 O
) O
, O
a O
mixed O
basketball O
plus O
conditioning O
training O
group O
( O
MX O
, O
n=10 O
) O
and O
a O
control O
group O
( O
n=7 O
) O
. O
[]

The O
half-life B-outcome ['Physiological-Clinical']
of O
radioactivity O
in O
plasma O
is O
39 O
h O
; O
16 O
% O
of O
C O
is O
excreted O
in O
urine O
in O
the O
form O
of O
metabolites O
and O
only O
0.3 O
% O
unchanged O
. O
['Physiological-Clinical']

14 O
] O
% O
to O
21 O
[ O
17 O
] O
) O
, O
but O
was O
not O
in O
subjects O
receiving O
casein O
( O
from O
37 O
[ O
13 O
] O
% O
to O
36 O
[ O
12 O
] O
) O
. O
[]

151 O
patients O
with O
locally O
advanced O
prostatic O
cancer O
( O
T3-4 O
M0 O
) O
, O
representing O
38 O
% O
of O
the O
404 O
cancer O
patients O
in O
a O
Finnish O
multicenter O
study O
, O
were O
randomly O
assigned O
to O
one O
of O
three O
treatment O
arms O
: O
orchiectomy O
, O
estrogens O
or O
radiotherapy O
. O
[]

RESULTS O
Both O
medications O
were O
highly O
effective O
in O
relieving O
pain B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
statistically O
significant O
difference O
between O
the O
two O
groups O
of O
patients O
with O
respect O
to O
age O
, O
sex B-outcome ['Physiological-Clinical']
ratio O
, O
chest B-outcome ['Life-Impact']
drainage I-outcome ['Life-Impact']
duration I-outcome ['Life-Impact']
, O
postprocedural B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
parenteral B-outcome ['Life-Impact']
narcotics I-outcome ['Life-Impact']
requirement I-outcome ['Life-Impact']
, O
complications B-outcome ['Adverse-effects']
, O
or O
procedure B-outcome ['Life-Impact']
failure I-outcome ['Life-Impact']
( O
ie O
, O
recurrence B-outcome ['Physiological-Clinical']
) O
. O
['Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Life-Impact', 'Adverse-effects', 'Life-Impact', 'Physiological-Clinical']

Journal O
ID: O
2985248R O
[]

CONCLUSIONS O
CYP2C19 O
genotypes O
play O
a O
role O
in O
H. O
pylori O
eradication O
therapy O
. O
[]

Complete O
response O
( O
CR B-outcome ['Physiological-Clinical']
) O
rates O
were O
not O
statistically O
different O
: O
64 O
% O
[ O
95 O
percent O
confidence O
interval O
( O
CI O
) O
: O
58 O
percent O
to O
70 O
percent O
] O
for O
conventional O
arm O
vs O
81 O
percent O
( O
95 O
CI O
: O
77-86 O
percent O
) O
in O
the O
intensive O
group O
( O
p=0.2 O
) O
. O
['Physiological-Clinical']

Exclusion O
criteria O
were O
: O
insertional O
disorders O
, O
partial O
or O
complete O
ruptures O
, O
or O
systemic O
illness O
. O
[]

Clinical O
and O
bacteriological O
responses O
were O
evaluated O
in O
all O
patients O
( O
n O
= O
103 O
) O
. O
[]

RESULTS O
The O
effective O
rate O
was O
96.7 O
% O
in O
the O
observation O
group O
which O
was O
better O
than O
86.7 O
% O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
[]

To O
analyze O
if O
25(OH)D O
was O
a O
good O
predictor O
of O
testosterone B-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
testosterone/cortisol B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
a O
stepwise O
regression O
model O
was O
performed. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

FINDINGS O
The O
two O
randomised O
groups O
were O
similar O
in O
demographic O
, O
physical O
, O
and O
clinical O
characteristics O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
association O
between O
severity O
of O
coexisting O
patellofemoral O
( O
PF O
) O
disease O
with O
lower O
extremity O
impairments O
and O
functional O
limitations O
in O
patients O
with O
tibiofemoral O
( O
TF O
) O
osteoarthritis O
( O
OA O
) O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
This O
was O
a O
randomized O
, O
placebo-controlled O
, O
multi-center O
, O
phase O
III O
trial O
, O
conducted O
in O
opioid-tolerant O
male O
and O
female O
patients O
( O
aged O
> O
or O
=17 O
years O
) O
with O
BTcP O
. O
[]

Patients O
were O
randomized O
to O
dual-chamber O
pacemaker O
implant O
( O
paced O
patients O
) O
or O
standard O
treatment O
( O
controls O
) O
. O
[]

HBV B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
turned O
negative O
in O
6/24 O
of O
the O
patients O
treated O
with O
recombinant O
hepatitis O
B O
vaccine O
( O
at O
both O
the O
doses O
of O
90 O
micrograms O
and O
60 O
micrograms O
) O
, O
and O
HBeAg/Anti-HBe B-outcome ['Physiological-Clinical']
seroconversion B-outcome ['Physiological-Clinical']
or O
HBeAg B-outcome ['Physiological-Clinical']
became O
negative O
in O
7/24 O
of O
them O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

2004 O
; O
15:440-449 O
) O
. O
[]

There O
were O
no O
differences O
in O
overall O
change O
across O
goal O
domains O
between O
the O
FF O
and O
WEB O
groups O
, O
suggesting O
the O
efficacy O
of O
videoconferencing O
technology O
. O
[]

Transient O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
noted O
in O
10 O
patients O
( O
26 O
% O
) O
after O
flecainide O
. O
['Adverse-effects']

Actigraphy O
data O
were O
collected O
a O
second O
time O
2 O
weeks O
after O
the O
parent O
received O
the O
randomization O
assignment O
and O
analyzed O
by O
using O
Student O
's O
t O
test O
. O
[]

CLASSIFICATION O
OF O
EVIDENCE O
This O
study O
provides O
Class O
I O
evidence O
that O
iTBS O
was O
not O
effective O
for O
gait B-outcome ['Life-Impact']
, O
upper B-outcome ['Physiological-Clinical']
extremity I-outcome ['Physiological-Clinical']
bradykinesia I-outcome ['Physiological-Clinical']
, O
or O
other O
motor B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
PD O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
degree O
of O
anesthesia B-outcome ['Resource-use']
was O
comparable O
for O
the O
three O
solutions O
following O
the O
administration O
of O
3.6 O
ml O
of O
each O
solution O
. O
['Resource-use']

There O
were O
no O
significant O
differences O
in O
the O
GMTs O
of O
tetanus B-outcome ['Physiological-Clinical']
and O
diphtheria B-outcome ['Physiological-Clinical']
antitoxins I-outcome ['Physiological-Clinical']
between O
the O
two O
groups O
after O
each O
vaccination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
overall O
main O
reason B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
sunbathing I-outcome ['Life-Impact']
was O
appearance O
, O
both O
for O
own O
sunbathing O
, O
and O
to O
an O
even O
higher O
degree O
, O
as O
a O
supposed O
reason O
for O
other O
adolescents O
' O
behaviour O
, O
and O
was O
reported O
most O
frequently O
by O
girls O
and O
the O
older O
age O
groups O
. O
['Life-Impact']

CONCLUSIONS O
Individual O
assessments O
of O
obesity O
and O
overweight O
should O
also O
include O
an O
assessment O
for O
subthreshold O
depression O
, O
mainly O
anhedonia O
. O
[]

All O
patients O
received O
therapy O
with O
salbutamol O
delivered O
with O
metered-dose O
inhaler O
( O
MDI O
) O
into O
a O
spacer O
device O
( O
Volumatic O
) O
in O
four O
puffs O
( O
400 O
micrograms O
) O
at O
10-min O
interval O
, O
and O
intravenous O
hydrocortisone O
( O
500 O
mg O
) O
. O
[]

CONCLUSION O
At O
this O
time O
, O
the O
evidence O
is O
insufficient O
to O
state O
whether O
catheter O
washout O
with O
saline O
or O
Contisol O
is O
more O
effective O
than O
usual O
care O
with O
no O
washout O
in O
preventing O
blocking O
. O
[]

Forty O
patients O
were O
randomized O
for O
being O
operated O
on O
with O
either O
MECC O
or O
CECC O
. O
[]

They O
were O
divided O
randomly O
into O
experimental O
group O
and O
control O
one O
, O
and O
respectively O
received O
auditory O
integrative O
training O
and O
no O
training O
based O
on O
the O
multiple O
therapies O
. O
[]

Pathological O
features O
and O
inhaled O
corticosteroid O
response O
of O
eosinophilic O
and O
non-eosinophilic O
asthma O
. O
[]

2 O
) O
Macroscopic O
diagnosis O
as O
being O
noncuratively O
resected O
on O
completion O
of O
the O
surgical O
procedure O
. O
[]

BACKGROUND O
Beyond O
lipid O
lowering O
, O
various O
antiinflammatory O
properties O
have O
been O
ascribed O
to O
statins O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Visual O
field O
progression O
, O
measured O
by O
Humphrey O
24-2 O
full-threshold O
testing O
and O
assessed O
by O
the O
change O
in O
the O
mean O
deviation O
( O
MD O
) O
, O
and O
an O
indicator O
of O
substantial B-outcome ['Physiological-Clinical']
worsening I-outcome ['Physiological-Clinical']
of O
the O
VF B-outcome ['Physiological-Clinical']
( O
MD O
decrease O
of O
> O
or O
=3 O
dB O
from O
baseline O
) O
, O
assessed O
at O
each O
follow-up O
visit O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Visualization O
of O
the O
esophageal O
course O
by O
barium O
contrast O
was O
not O
able O
to O
prevent O
ESUL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Patients O
receiving O
a O
late O
intensification O
had O
the O
same O
relapse B-outcome ['Physiological-Clinical']
rate O
as O
the O
other O
patients O
. O
['Physiological-Clinical']

At O
the O
end O
of O
the O
3 O
wk O
, O
we O
measured O
plasma O
inflammatory O
markers O
IL-6 O
, O
C-reactive O
protein O
, O
tumor O
necrosis O
factor O
receptors O
I O
and O
II O
( O
TNF-RI O
and O
-RII O
) O
, O
monocyte O
chemotactic O
protein-1 O
and O
E-selectin O
, O
and O
urinary O
8-iso-PGF O
( O
2? O
) O
, O
a O
marker O
of O
lipid O
peroxidation O
. O
[]

PARTICIPANTS: O
13 O
046 O
women O
aged O
16 O
years O
or O
older O
with O
a O
low O
risk O
singleton O
pregnancy. O
[]

Effect O
of O
pravastatin O
on O
cardiovascular B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
women O
after O
myocardial O
infarction O
: O
the O
cholesterol O
and O
recurrent O
events O
( O
CARE O
) O
trial O
. O
['Physiological-Clinical']

They O
had O
all O
had O
at O
least O
6 O
months O
of O
chronic O
LBP O
. O
[]

In O
vivo O
assessment O
of O
catheter-tip O
PO2 O
sensor O
: O
sampling O
lumen O
fabrication O
. O
[]

Journal O
ID: O
2985248R O
[]

Effect O
of O
a O
nutritional O
supplement O
containing O
vitamin O
E O
, O
selenium O
, O
vitamin O
c O
and O
coenzyme O
Q10 O
on O
serum B-outcome ['Physiological-Clinical']
PSA I-outcome ['Physiological-Clinical']
in O
patients O
with O
hormonally O
untreated O
carcinoma O
of O
the O
prostate O
: O
a O
randomised O
placebo-controlled O
study O
. O
['Physiological-Clinical']

By O
study O
endpoint O
, O
risperidone-treated O
subjects O
exhibited O
a O
64 O
% O
improvement O
over O
baseline O
in O
the O
irritability B-outcome ['Life-Impact']
score O
almost O
double O
that O
of O
placebo-treated O
subjects O
( O
31 O
% O
) O
. O
['Life-Impact']

Anesthesia O
was O
induced O
with O
thiopental O
sodium O
5 O
mg/kg O
, O
followed O
by O
rocuronium O
1.0 O
mg/kg O
. O
[]

Before O
treatment, O
2 O
weeks O
and O
1 O
month O
after O
treatment, O
the O
Gross B-outcome ['Life-Impact']
Motor I-outcome ['Life-Impact']
Function I-outcome ['Life-Impact']
Measure O
(GMFM)], O
modified O
Ashworth O
Scale O
(MAS)] O
of O
the O
hamstrings O
and O
triceps O
, O
plantar B-outcome ['Physiological-Clinical']
area I-outcome ['Physiological-Clinical']
and O
plantar B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
were O
examined O
for O
efficacy O
assessment. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical']]

The O
findings O
provide O
novel O
detail O
to O
the O
abnormal O
way O
in O
which O
people O
with O
autism O
look O
at O
faces O
, O
an O
impairment O
that O
likely O
influences O
all O
subsequent O
face O
processing O
. O
[]

Symptom O
diaries O
were O
filled O
during O
the O
study O
periods O
. O
[]

MATERIALS O
AND O
METHODS O
The O
Microvasive O
Zerotip O
( O
2.4Fr O
, O
3.0Fr O
) O
, O
Cook O
N-Circle O
( O
2.2Fr O
, O
3.0Fr O
, O
3.2Fr O
) O
, O
Bard O
Dimension O
( O
3.0Fr O
, O
Sacred O
Heart O
Medical O
Halo O
( O
1.9Fr O
) O
, O
Vantage O
( O
1.9Fr O
) O
and O
Circon-ACMI O
Sur-Catch-NT O
( O
3.0Fr O
) O
were O
tested O
by O
3 O
novice O
and O
3 O
experienced O
basket O
operators O
. O
[]

Improved O
adherence B-outcome ['Life-Impact']
with O
once-daily O
versus O
twice-daily O
dosing O
of O
mometasone O
furoate O
administered O
via O
a O
dry O
powder O
inhaler O
: O
a O
randomized O
open-label O
study O
. O
['Life-Impact']

A O
novel O
aspect O
of O
the O
design O
is O
the O
use O
of O
a O
preliminary O
cost-effectiveness O
analysis O
, O
based O
on O
best-guess O
values O
, O
and O
a O
sensitivity O
analysis O
over O
plausible O
ranges O
to O
guide O
the O
choice O
of O
subsample O
size O
. O
[]

Logistic O
regression O
analyses O
showed O
that O
no O
having O
creation O
a O
pleural O
tent O
procedure O
was O
the O
most O
significant O
predictive O
factor O
of O
the O
occurrence O
and O
duration O
of O
prolonged B-outcome ['Physiological-Clinical']
air I-outcome ['Physiological-Clinical']
leaks I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Social O
phobics O
reported O
substantially O
more O
anxiety B-outcome ['Life-Impact']
than O
controls O
. O
['Life-Impact']

Survival B-outcome ['Mortality']
without O
moderate O
or O
severe O
neurodevelopmental B-outcome ['Life-Impact']
disability I-outcome ['Life-Impact']
at O
24 O
months O
occurred O
in O
802 O
of O
1224 O
infants O
(65.5%) O
assigned O
to O
the O
faster O
increment O
and O
848 O
of O
1246 O
(68.1%) O
assigned O
to O
the O
slower O
increment O
(adjusted O
risk O
ratio, O
0.96; O
95% O
confidence O
interval O
[CI], O
0.92 O
to O
1.01; O
P O
= O
0.16). O
[['Mortality'], ['Life-Impact']]

Behavioral O
symptoms O
were O
assessed O
using O
the O
Aberrant B-outcome ['Life-Impact']
Behavior I-outcome ['Life-Impact']
Checklist O
( O
ABC O
) O
, O
Nisonger O
Child O
Behavior O
Rating O
Form O
, O
and O
Clinical O
Global O
Impression-Change O
. O
['Life-Impact']

RESULTS O
The O
oat O
cereal O
group O
experienced O
a O
7.5 O
mm O
Hg O
reduction O
in O
SBP B-outcome ['Physiological-Clinical']
( O
P O
& O
lt.01 O
) O
and O
a O
5.5 O
mm O
Hg O
reduction O
in O
DBP B-outcome ['Physiological-Clinical']
( O
P O
& O
lt.02 O
) O
, O
while O
there O
was O
virtually O
no O
change O
in O
either O
SBP O
or O
DBP O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
stratified O
according O
to O
esophageal O
size O
, O
based O
on O
the O
diameter O
of O
the O
divided O
esophagus O
( O
< O
or O
> O
or O
= O
30 O
mm O
) O
and O
then O
were O
randomized O
to O
have O
either O
a O
hand-sewn O
or O
a O
stapled O
anastomosis O
. O
[]

Controversy O
exists O
regarding O
the O
extent O
and O
possible O
causal O
relationship O
between O
gastrointestinal O
symptoms O
and O
autism O
. O
[]

METHODS: O
The O
study O
included O
20 O
men O
(20-31 O
yrs., O
[]

The O
training O
intervention O
consisted O
of O
6 O
supervised O
training O
sessions O
over O
7 O
weeks O
, O
targeting O
the O
improvement O
of O
the O
players O
' O
speed B-outcome ['Life-Impact']
and O
power B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

RESULTS O
A O
total O
of O
1905 O
of O
the O
randomized O
subjects O
( O
91.6 O
percent O
) O
completed O
the O
study O
. O
[]

Alkalinized O
lidocaine O
and O
heparin O
provide O
immediate O
relief O
of O
pain B-outcome ['Physiological-Clinical']
and O
urgency O
in O
patients O
with O
interstitial O
cystitis O
. O
['Physiological-Clinical']

RESULTS O
A O
Global O
Impressions O
parental O
questionnaire O
found O
that O
the O
supplement O
group O
reported O
statistically O
significant O
improvements O
in O
sleep B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
gastrointestinal I-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
compared O
to O
the O
placebo O
group O
. O
['Physiological-Clinical']

Two O
reviewers O
evaluated O
the O
relevance O
of O
each O
candidate O
study O
and O
the O
validity O
of O
eligible O
trials O
. O
[]

Birth B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
did O
not O
differ O
between O
groups O
and O
13 O
of O
the O
22 O
infants O
weighed O
below O
1000 O
g. O
There O
was O
a O
tendency O
to O
lower O
Apgar B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
at O
five O
minutes O
in O
the O
hydralazine O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

AIM O
The O
aim O
of O
our O
study O
was O
to O
assess O
the O
influence O
of O
oral O
corticosteroids O
and O
oral O
corticosteroids O
combined O
with O
vitamin O
D O
( O
3 O
) O
on O
the O
early O
clinical O
and O
immunological O
effects O
of O
SIT O
. O
[]

Antibodies B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
rHCNTF I-outcome ['Physiological-Clinical']
were O
observed O
in O
sera O
of O
most O
patients O
tested O
after O
2 O
weeks O
of O
continuous O
treatment O
and O
4 O
weeks O
' O
withdrawal O
period O
. O
['Physiological-Clinical']

CONCLUSION O
There O
is O
tentative O
indication O
that O
minimally-invasive O
surgery O
plus O
rtPA O
shows O
greater B-outcome ['Physiological-Clinical']
clot I-outcome ['Physiological-Clinical']
resolution I-outcome ['Physiological-Clinical']
than O
traditional O
medical O
management O
. O
['Physiological-Clinical']

Hypertension B-outcome ['Physiological-Clinical']
following O
coronary O
artery O
bypass O
grafting O
is O
a O
common O
problem O
that O
may O
result O
in O
postoperative B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
infraction I-outcome ['Physiological-Clinical']
or O
bleeding B-outcome ['Physiological-Clinical']
, O
Hemodynamic B-outcome ['Physiological-Clinical']
effects O
were O
compared O
in O
45 O
hypertensive O
coronary O
bypass O
patients O
randomized O
to O
receive O
either O
diltiazem O
, O
nitroglycerin O
, O
or O
sodium O
nitroprusside O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
procedure O
was O
then O
repeated O
on O
the O
finger O
pulps O
. O
[]

Results O
suggest O
that O
EBTs O
can O
retain O
their O
effectiveness O
when O
transported O
to O
a O
community O
context O
. O
[]

Primary O
endpoints O
of O
the O
study O
were O
the O
number O
of O
CD34+ B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
harvested O
per O
kg O
body O
weight O
on O
the O
occasion O
of O
six O
consecutive B-outcome ['Physiological-Clinical']
leukaphereses I-outcome ['Physiological-Clinical']
and O
the O
time B-outcome ['Life-Impact']
needed I-outcome ['Life-Impact']
for O
hematological B-outcome ['Physiological-Clinical']
reconstitution B-outcome ['Physiological-Clinical']
following O
autografting B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MATERIALS O
AND O
METHODS O
Patients O
undergoing O
MMS O
were O
prospectively O
randomized O
to O
have O
their O
tissue O
margins O
oriented O
using O
light O
scoring O
using O
a O
scalpel O
versus O
marking O
them O
using O
a O
gentian O
violet O
marker O
. O
[]

In O
all O
six O
cases O
in O
the O
nonstoma O
group O
, O
reoperations B-outcome ['Resource-use']
were O
necessary O
. O
['Resource-use']

Increased O
macular O
zeaxanthin O
is O
suggested O
to O
lower O
the O
risk O
of O
age-related B-outcome ['Physiological-Clinical']
macular I-outcome ['Physiological-Clinical']
degeneration I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
observed O
decline O
in O
spirochetes O
was O
then O
used O
to O
determine O
which O
patients O
had O
been O
compliant O
in O
a O
double-blind O
clinical O
trial O
involving O
the O
unsupervised O
usage O
of O
metronidazole O
. O
[]

CONCLUSION: O
Our O
study O
indicates O
that O
mitochondrial B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
could O
be O
the O
hallmark O
of O
tubular O
injury O
in O
DKD O
patients, O
and O
this O
would O
provide O
a O
novel O
and O
attractive O
therapeutic O
target O
to O
improve O
this O
disease. O
[['Physiological-Clinical']]

Title: O
Comparison O
of O
oncological O
benefits O
of O
deep O
neuromuscular O
block O
in O
obese O
patients O
with O
gastric O
cancer O
(DEBLOQS_GC O
study): O
A O
study O
protocol O
for O
a O
double-blind, O
randomized O
controlled O
trial. O
[]

Twenty-six O
patients O
in O
the O
ketorolac O
group O
and O
17 O
patients O
in O
the O
pethidine O
group O
requested O
further O
analgesia B-outcome ['Resource-use']
by O
90 O
minutes O
. O
['Resource-use']

Title: O
Cardiac O
events O
after O
macrolides O
or O
fluoroquinolones O
in O
patients O
hospitalized O
for O
community-acquired O
pneumonia: O
post-hoc O
analysis O
of O
a O
cluster-randomized O
trial. O
[]

NaCl O
is O
an O
appropriate O
first-line O
treatment O
, O
but O
for O
subjects O
with O
fluorescein-staining O
punctuations O
, O
lubrication O
with O
PVP O
is O
preferable O
. O
[]

Patients O
received O
the O
study O
drug O
on O
days O
1 O
, O
3 O
, O
and O
5 O
before O
initiation O
of O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
10 O
microg/kg/day O
on O
day O
5 O
and O
pheresis O
starting O
on O
day O
9 O
. O
[]

RESULTS O
Serum O
levels O
of O
creatine O
phosphokinase O
( O
CPK O
) O
, O
the O
MB B-outcome ['Physiological-Clinical']
isoenzyme I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
creatine I-outcome ['Physiological-Clinical']
kinase I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
CK-MB I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
occurrence O
of O
myocardial B-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
or O
infarction B-outcome ['Physiological-Clinical']
, O
and O
mean O
duration O
of O
using B-outcome ['Physiological-Clinical']
inotropic I-outcome ['Physiological-Clinical']
agents I-outcome ['Physiological-Clinical']
were O
significantly O
lower O
in O
the O
milrinone O
group O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Analysis O
modalities O
and O
clinical O
applicability O
of O
QoL B-outcome ['Life-Impact']
in O
randomized O
phase O
II O
trial O
in O
a O
digestive O
oncology O
. O
['Life-Impact']

There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
in O
VISA-A O
score O
( O
p O
= O
0.815 O
) O
and O
[]

High-dose O
weekly O
fractionation O
radiotherapy O
in O
advanced O
cancer O
of O
the O
uterine O
cervix O
. O
[]

The O
aim O
was O
to O
investigate O
which O
baseline O
variables O
predict O
a O
stable O
return-to-work O
during O
a O
2-year O
period O
after O
baseline O
: O
objective O
variables O
from O
function O
tests O
, O
socioeconomic O
, O
subjective O
and/or O
treatment O
variables O
. O
[]

RESULTS O
The O
amount O
of O
urethral B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
slight O
and O
similar O
in O
the O
2 O
groups O
. O
['Physiological-Clinical']

BACKGROUND O
Methylphenidate O
has O
been O
shown O
elsewhere O
to O
improve O
hyperactivity B-outcome ['Life-Impact']
in O
about O
half O
of O
treated O
children O
who O
have O
pervasive O
developmental O
disorders O
( O
PDD O
) O
and O
significant O
hyperactive-inattentive O
symptoms O
. O
['Life-Impact']

The O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
a O
commercial O
inactivated O
bivalent O
( O
H1N1/H3N2 O
) O
vaccine O
under O
conditions O
of O
natural O
exposure O
to O
a O
field O
SI O
variant O
. O
[]

This O
may O
partly O
be O
explained O
by O
intertrial O
differences O
in O
dosage O
and O
study O
design O
. O
[]

Sera O
obtained O
from O
439 O
children O
at O
two O
, O
four O
, O
and O
six O
months O
of O
age O
and O
from O
85 O
children O
at O
18 O
and O
20 O
months O
of O
age O
were O
examined O
for O
neutralizing B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

13 O
046 O
women O
(intervention O
n=7067, O
usual O
care O
n=5979) O
with O
data O
based O
on O
the O
national O
Dutch O
perinatal O
registry O
or O
hospital O
records O
were O
included O
in O
the O
analyses. O
[]

Rapid O
release O
of O
cardiac B-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
was O
observed O
in O
Group O
1 O
as O
compared O
with O
Group O
2 O
: O
rate O
of O
rise O
of O
CK B-outcome ['Physiological-Clinical']
was O
210+/-209 O
vs O
97+/-95 O
U/l/h O
( O
p=0.015 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE: O
To O
investigate O
the O
rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
MW O
after O
exercise-induced O
dehydration. O
[['Physiological-Clinical']]

This O
study O
does O
not O
support O
the O
clinical O
use O
of O
insulin B-outcome ['Resource-use']
as O
a O
means O
of O
modifying O
protein O
metabolic O
losses O
after O
major O
surgery O
. O
['Resource-use']

Better O
event-related O
modulation O
of O
inhibition O
correlated O
with O
better O
performance O
in O
more O
demanding O
tasks O
, O
in O
which O
fast O
alternating O
activation O
of O
cortical O
representations O
are O
necessary O
. O
[]

RESULTS O
The O
duration O
of O
postoperative B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
in O
Group O
I O
( O
5.1 O
+/- O
2.3 O
hr O
) O
was O
significantly O
shorter O
than O
in O
the O
other O
three O
groups O
( O
II O
-16.6 O
+/- O
4.9 O
hr O
; O
III O
- O
17.2 O
+/- O
5.5 O
hr O
; O
IV O
- O
17.0 O
+/- O
5.8 O
hr O
; O
P O
< O
0.05 O
) O
. O
['Resource-use']

Considerations O
for O
feasibility O
and O
effectiveness, O
including O
barriers O
to O
attendance, O
are O
discussed. O
[]

A O
total O
of O
206 O
randomized O
FAP O
patients O
commenced O
intervention O
, O
of O
whom O
133 O
had O
at O
least O
one O
follow-up O
endoscopy O
and O
were O
therefore O
included O
in O
the O
primary O
analysis O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
effect O
of O
modified O
CIMT O
on O
improving O
paretic O
arm O
function O
in O
poststroke O
patients O
during O
a O
subacute O
rehabilitation O
period O
. O
[]

An O
unfavorable O
outcome O
was O
significantly O
less O
frequent O
in O
the O
eyes O
undergoing O
cryotherapy O
( O
21.8 O
% O
) O
compared O
with O
the O
untreated O
eyes O
( O
43 O
% O
) O
. O
[]

Gastric B-outcome ['Physiological-Clinical']
contents I-outcome ['Physiological-Clinical']
and O
pH O
after O
oral O
premedication O
. O
['Physiological-Clinical']

The O
primary O
outcome O
was O
the O
incidence O
of O
low O
cardiac O
output O
syndrome O
( O
standardized O
score O
) O
or O
death O
36 O
hours O
postoperatively O
. O
[]

The O
intervention O
provides O
individualized O
feedback O
that O
guides O
participants O
through O
the O
stages O
of O
change O
for O
cessation O
. O
[]

BACKGROUND O
Contrary O
to O
aerobic O
exercise O
, O
strength O
training O
( O
ST O
) O
is O
associated O
with O
decreased O
central B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
compliance I-outcome ['Physiological-Clinical']
in O
young O
men O
. O
['Physiological-Clinical']

The O
Studies O
to O
Advance O
Autism O
Research O
and O
Treatment O
Network O
conducted O
a O
randomized O
trial O
with O
citalopram O
in O
children O
with O
Pervasive O
developmental O
disorders O
( O
PDDs O
) O
. O
[]

To O
assess O
the O
rationale O
of O
albumin O
priming O
prior O
to O
exchange O
transfusions O
, O
42 O
hyperbilirubinemic O
infants O
who O
required O
exchange O
transfusions O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
[]

AIMS O
To O
examine O
the O
role O
of O
other O
psychosocial O
factors O
relevant O
for O
outcome O
. O
[]

There O
are O
no O
significant O
differences O
within O
each O
group O
in O
preoperative O
comorbidity O
, O
age O
, O
or O
urgency O
. O
[]

Both O
the O
NIH-CPSI B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
and O
the O
improvement O
of O
complications B-outcome ['Adverse-effects']
were O
significantly O
higher O
in O
the O
experimental O
than O
in O
the O
control O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
treatment O
was O
well O
tolerated B-outcome ['Life-Impact']
, O
without O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
or O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
Thus, O
our O
WSP O
formula O
as O
an O
MR O
can O
facilitate O
individual O
weight B-outcome ['Physiological-Clinical']
loss O
and O
thus O
has O
commercial O
application O
in O
the O
food O
industry. O
[['Life-Impact'], ['Adverse-effects'], ['Adverse-effects'], ['Physiological-Clinical']]

There O
was O
a O
significant O
decrease O
in O
pain B-outcome ['Physiological-Clinical']
severity I-outcome ['Physiological-Clinical']
and O
analgesic B-outcome ['Resource-use']
intake I-outcome ['Resource-use']
in O
both O
active O
and O
sham O
TENS O
groups O
when O
compared O
with O
the O
control O
group O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Resource-use']

In O
26 O
of O
the O
106 O
patients O
, O
there O
was O
fertilization O
only O
after O
ICSI O
and O
not O
after O
IVF O
( O
IVF- O
group O
) O
. O
[]

Comparison O
of O
adaptive O
pacing O
therapy O
, O
cognitive O
behaviour O
therapy O
, O
graded O
exercise O
therapy O
, O
and O
specialist O
medical O
care O
for O
chronic O
fatigue O
syndrome O
( O
PACE O
) O
: O
a O
randomised O
trial O
. O
[]

Contrast O
ventriculography B-outcome ['Physiological-Clinical']
demonstrated O
improvement O
in O
immediate O
( O
54 O
+/- O
12 O
% O
) O
versus O
6-month O
( O
60 O
+/- O
15 O
% O
, O
p O
< O
0.05 O
) O
values O
for O
the O
overall O
group O
. O
['Physiological-Clinical']

Reduction O
in O
bone O
turnover O
markers O
was O
greater O
with O
denosumab O
. O
[]

All O
patients O
survived B-outcome ['Mortality']
PBSCT O
. O
['Mortality']

RESULTS O
Analysis O
of O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
data O
revealed O
a O
statistically O
significant O
increase O
in O
strength B-outcome ['Life-Impact']
within O
the O
treatment O
group O
after O
the O
first O
intervention O
( O
6.95 O
% O
right O
, O
12.61 O
% O
left O
) O
as O
compared O
with O
the O
second O
( O
11.53 O
% O
right O
, O
17.02 O
% O
left O
) O
and O
the O
third O
interventions O
( O
10.53 O
% O
right O
, O
16.81 O
% O
left O
) O
. O
['Life-Impact', 'Life-Impact']

METHODS O
Twenty-four O
volunteers O
were O
recruited O
into O
an O
open-label O
, O
randomised O
, O
two-period O
, O
single-centre O
study O
with O
crossover O
design O
. O
[]

No O
significant O
differences O
were O
detected O
between O
the O
two O
treatment O
groups O
in O
time O
to O
progression B-outcome ['Physiological-Clinical']
, O
objective O
response O
rates O
, O
duration O
of O
response B-outcome ['Physiological-Clinical']
, O
and O
survival B-outcome ['Mortality']
in O
either O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

OBJECTIVE O
We O
evaluated O
in O
a O
manikin O
model O
whether O
using O
the O
single-use O
laryngeal O
tube O
with O
suction O
option O
( O
LTS-D O
) O
instead O
of O
endotracheal O
intubation O
( O
ET O
) O
and O
bag-mask-valve O
ventilation O
( O
BMV O
) O
for O
emergency O
airway O
management O
could O
reduce O
the O
no-flow O
time O
( O
NFT O
) O
. O
[]

Participants O
in O
music O
training O
( O
n O
= O
18 O
) O
watched O
a O
music O
video O
containing O
6 O
songs O
and O
pictures O
of O
the O
36 O
target O
words O
; O
those O
in O
speech O
training O
( O
n O
= O
18 O
) O
watched O
a O
speech O
video O
containing O
6 O
stories O
and O
pictures O
, O
and O
those O
in O
the O
control O
condition O
( O
n O
= O
14 O
) O
received O
no O
treatment O
. O
[]

MATERIALS O
AND O
METHODS O
A O
total O
of O
2,802 O
men O
50 O
years O
or O
older O
with O
a O
clinical O
diagnosis O
of O
benign O
prostatic O
hyperplasia O
, O
no O
history O
of O
prostate O
cancer O
, O
PSA O
1.5 O
to O
10 O
ng/ml O
, O
prostate O
volume O
30 O
cc O
or O
greater O
, O
an O
American O
Urological O
Association O
symptom O
score O
of O
12 O
or O
greater O
and O
peak O
urinary O
flow O
rate O
15 O
ml O
per O
second O
or O
less O
were O
randomized O
to O
0.5 O
mg O
dutasteride O
daily O
or O
matching O
placebo O
for O
24 O
months O
. O
[]

Oral B-outcome ['Physiological-Clinical']
mucositis B-outcome ['Physiological-Clinical']
was O
analyzed O
using O
the O
unadjusted O
chi-square O
test O
, O
and O
time O
to O
first B-outcome ['Physiological-Clinical']
episode I-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Among O
the O
cases O
treated O
with O
pyrantel O
, O
the O
egg B-outcome ['Physiological-Clinical']
negative O
conversion B-outcome ['Life-Impact']
['Physiological-Clinical', 'Life-Impact']

Tracheostomy B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
not O
associated O
with O
either O
anticoagulant O
therapy O
or O
an O
abnormal O
clotting O
profile O
. O
['Physiological-Clinical']

Prior O
to O
challenge O
, O
patients O
manifested O
some O
subjective B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
but O
few O
objective O
signs O
of O
opioid O
withdrawal O
. O
['Life-Impact']

Changing O
Childbirth O
: O
a O
pilot O
project O
. O
[]

Those O
infants O
weighing O
1500 O
to O
1999 O
g O
( O
23 O
treated O
, O
9 O
control O
) O
were O
treated O
for O
8 O
days O
. O
[]

Pretrial O
USG O
was O
1.022 O
? O
[]

RESULTS O
In O
the O
1202 O
men O
studied O
, O
361 O
cases O
of O
prostate O
cancer O
were O
diagnosed O
. O
[]

In O
our O
previous O
study O
on O
individuals O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
( O
Sokhadze O
et O
al. O
, O
Appl O
Psychophysiol O
Biofeedback O
34:37-51 O
, O
2009a O
) O
we O
reported O
abnormalities O
in O
the O
attention-orienting O
frontal O
event-related O
potentials O
( O
ERP O
) O
and O
the O
sustained-attention O
centro-parietal O
ERPs O
in O
a O
visual O
oddball O
experiment O
. O
[]

A O
day O
before O
scanning O
, O
participants O
undertook O
an O
active O
object O
location O
memory O
task O
within O
a O
virtual O
house O
in O
which O
each O
room O
was O
associated O
with O
a O
different O
schedule O
of O
task-irrelevant O
emotional O
events O
. O
[]

Expanded O
blastocysts O
were O
vitrified O
in O
a O
solution O
containing O
6 O
M O
ethylene O
glycol O
, O
0.6 O
M O
trehalose O
and O
2 O
% O
( O
wt/vol O
) O
polyethylene O
glycol O
in O
10 O
% O
HEPES-buffered O
PZM-5 O
. O
[]

SETTING O
Eighty-four O
outpatient O
centers O
throughout O
the O
United O
States O
. O
[]

An O
analysis O
of O
the O
mortality O
effect O
in O
a O
breast O
cancer O
screening O
study O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

SVR B-outcome ['Physiological-Clinical']
rates O
were O
23 O
% O
, O
17 O
% O
, O
10 O
% O
, O
and O
9 O
% O
in O
groups O
A O
, O
B O
, O
C O
, O
and O
D O
, O
respectively O
( O
P O
< O
.0001 O
for O
trend O
) O
. O
['Physiological-Clinical']

Four O
population-based O
breast O
cancer O
screening O
projects O
are O
in O
progress O
in O
Sweden O
, O
three O
of O
which O
are O
randomized O
studies O
. O
[]

The O
diode O
laser O
treatment O
was O
better O
tolerated B-outcome ['Life-Impact']
than O
cryotherapy O
, O
and O
the O
treatment O
apparatus O
was O
more O
easily O
transported O
. O
['Life-Impact']

Those O
patients O
not O
responding O
to O
treatment O
were O
enrolled O
in O
the O
second O
part O
of O
the O
study O
, O
treated O
with O
an O
individualized O
combination O
of O
CRM O
and O
VR O
, O
and O
then O
reevaluated O
3 O
months O
later O
. O
[]

A O
whole-cell O
vaccine O
( O
SsWC O
) O
was O
then O
produced O
by O
formalin O
inactivation O
. O
[]

The O
2 O
groups O
were O
compared O
for O
mean O
survival B-outcome ['Mortality']
, O
hazard O
ratio O
, O
1-year O
survival B-outcome ['Mortality']
, O
quality O
of O
life O
scores O
, O
and O
hematologic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
chemical I-outcome ['Physiological-Clinical']
data I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Mortality', 'Physiological-Clinical']

Atomoxetine O
alone O
or O
combined O
with O
fluoxetine O
for O
treating O
ADHD O
with O
comorbid O
depressive O
or O
anxiety O
symptoms O
. O
[]

Overall O
, O
complementary B-outcome ['Life-Impact']
and O
alternative B-outcome ['Resource-use']
medicine I-outcome ['Resource-use']
( I-outcome ['Resource-use']
CAM I-outcome ['Resource-use']
) I-outcome ['Resource-use']
use O
was O
not O
significantly O
different O
in O
ASD O
( O
39 O
% O
) O
versus O
DD O
( O
30 O
% O
) O
. O
['Life-Impact', 'Resource-use']

Acid B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
for I-outcome ['Physiological-Clinical']
each I-outcome ['Physiological-Clinical']
hour I-outcome ['Physiological-Clinical']
over O
a O
3-h O
postprandial O
( O
PP O
) O
period O
was O
assessed O
as O
the O
percent O
time O
pH O
less O
than O
4.0 O
. O
['Physiological-Clinical']

The O
median O
blood B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
the O
laser O
group O
of O
55 O
patients O
was O
4.6 O
milliliters O
at O
, O
and O
within O
, O
24 O
hours O
after O
operation O
compared O
with O
30.1 O
milliliters O
in O
the O
cold O
knife O
group O
of O
55 O
patients O
. O
['Physiological-Clinical']

Much O
data O
have O
accrued O
in O
support O
of O
the O
concept O
that O
oxidation O
of O
LDL O
is O
a O
key O
early O
step O
in O
atherogenesis O
. O
[]

In O
contrast O
to O
group O
C O
and O
B O
, O
group O
DB O
was O
given O
dexketoprofen O
. O
[]

However O
, O
further O
research O
investigating O
and O
identifying O
intervention O
approaches O
that O
improve O
both O
[]

RESULTS O
ICE O
chemotherapy O
with O
G-CSF O
was O
effective O
in O
mobilizing B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
progenitors I-outcome ['Physiological-Clinical']
( O
median O
, O
120-fold O
) O
. O
['Physiological-Clinical']

The O
children O
received O
a O
daily O
dose O
of O
3 O
mg O
tetrahydrobiopterin O
per O
kilogram O
during O
6 O
months O
alternating O
with O
placebo O
. O
[]

RESULTS O
Patient O
characteristics O
were O
similar O
among O
the O
groups O
. O
[]

For O
postoperative O
analgesia O
, O
0.05 O
mg/kg O
morphine O
was O
administrated O
epidurally O
30 O
min O
before O
the O
end O
of O
the O
operation O
; O
30 O
, O
60 O
, O
90 O
, O
and O
120 O
min O
after O
arriving O
in O
the O
recovery O
room O
, O
vigilance O
was O
assessed O
using O
a O
modified O
Steward O
score O
, O
the O
Trieger O
test O
, O
the O
ability O
to O
recall O
a O
column O
of O
numbers O
( O
KAI O
test O
) O
, O
and O
symbol O
counting O
( O
CI O
test O
) O
. O
[]

METHODS O
Forty O
patients O
received O
lumbar O
epidural O
catheters O
. O
[]

On O
the O
last O
treatment O
day O
of O
each O
arm O
a O
20 O
min O
intravenous O
infusion O
of O
GTN O
( O
0.25 O
microg/kg/min O
) O
was O
given O
. O
[]

METHODS O
The O
study O
included O
42 O
patients O
( O
29 O
women O
and O
13 O
men O
; O
mean O
age O
53.2+/-14.2 O
years O
; O
body O
surface O
area O
1.76+/-0.14 O
m2 O
) O
with O
SH O
, O
as O
judged O
by O
elevated O
serum O
TSH O
levels O
( O
> O
3.6 O
mIU/l O
; O
range O
, O
3.8-12.0 O
) O
and O
normal O
free O
thyroid O
hormones O
( O
FT4 O
and O
FT3 O
) O
and O
30 O
euthyroid O
volunteer O
. O
[]

In O
a O
double-blind O
multicentric O
trial, O
109 O
PKU O
patients O
were O
randomized O
to O
DHA O
doses O
from O
0 O
to O
7 O
mg/kg&amp;day O
for O
six O
months. O
[]

A O
study O
in O
ASA O
I O
and O
II O
patients O
. O
[]

The O
median O
length O
of O
follow-up O
in O
surviving O
patients O
was O
58 O
months O
( O
range O
, O
10 O
to O
124 O
) O
. O
[]

Toxicity B-outcome ['Adverse-effects']
was O
unexpectedly O
high O
in O
both O
treatment O
arms O
and O
led O
to O
treatment O
withdrawal O
or O
refusal O
in O
49 O
% O
of O
all O
patients O
, O
predominantly O
already O
during O
the O
first O
treatment O
cycle O
. O
['Adverse-effects']

BACKGROUND O
MRI O
signal O
hyperintensities O
predict O
poor O
remission B-outcome ['Physiological-Clinical']
to O
antidepressant O
treatment O
. O
['Physiological-Clinical']

Nimesulide O
evidenced O
greater O
speed B-outcome ['Physiological-Clinical']
and O
duration O
of O
therapeutic O
action O
. O
['Physiological-Clinical']

Despite O
growing O
prospects O
for O
oxytocin O
as O
a O
therapeutic O
agent O
for O
ASD O
, O
no O
direct O
neurobiological O
evidence O
exists O
for O
oxytocin O
's O
beneficial O
effects O
on O
this O
core O
symptom O
of O
ASD O
. O
[]

Fifty-nine O
junior O
high O
school O
students O
who O
volunteered O
to O
participate O
in O
treatment O
for O
interpersonal B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
were O
randomly O
assigned O
to O
rational-emotive O
therapy O
without O
imagery O
( O
RET O
) O
, O
rational-emotive O
therapy O
with O
imagery O
( O
REI O
) O
, O
relationship-oriented O
counseling O
( O
ROC O
) O
, O
and O
waiting-list O
control O
( O
WLC O
) O
groups O
. O
['Life-Impact']

Although O
both O
groups O
improved O
in O
their O
knowledge B-outcome ['Life-Impact']
score O
, O
the O
intervention O
group O
showed O
a O
significantly O
greater O
improvement O
at O
posttest O
. O
['Life-Impact']

The O
levels O
of O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
about O
2 O
weeks O
after O
admission O
were O
significantly O
higher O
in O
the O
imidapril O
group O
than O
in O
the O
placebo O
group O
( O
65.9 O
% O
+/- O
2.5 O
% O
vs O
49.1 O
% O
+/- O
4.4 O
% O
; O
p O
< O
0.01 O
) O
. O
['Physiological-Clinical']

The O
development O
and O
evaluation O
of O
a O
computer-based O
program O
to O
test O
and O
to O
teach O
the O
recognition O
of O
facial B-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
['Life-Impact']

BACKGROUND O
Acute O
invasive O
diarrhea O
is O
a O
potentially O
serious O
condition O
in O
children O
. O
[]

Enhancing O
the O
working B-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
of O
stroke O
patients O
using O
tDCS O
. O
['Life-Impact']

PRINCIPAL O
FINDINGS O
Four O
discharge O
screens O
indicated O
an O
increased O
risk O
of O
an O
adverse B-outcome ['Adverse-effects']
outcome-absence O
of O
documentation O
of O
discharge O
planning O
, O
elevated B-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
, O
abnormal B-outcome ['Physiological-Clinical']
pulse I-outcome ['Physiological-Clinical']
, O
and O
unaddressed O
abnormal O
test O
results O
at O
discharge O
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Microbiologic O
studies O
showed O
a O
reduction O
in O
colony-forming B-outcome ['Physiological-Clinical']
units O
in O
87 O
% O
of O
the O
BID O
group O
and O
in O
80 O
% O
of O
the O
QID O
group O
. O
['Physiological-Clinical']

Both O
techniques O
were O
performed O
using O
a O
27G O
pencil O
point O
needle O
, O
an O
18G O
Tuohy O
needle O
, O
and O
a O
20G O
multiport O
epidural O
catheter O
from O
the O
same O
manufacturer O
. O
[]

Additionally O
, O
JASP/ER O
children O
spent O
more O
time O
in O
supported O
engagement O
and O
less O
time O
in O
object O
engagement O
than O
control O
preschoolers O
on O
a O
taped O
play O
interaction O
. O
[]

BACKGROUND: O
The O
aim O
of O
this O
analysis O
was O
to O
ascertain O
the O
type O
of O
relationship O
between O
fish O
and O
seafood O
consumption, O
omega-3 O
polyunsaturated O
fatty O
acids O
(omega-3 O
PUFA) O
intake, O
and O
depression B-outcome ['Physiological-Clinical', 'Life-Impact']
prevalence. O
[['Physiological-Clinical', 'Life-Impact']]

This O
finding O
may O
indicate O
that O
the O
level O
of O
infection B-outcome ['Physiological-Clinical']
or O
the O
frequency O
of O
infection B-outcome ['Physiological-Clinical']
may O
have O
to O
be O
altered O
in O
future O
trials O
to O
induce O
a O
therapeutically O
conducive O
immunologic O
phenotype O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
, O
with O
exclusion O
of O
patients O
subsequently O
found O
to O
be O
negative O
for O
C O
parvum O
or O
co-infected O
at O
baseline O
. O
[]

INTERVENTION O
The O
STG O
was O
instructed O
to O
perform O
strength O
training O
and O
both O
the O
STG O
and O
CG O
were O
instructed O
in O
the O
same O
stretching O
and O
stabilization O
exercises O
for O
12 O
months O
. O
[]

A O
cohort O
of O
39 O
patients O
with O
APC O
, O
without O
thrombosis O
, O
receiving O
chemotherapy O
, O
were O
entered O
in O
a O
randomized O
controlled O
trial O
( O
ISRCTN O
= O
76464767 O
) O
of O
thromboprevention O
with O
weight-adjusted O
dalteparin O
( O
WAD O
) O
. O
[]

Drowsiness O
differed O
; O
15 O
% O
and O
14 O
% O
were O
drowsy O
in O
Mi+Mo O
versus O
2 O
% O
and O
3 O
% O
in O
Mo O
alone O
respectively O
( O
p O
< O
0.001 O
) O
. O
[]

Predefined O
study O
endpoints O
are O
gastric B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
precancerous B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
( O
dysplasia B-outcome ['Physiological-Clinical']
, O
adenoma B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

DESIGN O
Randomized O
, O
multisite O
clinical O
trial O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
was O
more O
pronounced O
in O
patients O
receiving O
two O
or O
three O
drugs O
. O
['Physiological-Clinical']

Primary O
end O
point O
was O
overall O
response O
rate O
( O
ORR O
; O
partial B-outcome ['Physiological-Clinical']
or O
complete B-outcome ['Physiological-Clinical']
response O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Undesirable B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
occurred O
in O
137 O
patients O
(22.3%) O
in O
the O
guided O
and O
95 O
(15.4%) O
in O
the O
usual O
care O
group. O
[['Physiological-Clinical']]

PATIENTS O
AND O
METHODS O
Patients O
with O
advanced O
cancer O
with O
a O
fatigue O
score O
of O
? O
[]

The O
primary O
end O
points O
were O
the O
Investigator O
's O
Static B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Assessment I-outcome ['Physiological-Clinical']
( O
ISGA O
) O
score O
and O
lesion B-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
; O
the O
secondary O
end O
point O
was O
the O
Dermatology B-outcome ['Life-Impact']
Life I-outcome ['Life-Impact']
Quality I-outcome ['Life-Impact']
Index O
( O
DLQI O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Levels O
of O
recombinant B-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
granulocyte I-outcome ['Physiological-Clinical']
colony-stimulating I-outcome ['Physiological-Clinical']
factor I-outcome ['Physiological-Clinical']
in O
serum O
are O
inversely O
correlated O
with O
circulating O
neutrophil O
counts O
. O
['Physiological-Clinical']

No O
significant O
group O
differences O
in O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
readmissions I-outcome ['Resource-use']
, O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
or O
cost B-outcome ['Resource-use']
were O
evident O
at O
90-days O
, O
although O
the O
heart B-outcome ['Resource-use']
failure I-outcome ['Resource-use']
readmission I-outcome ['Resource-use']
rate I-outcome ['Resource-use']
was O
96 O
% O
higher O
in O
the O
intervention O
group O
when O
compared O
to O
that O
in O
the O
control O
group O
. O
['Resource-use', 'Resource-use', 'Resource-use', 'Resource-use']

Our O
results O
also O
revealed O
significant O
gender O
differences O
of O
addictive B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
use O
in O
its O
associated O
individual- O
and O
school-level O
factors O
. O
['Life-Impact']

Single O
doses O
of O
norfloxacin O
and O
trimethoprim/sulfamethoxazole O
were O
administered O
to O
13 O
and O
5 O
patients O
, O
respectively O
, O
( O
temporal O
profile O
group O
) O
and O
samples O
were O
collected O
at O
0 O
, O
0.5 O
, O
1 O
, O
1.5 O
, O
2 O
, O
4 O
, O
and O
24 O
hours O
. O
[]

MATERIALS O
AND O
METHODS O
Twenty-four O
subjects O
, O
each O
requiring O
a O
nonmolar O
extraction O
and O
delayed O
implant O
placement O
, O
were O
randomly O
selected O
to O
receive O
ridge O
preservation O
treatment O
with O
either O
an O
allograft O
in O
an O
experimental O
putty O
carrier O
plus O
a O
calcium O
sulfate O
barrier O
( O
PUT O
) O
or O
a O
bovine-derived O
xenograft O
( O
BDX O
) O
plus O
a O
collagen O
membrane O
. O
[]

Eighteen O
variables O
contributed O
independent O
prognostic O
information O
, O
but O
a O
reduced O
model O
using O
only O
8 O
items O
( O
age O
, O
previous O
heart O
failure O
hospitalization O
, O
peripheral O
edema O
, O
systolic O
blood O
pressure O
, O
serum O
sodium O
, O
urea O
, O
creatinine O
, O
and O
albumin O
) O
performed O
similarly O
. O
[]

The O
safety O
of O
these O
regimens O
was O
similar O
, O
and O
triple O
therapy O
was O
found O
to O
be O
clinically O
acceptable O
. O
[]

HDL B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
change O
differed O
among O
groups O
but O
without O
significant O
post O
hoc O
differences O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
primary O
endpoint O
achievement O
did O
not O
correlate O
with O
PR O
. O
[]

CONCLUSIONS O
A O
targeted O
e-learning O
module O
on O
leukaemia O
had O
a O
significant O
effect O
on O
learning B-outcome ['Life-Impact']
in O
this O
cohort O
, O
compared O
with O
existing O
online O
resources O
. O
['Life-Impact']

METHODS O
A O
total O
of O
27 O
infants O
, O
mean O
age O
4.6 O
months O
, O
who O
manifested O
atopic O
eczema O
during O
exclusive O
breast-feeding O
and O
who O
have O
had O
no O
exposure O
to O
any O
infant O
or O
substitute O
formula O
were O
weaned O
to O
probiotic-supplemented O
, O
Bifidobacterium O
lactis O
Bb-12 O
or O
Lactobacillus O
strain O
GG O
( O
ATCC O
53103 O
) O
, O
extensively O
hydrolysed O
whey O
formulas O
or O
to O
the O
same O
formula O
without O
probiotics O
. O
[]

One O
possible O
reason O
for O
tumor O
recurrence O
may O
be O
intraoperative O
hematogenous O
tumor O
cell O
dissemination O
due O
to O
mechanical O
manipulation O
of O
the O
tumor O
during O
hepatic O
resection O
. O
[]

Stage B-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
sleep I-outcome ['Physiological-Clinical']
and O
the O
frequency O
of O
nocturnal B-outcome ['Physiological-Clinical']
awakenings B-outcome ['Physiological-Clinical']
were O
each O
significantly O
decreased O
at O
the O
6 O
and O
9 O
g/night O
doses O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Sensory B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
was O
determined O
by O
the O
pinprick O
method O
and O
motor B-outcome ['Physiological-Clinical']
blockade I-outcome ['Physiological-Clinical']
by O
the O
Bromage O
method O
at O
2-min O
intervals O
for O
the O
first O
20 O
min O
, O
at O
5-min O
intervals O
for O
the O
next O
10 O
min O
, O
and O
then O
every O
15 O
min O
to O
a O
total O
of O
240 O
min O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
promoter O
methylation O
of O
the O
MGMT O
gene O
in O
the O
plasma O
DNA O
samples O
form O
middle-and-late O
stage O
tumor O
patients O
receiving O
chemotherapy O
was O
detected O
before O
and O
after O
treatment O
using O
nested O
methylation-specific O
polymerase O
chain O
reaction O
( O
MSP O
) O
. O
[]

INTERVENTION O
CGs O
were O
assigned O
to O
the O
REACH O
intervention O
or O
a O
no-treatment O
control O
group O
. O
[]

METHODS O
A O
total O
of O
81 O
cases O
of O
autistic O
children O
were O
selected O
through O
the O
standard O
of O
DSM-4 O
and O
clinical O
case O
study O
was O
used O
. O
[]

Here O
we O
used O
fMRI O
to O
measure O
the O
neural B-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
emotional I-outcome ['Physiological-Clinical']
experiences I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
place I-outcome ['Physiological-Clinical']
memory I-outcome ['Physiological-Clinical']
during O
navigation O
. O
['Physiological-Clinical']

In O
those O
with O
prostate O
cancer O
these O
changes O
were O
23.8 O
% O
and O
-37.2 O
% O
, O
respectively O
. O
[]

Renal O
function O
was O
studied O
in O
18 O
patients O
with O
Type O
1 O
diabetes O
mellitus O
. O
[]

Responders O
( O
n O
= O
26 O
) O
continued O
treatment O
for O
another O
16 O
weeks O
, O
followed O
by O
a O
double-blind O
discontinuation O
( O
n O
= O
24 O
; O
two O
patients O
discontinued O
treatment O
because O
of O
weight O
gain O
) O
consisting O
of O
either O
3 O
weeks O
of O
taper O
and O
5 O
weeks O
of O
placebo O
only O
or O
continuing O
use O
of O
risperidone O
. O
[]

Examination B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
, O
diagnostic B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
and O
patient B-outcome ['Life-Impact']
acceptability I-outcome ['Life-Impact']
( O
rated O
with O
a O
self-completed O
questionnaire O
) O
in O
the O
two O
groups O
of O
patients O
were O
compared O
by O
using O
the O
McNemar O
test O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Publication O
date: O
2019/03/06 O
06:00 O
[medline] O
[]

PURPOSE: O
The O
purpose O
of O
this O
study O
is O
to O
translate O
laboratory-based O
research O
on O
beverage-based O
supplements O
to O
a O
naturalistic, O
field O
setting O
in O
adolescent O
athletes. O
[]

This O
study O
therefore O
investigated O
the O
effect O
of O
two O
betaA O
dosing O
strategies O
on O
30-min O
rowing B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
subsequent X ['Physiological-Clinical', 'Physiological-Clinical']
sprint B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
performance E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
. O
METHODS: O
Following O
University O
Ethics O
approval, O
twenty-seven O
healthy, O
male O
rowers O
(age: O
24 O
+/- O
2 O
years; O
body-height: O
1.81 O
+/- O
0.02 O
m; O
body-mass: O
82.3 O
+/- O
2.5 O
kg; O
body-fat: O
14.2 O
+/- O
1.0%) O
were O
randomised O
in O
a O
double-blind O
manner O
to O
4 O
weeks O
of: O
i) O
betaA O
(2.4 O
g.d(- O
1), O
betaA1); O
ii) O
matched O
total O
betaA O
(4.8 O
g O
on O
alternate O
days, O
betaA2); O
or O
iii) O
cornflour O
placebo O
(2.4 O
g.d(- O
1), O
PL). O
[['Physiological-Clinical', 'Physiological-Clinical']]

OBJECTIVE O
To O
test O
the O
hypothesis O
that O
amantadine O
hydrochloride O
is O
a O
safe O
and O
effective O
treatment O
for O
behavioral B-outcome ['Life-Impact']
disturbances I-outcome ['Life-Impact']
-- O
for O
example O
, O
hyperactivity B-outcome ['Life-Impact']
and O
irritability B-outcome ['Life-Impact']
-- O
in O
children O
with O
autism O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

The O
patients O
' O
evaluation O
was O
significant O
for O
the O
first B-outcome ['Physiological-Clinical']
attack I-outcome ['Physiological-Clinical']
( O
p O
= O
0.002 O
) O
. O
['Physiological-Clinical']

Rehabilitation O
of O
therapy-related O
cognitive O
deficits O
in O
patients O
after O
hematopoietic O
stem O
cell O
transplantation O
. O
[]

The O
present O
study O
was O
designed O
to O
identify O
optimal O
patient O
positioning O
for O
the O
induction O
of O
general O
anesthesia O
that O
minimizes O
the O
risk O
of O
hypoxemia O
in O
these O
patients O
. O
[]

Comprehensive O
interventions O
are O
needed O
to O
address O
socioeconomic O
and O
lifestyle O
issues O
as O
well O
as O
other O
barriers O
to O
care O
and O
treatment O
, O
if O
HBP O
care O
is O
to O
be O
salient O
and O
effective O
in O
this O
high O
risk O
group O
. O
[]

Evoked O
potentials O
to O
auditory O
stimulations O
varying O
in O
intensity O
were O
studied O
in O
13 O
children O
with O
autistic O
behavior O
treated O
with O
fenfluramine O
. O
[]

Investigator-rated O
ADHD B-outcome ['Life-Impact']
Rating O
Scale-IV O
and O
Clinical O
Global O
Impression O
( O
CGI O
) O
scale O
were O
outcome O
measures O
. O
['Physiological-Clinical', 'Life-Impact']

Also O
the O
frequency O
of O
the O
troponin B-outcome ['Physiological-Clinical']
increase O
above O
the O
UNL(upper O
normal O
level) O
in O
the O
nicorandal O
group, O
was O
significantly O
(p O
= O
0.03) O
lower O
(in O
62% O
of O
cases O
compared O
to O
85% O
of O
the O
control O
group). O
[['Physiological-Clinical']]

Effects O
of O
clonidine O
on O
postoperative O
nausea O
and O
vomiting O
in O
breast O
cancer O
surgery O
. O
[]

Title: O
[Effect O
of O
dexmedetomidine O
on O
perioperative O
stress B-outcome ['Physiological-Clinical']
and O
postoperative O
pain B-outcome ['Physiological-Clinical']
in O
patients O
with O
radical O
resection O
of O
esophageal O
cancer O
under O
combined O
thoracoscope O
and O
laparoscope]. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

We O
registered O
a O
significant O
improvement O
of O
tactile O
roughness O
and O
fine O
lines O
in O
the O
half O
side O
of O
the O
face O
treated O
with O
BAs O
; O
noninvasive O
instrumental O
diagnostic O
investigations O
showed O
an O
improvement O
of O
elasticity B-outcome ['Physiological-Clinical']
, O
a O
decrease O
of O
sebum B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
, O
and O
a O
change O
of O
echographic B-outcome ['Physiological-Clinical']
parameters O
suggesting O
a O
reshaping O
of O
dermal B-outcome ['Physiological-Clinical']
tissue I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
incremental B-outcome ['Resource-use']
cost I-outcome ['Resource-use']
per O
life-year O
saved O
( O
LYS O
) O
was O
3205 O
at O
the O
European O
level O
; O
in O
the O
individual O
countries O
the O
cost O
per O
LYS O
ranged O
between O
3091 O
and O
3331 O
. O
['Resource-use']

RESULTS O
The O
self-reported O
use B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
various I-outcome ['Life-Impact']
methods I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
sun I-outcome ['Life-Impact']
protection I-outcome ['Life-Impact']
was O
low O
. O
['Life-Impact']

CONCLUSIONS O
The O
combination O
of O
clonidine O
( O
2 O
microg/kg O
) O
and O
ropivacaine O
0.1 O
% O
is O
associated O
with O
an O
improved O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
postoperative I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
compared O
to O
plain O
0.2 O
% O
ropivacaine O
. O
['Life-Impact']

A O
comparative O
randomized O
trial O
. O
[]

Patients O
were O
randomly O
assigned O
to O
two O
equal O
groups O
: O
in O
Group O
I O
, O
blood O
cardioplegia O
was O
administered O
using O
leukocyte O
reduction O
filters O
, O
and O
in O
Group O
II O
, O
leukocyte O
reduction O
filters O
were O
not O
used O
for O
blood O
cardioplegia O
. O
[]

TTCW B-outcome ['Physiological-Clinical']
was O
not O
significantly O
different O
for O
100-mg O
sitaxsentan O
patients O
than O
placebo O
( O
P O
= O
0.090 O
) O
. O
['Physiological-Clinical']

PURPOSE O
This O
controlled O
clinical O
study O
was O
designed O
to O
simulate O
the O
dentin/composite O
cement O
interface O
immediately O
after O
cementation O
of O
a O
cast O
restoration O
. O
[]

Overall O
, O
1 O
additional O
infant O
survived O
without O
chronic B-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
for O
every O
14 O
to O
15 O
infants O
who O
received O
vitamin O
A O
supplements O
. O
['Physiological-Clinical']

Breast O
cancer O
screening O
in O
Sweden O
. O
[]

Duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
, O
as O
well O
as O
the O
requirement O
of O
additional O
analgesics O
, O
were O
noted O
. O
['Life-Impact']

RESULTS O
The O
median O
follow-up O
was O
32 O
and O
35 O
months O
in O
the O
hypofractionation O
and O
conventional O
fractionation O
arms O
, O
respectively O
. O
[]

Once-daily O
versus O
twice-daily O
lamivudine O
, O
in O
combination O
with O
zidovudine O
and O
efavirenz O
, O
for O
the O
treatment O
of O
antiretroviral-naive O
adults O
with O
HIV O
infection O
: O
a O
randomized O
equivalence O
trial O
. O
[]

Patients O
receiving O
6 O
and O
9 O
g/night O
doses O
were O
titrated O
to O
their O
final O
dose O
in O
weekly O
1.5 O
g O
increments O
, O
while O
patients O
receiving O
placebo O
were O
randomized O
to O
undergo O
a O
similar O
mock O
dose O
titration O
. O
[]

We O
report O
the O
first O
double O
blind O
randomised O
controlled O
trial O
of O
regular O
opioids O
and O
an O
infusion O
of O
low O
dose O
( O
0.6 O
mg/kg O
) O
intravenous O
ketamine O
compared O
with O
opioids O
and O
placebo O
in O
patients O
with O
allodynia O
, O
hyperalgesia O
and O
hyperpathia O
secondary O
to O
critical O
limb O
ischaemia O
. O
[]

The O
decrease O
was O
of O
similar O
magnitude O
whether O
failure O
was O
due O
to O
extravasation O
or O
phlebitis O
. O
[]

Concomitant O
, O
sequential O
, O
and O
hybrid O
therapy O
for O
H. O
pylori B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
: O
a O
pilot O
study O
. O
['Physiological-Clinical']

All O
episodes O
of O
PONV O
during O
the O
first O
24 O
hours O
after O
anesthesia O
administration O
were O
recorded O
by O
an O
investigator O
who O
was O
blinded O
to O
treatment O
assignment O
. O
[]

All O
children O
had O
access O
to O
picture O
symbols O
during O
assessments O
. O
[]

These O
meetings, O
called O
Community O
Health O
Data O
Review O
(CHDR) O
meetings, O
were O
attended O
by O
community O
leaders, O
including O
members O
of O
the O
Ward O
Development O
Committee O
(WDC) O
and O
Health O
Management O
Committee O
(HMC), O
by O
the O
CHW O
Peer O
Supervisors, O
and O
by O
representatives O
of O
the O
Peripheral O
Health O
Unit. O
[]

Specifically O
, O
it O
is O
proposed O
that O
attitude O
certainty O
can O
be O
conceptualized O
, O
and O
empirically O
separated O
, O
in O
terms O
of O
attitude O
clarity O
( O
the O
subjective O
sense O
that O
one O
knows O
what O
one O
's O
attitude O
is O
) O
and O
attitude O
correctness O
( O
the O
subjective O
sense O
that O
one O
's O
attitude O
is O
correct O
or O
valid O
) O
. O
[]

Changes O
on O
the O
DD-CGAS O
correlated O
with O
changes O
on O
the O
[]

Exercise O
consisted O
of O
20 O
minutes O
of O
trotting O
on O
a O
treadmill O
( O
4 O
m/s O
) O
, O
3 O
days O
per O
week O
for O
13 O
weeks O
. O
[]

We O
conducted O
a O
double-blind O
study O
in O
173 O
newly O
diagnosed O
multiple O
myeloma O
patients O
of O
etidronate O
disodium O
( O
EHDP O
) O
, O
a O
diphosphonate O
compound O
that O
reduces O
bone O
resorption O
by O
inhibiting O
osteoclastic O
activity O
. O
[]

We O
set O
out O
to O
clarify O
the O
role O
of O
YAP1 B-outcome ['Physiological-Clinical']
in O
breast O
cancer O
by O
examining O
gene O
and O
protein O
expression O
in O
subgroups O
of O
patient O
material O
and O
by O
downregulating O
YAP1 O
in O
vitro O
and O
studying O
its O
role O
in O
response O
to O
the O
widely O
used O
anti-estrogen O
tamoxifen O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
safety O
and O
efficacy O
of O
longterm O
etanercept O
treatment O
in O
patients O
with O
disease O
modifying O
antirheumatic O
drug O
( O
DMARD O
) O
refractory O
rheumatoid O
arthritis O
( O
RA O
) O
. O
[]

After O
a O
total O
of O
15,000 O
protein O
nitrogen O
units O
( O
PNU O
) O
had O
been O
given O
, O
blocking B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
in O
the O
monomer O
group O
rose O
from O
a O
mean O
of O
170 O
ng O
AgE O
bound O
per O
ml O
to O
a O
mean O
of O
2,813 O
. O
['Physiological-Clinical']

Concerning O
the O
three O
different O
techniques O
, O
TBNA O
showed O
the O
highest B-outcome ['Physiological-Clinical']
diagnostic I-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
( O
62.5 O
% O
) O
in O
comparison O
to O
TBB O
( O
48.9 O
% O
) O
and O
to O
BW O
( O
19.8 O
% O
) O
. O
['Physiological-Clinical']

RESULTS O
Analysis O
of O
interviews O
identified O
a O
complex O
picture O
concerning O
expectations O
These O
could O
be O
classified O
as O
ideal O
, O
realistic O
, O
normative O
and O
unformed O
. O
[]

Implementation O
of O
multi-component O
PA O
interventions O
within O
schools O
is O
advocated O
but O
research O
has O
showed O
that O
they O
may O
not O
always O
be O
effective O
at O
increasing O
child O
PA. O
[]

on O
days O
1 O
to O
4 O
. O
[]

A O
leak O
occurred O
in O
8.3 O
% O
. O
[]

Patient O
characteristics O
including O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
prior O
history O
of O
low O
back O
pain O
, O
and O
number O
of O
visits B-outcome ['Resource-use']
during O
the O
illness O
episode O
were O
strong O
predictors O
of O
service O
utilization O
and O
guideline-consistent O
behavior O
. O
['Physiological-Clinical', 'Resource-use']

Future O
studies O
need O
to O
examine O
the O
long-term O
effects O
of O
these O
early O
interventions O
on O
children O
's O
development O
. O
[]

HDPM O
at O
an O
average O
dose O
of O
638.9 O
mg O
of O
pyridoxine O
and O
216.3 O
mg O
of O
magnesium O
oxide O
was O
ineffective O
in O
ameliorating B-outcome ['Life-Impact']
autistic I-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
as O
assessed O
by O
the O
Children O
's O
Psychiatric O
Rating O
Scale O
( O
CPRS O
) O
, O
the O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
Scale O
, O
and O
the O
NIMH O
Global B-outcome ['Life-Impact']
Obsessive I-outcome ['Life-Impact']
Compulsive I-outcome ['Life-Impact']
Scale O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact']

Gefitinib O
or O
placebo O
in O
combination O
with O
tamoxifen O
in O
patients O
with O
hormone B-outcome ['Physiological-Clinical']
receptor-positive I-outcome ['Physiological-Clinical']
metastatic I-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
: O
a O
randomized O
phase O
II O
study O
. O
['Physiological-Clinical']

RESULTS: O
All O
groups O
significantly O
improved O
handling B-outcome ['Life-Impact']
performance. O
[['Life-Impact']]

The O
Aberrant O
Behavior O
Checklist O
-- O
Community O
Scale O
( O
ABC-C O
) O
Irritability O
subscale O
was O
the O
primary O
outcome O
measure O
( O
p O
= O
0.65 O
) O
, O
and O
CGI O
-- O
Improvement O
( O
p O
= O
0.16 O
) O
and O
OAS O
( O
p O
= O
0.96 O
) O
were O
secondary O
outcome O
measures O
. O
[]

The O
effect O
was O
evaluated O
through O
the O
changes O
of O
clinical O
manifestations O
and O
scores O
of O
ABC O
and O
IQ B-outcome ['Life-Impact']
. O
['Life-Impact']

CONCLUSIONS O
A O
surrogate O
PD O
model O
to O
assess O
retinoid B-outcome ['Physiological-Clinical']
bioequivalence I-outcome ['Physiological-Clinical']
has O
been O
developed O
. O
['Physiological-Clinical']

The O
use O
of O
Cmax B-outcome ['Physiological-Clinical']
or O
Tmax B-outcome ['Physiological-Clinical']
as O
a O
measure O
of O
rate O
of O
absorption O
, O
to O
correlate O
with O
clinical O
relevance O
, O
is O
widely O
criticized O
on O
logical O
, O
technical O
, O
and O
statistical O
grounds O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
People O
with O
BBTW O
showed O
a O
significant O
improvement O
in O
the O
25-foot B-outcome ['Physiological-Clinical']
walk I-outcome ['Physiological-Clinical']
( O
P O
= O
.01 O
) O
over O
those O
with O
no O
weight O
, O
and O
the O
TUG B-outcome ['Physiological-Clinical']
( O
P O
= O
.01 O
) O
over O
those O
with O
standard O
weight O
placement O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Previous O
research O
has O
demonstrated O
the O
efficacy O
of O
an O
interactive O
expert O
system O
intervention O
for O
smoking O
cessation O
for O
a O
general O
population O
. O
[]

A O
prospective O
double-blind O
placebo-controlled O
trial O
of O
intramuscular O
Naftidrofuryl O
was O
carried O
out O
on O
32 O
randomly O
selected O
hospitalized O
male O
alcoholic O
patients O
with O
clinical O
, O
biochemical O
and O
histological O
evidence O
of O
hepatic O
damage O
. O
[]

Variables O
of O
interest O
were O
resting B-outcome ['Physiological-Clinical']
motor I-outcome ['Physiological-Clinical']
threshold I-outcome ['Physiological-Clinical']
( O
RMT B-outcome ['Physiological-Clinical']
) O
, O
short-interval B-outcome ['Physiological-Clinical']
intra-cortical I-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SICI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
intracortical B-outcome ['Physiological-Clinical']
facilitation I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ICF I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
cortical B-outcome ['Physiological-Clinical']
silent I-outcome ['Physiological-Clinical']
period O
( O
CSP O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Since O
1988 O
, O
when O
the O
term O
chronic O
fatigue O
syndrome O
( O
CFS O
) O
was O
coined O
, O
considerable O
discussion O
has O
occurred O
about O
stigma O
associated O
with O
this O
diagnostic O
term O
. O
[]

Implant B-outcome ['Physiological-Clinical']
stability I-outcome ['Physiological-Clinical']
at O
the O
moment O
of O
implant O
placement O
is O
slightly O
inferior O
in O
the O
immediate O
replacement O
group O
, O
but O
it O
does O
not O
affect O
the O
treatment O
result O
. O
['Physiological-Clinical']

Exploratory O
analyses O
demonstrated O
no O
DFS B-outcome ['Mortality']
( O
HR O
, O
1.28 O
; O
95 O
% O
CI O
, O
0.92 O
to O
1.76 O
; O
P O
= O
.14 O
) O
or O
OS B-outcome ['Mortality']
benefit O
( O
HR O
, O
1.24 O
; O
95 O
% O
CI O
, O
0.90 O
to O
1.71 O
; O
P O
= O
.18 O
) O
from O
gefitinib O
for O
344 O
patients O
with O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
wild-type O
tumors O
. O
['Mortality', 'Mortality']

We O
investigated O
whether O
( O
a O
) O
cigarette O
smoking O
is O
linked O
to O
increased O
cytokine O
production O
, O
which O
may O
mediate O
platelet O
activation O
and O
thrombin O
generation O
in O
chronic O
coronary O
artery O
disease O
( O
CAD O
) O
, O
and O
( O
b O
) O
aspirin O
treatment O
inhibits O
smoking-related O
changes O
on O
cytokines O
, O
platelets O
, O
and O
thrombin O
. O
[]

4 O
. O
[]

Title: O
Comparison O
the O
cost-efficacy O
of O
furazolidone-based O
versus O
clarithromycin-based O
quadruple O
therapy O
in O
initial O
treatment O
of O
Helicobacter O
pylori O
infection O
in O
a O
variable O
clarithromycin O
drug-resistant O
region, O
a O
single-center, O
prospective, O
randomized, O
open-label O
study. O
[]

Principal O
findings O
from O
a O
multicenter O
trial O
investigating O
the O
safety O
of O
follicular-fluid O
meiosis-activating O
sterol O
for O
in O
vitro O
maturation O
of O
human O
cumulus-enclosed O
oocytes O
. O
[]

CONCLUSIONS O
The O
effectiveness O
of O
inguinal O
herniorrhaphy O
should O
be O
measured O
by O
the O
rate O
of O
recurrence B-outcome ['Physiological-Clinical']
and O
neuralgia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
this O
application O
also O
provides O
evidence O
to O
support O
a O
change O
in O
the O
label O
to O
allow O
for O
an O
escalation O
of O
imatinib O
dosing O
to O
800 O
mg/day O
for O
patients O
with O
progressive O
disease O
on O
a O
lower O
dose O
. O
[]

3 O
. O
[]

The O
24-gauge O
Gertie O
Marx O
needle O
resulted O
in O
more O
successful B-outcome ['Physiological-Clinical']
location O
of O
the O
['Physiological-Clinical']

Effect O
of O
pravastatin O
on O
kidney B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
in O
autosomal O
dominant O
polycystic O
kidney O
disease O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Systemic O
antibiotics O
significantly O
accelerate O
the O
suppression O
of O
the O
periodontal B-outcome ['Physiological-Clinical']
microflora I-outcome ['Physiological-Clinical']
, O
but O
have O
limited O
effect O
on O
the O
elimination O
of O
target O
isolates O
during O
healing O
. O
['Physiological-Clinical']

Journal-Name:Nutrients O
[]

Haloperidol O
blood O
levels O
and O
effects O
in O
schizophrenia B-outcome ['Life-Impact']
and O
schizoaffective B-outcome ['Life-Impact']
disorder O
: O
a O
progress O
report O
. O
['Life-Impact', 'Life-Impact']

70.5 O
kg O
; O
p O
= O
0.01 O
) O
. O
[]

Journal O
ID: O
8109958 O
[]

METHODS O
Patients O
( O
n=766 O
) O
, O
aged O
18 O
to O
65 O
years O
inclusive O
, O
with O
current O
manic O
or O
mixed O
episodes O
were O
initially O
randomized O
( O
4:1 O
) O
to O
flexibly-dosed O
paliperidone O
ER O
( O
3-12 O
mg/day O
) O
or O
olanzapine O
( O
5-20 O
mg/day O
; O
3-week O
acute O
treatment O
phase O
) O
; O
responders O
continued O
the O
same O
treatment O
( O
12-week O
continuation O
phase O
) O
. O
[]

In O
as-treated O
analyses, O
participants O
in O
the O
decolonization O
group O
who O
adhered O
fully O
to O
the O
regimen O
had O
44% O
fewer O
MRSA B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
than O
the O
education O
group O
(hazard O
ratio, O
0.56; O
95% O
CI, O
0.36 O
to O
0.86) O
and O
had O
40% O
fewer O
infections B-outcome ['Physiological-Clinical']
from O
any O
cause O
(hazard O
ratio, O
0.60; O
95% O
CI, O
0.46 O
to O
0.78). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

During O
induction O
and O
maintenance O
of O
anaesthesia O
body O
temperature O
fell O
( O
NA O
group O
from O
36.7 O
to O
35.3 O
degrees O
C O
; O
epidural O
group O
from O
36.7 O
to O
34.9 O
degrees O
C O
) O
but O
no O
statistically O
significant O
difference O
could O
be O
found O
between O
the O
groups O
, O
in O
spite O
of O
better O
surface B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
of O
the O
lower O
part O
of O
the O
body O
in O
the O
epidural O
group O
. O
['Physiological-Clinical']

In O
the O
RA O
group O
the O
simple O
formula O
published O
by O
Cockcroft O
[ O
Clcr O
= O
( O
( O
140 O
- O
age O
) O
x O
body O
weight O
) O
/ O
( O
72 O
x O
Scr O
) O
, O
x O
0.85 O
for O
females O
] O
showed O
the O
best O
correlation O
with O
the O
measured O
Clcr B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Independent O
risk O
factors O
for O
intermediate-term O
mortality O
include O
lower O
socioeconomic O
status O
, O
anatomy O
, O
genetic O
syndrome O
, O
and O
lower O
gestational O
age O
. O
[]

As O
such O
, O
UTC O
might O
be O
useful O
to O
monitor O
treatment O
protocols O
. O
[]

CONCLUSIONS: O
Among O
patients O
who O
were O
scheduled O
for O
CABG O
and O
had O
been O
randomly O
assigned O
to O
undergo O
bilateral O
or O
single O
internal-thoracic-artery O
grafting, O
there O
was O
no O
significant O
between-group O
difference O
in O
the O
rate O
of O
death B-outcome ['Mortality']
from I-outcome ['Mortality']
any I-outcome ['Mortality']
cause I-outcome ['Mortality']
at O
10 O
years O
in O
the O
intention-to-treat O
analysis. O
[['Mortality']]

Comparison O
of O
warfarin O
and O
aspirin O
for O
symptomatic O
intracranial O
arterial O
stenosis O
. O
[]

An O
empirical O
comparison O
of O
the O
St O
George O
's O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
and O
the O
Chronic O
Respiratory O
Disease O
Questionnaire O
( O
CRQ O
) O
in O
a O
clinical O
trial O
setting O
. O
[]

TRIAL O
REGISTRATION O
ISRCTN O
ISRCTN58280620 O
. O
[]

RESULTS O
Mean O
plasma B-outcome ['Physiological-Clinical']
vWf I-outcome ['Physiological-Clinical']
was O
higher O
among O
patients O
with O
AF O
and O
CHF O
( O
154 O
( O
29 O
) O
v O
144 O
( O
31 O
) O
IU/dl O
, O
p O
< O
0.001 O
) O
, O
particularly O
those O
with O
acute O
or O
recent O
decompensated O
symptoms O
. O
['Physiological-Clinical']

Fourteen O
patients O
with O
Helicobacter O
pylori O
infection O
were O
treated O
with O
omeprazole O
capsules O
20 O
mg O
and O
amoxycillin O
capsules O
1000 O
mg O
twice O
daily O
for O
14 O
days O
and O
14 O
patients O
with O
omeprazole O
capsules O
20 O
mg O
and O
placebo O
twice O
daily O
for O
14 O
days O
. O
[]

MATERIAL O
AND O
METHODS O
A O
gastric O
electrical O
stimulator O
was O
implanted O
in O
seven O
diabetic O
patients O
with O
medically O
refractory O
gastroparesis O
. O
[]

Treatment O
was O
started O
within O
14 O
days O
of O
surgery O
in O
94 O
% O
of O
patients O
. O
[]

3 O
The O
overall O
incidence O
of O
side-effects B-outcome ['Adverse-effects']
was O
similar O
with O
atenolol O
, O
metoprolol O
and O
pindolol O
but O
was O
slightly O
less O
with O
labetalol O
. O
['Adverse-effects']

DESIGN O
Randomized O
, O
controlled O
clinical O
trial O
. O
[]

One O
or O
2 O
units O
of O
blood O
were O
transfused O
to O
patients O
in O
both O
groups O
according O
to O
postoperative O
Hb O
level O
( O
between O
60 O
and O
70 O
g/L O
or O
betweeen O
50 O
and O
60 O
g/L O
, O
respectively O
) O
. O
[]

METHODS: O
We O
evaluated O
40 O
patients O
aged O
>/=18 O
years O
who O
underwent O
elective O
muscle O
sparing O
thoracotomies. O
[]

Bisphosphonates O
are O
used O
in O
oncology O
as O
a O
means O
of O
decreasing O
complications O
due O
to O
bone O
metastases O
, O
in O
association O
with O
anticancer O
treatment O
, O
especially O
in O
patients O
with O
breast O
cancer O
, O
prostate O
cancer O
and O
myeloma O
. O
[]

CONCLUSION O
The O
GH O
response O
to O
bolus O
GHRH O
( O
1-29 O
) O
NH O
( O
2 O
) O
is O
attenuated O
in O
adult O
long-term O
survivors O
of O
childhood O
brain O
tumours O
. O
[]

The O
in O
vitro O
assay O
showed O
similar O
solubility B-outcome ['Physiological-Clinical']
after O
the O
in O
vitro O
digestion O
and O
similar O
transport O
across O
Caco-2 O
cells O
. O
['Physiological-Clinical']

However O
, O
FMD O
and O
digital O
vasodilator O
response O
did O
not O
significantly O
change O
from O
baseline O
with O
long-term O
sulfasalazine O
treatment O
. O
[]

anova O
and O
Dunnett O
's O
test O
showed O
that O
groups O
A-D O
did O
not O
differ O
statistically O
from O
the O
control O
group O
E O
but O
differed O
from O
the O
control O
group O
F. O
The O
lowest O
mean O
value O
was O
found O
for O
group O
F. O
Regression O
analysis O
was O
unable O
to O
show O
salivary O
effect O
on O
dentine B-outcome ['Physiological-Clinical']
wear I-outcome ['Physiological-Clinical']
reduction O
. O
['Physiological-Clinical']

Of O
54 O
evaluable O
women O
treated O
with O
tamoxifen O
, O
24 O
% O
had O
an O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
21 O
% O
of O
53 O
women O
having O
an O
oophorectomy O
. O
['Physiological-Clinical']

In O
four O
cases O
( O
12.9 O
% O
) O
the O
sentinel O
lymph O
node O
was O
the O
only O
site O
of O
metastasis O
, O
all O
of O
them O
being O
detected O
by O
association O
of O
hematoxylin B-outcome ['Physiological-Clinical']
and O
eosin B-outcome ['Physiological-Clinical']
and O
immunohistochemical B-outcome ['Physiological-Clinical']
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Volunteers O
with O
H. O
pylori O
infection O
( O
by O
13C-urea O
breath O
test O
) O
were O
randomly O
assigned O
to O
2-week O
treatment O
regimens O
. O
[]

Analysis O
of O
multiple-dose O
bioequivalence O
studies O
. O
[]

The O
diagnosis O
of O
left O
ventricular O
thrombosis O
was O
based O
on O
the O
detection O
of O
an O
echo O
dense O
mass O
with O
defined O
margins O
visible O
throughout O
the O
cardiac O
cycle O
in O
at O
least O
two O
orthogonal O
views O
. O
[]

CONCLUSIONS O
The O
off-pump O
group O
appears O
to O
be O
generally O
comparable O
to O
the O
on-pump O
group O
in O
terms O
of O
short-term O
and O
long-term O
postsurgical O
neurocognitive O
outcomes O
. O
[]

METHODS O
Sixty-five O
day-only O
patients O
with O
renal O
impairment O
( O
mean O
serum O
creatinine O
concentration O
0.16+/-0.03 O
mmol/l O
) O
due O
to O
undergo O
coronary O
or O
peripheral O
angiography O
and/or O
stenting O
were O
randomly O
assigned O
to O
IV O
NAC O
300 O
or O
600 O
mg O
immediately O
before O
and O
after O
the O
procedure O
or O
IV O
fluid O
alone O
. O
[]

Improved O
selectivity O
in O
early O
cortical O
responses O
lead O
to O
better B-outcome ['Physiological-Clinical']
stimulus I-outcome ['Physiological-Clinical']
differentiation I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
later-stage I-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
as O
was O
made O
evident O
by O
our O
P3b O
and O
P3a O
component O
findings O
. O
['Physiological-Clinical']

Journal O
ID: O
101234168 O
[]

Subjects O
made O
a O
fast O
elbow O
extension O
movement O
to O
designated O
target O
in O
response O
to O
a O
go O
signal O
. O
[]

Journal-Name:The O
American O
surgeon O
[]

Left O
ventricular O
mass O
regression O
in O
elderly O
hypertensives O
. O
[]

Achaogen, O
South O
San O
Francisco, O
CA. O
[]

In O
the O
active O
rTMS O
group O
, O
ten O
sessions O
with O
a O
total O
of O
10,000 O
stimuli O
were O
applied O
over O
the O
left O
dorsolateral O
prefrontal O
cortex O
at O
110 O
% O
of O
motor O
threshold O
. O
[]

High-scoring O
individuals O
also O
demonstrated O
difficulty O
in O
[]

The O
purpose O
of O
this O
study O
was O
to O
test O
in O
vivo O
biofilm O
formation O
on O
polymethyl O
methacrylate O
( O
PMMA O
) O
self-cured O
acrylic O
resin O
provisional O
crowns O
. O
[]

Both O
groups O
had O
definitive O
screw-retained O
metal-ceramic O
crowns O
placed O
in O
occlusion O
8 O
weeks O
later O
. O
[]

RESULTS O
Only O
the O
glucose B-outcome ['Physiological-Clinical']
levels O
of O
patients O
who O
received O
no O
carbohydrate-containing O
infusion O
fluids O
were O
used O
for O
evaluation O
of O
the O
stress O
response O
. O
['Physiological-Clinical']

Constant O
scores O
were O
significantly O
higher O
after O
6 O
months O
and O
2 O
years O
after O
intramedullary O
stabilization O
. O
[]

Publication O
date: O
2018/10/28 O
00:00 O
[accepted] O
[]

One O
hundred O
and O
fourteen O
obese O
women O
aged O
from O
18 O
to O
40 O
years O
were O
divided O
into O
insulin O
sensitive O
(IS) O
and O
insulin O
resistant O
(IR) O
groups O
and O
received O
a O
low O
calorie O
diet O
(LC), O
or O
an O
isocaloric O
diet O
and O
500 O
mg O
metformin O
twice O
daily O
(IM), O
or O
isocaloric O
diet O
with O
120 O
mg O
orlistat O
three O
times O
daily O
(IO). O
[]

None O
of O
the O
between-group O
differences O
in O
response O
rates O
were O
significant O
. O
[]

Follow-up O
endoscopy O
is O
scheduled O
3 O
months O
after O
therapy O
, O
and O
thereafter O
in O
one-year O
intervals O
. O
[]

Change O
in O
behavioral O
ratings O
from O
pretest O
to O
post-test O
showed O
significant O
differences O
in O
motivational O
interviewing O
skills O
between O
the O
experimental O
and O
control O
groups O
. O
[]

Publication O
date: O
2019/02/23 O
06:00 O
[medline] O
[]

The O
FEV1/FVC O
( O
% O
) O
and O
the O
FEV1 O
% O
were O
calculated O
. O
[]

OBJECTIVES: O
To O
investigate O
the O
effectiveness O
of O
routine O
ultrasonography O
in O
the O
third O
trimester O
in O
reducing O
adverse B-outcome ['Physiological-Clinical', 'Mortality']
perinatal I-outcome ['Physiological-Clinical', 'Mortality']
outcomes O
in O
low O
risk O
pregnancies O
compared O
with O
usual O
care O
and O
the O
effect O
of O
this O
policy O
on O
maternal B-outcome ['Physiological-Clinical']
outcomes O
and O
obstetric B-outcome ['Resource-use']
interventions I-outcome ['Resource-use']
. O
DESIGN: O
Pragmatic, O
multicentre, O
stepped O
wedge O
cluster O
randomised O
trial. O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Resource-use']]

METHODS O
Forty-three O
patients O
suffering O
from O
premature O
ejaculation O
were O
studied O
. O
[]

Long-term O
follow-up O
of O
the O
Stockholm O
randomized O
trials O
of O
postoperative O
radiation O
therapy O
versus O
adjuvant O
chemotherapy O
among O
'high O
risk O
' O
pre- O
and O
postmenopausal O
breast O
cancer O
patients O
. O
[]

The O
same O
was O
also O
true O
for O
hormonal O
parameters O
as O
STH B-outcome ['Physiological-Clinical']
, O
ACTH B-outcome ['Physiological-Clinical']
, O
cortisol B-outcome ['Physiological-Clinical']
, O
and O
catecholamines B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

These O
changes O
regressed O
in O
all O
but O
four O
patients O
after O
12 O
months O
. O
[]

The O
past O
20 O
years O
have O
seen O
an O
overall O
decline O
in O
survey O
response O
rates O
and O
an O
even O
more O
pronounced O
decline O
in O
samples O
of O
health O
care O
professionals O
. O
[]

There O
was O
no O
significant O
(p O
= O
0.774) O
difference, O
however, O
between O
the O
low O
dose O
and O
placebo O
groups. O
[]

18F-FDG O
PET/CT O
for O
early O
prediction O
of O
response O
to O
neoadjuvant O
lapatinib O
, O
trastuzumab O
, O
and O
their O
combination O
in O
HER2-positive O
breast O
cancer O
: O
results O
from O
Neo-ALTTO O
. O
[]

51.9 O
% O
( O
RR O
= O
0.42 O
; O
0.23-0.73 O
) O
, O
( O
P O
< O
0.001 O
) O
and O
day O
14 O
: O
93.6 O
% O
vs O
. O
[]

We O
recently O
assessed O
efficacy O
of O
high-dose O
DHA O
supplementation O
to O
slow O
vision B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
in O
patients O
with O
X-linked O
retinitis O
pigmentosa O
( O
XLRP O
) O
in O
a O
randomized O
clinical O
trial O
. O
['Physiological-Clinical']

Two O
hour O
control O
urine O
collections O
were O
followed O
by O
2 O
h O
postdose O
urine O
collections O
and O
subsequently O
2.5 O
% O
saline O
was O
given O
i.v O
. O
[]

The O
clinically O
important O
difference O
was O
defined O
as O
10 O
% O
of O
the O
maximum O
score O
. O
[]

In O
this O
study O
, O
vincristine O
was O
administered O
by O
bolus O
injection O
followed O
by O
a O
3-day O
continuous O
intravenous O
( O
IV O
) O
infusion O
( O
total O
dose O
of O
2.0 O
mg/m2 O
every O
other O
week O
) O
; O
the O
maximum O
dose O
of O
vincristine O
was O
not O
arbitrarily O
limited O
. O
[]

Prospective O
randomized O
evaluation O
of O
diode-laser O
and O
cryotherapy O
in O
prethreshold B-outcome ['Physiological-Clinical']
retinopathy I-outcome ['Physiological-Clinical']
of O
prematurity O
. O
['Physiological-Clinical']

Pigs O
were O
inoculated O
intranasally O
with O
the O
virulent O
NIA-3 O
strain O
or O
the O
avirulent O
Bartha O
strain O
, O
or O
they O
were O
inoculated O
IM O
with O
an O
inactivated O
vaccine O
containing O
the O
Phylaxia O
strain O
. O
[]

Massively O
elevated O
levels O
of O
beta-endorphin B-outcome ['Physiological-Clinical']
were O
observed O
in O
all O
children O
with O
assays O
using O
C-terminal O
antibody O
but O
not O
with O
an O
N-terminal O
antibody O
assay O
. O
['Physiological-Clinical']

In O
a O
previous O
prospective O
randomized O
clinical O
study O
comparing O
in O
the O
same O
patient O
textured O
and O
smooth O
saline-filled O
mammary O
implants O
( O
Biocell O
) O
with O
large O
pore O
size O
( O
300 O
to O
600 O
microm O
) O
, O
we O
saw O
no O
difference O
in O
capsular O
contracture O
. O
[]

Indomethacin O
significantly O
attenuated O
the O
antihypertensive B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
cilazapril O
. O
['Physiological-Clinical']

BACKGROUND O
A O
psychological O
disorder O
called O
'Internet O
addiction O
' O
has O
newly O
emerged O
along O
with O
a O
dramatic O
increase O
of O
worldwide O
Internet O
use O
. O
[]

Primary O
outcome O
measures O
were O
median O
atropine B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
needed O
within O
24 O
h O
, O
proportion O
of O
patients O
who O
needed O
intubation B-outcome ['Resource-use']
, O
and O
number O
of O
days B-outcome ['Resource-use']
on I-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use', 'Resource-use']

The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
a O
shortened O
postpartum O
course O
of O
magnesium O
sulphate O
is O
as O
effective O
as O
the O
standard O
Pritchard O
regimen O
in O
controlling O
fits O
in O
eclampsia O
Between O
January O
and O
June O
2011 O
, O
98 O
eclamptic O
mothers O
presenting O
at O
the O
labour O
ward O
of O
the O
University O
of O
Maiduguri O
Teaching O
Hospital O
were O
randomised O
to O
receive O
either O
the O
standard O
Pritchard O
regimen O
of O
magnesium O
sulphate O
or O
a O
shortened O
postpartum O
course O
in O
which O
only O
two O
doses O
of O
intramuscular O
magnesium O
sulphate O
is O
given O
four O
hours O
apart O
. O
[]

Ketorolac O
is O
a O
non-steroidal O
anti-inflammatory O
drug O
approved O
in O
the O
United O
States O
for O
the O
relief O
of O
ocular O
itching O
associated O
with O
seasonal O
allergic O
conjunctivitis O
. O
[]

Journal-Name:Progress O
in O
community O
health O
partnerships O
: O
research, O
education, O
and O
action O
[]

Venlafaxine O
induced O
more O
side O
effects O
. O
[]

Significantly O
lower O
PIPP O
scores O
at O
second O
ROP O
examinations O
suggested O
that O
infants O
of O
older O
GA O
may O
have O
a O
greater O
ability O
to O
tolerate O
ROP O
screening O
. O
[]

The O
scores O
from O
5-items O
questionnaires O
and O
6-items O
clinical O
score O
were O
significantly O
associated O
with O
the O
physician-diagnosed O
groups O
( O
i.e. O
, O
controlled O
, O
partly O
controlled O
and O
uncontrolled O
groups O
) O
. O
[]

Participants O
assigned O
to O
3CM O
were O
more O
likely O
to O
have O
a O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
visit I-outcome ['Life-Impact']
, O
fill O
an O
antidepressant O
prescription O
, O
and O
have O
adequate B-outcome ['Life-Impact']
antidepressant I-outcome ['Life-Impact']
refills I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

This O
study O
investigated O
whether O
sheltered O
workshops O
help O
prepare O
individuals O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
for O
competitive B-outcome ['Life-Impact']
employment I-outcome ['Life-Impact']
within O
the O
community O
. O
['Life-Impact']

Hemoglobin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
during O
the O
study O
decreased O
by O
1.4 O
+/- O
2.2 O
g/dL O
in O
the O
control O
group O
and O
1.0 O
+/- O
2.3 O
g/dL O
in O
the O
blood O
conservation O
group O
( O
p O
= O
nonsignificant O
) O
. O
['Physiological-Clinical']

Patients O
in O
CC O
( O
n O
= O
57 O
) O
received O
educational O
videotapes O
and O
pamphlets O
; O
pharmacotherapy O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
paroxetine O
; O
2 O
psychiatrist O
visits O
and O
2 O
telephone O
calls O
in O
the O
first O
8 O
weeks O
; O
and O
up O
to O
5 O
telephone O
calls O
between O
3 O
and O
12 O
months O
' O
follow-up O
. O
[]

In O
vitro-in O
vivo O
correlations O
were O
obtained O
by O
comparing O
the O
logarithm O
of O
the O
in O
vitro O
burst O
time O
with O
time O
to O
peak O
plasma B-outcome ['Physiological-Clinical']
level I-outcome ['Physiological-Clinical']
and O
the O
time O
to O
the O
first O
measurable O
['Physiological-Clinical']

There O
was O
a O
suggestion O
that O
it O
had O
a O
beneficial O
effect O
on O
decreasing O
self-injurious B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
. O
['Life-Impact']

Modifications O
of O
both O
amplitude O
and O
single-trial O
potential O
variability O
were O
considered O
according O
to O
the O
clinical O
and O
biochemical O
responsiveness O
to O
this O
drug O
. O
[]

In O
prenatal O
women O
, O
neither O
approach O
was O
effective O
. O
[]

Holter O
monitoring O
could O
not O
be O
used O
as O
an O
early O
predictor O
of O
late O
coronary O
restenosis O
. O
[]

Unopposed O
estrogen O
increases O
total O
plasma O
factor O
VII O
, O
but O
not O
active O
factor O
VII O
-- O
a O
short-term O
placebo-controlled O
study O
in O
healthy O
postmenopausal O
women O
. O
[]

OBJECTIVE O
The O
mechanisms O
underlying O
symptom O
improvement O
in O
gastric O
electrical O
stimulation O
( O
GES O
) O
are O
not O
fully O
understood O
. O
[]

RESULTS O
The O
mean O
number O
of O
sentinel B-outcome ['Physiological-Clinical']
nodes I-outcome ['Physiological-Clinical']
per O
patient O
was O
1.96 O
ranging O
from O
1 O
to O
3 O
nodes O
. O
['Physiological-Clinical']

Patients O
in O
the O
early O
group O
were O
faster O
to O
ambulate B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
only I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
cane I-outcome ['Life-Impact']
( O
P=.03 O
) O
, O
without O
a O
cane B-outcome ['Life-Impact']
( O
P O
< O
.001 O
) O
, O
and O
without O
a O
limp B-outcome ['Life-Impact']
( O
P=.003 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

In O
ASSURE O
, O
310 O
patients O
with O
angiographic O
coronary O
artery O
disease O
and O
low O
HDL-C O
levels O
will O
be O
randomized O
to O
receive O
RVX-208 O
100 O
mg O
bid O
or O
placebo O
for O
26 O
weeks O
. O
[]

102 O
subjects O
received O
the O
first O
booster O
vaccination O
, O
and O
83 O
were O
vaccinated O
twice O
. O
[]

OBJECTIVE O
Compare O
the O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
adults O
after O
0.9 O
vs. O
1.2 O
mg O
of O
atropine O
plus O
neostigmine O
2.5 O
mg O
as O
the O
non-depolarizing O
muscle O
relaxant O
reversal O
agent O
. O
['Physiological-Clinical']

Nurses O
and O
physician O
assistants O
( O
PAs O
) O
were O
presented O
a O
case O
study O
of O
a O
patient O
with O
symptoms O
of O
CFS O
. O
[]

Compared O
with O
povidone-iodine O
, O
the O
chlorhexidine-based O
solution O
was O
associated O
with O
a O
50 O
% O
decrease O
in O
the O
incidence O
of O
catheter B-outcome ['Physiological-Clinical']
colonization I-outcome ['Physiological-Clinical']
( O
11.6 O
% O
vs O
22.2 O
% O
[ O
P O
= O
.002 O
] O
; O
incidence O
density O
, O
9.7 O
vs O
18.3 O
per O
1000 O
catheter-days O
) O
and O
with O
a O
trend O
toward O
lower O
rates O
of O
catheter-related B-outcome ['Physiological-Clinical']
bloodstream I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
( O
1.7 O
% O
vs O
4.2 O
% O
[ O
P O
= O
.09 O
] O
; O
incidence O
density O
, O
1.4 O
vs O
3.4 O
per O
1000 O
catheter-days O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

All O
procedures O
will O
be O
limited O
to O
one O
session O
and O
the O
symptoms O
before O
and O
after O
treatment O
will O
be O
measured O
by O
assessors O
blinded O
to O
treatment O
allocation O
. O
[]

A O
total O
of O
335 O
patients O
were O
randomized O
into O
treatment O
with O
the O
oral O
administration O
of O
XS0601 O
, O
or O
a O
placebo O
for O
6 O
months O
after O
successful O
PCI O
. O
[]

Five O
of O
six O
in O
the O
olanzapine O
group O
and O
three O
of O
six O
in O
the O
haloperidol O
group O
were O
rated O
as O
responders O
according O
to O
the O
CGI O
Improvement O
item O
. O
[]

IHC B-outcome ['Physiological-Clinical']
( O
n O
= O
84 O
) O
, O
ELISAs O
of O
blood/BM O
sera O
( O
n O
= O
41 O
) O
, O
and O
microarray O
data O
for O
mRNA O
levels O
( O
n O
= O
261 O
) O
were O
performed O
. O
['Physiological-Clinical']

RESULTS O
The O
trial O
was O
planned O
for O
150 O
patients O
, O
but O
was O
halted O
after O
75 O
patients O
when O
planned O
interim O
analysis O
showed O
that O
SILS O
patients O
had O
more O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
pain O
score O
: O
4.4 O
? O
['Physiological-Clinical']

Samples O
of O
blood O
and O
urine O
were O
collected O
at O
baseline O
, O
week O
4 O
, O
and O
week O
8 O
and O
then O
every O
8 O
weeks O
from O
310 O
patients O
entering O
a O
controlled O
trial O
of O
prophylaxis O
with O
valaciclovir O
versus O
acyclovir O
. O
[]

The O
estimated O
7-year O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
EFS I-outcome ['Mortality']
) I-outcome ['Mortality']
for O
subjects O
randomized O
to O
TG O
was O
84.1 O
% O
( O
+/- O
1.8 O
% O
) O
and O
to O
MP O
was O
79.0 O
% O
( O
+/- O
2.1 O
% O
; O
P O
= O
.004 O
log O
rank O
) O
, O
although O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
was O
91.9 O
% O
( O
+/- O
1.4 O
% O
) O
and O
91.2 O
% O
( O
+/- O
1.5 O
% O
) O
, O
respectively O
( O
P O
= O
.6 O
log O
rank O
) O
. O
['Mortality', 'Mortality']

This O
study O
was O
conducted O
to O
test O
the O
hypothesis O
that O
weaning O
or O
glutamine O
may O
modulate O
expression O
of O
genes O
that O
are O
crucial O
for O
intestinal O
metabolism O
and O
function O
. O
[]

After O
medication O
washout O
, O
patients O
were O
treated O
with O
placebo O
followed O
by O
hydrochlorothiazide O
. O
[]

Twenty O
healthy O
subjects O
received O
lorazepam O
0.5 O
mg O
, O
1 O
mg O
and O
2 O
mg O
, O
sertraline O
50 O
mg O
and O
placebo O
in O
a O
balanced O
, O
repeated O
measures O
study O
design O
. O
[]

RESULTS O
After O
treatment O
, O
the O
behavioral O
plus O
nutrition O
education O
intervention O
as O
compared O
with O
the O
nutrition O
education O
intervention O
alone O
had O
a O
statistically O
greater O
average O
increase O
on O
the O
primary O
and O
secondary O
outcomes O
of O
caloric B-outcome ['Physiological-Clinical']
intake O
( O
mean O
, O
872 O
vs O
489 O
cal/d O
, O
respectively O
) O
, O
percentage O
of O
the O
estimated O
energy O
requirement O
( O
mean O
, O
148 O
% O
vs O
127 O
% O
, O
respectively O
) O
, O
weight O
gain O
( O
mean O
, O
1.47 O
vs O
0.92 O
kg O
, O
respectively O
) O
, O
and O
body O
mass O
index O
['Physiological-Clinical']

We O
compared O
rates O
of O
decline O
in O
ocular O
function O
in O
the O
DHA O
+ O
A O
vs O
control O
+ O
A O
groups O
among O
the O
subgroups O
defined O
by O
use O
or O
nonuse O
of O
vitamin O
A O
prior O
to O
entry O
. O
[]

Group O
50 O
received O
0.3 O
mg O
kg-1 O
diazepam O
with O
50 O
ml O
of O
water O
2 O
h O
before O
surgery O
. O
[]

Secondary O
outcomes O
included O
clinical B-outcome ['Physiological-Clinical']
and O
microbiological B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates O
5 O
to O
9 O
days O
after O
therapy O
and O
, O
for O
trimethoprim-sulfamethoxazole-treated O
women O
, O
clinical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
stratified O
by O
the O
trimethoprim-sulfamethoxazole O
susceptibility O
of O
the O
uropathogen O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
this O
study O
, O
the O
efficacy O
and O
safety O
of O
tracheal O
intubation O
with O
the O
LFS O
was O
compared O
with O
that O
of O
the O
Macintosh O
laryngoscope O
utilizing O
manual O
in-line O
stabilization O
( O
MILS O
) O
to O
simulate O
difficult O
airways O
. O
[]

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O
[]

This O
study O
applied O
a O
12-week O
educational O
intervention O
that O
used O
both O
the O
cellular O
phone O
and O
the O
Internet O
to O
send O
short O
message O
service O
. O
[]

Asperger O
syndrome O
( O
AS O
) O
is O
a O
pervasive O
developmental O
disorder O
recently O
introduced O
as O
a O
new O
diagnostic O
category O
in O
the O
ICD-10 O
and O
the O
DSM-IV O
. O
[]

This O
study O
suggests O
that O
epithelial O
remodeling O
may O
correlate O
with O
relative O
curvature O
changes O
resulting O
after O
both O
techniques, O
rather O
than O
the O
obvious O
difference O
of O
subepithelial O
corneal O
denervation O
changes. O
[]

Title: O
Mothers O
In O
Motion O
intervention O
effect O
on O
psychosocial B-outcome ['Life-Impact', 'Life-Impact']
health I-outcome ['Life-Impact', 'Life-Impact']
in O
young, O
low-income O
women O
with O
overweight O
or O
obesity. O
[['Life-Impact', 'Life-Impact']]

Joint O
mobilization O
has O
been O
shown O
to O
improve O
ankle O
joint O
motion O
, O
but O
effects O
on O
surrounding O
musculature O
is O
unknown O
. O
[]

After O
randomization O
, O
PTF O
( O
1,200 O
mg/d O
) O
was O
administered O
for O
4 O
months O
to O
30 O
patients O
and O
results O
were O
compared O
with O
data O
from O
a O
control O
group O
( O
n O
= O
15 O
) O
. O
[]

The O
respective O
five-year O
survival B-outcome ['Mortality']
rates O
free I-outcome ['Mortality']
from I-outcome ['Mortality']
Q-wave I-outcome ['Mortality']
myocardial I-outcome ['Mortality']
infarction I-outcome ['Mortality']
were O
80.4 O
percent O
and O
78.7 O
percent O
. O
['Mortality']

Auditory O
evoked O
potential O
modifications O
according O
to O
clinical O
and O
biochemical O
responsiveness O
to O
fenfluramine O
treatment O
in O
children O
with O
autistic O
behavior O
. O
[]

Twelve O
subjects O
in O
the O
fenretinide O
arm O
complained O
of O
diminished O
dark B-outcome ['Physiological-Clinical']
adaptability I-outcome ['Physiological-Clinical']
, O
and O
nine O
subjects O
in O
the O
fenretinide O
arm O
versus O
one O
control O
subject O
had O
mild B-outcome ['Physiological-Clinical']
dermatological I-outcome ['Physiological-Clinical']
alterations I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
fluticasone O
group O
had O
one O
and O
the O
placebo O
group O
three O
episodes O
of O
exacerbation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Overall O
, O
the O
use O
of O
the O
MTL O
appears O
well O
tolerated O
by O
healthy O
, O
adult O
volunteers O
. O
[]

Measurement O
of O
tissue B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
was O
made O
on O
days O
5 O
and O
10 O
of O
each O
period O
using O
a O
profilometer O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
improvement O
in O
shoulder B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
on O
Oxford O
and O
Constant O
scores O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
KC O
11458 O
, O
in O
a O
dose O
of O
8 O
mg O
t.d.s O
. O
[]

In O
the O
control O
group O
, O
patients O
were O
discharged O
from O
hospital O
following O
standard O
procedures O
that O
included O
a O
discharge O
letter O
to O
the O
general O
practitioner O
listing O
current O
medications O
. O
[]

Official O
documentation O
from O
the O
hospital O
were O
accessed O
and O
six O
staff O
interviewed O
to O
identify O
assumptions O
underlying O
practice O
. O
[]

Three-year O
clinical O
outcome O
after O
primary O
stenting O
of O
totally O
occluded O
native O
coronary O
arteries O
: O
a O
randomized O
comparison O
of O
bare-metal O
stent O
implantation O
with O
sirolimus-eluting O
stent O
implantation O
for O
the O
treatment O
of O
total O
coronary O
occlusions O
( O
Primary O
Stenting O
of O
Totally O
Occluded O
Native O
Coronary O
Arteries O
[ O
PRISON O
] O
II O
study O
) O
. O
[]

Hydrocele B-outcome ['Physiological-Clinical']
occurred O
only O
in O
the O
group O
which O
received O
the O
Ivanissevich O
technique O
( O
5.5 O
% O
) O
. O
['Physiological-Clinical']

Recurrence O
of O
active B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
after O
treatment O
can O
be O
due O
to O
relapse O
of O
infection O
with O
the O
same O
strain O
or O
reinfection O
with O
a O
new O
strain O
of O
Mycobacterium O
tuberculosis O
. O
['Physiological-Clinical']

CONCLUSIONS O
The O
administration O
of O
L-arginine O
and O
citrulline O
has O
a O
beneficial O
effect O
on O
endothelial O
function O
as O
shown O
by O
the O
normalized O
MAT/TT O
index O
. O
[]

METHODS O
A O
multicentre O
, O
double-blind O
, O
parallel O
group O
study O
was O
designed O
in O
which O
247 O
patients O
with O
CIU O
were O
randomised O
after O
a O
1-week O
placebo O
run-in O
period O
to O
10 O
mg O
daily O
mizolastine O
( O
n O
= O
88 O
) O
, O
10 O
mg O
daily O
loratadine O
( O
n O
= O
79 O
) O
, O
or O
placebo O
( O
n O
= O
80 O
) O
for O
a O
4-week O
treatment O
period O
. O
[]

OBJECTIVE O
We O
assessed O
the O
effectiveness O
of O
distraction O
techniques O
in O
reducing O
the O
sensory O
and O
affective O
components O
of O
pain O
among O
pediatric O
patients O
undergoing O
laceration O
repair O
in O
the O
ED O
. O
[]

The O
effects O
of O
haloperidol O
on O
discrimination B-outcome ['Life-Impact']
learning I-outcome ['Life-Impact']
and O
behavioral B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
in O
autistic O
children O
. O
['Life-Impact', 'Life-Impact']

Using O
motivational O
interviewing O
with O
this O
population O
holds O
promise O
for O
helping O
prevent O
alcohol-related O
health O
problems O
. O
[]

In O
33 O
patients O
with O
PAN O
related O
to O
HBV O
, O
a O
new O
therapeutic O
strategy O
was O
applied O
as O
an O
alternative O
to O
long-term O
steroid O
and O
immunosuppressive O
therapy O
: O
short-term O
steroid O
therapy O
and O
PE O
were O
used O
to O
control O
the O
evolution O
of O
PAN O
and O
anti-viral O
therapy O
was O
administered O
to O
suppress O
the O
etiological B-outcome ['Physiological-Clinical']
agent I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
vasculitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
The O
overall O
sensitivity O
of O
endocervical B-outcome ['Resource-use']
sampling I-outcome ['Resource-use']
was O
56 O
% O
, O
with O
a O
false O
negative O
rate O
of O
44 O
% O
and O
a O
negative O
predictive O
value O
of O
26 O
% O
. O
['Resource-use']

in O
J O
Autism O
Dev O
Disord O
39 O
( O
4 O
) O
:596-606 O
, O
2009 O
) O
. O
[]

BACKGROUND: O
This O
study O
assessed O
the O
effectiveness O
and O
safety O
of O
ultrasound-guided O
pulsed O
radiofrequency O
(UGPRF) O
for O
patients O
with O
frozen O
shoulder O
(FS). O
[]

We O
determined O
whether O
a O
pamphlet O
alone O
could O
be O
used O
by O
parents O
to O
help O
their O
child O
's O
insomnia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
spirometry O
substudy O
evaluates O
the O
bronchodilator O
efficacy O
. O
[]

Patients O
treated O
with O
intravenous O
betalactam O
and O
tobramycin O
were O
randomly O
allocated O
to O
receive O
aerosolized O
tobramycin O
( O
6 O
mg/kg/day O
, O
n O
= O
21 O
) O
or O
placebo O
( O
n O
= O
17 O
) O
. O
[]

Journal O
ID: O
0374675 O
[]

BACKGROUND O
Many O
infants O
admitted O
to O
hospital O
undergo O
repeated O
invasive O
procedures O
. O
[]

CONCLUSIONS O
These O
data O
suggest O
that O
long-term O
treatment O
with O
pioglitazone O
enhances O
insulin O
sensitivity O
relative O
to O
glimepiride O
in O
Mexican O
patients O
with O
type O
2 O
diabetes O
and O
that O
pioglitazone O
may O
have O
a O
more O
sustained O
antihyperglycemic O
effect O
. O
[]

Intranasal O
oxytocin O
improves O
emotion B-outcome ['Life-Impact']
recognition I-outcome ['Life-Impact']
for O
youth O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

METHODS O
Thirty O
premolars O
were O
divided O
into O
three O
groups O
: O
I O
- O
high-speed O
handpiece O
+ O
37 O
% O
phosphoric O
acid O
; O
II O
- O
Er O
: O
YAG O
laser O
( O
350 O
mJ O
, O
4 O
Hz O
and O
112 O
J/cm O
( O
2 O
) O
) O
+ O
37 O
% O
phosphoric O
acid O
; O
and O
III O
- O
Er O
: O
YAG O
laser O
( O
350 O
mJ O
, O
4 O
Hz O
and O
112 O
J/cm O
( O
2 O
) O
) O
+ O
Er O
: O
YAG O
laser O
( O
80 O
mJ O
, O
4 O
Hz O
, O
and O
25 O
mJ/cm O
( O
2 O
) O
) O
. O
[]

Models O
of O
couple-responsible O
and O
therapist-responsible O
process O
in O
couple O
therapy O
were O
developed O
. O
[]

Side O
effects O
were O
mild O
. O
[]

Eight O
of O
the O
ten O
children O
used O
five O
or O
more O
novel O
, O
functional B-outcome ['Life-Impact']
words O
spontaneously O
and O
spoke O
multiple O
times O
per O
hour O
by O
the O
conclusion O
of O
treatment O
. O
['Life-Impact']

Forty O
patients O
scheduled O
to O
undergo O
thoracotomy O
were O
randomly O
allocated O
to O
receive O
either O
transcutaneous O
electrical O
nerve O
stimulation O
with O
intramuscular O
papaveretum O
( O
20 O
patients O
) O
or O
intramuscular O
papaveretum O
alone O
( O
20 O
patients O
) O
for O
postoperative O
pain O
relief O
. O
[]

Increases O
in O
fitness O
were O
reported O
as O
having O
a O
positive O
impact O
on O
the O
functional B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
of O
individuals O
in O
the O
exercise O
group O
as O
well O
as O
enhancing O
the O
individual O
's O
ability B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
complete I-outcome ['Life-Impact']
activities I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
daily I-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
successfully O
. O
['Life-Impact', 'Life-Impact']

Oxygen B-outcome ['Physiological-Clinical']
saturation I-outcome ['Physiological-Clinical']
decreased O
in O
group O
I O
without O
reaching O
statistical O
significance O
. O
['Physiological-Clinical']

The O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
monitored O
with O
and O
without O
CPRV O
for O
60 O
min O
. O
['Physiological-Clinical']

Experimental O
and O
clinical O
application O
] O
. O
[]

Journal-Name:Journal O
of O
global O
health O
[]

In O
the O
group O
treated O
with O
calcium O
heparin O
2 O
cases O
of O
clinically O
and O
radiologically B-outcome ['Physiological-Clinical']
diagnosed I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
embolism I-outcome ['Physiological-Clinical']
and O
4 O
cases O
of O
DVT B-outcome ['Physiological-Clinical']
were O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
of O
this O
study O
show O
that O
high-dose O
fluticasone O
is O
effective O
in O
reducing O
the O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
in O
bronchiectasis O
. O
['Physiological-Clinical']

[ O
Clinical O
observation O
on O
different O
acupuncture O
and O
moxibustion O
therapies O
for O
treatment O
of O
postsurgical O
gastroparesis O
syndrome O
] O
. O
[]

Title: O
Decolonization O
to O
Reduce O
Postdischarge O
Infection B-outcome ['Physiological-Clinical']
Risk O
among O
MRSA O
Carriers. O
[['Physiological-Clinical']]

MSQ B-outcome ['Physiological-Clinical']
scores O
( O
0 O
to O
100 O
, O
higher O
score O
indicates O
better O
functioning O
) O
were O
assessed O
for O
the O
following O
three O
domains O
: O
role O
restriction O
( O
examines O
the O
degree O
to O
which O
performance O
of O
daily O
activities O
is O
limited O
by O
migraine O
) O
, O
role O
prevention O
( O
examines O
the O
degree O
to O
which O
performance O
of O
daily O
activities O
is O
interrupted O
by O
migraine O
) O
, O
and O
emotional B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
( O
examines O
feelings O
of O
frustration O
and O
helplessness O
due O
to O
migraine O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Hb B-outcome ['Physiological-Clinical']
, O
Hct B-outcome ['Physiological-Clinical']
, O
FEP B-outcome ['Physiological-Clinical']
, O
and O
ferritin B-outcome ['Physiological-Clinical']
were O
similar O
in O
both O
groups O
with O
the O
exception O
of O
lower O
ferritin O
values O
at O
age O
365 O
d O
( O
p O
less O
than O
0.05 O
) O
in O
the O
group O
fed O
the O
nonfortified O
formula O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
Etomidate O
resulted O
in O
stable O
hemodynamic B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
and O
relatively O
less O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
, O
and O
flumazenil O
antagonized O
the O
anesthetic B-outcome ['Resource-use']
effect O
of O
etomidate O
; O
thus O
, O
etomidate O
with O
flumazenil O
is O
suitable O
for O
performing O
stem O
cell O
transplantation O
in O
autistic O
children O
. O
['Physiological-Clinical', 'Adverse-effects', 'Resource-use']

TSAb B-outcome ['Physiological-Clinical']
was O
undetectable O
in O
24/55 O
patients O
at O
the O
end O
of O
treatment O
. O
['Physiological-Clinical']

In O
Arm O
2 O
, O
patients O
will O
undergo O
TORS O
along O
with O
selective O
neck O
dissections O
, O
which O
may O
be O
staged O
. O
[]

The O
changes O
between O
pre-treatment O
and O
the O
eight-week O
follow-up O
also O
showed O
a O
significant O
improvement O
in O
group O
A O
compared O
with O
group O
B O
( O
p=0.03 O
) O
. O
[]

A O
total O
of O
1367 O
patients O
participated O
in O
the O
study O
; O
mean O
age O
was O
52.5 O
years O
, O
40.8 O
% O
were O
male O
, O
76.5 O
% O
were O
black O
, O
50.8 O
% O
graduated O
from O
high O
school O
, O
26 O
% O
were O
married O
, O
and O
54.1 O
% O
had O
income O
< O
$ O
5,000 O
. O
[]

Patients O
following O
an O
sVLPD O
started O
dialysis O
therapy O
in O
the O
case O
of O
malnutrition O
, O
intractable O
fluid O
overload O
, O
hyperkalemia O
, O
or O
appearance O
of O
uremic O
symptoms O
. O
[]

Randomized O
, O
controlled O
trial O
of O
an O
intervention O
for O
toddlers O
with O
autism O
: O
the O
Early O
Start O
Denver O
Model O
. O
[]

Tacrolimus O
monotherapy O
without O
steroids O
after O
liver O
transplantation O
-- O
a O
prospective O
randomized O
double-blinded O
placebo-controlled O
trial O
. O
[]

SETTING O
Clinical O
Research O
Unit O
, O
University O
of O
Wisconsin-Madison O
. O
[]

Half O
received O
a O
training O
intervention O
following O
the O
initial O
interview O
and O
the O
half O
who O
served O
as O
a O
contrast O
group O
did O
not O
. O
[]

Publication O
date: O
2019/02/09 O
06:00 O
[medline] O
[]

INTERPRETATION O
Use O
of O
aspergillus O
galactomannan O
and O
PCR O
to O
direct O
treatment O
reduced O
use O
of O
empirical O
antifungal O
treatment O
. O
[]

Postmenopausal O
overweight O
women O
were O
randomized O
to O
a O
diet O
(n O
= O
97), O
exercise O
plus O
diet O
(n O
= O
98) O
or O
control O
group O
(n O
= O
48). O
[]

AIMS O
To O
investigate O
the O
effect O
of O
rectal O
distension O
on O
bladder B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
volumes I-outcome ['Physiological-Clinical']
and O
the O
number O
of O
detrusor B-outcome ['Physiological-Clinical']
contractions I-outcome ['Physiological-Clinical']
in O
patients O
with O
overactive O
bladder O
( O
OAB O
) O
symptoms O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
interobserver O
variability O
of O
digital O
rectal O
examination O
in O
a O
large O
randomized O
trial O
for O
the O
screening O
of O
prostate O
cancer O
. O
[]

4 O
. O
[]

BACKGROUND O
Children O
who O
have O
a O
combination O
of O
language O
and O
developmental O
disabilities O
with O
autism O
often O
experience O
major O
difficulties O
in O
learning O
relations O
between O
objects O
and O
their O
graphic O
representations O
. O
[]

IMPLICATIONS O
Attention O
to O
the O
psychological O
aspects O
of O
breast O
cancer O
risk O
will O
be O
critical O
in O
the O
development O
of O
risk-counseling O
programs O
that O
incorporate O
testing O
for O
the O
recently O
cloned O
breast O
cancer O
susceptibility O
gene O
, O
BRCA1 O
( O
and O
BRCA2 O
when O
that O
gene O
has O
also O
been O
cloned O
) O
. O
[]

Independent O
evaluators O
blind O
to O
treatment O
condition O
conducted O
structured O
diagnostic O
interviews O
and O
parents O
and O
children O
completed O
anxiety B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
checklists O
at O
baseline O
and O
posttreatment/postwaitlist O
. O
['Life-Impact']

At O
the O
time O
of O
enrollment O
, O
patients O
were O
stratified O
according O
to O
diabetes O
status O
. O
[]

There O
appears O
no O
obvious O
adverse O
effect O
on O
uterine B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
or O
ovarian B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

There O
was O
a O
trend O
toward O
the O
reduction O
in O
mean O
units O
of O
blood B-outcome ['Resource-use']
transfused I-outcome ['Resource-use']
per O
patient O
during O
months O
2 O
and O
3 O
of O
therapy O
combined O
in O
rHuEPO-treated O
patients O
compared O
with O
placebo-treated O
patients O
( O
0.91 O
U O
versus O
1.65 O
U O
; O
P O
= O
.056 O
) O
. O
['Resource-use']

After O
2 O
years O
, O
the O
drug-treatment O
strategy O
became O
unrestricted O
, O
but O
still O
targeted O
remission O
. O
[]

The O
smaller O
sample O
size O
for O
women O
may O
account O
for O
some O
observed O
discrepancies O
in O
treatment B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
. O
CONCLUSIONS: O
Although O
there O
were O
gender O
differences O
in O
baseline O
characteristics, O
IND/GLY O
demonstrated O
similar O
trends O
for O
exacerbation B-outcome ['Physiological-Clinical']
prevention O
and O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
improvement O
in O
men O
and O
women O
with O
moderate-to-very-severe O
COPD O
and O
a O
history O
of O
exacerbations O
compared O
with O
SFC. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Revised O
WHO O
guidelines O
now O
recommend O
antiretroviral O
prophylaxis O
( O
either O
to O
the O
mother O
or O
to O
the O
baby O
) O
during O
breastfeeding O
if O
the O
mother O
is O
not O
already O
receiving O
antiretroviral O
treatment O
for O
her O
own O
health O
. O
[]

Title: O
Rehydrating B-outcome ['Physiological-Clinical']
efficacy O
of O
maple O
water O
after O
exercise-induced O
dehydration. O
[['Physiological-Clinical']]

By O
a O
double-blind O
, O
placebo-controlled O
, O
balanced O
randomization O
, O
subjects O
received O
GM-CSF O
priming O
on O
days O
5 O
to O
1 O
for O
courses O
1 O
and O
3 O
or O
courses O
2 O
and O
4 O
. O
[]

This O
elevation O
occurs O
in O
patients O
with O
overt O
, O
symptomatic O
heart O
failure O
( O
HF O
) O
and O
in O
patients O
with O
asymptomatic O
left O
ventricular O
dysfunction O
. O
[]

RESULTS: O
At O
a O
median O
follow-up O
of O
33.6 O
months, O
the O
median O
disease-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
was O
21.6 O
months O
in O
the O
modified-FOLFIRINOX O
group O
and O
12.8 O
months O
in O
the O
gemcitabine O
group O
(stratified O
hazard O
ratio O
for O
cancer-related B-outcome ['Physiological-Clinical']
event I-outcome ['Physiological-Clinical']
, O
second B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
, O
or O
death B-outcome ['Mortality']
, O
0.58; O
95% O
confidence O
interval O
[CI], O
0.46 O
to O
0.73; O
P<0.001). O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Mortality']]

Immediately O
before O
and O
after O
the O
five O
treatment O
sessions O
and O
7 O
days O
after O
treatment O
ended O
, O
both O
patient O
and O
physician O
measured O
the O
degree O
of O
pain B-outcome ['Physiological-Clinical']
using O
a O
categoric O
scale O
( O
no O
pain O
, O
slight O
pain O
, O
intermediate O
pain O
, O
strong O
pain O
, O
and O
very O
strong O
pain O
) O
and O
evaluated O
pain B-outcome ['Physiological-Clinical']
intensity I-outcome ['Physiological-Clinical']
using O
the O
Scott O
and O
Huskisson O
Visual O
Analogue O
Scale O
( O
VAS O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Further O
research O
is O
necessary O
to O
determine O
long-term O
gains O
in O
rates O
of O
physician O
counseling O
and O
improvements O
in O
the O
course O
of O
these O
patients O
. O
[]

BACKGROUND O
This O
placebo-controlled O
phase O
III O
study O
investigated O
the O
effect O
on O
survival B-outcome ['Mortality']
of O
gefitinib O
as O
second-line O
or O
third-line O
treatment O
for O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small-cell O
lung O
cancer O
. O
['Mortality']

METHODS O
Totally O
180 O
patients O
with O
NPC O
were O
divided O
equally O
into O
3 O
groups O
with O
the O
same O
radiotherapeutic O
protocols O
. O
[]

No O
significant O
difference O
of O
pain B-outcome ['Physiological-Clinical']
and O
walking B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
after O
further O
nonsurgical O
treatment O
( O
3 O
months O
) O
was O
seen O
in O
group O
2 O
. O
['Physiological-Clinical', 'Life-Impact']

Proteinuria B-outcome ['Physiological-Clinical']
reduction I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
patients O
receiving O
combined O
therapy O
in O
comparison O
with O
losartan O
treatment O
after O
3 O
months O
of O
therapy O
( O
p O
= O
0.02 O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
In O
the O
present O
study O
the O
diet O
and O
the O
nutritional O
status O
of O
pregnant O
Pakistani O
immigrant O
women O
have O
been O
compared O
with O
a O
group O
of O
Norwegian O
women O
. O
[]

In O
addition O
, O
white O
women O
were O
less O
likely O
to O
benefit O
than O
African-American O
women O
( O
OR O
= O
0.34 O
; O
95 O
% O
CI O
= O
0.11-0.99 O
; O
P O
= O
.05 O
) O
. O
[]

CONCLUSION O
Electro-acupuncture O
may O
reduce O
immunologic B-outcome ['Physiological-Clinical']
damage I-outcome ['Physiological-Clinical']
caused O
by O
chemotherapy O
, O
thus O
it O
can O
be O
used O
as O
the O
auxiliary O
therapy O
for O
patients O
undergoing O
chemotherapy O
. O
['Physiological-Clinical']

The O
proportion O
of O
infants O
with O
serum O
retinol O
values O
below O
20 O
microg O
per O
deciliter O
( O
0.70 O
micromol O
per O
liter O
) O
was O
lower O
in O
the O
vitamin O
A O
group O
than O
in O
the O
control O
group O
( O
25 O
percent O
vs. O
54 O
percent O
, O
P O
< O
0.001 O
) O
. O
[]

The O
hi-fi O
plug O
was O
somewhat O
better O
than O
foam O
plugs O
, O
and O
the O
custom O
made O
ear O
plug O
provided O
a O
speech B-outcome ['Life-Impact']
intelligibility I-outcome ['Life-Impact']
close O
to O
the O
headset-only O
situation O
. O
['Life-Impact']

Further O
studies O
are O
needed O
to O
examine O
the O
efficacy O
of O
hygienic O
measures O
such O
as O
using O
skin O
disinfectants O
to O
prevent O
infections O
in O
patients O
who O
are O
immunocompromised O
. O
[]

This O
difference O
was O
counteracted O
by O
caffeine O
. O
[]

28.3 O
% O
; O
P O
< O
0.001 O
) O
following O
strength O
training O
, O
but O
the O
maximal O
H B-outcome ['Physiological-Clinical']
wave-to-maximal I-outcome ['Physiological-Clinical']
M I-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
( O
H B-outcome ['Physiological-Clinical']
( O
max O
) O
/M O
( O
max O
) O
) O
ratio O
remained O
unchanged O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Young O
children O
with O
pervasive O
developmental O
disorder O
were O
randomly O
assigned O
to O
intensive O
treatment O
or O
parent O
training O
. O
[]

A O
randomized O
intervention O
to O
improve O
ongoing O
participation O
in O
mammography B-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

The O
first O
long-term O
results O
, O
recorded O
after O
2 O
years O
, O
indicate O
statistically O
significant O
differences O
in O
the O
complication B-outcome ['Adverse-effects']
rate O
( O
after O
stenting O
2/62 O
and O
after O
angioplasty O
5/69 O
) O
and O
patency B-outcome ['Physiological-Clinical']
( O
greater O
than O
or O
equal O
to O
70 O
% O
of O
original O
lumen O
size O
upon O
stent O
implantation O
or O
balloon O
inflation O
: O
95 O
% O
after O
stenting O
and O
72 O
% O
after O
angioplasty O
) O
. O
['Adverse-effects', 'Physiological-Clinical']

Further O
research O
is O
needed O
to O
fully O
elucidate O
the O
role O
of O
lactoferrin O
, O
and O
possible O
benefits O
during O
different O
feeding O
conditions O
or O
milk O
sources O
. O
[]

Thirty O
of O
32 O
patients O
maintained O
response O
throughout O
the O
24-hour O
infusion O
of O
diltiazem O
. O
[]

CONCLUSION O
These O
results O
indicate O
that O
low O
atrial O
DFTs O
can O
be O
achieved O
using O
a O
transvenous O
ventricular O
defibrillation O
lead O
. O
[]

There O
were O
no O
statistical O
differences O
in O
the O
incidence O
of O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
between O
the O
two O
groups. O
[['Adverse-effects']]

OBJECTIVE O
We O
performed O
a O
randomized O
, O
prospective O
trial O
to O
assess O
the O
impact O
of O
fibrin O
glue O
on O
the O
incidence O
of O
lymphocysts O
after O
systematic O
pelvic O
or O
pelvic O
and O
paraaortic O
lymphadenectomy O
in O
patients O
with O
gynecologic O
malignancies O
. O
[]

This O
study O
evaluated O
the O
effect O
of O
a O
calculus O
scaling O
gel O
( O
SofScale O
) O
on O
time B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
ease I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
scaling I-outcome ['Life-Impact']
procedure I-outcome ['Life-Impact']
in O
a O
double-blind O
, O
split-mouth O
clinical O
study O
of O
32 O
subjects O
. O
['Life-Impact']

One O
hundred O
milliliter O
venous O
blood O
was O
drawn O
from O
each O
patient O
, O
and O
was O
mixed O
with O
100 O
ml O
( O
35 O
?g/ml O
) O
medical O
ozone O
and O
then O
was O
returned O
the O
blood O
to O
the O
patient O
intravenously O
, O
once O
every O
other O
day O
for O
20 O
days O
. O
[]

RESULTS O
None O
of O
the O
implants O
were O
found O
loose O
during O
the O
follow-up O
period O
( O
100 O
% O
) O
. O
[]

CONCLUSIONS: O
The O
findings O
of O
the O
current O
study O
demonstrate O
that O
consumption O
of O
900 O
mg O
of O
PSE O
improved O
specific O
measures O
of O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
in O
a O
young, O
active O
population. O
[['Life-Impact']]

Participants O
randomised O
to O
receive O
an O
X-ray O
were O
not O
less O
worried B-outcome ['Life-Impact']
, O
or O
more O
reassured B-outcome ['Life-Impact']
about O
serious O
disease O
causing O
their O
low O
back O
pain O
. O
['Life-Impact', 'Life-Impact']

If O
the O
ulcer O
was O
still O
present O
at O
this O
time O
, O
the O
second O
endoscopic O
examination O
was O
done O
after O
a O
further O
14 O
days O
. O
[]

METHODS O
A O
descriptive O
report O
using O
data O
entered O
in O
the O
COMET O
study O
data-base O
. O
[]

There O
is O
no O
known O
definite O
cure O
for O
mucositis O
. O
[]

The O
ewes O
were O
randomly O
allocated O
into O
four O
groups O
, O
viz. O
, O
GI O
( O
n=7 O
; O
control O
) O
, O
GII O
( O
n=7 O
; O
thermal O
stress O
) O
, O
GIII O
( O
n=7 O
; O
restricted O
feeding O
) O
and O
GIV O
( O
n=7 O
; O
combined O
stress O
) O
. O
[]

The O
six-session O
intervention O
that O
emerged O
from O
the O
development O
process O
relied O
on O
both O
social-cognitive O
theories O
and O
peer O
influence O
models O
. O
[]

The O
tools O
were O
also O
reviewed O
by O
a O
plain O
language O
expert O
and O
the O
interdisciplinary O
research O
team O
. O
[]

Results: O
Smoking O
a O
cigarette O
for O
five O
minutes O
resulted O
in O
a O
significant O
increase O
of O
exhaled B-outcome ['Physiological-Clinical']
CO I-outcome ['Physiological-Clinical']
, O
whereas O
using O
an O
IQOS(TM) O
resulted O
in O
a O
small O
but O
reliable O
increase O
(0.3 O
ppm). O
[['Physiological-Clinical']]

The O
aim O
of O
this O
trial O
was O
, O
to O
compare O
the O
efficacy O
of O
two O
doses O
of O
UK O
administered O
via O
a O
catheter O
in O
the O
pulmonary O
artery O
: O
2000 O
IU O
kg-1 O
h-1 O
for O
24 O
hours O
( O
UK O
2000 O
) O
in O
conjunction O
with O
heparin O
versus O
4400 O
IU O
kg-1 O
h-1 O
UK O
alone O
for O
12 O
hours O
( O
UK O
4400 O
) O
followed O
by O
heparin O
. O
[]

OBJECTIVE O
To O
evaluate O
postoperative O
pain O
relief O
of O
intramuscular O
ketorolac O
, O
topical O
bupivacaine O
, O
and O
placebo O
in O
patients O
undergoing O
laparoscopic O
tubal O
sterilization O
with O
silastic O
bands O
. O
[]

Per-protocol O
eradication B-outcome ['Physiological-Clinical']
rate O
of O
sequential O
therapy O
was O
92.4 O
% O
( O
95 O
% O
CI O
85.8-96.1 O
% O
) O
vs. O
81.8 O
% O
( O
95 O
% O
CI O
73.9-87.8 O
% O
) O
( O
p O
= O
0.027 O
) O
for O
standard O
drug O
therapy O
. O
['Physiological-Clinical']

When O
aerobic O
exercise O
preceded O
the O
vocational O
task O
, O
similar O
reductions O
were O
observed O
. O
[]

Accordingly O
, O
it O
is O
suggested O
that O
pindolol O
could O
be O
a O
more O
favorable O
beta-blocker O
drug O
to O
be O
used O
on O
hypertensive O
subjects O
with O
metabolic O
coronary O
risk O
factors O
. O
[]

The O
most O
common O
reasons O
for O
delay O
were O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
and O
personal/logistical O
reasons O
. O
['Adverse-effects']

The O
toxicity B-outcome ['Adverse-effects']
were O
evaluated O
in O
all O
patients O
this O
study O
according O
to O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
4 O
(NCI O
CTC O
version O
4.0).A O
total O
of O
53 O
well-matched O
patients O
with O
advanced O
colorectal O
cancer O
were O
retrospectively O
analyzed. O
[['Adverse-effects']]

Using O
the O
virtual O
reality-cognitive O
rehabilitation O
approach O
to O
improve O
contextual B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

BACKGROUND O
A O
new O
approach O
in O
the O
treatment O
of O
cystic O
fibrosis O
involves O
improving O
the O
function O
of O
mutant O
cystic O
fibrosis O
transmembrane O
conductance O
regulator O
( O
CFTR O
) O
. O
[]

Journal O
ID: O
0404312 O
[]

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
pentoxifylline O
for O
the O
treatment O
of O
recurrent O
aphthous O
stomatitis O
. O
[]

P O
less O
than O
0.05 O
) O
and O
this O
change O
was O
sustained O
for O
40 O
min O
. O
[]

Pre-operative O
and O
post-operative O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
, O
inspiratory B-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
, O
post-operative B-outcome ['Life-Impact']
ventilation I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
post-operative B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
complication B-outcome ['Adverse-effects']
and O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
were O
determined O
in O
both O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Resource-use', 'Resource-use']

Group O
2 O
received O
only O
a O
face-to-face O
presentation O
, O
given O
to O
departmental O
groups O
, O
as O
well O
as O
the O
same O
written O
educational O
materials O
used O
in O
group O
1 O
. O
[]

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF B-outcome ['Physiological-Clinical']
level O
. O
['Physiological-Clinical']

Exenatide O
administration O
failed B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
suppress I-outcome ['Physiological-Clinical']
glucagon I-outcome ['Physiological-Clinical']
but I-outcome ['Physiological-Clinical']
delayed I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
( O
P O
< O
0.004 O
) O
. O
['Physiological-Clinical']

The O
reversibility O
of O
increased O
airways O
resistance O
in O
chronic O
heart O
failure O
measured O
by O
impulse O
oscillometry O
. O
[]

A O
prospective O
, O
randomized O
open-label O
trial O
of O
sevelamer O
hydrochloride O
with O
or O
without O
calcium O
carbonate O
( O
CC O
) O
involved O
86 O
hemodialysis O
patients O
in O
Japan O
. O
[]

Effect O
of O
surgical O
technique O
in O
subtotal O
and O
bilateral O
thyroidectomy O
on O
risk O
of O
postoperative O
parathyroid O
insufficiency O
development O
-- O
our O
experience O
. O
[]

The O
[]

The O
AQ-J-21 B-outcome ['Physiological-Clinical']
( O
consisting O
of O
21 O
items O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES: O
Resting B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
measured O
and O
standard O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
variability I-outcome ['Physiological-Clinical']
(HRV) I-outcome ['Physiological-Clinical']
indices O
were O
calculated O
using O
time O
domain O
( O
SDNN B-outcome ['Physiological-Clinical']
, O
pNN50 B-outcome ['Physiological-Clinical']
, O
RMSSD B-outcome ['Physiological-Clinical']
) O
and O
frequency O
domain O
( O
LFnu B-outcome ['Physiological-Clinical']
, O
HFnu B-outcome ['Physiological-Clinical']
, O
LF/HF B-outcome ['Physiological-Clinical']
and O
TP B-outcome ['Physiological-Clinical']
) O
analysis. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

After O
a O
2-week O
familiarization O
period O
, O
the O
participants O
were O
assigned O
to O
either O
a O
reduced O
alcohol O
drinking O
group O
or O
a O
usual O
drinking O
group O
for O
3 O
weeks O
( O
experimental O
period O
1 O
) O
. O
[]

The O
results O
indicated O
that O
amprenavir B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
decreased O
by O
saquinavir O
soft O
gel O
capsule O
( O
by O
32 O
% O
for O
area O
under O
the O
concentration-time O
curve O
at O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
[ O
AUC O
( O
ss O
) O
] O
and O
37 O
% O
for O
peak O
plasma O
concentration O
at O
steady B-outcome ['Physiological-Clinical']
state I-outcome ['Physiological-Clinical']
[ O
C O
( O
max O
, O
ss O
) O
] O
) O
and O
increased O
by O
indinavir O
( O
33 O
% O
for O
AUC O
( O
ss O
) O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Fibrinogen O
was O
reduced O
in O
both O
groups O
but O
more O
markedly O
in O
the O
DYDR O
group O
. O
[]

Mann-Whitney O
U O
test O
was O
used O
for O
significance O
of O
difference O
between O
both O
the O
groups O
. O
[]

The O
last O
two O
decades O
have O
witnessed O
a O
surge O
in O
research O
investigating O
the O
application O
of O
oxytocin O
as O
a O
method O
of O
enhancing O
social O
behaviour O
in O
humans O
. O
[]

The O
production O
of O
new B-outcome ['Physiological-Clinical']
red I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
was O
176.3+/-90.8 O
ml O
in O
the O
200 O
U/kg O
group O
and O
268.4+/-79.4 O
ml O
in O
the O
400 O
U/kg O
group O
( O
p O
= O
0.036 O
) O
. O
['Physiological-Clinical']

RESPECT O
includes O
Danish-speaking O
children O
diagnosed O
with O
cancer O
and O
treated O
at O
pediatric O
oncology O
units O
in O
Denmark O
. O
[]

Exercise B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
lower O
after O
the O
pindolol/clopamide O
combination O
at O
low O
dose O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Single-dose O
metronidazole O
treatment O
of O
the O
sexual O
partner O
of O
women O
with O
bacterial O
vaginosis O
improves O
initial O
bacterial B-outcome ['Physiological-Clinical']
vaginosis I-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Weekly O
intake O
of O
alendronate O
, O
whether O
conventional O
or O
enteric-coated O
; O
is O
associated O
with O
less O
heartburn B-outcome ['Physiological-Clinical']
and O
nausea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
goal O
of O
the O
current O
study O
was O
to O
measure O
the O
effectiveness O
of O
a O
tailored O
decision O
aid O
designed O
specifically O
to O
assist O
individuals O
to O
make O
informed O
decisions O
regarding O
genetic O
testing O
for O
HNPCC O
risk O
. O
[]

It O
may O
aggravate O
[]

MATERIAL O
AND O
METHODS O
The O
study O
, O
comprising O
11 O
patients O
with O
at O
least O
two O
screw O
type O
implants O
with O
bleeding B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
( O
BOP B-outcome ['Physiological-Clinical']
) O
, O
probing B-outcome ['Physiological-Clinical']
pocket I-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
( O
PPD B-outcome ['Physiological-Clinical']
) O
> O
or O
=5 O
mm O
, O
and O
at O
least O
1.5 O
mm O
radiographic O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
and O
exposed O
implant O
threads O
, O
was O
carried O
out O
as O
a O
single O
blind O
randomized O
clinical O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
was O
considered O
to O
have O
occurred O
if O
a O
patient O
reported O
any O
clinical O
sign O
or O
symptom O
of O
oral B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
with O
or O
without B-outcome ['Physiological-Clinical']
oral I-outcome ['Physiological-Clinical']
candidiasis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Serum B-outcome ['Physiological-Clinical']
and O
fecal B-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against I-outcome ['Physiological-Clinical']
SsWC I-outcome ['Physiological-Clinical']
, O
LPS B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Forty-three O
chronic O
stroke O
patients O
with O
mild O
to O
moderate O
upper O
extremity O
impairment O
were O
randomly O
assigned O
to O
receive O
MT O
+ O
MG O
, O
MT O
, O
or O
CT O
for O
1.5 O
hours/day O
, O
5 O
days/week O
for O
4 O
weeks O
. O
[]

The O
mean O
arterial B-outcome ['Physiological-Clinical']
carboxyhemoglobin I-outcome ['Physiological-Clinical']
level O
was O
1.52 O
percent O
in O
the O
air O
control O
period O
and O
decreased O
from O
1.47 O
to O
1.34 O
per O
cent O
after O
purified O
air O
( O
P O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
The O
prognostic O
model O
included O
37 O
clinical O
characteristics O
collected O
at O
baseline O
in O
PROTECT O
, O
a O
study O
comparing O
rolofylline O
and O
placebo O
in O
2033 O
patients O
admitted O
with O
acute O
heart O
failure O
. O
[]

Levels O
of O
serum B-outcome ['Physiological-Clinical']
cytokines I-outcome ['Physiological-Clinical']
were O
measured O
before O
therapy O
and O
after O
three O
and O
6 O
months O
. O
['Physiological-Clinical']

The O
evaluation O
of O
clinical O
efficacy O
was O
based O
on O
the O
change O
in O
the O
number O
of O
facial B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
from O
baseline O
to O
the O
end O
of O
treatment O
, O
and O
noninferiority O
was O
defined O
by O
the O
upper O
95 O
% O
confidence O
limit O
of O
the O
difference O
between O
two O
treatments O
being O
less O
than O
9 O
. O
['Physiological-Clinical']

DESIGN O
Randomized O
, O
double-masked O
, O
placebo-controlled O
, O
parallel O
group O
multicenter O
study O
of O
6 O
weeks O
duration O
. O
[]

CONCLUSION O
With O
the O
effective O
use O
of O
goal-directed O
fluid O
therapy O
in O
elective O
surgical O
patients O
, O
the O
routine O
use O
of O
dopexamine O
does O
not O
confer O
an O
additional O
clinical O
benefit O
. O
[]

When O
calculated O
per O
month O
, O
the O
median O
sum O
of O
vitagram O
points O
was O
5.9 O
for O
radiotherapy O
, O
5.7 O
for O
cyclophosphamide O
and O
4.8 O
for O
placebo O
. O
[]

METHODS O
A O
randomised O
, O
double-blind O
, O
crossover O
trial O
was O
performed O
in O
14 O
patients O
with O
nondiabetic O
chronic O
kidney O
disease O
with O
24-h O
mean O
proteinuria O
of O
2.01 O
g O
( O
95 O
% O
CI O
, O
1.36?2.66 O
) O
and O
estimated O
creatinine O
clearance O
of O
93?6.8 O
ml/min O
. O
[]

Comparisons O
with O
the O
cyclophosphamide-doxorubicin-5-fluorouracil O
arm O
will O
not O
be O
addressed O
. O
[]

Safety O
was O
evaluated O
for O
28 O
days O
postvaccination O
. O
[]

RESULTS O
Clinical O
benefit O
assessments O
were O
performed O
in O
more O
than O
75 O
% O
of O
patients O
throughout O
V325 O
. O
[]

INTRODUCTION O
There O
is O
an O
increasing O
amount O
of O
evidence O
showing O
that O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
and O
sun B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
are O
effective O
coadjuvant O
treatments O
for O
patients O
with O
mild O
to O
moderate O
depression O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
Fifty-four O
( O
51 O
% O
) O
of O
the O
105 O
eyes O
in O
the O
5-fluorouracil O
group O
and O
80 O
( O
74 O
% O
) O
of O
the O
108 O
eyes O
in O
the O
standard O
filtering O
surgery O
group O
were O
classified O
as O
failures O
( O
P O
< O
.001 O
, O
Mantel-Cox O
survival O
analysis O
) O
. O
[]

One O
group O
was O
treated O
with O
estramustine O
phosphate O
, O
another O
with O
Epirubicin O
plus O
Medroxyprogesterone O
acetate O
( O
MPA O
) O
, O
while O
the O
third O
arm O
consisted O
of O
Epirubicin O
plus O
placebo O
. O
[]

As O
part O
of O
the O
comprehensive O
Dental O
Implant O
Clinical O
Research O
Group O
clinical O
implant O
study O
, O
the O
preoperative O
or O
postoperative O
use O
of O
antibiotics O
, O
the O
type O
used O
, O
and O
the O
duration O
of O
coverage O
was O
left O
to O
the O
discretion O
of O
the O
surgeon O
. O
[]

We O
evaluated O
cases O
of O
recurrent B-outcome ['Physiological-Clinical']
tuberculosis I-outcome ['Physiological-Clinical']
in O
two O
prospective O
clinical O
trials O
: O
a O
randomized O
study O
of O
two O
regimens O
for O
the O
last O
4 O
months O
of O
treatment O
( O
n O
= O
1,075 O
) O
and O
a O
study O
of O
a O
twice-weekly O
rifabutin-containing O
regimen O
for O
human O
immunodeficiency O
virus-infected O
tuberculosis O
( O
n O
= O
169 O
) O
. O
['Physiological-Clinical']

Each O
subject O
received O
a O
total O
of O
four O
treatments O
, O
each O
separated O
by O
one O
week O
. O
[]

Since O
the O
conventional O
angiographic O
parameters O
analysed O
in O
this O
study O
failed O
to O
identify O
individual O
arterial O
sites O
with O
an O
increased O
risk O
for O
progression O
, O
definition O
of O
new O
angiographic O
parameters O
or O
application O
of O
new O
techniques O
seem O
mandatory O
to O
this O
end O
. O
[]

Exogenous O
glucocorticoids O
are O
thus O
unlikely O
to O
have O
any O
more O
beneficial O
effects O
than O
endogenous O
cortisol O
. O
[]

Study O
exclusion O
criteria O
were O
patient O
age O
greater O
than O
80 O
years O
, O
body O
mass O
index O
greater O
than O
40 O
, O
bilateral O
adrenalectomy O
and O
significant O
prior O
abdominal O
surgery O
in O
the O
quadrant O
of O
interest O
. O
[]

Los O
Angeles O
Biomedical O
Research O
Institute, O
Los O
Angeles, O
CA O
dr.mckinnell@gmail.com. O
[]

Six O
patients O
entered O
and O
completed O
the O
study O
. O
[]

Rhinocort O
Study O
Group O
. O
[]

We O
assessed O
a O
newer O
macrolide O
, O
dirithromycin O
, O
for O
the O
treatment O
of O
H. O
pylori O
in O
two O
separate O
studies O
. O
[]

Visual O
impairment O
is O
common O
among O
rural O
Chinese O
children, O
but O
fewer O
than O
a O
quarter O
of O
children O
who O
need O
glasses O
actually O
own O
and O
use O
them. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
We O
conducted O
a O
randomized O
crossover O
trial O
of O
the O
effects O
of O
12 O
g O
decaffeinated O
coffee O
, O
1 O
g O
chlorogenic O
acid O
, O
500 O
mg O
trigonelline O
, O
and O
placebo O
( O
1 O
g O
mannitol O
) O
on O
glucose O
and O
insulin O
concentrations O
during O
a O
2-h O
oral O
glucose O
tolerance O
test O
( O
OGTT O
) O
in O
15 O
overweight O
men O
. O
[]

Grade O
4 O
neutropaenia B-outcome ['Physiological-Clinical']
, O
grade O
3/4 O
anaemia B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
Periprostatic O
local O
anesthesia O
for O
prostate O
biopsy O
requires O
2 O
or O
more O
extra O
needle O
punctures O
and O
injection O
of O
the O
local O
anesthetic O
through O
the O
highly O
colonized O
rectum O
. O
[]

Rapid-sequence O
intubation O
of O
head O
trauma O
patients O
: O
prevention O
of O
fasciculations B-outcome ['Physiological-Clinical']
with O
pancuronium O
versus O
minidose O
succinylcholine O
. O
['Physiological-Clinical']

These O
children O
were O
randomly O
assigned O
to O
the O
treatment O
group O
with O
tongue O
acupuncture O
( O
40 O
sessions O
over O
8 O
weeks O
) O
or O
the O
control O
group O
( O
sham O
tongue O
acupuncture O
to O
nonacupoints O
in O
the O
tongue O
) O
. O
[]

CS O
and O
OS O
were O
performed O
in O
random O
order O
, O
30 O
minutes O
apart O
. O
[]

Safety O
and O
efficacy O
of O
oral O
DMSA O
therapy O
for O
children O
with O
autism O
spectrum O
disorders O
: O
Part O
A O
-- O
medical O
results O
. O
[]

Fibula O
, O
scapula O
, O
iliac O
crest O
, O
rib O
, O
and O
metatarsal O
as O
well O
as O
the O
radial O
forearm O
osseocutaneous O
flaps O
have O
all O
been O
utilized O
for O
this O
purpose O
. O
[]

Postoperative O
radiotherapy O
in O
breast O
cancer O
-- O
long-term O
results O
from O
the O
Oslo O
study O
. O
[]

We O
conclude O
that O
cyclo-oxygenase O
is O
rapidly B-outcome ['Physiological-Clinical']
synthesised I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
bradykinin-responsive I-outcome ['Physiological-Clinical']
tissues I-outcome ['Physiological-Clinical']
in O
vivo O
and O
that O
this O
reflects O
similarly O
rapid O
enzyme O
biosynthesis O
in O
tissues O
that O
produce O
PGI2 O
under O
basal O
conditions O
. O
['Physiological-Clinical']

Results O
support O
the O
usefulness O
of O
the O
program O
to O
teach O
the O
detection B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
facial I-outcome ['Life-Impact']
affect I-outcome ['Life-Impact']
. O
['Life-Impact']

There O
were O
no O
statistically O
significant O
differences O
in O
death B-outcome ['Mortality']
, O
myocardial B-outcome ['Physiological-Clinical']
infarction I-outcome ['Physiological-Clinical']
, O
and O
stent B-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
according O
to O
the O
Academic O
Research O
Consortium O
criteria O
between O
the O
2 O
groups O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

Four O
patients O
assigned O
to O
sclerotherapy O
and O
12 O
assigned O
to O
staple O
transection O
did O
not O
actually O
undergo O
those O
procedures O
, O
but O
all O
analyses O
were O
made O
on O
an O
intention-to-treat O
basis O
. O
[]

The O
principal O
outcome O
measure O
was O
pain O
on O
a O
self-selected O
activity B-outcome ['Life-Impact']
assessed O
by O
Vas O
. O
['Life-Impact']

The O
incidence O
of O
the O
primary O
endpoint O
in O
these O
patients O
was O
compared O
to O
that O
in O
178 O
patients O
out O
of O
the O
initial O
256 O
rate-control O
patients O
of O
RACE O
who O
were O
in O
AF O
and O
using O
oral O
anticoagulation O
continuously O
. O
[]

However O
, O
a O
subsequent O
study O
did O
not O
find O
evidence O
for O
a O
drug O
effect O
. O
[]

This O
number O
declined O
as O
the O
trial O
progressed O
and O
coincided O
with O
investigator O
training O
and O
feedback O
from O
central O
review O
. O
[]

Circadian O
rhythms O
in O
dietary O
and O
water O
intake O
and O
levels O
of O
plasma B-outcome ['Physiological-Clinical']
total O
fatty B-outcome ['Physiological-Clinical']
acids B-outcome ['Physiological-Clinical']
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Comparisons O
between O
the O
two O
conditions O
indicated O
significant O
reductions O
in O
anxiety B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
as O
measured O
by O
self-report O
, O
parent O
report O
and O
['Life-Impact']

The O
achievement O
of O
learning B-outcome ['Life-Impact']
objectives O
was O
predicted O
by O
caregiver B-outcome ['Life-Impact']
factors I-outcome ['Life-Impact']
, O
such O
as O
education B-outcome ['Life-Impact']
, O
presence B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
father I-outcome ['Life-Impact']
or O
surrogate B-outcome ['Life-Impact']
father I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
household I-outcome ['Life-Impact']
, O
and O
safety B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
neighborhood I-outcome ['Life-Impact']
, O
but O
not O
by O
child O
factors O
, O
such O
as O
age O
or O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
as O
implied O
by O
the O
prescribed O
asthma O
medication O
regimen O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

Neuropsychological B-outcome ['Physiological-Clinical']
deficits I-outcome ['Physiological-Clinical']
were O
still O
evident O
in O
a O
subgroup O
of O
patients O
6 O
months O
later O
. O
['Physiological-Clinical']

The O
decrease O
in O
serum B-outcome ['Physiological-Clinical']
Na I-outcome ['Physiological-Clinical']
level O
was O
found O
to O
be O
significantly O
higher O
in O
the O
TURP O
group O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

Three O
patients O
in O
each O
group O
were O
treated O
for O
croup B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
( O
1.2 O
% O
cuffed O
; O
1.3 O
% O
uncuffed O
) O
. O
['Physiological-Clinical']

Signs O
, O
symptoms O
, O
and O
cultures O
were O
evaluated O
at O
the O
beginning O
and O
at O
the O
end O
of O
the O
study O
. O
[]

Baseline O
screening O
coverage O
interviews O
were O
then O
performed O
: O
58 O
of O
158 O
women O
in O
the O
intervention O
zone O
and O
46 O
of O
146 O
in O
the O
control O
zone O
were O
excluded O
from O
the O
study O
because O
of O
having O
had O
a O
Pap O
smear O
within O
5 O
years O
, O
but O
these O
were O
included O
in O
the O
final O
analysis O
. O
[]

Practices O
were O
then O
given O
access O
to O
an O
ADHD O
Internet O
portal O
that O
allowed O
parents O
, O
teachers O
, O
and O
pediatricians O
to O
input O
information O
( O
eg O
, O
rating O
scales O
) O
about O
patients O
, O
after O
which O
information O
was O
scored O
, O
interpreted O
, O
and O
formatted O
in O
a O
report O
style O
that O
was O
helpful O
for O
assessment O
and O
treatment O
of O
patients O
with O
ADHD O
. O
[]

CONCLUSIONS O
Epileptiform O
discharges O
are O
common O
in O
SLOS O
, O
despite O
a O
relatively O
low O
prevalence O
of O
epilepsy O
. O
[]

METHODS O
a O
) O
. O
[]

In O
the O
first O
study O
the O
efficacy O
of O
the O
antidepressant O
paroxetine O
( O
20 O
mg O
daily O
) O
, O
the O
phosphodiesterase O
inhibitor O
pentoxifylline O
( O
1200 O
mg O
daily O
) O
and O
the O
glutamate O
release O
inhibitor O
riluzole O
( O
100 O
mg O
daily O
) O
was O
assessed O
. O
[]

After O
the O
initial O
clinical O
evaluation O
, O
including O
plain O
radiography O
and O
MRI O
, O
37 O
hips O
with O
early-stage O
osteonecrosis O
( O
ON O
) O
in O
33 O
patients O
were O
randomly O
assigned O
to O
a O
core-decompression O
group O
or O
a O
conservatively-treated O
group O
. O
[]

In O
all O
three O
classifications O
there O
were O
no O
statistically O
significant O
differences O
between O
the O
incidences O
in O
placebo O
and O
combined O
active O
treatment O
groups O
, O
or O
between O
those O
in O
the O
two O
quinapril O
groups O
. O
[]

CONCLUSIONS: O
Single-dose O
tafenoquine O
resulted O
in O
a O
significantly O
lower O
risk O
of O
P. O
vivax O
recurrence O
than O
placebo O
in O
patients O
with O
phenotypically O
normal O
G6PD O
activity. O
( O
[]

Measurement O
of O
health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
in O
multiple O
myeloma O
. O
['Life-Impact']

One O
hundred O
and O
fifty-six O
infants O
aged O
between O
7 O
weeks O
and O
24 O
months O
who O
had O
had O
an O
episode O
of O
wheezing O
and O
other O
signs O
and O
symptoms O
of O
bronchiolitis O
were O
randomized O
to O
three O
groups O
as O
follows O
: O
( O
i O
) O
nebulized O
salbutamol O
was O
administered O
to O
52 O
patients O
in O
group O
I O
at O
a O
dose O
of O
0.15 O
mg/kg O
in O
2 O
mL O
saline O
; O
( O
ii O
) O
saline O
was O
nebulized O
to O
52 O
patients O
in O
group O
II O
and O
( O
iii O
) O
in O
group O
III O
52 O
patients O
received O
mist O
in O
a O
tent O
. O
[]

The O
recurrence B-outcome ['Physiological-Clinical']
rate O
in O
the O
doxorubicin O
group O
was O
30 O
% O
( O
95 O
% O
CI O
: O
19.8 O
% O
-38.8 O
% O
) O
, O
while O
it O
was O
27.3 O
% O
( O
95 O
% O
CI O
: O
17.5 O
% O
-36.8 O
% O
) O
in O
the O
mitoxantrone O
group O
. O
['Physiological-Clinical']

A O
double-blind O
randomized O
clinical O
evaluation O
of O
enamel O
matrix O
derivative O
proteins O
for O
the O
treatment O
of O
proximal O
class-II O
furcation O
involvements O
. O
[]

MANCOVA O
, O
ANCOVA O
and O
Post O
Hoc O
analyses O
were O
utilized O
to O
test O
for O
significant O
differences O
among O
the O
three O
groups O
. O
[]

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
has O
not O
yet O
been O
reached O
in O
group O
A O
while O
it O
was O
34 O
months O
for O
patients O
of O
group O
B. O
Metrorrhagia B-outcome ['Physiological-Clinical']
was O
observed O
in O
two O
cases O
of O
group O
A O
and O
in O
6 O
of O
group O
B O
, O
and O
thrombophlebitis O
in O
1 O
and O
3 O
cases O
, O
respectively O
. O
['Mortality', 'Physiological-Clinical']

We O
designed O
a O
randomized O
trial O
to O
assess O
whether O
the O
early O
withdrawal O
of O
cyclosporine O
( O
CsA O
) O
followed O
by O
the O
initiation O
of O
everolimus O
( O
Evr O
) O
monotherapy O
in O
de O
novo O
liver O
transplantation O
( O
LT O
) O
patients O
would O
result O
in O
superior O
renal O
function O
compared O
to O
a O
CsA-based O
immunosuppression O
protocol O
. O
[]

These O
observations O
led O
to O
a O
proposed O
model O
of O
the O
interaction O
between O
the O
basal O
ganglia O
and O
the O
supplementary O
motor O
area O
, O
involving O
the O
temporal O
organization O
of O
voluntary O
and O
internally O
determined O
sequential O
movements O
. O
[]

SUBJECTS O
AND O
METHODS O
A O
population-based O
crosssectional O
survey O
was O
conducted O
in O
Qingdao O
, O
China O
in O
2006 O
with O
6100 O
Chinese O
aged O
35-74 O
yr O
invited O
and O
5355 O
who O
attended O
; O
3357 O
subjects O
, O
1562 O
urban O
( O
46.5 O
% O
) O
and O
1795 O
rural O
residents O
( O
53.5 O
% O
) O
met O
the O
inclusion O
criteria O
for O
the O
current O
data O
analysis O
. O
[]

The O
[]

Patients O
with O
clinically O
diagnosed O
osteoarthritis O
of O
knee O
were O
injected O
either O
Triamcinolone O
or O
Placebo O
after O
recording O
the O
baseline O
scores O
of O
the O
knee O
by O
Knee O
injury O
and O
Osteoarthritis O
Outcome O
Score O
(KOOS) O
- O
Physical O
Function O
Short O
form O
(KOOS-PS), O
the O
Western O
Ontario O
and O
McMaster O
Universities O
Osteoarthritis O
Index O
(WOMAC) O
and O
Visual O
Analogue O
Scale O
(VAS). O
[]

METHODS O
Seventy-one O
children O
aged O
ten O
to O
twelve O
years O
were O
recruited O
to O
participate O
in O
the O
anxiety O
programme O
. O
[]

This O
paper O
presents O
results O
of O
3 O
weeks O
physical O
training O
on O
glucosamine O
level O
in O
serum O
of O
male O
patients O
after O
myocardial O
infarction O
( O
MI O
) O
aged O
between O
38 O
and O
61 O
. O
[]

All O
20 O
stabilized O
patients O
in O
the O
analog-computer O
group O
achieved O
a O
stable O
PT O
ratio O
by O
the O
fourth O
dosage O
prediction O
. O
( O
[]

CONCLUSIONS O
Patient O
age O
, O
gender O
, O
and O
cancer-type O
may O
be O
important O
factors O
to O
consider O
when O
developing O
and O
implementing O
smoking O
cessation O
interventions O
for O
cancer O
patients O
. O
[]

For O
six O
months O
36 O
U O
factor O
VIII O
concentrates O
per O
kg O
bodyweight O
and O
week O
were O
administered O
to O
six O
out-patients O
with O
severe O
haemophilia O
A O
. O
[]

After O
to O
basal O
evaluation O
, O
the O
patients O
were O
revised O
in O
a O
monthly O
way O
evaluating O
the O
following O
symptoms O
and O
signs O
: O
mastalgia B-outcome ['Physiological-Clinical']
, O
mammary B-outcome ['Physiological-Clinical']
tension I-outcome ['Physiological-Clinical']
, O
presence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
nodules I-outcome ['Physiological-Clinical']
, O
nipple B-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
, O
and O
the O
presence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

In O
78 O
patients O
without O
HBV O
markers O
, O
we O
compared O
prednisone O
and O
PE O
to O
prednisone O
alone O
as O
the O
initial O
therapeutic O
regimen O
. O
[]

We O
hypothesized O
that O
re-training O
reduces O
the O
impaired O
performance O
on O
neurosensory O
tests O
of O
tactile O
function O
that O
is O
commonly O
observed O
post-surgically O
. O
[]

Three O
randomized O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
2 O
patients O
received O
less O
than O
50 O
mL O
of O
study O
solution O
due O
to O
an O
interstitial O
intravenous O
line O
and O
1 O
lost O
randomization O
identification O
. O
[]

There O
was O
no O
significant O
difference O
among O
the O
drugs O
in O
the O
Holter-monitoring O
group O
. O
[]

To O
test O
this O
hypothesis O
, O
we O
carried O
out O
a O
randomized O
, O
controlled O
trial O
in O
patients O
with O
type O
2 O
diabetes O
that O
compared O
changes O
in O
HbA1c B-outcome ['Physiological-Clinical']
as O
the O
primary O
outcome O
. O
['Physiological-Clinical']

At O
week O
4 O
, O
doses O
were O
titrated O
to O
40 O
, O
100 O
, O
and O
160 O
mg O
once O
daily O
for O
olmesartan O
, O
losartan O
, O
and O
valsartan O
, O
respectively O
. O
[]

Rioprostil O
, O
a O
new O
prostaglandin O
E1 O
analogue O
, O
in O
the O
once-daily O
treatment O
for O
the O
prevention O
of O
duodenal O
ulcer O
recurrence O
: O
a O
comparison O
with O
ranitidine O
. O
[]

Publication O
Type: O
Clinical O
Trial, O
Phase O
III O
[]

The O
secondary O
outcome O
composite O
of O
requirement O
of O
hemodialysis B-outcome ['Resource-use']
, O
death B-outcome ['Mortality']
and O
rehospitalization B-outcome ['Resource-use']
for O
heart O
failure O
was O
not O
statistically O
significant O
(p: O
0.646). O
[['Resource-use'], ['Mortality'], ['Resource-use']]

Inflammatory O
markers O
were O
significantly O
increased O
at O
24 O
h O
in O
patients O
with O
< O
40 O
% O
TBSA O
burn O
. O
[]

Stimulation O
of O
the O
ear O
induced O
a O
significant O
increase O
in O
the O
parasympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
stimulation O
period O
of O
25 O
min O
( O
P O
< O
0.05 O
) O
and O
during O
the O
post-stimulation O
period O
of O
60 O
min O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

MDM2 O
and O
Ki-67 O
predict O
for O
distant B-outcome ['Physiological-Clinical']
metastasis I-outcome ['Physiological-Clinical']
and O
mortality B-outcome ['Mortality']
in O
men O
treated O
with O
radiotherapy O
and O
androgen O
deprivation O
for O
prostate O
cancer O
: O
RTOG O
92-02 O
. O
['Physiological-Clinical', 'Mortality']

Errors O
during O
the O
preparation O
of O
drug O
infusions O
: O
a O
randomized O
controlled O
trial O
. O
[]

There O
were O
no O
significant O
differences O
in O
[]

Standard O
red O
cell O
serological O
techniques O
were O
used O
. O
[]

METHODS O
The O
women O
were O
randomised O
to O
either O
1000 O
micrograms O
of O
self-administered O
vaginal O
misoprostol O
or O
self-administered O
vaginal O
placebo O
the O
evening O
before O
outpatient O
resectoscopy O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
was O
measured O
serially O
. O
['Physiological-Clinical']

Effects O
of O
low O
and O
high O
doses O
of O
atorvastatin O
on O
arterial O
compliance O
. O
[]

In O
this O
study O
, O
150 O
patients O
with O
gallbladder O
lithiasis O
who O
underwent O
laparoscopy O
were O
randomly O
assigned O
to O
two O
groups O
, O
a O
blind O
( O
V O
group O
) O
or O
an O
open O
( O
H O
group O
) O
, O
in O
order O
to O
compare O
the O
results O
and O
the O
rate O
of O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

Primary O
efficacy O
criteria O
included O
the O
change O
after O
one O
year O
in O
the O
number O
of O
closed B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
segments I-outcome ['Physiological-Clinical']
and O
the O
occurrence O
of O
postthrombotic O
syndrome O
. O
['Physiological-Clinical']

Accordingly O
, O
the O
current O
study O
examined O
within-person O
covariation O
between O
time-varying O
abstinence O
and O
depressive B-outcome ['Life-Impact']
symptom I-outcome ['Life-Impact']
in O
a O
multilevel O
model O
( O
MLM O
) O
, O
which O
allowed O
for O
transitions O
between O
smoking O
statuses O
within O
a O
participant O
. O
['Life-Impact']

METHODS O
Three O
hundred O
twenty-nine O
patients O
were O
evaluated O
. O
[]

RESULTS O
When O
assessed O
on O
the O
basis O
of O
parent-rated O
ABC-CV O
ratings O
of O
irritability B-outcome ['Life-Impact']
and O
hyperactivity B-outcome ['Life-Impact']
, O
the O
mean O
placebo O
response O
rate O
was O
37 O
% O
versus O
amantadine O
at O
47 O
% O
( O
not O
significant O
) O
. O
['Life-Impact', 'Life-Impact']

OBJECTIVE O
To O
evaluate O
parenting O
stress O
following O
infants O
' O
cataract O
extraction O
surgery O
, O
and O
to O
determine O
if O
levels O
of O
stress O
differ O
between O
2 O
treatments O
for O
unilateral B-outcome ['Physiological-Clinical']
congenital I-outcome ['Physiological-Clinical']
cataract O
in O
a O
randomized O
clinical O
trial O
. O
['Physiological-Clinical']

Still O
, O
the O
muscle B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
ratio O
of O
the O
thigh B-outcome ['Physiological-Clinical']
was O
significantly O
lower O
compared O
with O
that O
of O
normal O
subjects O
( O
72.6/27.4 O
vs O
77.9/22.1 O
) O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Among O
participants O
who O
completed O
the O
study O
the O
rate O
of O
compliance O
was O
72 O
% O
. O
[]

About O
14/16 O
patients O
with O
encephalopathic O
syndrome O
of O
the O
coma O
type O
were O
infected O
with O
malaria O
. O
[]

METHODS O
This O
prospective O
study O
was O
performed O
in O
50 O
consecutive O
patients O
. O
[]

METHODS O
Airway O
immunopathology O
was O
investigated O
using O
induced O
sputum O
, O
bronchial O
biopsies O
, O
bronchial O
wash O
and O
bronchoalveolar O
lavage O
in O
12 O
patients O
with O
symptomatic O
eosinophilic O
asthma O
, O
11 O
patients O
with O
non-eosinophilic O
asthma O
and O
10 O
healthy O
controls O
. O
[]

Half O
of O
the O
participants O
complained O
about O
deficiencies O
concerning O
the O
ergonomic B-outcome ['Physiological-Clinical']
hardware I-outcome ['Physiological-Clinical']
design I-outcome ['Physiological-Clinical']
of O
the O
AR O
system O
. O
['Physiological-Clinical']

The O
volume O
in O
the O
pelvic B-outcome ['Physiological-Clinical']
drain I-outcome ['Physiological-Clinical']
20 O
min O
post-operatively O
and O
after O
48 O
hours O
failed O
to O
reach O
statistical O
significance O
between O
the O
two O
groups O
( O
P= O
0.10 O
and O
P= O
0.165 O
) O
. O
['Physiological-Clinical']

We O
applied O
hyperinsulinemic-euglycemic O
clamps O
with O
higher O
insulin O
dosing O
in O
obese O
subjects O
than O
lean O
subjects O
( O
30 O
vs. O
10 O
mU.m O
( O
-2 O
) O
.min O
( O
-1 O
) O
, O
respectively O
) O
, O
with O
the O
goal O
of O
matching O
insulin O
's O
nitric O
oxide O
( O
NO O
) O
-mediated O
vascular O
effects O
. O
[]

Title: O
The O
analgesic O
efficacy O
of O
oblique O
subcostal O
transversus O
abdominis O
plane O
block O
after O
laparoscopic O
hysterectomy: O
A O
randomized, O
controlled, O
observer-blinded O
study. O
[]

METHODS O
52 O
hips O
in O
52 O
patients O
( O
median O
age O
60 O
( O
51-64 O
) O
years O
, O
30 O
women O
) O
were O
randomized O
to O
either O
a O
MOM O
hip O
resurfacing O
system O
( O
ReCap O
) O
or O
a O
standard O
MOP O
total O
hip O
arthoplasty O
( O
Mallory O
Head/Exeter O
) O
. O
[]

1 O
. O
[]

Publication O
date: O
2019/01/12 O
06:00 O
[entrez] O
[]

No O
significant O
differences O
were O
found O
in O
the O
lipid B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
LDL I-outcome ['Physiological-Clinical']
from O
the O
two O
groups O
. O
['Physiological-Clinical']

Thirty-five O
healthy O
adults O
age O
35-69 O
years O
were O
enrolled O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
8 O
weeks O
' O
duration O
. O
[]

All O
participants O
will O
also O
have O
a O
structured O
2 O
hour O
home O
practice O
program O
for O
each O
week O
during O
the O
8 O
week O
intervention O
phase O
. O
[]

The O
antiFXa B-outcome ['Physiological-Clinical']
level O
in O
the O
plasma O
was O
correlated O
strongly O
with O
patient O
weight O
. O
['Physiological-Clinical']

Association O
of O
severity O
of O
coexisting O
patellofemoral O
disease O
with O
increased O
impairments O
and O
functional O
limitations O
in O
patients O
with O
knee O
osteoarthritis O
. O
[]

DESIGN: O
Double O
blind, O
parallel O
group, O
placebo O
controlled, O
multicentre O
trial. O
[]

No O
allergic B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
, O
increased O
respiratory B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Several O
indicators B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
oxidative I-outcome ['Physiological-Clinical']
stress O
, O
immunity B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

Irrespective O
of O
MIC O
and O
dose O
of O
mefloquine O
, O
parasitaemia O
cleared O
in O
all O
subjects O
in O
96 O
h O
or O
less O
. O
( O
[]

No O
dyskinesias B-outcome ['Physiological-Clinical']
, O
adverse B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
, O
or O
seizures B-outcome ['Physiological-Clinical']
occurred O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
efficacy O
of O
diethylpropion O
on O
a O
long-term O
basis O
, O
with O
emphasis O
in O
cardiovascular O
and O
psychiatric O
safety O
aspects O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS O
A O
total O
of O
136 O
patients O
presented O
severe B-outcome ['Adverse-effects']
AEs I-outcome ['Adverse-effects']
. O
['Adverse-effects']

They O
ranged O
in O
age O
from O
4 O
months O
to O
15 O
years O
. O
[]

With O
regard O
to O
age O
, O
sex O
, O
diagnosis O
and O
the O
site O
of O
te O
trepanation O
, O
control O
patients O
( O
n O
= O
355 O
) O
and O
cefotiam O
treated O
patients O
( O
n O
= O
356 O
) O
were O
shown O
to O
be O
comparable O
. O
[]

METHOD O
The O
two O
interventions O
were O
crossed O
in O
a O
2 O
? O
[]

Murine O
embryos O
grown O
in O
the O
presence O
of O
lipoprotein O
free O
SSS O
showed O
significantly O
accelerated O
( O
P O
< O
0.01 O
) O
growth O
at O
17 O
hr O
postthaw O
compared O
to O
Plasmatein O
and O
all O
embryos O
progressed O
to O
[]

We O
conclude O
that O
Grenz O
ray O
therapy O
is O
a O
useful O
treatment O
modality O
for O
scalp B-outcome ['Physiological-Clinical']
psoriasis I-outcome ['Physiological-Clinical']
, O
but O
that O
the O
addition O
of O
a O
topical O
corticosteroid O
has O
only O
a O
minor O
effect O
. O
['Physiological-Clinical']

We O
also O
observed O
a O
reduction O
in O
the O
percentage O
of O
patients O
who O
reported O
hard O
stools O
( O
hard B-outcome ['Physiological-Clinical']
scybalous I-outcome ['Physiological-Clinical']
or O
pebble-like B-outcome ['Physiological-Clinical']
stools I-outcome ['Physiological-Clinical']
) O
, O
although O
this O
reduction O
was O
significantly O
greater O
in O
the O
cocoa O
husk O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
compound O
may O
be O
beneficial O
in O
patients O
with O
vasospastic B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

60 O
% O
) O
were O
randomized O
to O
receive O
PR-STENT O
( O
N=9 O
) O
or O
to O
NO-STENT O
( O
N=9 O
) O
. O
[]

Neither O
treatment O
significantly O
influenced O
the O
agonist-induced B-outcome ['Physiological-Clinical']
accumulation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
lysoplasmenylethanolamine I-outcome ['Physiological-Clinical']
as O
derived O
via O
phospholipase O
A2 O
hydrolysis O
of O
plasmenylethanolamine O
. O
['Physiological-Clinical']

The O
most O
frequently O
cultured O
organisms O
were O
Escherichia O
coli O
( O
15 O
) O
, O
Klebsiella O
sp O
( O
9 O
) O
, O
Proteus O
sp O
( O
6 O
) O
, O
and O
Bacteroides O
sp O
( O
4 O
) O
. O
[]

A O
slight O
but O
nonsignificant O
increase O
occurred O
in O
fat B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
the O
milk O
of O
vaccinated O
cows O
. O
['Physiological-Clinical']

Further O
replication O
and O
long-term O
maintenance O
trials O
are O
needed O
. O
[]

CONCLUSIONS: O
A O
diet O
intervention O
that O
produced O
clinically O
relevant O
postpartum O
weight O
loss O
also O
resulted O
in O
increased O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
and O
was O
cost-effective. O
[['Life-Impact']]

INTERPRETATION O
AND O
CONCLUSIONS O
Increasing O
the O
dose O
of O
G-CSF O
does O
not O
appear O
to O
reduce O
early B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
does O
not O
improve O
peripheral B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
nor O
survival B-outcome ['Mortality']
, O
and O
may O
reduce O
the O
response O
rate O
in O
patients O
with O
SAA O
receiving O
ALG O
and O
CyA O
. O
['Mortality', 'Physiological-Clinical', 'Mortality']

After O
8 O
weeks O
of O
treatment O
, O
all O
active O
treatments O
were O
superior O
to O
placebo O
( O
effect O
sizes O
ranging O
from O
0.42 O
to O
0.65 O
) O
. O
[]

METHODS O
An O
assessment O
of O
CSP O
efficacy O
and O
safety O
was O
conducted O
in O
an O
international O
, O
multicentre O
, O
assessor-blinded O
study O
, O
which O
enrolled O
728 O
subjects O
with O
a O
history O
of O
recurrent O
HSL O
. O
[]

BACKGROUND O
The O
aim O
of O
the O
study O
was O
to O
investigate O
safety O
, O
efficacy O
and O
tolerability B-outcome ['Life-Impact']
of O
risperidone O
in O
comparison O
with O
haloperidol O
in O
the O
long-term O
treatment O
of O
autistic O
disorder O
. O
['Life-Impact']

Nelfinavir O
significantly O
increased O
amprenavir B-outcome ['Physiological-Clinical']
minimum I-outcome ['Physiological-Clinical']
drug I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
at O
steady O
state O
( O
by O
189 O
% O
) O
but O
did O
not O
affect O
amprenavir O
AUC O
( O
ss O
) O
or O
C O
( O
max O
, O
ss O
) O
. O
['Physiological-Clinical']

Safety O
and O
efficacy O
of O
sitaxsentan O
50 O
and O
100 O
mg O
in O
patients O
with O
pulmonary O
arterial O
hypertension O
. O
[]

One O
hundred O
and O
fifty-three O
patients O
( O
all O
of O
whom O
had O
stage O
III O
or O
IV O
unresectable O
disease O
with O
no O
distant O
metastases O
and O
who O
had O
received O
two O
cycles O
of O
taxol O
and O
cisplatin O
chemotherapy O
) O
were O
randomly O
assigned O
to O
receive O
either O
concurrent O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
in O
day O
1 O
and O
2 O
) O
and O
5-FU O
( O
750 O
mg/m O
( O
2 O
) O
in O
day O
1 O
, O
2 O
, O
and O
3 O
) O
from O
the O
first O
day O
of O
radiotherapy O
at O
an O
interval O
of O
3 O
weeks O
( O
Arm O
I O
) O
or O
cisplatin O
( O
75 O
mg/m O
( O
2 O
) O
in O
day O
1 O
and O
2 O
) O
and O
capecitabine O
( O
750 O
mg/m O
( O
2 O
) O
in O
two O
divided O
doses O
from O
day O
1-14 O
) O
from O
the O
first O
day O
of O
radiotherapy O
at O
a O
3-week O
interval O
( O
Arm O
II O
) O
. O
[]

The O
misattribution O
of O
salience O
in O
delusional O
patients O
with O
schizophrenia O
. O
[]

BACKGROUND O
We O
investigated O
the O
extent O
and O
frequency O
of O
dose O
errors O
and O
treatment O
delays O
made O
as O
a O
consequence O
of O
preparing O
drug O
infusions O
at O
the O
bedside O
, O
rather O
than O
using O
pre-filled O
syringes O
. O
[]

diltiazem O
in O
the O
management O
of O
atrial B-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Publication O
Type: O
Observational O
Study O
[]

The O
infants O
' O
rate O
of O
weight O
gain O
decreased O
on O
the O
first O
three O
days O
of O
diuretic O
treatment O
, O
but O
was O
thereafter O
comparable O
with O
weight O
gain O
during O
treatment O
with O
placebo O
. O
[]

Journal O
ID: O
101479826 O
[]

One O
patient O
in O
the O
amlodipine O
camsylate O
group O
dropped O
out O
of O
the O
study O
at O
week O
0 O
of O
treatment O
( O
this O
patient O
did O
not O
use O
any O
study O
medication O
) O
and O
was O
excluded O
from O
the O
modified O
intent-to-treat O
( O
ITT O
) O
analysis O
. O
[]

The O
effects O
of O
a O
10-week O
aerobic O
exercise O
and O
progressive O
relaxation O
training O
program O
on O
somatic O
, O
emotional O
, O
and O
behavioral O
responses O
to O
acute O
stress O
, O
as O
determined O
by O
quality O
of O
motor O
performance O
and O
affect O
, O
were O
examined O
. O
[]

The O
sites O
were O
randomly O
assigned O
to O
either O
the O
experimental O
group O
( O
implemented O
the O
intervention O
) O
or O
the O
control O
group O
( O
continued O
usual O
training O
) O
. O
[]

No O
significant O
differences O
were O
seen O
in O
the O
amount O
of O
lactobacilli B-outcome ['Physiological-Clinical']
or O
LGG B-outcome ['Physiological-Clinical']
, O
nor O
did O
gastrointestinal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
, O
defecation B-outcome ['Physiological-Clinical']
frequency O
, O
consistency O
of O
stools B-outcome ['Physiological-Clinical']
or O
ease B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
defecation I-outcome ['Physiological-Clinical']
differ O
between O
the O
two O
study O
periods O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Impact O
of O
angiotensin O
II O
receptor O
blocker O
therapy O
( O
olmesartan O
or O
valsartan O
) O
on O
coronary O
atherosclerotic O
plaque O
volume O
measured O
by O
intravascular O
ultrasound O
in O
patients O
with O
stable O
angina O
pectoris O
. O
[]

The O
extent O
of O
late O
skin B-outcome ['Physiological-Clinical']
reactions I-outcome ['Physiological-Clinical']
was O
slightly O
, O
but O
not O
significantly O
reduced O
. O
['Physiological-Clinical']

The O
relative O
efficacy O
of O
HAI O
FUDR O
, O
HAI O
5-FU/FA O
, O
and O
i.v O
. O
[]

RESULTS O
Meals O
with O
rye O
bran O
gave O
a O
lower O
postprandial B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
control O
meal O
, O
and O
this O
effect O
was O
more O
pronounced O
in O
women O
compared O
to O
men O
. O
['Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
ibuprofen O
and O
ibuprofen-arginate O
in O
PGE2 O
, O
or O
enzymes O
. O
[]

T O
lymphocyte O
subsets O
and O
NK O
cell O
cytotoxicity O
in O
chronic O
hemodialysis O
patients O
. O
[]

Our O
purpose O
was O
to O
evaluate O
the O
safety O
of O
marine O
lipid O
suppositories O
and O
ointment O
in O
healthy O
volunteers O
and O
to O
explore O
the O
laxative B-outcome ['Physiological-Clinical']
effect O
of O
the O
suppositories O
. O
['Physiological-Clinical']

A O
total O
of O
12 O
were O
intubated O
using O
the O
TAMS O
. O
[]

METHODS: O
In O
a O
crossover O
design O
with O
a O
1 O
wk. O
[]

AIM O
To O
evaluate O
neoton O
therapy O
effects O
in O
acute O
myocardial O
infarction O
( O
MI O
) O
on O
systolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricle I-outcome ['Physiological-Clinical']
, O
arrhythmia B-outcome ['Physiological-Clinical']
and O
clinical B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
in O
patients O
on O
thrombolytic O
therapy O
( O
TLT O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Thus O
, O
a O
combination O
product O
of O
buprenorphine O
and O
naloxone O
may O
have O
lower O
abuse B-outcome ['Physiological-Clinical']
liability I-outcome ['Physiological-Clinical']
than O
buprenorphine O
alone O
. O
['Physiological-Clinical']

Subjects O
accumulated O
1703 O
person O
years O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Those O
assigned O
to O
the O
intervention O
arm O
were O
given O
a O
choice O
of O
age-appropriate O
distracters O
during O
laceration O
repair O
. O
[]

The O
ETT O
with O
selective O
follow-up O
testing O
should O
be O
considered O
as O
the O
initial O
diagnostic O
strategy O
in O
symptomatic O
women O
with O
suspected O
CAD O
. O
[]

Also O
it O
was O
evaluated O
the O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
the O
range O
of O
motion B-outcome ['Life-Impact']
and O
weight O
test O
. O
['Life-Impact', 'Life-Impact']

Six O
patients O
died B-outcome ['Mortality']
of I-outcome ['Mortality']
infections I-outcome ['Mortality']
( O
A O
= O
four O
patients O
and O
C O
= O
two O
patients O
) O
. O
['Mortality']

During O
the O
two O
basal O
tilts O
, O
all O
the O
control O
subjects O
completed O
the O
study O
, O
whereas O
all O
the O
NMS O
patients O
developed O
syncope O
. O
[]

It O
was O
found O
that O
parasites O
play O
an O
important O
role O
in O
the O
multifactorial O
etiology O
of O
this O
condition O
and O
their O
eradication B-outcome ['Physiological-Clinical']
by O
deworming O
drugs O
gives O
better O
results O
than O
the O
traditional O
therapies O
. O
['Physiological-Clinical']

The O
introduction O
of O
artemisinin-based O
combination O
therapy O
in O
sub-Saharan O
Africa O
has O
prompted O
calls O
for O
increased O
use O
of O
parasitologic O
diagnosis O
for O
malaria O
. O
[]

A O
single-blind O
placebo O
baseline O
was O
followed O
by O
double-blind O
nizatidine O
CR O
( O
150 O
and O
300 O
mg O
) O
in O
randomized O
sequence O
, O
2 O
to O
5 O
days O
apart O
. O
[]

Sixty-one O
patients O
( O
mean O
age O
, O
41 O
years O
) O
with O
nonspecific O
low O
back O
pain O
were O
randomized O
into O
two O
subgroups O
by O
treatment O
. O
[]

OBJECTIVE O
To O
optimize O
therapy O
of O
acupuncture O
and O
moxibustion O
for O
postsurgical O
gastroparesis O
syndrome O
( O
PGS O
) O
. O
[]

Both O
PVP O
and O
NaCl O
improved O
the O
comfort O
of O
contact B-outcome ['Life-Impact']
lens I-outcome ['Life-Impact']
wear I-outcome ['Life-Impact']
( O
P O
= O
0.0003 O
) O
, O
with O
no O
difference O
between O
them O
( O
P O
= O
0.25 O
) O
. O
['Life-Impact']

No O
additional O
differences O
were O
found O
between O
treatments O
in O
the O
physiological O
responses O
and O
heat O
balance O
parameters O
at O
the O
end O
of O
exposure O
: O
heart O
rate O
( O
HR O
) O
was O
( O
mean O
+/- O
S.D O
. O
) O
[]

At O
baseline O
, O
the O
mean O
density O
of O
the O
proteoglycans B-outcome ['Physiological-Clinical']
( O
PGS B-outcome ['Physiological-Clinical']
) O
biglycan B-outcome ['Physiological-Clinical']
and O
decorin B-outcome ['Physiological-Clinical']
were O
, O
respectively O
, O
higher O
and O
lower O
in O
the O
bronchial O
mucosa O
of O
asthmatics O
as O
compared O
with O
normal O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
assess O
whether O
action O
observation O
treatment O
( O
AOT O
) O
may O
also O
improve O
motor O
recovery O
in O
postsurgical O
orthopedic O
patients O
, O
in O
addition O
to O
conventional O
physiotherapy O
. O
[]

Materials O
and O
Methods: O
In O
this O
prospective O
study, O
80 O
patients O
that O
underwent O
radical O
resection O
for O
colorectal O
cancer O
were O
randomly O
divided O
into O
four O
groups: O
(1) O
the O
parecoxib O
group, O
with O
preintravenous O
injection O
of O
parecoxib O
and O
postoperative O
PCIA O
after O
surgery; O
(2) O
the O
TAP O
group, O
with O
TAP O
block O
and O
postoperative O
PCIA; O
(3) O
the O
parecoxib O
+ O
TAP O
group, O
with O
parecoxib O
combined O
with O
TAP O
block O
and O
postoperative O
PCIA; O
and O
(4) O
the O
control O
group, O
with O
only O
postoperative O
PCIA O
and O
preinjection O
of O
normal O
saline. O
[]

Krill-derived O
protein O
hydrolysates/peptides O
may O
have O
positive O
effect O
on O
blood O
pressure O
and O
astaxanthin O
has O
anti-oxidative O
and O
anti-inflammatory O
properties. O
[]

A O
randomized O
controlled O
trial. O
[]

The O
studyPeden O
CJ, O
Stephens O
T, O
Martin O
G O
et O
al. O
[]

Publication O
Type: O
Journal O
Article O
[]

The O
addition O
of O
tazarotene O
affords O
sustained O
benefits O
posttreatment. O
[]

RESULTS O
Relapses B-outcome ['Physiological-Clinical']
occurred O
in O
21 O
( O
43 O
% O
) O
of O
49 O
patients O
, O
predominantly O
in O
the O
CNS O
( O
71 O
% O
) O
and O
bone O
marrow O
( O
52 O
% O
) O
. O
['Physiological-Clinical']

If O
adjuvant O
treatment O
seems O
to O
delay B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
it O
did O
not O
significantly O
decrease O
the O
recurrence B-outcome ['Physiological-Clinical']
rate O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Combination O
of O
arteriovenous O
extracorporeal O
lung O
assist O
and O
high-frequency O
oscillatory O
ventilation O
in O
a O
porcine O
model O
of O
lavage-induced O
acute O
lung O
injury O
: O
a O
randomized O
controlled O
trial O
. O
[]

Why O
are O
there O
sometimes O
concreteness B-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
memory I-outcome ['Life-Impact']
for O
prose O
? O
['Life-Impact']

Circulating O
concentrations O
of O
carotenoids B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical']

Treatment O
reduced O
BP B-outcome ['Physiological-Clinical']
to O
a O
similar B-outcome ['Physiological-Clinical']
extent I-outcome ['Physiological-Clinical']
in O
both O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
Study O
1 O
, O
27 O
healthy O
, O
Thai O
adults O
received O
a O
40 O
IU O
kg O
( O
-1 O
) O
dose O
of O
either O
Erig O
PMC O
( O
n O
= O
12 O
) O
or O
PHT-Erig O
( O
n O
= O
15 O
) O
via O
the O
intramuscular O
( O
i.m O
. O
) O
[]

RESULTS O
We O
undertook O
a O
short-term O
, O
placebo-controlled O
study O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
risperidone O
in O
children O
and O
adolescents O
with O
autistic O
disorder O
. O
[]

Thus O
, O
compared O
with O
tPA O
, O
primary O
PTCA O
in O
patients O
with O
anterior O
wall O
AMI O
results O
in O
significantly O
improved O
survival B-outcome ['Mortality']
, O
with O
lower O
rates O
of O
stroke B-outcome ['Physiological-Clinical']
, O
reinfarction B-outcome ['Physiological-Clinical']
, O
and O
recurrent B-outcome ['Physiological-Clinical']
myocardial I-outcome ['Physiological-Clinical']
ischemia I-outcome ['Physiological-Clinical']
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
Evaluate O
the O
impact O
of O
an O
intensive O
insulin O
therapy O
and O
conventional O
glucose O
control O
protocol O
during O
staying O
in O
neurological O
intensive O
care O
unit O
( O
NICU O
) O
on O
infection B-outcome ['Physiological-Clinical']
rate O
, O
days B-outcome ['Resource-use']
in I-outcome ['Resource-use']
NICU I-outcome ['Resource-use']
, O
in-hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
and O
long-term B-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
in O
severe O
traumatic O
brain O
injury O
( O
TBI O
) O
patients O
. O
['Physiological-Clinical', 'Resource-use', 'Mortality', 'Physiological-Clinical']

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
normalized O
in O
the O
combination O
group O
in O
67 O
% O
of O
patients O
, O
a O
significantly O
higher O
proportion O
than O
either O
trandolapril O
( O
63 O
% O
) O
or O
HCTZ O
( O
60 O
% O
; O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical']

CONCLUSIONS O
Combination O
of O
risperidone O
and O
celecoxib O
was O
superior O
to O
risperidone O
alone O
in O
treating O
irritability O
, O
social O
withdrawal O
, O
and O
stereotypy O
of O
children O
with O
autism O
. O
( O
[]

For O
needle O
placement O
into O
the O
incisive O
canal O
, O
54 O
% O
of O
the O
subjects O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
lidocaine O
solution O
and O
58 O
% O
reported O
moderate/severe B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
with O
the O
mepivacaine O
solution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
randomized O
, O
double-blind O
, O
placebo-controlled O
crossover O
study O
of O
Cappra? O
for O
the O
treatment O
of O
mild O
or O
mild O
to O
moderate O
erectile O
dysfunction O
in O
Thai O
male O
. O
[]

Low O
initial B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
and O
young O
patient O
age O
independently O
predicted O
increased O
blood B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
during O
bicarbonate B-outcome ['Physiological-Clinical']
APD I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
All-cause O
mortality O
of O
women O
related O
to O
pregnancy O
, O
stillbirth O
, O
and O
infant O
mortality O
to O
12 O
weeks O
( O
84 O
days O
) O
following O
pregnancy O
outcome O
. O
[]

Results O
of O
these O
studies O
indicated O
that O
selamectin O
was O
highly O
effective O
in O
the O
control O
of O
flea O
infestations O
in O
dogs O
and O
cats O
without O
the O
need O
for O
simultaneous O
treatment O
of O
the O
environment O
or O
of O
in-contact O
animals O
and O
also O
was O
beneficial O
in O
alleviating O
signs O
associated O
with O
FAD O
. O
[]

Clozapine O
was O
more O
effective O
than O
usual O
care O
on O
many O
but O
not O
all O
measures O
. O
[]

Recombinant O
human O
granulocyte O
colony-stimulating O
factor O
( O
rhG-CSF O
) O
is O
effective O
in O
countering O
chemotherapy-induced O
neutropenia O
. O
[]

This O
indicated O
the O
beneficial O
effect O
on O
ulcers O
of O
oral O
administration O
of O
EGF O
with O
agents O
allowing O
it O
to O
remain O
at O
high O
levels O
in O
the O
stomach O
, O
whereas O
most O
reports O
suggested O
less O
effect O
of O
oral O
EGF O
on O
healing O
of O
gastroduodenal O
ulcers O
. O
[]

None O
of O
the O
intervention-arms O
was O
cost-effective O
for O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
. O
There O
was O
85% O
probability O
of O
exercise-arm O
being O
cost-effective O
if O
willing O
to O
pay O
euro3550 O
for O
QALY O
gained. O
[['Life-Impact']]

OBJECTIVE O
To O
directly O
examine O
whether O
oxytocin O
has O
beneficial O
effects O
on O
the O
sociocommunicational O
deficits O
of O
ASD O
using O
both O
behavioral O
and O
neural O
measures O
. O
[]

Overall O
, O
these O
findings O
indicate O
that O
there O
are O
no O
apparent O
advantages O
in O
toxicity B-outcome ['Adverse-effects']
and O
efficacy O
by O
giving O
CDA O
weekly O
rather O
than O
daily O
. O
['Adverse-effects']

Our O
aim O
with O
this O
pilot O
study O
was O
to O
evaluate O
if O
fiber O
supplementation O
is O
beneficial O
for O
the O
treatment O
of O
children O
with O
idiopathic B-outcome ['Physiological-Clinical']
chronic I-outcome ['Physiological-Clinical']
constipation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Endotracheal O
cuff O
pressure O
and O
tracheal O
mucosal O
blood O
flow O
: O
endoscopic O
study O
of O
effects O
of O
four O
large O
volume O
cuffs O
. O
[]

Patients O
started O
taking O
aspirin O
( O
at O
a O
dose O
of O
200 O
mg O
) O
or O
placebo O
just O
before O
surgery O
and O
continued O
it O
daily O
( O
at O
a O
dose O
of O
100 O
mg O
) O
for O
30 O
days O
in O
the O
initiation O
stratum O
and O
for O
7 O
days O
in O
the O
continuation O
stratum O
, O
after O
which O
patients O
resumed O
their O
regular O
aspirin O
regimen O
. O
[]

Comparison O
of O
different O
approaches O
for O
assessment O
of O
HER2 O
expression O
on O
protein O
and O
mRNA O
level O
: O
prediction O
of O
chemotherapy O
response O
in O
the O
neoadjuvant O
GeparTrio O
trial O
( O
NCT00544765 O
) O
. O
[]

Twenty O
subjects O
with O
chronic O
CRPS1 O
initiated O
by O
wrist O
fracture O
and O
who O
satisfied O
stringent O
inclusion O
criteria O
, O
were O
randomly O
allocated O
to O
one O
of O
three O
groups O
: O
hand O
laterality O
recognition O
, O
imagined O
movements O
, O
mirror O
movements O
( O
RecImMir O
, O
MIP O
) O
; O
imagined O
movements O
, O
recognition O
, O
imagined O
movements O
( O
ImRecIm O
) O
; O
recognition O
, O
mirror O
movements O
, O
recognition O
( O
RecMirRec O
) O
. O
[]

Dietary O
intake O
was O
correlated O
with O
descriptors O
of O
stool O
consistency O
using O
cumulative O
logistic O
regression O
methods O
. O
[]

Naltrexone O
in O
autistic O
children O
: O
a O
double-blind O
and O
placebo-controlled O
study O
. O
[]

To O
evaluates O
the O
eye-lens O
radiation O
exposure O
of O
workers O
during O
medical O
interventional O
procedures O
and O
surgery O
in O
a O
military O
hospital O
as O
well O
as O
of O
the O
equine O
veterinarians. O
[]

AIM O
During O
the O
last O
decade O
laparoscopic O
techniques O
have O
been O
applied O
to O
the O
treatment O
of O
inguinal B-outcome ['Physiological-Clinical']
hernia I-outcome ['Physiological-Clinical']
to O
combine O
tension-free O
technique O
, O
esthetic O
, O
and O
functional O
benefits O
of O
mini-invasive O
surgery O
. O
['Physiological-Clinical']

In O
the O
other O
10 O
patients O
the O
second O
flow O
measurement O
was O
performed O
before O
the O
administration O
of O
flumazenil O
. O
[]

Shear B-outcome ['Physiological-Clinical']
bond I-outcome ['Physiological-Clinical']
and O
microtensile B-outcome ['Physiological-Clinical']
bond I-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
data I-outcome ['Physiological-Clinical']
were O
analyzed O
using O
two-way O
ANOVA O
and O
Tukey O
's O
post-hoc O
test O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND: O
Treatment O
of O
Plasmodium O
vivax O
malaria O
requires O
the O
clearing O
of O
asexual O
parasites, O
but O
relapse O
can O
be O
prevented O
only O
if O
dormant O
hypnozoites O
are O
cleared O
from O
the O
liver O
(a O
treatment O
termed O
"radical O
cure"). O
[]

Patients O
with O
glutamine O
substitution O
showed O
decreased O
systemic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
significant O
faster O
compensation O
for O
postoperative B-outcome ['Physiological-Clinical']
immunosuppression I-outcome ['Physiological-Clinical']
and O
a O
lower O
incidence O
of O
postoperative B-outcome ['Adverse-effects']
complications I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

A O
selection O
of O
resistant B-outcome ['Physiological-Clinical']
enterobacteria I-outcome ['Physiological-Clinical']
and O
an O
increase O
in O
beta-lactamase B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
was O
observed O
in O
the O
faecal O
samples O
during O
the O
omeprazole O
plus O
amoxycillin O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
change O
from O
baseline O
in O
SiDBP B-outcome ['Physiological-Clinical']
at O
week O
8 O
. O
['Physiological-Clinical']

Angioplasty O
was O
successful O
in O
95 O
% O
of O
patients O
, O
with O
no O
difference O
in O
placebo O
( O
93 O
% O
) O
and O
streptokinase O
( O
98 O
% O
) O
groups O
. O
[]

A O
multi-component O
social O
skills O
intervention O
for O
children O
with O
Asperger O
syndrome O
: O
the O
Junior O
Detective O
Training O
Program O
. O
[]

Secondary O
outcome O
measures O
included O
the O
American O
Shoulder O
and O
Elbow O
Surgeons O
( O
ASES O
) O
shoulder O
assessment O
form O
and O
a O
count O
of O
revisions B-outcome ['Life-Impact']
required O
in O
each O
group O
. O
['Life-Impact']

CONCLUSIONS O
An O
adaptive O
low-pass O
filtered O
speech O
test O
such O
as O
the O
UCAST-FW O
is O
sensitive O
to O
maturational B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
auditory I-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
ability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
conclusion O
, O
this O
study O
shows O
that O
a O
2-dimensional O
, O
handheld O
ultrasound O
device O
and O
a O
newly O
developed O
ultrasound O
volume O
scanner O
can O
effectively O
identify O
patients O
with O
AAAs O
confirmed O
by O
CT O
. O
[]

However, O
the O
benefit O
of O
thromboprophylaxis O
in O
these O
patients O
is O
uncertain. O
[]

METHODS O
Sixty O
patients O
were O
randomised O
to O
receive O
two O
single O
doses O
of O
cediranib O
in O
either O
fed/fasted O
or O
fasted/fed O
state O
( O
Part O
A O
) O
. O
[]

0.05 O
) O
. O
[]

Symptom B-outcome ['Physiological-Clinical']
scores I-outcome ['Physiological-Clinical']
and O
spirometry B-outcome ['Resource-use']
did O
not O
differ O
between O
the O
crossover O
trials O
, O
and O
overall O
clinical O
status O
was O
not O
altered O
. O
['Physiological-Clinical', 'Resource-use']

Journal O
ID: O
101234168 O
[]

After O
delivering O
IVR O
messages O
targeting O
these O
reported O
barriers O
, O
32 O
% O
of O
the O
smokers O
reporting O
low O
self-efficacy B-outcome ['Life-Impact']
and O
4.8 O
% O
of O
those O
reporting O
lack O
of O
interest O
in O
quitting O
re-engaged O
in O
a O
new O
QL O
treatment O
cycle O
. O
['Life-Impact']

Nebulized O
racemic O
epinephrine O
by O
IPPB O
for O
the O
treatment O
of O
croup O
: O
a O
double-blind O
study O
. O
[]

The O
pathogenesis O
of O
stress O
ulcers O
is O
still O
far O
from O
being O
understood O
. O
[]

METHOD O
All O
general O
practitioners O
from O
the O
four O
practices O
in O
Ebeltoft O
and O
a O
random O
sample O
of O
2000 O
people O
aged O
between O
30 O
and O
50 O
years O
were O
invited O
to O
participate O
. O
[]

This O
clinical O
trial O
was O
conducted O
to O
determine O
if O
repeated O
intravenous O
paracetamol O
could O
decrease O
postoperative O
pain O
and O
rescue O
analgesic O
requirements O
after O
robot-assisted O
endoscopic O
thyroidectomy O
via O
the O
transaxillary O
approach O
. O
[]

Clear O
recommendations O
regarding O
the O
dosage O
should O
be O
established. O
[]

Desmopressin O
in O
the O
treatment O
of O
nocturia O
: O
a O
double-blind O
, O
placebo-controlled O
study O
. O
[]

The O
participants O
in O
the O
intervention O
group O
met O
every O
6 O
months O
during O
the O
5-year O
study O
for O
clinical O
examination O
and O
for O
dietary O
and O
smoking B-outcome ['Resource-use']
counselling I-outcome ['Resource-use']
. O
['Resource-use']

Title: O
Performance O
of O
Litholyme O
compared O
with O
Sodasorb O
carbon O
dioxide O
absorbents O
in O
a O
standard O
clinical O
setting. O
[]

Side O
effects O
are O
the O
main O
reason O
for O
drug O
discontinuation O
, O
occurring O
more O
often O
with O
venlafaxine O
. O
[]

In O
both O
arms O
combined O
, O
declines O
from O
baseline O
to O
3 O
months O
were O
observed O
in O
sexual B-outcome ['Life-Impact']
risk O
behaviors B-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
were O
no O
significant O
differences O
between O
treatment O
conditions O
on O
the O
Purdue O
Pegboard O
( O
hand-eye B-outcome ['Life-Impact']
coordination I-outcome ['Life-Impact']
) O
task O
or O
the O
Analog O
Classroom O
Task O
( O
timed B-outcome ['Life-Impact']
math I-outcome ['Life-Impact']
test O
) O
. O
['Life-Impact', 'Life-Impact']

RESULTS O
At O
day O
28 O
, O
in O
the O
group O
of O
subjects O
who O
received O
150 O
mg O
of O
VX-770 O
, O
the O
median O
change O
in O
the O
nasal B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
difference I-outcome ['Physiological-Clinical']
( O
in O
response O
to O
the O
administration O
of O
a O
chloride-free O
isoproterenol O
solution O
) O
from O
baseline O
was O
-3.5 O
mV O
( O
range O
, O
-8.3 O
to O
0.5 O
; O
P=0.02 O
for O
the O
within-subject O
comparison O
, O
P=0.13 O
vs. O
placebo O
) O
, O
and O
the O
median O
change O
in O
the O
level O
of O
sweat B-outcome ['Physiological-Clinical']
chloride I-outcome ['Physiological-Clinical']
was O
-59.5 O
mmol O
per O
liter O
( O
range O
, O
-66.0 O
to O
-19.0 O
; O
P=0.008 O
within-subject O
, O
P=0.02 O
vs. O
placebo O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Ten O
males O
and O
nine O
females O
( O
age O
range O
20-33 O
years O
) O
were O
studied O
in O
a O
double-blind O
, O
randomized O
, O
cross-over O
trial O
. O
[]

Interventions: O
Participants O
were O
randomized O
to O
a O
systolic O
blood O
pressure O
goal O
of O
either O
less O
than O
120 O
mm O
Hg O
(intensive O
treatment O
group; O
n O
= O
4678) O
or O
less O
than O
140 O
mm O
Hg O
(standard O
treatment O
group; O
n O
= O
4683). O
[]

Outcome O
measures O
included O
improvements O
in O
severity O
and O
behavioral O
features O
of O
autistic B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( O
stereotypies B-outcome ['Life-Impact']
, O
lethargy B-outcome ['Life-Impact']
, O
irritability B-outcome ['Life-Impact']
, O
hyperactivity B-outcome ['Life-Impact']
, O
emotional B-outcome ['Life-Impact']
reciprocity I-outcome ['Life-Impact']
, O
sharing B-outcome ['Life-Impact']
pleasures I-outcome ['Life-Impact']
) O
and O
improvements O
in O
language B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
, O
socialization B-outcome ['Life-Impact']
, O
and I-outcome ['Life-Impact']
daily B-outcome ['Life-Impact']
living I-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
noted O
after O
12 O
weeks O
( O
the O
end O
of O
a O
4-week O
maintenance O
phase O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

For O
example O
, O
subjects O
may O
be O
uncommunicative O
and O
extremely O
heterogeneous O
in O
problem O
presentation O
, O
and O
current O
pharmacological O
treatments O
are O
not O
likely O
to O
alter O
most O
core O
features O
of O
autism O
. O
[]

RESULTS O
The O
median O
time B-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
ED I-outcome ['Life-Impact']
discharge O
to O
follow-up O
was O
26 O
hours O
( O
interquartile O
range O
[ O
IQR O
] O
= O
24 O
to O
39 O
hours O
) O
. O
['Life-Impact']

Patients O
and O
their O
partners O
completed O
a O
questionnaire O
regarding O
functional O
disability O
. O
[]

This O
clinical O
trial O
aimed O
to O
determine O
whether O
a O
structured O
multidisciplinary, O
multisite O
intervention O
resulted O
in O
improved O
clinical O
outcomes O
compared O
with O
standard O
care. O
[]

A O
significant O
decrease O
in O
the O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
frequency I-outcome ['Physiological-Clinical']
( O
P O
< O
0.05 O
) O
at O
the O
end O
of O
the O
post-stimulation O
period O
was O
also O
demonstrated O
. O
['Physiological-Clinical']

Following O
a O
12 O
hour O
fast O
, O
heart O
rate O
, O
arterial O
blood O
pressure O
, O
light O
reflex O
plethysmography O
of O
the O
finger O
, O
resting O
blood O
flow O
volume O
in O
the O
lower O
arm O
and O
leg O
and O
peripheral B-outcome ['Physiological-Clinical']
vascular I-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
were O
measured O
at O
10 O
min O
. O
['Physiological-Clinical']

The O
first B-outcome ['Life-Impact']
out-of-bed I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
first B-outcome ['Physiological-Clinical']
anus I-outcome ['Physiological-Clinical']
exhaust I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
, O
and O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
time I-outcome ['Resource-use']
of O
the O
parecoxib O
+ O
TAP O
group O
were O
significantly O
shorter O
than O
those O
of O
the O
other O
groups, O
while O
the O
control O
group O
was O
all O
significantly O
higher O
than O
the O
other O
groups. O
[['Life-Impact'], ['Physiological-Clinical'], ['Resource-use']]

OBJECTIVE O
It O
has O
been O
proposed O
that O
a O
deficit O
of O
adenosinergic O
activity O
could O
contribute O
to O
the O
pathophysiology O
of O
schizophrenia O
. O
[]

A O
pilot O
study O
of O
extended O
duration O
peginterferon O
alfa-2a O
for O
patients O
with O
hepatitis O
B O
e O
antigen-negative O
chronic O
hepatitis O
B O
. O
[]

RESULTS O
All O
subjects O
completed O
the O
trial O
. O
[]

Hysteroscopic O
morcellation O
compared O
with O
electrical O
resection O
of O
endometrial O
polyps O
: O
a O
randomized O
controlled O
trial O
. O
[]

AMP O
and O
CB O
are O
equivalent O
for O
the O
treatment O
of O
bacterial O
meningitis O
due O
to O
susceptible O
organisms O
. O
[]

A O
placebo O
controlled O
crossover O
trial O
of O
liquid O
fluoxetine O
on O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
in O
childhood O
and O
adolescent O
autism O
. O
['Life-Impact']

A O
standard O
CBT O
program O
was O
augmented O
with O
multiple O
treatment O
components O
designed O
to O
accommodate O
or O
remediate O
the O
social O
and O
adaptive O
skill O
deficits O
of O
children O
with O
ASD O
that O
could O
pose O
barriers O
to O
anxiety B-outcome ['Life-Impact']
reduction I-outcome ['Life-Impact']
. O
['Life-Impact']

Beneficial O
effects O
of O
albumin O
therapy O
was O
apparent O
only O
in O
those O
infants O
with O
low O
RABC O
as O
determined O
by O
the O
sephadex O
gel O
filtration O
technique O
. O
[]

Risperidone O
also O
improved O
social B-outcome ['Life-Impact']
responsiveness I-outcome ['Life-Impact']
and O
nonverbal B-outcome ['Life-Impact']
communication I-outcome ['Life-Impact']
and O
reduced O
the O
symptoms B-outcome ['Physiological-Clinical']
of O
hyperactivity B-outcome ['Life-Impact']
and O
aggression B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

For O
this O
purpose O
, O
a O
placebo-controlled O
, O
double-blind O
, O
three-time O
cross-over O
study O
using O
17beta-estradiol O
combined O
with O
norethisterone O
acetate O
for O
replacement O
therapy O
and O
as O
an O
adjunct O
to O
a O
naturalistic O
maintenance O
antipsychotic O
treatment O
was O
carried O
out O
over O
a O
period O
of O
8 O
months O
. O
[]

Peripheral B-outcome ['Physiological-Clinical']
muscle B-outcome ['Physiological-Clinical']
strength I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
dynamometry O
and O
spirometry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
assessed O
whether O
daclizumab O
high-yield O
process O
( O
HYP O
) O
would O
be O
effective O
when O
given O
as O
monotherapy O
for O
a O
1 O
year O
treatment O
period O
in O
patients O
with O
relapsing-remitting O
multiple O
sclerosis O
. O
[]

Left O
ventricular O
performance O
was O
assessed O
by O
radionuclide O
ventriculography O
at O
baseline O
and O
within O
60 O
minutes O
after O
the O
fourth O
infusion O
. O
[]

Serum O
samples O
were O
obtained O
at O
Baseline O
and O
Week-8 O
( O
N O
= O
78 O
) O
, O
and O
at O
6-month O
( O
N O
= O
43 O
) O
and O
22-month O
( O
N O
= O
30 O
) O
follow-up O
. O
[]

Most O
AEs O
were O
mild O
to O
moderate O
and O
failed O
to O
interfere O
with O
therapeutic O
changes O
; O
there O
were O
no O
unanticipated O
AEs O
. O
[]

Adverse O
effects O
within O
2 O
weeks O
after O
TAI O
were O
evaluated O
by O
subjective O
signs O
and O
symptoms O
such O
as O
fever B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
maximum I-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
temperature I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
the O
frequency O
of O
shaking B-outcome ['Physiological-Clinical']
chills I-outcome ['Physiological-Clinical']
and O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
and O
by O
biochemical O
parameters O
such O
as O
albumin O
, O
prothrombin O
time O
, O
and O
aspartate O
and O
alanine O
aminotransferases O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
response O
rate O
for O
the O
HAC O
group O
was O
31 O
% O
and O
for O
the O
melphalan-platinum O
group O
was O
37.8 O
% O
. O
[]

Safety O
assessment O
of O
docosahexaenoic O
acid O
in O
X-linked O
retinitis O
pigmentosa O
: O
the O
4-year O
DHAX O
trial O
. O
[]

RESULTS O
In O
stratum O
1 O
( O
n O
= O
206 O
) O
, O
the O
PFS B-outcome ['Mortality']
HR O
( O
gefitinib O
: O
placebo O
) O
was O
0.84 O
( O
95 O
% O
CI O
, O
0.59-1.18 O
; O
median O
PFS B-outcome ['Mortality']
10.9 O
versus O
8.8 O
months O
) O
. O
['Mortality', 'Mortality']

CONCLUSIONS O
Intravitreous O
fomivirsen O
is O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
with O
an O
acceptable O
safety O
profile O
. O
['Life-Impact']

Grade O
III B-outcome ['Physiological-Clinical']
or O
IV B-outcome ['Physiological-Clinical']
hemorrhoids I-outcome ['Physiological-Clinical']
were O
more O
common O
in O
men O
( O
ie O
, O
80.9 O
% O
and O
85.7 O
% O
in O
the O
stapled O
and O
open O
group O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Camazepam B-outcome ['Resource-use']
shows O
modification O
, O
with O
the O
same O
trend O
, O
but O
not O
reaching O
statistical O
significance O
. O
['Resource-use']

Patients O
in O
both O
groups O
were O
well-matched O
with O
baseline O
disease O
characteristics O
. O
[]

Twenty-four O
living O
liver O
donors O
( O
n O
= O
12 O
for O
each O
group O
) O
were O
randomized O
to O
undergo O
hepatic O
transection O
using O
CUSA O
with O
BP O
or O
CUSA O
with O
TL O
. O
[]

SETTING O
Outpatient O
with O
sleep O
laboratory O
assessments O
in O
months O
1 O
and O
8 O
of O
treatment O
. O
[]

Phase O
II O
study O
of O
the O
effects O
of O
ginger O
root O
extract O
on O
eicosanoids O
in O
colon O
mucosa O
in O
people O
at O
normal O
risk O
for O
colorectal O
cancer O
. O
[]

Anesthesia O
was O
standardized O
( O
laryngeal O
mask O
airway O
, O
fentanyl O
, O
propofol O
, O
sevoflurane O
, O
nitrous O
oxide O
, O
and O
oxygen O
) O
. O
[]

The O
incidence O
of O
new O
opacity B-outcome ['Physiological-Clinical']
on O
chest O
radiography O
in O
the O
48 O
hours O
after O
tracheal O
intubation O
was O
16.4% O
and O
14.8%, O
respectively O
(P O
= O
0.73). O
[['Physiological-Clinical']]

Children O
in O
the O
riluzole O
group O
experienced O
significantly O
more O
increases O
in O
their O
appetite O
and O
bodyweight O
than O
children O
in O
the O
placebo O
group O
by O
the O
end O
of O
the O
study O
. O
[]

Survival O
and O
resource O
utilisation O
data O
were O
collected O
for O
6 O
months O
; O
survival O
was O
extrapolated O
assuming O
a O
mean O
additional O
lifetime O
of O
3 O
years O
based O
on O
data O
from O
the O
Cooperative O
North O
Scandinavian O
Enalapril O
Survival O
Study O
trial O
. O
[]

The O
disease B-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
rate O
of O
the O
apatinib O
group O
was O
significantly O
better O
than O
that O
of O
the O
observation O
group O
(70.4% O
vs O
26.9%, O
P O
= O
.002). O
[['Physiological-Clinical']]

Spinal B-outcome ['Physiological-Clinical']
cord I-outcome ['Physiological-Clinical']
excitability I-outcome ['Physiological-Clinical']
was O
investigated O
by O
distal O
latencies O
and O
M-amplitudes B-outcome ['Physiological-Clinical']
of O
the O
abductor O
digiti O
minimi O
muscle O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
investigated O
SPC O
and O
the O
status O
of O
MSI O
and O
Epstein-Barr O
virus O
(EBV) O
as O
combinatory O
biomarkers O
to O
predict O
the O
prognosis O
and O
responsiveness O
of O
adjuvant O
chemotherapy O
for O
stage O
II/III O
gastric O
cancer. O
[]

TMN B-outcome ['Physiological-Clinical']
staging O
at O
baseline O
was O
: O
T4N2 O
, O
11 O
% O
; O
T3N2 O
, O
40 O
% O
; O
T2N2 O
, O
3 O
% O
; O
T3N1 O
, O
35 O
% O
; O
T2N1 O
, O
3 O
% O
and O
T3N0 O
8 O
% O
. O
['Physiological-Clinical']

CONCLUSIONS O
There O
is O
an O
advantage O
to O
administering O
xylitol O
and O
fructose O
with O
regard O
to O
the O
intestinal B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
and O
concomitant O
symptoms O
as O
compared O
with O
sorbitol O
. O
['Physiological-Clinical']

The O
percentage O
mean O
treatment O
difference O
between O
Abalon O
and O
placebo O
demonstrated O
significantly O
lower O
mean O
values O
after O
Abalon O
for O
LDL B-outcome ['Physiological-Clinical']
cholesterol B-outcome ['Physiological-Clinical']
( O
10 O
+/- O
15 O
% O
, O
P O
< O
0.05 O
) O
, O
LDL/UHDL B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
( O
12 O
+/- O
18 O
% O
, O
P O
< O
0.05 O
) O
, O
apolipoprotein B-outcome ['Physiological-Clinical']
( O
apo O
) O
B100 O
( O
30 O
+/- O
38 O
% O
, O
P O
< O
0.01 O
) O
, O
triglycerides B-outcome ['Physiological-Clinical']
( O
22 O
+/- O
10 O
% O
, O
P O
< O
0.05 O
) O
, O
and O
homocysteine B-outcome ['Physiological-Clinical']
( O
14 O
+/- O
21 O
% O
, O
P O
< O
0.01 O
) O
, O
whereas O
the O
total O
cholesterol B-outcome ['Physiological-Clinical']
value O
tended O
to O
be O
less O
significant O
but O
still O
lower O
( O
8 O
+/- O
15 O
% O
, O
P O
< O
0.08 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

This O
study O
shows O
that O
combining O
a O
single O
infusion O
of O
low O
dose O
ketamine O
with O
regular O
opioid O
analgesia O
can O
result O
in O
a O
significant O
improvement O
in O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
for O
this O
patient O
group O
. O
['Physiological-Clinical']

It O
is O
concluded O
that O
nitrous O
oxide O
does O
not O
contribute O
to O
the O
occurrence O
of O
nausea B-outcome ['Physiological-Clinical']
or O
vomiting B-outcome ['Physiological-Clinical']
after O
isoflurane O
anesthesia O
for O
gynecologic O
laparotomies O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
results O
show O
the O
potential O
merits O
of O
unconscious O
processing O
in O
diagnostic B-outcome ['Life-Impact']
decision I-outcome ['Life-Impact']
making I-outcome ['Life-Impact']
. O
['Life-Impact']

A O
greater O
number O
of O
patients O
showed O
[]

Dimensions O
of O
the O
bruising O
on O
the O
heparin O
applied O
areas O
were O
measured O
using O
transparent O
millimetric O
measuring O
paper O
. O
[]

In O
conclusion O
, O
our O
study O
demonstrated O
that O
while O
the O
manipulation O
of O
hormone O
receptors O
seems O
possible O
, O
results O
indicating O
better O
overall O
survival O
and O
time O
to O
progression O
were O
not O
obtained O
with O
alternate O
sequential O
TAM-MPA O
therapy O
. O
[]

No O
differences O
between O
study O
arms O
were O
observed O
with O
respect O
to O
hepatotoxicity B-outcome ['Physiological-Clinical']
or O
side B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Adverse-effects']

Participants O
with O
2 O
study O
eyes O
had O
1 O
eye O
randomized O
to O
sham O
plus O
prompt O
laser O
and O
1 O
eye O
randomized O
to O
a O
real O
injection O
group O
. O
[]

The O
remaining O
174 O
patients O
were O
included O
in O
the O
analysis O
. O
[]

The O
association O
between O
treatment O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
first I-outcome ['Physiological-Clinical']
nonmelanoma I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
and O
between O
treatment O
and O
time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
multiple I-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
tumors I-outcome ['Physiological-Clinical']
overall O
and O
within O
subgroups O
, O
defined O
by O
baseline O
characteristics O
, O
was O
evaluated O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
young O
children O
only O
succeeded O
on O
TOM O
items O
that O
tap O
the O
basic O
domains O
of O
theory O
of O
mind O
( O
e.g. O
, O
emotion O
recognition O
) O
, O
whereas O
older O
children O
also O
passed O
items O
that O
measure O
the O
more O
mature O
areas O
of O
theory O
of O
mind O
( O
e.g. O
, O
understanding O
of O
humor O
, O
understanding O
of O
second-order O
beliefs O
) O
. O
[]

Comparison O
of O
sedative O
drugs O
under O
peribulbar O
or O
topical O
anesthesia O
during O
phacoemulsification O
. O
[]

We O
conclude O
that O
some O
, O
but O
not O
all O
, O
of O
the O
breast O
cancer O
cases O
detected O
early O
as O
a O
result O
of O
screening O
realized O
a O
benefit O
in O
terms O
of O
elimination O
of O
the O
risk O
of O
breast B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

BACKGROUND O
Duration O
of O
untreated O
psychosis O
( O
DUP O
) O
has O
been O
significantly O
associated O
with O
poor O
clinical B-outcome ['Physiological-Clinical']
and O
social B-outcome ['Physiological-Clinical']
outcomes O
in O
First O
Episode O
Psychosis O
( O
FEP O
) O
patients O
, O
but O
an O
association O
with O
cognitive O
outcomes O
has O
not O
been O
clearly O
established O
. O
['Physiological-Clinical']

Stimulation O
of O
the O
thenar O
muscle O
resulted O
in O
a O
significant O
increase O
in O
the O
sympathetic B-outcome ['Physiological-Clinical']
and O
the O
parasympathetic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
during O
the O
stimulation O
period O
( O
P O
< O
0.01 O
) O
and O
during O
the O
post-stimulation O
period O
( O
P O
< O
0.01 O
and O
P O
< O
0.001 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
Subgroups O
of O
breast O
cancer O
that O
have O
an O
impaired O
response O
to O
endocrine O
treatment O
, O
despite O
hormone O
receptor O
positivity O
, O
are O
still O
poorly O
defined O
. O
[]

Each O
treatment O
period O
was O
followed O
by O
a O
2-week O
, O
drug-free O
washout O
period O
. O
[]

Multifactor O
dimensionality O
reduction O
analysis O
was O
used O
to O
identify O
a O
genetic B-outcome ['Physiological-Clinical']
interaction O
profile O
for O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) O
. O
['Physiological-Clinical', 'Mortality']

CONCLUSIONS O
Patients O
receiving O
supplemental O
inspired O
oxygen O
had O
a O
significant O
reduction O
in O
the O
risk O
of O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

INTRODUCTION O
To O
investigate O
the O
feasibility B-outcome ['Life-Impact']
of O
improving O
asthma O
management O
- O
in O
particular O
, O
the O
implementation O
of O
individualised O
asthma O
action O
plans O
( O
AAPs O
) O
for O
poorly-controlled O
adult O
asthma O
patients O
- O
by O
providing O
training O
in O
asthma-focused O
clinical O
and O
communication O
skills O
for O
practice O
nurses O
who O
deliver O
asthma O
clinics O
. O
['Life-Impact']

The O
data O
were O
analysed O
by O
the O
non-parametric O
Wilcoxon O
rank O
sum O
test O
using O
STATA O
7.0 O
. O
[]

Despite O
considerable O
efforts O
, O
it O
is O
sometimes O
hard O
to O
reach O
treatment O
goals O
for O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
with O
classical O
treatment O
options O
. O
['Physiological-Clinical']

Lambs O
were O
fed O
until O
the O
average O
BW O
of O
each O
pen O
reached O
a O
target O
BW O
( O
55.4 O
kg O
for O
wethers O
and O
50.0 O
kg O
for O
ewes O
) O
, O
at O
which O
time O
the O
entire O
pen O
of O
lambs O
was O
slaughtered O
. O
[]

To O
identify O
associated O
factors O
with O
addictive B-outcome ['Life-Impact']
Internet I-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
, O
two-level O
multilevel O
regression O
models O
were O
fitted O
with O
individual-level O
responses O
( O
1st O
level O
) O
nested O
within O
schools O
( O
2nd O
level O
) O
to O
estimate O
associations O
of O
individual O
and O
school O
characteristics O
simultaneously O
. O
['Life-Impact']

Analysis O
by O
Choi O
criteria O
on O
survival O
for O
BCL2 O
, O
no O
matter O
for O
which O
subsets O
( O
GCB O
or O
ABC O
) O
or O
treatment O
modality O
( O
chemotherapy O
with O
or O
without O
the O
addition O
of O
rituximab O
) O
showed O
no O
difference O
in O
5 O
years O
OS O
or O
EFS O
. O
[]

BACKGROUND/AIMS O
Retrospective O
studies O
suggest O
that O
the O
prognosis O
of O
patients O
with O
cirrhosis O
and O
variceal O
hemorrhage O
has O
improved O
in O
more O
recent O
decades O
. O
[]

A O
controlled O
trial O
of O
trimethoprim-sulfamethoxazole O
or O
aerosolized O
pentamidine O
for O
secondary O
prophylaxis O
of O
Pneumocystis O
carinii O
pneumonia O
in O
patients O
with O
the O
acquired O
immunodeficiency O
syndrome O
. O
[]

In O
a O
classical O
test O
of O
executive O
function O
( O
random O
response O
generation O
) O
, O
BOLD B-outcome ['Physiological-Clinical']
signal I-outcome ['Physiological-Clinical']
differed O
between O
the O
groups O
in O
the O
cerebellum O
but O
not O
in O
the O
frontal O
lobes O
. O
['Physiological-Clinical']

Plasma O
levels O
of O
acute O
phase O
reactants O
, O
interleukins B-outcome ['Physiological-Clinical']
, O
granulocytic B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
and O
complement B-outcome ['Physiological-Clinical']
factors I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
101160020 O
[]

BACKGROUND: O
Desmoid O
tumors O
(also O
referred O
to O
as O
aggressive O
fibromatosis) O
are O
connective O
tissue O
neoplasms O
that O
can O
arise O
in O
any O
anatomical O
location O
and O
infiltrate O
the O
mesentery, O
neurovascular O
structures, O
and O
visceral O
organs. O
[]

OBJECTIVE O
Although O
most O
cases O
of O
epistaxis O
are O
managed O
conservatively O
, O
occasionally O
they O
can O
progress O
to O
significant O
hemorrhage O
requiring O
more O
involved O
management O
or O
surgery O
. O
[]

Duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
analgesia I-outcome ['Life-Impact']
was O
longer O
in O
group O
BM O
( O
11 O
+/- O
0.5 O
h O
) O
as O
compared O
to O
group O
B O
( O
7.4 O
+/- O
2.1 O
hours O
) O
( O
p O
< O
0.05 O
) O
. O
['Life-Impact']

Cytosine O
arabinoside O
( O
CA O
) O
was O
utilized O
in O
efforts O
to O
synchronize O
leukemic O
cells O
in O
DNA O
synthesis O
for O
treatment O
with O
vincristine O
, O
prednisone O
, O
and O
L-asparaginase O
in O
children O
with O
acute O
leukemia O
in O
relapse O
. O
[]

Comparative O
bioavailability B-outcome ['Physiological-Clinical']
of O
two O
formulations O
of O
terbinafine O
. O
['Physiological-Clinical']

A O
randomized O
trial O
of O
radiation O
therapy O
compared O
to O
split O
course O
radiation O
therapy O
combined O
with O
mitomycin O
C O
and O
5 O
fluorouracil O
as O
initial O
treatment O
for O
advanced O
laryngeal O
and O
hypopharyngeal O
squamous O
carcinoma O
. O
[]

This O
study O
involves O
118 O
evaluable O
patients O
: O
32 O
in O
the O
laser-CO2 O
group O
, O
34 O
in O
the O
5-fluorouracil O
group O
and O
52 O
in O
the O
interferon O
group O
. O
[]

METHODS O
This O
study O
was O
a O
randomized O
controlled O
trial O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

A O
vigilance O
decrement O
was O
seen O
only O
for O
the O
positive O
feedback O
, O
experimental O
group O
. O
[]

SETTING O
Recruitment O
of O
patients O
from O
hospitals O
, O
primary O
health O
care O
and O
advertisement O
, O
Oslo O
, O
Norway O
. O
[]

Financial O
and O
quality-of-life O
burden O
of O
dysfunctional O
uterine O
bleeding O
among O
women O
agreeing O
to O
obtain O
surgical O
treatment O
. O
[]

Stability B-outcome ['Physiological-Clinical']
, O
segmental B-outcome ['Physiological-Clinical']
maxillary I-outcome ['Physiological-Clinical']
tipping I-outcome ['Physiological-Clinical']
and O
relapse B-outcome ['Physiological-Clinical']
were O
studied O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
the O
3-month O
follow-up O
assessment O
, O
PSE O
mothers O
were O
significantly O
less O
likely O
than O
those O
serving O
as O
controls O
to O
have O
clinically O
significant O
parental B-outcome ['Life-Impact']
stress I-outcome ['Life-Impact']
( O
3.8 O
% O
vs O
29.3 O
% O
; O
adjusted O
relative O
risk O
[ O
aRR O
] O
, O
0.17 O
; O
95 O
% O
CI O
, O
0.04 O
to O
0.65 O
) O
. O
['Life-Impact']

We O
hypothesized O
that O
adding O
CPG O
7909 O
, O
a O
toll-like O
receptor O
9 O
( O
TLR9 O
) O
agonist O
and O
vaccine O
adjuvant O
, O
to O
7-valent O
pneumococcal O
conjugate O
vaccine O
( O
7vPnC O
) O
would O
increase O
its O
immunogenicity O
in O
HIV-infected O
adults O
. O
[]

The O
number O
of O
brain B-outcome ['Physiological-Clinical']
infarcts I-outcome ['Physiological-Clinical']
as O
detected O
by O
MRI O
was O
recorded O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
. O
['Physiological-Clinical']

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
postoperative O
magnesium O
infusion O
on O
duration O
of O
block O
, O
sedation B-outcome ['Physiological-Clinical']
and O
analgesic B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
after O
spinal O
anaesthesia O
. O
['Physiological-Clinical', 'Resource-use']

The O
reliability O
of O
the O
overall O
exposure O
prevention O
ratings O
was O
excellent O
( O
weighted O
kappa O
= O
0.84 O
) O
. O
[]

In O
Asian O
patients O
with O
chronic O
hepatitis O
B O
, O
quantitative O
analyses O
of O
subpopulations O
of O
peripheral O
blood O
lymphocytes O
have O
not O
been O
able O
to O
confirm O
these O
findings O
. O
[]

CDP571 O
, O
a O
humanized O
monoclonal O
antibody O
to O
tumour O
necrosis O
factor-alpha O
, O
for O
steroid-dependent O
Crohn O
's O
disease O
: O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

Visualization O
and O
25 O
W O
short O
burns O
: O
Ablation O
guided O
by O
barium O
visualization O
using O
25 O
W O
and O
short O
burns O
( O
max O
. O
[]

In O
Study O
2 O
, O
one O
group O
of O
19 O
alpacas O
received O
four O
administrations O
at O
weekly O
interval O
of O
topical O
eprinomectin O
at O
the O
dose O
rate O
of O
500mug/kg O
, O
and O
response O
to O
treatment O
was O
monitored O
by O
mite B-outcome ['Physiological-Clinical']
counts O
. O
['Physiological-Clinical']

Days O
of O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
for I-outcome ['Resource-use']
CHF I-outcome ['Resource-use']
exacerbations I-outcome ['Resource-use']
in O
the O
6 O
month O
follow-up O
were O
significantly O
greater O
in O
the O
intervention O
group O
( O
IRR O
= O
2.34 O
95 O
% O
CI O
: O
1.80-3.05 O
P O
= O
0.000 O
) O
. O
['Resource-use']

METHODS O
Separate O
patient O
and O
clinician O
web-tools O
comprised O
of O
over O
500 O
, O
10-s O
video O
clips O
demonstrating O
patient-centered B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
various O
ways O
. O
['Life-Impact']

Three O
patients O
of O
colorectal O
cancer O
from O
an O
unresectable O
group O
were O
presumed O
to O
have O
micrometastases O
to O
the O
liver O
as O
suggested O
by O
an O
elevated O
serum O
CEA O
level O
. O
[]

There O
were O
no O
statistically O
significant O
regression-adjusted O
effects O
on O
other O
outcomes, O
although O
the O
direction O
of O
change O
was O
consistent O
with O
improvements. O
[]

In O
a O
prospective O
non-randomized O
trial O
, O
59 O
patients O
with O
sepsis O
( O
n O
= O
43 O
) O
and O
SIRS O
( O
n O
= O
16 O
) O
were O
treated O
on O
a O
surgical O
intensive O
care O
unit O
. O
[]

The O
interaction O
in O
the O
field O
trial O
showed O
a O
trend O
( O
p=0.138 O
) O
toward O
a O
beneficial O
treatment O
effect O
when O
the O
individual O
ODR O
values O
, O
measured O
in O
late O
lactation O
and O
using O
Svanovir O
( O
? O
) O
, O
[]

Patients O
with O
T18N0M0 O
( O
A2 O
) O
or O
T2N0M0 O
( O
B O
) O
disease O
after O
lymphangiogram O
( O
LAG O
) O
or O
staging O
laparotomy O
( O
SL O
) O
were O
randomized O
between O
prophylactic O
radiation O
to O
the O
pelvic O
lymph O
nodes O
and O
prostatic O
bed O
vs. O
prostatic O
bed O
alone O
. O
[]

Clinical O
evaluation O
of O
Er O
, O
Cr O
: O
YSGG O
and O
GaAlAs O
laser O
therapy O
for O
treating O
dentine B-outcome ['Physiological-Clinical']
hypersensitivity I-outcome ['Physiological-Clinical']
: O
A O
randomized O
controlled O
clinical O
trial O
. O
['Physiological-Clinical']

If O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
not O
adequately O
controlled O
( O
less O
than O
85 O
mm O
Hg O
) O
after O
four O
weeks O
of O
monotherapy O
, O
1 O
mg O
of O
polythiazide O
was O
added O
to O
the O
daily O
regimen O
. O
['Physiological-Clinical']

Results O
support O
the O
ability O
of O
vouchers O
to O
produce O
modest O
improvements O
in O
abstinence B-outcome ['Life-Impact']
initiation I-outcome ['Life-Impact']
rates O
during O
brief O
detoxification O
but O
suggest O
that O
additional O
interventions O
are O
needed O
to O
sustain O
improvements O
. O
['Life-Impact']

In O
the O
bilateral-graft O
group, O
13.9% O
of O
the O
patients O
received O
only O
a O
single O
internal-thoracic-artery O
graft, O
and O
in O
the O
single-graft O
group, O
21.8% O
of O
the O
patients O
also O
received O
a O
radial-artery O
graft. O
[]

2 O
. O
[]

RESULTS O
Twenty O
participants O
( O
24.4 O
% O
) O
quit O
during O
the O
6-month O
intervention O
period O
. O
[]

RESULTS: O
In O
1st O
group O
of O
children O
operated O
with O
cadaver O
allografts, O
the O
Kujala O
score O
significantly O
improved O
from O
73.91 O
points O
preoperatively O
to O
94.50 O
points O
postoperatively O
(P O
< O
.001). O
[]

Among O
diabetic O
patients O
who O
were O
being O
treated O
with O
insulin O
or O
oral O
hypoglycemic O
agents O
at O
base O
line O
, O
a O
subgroup O
not O
specified O
by O
the O
protocol O
, O
five-year O
survival B-outcome ['Mortality']
was O
80.6 O
percent O
for O
the O
CABG O
group O
as O
compared O
with O
65.5 O
percent O
for O
the O
PTCA O
group O
( O
P O
= O
0.003 O
) O
. O
['Mortality']

It O
has O
been O
suggested O
that O
, O
in O
view O
of O
the O
number O
of O
tablets O
to O
be O
taken O
( O
particularly O
in O
adults O
) O
, O
it O
may O
be O
possible O
to O
improve O
compliance B-outcome ['Life-Impact']
by O
allowing O
patients O
to O
divide O
the O
daily O
dose O
. O
['Life-Impact']

The O
warfarin O
( O
n O
= O
56 O
) O
and O
the O
control O
( O
n O
= O
54 O
) O
groups O
were O
not O
different O
in O
terms O
of O
age O
, O
sex O
, O
previous O
coronary O
bypass O
surgery O
or O
coronary O
balloon O
angioplasty O
, O
severity O
of O
symptoms O
, O
and O
frequency O
of O
multivessel O
disease O
or O
of O
total O
coronary O
occlusions O
. O
[]

The O
risk O
of O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
was O
reduced O
by O
62 O
% O
in O
the O
therapy O
group O
, O
p O
= O
.13 O
. O
['Mortality']

Patients O
were O
randomised O
to O
receive O
either O
four O
or O
eight O
courses O
of O
cytotoxic O
chemotherapy O
with O
cyclophosphamide O
, O
vincristine O
and O
etoposide O
and O
also O
randomised O
to O
receive O
, O
on O
disease O
progression O
, O
either O
second O
line O
chemotherapy O
( O
methotrexate O
and O
doxorubicin O
) O
or O
symptomatic O
treatment O
only O
. O
[]

DESIGN O
, O
SETTING O
, O
AND O
PARTICIPANTS O
Randomized O
clinical O
trial O
of O
citalopram O
hydrobromide O
for O
children O
and O
adolescents O
with O
autism O
spectrum O
disorders O
and O
prominent O
repetitive O
behavior O
. O
[]

At O
10 O
minutes O
after O
the O
beginning O
of O
atomization, O
the O
inspiratory B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
monitored O
by O
ventilator O
in O
different O
preset O
VT O
groups O
was O
significantly O
lower O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
649.67+/-5.03 O
vs. O
840.00+/-10.00 O
at O
650 O
mL O
of O
preset O
VT O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05), O
and O
exhaled B-outcome ['Physiological-Clinical']
tidal I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
significantly O
higher O
than O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
showed O
by O
simulated O
water O
lung O
(mL: O
1 O
270.33+/-11.06 O
vs. O
840.00+/-10.00 O
at O
650 O
mL O
of O
preset O
VT O
and O
9 O
L/min O
of O
atomized O
oxygen O
flow, O
P O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

TRIAL O
REGISTRATION: O
This O
trial O
is O
registered O
on O
ClinicalTrials.gov O
(identifier: O
NCT01838668 O
), O
April O
20, O
2013 O
(retrospectively O
registered). O
[]

Mediastinal O
lymphadenectomy O
in O
non-small O
cell O
lung O
cancer O
: O
effectiveness O
in O
patients O
with O
or O
without O
nodal O
micrometastases O
- O
results O
of O
a O
preliminary O
study O
. O
[]

Fifty O
patients O
completed O
an O
investigator-blind O
trial O
comparing O
bismuth O
subsalicylate O
, O
erythromycin O
ethylsuccinate O
, O
and O
placebo O
matched O
to O
the O
bismuth O
salt O
in O
the O
treatment O
of O
gastritis O
associated O
with O
Campylobacter O
pylori O
. O
[]

Levels O
were O
measured O
as O
relative O
concentrations O
by O
the O
electron O
spin O
resonance O
method O
. O
[]

Dose-related O
changes O
in O
parameters O
of O
the O
acute-phase B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
were O
noted O
, O
consistent O
with O
the O
relationship O
of O
CNTF O
and O
its O
receptor O
system O
to O
the O
cytokine O
interleukin-6 O
( O
IL-6 O
) O
and O
its O
receptor O
. O
['Physiological-Clinical']

The O
changes O
in O
enzyme B-outcome ['Physiological-Clinical']
levels O
confirm O
the O
cholestatic O
type O
of O
hepatobiliary O
deviations O
without O
clinical O
impact O
on O
short-term O
TPN O
therapy O
. O
['Physiological-Clinical']

[ O
Management O
of O
the O
perineal O
wounds O
after O
abdominoperineal O
resection O
: O
simple O
drainage O
only O
or O
with O
continuous O
irrigation O
? O
] O
. O
[]

Assessments O
were O
made O
at O
baseline O
and O
on O
Day O
10 O
of O
each O
period O
. O
[]

Feasibility O
of O
two O
dose-dense O
FEC O
regimens O
with O
growth O
factor O
support O
for O
adjuvant O
therapy O
in O
patients O
with O
early O
breast O
cancer O
: O
results O
from O
a O
randomised O
study O
of O
the O
Central O
European O
Cooperative O
Oncology O
Group O
( O
CECOG O
) O
. O
[]

Wards O
( O
villages O
) O
were O
randomly O
assigned O
to O
either O
a O
standard O
care O
group O
or O
a O
standard O
care O
plus O
green O
banana O
group O
where O
mothers O
were O
instructed O
to O
add O
cooked O
green O
banana O
to O
the O
diets O
of O
diarrhoeal O
children O
. O
[]

Publication O
date: O
2019/01/18 O
06:00 O
[entrez] O
[]

This O
RCT O
examined O
the O
efficacy O
of O
a O
manualized O
social O
intervention O
for O
children O
with O
HFASDs O
. O
[]

Duration O
of O
whoops B-outcome ['Physiological-Clinical']
post-treatment I-outcome ['Physiological-Clinical']
was O
8.7 O
days O
( O
95 O
% O
Cl O
4.8 O
, O
12.6 O
) O
in O
the O
33 O
children O
receiving O
immunoglobulin O
vs O
20.6 O
( O
95 O
% O
Cl O
11.9 O
, O
29.3 O
) O
in O
the O
14 O
receiving O
placebo O
( O
p O
= O
0.0041 O
) O
. O
['Physiological-Clinical']

DESIGN O
A O
single-blind O
randomized O
AB/BA O
crossover O
design O
. O
[]

Biomarkers O
of O
dietary O
exposure O
are O
associated O
with O
lower O
risk O
of O
breast O
fibroadenomas O
in O
Chinese O
women O
. O
[]

Then O
the O
teeth O
were O
prepared O
and O
obturated O
with O
gutta-percha O
by O
a O
lateral O
condensation O
and O
either O
AH O
plus O
and O
EndoRez O
used O
as O
a O
sealer O
. O
[]

We O
analyzed O
incidence O
of O
cardiovascular B-outcome ['Mortality']
death I-outcome ['Mortality']
or O
rehospitalization B-outcome ['Resource-use']
for O
congestive B-outcome ['Physiological-Clinical']
heart I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
after O
PCI O
as O
well O
as O
various O
aspects O
of O
epicardial O
flow O
and O
microvascular O
function O
. O
['Mortality', 'Resource-use', 'Physiological-Clinical']

However O
, O
no O
field O
data O
exist O
on O
the O
impact O
of O
chemotherapy O
alone O
on O
vector O
efficiency O
and O
transmission O
intensity O
of O
W O
bancrofti O
. O
[]

Hypothyroidism O
resulted O
in O
hyperfibrinolysis B-outcome ['Physiological-Clinical']
and O
a O
reduced O
TAFIa-dependent B-outcome ['Physiological-Clinical']
prolongation I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
clot B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
prospective O
, O
randomized O
study O
of O
5-fluorouracil O
and O
filtration O
surgery O
. O
[]

The O
median O
( O
25th O
and O
75th O
percentiles O
) O
annual O
change O
in O
BMD B-outcome ['Physiological-Clinical']
was O
-0.5 O
( O
-1.8 O
, O
1.3 O
% O
) O
in O
the O
treated O
group O
and O
-1.5 O
( O
-3.8 O
, O
-0.7 O
% O
) O
in O
the O
control O
group O
. O
['Physiological-Clinical']

Hypercholesterolaemic O
, O
postmenopausal O
women O
were O
given O
30 O
mg O
beta-carotene O
per O
day O
( O
n O
= O
15 O
subjects O
) O
or O
placebo O
capsules O
( O
n O
= O
15 O
subjects O
) O
for O
10 O
weeks O
. O
[]

The O
control O
group O
receives O
treatment O
as O
usual O
with O
no O
additional O
social O
support O
. O
[]

The O
findings O
were O
consistent O
with O
a O
rapid O
metabolism O
of O
RU B-outcome ['Physiological-Clinical']
486 I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
RU I-outcome ['Physiological-Clinical']
42633 I-outcome ['Physiological-Clinical']
; O
removal O
of O
the O
second O
methyl O
group O
leading O
to O
RU O
42698 O
occurred O
much O
more O
slowly O
and O
to O
a O
much O
less O
extent O
than O
removal O
of O
the O
first O
. O
['Physiological-Clinical']

Three-year-survival O
rate O
of O
histologically O
confirmed O
non-curatively O
resected O
colon O
carcinoma O
patients O
was O
higher O
in O
the O
group O
receiving O
regimen O
C O
than O
in O
regimen O
D. O
But O
no O
significant O
difference O
was O
found O
among O
the O
other O
groups O
. O
['Mortality']

Vaccination O
with O
live O
oral O
heterologous O
rotavirus O
vaccines O
may O
prevent O
rotavirus O
gastroenteritis O
. O
[]

During O
the O
2-year O
period O
after O
therapy O
, O
10 O
% O
in O
MT O
and O
59 O
% O
in O
BT O
required O
no O
further O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
due O
to O
low B-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Physiological-Clinical']

Publication O
Type: O
Journal O
Article O
[]

Persistent O
muscle O
inhibition O
of O
the O
fibularis O
longus O
and O
soleus O
muscles O
and O
altered O
joint O
arthrokinematics O
may O
play O
a O
role O
in O
chronic O
ankle O
instability O
( O
CAI O
) O
. O
[]

RESULTS O
The O
mean O
( O
+/-SD O
) O
of O
reported O
fish O
meals O
per O
week O
was O
4.3 O
+/- O
0.4 O
, O
4.7 O
+/- O
1.1 O
and O
0.6 O
+/- O
0.4 O
in O
the O
groups O
, O
respectively O
. O
[]

Randomisation O
was O
done O
by O
minimisation O
, O
with O
stratification O
for O
WHO O
performance O
status O
, O
histology O
, O
and O
centre O
. O
[]

A O
microprecipitate O
developed O
in O
media O
supplemented O
with O
lot O
1 O
after O
several O
days O
of O
culture O
. O
[]

SETTING O
Research O
laboratory O
in O
a O
rehabilitation O
hospital O
. O
[]

The O
effect O
of O
neighborhood-based O
community O
organizing O
: O
results O
from O
the O
Seattle O
Minority O
Youth O
Health O
Project O
. O
[]

The O
rCsA O
with O
sirolimus O
and O
corticosteroid O
regimen O
resulted O
in O
excellent O
12-month O
patient O
and O
graft O
survival O
, O
a O
low O
incidence O
of O
BCAR O
, O
and O
improved O
renal O
function O
in O
renal O
allograft O
recipients O
. O
[]

Diltiazem O
was O
administered O
as O
an O
intravenous O
bolus O
of O
0.3 O
mg.kg-1 O
within O
5 O
min O
, O
followed O
by O
infusion O
of O
0.1-0.8 O
mg.kg-1.h-1 O
in O
group O
1 O
. O
[]

Baseline O
tear O
and O
saliva O
production O
was O
significantly O
reduced O
during O
disopyramide O
therapy O
, O
but O
was O
restored O
toward O
normal O
by O
the O
addition O
of O
pyridostigmine O
. O
( O
[]

We O
reviewed O
records O
for O
pediatric O
patients O
who O
had O
postoperative O
arrhythmias O
between O
January O
2006 O
and O
June O
2010 O
at O
a O
large O
tertiary-care O
children O
's O
hospital O
. O
[]

One O
hundred O
anaesthetized O
patients O
( O
ASA O
1-2 O
, O
aged O
18 O
to O
80 O
years O
) O
were O
randomized O
for O
the O
second O
insertion O
attempt O
using O
either O
the O
gum O
elastic O
bougie-guided O
or O
introducer O
tool O
techniques O
. O
[]

The O
results O
were O
analyzed O
using O
descriptive O
and O
inferential O
statistical O
tests O
in O
SPSS O
software. O
[]

RESULTS O
Single O
agent O
or O
combination O
chemotherapy O
regimens O
including O
doxorubicin O
( O
A O
) O
( O
12 O
% O
) O
, O
doxorubicin/cisplatin O
( O
AP O
) O
( O
63 O
% O
) O
, O
doxorubicin/paclitaxel O
( O
AT O
) O
( O
13 O
% O
) O
, O
and O
paclitaxel/doxorubicin/cisplatin O
( O
TAP O
) O
( O
11 O
% O
) O
were O
used O
among O
1203 O
patients O
treated O
on O
4 O
randomized O
clinical O
trials O
. O
[]

METHODS O
Elite O
sprint O
and O
middle-distance O
swimmers O
( O
three O
females O
and O
six O
males O
; O
aged O
21-26 O
yr O
) O
performed O
6-13 O
time O
trials O
in O
training O
and O
competition O
in O
the O
9 O
wk O
before O
and O
including O
Olympic-qualifying O
trials O
, O
all O
in O
their O
specialty O
event O
. O
[]

Descriptive O
statistics O
were O
used O
to O
answer O
the O
research O
questions O
. O
[]

Manipulation O
of O
afferent O
inputs O
may O
temporarily O
modulate O
dystonic O
spasms O
. O
[]

An O
intent-to-treat O
comparison O
of O
the O
numbers O
of O
courses O
affected O
by O
acute O
toxicity O
( O
fever O
, O
rigors O
) O
and O
chronic O
toxicity O
( O
nephrotoxicity O
) O
also O
indicated O
that O
there O
was O
no O
significant O
difference O
between O
AmB O
infused O
in O
dextrose O
( O
78 O
courses O
) O
and O
AmB O
infused O
in O
lipid O
emulsion O
( O
84 O
courses O
) O
. O
[]

Serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
occurred O
in O
? O
['Adverse-effects']

Publication O
date: O
2018/12/17 O
00:00 O
[accepted] O
[]

However O
, O
the O
weighted O
blanket O
was O
favored O
by O
children O
and O
parents O
, O
and O
blankets O
were O
well B-outcome ['Life-Impact']
tolerated I-outcome ['Life-Impact']
over O
this O
period O
. O
['Life-Impact']

Parent O
management O
training O
and O
Asperger O
syndrome O
: O
a O
randomized O
controlled O
trial O
to O
evaluate O
a O
parent O
based O
intervention O
. O
[]

Fifteen O
of O
18 O
( O
83.3 O
% O
) O
evaluated O
episodes O
in O
the O
od O
and O
12/16 O
( O
75.0 O
% O
) O
evaluated O
episodes O
in O
the O
bd O
group O
showed O
a O
favourable O
bacteriological B-outcome ['Physiological-Clinical']
response O
. O
['Physiological-Clinical']

No O
signs O
of O
abrupt B-outcome ['Physiological-Clinical']
dissipation I-outcome ['Physiological-Clinical']
of O
the O
achieved O
clinical O
effects O
were O
observed O
during O
continued O
treatment O
, O
and O
no O
['Physiological-Clinical']

A O
significant O
increase O
in O
the O
duration O
of O
the O
motor B-outcome ['Physiological-Clinical']
response O
to O
levodopa B-outcome ['Resource-use']
was O
seen O
when O
200 O
mg O
entacapone O
was O
given O
with O
levodopa/carbidopa O
. O
['Physiological-Clinical', 'Resource-use']

BACKGROUND O
Incidence O
and O
severity O
of O
herpes O
zoster O
( O
HZ O
) O
and O
postherpetic O
neuralgia O
increase O
with O
age O
, O
associated O
with O
age-related O
decrease O
in O
immunity O
to O
varicella-zoster O
virus O
( O
VZV O
) O
. O
[]

Virologic B-outcome ['Physiological-Clinical']
success I-outcome ['Physiological-Clinical']
( O
HIV-1 O
RNA O
< O
50 O
copies/mL O
) O
was O
maintained O
at O
week O
96 O
( O
84 O
% O
vs O
82 O
% O
, O
difference O
+2.7 O
% O
, O
95 O
% O
CI O
: O
-2.9 O
% O
to O
8.3 O
% O
) O
. O
['Physiological-Clinical']

However O
, O
only O
limited O
information O
is O
available O
on O
the O
ability O
of O
patients O
with O
dystonia O
to O
process O
the O
time-dependent O
features O
( O
e.g O
. O
[]

GH O
treatment O
caused O
a O
1.6-fold O
increase O
in O
the O
fraction O
of O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
lost O
as O
fat O
and O
a O
greater O
loss B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
visceral I-outcome ['Physiological-Clinical']
fat I-outcome ['Physiological-Clinical']
area O
than O
placebo O
treatment O
( O
35.3 O
vs. O
28.5 O
% O
, O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Similarly O
, O
the O
[]

Effect O
of O
ibuprofen O
on O
cyclooxygenase B-outcome ['Physiological-Clinical']
and O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
synthase I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
gastric I-outcome ['Physiological-Clinical']
mucosa I-outcome ['Physiological-Clinical']
: O
correlation O
with O
endoscopic B-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Adverse-effects']

A O
total O
of O
824 O
women O
were O
randomized O
to O
ETT O
or O
exercise O
MPI O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
different O
intensities O
and O
durations O
of O
GWU O
on O
1RM O
performance O
. O
[]

After O
a O
2-week O
washout O
period O
, O
the O
E O
( O
+ O
) O
group O
was O
changed O
to O
L O
( O
+ O
) O
and O
vice O
versa O
in O
a O
crossover O
design O
. O
[]

BACKGROUND: O
Pregnancy O
has O
been O
identified O
as O
a O
contributor O
to O
obesity. O
[]

Patients O
of O
ldMDCT O
group O
with O
large O
growth O
of O
nasal O
polyps O
(P O
= O
.03, O
q O
= O
5.35) O
and O
complete O
opacification O
of O
sinuses O
(P O
= O
.03, O
q O
= O
7.94) O
had O
complications B-outcome ['Adverse-effects']
after O
sinus O
surgeries. O
[['Adverse-effects']]

Transcutaneous O
electrical O
acupoint O
stimulation O
(TEAS) O
is O
a O
emerging O
treatment O
which O
combines O
transcutaneous O
electrical O
nerve O
stimulation O
with O
traditional O
acupoint O
therapy. O
[]

The O
vaccine O
did O
not O
elicit O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
except O
in O
two O
vaccine O
recipients O
with O
mild B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
. O
['Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

Clinical O
check-ups O
and O
treatment O
of O
acute O
PCP O
could O
be O
a O
justifiable O
alternative O
to O
drug O
prophylaxis O
with O
aerosolized O
pentamidine O
in O
selected O
patients O
. O
[]

There O
were O
only O
2 O
( O
1.2 O
% O
) O
of O
retinal B-outcome ['Physiological-Clinical']
detachment I-outcome ['Physiological-Clinical']
and O
no O
case O
of O
corneal B-outcome ['Physiological-Clinical']
decompensation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
during O
PGE1 O
infusion O
; O
the O
pre-ejection O
period O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
period O
were O
shortened O
. O
['Physiological-Clinical', 'Physiological-Clinical']

A O
one-year O
followup O
study O
. O
[]

The O
baseline O
temperature O
, O
final O
temperature O
, O
total O
time O
in O
the O
operating O
room O
, O
and O
amount O
of O
irrigation O
fluid O
used O
during O
the O
procedure O
were O
recorded O
for O
each O
patient O
. O
[]

Behaviourally O
, O
there O
were O
no O
significant O
differences O
between O
the O
two O
groups O
. O
[]

All O
these O
patients O
had O
received O
steroids O
and O
none O
of O
the O
patients O
without O
steroids O
had O
these O
abnormalities O
. O
[]

Pharmacokinetic-pharmacodynamic B-outcome ['Physiological-Clinical']
modelling O
of O
the O
antihistaminic O
( O
H1 O
) O
effect O
of O
bilastine O
. O
['Physiological-Clinical']

Although O
the O
consequences O
of O
HIV B-outcome ['Life-Impact']
stigma I-outcome ['Life-Impact']
have O
been O
documented O
extensively O
, O
efforts O
to O
reduce O
these O
negative O
attitudes O
have O
been O
scarce O
. O
['Life-Impact']

There O
was O
no O
difference O
in O
the O
incidence O
of O
grade O
2+ B-outcome ['Physiological-Clinical']
SN I-outcome ['Physiological-Clinical']
between O
the O
two O
arms O
( O
34 O
% O
-vitamin O
E O
, O
29 O
% O
-placebo O
; O
P O
= O
0.43 O
) O
. O
['Physiological-Clinical']

Title: O
The O
immediate O
sensorimotor B-outcome ['Physiological-Clinical']
effects O
of O
elbow O
orthoses O
in O
patients O
with O
lateral O
elbow O
tendinopathy: O
a O
prospective O
crossover O
study. O
[['Physiological-Clinical']]

The O
subject O
's O
fist B-outcome ['Life-Impact']
clenching I-outcome ['Life-Impact']
was O
used O
as O
an O
indicator O
of O
aggression B-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact']

Ozone O
gas O
was O
applied O
for O
80 O
s. O
Shear O
bond O
strength O
was O
measured O
with O
a O
universal O
testing O
machine O
. O
[]

20 O
mm O
, O
in O
view O
of O
the O
lower O
incidence O
of O
complications O
. O
[]

It O
is O
two-pronged O
: O
Trainers O
work O
with O
children O
directly O
20 O
times O
over O
5 O
months O
, O
and O
parents O
give O
the O
massage O
daily O
to O
their O
children O
. O
[]

Six O
HIV-seropositive O
subjects O
with O
elevated O
amounts O
of O
TNF-alpha O
in O
plasma O
at O
least O
at O
two O
occasions O
were O
included O
in O
an O
open O
, O
controlled O
, O
randomized O
, O
cross-over O
study O
consisting O
of O
a O
6 O
week O
treatment O
period O
and O
a O
6 O
week O
control O
period O
. O
[]

Effect O
of O
allopurinol O
on O
myocardial O
oxygen B-outcome ['Physiological-Clinical']
free I-outcome ['Physiological-Clinical']
radical I-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
in O
coronary O
bypass O
surgery O
. O
['Physiological-Clinical']

Here O
, O
we O
present O
a O
novel O
method O
to O
automatically O
create O
personalised O
3D O
models O
from O
standard O
2D O
hip O
radiographs O
. O
[]

OBJECTIVES O
We O
sought O
to O
assess O
the O
feasibility O
and O
accuracy O
of O
myocardial O
contrast O
echocardiography O
( O
MCE O
) O
using O
standard O
imaging O
approaches O
for O
the O
detection O
of O
perfusion O
defects O
in O
patients O
who O
had O
a O
myocardial O
infarction O
( O
MI O
) O
. O
[]

Efficacy O
, O
safety O
, O
and O
durability B-outcome ['Life-Impact']
were O
evaluated O
over O
follow-up O
of O
1 O
to O
9 O
years O
( O
mean O
, O
31/2 O
years O
) O
. O
['Life-Impact']

The O
suction O
needle O
was O
repeatedly B-outcome ['Life-Impact']
reusable I-outcome ['Life-Impact']
and O
considerably O
cheaper O
than O
the O
sheathed O
needle O
, O
which O
may O
be O
used O
once O
only O
. O
['Life-Impact']

In O
Regimen O
B O
, O
CNS B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
testicular I-outcome ['Physiological-Clinical']
relapses I-outcome ['Physiological-Clinical']
increased O
after O
3 O
years O
of O
CCR O
. O
['Physiological-Clinical']

Title: O
Piloting O
a O
participatory, O
community-based O
health O
information O
system O
for O
strengthening O
community-based O
health O
services: O
findings O
of O
a O
cluster-randomized O
controlled O
trial O
in O
the O
slums O
of O
Freetown, O
Sierra O
Leone. O
[]

BACKGROUND O
Allergen O
vaccination O
is O
effective O
in O
mite-allergic O
asthma O
. O
[]

There O
is O
little O
robust O
evidence O
of O
effectiveness O
of O
speech-language O
interventions O
which O
target O
the O
language O
, O
pragmatic O
or O
social O
communication O
needs O
of O
these O
children O
. O
[]

We O
designed O
a O
randomized O
, O
double O
blind O
, O
dose-assessing O
study O
. O
[]

RESULTS O
ADHD O
, O
AS/HFA O
, O
and O
RD/WD O
all O
had O
severe O
impact O
on O
family B-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
. O
['Life-Impact']

Ten O
treatment O
periods O
on O
zidovudine O
and O
7 O
on O
didanosine O
were O
analysed O
. O
[]

The O
subjects O
in O
D1 O
and O
D2 O
groups O
must O
consume O
the O
congee O
containing O
the O
combined O
extract O
of O
M. O
alba O
and O
P. O
odoratum O
leaves O
at O
doses O
of O
50 O
and O
1500 O
mg/day, O
respectively. O
[]

Pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
and O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
-- O
a O
trial O
of O
transcutaneous O
electrical O
nerve O
stimulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomized O
to O
receive O
either O
clodronate O
1,600 O
mg/day O
for O
one O
year O
or O
identical O
placebo-containing O
tablets O
. O
[]

once O
daily O
( O
marketed O
) O
. O
[]

Survival B-outcome ['Mortality']
was O
not O
statistically O
different O
between O
the O
two O
treatment O
arms O
. O
['Mortality']

RESULTS: O
The O
success B-outcome ['Physiological-Clinical']
rates O
in O
the O
tobramycin/dexamethasone O
eye O
drops O
group O
in O
both O
2 O
age O
subgroups O
were O
significantly O
higher O
than O
that O
in O
the O
ointment O
group O
and O
NS O
group O
(P O
< O
.05). O
[['Physiological-Clinical']]

METHODS O
This O
was O
a O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
heparin-resistant O
patients O
undergoing O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
. O
[]

The O
incidence O
of O
side O
effects O
was O
20 O
% O
in O
the O
doxorubicin O
group O
and O
21.2 O
% O
in O
the O
mitoxantrone O
group O
. O
[]

Using O
an O
imaging O
genetics O
approach O
, O
we O
studied O
differential O
effects O
of O
an O
intranasal O
OT O
application O
on O
neural B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
social I-outcome ['Life-Impact']
stimuli I-outcome ['Life-Impact']
in O
55 O
healthy O
young O
men O
depending O
on O
their O
CD38 O
gene O
variant O
in O
a O
double-blind O
placebo-controlled O
crossover O
design O
. O
['Life-Impact']

The O
teeth O
were O
divided O
into O
two O
groups O
of O
25 O
teeth O
and O
the O
remaining O
five O
teeth O
served O
as O
control O
. O
[]

5.2 O
days O
, O
both O
P O
< O
0.01 O
) O
. O
[]

No O
beneficial O
effects O
of O
CCB O
treatment O
on O
clinical B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
observed O
during O
the O
2-year O
study O
follow-up O
. O
['Physiological-Clinical']

RESULTS O
There O
was O
no O
statistically O
significant O
( O
P O
= O
.117 O
) O
difference O
in O
filtration B-outcome ['Physiological-Clinical']
success B-outcome ['Physiological-Clinical']
of O
primary O
glaucoma O
triple O
procedure O
between O
the O
control O
and O
mitomycin O
C O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Analysis O
was O
by O
intention O
to O
treat O
. O
[]

Randomization O
was O
successful O
in O
that O
three O
was O
no O
significant O
difference O
in O
male O
to O
female O
ratio O
, O
age O
, O
preoperative O
hemoglobin O
, O
or O
number O
of O
units O
predonated O
between O
the O
early O
and O
delayed O
reinfusion O
groups O
. O
[]

RESULTS O
Prior O
AIDS O
diagnosis O
, O
low O
Karnofsky O
score O
, O
active O
unstable O
AIDS-related O
conditions O
, O
absence O
of O
antiretroviral O
therapy O
and O
absence O
of O
Pneumocystis O
carinii O
pneumonia O
prophylaxis O
were O
associated O
with O
shorter O
survival B-outcome ['Mortality']
by O
univariate O
regression O
using O
the O
proportional O
hazards O
model O
. O
['Mortality']

The O
actuarial O
survival B-outcome ['Mortality']
at O
4 O
years O
is O
72 O
% O
in O
group O
A O
and O
67 O
% O
in O
group O
B O
( O
p=0.3 O
) O
. O
['Mortality']

Visual O
analog O
scale O
pain B-outcome ['Physiological-Clinical']
scores O
at O
rest O
, O
with O
cough B-outcome ['Physiological-Clinical']
, O
and O
with O
movement B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
ipsilateral I-outcome ['Physiological-Clinical']
arm O
, O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
second I-outcome ['Physiological-Clinical']
( O
FEV1 B-outcome ['Physiological-Clinical']
) O
, O
and O
forced B-outcome ['Physiological-Clinical']
vital I-outcome ['Physiological-Clinical']
capacity I-outcome ['Physiological-Clinical']
( O
FVC B-outcome ['Physiological-Clinical']
) O
were O
measured O
at O
4 O
, O
24 O
, O
48 O
, O
and O
72 O
hours O
after O
the O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
beta-carotene O
on O
the O
susceptibility O
of O
low O
density O
lipoprotein O
( O
LDL O
) O
to O
oxidative O
modification O
was O
investigated O
in O
a O
double-blind O
, O
randomized O
placebo-controlled O
study O
. O
[]

Journal-Name:Journal O
of O
medical O
microbiology O
[]

Spearman O
's O
coefficients O
for O
correlation O
of O
quantitative O
spasticity O
measures O
with O
MAS O
scores O
ranged O
from O
0.39 O
to O
0.49 O
with O
associated O
probabilities O
< O
or O
= O
0.002 O
. O
[]

Field O
efficacy O
of O
an O
inactivated B-outcome ['Resource-use']
bivalent I-outcome ['Resource-use']
influenza I-outcome ['Resource-use']
vaccine I-outcome ['Resource-use']
in O
a O
multi-site O
swine O
production O
system O
during O
an O
outbreak O
of O
systemic O
porcine O
circovirus O
associated O
disease O
. O
['Resource-use']

BACKGROUND O
The O
efficacy O
of O
nebulized O
corticosteroids O
in O
the O
prevention O
of O
exacerbation O
of O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
has O
been O
poorly O
studied O
. O
[]

Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
of O
grade O
3 O
or O
4 O
occurred O
in O
75.9% O
of O
the O
patients O
in O
the O
modified-FOLFIRINOX O
group O
and O
in O
52.9% O
of O
those O
in O
the O
gemcitabine O
group. O
[['Adverse-effects']]

Variables O
such O
as O
level O
of I-outcome ['Physiological-Clinical']
function O
, O
immunization B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
the O
presence B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
an I-outcome ['Physiological-Clinical']
identified I-outcome ['Physiological-Clinical']
neurogenetic I-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
were O
not O
predictive O
of O
CAM O
use O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
with O
preoperative O
CEA O
levels O
< O
5.0 O
ng/ml O
were O
excluded O
. O
[]

In O
the O
five O
patients O
who O
received O
fat O
emulsion O
into O
the O
ECMO O
circuit O
, O
three O
had O
layering O
out O
of O
the O
emulsion O
and O
agglutination B-outcome ['Physiological-Clinical']
, O
and O
all O
developed O
clots B-outcome ['Physiological-Clinical']
in O
the O
circuit O
despite O
adequate O
anticoagulation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

induction O
doss O
were O
0.7 O
+/- O
0.1 O
mg.kg-1 O
( O
group O
E1 O
) O
, O
0.8 O
+/- O
0.1 O
mg.kg-1 O
( O
group O
E2 O
) O
and O
4.0 O
+/- O
0.0 O
mg.kg-1 O
( O
group O
T O
) O
. O
[]

OBJECTIVE: O
To O
develop O
an O
intervention O
protocol O
for O
children's O
unintentional O
injury O
risk O
behaviors, O
and O
to O
evaluate O
the O
feasibility B-outcome ['Life-Impact']
of O
the O
protocol. O
[['Life-Impact']]

Composite O
incidences O
of O
death B-outcome ['Mortality']
, O
myocardial O
infarction O
, O
and O
urgent O
revascularization O
until O
day O
30 O
were O
not O
significantly O
different O
between O
the O
groups O
( O
ARG250 O
: O
2.8 O
% O
, O
ARG300 O
: O
0.0 O
% O
, O
ARG350 O
: O
3.2 O
% O
vs. O
UFH O
: O
3.0 O
% O
) O
. O
['Mortality']

Thus O
it O
does O
not O
appear O
that O
postexercise B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
is O
dependent O
on O
increased O
production O
of O
nitric B-outcome ['Physiological-Clinical']
oxide I-outcome ['Physiological-Clinical']
in O
humans O
. O
['Physiological-Clinical', 'Physiological-Clinical']

As O
a O
consequence O
, O
baseline O
VEGF B-outcome ['Physiological-Clinical']
had O
a O
negative O
prognostic O
role O
in O
patients O
who O
received O
epirubicin O
alone O
but O
not O
in O
patients O
receiving O
epirubicin O
plus O
tamoxifen O
( O
interaction O
test O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

RESULTS: O
A O
total O
of O
1548 O
patients O
were O
randomly O
assigned O
to O
undergo O
bilateral O
internal-thoracic-artery O
grafting O
(the O
bilateral-graft O
group) O
and O
1554 O
to O
undergo O
single O
internal-thoracic-artery O
grafting O
(the O
single-graft O
group). O
[]

Result/Key O
findings. O
[]

Compliance B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
referral I-outcome ['Life-Impact']
was O
analysed O
according O
to O
the O
socio-demographic O
characteristics O
of O
screen-positives O
. O
['Life-Impact']

Efficacy O
of O
nebulized O
flunisolide O
combined O
with O
salbutamol O
and O
ipratropium O
bromide O
in O
stable O
patients O
with O
moderate-to-severe O
chronic O
obstructive O
pulmonary O
disease O
. O
[]

Title: O
Randomized O
Delayed-Start O
Trial O
of O
Levodopa O
in O
Parkinson's O
Disease. O
[]

The O
CBT O
program O
emphasized O
in O
vivo O
exposure O
supported O
by O
parent O
training O
and O
school O
consultation O
to O
promote O
social O
communication O
and O
emotion O
regulation O
skills O
. O
[]

The O
effects O
of O
improvisational O
music O
therapy O
on O
joint O
attention O
behaviors O
in O
autistic O
children O
: O
a O
randomized O
controlled O
study O
. O
[]

RATIONALE O
( O
+/- O
) O
3,4-Methylenedioxymethamphetamine O
( O
MDMA O
or O
ecstasy O
) O
has O
been O
shown O
to O
cause O
long O
term O
damage O
to O
serotonergic O
cerebral O
neurons O
in O
animals O
. O
[]

From O
March O
1998 O
to O
June O
2000 O
, O
a O
total O
of O
28 O
women O
underwent O
36 O
completed O
treatment O
cycles O
, O
randomized O
sequentially O
in O
one O
of O
two O
groups O
. O
[]

The O
two O
groups O
were O
compared O
for O
operative O
and O
hospitalization O
times O
and O
postoperative O
course O
. O
[]

Mean O
adherence B-outcome ['Life-Impact']
rates O
based O
on O
self-reports O
were O
also O
significantly O
better O
( O
P O
< O
0.001 O
) O
with O
MF-DPI O
400 O
microg O
QD O
PM O
( O
97.2 O
% O
) O
than O
with O
MF-DPI O
200 O
microg O
twice-daily O
( O
95.3 O
% O
) O
. O
['Life-Impact']

There O
was O
no O
significant O
difference O
in O
the O
control O
group O
(p=0.3). O
[]

Among O
these O
patients O
, O
48 O
( O
47 O
% O
) O
had O
metastatic O
deposits O
> O
2 O
mm O
( O
macrometastasis O
) O
, O
49 O
( O
47 O
% O
) O
had O
metastatic O
deposits O
< O
or O
=2 O
mm O
but O
> O
0.2 O
mm O
( O
micrometastasis O
) O
, O
and O
6 O
( O
6 O
% O
) O
had O
metastatic O
deposits O
< O
or O
=0.2 O
mm O
( O
submicrometastasis O
) O
. O
[]

Statistical O
analysis O
was O
performed O
with O
ANOVA O
. O
[]

The O
objective O
of O
this O
case O
was O
report O
on O
the O
effects O
of O
acute O
whole O
body O
vibration O
exposure O
on O
stereotyped B-outcome ['Life-Impact']
behaviour I-outcome ['Life-Impact']
of O
young O
children O
with O
autism O
. O
['Life-Impact']

Follow-up O
of O
a O
randomised O
controlled O
trial O
. O
[]

The O
series O
consisted O
of O
300 O
patients O
with O
C4 O
CVI O
, O
119 O
patients O
with O
C5 O
CVI O
, O
and O
413 O
patients O
with O
C6 O
CVI O
. O
[]

CONCLUSIONS O
Family O
education O
on O
schizophrenia O
by O
nurses O
in O
China O
was O
effective O
in O
improving O
knowledge O
and O
promoting O
improvement O
in O
patients O
' O
symptoms O
. O
[]

For O
each O
interview O
, O
they O
were O
randomized O
to O
receive O
1 O
of O
2 O
elicitation O
methods O
: O
ping-ponging O
or O
starting O
at O
the O
known O
efficacy O
. O
[]

Publication O
date: O
2019/02/16 O
06:00 O
[medline] O
[]

Pre-treatment O
proliferation O
and O
the O
outcome O
of O
conventional O
and O
accelerated O
radiotherapy O
. O
[]

For O
the O
diagnosis O
of O
sepsis O
, O
patients O
were O
randomly O
divided O
into O
CRRT O
( O
n=10 O
) O
and O
Control O
( O
n=10 O
) O
. O
[]

This O
effect O
was O
seen O
only O
during O
supine O
sleep O
and O
non-rapid O
eye O
movement O
sleep O
and O
was O
absent O
in O
non-supine O
sleep O
, O
rapid O
eye O
movement O
sleep O
, O
and O
during O
periods O
of O
wakefulness O
. O
[]

In O
a O
randomized O
diltiazem-placebo-controlled O
therapeutic O
trial O
of O
non-Q-wave O
AMI O
confirmed O
by O
creatine O
kinase-MB O
( O
CK-MB O
) O
, O
126 O
of O
544 O
patients O
( O
23 O
% O
) O
exhibited O
LV O
hypertrophy O
using O
standard O
voltage O
criteria O
. O
[]

Bioavailability B-outcome ['Physiological-Clinical']
of O
omega-3 O
essential O
fatty O
acids O
from O
perilla O
seed O
oil O
. O
['Physiological-Clinical']

Indeed O
, O
suicidality O
( O
ideation O
or O
behavior O
) O
is O
generally O
an O
exclusion O
criterion O
for O
participation O
in O
treatment O
studies O
of O
subjects O
with O
alcohol O
or O
drug O
abuse O
. O
[]

SETTING O
Eight O
sites O
, O
heterogeneous O
for O
sociodemographic O
and O
health O
care O
use O
. O
[]

IGOH O
was O
well-tolerated B-outcome ['Life-Impact']
; O
there O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
. O
['Life-Impact', 'Adverse-effects']

These O
favorable O
changes O
in O
hemorheological O
parameters O
improves O
myocardial B-outcome ['Physiological-Clinical']
perfusion I-outcome ['Physiological-Clinical']
, O
lowers O
the O
strength B-outcome ['Physiological-Clinical']
and O
frequency O
of O
coronary B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
attacks I-outcome ['Physiological-Clinical']
, O
retards O
postinfarction B-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
, O
and O
increases O
the O
quality O
of O
life O
of O
patients O
with O
various O
CAD O
forms O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
No O
pre-existing O
differences O
were O
found O
between O
groups O
on O
any O
demographic O
variable O
or O
movement O
scale O
. O
[]

The O
study O
comprised O
of O
two O
treatments O
. O
[]

Kidney O
biopsies O
were O
examined O
with O
light O
and O
electron O
microscopy O
, O
glomerular O
filtration O
rate O
and O
effective O
renal O
plasma O
flow O
determined O
with O
inulin O
and O
para-aminohippuric O
acid O
clearances O
. O
[]

Both O
interventions O
were O
delivered O
with O
high O
fidelity O
and O
participants O
in O
both O
groups O
reported O
positive O
experiences O
. O
[]

17 O
beta-Oestradiol O
( O
9 O
mg O
) O
or O
progesterone O
( O
300 O
mg O
) O
were O
given O
before O
the O
second O
test O
, O
after O
a O
first O
test O
with O
placebo O
. O
[]

Other O
aspects O
of O
therapy O
were O
constant O
. O
[]

Serial O
blood B-outcome ['Physiological-Clinical']
and O
urine B-outcome ['Physiological-Clinical']
samples O
were O
obtained O
after O
the O
first- O
and O
multiple-dose O
administrations O
for O
up O
to O
18 O
days O
. O
['Physiological-Clinical']

METHODS O
The O
provocative O
antigen O
challenge O
model O
was O
used O
in O
this O
randomized O
, O
double-blind O
, O
single-center O
, O
crossover O
study O
. O
[]

The O
patients O
in O
the O
control O
group O
received O
an O
equivalent O
volume O
of O
normal O
saline O
. O
[]

Postoperative O
injection O
of O
phenylbutazone O
does O
not O
influence O
fibrinolytic B-outcome ['Physiological-Clinical']
shutdown I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

[ O
Medical O
safety O
and O
staff O
mental O
health O
] O
. O
[]

METHODS O
Three O
hundred O
and O
five O
cases O
were O
randomly O
divided O
into O
a O
needle-knife O
group O
of O
153 O
cases O
and O
a O
physiotherapy O
group O
of O
152 O
cases O
. O
[]

There O
were O
no O
clinical O
characteristics O
that O
differentiated O
patients O
with O
and O
without O
an O
increase O
in O
the O
DFT B-outcome ['Resource-use']
. O
['Resource-use']

Each O
subject O
received O
either O
100 O
microg O
of O
octreotide O
or O
10 O
mg O
of O
prochlorperazine O
intravenously O
for O
a O
2-minute O
period O
. O
[]

RESULTS O
Detrusor B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
at O
maximum O
flow O
( O
PdetQmax B-outcome ['Physiological-Clinical']
) O
continued O
to O
decrease O
during O
the O
second O
12 O
months O
of O
therapy O
( O
decreases O
of O
5.3 O
and O
11.7 O
cm O
H2O O
at O
months O
12 O
and O
24 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2019/02/20 O
06:00 O
[medline] O
[]

Consent O
and O
recruitment O
to O
the O
trial O
will O
be O
obtained O
when O
the O
mother O
requests O
opioid O
analgesia O
. O
[]

To O
quantify O
these O
rules O
, O
we O
used O
stimuli O
composed O
of O
randomly O
oriented O
nonoverlapping O
line O
segments O
. O
[]

METHODS O
An O
active O
and O
sham O
ITD O
were O
randomly O
applied O
first O
to O
a O
facemask O
and O
then O
to O
an O
ETT O
during O
active O
compression-decompression O
cardiopulmonary O
resuscitation O
in O
13 O
out-of-hospital O
cardiac O
arrest O
patients O
in O
a O
randomized O
, O
double-blinded O
, O
prospective O
clinical O
trial O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND O
The O
maximal O
calcium O
absorption O
in O
response O
to O
vitamin O
D O
has O
been O
proposed O
as O
a O
biomarker O
for O
vitamin O
D O
sufficiency O
. O
[]

CONCLUSION O
Combined O
preoperative O
xeloda O
and O
radiotherapy O
for O
lower O
rectal O
cancer O
is O
able O
to O
significantly O
improve O
the O
operative O
resection O
, O
anal O
preservation O
and O
decrease O
the O
local O
recurrence O
rates O
. O
[]

METHODS O
In O
a O
randomized O
controlled O
study O
, O
20 O
healthy O
women O
( O
median O
age O
33 O
years O
, O
range O
21-47 O
; O
phototype O
I/II O
) O
ingested O
55 O
g O
tomato O
paste O
( O
16 O
mg O
lycopene O
) O
in O
olive O
oil O
, O
or O
olive O
oil O
alone O
, O
daily O
for O
12 O
weeks O
. O
[]

TTI B-outcome ['Physiological-Clinical']
was O
recorded O
pre-operatively O
at O
end-expiration O
with O
the O
apical O
paddle O
in O
both O
longitudinal O
and O
transverse O
orientations O
. O
['Physiological-Clinical']

SIM O
group O
learned O
the O
AHA O
guidelines O
for O
high-quality O
CPR O
via O
an O
hour O
session O
that O
included O
a O
PowerPoint O
lecture O
with O
training O
on O
a O
high-fidelity O
simulator. O
[]

The O
explanation O
may O
be O
part O
that O
BCAH O
preceded O
PTFE O
grafts O
into O
clinical O
use O
, O
and O
inexperience O
in O
the O
operating O
room O
and O
in O
the O
dialysis O
unit O
had O
an O
effect O
on O
BCAH O
results O
. O
[]

Consecutive O
patients O
were O
randomized O
to O
undergo O
colonoscopy O
with O
either O
intermediate O
length O
adult O
colonoscope O
( O
CF-240I O
) O
or O
long O
pediatric O
colonoscope O
( O
PCF-240L O
) O
. O
[]

A O
number O
of O
studies O
have O
attempted O
to O
evaluate O
the O
effect O
of O
low-power O
laser O
on O
radiotherapy- O
and O
chemotherapy-induced B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Cellular B-outcome ['Physiological-Clinical']
infiltration I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
adhesion I-outcome ['Physiological-Clinical']
molecule I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
evaluated O
after O
immunohistochemical O
staining O
. O
['Physiological-Clinical']

NFV O
pharmacokinetic O
measurements O
were O
not O
statistically O
different O
between O
the O
treatment O
groups O
, O
yet O
exposure O
to O
the O
NFV O
metabolite O
, O
M8 O
, O
was O
significantly O
higher O
in O
subjects O
receiving O
RTV O
. O
[]

In O
part O
II O
the O
subjects O
received O
80 O
mg O
+ O
8 O
mg/h O
during O
3 O
days O
followed O
by O
20 O
mg O
omeprazole O
orally O
, O
once O
or O
twice O
daily O
until O
day O
10 O
. O
[]

The O
bodyweight-corrected O
area O
under O
the O
curve O
( O
[]

Households O
with O
young O
children O
and O
use O
of O
freely O
distributed O
bednets O
in O
rural O
Madagascar O
. O
[]

However O
, O
the O
survey O
indicated O
that O
the O
telephone O
calls O
were O
clinically O
significant O
and O
provided O
a O
mechanism O
for O
demonstrating O
that O
the O
health O
care O
professionals O
cared O
about O
their O
patients O
and O
provided O
an O
opportunity O
for O
patients O
to O
talk O
about O
their O
concerns O
. O
[]

The O
dose O
per O
treatment O
was O
22.5 O
joule O
. O
[]

Differences O
between O
the O
two O
groups O
were O
significant O
( O
p O
less O
than O
0.05 O
) O
. O
[]

Sixty O
percent O
of O
the O
dose O
is O
recovered O
in O
the O
feces O
. O
[]

We O
discuss O
potential O
modification O
of O
current O
memory-based O
processing O
theories O
to O
account O
for O
these O
effects O
. O
[]

After O
controlling O
for O
potential O
confounding O
variables O
, O
the O
average O
distance O
walked B-outcome ['Life-Impact']
in O
6 O
minutes O
at O
8 O
weeks O
among O
patients O
in O
the O
treatment O
group O
was O
170 O
m O
( O
95 O
% O
CI O
, O
71 O
to O
270 O
m O
) O
more O
than O
that O
in O
the O
placebo O
group O
and O
the O
average O
WOMAC O
scores O
were O
599 O
mm O
higher O
( O
95 O
% O
CI O
, O
197 O
to O
1002 O
mm O
) O
. O
['Life-Impact']

The O
patients O
had O
ECG-verified O
left O
ventricular O
hypertrophy O
, O
mean O
age O
67 O
years O
, O
blood O
pressure O
177/96 O
mmHg O
after O
two O
weeks O
placebo O
run-in O
period O
. O
[]

RESULTS: O
The O
overall O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
HR O
group O
compared O
with O
that O
in O
the O
LR O
group O
[33 O
(72%) O
vs O
18 O
(39%), O
P O
= O
.022]. O
The O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
sore I-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
at O
0, O
2, O
and O
24 O
hours O
after O
surgery O
was O
higher O
in O
the O
HR O
group O
compared O
with O
that O
in O
the O
LR O
group O
(P O
< O
.001, O
P O
= O
.001, O
and O
P O
= O
.001, O
respectively). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

We O
tested O
the O
hypothesis O
that O
the O
ITD O
could O
lower O
intratracheal O
pressures O
when O
attached O
to O
either O
a O
facemask O
or O
ETT O
. O
[]

BACKGROUND: O
Counterforce O
orthoses O
are O
used O
to O
manage O
lateral O
elbow O
tendinopathy, O
and O
their O
effectiveness O
in O
improving O
motor O
function O
has O
been O
documented. O
[]

0.30 O
kg O
) O
( O
85 O
% O
fat O
mass O
) O
treatments O
( O
both O
P O
< O
0.0005 O
) O
. O
[]

100 O
patients O
were O
randomized O
. O
[]

Vitamin O
C O
was O
measured O
in O
plasma O
and O
vitamin O
E O
and O
carotenoids O
were O
measured O
in O
serum O
by O
high-performance O
liquid O
chromatography O
( O
HPLC O
) O
. O
[]

Phase O
II O
multi-institutional O
prospective O
randomised O
trial O
comparing O
S-1+paclitaxel O
with O
S-1+cisplatin O
in O
patients O
with O
unresectable O
and/or O
recurrent O
advanced O
gastric O
cancer O
. O
[]

During O
the O
trial O
there O
were O
16 O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
for O
infants O
in O
the O
lactoferrin O
group O
and O
10 O
for O
infants O
in O
the O
control O
group. O
[['Adverse-effects']]

Jejunal O
feeding O
was O
tolerated B-outcome ['Life-Impact']
unconditionally O
in O
25 O
( O
86 O
% O
) O
of O
the O
TEN O
group O
. O
['Life-Impact']

One-month O
urinalysis O
follow-up O
data O
showed O
a O
significant O
reduction O
in O
heroin B-outcome ['Life-Impact']
use I-outcome ['Life-Impact']
in O
the O
experimental O
group O
( O
from O
63 O
% O
positive O
at O
intake O
to O
29 O
% O
positive O
) O
with O
no O
change O
in O
the O
control O
group O
( O
62 O
% O
to O
60 O
% O
positive O
) O
. O
['Life-Impact']

At O
7 O
days O
post O
treatment O
, O
all O
three O
formulations O
reduced O
flea B-outcome ['Physiological-Clinical']
populations I-outcome ['Physiological-Clinical']
within O
6 O
and O
24 O
hours O
by O
68.4 O
% O
and O
99.4 O
% O
, O
respectively O
. O
['Physiological-Clinical']

Journal O
ID: O
2985248R O
[]

These O
reactivations B-outcome ['Physiological-Clinical']
required O
urgent O
intervention O
( O
thrombolysis O
, O
angioplasty O
, O
or O
coronary-bypass O
surgery O
) O
in O
11 O
patients O
treated O
with O
heparin O
alone O
, O
but O
in O
only O
2 O
patients O
in O
the O
other O
groups O
combined O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

There O
was O
a O
significantly O
higher O
death O
rate O
among O
patients O
receiving O
pyrimethamine O
( O
relative O
risk O
[ O
RR O
] O
, O
2.5 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.3-4.8 O
; O
P O
= O
.006 O
) O
, O
even O
after O
adjusting O
for O
factors O
predictive O
of O
survival O
. O
[]

Combined O
therapy O
for O
obese B-outcome ['Physiological-Clinical']
type O
2 O
diabetes B-outcome ['Physiological-Clinical']
: O
suppertime O
mixed O
insulin O
with O
daytime O
sulfonylurea O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
determine O
whether O
moxifloxacin O
penetrates O
the O
uterine O
tissue O
and O
accumulates O
at O
levels O
sufficient O
to O
eradicate O
the O
major B-outcome ['Physiological-Clinical']
pathogens I-outcome ['Physiological-Clinical']
causing O
pelvic O
inflammatory O
disease O
( O
PID O
) O
. O
['Physiological-Clinical']

BACKGROUND O
The O
objective O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
toxicity O
of O
the O
liposome-encapsulated O
doxorubicin O
, O
TLC O
D-99 O
( O
Myocet O
, O
Elan O
Pharmaceuticals O
, O
Princeton O
, O
NJ O
) O
, O
and O
conventional O
doxorubicin O
in O
first-line O
treatment O
of O
metastatic O
breast O
carcinoma O
( O
MBC O
) O
. O
[]

RESULTS O
Overall O
, O
a O
response O
rate O
of O
75 O
% O
was O
observed O
. O
[]

Patients O
were O
ventilated O
with O
nitrous O
oxide O
, O
oxygen O
and O
either O
halothane O
or O
enflurane O
. O
[]

No O
significant O
difference O
in O
median O
CD4 B-outcome ['Physiological-Clinical']
% I-outcome ['Physiological-Clinical']
change I-outcome ['Physiological-Clinical']
from O
baseline O
to O
week O
48 O
was O
found O
( O
3 O
% O
versus O
1 O
% O
) O
. O
['Physiological-Clinical']

Clinical O
characteristics O
and O
disease O
progression O
were O
compared O
between O
patients O
with O
spotty O
calcification O
( O
n O
= O
922 O
) O
and O
those O
with O
no O
calcification O
( O
n O
= O
425 O
) O
. O
[]

Patients O
in O
both O
arms O
were O
well O
balanced O
with O
regard O
to O
clinical O
variables O
. O
[]

RESULTS O
In O
the O
39 O
patients O
identified O
with O
DGE O
, O
change O
from O
placebo O
baseline O
( O
CFB B-outcome ['Physiological-Clinical']
) O
for O
percent O
gastric B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
at O
4-hour O
postmeal O
with O
nizatidine O
CR O
( O
150 O
and O
300 O
mg O
) O
was O
each O
improved O
and O
statistically O
significant O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
patients O
with O
MDS O
or O
in O
the O
remission-induction O
phase O
of O
chemotherapy O
, O
the O
numbers O
of O
cases O
with O
probable B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
possible I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
were O
lower O
in O
the O
itraconazole O
group O
than O
in O
the O
fluconazole O
group O
, O
whereas O
no O
difference O
was O
seen O
in O
patients O
with O
AML O
or O
in O
the O
consolidation O
phase O
of O
therapy O
. O
['Physiological-Clinical']

The O
trial O
was O
terminated O
on O
recommendation O
of O
the O
Policy O
and O
Data O
Monitoring O
Board O
9 O
months O
before O
the O
scheduled O
closing O
date O
. O
[]

Methylphenidate O
and O
baseball O
playing O
in O
ADHD O
children O
: O
who O
's O
on O
first O
? O
[]

Infarct B-outcome ['Physiological-Clinical']
size O
( O
additional O
aim O
) O
, O
and O
safety O
. O
['Physiological-Clinical']

The O
enlarged O
blood-buffering O
capacity O
after O
infusion O
of O
Bicarb O
eliminated O
metabolic O
acidosis O
during O
maximal O
exercise O
but O
that O
did O
not O
affect O
the O
cerebral O
lactate O
uptake O
and O
, O
therefore O
, O
the O
decrease O
in O
the O
cerebral O
metabolic O
ratio O
. O
[]

A O
review O
of O
impressions O
of O
the O
graft O
materials O
indicated O
a O
decided O
preference O
for O
PTFE O
grafts O
. O
[]

The O
intra-arterial O
chemotherapy O
represents O
an O
expensive O
, O
but O
effective O
method O
of O
treatment O
of O
advanced O
ovarian O
carcinomas O
. O
[]

The O
effect O
of O
epidural O
anesthesia O
over O
time O
was O
assessed O
by O
repeated O
measures O
analysis O
of O
variance O
. O
[]

Antibiotic O
therapy O
in O
the O
study O
group O
was O
not O
applied O
until O
clinical O
signs O
and O
symptoms O
of O
infection O
appeared O
( O
PCT O
value O
was O
> O
0.5ng/ml O
) O
. O
[]

PATIENTS O
Consecutive O
patients O
who O
were O
referred O
for O
evaluation O
of O
known O
or O
suspected O
coronary O
artery O
disease O
. O
[]

CONCLUSION O
Pruritus B-outcome ['Physiological-Clinical']
caused O
by O
epidural O
use O
of O
2 O
or O
4 O
mg O
of O
morphine O
is O
inhibited O
by O
the O
intravenous O
use O
of O
2.5 O
mg O
droperidol O
but O
not O
by O
a O
larger O
dose O
. O
['Physiological-Clinical']

A O
randomized O
controlled O
trial O
recently O
demonstrated O
that O
continuous O
positive O
airway O
pressure O
( O
CPAP O
) O
effectively O
decreases O
respiratory B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
in O
children O
presenting O
to O
Ghanaian O
district O
hospitals O
with O
respiratory O
distress O
. O
['Physiological-Clinical']

In O
this O
study O
a O
total O
of O
98 O
patients O
with O
MMC O
and O
hydrocephalus O
were O
randomly O
divided O
into O
two O
equal O
groups. O
[]

Eight O
gas O
mixtures O
of O
oxygen O
and O
nitrogen O
( O
fractional O
inspired O
oxygen O
concentration O
( O
FiO2 O
) O
0.1 O
to O
1.0 O
) O
were O
administered O
. O
[]

Effects O
of O
ursodeoxycholic O
acid O
on O
serum B-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
enzymes I-outcome ['Physiological-Clinical']
in O
patients O
with O
hepatitis O
C O
virus-related O
chronic O
liver O
disease O
. O
['Physiological-Clinical']

Cardiovascular O
risk O
is O
increased O
in O
GH O
deficiency O
( O
GHD O
) O
. O
[]

Patients O
were O
evaluated O
for O
the O
amount O
of O
rectal O
and O
urethral B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
and O
symptoms O
and O
signs O
of O
infection B-outcome ['Physiological-Clinical']
after I-outcome ['Physiological-Clinical']
biopsy I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name: O
Journal O
of O
computer O
assisted O
tomography O
[]

The O
effects O
of O
dried O
purple O
carrot O
on O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
, O
body B-outcome ['Physiological-Clinical']
composition I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
lipids B-outcome ['Physiological-Clinical']
, O
inflammatory B-outcome ['Physiological-Clinical']
markers I-outcome ['Physiological-Clinical']
, O
liver B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
, O
and O
appetite B-outcome ['Physiological-Clinical']
were O
investigated O
in O
16 O
males O
( O
aged O
53.1 O
? O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
In O
the O
NB O
group O
, O
stable B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
were O
obtained O
with O
a O
lower O
sevoflurane O
concentration O
than O
in O
the O
control O
group O
. O
['Physiological-Clinical']

The O
present O
study O
examined O
which O
other O
working O
memory O
components O
( O
visual O
, O
spatial O
, O
and O
phonological O
) O
influence O
visual B-outcome ['Life-Impact']
selective I-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
. O
['Life-Impact']

Outcome O
measures O
included O
total O
subjective O
neck B-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
shoulder I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
head I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
based O
on O
visual O
analog O
scales O
; O
objective O
total O
range O
of O
neck B-outcome ['Physiological-Clinical']
motion I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ROM I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
and O
the O
['Physiological-Clinical', 'Physiological-Clinical']

Volunteers O
in O
the O
verum O
group O
received O
10 O
ml O
of O
an O
ethanolic O
( O
vincamine O
free O
) O
eleutherococcus O
senticosus O
preparation O
, O
3 O
times O
daily O
for O
4 O
weeks O
. O
[]

STUDY O
DESIGN O
The O
study O
was O
designed O
as O
a O
randomized O
controlled O
trial O
with O
neighborhood O
as O
the O
unit O
of O
randomization O
. O
[]

Toxicity B-outcome ['Adverse-effects']
and O
efficacy O
of O
6-thioguanine O
versus O
6-mercaptopurine O
in O
childhood O
lymphoblastic O
leukaemia O
: O
a O
randomised O
trial O
. O
['Adverse-effects']

They O
represent O
an O
interesting O
model O
for O
studying O
GH O
secretion O
, O
as O
a O
slight O
degree O
of O
cortisol O
excess O
may O
frequently O
be O
observed O
in O
such O
patients O
who O
do O
not O
present O
with O
any O
clear O
Cushingoid O
sign O
. O
[]

CONCLUSIONS/SIGNIFICANCE O
This O
modelling O
study O
shows O
that O
a O
decision O
to O
adopt O
a O
Telephone O
Counselling O
program O
over O
existing O
practice O
( O
Real O
Control O
) O
is O
likely O
to O
be O
cost-effective O
. O
['Resource-use']

Patients O
were O
randomized O
to O
receive O
either O
an O
intraoperative O
bolus O
of O
milrinone O
( O
50 O
microg/kg O
) O
or O
saline O
as O
placebo O
followed O
by O
a O
24-hour O
infusion O
of O
each O
agent O
( O
0.5 O
microg/kg/min O
) O
. O
[]

CONCLUSIONS O
Findings O
indicate O
IBD O
patients O
may O
benefit O
from O
relaxation O
training O
in O
their O
holistic O
care O
. O
[]

The O
prophylaxis O
group O
received O
on O
the O
3rd O
, O
4th O
and O
5th O
day O
a O
daily O
dose O
of O
10 O
g O
each O
. O
[]

The O
authors O
studied O
20 O
patients O
, O
ASA O
I-II O
, O
aged O
20-54 O
, O
both O
sexes O
, O
scheduled O
for O
abdominal O
surgery O
. O
[]

This O
study O
looks O
for O
a O
rebound O
aggravation O
of O
symptoms O
after O
short-term O
treatment O
with O
lansoprazole O
. O
[]

[ O
Effect O
of O
alpha O
dihydroergocryptine O
in O
patients O
with O
fibrocystic O
breast O
disease O
] O
. O
[]

Contrast O
sensitivity B-outcome ['Physiological-Clinical']
was O
significantly O
reduced O
in O
a O
photopic O
condition O
with O
and O
without O
glare O
and O
in O
a O
scotopic O
condition O
without O
glare O
. O
['Physiological-Clinical']

METHODS O
A O
total O
of O
107 O
American O
Society O
of O
Anaesthesiologists O
physical O
status O
grade O
I O
and O
II O
patients O
between O
18 O
and O
65 O
years O
of O
age O
who O
were O
scheduled O
to O
undergo O
elective O
anterior O
crucial O
ligament O
( O
ACL O
) O
reconstruction O
with O
hamstring O
autografts O
were O
enrolled O
in O
the O
study O
. O
[]

The O
CM O
group O
(12.3% O
increase) O
had O
significantly O
greater O
improvements O
in O
composite O
strength B-outcome ['Life-Impact']
from O
pre- O
to O
post-test O
than O
CHO O
(2.7% O
increase). O
[['Life-Impact']]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Patient O
outcomes O
were O
measured O
as O
changes O
in O
global B-outcome ['Life-Impact']
anxiety I-outcome ['Life-Impact']
scores O
, O
functioning B-outcome ['Life-Impact']
and O
well-being B-outcome ['Life-Impact']
, O
and O
patients O
' O
reports O
of O
global O
['Life-Impact', 'Life-Impact', 'Life-Impact']

10 O
vs O
44 O
? O
[]

For O
drugs O
used O
on O
a O
multiple-dose O
basis O
, O
Cmax B-outcome ['Physiological-Clinical']
and O
Tmax B-outcome ['Physiological-Clinical']
evaluations O
become O
redundant O
since O
the O
average O
plateau B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
is O
not O
affected O
by O
these O
parameters O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

PURPOSE: O
To O
determine O
the O
effects O
of O
botulinum O
toxin O
type O
A O
(BTX-A) O
injection O
on O
dry B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
eye I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
signs I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, Seperator ['Physiological-Clinical', 'Physiological-Clinical']
symptoms S2-outcome ['Physiological-Clinical', 'Physiological-Clinical']
, O
and O
tear O
cytokine B-outcome ['Physiological-Clinical']
levels O
in O
patients O
with O
intractable O
dry O
eye O
disease O
(DED). O
[['Physiological-Clinical', 'Physiological-Clinical'], ['Physiological-Clinical']]

Title: O
Plazomicin O
for O
Infections O
Caused O
by O
Carbapenem-Resistant O
Enterobacteriaceae. O
[]

Results O
reveal O
that O
explicit O
instruction O
group O
patients O
demonstrated O
more O
improved O
memory B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
using O
semantic O
clustering O
, O
suggesting O
that O
explicit O
and O
direct O
teaching O
facilitates O
patients O
' O
learning O
of O
information O
. O
['Life-Impact']

Didanosine O
( O
125 O
to O
200 O
mg O
given O
as O
buffered O
tablets O
) O
and O
delavirdine O
mesylate O
( O
400 O
mg O
) O
pharmacokinetics O
were O
evaluated O
when O
each O
drug O
was O
given O
alone O
( O
treatments O
A O
and O
B O
, O
respectively O
) O
, O
when O
the O
two O
drugs O
were O
given O
concurrently O
( O
treatment O
C O
) O
, O
and O
when O
didanosine O
was O
given O
1 O
h O
after O
delavirdine O
( O
treatment O
D O
) O
. O
[]

We O
aimed O
to O
study O
whether O
oxycodone O
can O
be O
an O
effective O
alternative O
for O
fentanyl O
in O
the O
management O
of O
early O
postoperative O
pain B-outcome ['Physiological-Clinical']
after O
total O
hip O
replacement. O
[['Physiological-Clinical']]

Polysomnographic O
measures O
of O
sleep B-outcome ['Physiological-Clinical']
and O
self-report O
indexes O
of O
tobacco O
withdrawal O
were O
collected O
pre- O
and O
postcessation O
from O
an O
active O
nicotine O
patch O
group O
and O
a O
placebo O
patch O
group O
in O
a O
randomized O
, O
double-blind O
clinical O
trial O
( O
N O
= O
34 O
) O
. O
['Physiological-Clinical']

All O
groups O
showed O
additional O
improvement O
in O
efficacy O
scale O
scores O
during O
the O
OLE O
. O
[]

CONCLUSIONS O
Consistent O
with O
findings O
of O
the O
epidemiological O
study O
, O
our O
study O
suggests O
that O
statins O
may O
prevent O
the O
development O
of O
a O
new O
brain B-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Here O
we O
investigate O
the O
efficacy O
and O
safety O
of O
a O
selective O
serotonin O
reuptake O
inhibitor O
( O
SSRI O
) O
, O
citalopram O
, O
and O
a O
noradrenaline O
reuptake O
inhibitor O
( O
NARI O
) O
, O
reboxetine O
, O
in O
post-stroke O
patients O
affected O
by O
anxious O
depression O
or O
retarded O
depression O
. O
[]

[ O
The O
problems O
of O
prophylactic O
chemotherapy O
, O
the O
second-look O
operation O
and O
the O
maintenance O
of O
the O
remission O
in O
the O
treatment O
of O
ovarian O
cancer O
( O
author O
's O
transl O
) O
] O
. O
[]

CONCLUSIONS O
The O
rotational O
angiography O
technique O
leads O
to O
a O
significant O
decrease O
in O
[]

PURPOSE O
New O
effective O
chemotherapy O
is O
needed O
to O
improve O
the O
outcome O
of O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O
[]

The O
magnitude O
of O
the O
reduction O
in O
the O
intrinsic B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
of O
caffeine B-outcome ['Life-Impact']
produced O
by O
ciprofloxacin O
was O
greater O
than O
that O
described O
in O
the O
literature O
for O
ciprofloxacin O
and O
theophylline O
. O
['Physiological-Clinical', 'Life-Impact']

At O
the O
end O
of O
CPB O
, O
increased O
C3b/c B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
but I-outcome ['Physiological-Clinical']
not I-outcome ['Physiological-Clinical']
C4b/c I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
present O
in O
systemic O
T2 O
blood O
compared O
with O
T1 O
, O
while O
concentrations O
of O
microparticles O
binding O
complement O
components O
and O
of O
those O
binding O
complement O
activator O
molecules O
were O
similar O
. O
['Physiological-Clinical']

RESULTS: O
After O
treatment, O
the O
6-minute O
walk B-outcome ['Life-Impact']
test O
(6MWT)], O
chronic B-outcome ['Physiological-Clinical']
obstructive I-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
(COPD) I-outcome ['Physiological-Clinical']
assessment O
test O
(CAT)], O
body B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
, O
airflow B-outcome ['Physiological-Clinical']
obstruction I-outcome ['Physiological-Clinical']
, O
dyspnea B-outcome ['Physiological-Clinical']
, O
and O
exercise B-outcome ['Physiological-Clinical', 'Life-Impact']
capacity I-outcome ['Physiological-Clinical', 'Life-Impact']
(BODE) O
index O
were O
significantly O
increased O
compared O
with O
pre-treatment O
in O
both O
groups O
(P O
< O
.01), O
but O
not O
FVC% O
and O
FEVl%. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact']]

Publication O
date: O
2019/02/13 O
06:00 O
[medline] O
[]

However O
, O
no O
evidence O
of O
systemic B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
regulation I-outcome ['Physiological-Clinical']
was O
seen O
in O
infected O
participants O
. O
['Physiological-Clinical']

CONCLUSION O
Midazolam-tramadol O
combination O
may O
be O
used O
as O
an O
alternative O
to O
midazolam-pethidine O
combination O
for O
sedation O
during O
surgical O
procedures O
performed O
under O
regional O
anaesthesia O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Plasmatic O
levels O
of O
total O
antioxidant O
status O
as O
well O
as O
erythrocyte B-outcome ['Physiological-Clinical']
glutathione I-outcome ['Physiological-Clinical']
peroxidase I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical']

Patients O
were O
monitored O
for O
adverse O
events O
. O
[]

Participants O
will O
be O
recruited O
from O
two O
major O
maternity O
hospitals O
in O
Australia O
. O
[]

Comparative O
evaluation O
of O
olopatadine O
ophthalmic O
solution O
( O
0.1 O
% O
) O
versus O
ketorolac O
ophthalmic O
solution O
( O
0.5 O
% O
) O
using O
the O
provocative O
antigen O
challenge O
model O
. O
[]

After O
insertion O
of O
the O
endoscope O
, O
endoscopists O
recorded O
visibility O
scores O
before O
the O
procedure O
, O
imaging O
scores O
at O
endoscopic O
ultrasonography O
and O
the O
numbers O
of O
high-echo O
spots O
in O
the O
gastric O
cavity O
and O
on O
the O
gastric O
wall O
surface O
after O
the O
procedure O
. O
[]

In O
addition O
, O
costs O
for O
hemiarthroplasty O
were O
lower O
. O
[]

We O
studied O
137 O
women O
and O
treatments O
were O
found O
to O
be O
equivalent O
for O
onset O
, O
duration O
and O
quality O
of O
block O
. O
[]

METHODS O
It O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
conducted O
in O
54 O
asthmatic O
children O
allergic O
to O
house O
dust O
mites O
. O
[]

Three O
groups O
of O
young O
patients O
with O
borderline O
hypertension O
were O
studied O
for O
a O
12 O
months O
period O
. O
[]

CONCLUSIONS O
Fructose-1,6-diphosphate O
produces O
a O
modest O
but O
significant O
increase O
in O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
in O
patients O
with O
mild O
to O
moderate O
heart O
failure O
. O
['Physiological-Clinical']

The O
objective O
of O
current O
article O
is O
to O
present O
the O
protocol O
for O
a O
PE O
teacher-delivered O
theory-based O
trial O
to O
promote O
secondary O
school O
students' O
participation B-outcome ['Life-Impact']
in O
physical O
activity O
out-of-school O
contexts. O
[['Life-Impact']]

The O
meta-analysis O
of O
four O
accomplished O
comparative O
studies O
( O
including O
the O
present O
one O
) O
found O
a O
between-group O
mean O
effect O
size O
of O
( O
d= O
0.15 O
favouring O
individual O
over O
group O
CBT O
at O
posttreatment O
( O
95 O
% O
confidence O
interval O
, O
-0.12 O
, O
0.42 O
) O
. O
[]

The O
total O
power O
output O
used O
for O
RF O
was O
lower O
in O
group O
1 O
than O
in O
group O
2 O
( O
median O
271 O
vs. O
1,045 O
W.m O
) O
. O
[]

BACKGROUND O
Breathlessness O
in O
advanced O
disease O
causes O
significant O
distress B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
patients I-outcome ['Physiological-Clinical']
and O
carers O
and O
presents O
management O
challenges O
to O
health O
care O
professionals O
. O
['Physiological-Clinical']

This O
decrease O
was O
caused O
by O
a O
significant O
decrease O
in O
CBF B-outcome ['Physiological-Clinical']
associated O
with O
a O
significant O
increase O
in O
AVDO2 B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

h O
) O
, O
or O
saline O
for O
85 O
min O
. O
[]

Eighteen O
patients O
received O
the O
combination O
and O
were O
compared O
with O
six O
concurrent O
control O
and O
65 O
historical O
control O
patients O
treated O
with O
rhGM-CSF O
alone O
. O
[]

The O
fall B-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
tcPCO2 I-outcome ['Physiological-Clinical']
and O
the O
cardiovascular B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
was O
greater O
in O
panicking O
patients O
than O
patients O
who O
did O
not O
panic O
. O
['Physiological-Clinical', 'Physiological-Clinical']

American O
Knee O
Society O
score O
was O
used O
for O
clinical O
assessment O
preoperatively O
, O
and O
at O
1 O
and O
2 O
years O
. O
[]

Patients O
' O
anxiety B-outcome ['Life-Impact']
was O
assessed O
with O
the O
State B-outcome ['Life-Impact']
Trait I-outcome ['Life-Impact']
Anxiety I-outcome ['Life-Impact']
Inventory O
before O
and O
after O
a O
consultation O
. O
['Life-Impact', 'Life-Impact']

There O
is O
circumstantial O
evidence O
for O
an O
association O
between O
falls B-outcome ['Life-Impact']
and O
the O
syndrome O
. O
['Life-Impact']

Thus, O
PrimaVie(R) O
Shilajit O
supplementation O
at O
500 O
mg.d(- O
1) O
elicited O
favorable O
muscle B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
connective B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
tissue E1-outcome ['Physiological-Clinical', 'Physiological-Clinical']
adaptations. O
[['Physiological-Clinical', 'Physiological-Clinical']]

Effect O
of O
esomeprazole O
on O
nighttime O
heartburn O
and O
sleep O
quality O
in O
patients O
with O
GERD O
: O
a O
randomized O
, O
placebo-controlled O
trial O
. O
[]

We O
showed O
that O
prospective O
design O
path O
analysis O
using O
structural O
equation O
modeling O
( O
SEM O
) O
model O
for O
both O
direct O
and O
indirect O
effects O
enabled O
statistical O
exploration O
of O
root O
causes O
and O
estimation O
of O
their O
impact O
on O
the O
outcome O
. O
[]

The O
adverse O
reactions O
to O
FZ O
are O
not O
severe O
, O
and O
are O
well O
tolerated B-outcome ['Life-Impact']
in O
most O
patients O
. O
['Life-Impact']

Postdischarge B-outcome ['Resource-use']
community I-outcome ['Resource-use']
care I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
were O
lower O
. O
['Resource-use']

Main O
Outcomes O
and O
Measures: O
The O
primary O
outcome O
was O
all-cause B-outcome ['Mortality']
mortality I-outcome ['Mortality']
at O
28 O
days. O
[['Mortality']]

Sociodemographic O
data O
and O
clinical O
features O
were O
assessed O
. O
[]

CONTEXT O
Selective O
serotonin O
reuptake O
inhibitors O
are O
widely O
prescribed O
for O
children O
with O
autism O
spectrum O
disorders O
. O
[]

After O
6 O
months O
, O
body B-outcome ['Life-Impact']
image I-outcome ['Life-Impact']
and O
cosmetic B-outcome ['Life-Impact']
appearance I-outcome ['Life-Impact']
were O
assessed O
using O
a O
validated O
survey O
. O
['Life-Impact', 'Life-Impact']

Patients O
of O
the O
NLA O
group O
showed O
no O
hyperglycaemia O
and O
only O
mild O
elevations O
of O
the O
cortisol O
levels O
during O
the O
intraoperative O
period O
. O
( O
[]

The O
targeted O
mechanism O
of O
factor O
Xa O
inhibition O
has O
been O
studied O
extensively O
, O
initially O
as O
prophylaxis O
for O
venous O
thromboembolism O
( O
VTE O
) O
in O
the O
orthopedic O
surgical O
setting O
. O
[]

MAIN O
RESULTS O
Of O
132 O
eligible O
patients O
, O
113 O
were O
randomized O
. O
[]

Journal-Name:Japanese O
journal O
of O
clinical O
oncology O
[]

They O
were O
randomly O
divided O
into O
volume O
controlled O
ventilation O
(VCV) O
group O
and O
pressure O
controlled O
ventilation O
(PCV) O
group O
according O
to O
random O
number O
table. O
[]

This O
trial O
was O
registered O
at O
www.clinicaltrials.gov O
as O
# O
NCT00003389 O
. O
[]

The O
primary O
efficacy O
end-point O
was O
the O
difference O
in O
DMVF O
at O
12 O
weeks O
. O
[]

OBJECTIVES O
We O
examined O
the O
effects O
of O
a O
high O
fat O
diet O
rich O
in O
monounsaturated O
fat O
( O
MUFA-diet O
) O
and O
a O
moderate O
fat O
diet O
rich O
in O
polyunsaturated O
fat O
( O
PUFA-diet O
) O
on O
the O
susceptibility O
of O
LDL B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
haplotype O
HT4 O
, O
caffeine O
failed O
to O
counteract O
the O
waking-induced O
impairment O
of O
PVT O
performance O
and O
the O
rebound O
of O
SWA O
in O
recovery O
sleep O
. O
[]

This O
suggests O
that O
the O
use O
of O
maintenance O
therapy O
in O
maximally O
tolerated O
doses O
may O
be O
associated O
with O
an O
increased O
survival B-outcome ['Mortality']
in O
childhood O
ALL O
. O
['Mortality']

Journal-Name:Zhonghua O
wei O
zhong O
bing O
ji O
jiu O
yi O
xue O
[]

Predictors O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
change O
in O
a O
series O
of O
controlled O
dietary O
intervention O
studies O
. O
['Physiological-Clinical']

We O
examined O
vascular O
function O
and O
structure O
in O
: O
( O
1 O
) O
healthy O
lowlanders O
during O
acute O
hypoxia O
and O
prolonged O
( O
?2 O
weeks O
) O
exposure O
to O
high O
altitude O
, O
and O
( O
2 O
) O
high-altitude O
natives O
at O
5050 O
m O
( O
highlanders O
) O
. O
[]

These O
principles O
make O
it O
possible O
to O
reduce O
the O
need O
for O
primary B-outcome ['Physiological-Clinical']
colostomy I-outcome ['Physiological-Clinical']
to O
approximately O
50 O
per O
cent O
in O
a O
large O
ongoing O
group O
of O
patients O
with O
colonic O
injury O
. O
['Physiological-Clinical']

Osmotic-release O
oral O
system O
methylphenidate O
was O
dose O
optimized O
over O
the O
first O
6 O
weeks. O
[]

Using O
a O
multivariate O
model O
, O
a O
trend O
was O
seen O
towards O
a O
greater O
benefit O
from O
CHART O
in O
the O
lower O
Ki-67 O
tumours O
( O
P O
= O
0.08 O
) O
; O
this O
became O
significant O
by O
pooling O
the O
low O
and O
intermediate O
Ki-67 O
groups O
in O
comparison O
with O
the O
high O
Ki-67 O
group O
( O
P O
= O
0.032 O
) O
. O
[]

RESULTS O
Data O
were O
analyzed O
for O
101 O
tumors O
. O
[]

We O
report O
three O
experiments O
carried O
out O
in O
the O
development O
of O
DTkid O
-- O
interactive O
computer O
simulation O
software O
that O
presents O
SIMon O
, O
a O
realistic O
virtual O
child O
with O
whom O
novice O
tutors O
can O
learn O
and O
practise O
DTT O
techniques O
. O
[]

RESULTS O
The O
printed O
intervention O
resulted O
in O
a O
higher O
participation B-outcome ['Life-Impact']
rate O
( O
19 O
% O
) O
than O
the O
Web-based O
intervention O
( O
12 O
% O
) O
. O
['Life-Impact']

This O
randomized O
phase O
III O
trial O
compared O
concurrent O
chemoradiotherapy O
( O
CCRT O
) O
versus O
radiotherapy O
( O
RT O
) O
alone O
in O
patients O
with O
advanced O
NPC O
. O
[]

0.47 O
kg O
, O
P O
< O
0.0005 O
) O
groups O
during O
the O
beverage O
arm O
. O
[]

Leuprolide O
reduced O
PMS B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
to O
minimal O
levels O
where O
symptoms O
were O
limited O
to O
the O
luteal O
phase O
. O
['Physiological-Clinical']

Patients O
receive O
hyperbaric O
oxygen O
therapy O
every O
day O
for O
6 O
weeks O
during O
the O
treatment O
phase O
and O
are O
provided O
ongoing O
wound O
care O
and O
weekly O
assessments O
. O
[]

The O
primary O
end O
point O
was O
investigator-assessed O
progression-free B-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
; O
rates O
of O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
evaluated. O
[['Physiological-Clinical', 'Mortality'], ['Physiological-Clinical'], ['Adverse-effects']]

0.3 O
and O
6.8 O
? O
[]

The O
decrease O
in O
bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
was O
, O
however O
, O
more O
marked O
in O
the O
high O
dose O
budesonide O
group O
, O
reaching O
a O
borderline O
significance O
( O
P=0.10 O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

The O
treatment O
of O
asthma O
in O
adults O
using O
sodium O
cromoglycate O
pressurized O
aerosol O
: O
a O
double-blind O
controlled O
trial O
. O
[]

Serial O
radionuclide O
ventriculography O
demonstrated O
no O
difference O
in O
24-hour O
( O
52 O
+/- O
12 O
% O
versus O
50 O
+/- O
12 O
% O
) O
or O
6-week O
( O
51 O
+/- O
12 O
% O
versus O
51 O
+/- O
13 O
% O
) O
ejection B-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
values O
for O
placebo O
and O
streptokinase O
groups O
, O
respectively O
. O
['Physiological-Clinical']

BMD O
and O
BTM O
were O
assessed O
pre-randomization O
, O
during O
and O
after O
the O
end O
of O
treatment O
( O
EOT O
) O
. O
[]

Comparison O
of O
endotracheal O
and O
peripheral O
intravenous O
adrenaline O
in O
cardiac O
arrest O
. O
[]

Children O
from O
highly O
stressed O
families O
appeared O
to O
benefit O
most O
, O
reinforcing O
the O
importance O
of O
involving O
families O
in O
early O
childhood O
intervention O
programmes O
. O
[]

Demonstration O
enrollees O
included O
those O
eligible O
for O
PCS O
( O
in O
Arkansas O
) O
, O
those O
assessed O
to O
receive O
such O
services O
( O
in O
New O
Jersey O
) O
, O
and O
recipients O
of O
Medicaid O
HCBS O
( O
in O
Florida O
) O
. O
[]

OBJECTIVE O
To O
study O
the O
relation O
between O
moderate O
coronary O
dissections O
, O
coronary O
flow O
velocity O
reserve O
( O
CFVR O
) O
, O
and O
long O
term O
outcome O
. O
[]

However O
, O
while O
there O
is O
much O
anecdotal O
evidence O
to O
that O
effect O
, O
the O
empirical O
literature O
is O
very O
inconsistent O
. O
[]

At O
this O
point O
, O
there O
was O
a O
significant O
improvement O
to O
mean O
diet O
group O
scores O
( O
time*treatment O
interaction O
) O
on O
sub-domains O
of O
[]

We O
developed O
a O
checklist O
containing O
six O
unique O
sets O
of O
yes/no O
variables O
organized O
in O
a O
2 O
x O
3 O
matrix O
of O
exposure O
potential O
versus O
protection O
( O
two O
columns O
) O
at O
the O
levels O
of O
materials O
, O
processes O
, O
and O
human O
interface O
( O
three O
rows O
) O
. O
[]

This O
is O
the O
first O
experimental O
evidence O
of O
beta-Eudesmol O
effect O
for O
mental O
stress O
in O
human. O
[]

With O
the O
rigid O
fixation O
of O
the O
distal O
femoral O
fractures O
, O
bone O
grafting O
is O
frequently O
needed O
. O
[]

METHODS O
Forty O
individuals O
with O
single O
domain O
amnestic O
MCI O
and O
their O
program O
partners O
were O
randomized O
to O
receive O
the O
MSS O
, O
either O
with O
training O
or O
without O
( O
controls O
) O
. O
[]

The O
PICIHBI O
group O
demonstrated O
a O
significant O
increase O
in O
one O
Test O
of O
Playfulness B-outcome ['Life-Impact']
(ToP) O
item O
score O
at O
midassessment. O
[['Life-Impact']]

BACKGROUND O
Recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
SCCHN O
) O
is O
associated O
with O
poor O
survival O
. O
[]

In O
addition O
, O
the O
amount O
of O
narcotic B-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
in O
the O
PACU O
was O
less O
in O
the O
fentanyl O
group O
( O
P O
< O
0.005 O
) O
. O
['Life-Impact']

The O
total O
of O
120 O
patients O
studied O
in O
the O
two O
series O
showed O
wound B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
to O
occur O
in O
13 O
per O
cent O
of O
the O
62 O
patients O
receiving O
cefotaxime O
and O
30 O
per O
cent O
of O
the O
58 O
patients O
receiving O
cephamandole O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURE O
Clinical B-outcome ['Physiological-Clinical']
eradication I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
condylomata I-outcome ['Physiological-Clinical']
for O
six O
months O
following O
adjuvant B-outcome ['Resource-use']
chemotherapy I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

No O
interaction O
was O
found O
between O
aspirin O
and O
the O
most O
used O
antihypertensive O
drug O
classes O
( O
angiotensin O
converting O
enzyme O
inhibitors O
and O
calcium O
antagonists O
) O
. O
[]

Title: O
Rivaroxaban O
for O
Thromboprophylaxis O
in O
High-Risk O
Ambulatory O
Patients O
with O
Cancer. O
[]

Significant O
reduction O
in O
( O
BMI-Z O
) O
was O
achieved O
in O
both O
groups O
during O
intervention O
and O
was O
significantly O
greater O
for O
the O
HPLC O
group O
( O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

Lower O
fornix O
and O
lid O
margin O
cultures O
were O
taken O
from O
both O
eyes O
before O
and O
after O
treatment O
. O
[]

Difference O
between O
the O
two O
treatment O
arms O
was O
significant O
as O
the O
group O
that O
received O
memantine O
had O
greater O
reduction O
in O
ABC-C O
subscale O
scores O
for O
irritability O
, O
stereotypic O
behaviour O
and O
hyperactivity O
. O
[]

METHODS O
The O
study O
was O
a O
prospective O
analysis O
of O
95 O
patients O
who O
underwent O
fluoroscopy O
guided O
TBLB O
over O
a O
two O
year O
period O
. O
[]

More O
proven O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
occurred O
in O
flu O
( O
Aspergillus O
four O
, O
Candida O
tropicalis O
one O
, O
C. O
krusei O
one O
) O
than O
itra O
( O
C. O
albicans O
one O
) O
and O
more O
of O
these O
were O
fatal O
( O
four O
versus O
nil O
) O
. O
['Physiological-Clinical']

Femoral O
neck O
osteoporosis O
with O
low O
ASM B-outcome ['Physiological-Clinical']
predicted O
poor O
chair B-outcome ['Physiological-Clinical']
stand I-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
( O
beta O
-3.3 O
, O
standard O
error O
1.6 O
, O
p O
= O
0.04 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Assessment O
of O
analgesia O
and O
sedation O
during O
vagotonia O
( O
first O
part O
of O
the O
study O
) O
and O
hypokinetic O
type O
of O
haemodynamics O
( O
second O
part O
of O
the O
study O
) O
was O
carried O
out O
with O
visual O
analogue O
scale O
( O
VAS O
) O
and O
Richmond B-outcome ['Physiological-Clinical']
scale I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
following O
variables O
contributed O
significantly O
to O
predicting O
FH B-outcome ['Physiological-Clinical']
SD I-outcome ['Physiological-Clinical']
score O
: O
GH B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
, O
height B-outcome ['Physiological-Clinical']
SD I-outcome ['Physiological-Clinical']
score I-outcome ['Physiological-Clinical']
( O
ref O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

To O
address O
this O
issue O
and O
to O
evaluate O
the O
predictive O
value O
of O
HER2 O
on O
chemotherapy O
, O
we O
investigated O
a O
cohort O
of O
278 O
patients O
from O
the O
GeparTrio O
trial O
, O
a O
prospective O
neoadjuvant O
anthracycline/taxane-based O
multicenter O
study O
. O
[]

RESULTS O
After O
569 O
patients O
had O
undergone O
randomization O
, O
enrollment O
was O
stopped O
because O
of O
concerns O
about O
the O
safety O
of O
the O
patients O
who O
had O
been O
assigned O
to O
receive O
warfarin O
. O
[]

Few O
attempts O
have O
been O
made O
to O
conduct O
randomised O
control O
trials O
( O
RCTs O
) O
of O
interventions O
for O
pre-school O
children O
with O
autism O
. O
[]

After O
1 O
year O
of O
treatment O
, O
no O
consistent O
decrease O
in O
postseasonal B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
IgE I-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
could O
be O
shown O
in O
either O
group O
. O
['Physiological-Clinical']

CONCLUSIONS O
A O
single O
nasal O
allergen O
challenge O
in O
SAR O
patients O
increased O
markers O
of O
allergic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
in O
the O
lower O
respiratory O
tract O
, O
possibly O
via O
pronounced O
activation O
of O
inflammatory O
cells O
through O
circulating O
immediate-type O
reaction O
cytokines O
like O
IL-5 O
. O
['Physiological-Clinical']

Outcome O
measures O
were O
the O
Fugl-Meyer O
Assessment O
( O
FMA O
) O
and O
muscle O
tone O
measured O
by O
Myoton-3 O
for O
motor B-outcome ['Life-Impact']
impairment I-outcome ['Life-Impact']
and O
the O
Box O
and O
Block O
Test O
( O
BBT O
) O
and O
10-Meter O
Walk O
Test O
( O
10 O
MWT O
) O
for O
motor O
function O
. O
['Life-Impact']

Transverse O
paddle O
orientation O
resulted O
in O
a O
significantly O
( O
P O
< O
0.01 O
) O
higher O
TTI O
than O
longitudinal O
orientation O
at O
all O
paddle O
forces O
below O
12 O
kg O
force O
. O
[]

Erythropoiesis O
after O
therapy O
with O
recombinant O
human O
erythropoietin O
: O
a O
dose-response O
study O
in O
anemic O
cancer O
surgery O
patients O
. O
[]

The O
safety O
evaluation O
was O
performed O
during O
the O
28-day O
follow-up O
and O
serum O
samples O
for O
anti-rabies O
antibody O
titration O
were O
collected O
on O
D0 O
( O
before O
injection O
) O
D3 O
, O
D7 O
, O
D14 O
and O
D28 O
. O
[]

Hand O
laterality O
recognition O
imparted O
a O
consistent O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
across O
groups O
, O
however O
, O
this O
effect O
was O
limited O
in O
magnitude O
. O
['Physiological-Clinical', 'Life-Impact']

METHODS O
TCM B-outcome ['Physiological-Clinical']
typing I-outcome ['Physiological-Clinical']
and O
sCD44v6 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
determined O
in O
all O
the O
enrolled O
patients O
( O
30 O
in O
the O
control O
and O
32 O
in O
the O
trial O
group O
) O
before O
operation O
, O
and O
3-4 O
courses O
of O
chemotherapy O
was O
applied O
to O
them O
from O
3-4 O
weeks O
after O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
test O
the O
effect O
of O
valacyclovir O
alone O
and O
with O
aspirin O
on O
the O
asymptomatic O
shedding O
of O
HSV-1 O
DNA O
in O
tears O
and O
saliva O
of O
healthy O
individuals O
. O
[]

Effects O
of O
telephone O
call O
interventions O
on O
patients O
' O
well-being O
in O
a O
radiation O
therapy O
department O
. O
[]

The O
primary O
outcome O
measures O
were O
the O
score O
on O
the O
Irritability O
subscale O
of O
the O
Aberrant O
Behavior O
Checklist O
and O
the O
rating O
on O
the O
Clinical O
Global O
Impressions O
- O
Improvement O
( O
CGI-I O
) O
scale O
at O
eight O
weeks O
. O
[]

Outcome O
was O
favourable O
, O
with O
no O
seizures B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
mildly I-outcome ['Physiological-Clinical']
affected I-outcome ['Physiological-Clinical']
cognitive I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

For O
the O
first O
4 O
weeks O
, O
patients O
received O
amlodipine O
5 O
mg O
QD O
( O
morning O
) O
. O
[]

Effect O
of O
food O
on O
the O
antiviral B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
of O
didanosine O
enteric-coated O
capsules O
: O
a O
pilot O
comparative O
study O
. O
['Physiological-Clinical']

Seventy-five O
participants O
, O
25 O
per O
group O
, O
completed O
the O
study O
. O
[]

CONCLUSIONS O
Both O
diazepam O
and O
midazolam O
were O
shown O
to O
be O
effective O
sedative O
agents O
, O
successfully O
and O
safely O
used O
to O
sedate O
autistic O
patients O
for O
dental O
treatment O
. O
[]

SETTING O
Public O
rehabilitation O
center O
in O
France O
. O
[]

One O
hundred O
and O
ten O
patients O
were O
available O
for O
evaluation O
of O
response O
. O
[]

This O
study O
showed O
no O
benefit O
of O
preoperatively O
administered O
oral O
ibuprofen O
10 O
mg.kg-1 O
or O
acetaminophen O
15 O
mg.kg-1 O
over O
placebo O
for O
the O
relief O
of O
postoperative O
pain O
in O
children O
undergoing O
BM O
& O
T O
. O
[]

No O
significant O
side-effects O
were O
noted O
with O
SJW O
. O
[]

SETTING O
The O
sleep-disorders O
unit O
of O
a O
tertiary O
referral O
university O
hospital O
. O
[]

Further O
postsurgical O
follow O
up O
was O
carried O
on O
for O
up O
to O
10 O
years O
. O
[]

BACKGROUND: O
Total O
hip O
replacement O
(THR) O
is O
often O
accompanied O
by O
severe O
postoperative O
pain. O
[]

Two-hundred O
patients O
were O
randomized O
into O
2 O
groups O
to O
receive O
heparinized O
( O
group O
H O
, O
n O
= O
100 O
) O
or O
nonheparinized O
( O
group O
S O
, O
n O
= O
100 O
) O
flush O
solutions O
. O
[]

OBJECTIVES O
We O
explored O
whether O
a O
successful O
randomized O
controlled O
trial O
of O
early O
education O
, O
the O
Carolina O
Abecedarian O
Project O
( O
ABC O
) O
, O
which O
enrolled O
infants O
from O
1972 O
to O
1977 O
at O
the O
Frank O
Porter O
Graham O
Child O
Development O
Institute O
in O
Chapel O
Hill O
, O
North O
Carolina O
, O
improved O
health O
outcomes O
and O
behaviors O
by O
21 O
years O
of O
age O
. O
[]

Anxiety O
disorders O
in O
typically O
developing O
youth O
: O
autism O
spectrum O
symptoms O
as O
a O
predictor O
of O
cognitive-behavioral O
treatment O
. O
[]

However O
, O
MMR O
occurred O
faster O
among O
patients O
randomly O
assigned O
to O
imatinib O
800 O
mg/d O
, O
who O
had O
higher O
rates O
of O
MMR O
at O
3 O
and O
6 O
months O
compared O
with O
those O
in O
the O
imatinib O
400-mg/d O
arm O
( O
P O
= O
.0035 O
by O
log-rank O
test O
) O
. O
[]

Thus O
acute O
maternal B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
in O
normal O
patients O
can O
cause O
fetal B-outcome ['Physiological-Clinical']
hyperglycemia I-outcome ['Physiological-Clinical']
, O
metabolic B-outcome ['Physiological-Clinical']
acidosis I-outcome ['Physiological-Clinical']
, O
and O
neonatal B-outcome ['Physiological-Clinical']
hypoglycemia I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

10 O
ng/mL/cc O
would O
have O
avoided O
28 O
% O
of O
biopsies O
at O
the O
cost O
of O
10 O
% O
of O
detectable O
cancers O
. O
[]

CONCLUSION O
The O
[]

No O
serious O
spinal O
pathology O
was O
identified O
in O
either O
group O
. O
[]

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India. O
[]

BACKGROUND O
AND O
AIMS O
We O
undertook O
this O
study O
to O
determine O
the O
efficacy O
of O
oral O
magnesium O
supplementation O
in O
the O
improvement O
of O
the O
metabolic B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
metabolically O
obese O
, O
normal-weight O
( O
MONW O
) O
individuals O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Esmolol O
( O
0.3 O
mg. O
kg O
( O
-1 O
) O
. O
[]

The O
GMRs B-outcome ['Physiological-Clinical']
were O
2.6- O
and O
2.9-fold O
, O
respectively O
. O
['Physiological-Clinical']

Additionally, O
both O
groups O
will O
receive O
the O
same O
acupuncture O
treatment O
once O
a O
week O
for O
6 O
weeks O
as O
a O
concurrent O
treatment. O
[]

In O
contrast O
, O
GH-secretagogues O
elevated O
leptin B-outcome ['Physiological-Clinical']
levels O
within O
12 O
h. O
Infusion O
of O
GHRP-2 O
alone O
induced O
a O
maximal O
leptin B-outcome ['Physiological-Clinical']
increase O
of O
+87 O
% O
after O
24 O
h O
, O
whereas O
GHRH O
+ O
GHRP-2 O
elevated O
leptin B-outcome ['Physiological-Clinical']
by O
up O
to O
+157 O
% O
after O
24 O
h. O
The O
increase O
in O
leptin B-outcome ['Physiological-Clinical']
within O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Usual O
Care O
( O
brief O
intervention O
) O
compared O
to O
existing O
practice O
( O
Real O
Control O
) O
was O
also O
cost-effective O
( O
$ O
12,153 O
per O
quality O
adjusted O
life O
year O
gained O
) O
. O
['Resource-use']

[ O
Isometric O
hip O
muscle O
strength O
in O
posttraumatic O
below-knee O
amputees O
] O
. O
[]

Progression-free B-outcome ['Physiological-Clinical']
and O
cancer-specific B-outcome ['Mortality']
survivals I-outcome ['Mortality']
were O
determined O
by O
the O
Kaplan-Meier O
method O
. O
['Physiological-Clinical', 'Mortality']

We O
investigated O
the O
direct O
effect O
of O
a O
nutrition O
intervention O
in O
early O
childhood O
on O
adult O
economic O
productivity O
. O
[]

RESULTS O
The O
major O
finding O
of O
the O
study O
was O
the O
significant O
improvement O
in O
submaximal B-outcome ['Physiological-Clinical']
response O
to O
exercise B-outcome ['Life-Impact']
of O
experimental O
subjects O
, O
expressed O
by O
the O
reduction O
in O
HR B-outcome ['Physiological-Clinical']
, O
VO2 B-outcome ['Physiological-Clinical']
VE O
while O
VO2 B-outcome ['Physiological-Clinical']
max O
did O
not O
change O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:BMC O
psychology O
[]

Before O
, O
during O
, O
and O
after O
the O
procedure O
, O
infant O
stress O
was O
evaluated O
by O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
respiration B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
transcutaneous B-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
SL O
group O
had O
greater O
12-year O
survival B-outcome ['Mortality']
than O
the O
LAG O
group O
( O
48 O
% O
vs. O
38 O
% O
, O
p O
= O
0.02 O
) O
. O
['Mortality']

At O
6 O
min, O
hemostasis B-outcome ['Physiological-Clinical']
was O
achieved O
in O
93.0% O
(238/256) O
of O
the O
HP O
group O
compared O
to O
77.3% O
(102/132) O
of O
the O
G O
+ O
T O
group O
(non-inferiority O
P O
< O
0.0001, O
superiority O
P O
< O
0.0001). O
[['Physiological-Clinical']]

In O
conclusion O
, O
in O
treated O
patients O
with O
heart O
failure O
, O
increasing O
NT-ANP O
and O
BNP O
over O
time O
predict O
a O
decreasing O
EF B-outcome ['Physiological-Clinical']
and O
ventricular B-outcome ['Physiological-Clinical']
dilatation I-outcome ['Physiological-Clinical']
, O
while O
increasing O
NT-ANP O
and O
norepinephrine O
independently O
predict O
greater O
mortality B-outcome ['Mortality']
and O
morbidity B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

In O
conclusion O
, O
it O
is O
suggested O
that O
adaptive O
mechanisms O
, O
which O
would O
functionally O
modify O
the O
reflex O
responses O
, O
are O
also O
continuously O
working O
during O
voluntary O
movements O
in O
response O
to O
sudden O
changes O
in O
environmental O
information O
. O
[]

METHODS O
High O
resolution O
B-mode O
ultrasound O
was O
used O
to O
characterize O
plaque B-outcome ['Physiological-Clinical']
echogenicity I-outcome ['Physiological-Clinical']
in O
four O
subgroups O
- O
dominantly O
echolucent O
, O
substantially O
echolucent O
, O
dominantly O
echogenic O
, O
and O
uniformly O
echogenic O
. O
['Physiological-Clinical']

This O
difference O
was O
maintained O
at O
the O
6- O
and O
12-months O
follow-ups O
. O
[]

A O
multifactorial O
strategy O
of O
pain O
management O
is O
associated O
with O
less O
pain O
in O
scheduled O
vaccination O
of O
children O
. O
[]

RESULTS: O
CART O
group O
demonstrated O
an O
increase O
in O
HFnu B-outcome ['Physiological-Clinical']
, O
TP B-outcome ['Physiological-Clinical']
, O
SDNN B-outcome ['Physiological-Clinical']
, O
and O
RMSSD B-outcome ['Physiological-Clinical']
, O
(p<0.05) O
along O
with O
a O
significant O
decrease O
in O
LFnu B-outcome ['Physiological-Clinical']
, O
LF/HF B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
, O
systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
and O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
(p<0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Not O
Now O
! O
[]

Additional O
findings O
included O
that O
a O
10 O
% O
increase O
in O
physical B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
increased O
session B-outcome ['Life-Impact']
attendance I-outcome ['Life-Impact']
by O
0.4 O
% O
( O
P O
< O
.001 O
) O
and O
a O
10 O
% O
increase O
in O
mental B-outcome ['Life-Impact']
health I-outcome ['Life-Impact']
predicted O
a O
decrease O
in O
percent O
energy O
from O
fat O
of O
0.3 O
% O
( O
P O
< O
.001 O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

There O
was O
a O
significant O
correlation O
between O
propofol B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
and O
recovery B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical']

Participants O
were O
critically O
ill O
patients O
who O
regained O
mental O
capacity O
following O
receipt O
of O
level O
3 O
(intensive) O
care. O
[]

The O
medium O
term O
results O
confirmed O
the O
efficacity O
noted O
in O
the O
short O
term O
survey O
. O
[]

Intervention O
pilot O
for O
parents O
of O
children O
with O
autistic O
spectrum O
disorder O
. O
[]

In O
a O
residential O
laboratory O
seven O
non-physically-dependent O
opioid O
abuser O
volunteers O
received O
intramuscular O
buprenorphine O
( O
0.4 O
mg O
or O
0.8 O
mg/70 O
kg O
) O
alone O
and O
in O
combination O
with O
naloxone O
( O
0.4 O
mg O
or O
0.8 O
mg/70 O
kg O
) O
versus O
placebo O
. O
[]

METHODS O
A O
randomized O
, O
double-masked O
, O
two-way O
crossover O
study O
was O
performed O
in O
14 O
healthy O
volunteers O
. O
[]

The O
effects O
were O
observed O
in O
dissociation O
with O
effects O
of O
articulatory O
suppression O
and O
matrix O
tapping O
, O
so O
that O
the O
locus O
of O
the O
effects O
of O
the O
new O
task O
is O
not O
due O
to O
the O
slave O
systems O
. O
[]

A O
model O
for O
evaluating O
anticonvulsants O
. O
[]

After O
that O
the O
home O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
monitoring O
can O
be O
used O
to O
exclude O
individuals O
who O
are O
at O
risk O
for O
side O
effects O
due O
to O
low O
out-of-office O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
readings O
and O
to O
precisely O
monitor O
the O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
response O
to O
therapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Although O
this O
procedure O
provides O
long-term O
survival O
in O
a O
significant O
number O
of O
patients O
, O
50-75 O
% O
of O
the O
patients O
develop O
intra- O
and/or O
extrahepatic O
recurrence O
. O
[]

To O
investigate O
the O
existence O
of O
risk O
factors O
, O
the O
incidence O
of O
encephalopathic O
syndromes O
and O
the O
relationship O
between O
the O
development O
of O
different O
types O
of O
encephalopathies O
and O
the O
clinical O
outcome O
was O
studied O
in O
a O
clinical O
trial O
with O
588 O
patients O
under O
treatment O
with O
melarsoprol O
. O
[]

The O
primary O
outcome O
of O
the O
study O
is O
change O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
change O
in O
the O
percentage O
of O
patients O
in O
each O
group O
with O
controlled O
blood O
pressure O
. O
['Physiological-Clinical']

The O
primary O
endpoint O
evaluated O
was O
SWI B-outcome ['Physiological-Clinical']
, O
which O
was O
defined O
as O
purulent O
drainage O
or O
active O
wound O
treatment O
. O
['Physiological-Clinical']

Morbidity O
was O
estimated O
from O
the O
number O
of O
days O
patients O
were O
unable O
to O
work O
due O
to O
illness O
, O
number O
of O
days O
hospitalized O
and O
AIDS O
events O
. O
[]

The O
effect O
of O
risedronate O
treatment O
on O
serum O
cytokines O
in O
postmenopausal O
osteoporosis O
: O
a O
6-month O
randomized O
and O
controlled O
study O
. O
[]

OBJECTIVES O
To O
investigate O
whether O
cell-derived O
microparticles O
play O
a O
role O
in O
complement B-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
in O
pericardial O
blood O
of O
patients O
undergoing O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
( O
CPB O
) O
and O
whether O
microparticles O
in O
pericardial O
blood O
contribute O
to O
systemic B-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
activation I-outcome ['Physiological-Clinical']
upon O
retransfusion O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVES O
Sleep O
disturbances O
are O
common O
in O
patients O
with O
gastroesophageal O
reflux O
disease O
( O
GERD O
) O
. O
[]

It O
was O
found O
that O
exhausted O
terminal O
programmed O
cell O
death O
1 O
(PD1)+ O
CD8+ O
T O
cells O
in O
the O
peripheral O
blood O
are O
independently O
associated O
with O
worse O
progression B-outcome ['Physiological-Clinical', 'Mortality']
free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
. O
Notably, O
hydrogen O
gas O
decreased O
the O
abundance O
of O
exhausted O
terminal O
PD1+ B-outcome ['Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
increased O
that O
of O
active O
terminal O
PD1 B-outcome ['Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
and O
improved O
progression B-outcome ['Physiological-Clinical', 'Mortality']
free I-outcome ['Physiological-Clinical', 'Mortality']
survival I-outcome ['Physiological-Clinical', 'Mortality']
(PFS) I-outcome ['Physiological-Clinical', 'Mortality']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
(OS) I-outcome ['Mortality']
times, O
suggesting O
that O
the O
balance O
between O
terminal O
PD1+ B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
PD1 B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
CD8+ I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
cells E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
is O
critical O
for O
cancer O
prognosis. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Physiological-Clinical', 'Physiological-Clinical']]

We O
undertook O
the O
present O
analysis O
to O
evaluate O
the O
effect O
of O
NHT O
on O
pathologic B-outcome ['Physiological-Clinical']
stage B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCa I-outcome ['Physiological-Clinical']
and O
resection B-outcome ['Physiological-Clinical']
limit I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
in O
patients O
with O
prostate O
cancer O
and O
treated O
with O
total O
androgen O
ablation O
either O
for O
three O
or O
six O
months O
before O
RP O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
response O
to O
cardiopulmonary O
exercise O
( O
CPX O
) O
in O
patients O
with O
heart O
failure O
( O
HF O
) O
with O
normal O
left O
ventricular O
( O
LV O
) O
ejection O
fractions O
( O
EFs O
) O
is O
not O
well O
characterized O
. O
[]

This O
paper's O
objective O
is O
to O
fill O
that O
lack. O
[]

We O
are O
performing O
a O
randomized O
controlled O
trial O
of O
parenteral O
nutrition O
among O
children O
undergoing O
allogeneic O
HSCT O
. O
[]

However, O
data O
on O
the O
optimal O
route O
of O
administration O
are O
not O
consistent. O
[]

Each O
operator O
performed O
stone O
extraction O
of O
2 O
, O
5 O
and O
8 O
mm O
calculi O
( O
size O
determined O
by O
digital O
caliper O
with O
3 O
repetitions O
of O
each O
basket O
. O
[]

The O
duration O
of O
the O
standard O
changed O
between O
blocks O
. O
[]

CONCLUSION O
sICAM-1 B-outcome ['Physiological-Clinical']
levels O
in O
primary O
biliary O
cirrhosis O
are O
reduced O
by O
ursodeoxycholic O
acid O
. O
['Physiological-Clinical']

Effect O
of O
device-guided O
breathing O
exercises O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
in O
patients O
with O
hypertension O
: O
a O
randomized O
controlled O
trial O
. O
['Physiological-Clinical']

To O
determine O
the O
impact O
of O
indomethacin O
on O
the O
course O
of O
uremic O
pericarditis O
we O
performed O
a O
prospective O
, O
double O
blind O
study O
in O
which O
24 O
patients O
with O
endstage O
chronic O
renal O
failure O
and O
pericarditis O
randomly O
received O
indomethacin O
, O
25 O
mg O
four O
times O
daily O
, O
( O
11 O
patients O
) O
or O
a O
placebo O
( O
13 O
patients O
) O
for O
a O
3-week O
period O
. O
[]

CONCLUSION O
There O
were O
no O
different O
of O
seroconversion B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
between O
study O
population O
received O
1 O
dose O
and O
3 O
dose O
booster O
( O
P O
> O
0.05 O
) O
, O
but O
high O
titer O
was O
observed O
after O
3 O
dose O
booster O
. O
['Physiological-Clinical']

INTERPRETATION O
Annual O
single-dose O
community-wide O
treatment O
with O
diethylcarbamazine O
alone O
or O
with O
ivermectin O
is O
effective O
for O
the O
control O
of O
lymphatic O
filariasis O
in O
highly O
endemic O
areas O
, O
but O
combination O
therapy O
brings O
about O
greater O
decreases O
in O
rates O
and O
intensity O
of O
[]

The O
effect O
of O
body O
weight O
changes O
and O
endurance O
training O
on O
24h B-outcome ['Physiological-Clinical']
substrate I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Outcome O
measures O
were O
production O
of O
[]

Patients O
fulfilling O
the O
selection O
criteria O
were O
randomly O
assigned O
to O
receive O
urokinase O
900,000 O
units O
via O
intravenous O
or O
intra-arterial O
routes O
. O
[]

A O
clinically O
relevant O
rise O
in O
TSB B-outcome ['Physiological-Clinical']
took O
place O
after O
12 O
h O
into O
the O
fasting O
period O
( O
TSB O
of O
17.3 O
mumol O
l-1 O
in O
the O
fasted O
group O
vs O
14.0 O
mumol O
l-1 O
in O
the O
non-fasted O
group O
) O
. O
['Physiological-Clinical']

RE-LY O
is O
the O
largest O
AF O
stroke O
prevention O
trial O
yet O
undertaken O
. O
[]

The O
total O
transit B-outcome ['Life-Impact']
time O
decreased O
by O
45.4 O
+/- O
38.4 O
hours O
in O
the O
cocoa O
husk O
group O
and O
by O
8.7 O
+/- O
28.9 O
hours O
in O
the O
placebo O
group O
( O
-38.1 O
hours O
) O
. O
['Life-Impact']

In O
this O
study O
, O
47 O
preschool O
and O
K-1 O
students O
in O
ASD O
classrooms O
participated O
from O
Los O
Angeles O
Unified O
School O
District O
. O
[]

There O
were O
slight O
transient O
increases O
in O
scaling B-outcome ['Physiological-Clinical']
and O
burning B-outcome ['Physiological-Clinical']
over O
the O
first O
four O
weeks. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

GOAL O
The O
aim O
of O
this O
analysis O
was O
to O
determine O
whether O
patients O
' O
demographic O
variables O
affect O
the O
efficacy O
of O
imiquimod O
5 O
% O
cream O
versus O
vehicle O
cream O
for O
the O
treatment O
of O
external O
genital O
and O
perianal O
warts O
. O
[]

2 O
randomized O
, O
controlled O
, O
factorial O
design O
trial O
. O
[]

AIMS O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
fixed O
combination O
of O
timolol O
and O
dorzolamide O
and O
latanoprost O
plus O
timolol O
on O
retinal B-outcome ['Physiological-Clinical']
, O
choroidal B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

One-year O
survival B-outcome ['Mortality']
rate O
was O
57.4 O
% O
for O
bevacizumab-erlotinib O
and O
53.8 O
% O
for O
bevacizumab-chemotherapy O
compared O
with O
33.1 O
% O
for O
chemotherapy O
alone O
. O
['Mortality']

Publication O
date: O
2019/02/09 O
06:00 O
[medline] O
[]

54 O
patients O
were O
included O
, O
with O
6 O
losses O
. O
[]

Impact O
of O
different O
platelet O
glycoprotein O
IIb/IIIa O
receptor O
inhibitors O
among O
diabetic O
patients O
undergoing O
percutaneous O
coronary O
intervention O
: O
: O
Do O
Tirofiban O
and O
ReoPro O
Give O
Similar O
Efficacy O
Outcomes O
Trial O
( O
TARGET O
) O
1-year O
follow-up O
. O
[]

1 O
. O
[]

INTERVENTIONS O
Twelve O
weeks O
of O
treatment O
with O
citalopram O
( O
10 O
mg/5 O
mL O
) O
or O
placebo O
. O
[]

Amiodarone O
versus O
digoxin O
and O
metoprolol O
combination O
for O
the O
prevention O
of O
postcoronary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

70.4 O
kg O
, O
respectively O
; O
p O
= O
0.99 O
) O
. O
[]

In O
this O
8-week O
double-blind O
, O
placebo-controlled O
trial O
, O
we O
assessed O
the O
effects O
of O
cyproheptadine O
plus O
haloperidol O
in O
the O
treatment O
of O
autistic O
disorder O
. O
[]

Results O
of O
the O
therapeutic O
effects O
will O
not O
be O
available O
for O
some O
time O
, O
but O
the O
study O
has O
provided O
an O
opportunity O
to O
investigate O
influences O
on O
sensitization B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
allergens I-outcome ['Physiological-Clinical']
in O
a O
large O
cohort O
of O
1-2 O
years O
olds O
with O
already O
established O
atopic O
dermatitis O
, O
resident O
in O
different O
countries O
and O
in O
different O
environments O
. O
['Physiological-Clinical']

Relative O
numbers O
of O
CD16 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
were O
significantly O
elevated O
, O
but O
NK B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
cytotoxic I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
was O
within O
a O
normal O
range O
. O
['Physiological-Clinical', 'Physiological-Clinical']

This O
was O
well O
below O
the O
[]

BACKGROUND O
Little O
information O
is O
available O
on O
the O
effectiveness O
of O
lipid O
lowering O
in O
secondary O
prevention O
of O
coronary O
heart O
disease O
( O
CHD O
) O
in O
women O
; O
in O
particular O
, O
those O
with O
CHD O
and O
average O
cholesterol O
levels O
. O
[]

The O
social O
, O
language O
, O
and O
cognitive O
gains O
in O
our O
participants O
provide O
evidence O
for O
plasticity O
of O
these O
developmental O
systems O
in O
toddlers O
with O
ASD O
. O
[]

The O
initial O
complete B-outcome ['Physiological-Clinical']
response O
rate O
( O
CR O
) O
was O
79 O
% O
. O
['Physiological-Clinical']

Mefloquine O
kinetics O
in O
cured O
and O
recrudescent O
patients O
with O
acute O
falciparum O
malaria O
and O
in O
healthy O
volunteers O
. O
[]

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

METHODS O
Eighty-six O
patients O
underwent O
( O
18 O
) O
F-FDG O
PET/CT O
at O
baseline O
and O
weeks O
2 O
and O
6 O
of O
anti-HER2 O
treatment O
. O
[]

In O
the O
acupuncture O
group O
, O
the O
conventional O
acupuncture O
therapy O
was O
applied O
to O
Baihui O
( O
GV O
20 O
) O
, O
Sishencong O
( O
EX-HN O
1 O
) O
, O
Fengchi O
( O
GB O
20 O
) O
, O
Taiyang O
( O
EX-HN O
5 O
) O
, O
Touwei O
( O
ST O
18 O
) O
, O
Hegu O
( O
LI O
4 O
) O
, O
etc O
. O
[]

Furthermore, O
no O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
related O
to O
NES O
treatment O
were O
detected. O
[['Adverse-effects']]

Finding O
alternatives O
to O
these O
agents O
in O
the O
local O
treatment O
of O
the O
disease O
therefore O
seems O
desirable O
. O
[]

Journal O
ID: O
8109496 O
[]

The O
hepatic O
metabolism O
of O
lidocaine O
( O
1 O
mg/kg O
intravenously O
) O
to O
its O
metabolite O
monoethylglycinexylidide O
( O
MEG-X O
) O
is O
the O
basis O
of O
the O
standard O
MEG-X O
test O
. O
[]

INTERVENTION O
Patients O
were O
randomly O
assigned O
to O
receive O
enoxaparin O
( O
30 O
mg O
subcutaneously O
every O
12 O
hours O
) O
or O
adjusted-dose O
warfarin O
( O
international O
normalized O
ratio O
, O
2.0 O
to O
3.0 O
) O
. O
[]

The O
results O
showed O
that O
adherence O
measures O
varied O
with O
lowest O
adherence B-outcome ['Life-Impact']
from O
two O
items O
of O
['Life-Impact']

They O
were O
randomly O
assigned O
to O
an O
experimental O
group O
and O
a O
control O
group O
(14 O
individuals O
in O
each O
group) O
and O
then O
were O
post-tested O
after O
two O
months. O
[]

CONCLUSIONS O
In O
this O
multi-institutional O
study O
, O
the O
rates O
of O
recurrent B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
were O
similar O
after O
laparoscopically O
assisted O
colectomy O
and O
open O
colectomy O
, O
suggesting O
that O
the O
laparoscopic O
approach O
is O
an O
acceptable O
alternative O
to O
open O
surgery O
for O
colon O
cancer O
. O
['Physiological-Clinical']

Asymptomatic B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
were O
relatively O
infrequent O
and O
daily B-outcome ['Life-Impact']
drug I-outcome ['Life-Impact']
consumption I-outcome ['Life-Impact']
was O
high O
. O
['Physiological-Clinical', 'Life-Impact']

CONCLUSIONS O
There O
were O
no O
significant O
differences O
in O
efficacy O
or O
safety O
between O
20 O
and O
50 O
mg O
of O
arzoxifene O
. O
[]

METHODS O
Sixty-two O
( O
62 O
) O
community-recruited O
patients O
with O
fibromyalgia O
( O
FM O
) O
were O
assessed O
at O
baseline O
prior O
to O
a O
clinical O
trial O
of O
individualized O
homeopathy O
. O
[]

CONCLUSION O
Based O
on O
our O
data O
, O
combined O
treatment O
with O
prednisone O
, O
cyclophosphamide O
, O
and O
plasma O
exchanges O
is O
not O
superior O
to O
treatment O
with O
prednisone O
and O
cyclophosphamide O
alone O
, O
and O
plasma O
exchanges O
should O
not O
be O
systematically O
proposed O
for O
initial O
treatment O
of O
severe O
PAN O
or O
CSS O
. O
[]

METHODS O
A O
4-week O
, O
randomized O
, O
double O
blind O
, O
placebo-controlled O
, O
crossover O
design O
was O
conducted O
following O
a O
1-week O
baseline O
period O
. O
[]

Intervention O
group O
patients O
reported O
higher O
levels O
of O
satisfaction O
than O
controls O
in O
five O
of O
six O
domains O
( O
all O
p O
< O
.05 O
) O
. O
[]

SETTING O
University O
hospital O
; O
most O
patients O
from O
primary O
catchment O
area O
. O
[]

One O
solution O
that O
addresses O
many O
of O
these O
barriers O
is O
the O
adoption O
of O
computerized O
screening O
for O
symptom O
and O
quality-of-life O
information O
. O
[]

The O
participants O
were O
requested O
to O
limit O
their O
daily O
alcohol O
consumption O
to O
zero O
or O
reduce O
it O
as O
much O
as O
possible O
for O
the O
reduced O
alcohol O
consumption O
period O
. O
[]

Respiratory O
muscle O
training O
of O
the O
experiment O
group O
was O
performed O
using O
the O
respiratory O
endurance O
training O
device O
combined O
with O
traditional O
techniques. O
[]

Results O
showed O
significantly O
reduced O
pain B-outcome ['Physiological-Clinical']
during O
the O
first O
five O
postoperative O
days O
in O
patients O
treated O
with O
1,2,6-IP3 O
, O
as O
measured O
by O
using O
a O
VAS O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical']

We O
measured O
DR O
curves O
of O
PaO2/FIO2 B-outcome ['Physiological-Clinical']
versus O
the O
inhaled O
NO O
dose O
at O
regular O
intervals O
. O
['Physiological-Clinical']

Group O
A O
( O
19 O
patients O
) O
received O
4 O
mg O
of O
styrene O
maleic O
acid O
neocarzinostatin O
in O
4 O
ml O
of O
Lipiodol O
, O
and O
group O
B O
( O
18 O
patients O
) O
received O
100 O
mg O
of O
epirubicin O
in O
4 O
ml O
of O
Lipiodol O
via O
the O
tumor O
feeding O
arteries O
as O
peripherally O
as O
possible O
. O
[]

Standardized O
effect O
sizes O
[ O
last O
observation O
carried O
forward O
( O
LOCF O
) O
] O
at O
endpoint O
were O
calculated O
. O
[]

On O
study O
days O
, O
at O
the O
beginning O
of O
the O
study O
and O
after O
2 O
and O
4 O
weeks O
, O
treatments O
were O
given O
in O
the O
office O
or O
laboratory O
and O
patients O
were O
monitored O
with O
pulmonary B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
tests O
for O
eight O
hours O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
whether O
4-month O
preoperative O
lanreotide O
treatment O
would O
improve O
the O
surgical B-outcome ['Physiological-Clinical']
cure I-outcome ['Physiological-Clinical']
rate O
of O
newly O
diagnosed O
acromegalic O
patients O
with O
macroadenomas O
. O
['Physiological-Clinical']

Effects O
of O
a O
standardized O
pamphlet O
on O
insomnia O
in O
children O
with O
autism O
spectrum O
disorders O
. O
[]

There O
is O
evidence O
that O
supplementation O
with O
L-methylfolate O
augments O
antidepressant O
agent O
effects O
and O
thus O
might O
also O
augment O
ADHD O
treatment O
effects O
by O
a O
common O
catecholaminergic O
mechanism. O
[]

METHODS O
In O
this O
open-label O
, O
parallel-group O
, O
randomised O
controlled O
trial O
, O
eligible O
patients O
were O
adults O
undergoing O
allogeneic O
stem-cell O
transplantation O
or O
chemotherapy O
for O
acute O
leukaemia O
, O
with O
no O
history O
of O
invasive O
fungal O
disease O
. O
[]

Subjects O
were O
then O
exposed O
to O
0.4 O
ppm O
O O
( O
3 O
) O
for O
2 O
h O
and O
underwent O
a O
second O
BAL O
. O
[]

Similarly O
, O
the O
rate O
of O
change O
in O
aortic B-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
was O
significantly O
decreased O
with O
the O
use O
of O
the O
high-flux O
polyamide O
membrane O
. O
['Physiological-Clinical']

Experiment O
1 O
uses O
factor O
analysis O
and O
correlational O
data O
to O
provide O
evidence O
for O
viewing O
attitude B-outcome ['Life-Impact']
clarity I-outcome ['Life-Impact']
and O
attitude B-outcome ['Life-Impact']
correctness I-outcome ['Life-Impact']
as O
separate O
constructs O
. O
['Life-Impact', 'Life-Impact']

Histologic B-outcome ['Physiological-Clinical']
distribution B-outcome ['Physiological-Clinical']
was O
18 O
% O
S O
, O
3.7 O
% O
CC O
, O
8.5 O
% O
mixed O
, O
51.7 O
% O
E O
and O
18.1 O
% O
other O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
0255562 O
[]

They O
received O
either O
levodopa O
SR O
or O
ropinirole O
for O
6 O
weeks O
, O
followed O
by O
a O
washout O
week O
, O
then O
the O
alternate O
treatment O
for O
6 O
weeks O
. O
[]

In O
the O
present O
study O
we O
examine O
the O
effects O
of O
low-frequency O
, O
repetitive O
Transcranial O
Magnetic O
Stimulation O
( O
rTMS O
) O
on O
novelty O
processing O
as O
well O
as O
behavior O
and O
social O
functioning O
in O
13 O
individuals O
with O
ASD O
. O
[]

The O
haemostatic O
effect O
of O
desmopressin O
has O
been O
attributed O
to O
the O
release O
of O
von O
Willebrand O
factor O
( O
vWF O
) O
and O
a O
reduced O
bleeding B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
the O
expectant O
management O
group O
, O
40 O
women O
( O
32 O
% O
) O
conceived B-outcome ['Physiological-Clinical']
, O
of O
which O
34 O
pregnancies O
were O
ongoing O
( O
27 O
% O
) O
( O
relative O
risk O
: O
0.85 O
; O
95 O
% O
CI O
: O
0.63-1.1 O
) O
. O
['Physiological-Clinical']

The O
degree O
of O
association O
between O
BMI O
percentile O
and O
frequency O
of O
RTEC O
consumption O
adjusted O
for O
age O
, O
sex O
, O
ethnicity O
, O
and O
nutrition-related O
parameters O
were O
calculated O
using O
a O
partial O
correlation O
multivariate O
linear O
model O
analysis O
. O
[]

A O
refusal O
survey O
was O
provided O
for O
those O
who O
declined O
to O
join O
the O
study O
. O
[]

The O
Study O
group O
performed O
significantly O
better O
than O
the O
Control O
group O
in O
the O
post-test O
, O
in O
which O
the O
group O
to O
which O
the O
students O
had O
been O
allocated O
was O
the O
only O
significant O
predictor O
of O
performance O
. O
[]

Promoting O
imitation O
in O
young O
children O
with O
autism O
: O
a O
comparison O
of O
reciprocal O
imitation O
training O
and O
video O
modeling O
. O
[]

By O
subjective O
IRLS O
ratings O
, O
all O
pramipexole O
doses O
were O
significantly O
superior O
to O
placebo O
. O
[]

We O
have O
compared O
this O
method O
with O
two O
other O
methods O
based O
on O
ultrasonic O
waves O
to O
identify O
the O
IJV O
and O
the O
carotid O
artery O
( O
CA O
) O
( O
even O
in O
atypical O
positions O
) O
. O
[]

The O
purpose O
of O
the O
double-blind O
study O
was O
the O
demonstration O
of O
possible O
effects O
on O
the O
cellular B-outcome ['Physiological-Clinical']
immune I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
as O
determined O
by O
quantitative B-outcome ['Resource-use']
flow I-outcome ['Resource-use']
cytometry I-outcome ['Resource-use']
. O
['Physiological-Clinical', 'Resource-use']

Randomisation O
was O
done O
with O
a O
computer-generated O
randomisation O
code O
and O
was O
stratified O
by O
centre O
. O
[]

The O
aim O
of O
the O
present O
project O
was O
to O
investigate O
different O
types O
of O
ear O
plugs O
and O
their O
effect O
on O
speech O
intelligibility O
in O
helicopter O
noise O
. O
[]

CONCLUSIONS O
Cy O
seems O
to O
be O
more O
effective O
than O
MP O
in O
the O
treatment O
of O
acute O
, O
severe O
NPSLE O
. O
[]

Erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnover I-outcome ['Physiological-Clinical']
, O
an O
index O
of O
RBC O
production O
, O
increased O
in O
the O
one O
responder O
studied O
but O
not O
in O
the O
two O
nonresponders O
. O
['Physiological-Clinical']

Corresponding O
figures O
for O
fibrin B-outcome ['Physiological-Clinical']
deposition I-outcome ['Physiological-Clinical']
were O
64.9+/-4.8 O
% O
and O
18.3+/-9.7 O
% O
, O
respectively O
( O
58 O
% O
reduction O
; O
95 O
% O
CI O
, O
45-67 O
% O
; O
p O
< O
0.0001 O
) O
. O
['Physiological-Clinical']

RESULTS: O
At O
all O
time O
points, O
tramadol B-outcome ['Resource-use']
consumption O
of O
the O
OSTAP O
group O
remained O
significantly O
lower O
when O
compared O
with O
Sham O
group. O
[['Resource-use']]

The O
remaining O
256 O
patients O
were O
divided O
into O
two O
groups O
according O
to O
the O
presence O
( O
group O
A O
, O
n O
= O
45 O
) O
or O
absence O
( O
group O
B O
, O
n O
= O
211 O
) O
of O
moderate O
dissection O
. O
[]

In O
the O
intervention O
group O
, O
median O
nodule B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
at O
baseline O
was O
8.2 O
ml O
( O
range O
2.8-26.9 O
) O
and O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O
['Physiological-Clinical']

Publication O
date: O
2019/03/07 O
06:00 O
[medline] O
[]

Participants O
were O
followed O
for O
6 O
months O
. O
[]

In O
the O
two O
groups O
significant O
improvement O
of O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
, O
ESR B-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Systematic O
approach O
to O
benign O
paroxysmal O
positional O
vertigo O
in O
the O
elderly O
. O
[]

Playing O
on O
the O
typewriter O
, O
typing O
on O
the O
piano O
: O
manipulation O
knowledge O
of O
objects O
. O
[]

OBJECTIVE O
This O
study O
was O
done O
to O
compare O
percutaneous O
laser O
ablation O
( O
PLA O
) O
and O
radiofrequency O
thermoablation O
( O
RFA O
) O
for O
the O
treatment O
of O
hepatocellular O
carcinoma O
( O
HCC O
) O
? O
[]

Skeletal-related B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SREs I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
were O
defined O
as O
pathologic O
bone O
fractures O
, O
spinal O
cord O
compression O
, O
surgery O
to O
bone O
, O
radiation O
therapy O
to O
bone O
, O
and O
hypercalcemia O
of O
malignancy O
. O
['Physiological-Clinical']

MATERIAL O
AND O
METHOD O
A O
randomized O
, O
double O
blind O
, O
controlled O
trial O
on O
46 O
adults O
ASA O
I-II O
, O
undergoing O
elective O
gynecological O
or O
general O
surgery O
with O
balanced O
general O
anesthesia O
was O
performed O
. O
[]

Nausea B-outcome ['Physiological-Clinical']
was O
reduced O
from O
38 O
% O
( O
969/2585 O
) O
in O
the O
control O
to O
28 O
% O
( O
715/2576 O
) O
in O
the O
ondansetron O
group O
, O
corresponding O
to O
a O
relative O
risk O
of O
0.74 O
, O
or O
a O
relative O
risk O
reduction O
of O
26 O
% O
. O
['Physiological-Clinical']

Statistical O
analyses O
of O
the O
measurements O
at O
T0 O
and O
T1 O
were O
undertaken O
with O
a O
paired O
t-test O
, O
and O
the O
difference O
between O
the O
groups O
assesed O
with O
a O
Student O
's O
t-test O
. O
[]

The O
cutoff O
of O
these O
tests O
was O
0.1 O
IU/mL O
. O
[]

The O
quality-of-life B-outcome ['Life-Impact']
questionnaire O
score O
improved O
only O
in O
the O
intervention O
group O
( O
P O
< O
0.003 O
) O
. O
['Life-Impact']

Such O
a O
pattern O
is O
consistent O
with O
the O
role O
of O
the O
left O
DLPFC O
in O
implementing O
top-down O
attentional O
control O
. O
[]

Systemic O
exposure O
of O
these O
drugs O
was O
similar O
to O
that O
reported O
in O
other O
HIV-infected O
children O
and O
adults O
. O
[]

In O
conclusion O
, O
the O
myocardial O
ECV O
is O
elevated O
in O
patients O
with O
previous O
anthracycline O
treatment O
and O
is O
associated O
with O
the O
diastolic O
function O
and O
increased O
atrial O
volumes O
. O
[]

We O
quantified O
the O
embolic O
load O
to O
the O
lungs O
created O
with O
two O
different O
techniques O
of O
femoral O
nailing O
. O
[]

Fabrication O
of O
the O
sampling O
lumen O
of O
an O
intra-arterial O
PO2 O
sensor O
is O
performed O
in O
standard O
catheters O
mechanically O
or O
by O
laser O
. O
[]

Comparison O
of O
hypnotherapy O
with O
systematic O
relaxation O
in O
the O
treatment O
of O
cigarette O
habituation O
. O
[]

Blood O
losses O
were O
replaced O
with O
5 O
per O
cent O
human O
albumin O
, O
red O
cell O
concentrates O
, O
and O
fresh O
frozen O
plasma O
. O
[]

significantly O
improved O
erectile B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
men O
with O
lower O
urinary O
tract O
symptoms/ O
benign O
prostatic O
hypertrophy O
and O
had O
no O
adverse O
effect O
on O
ejaculatory O
function O
. O
['Physiological-Clinical']

Either O
melatonin O
, O
3 O
mg O
, O
or O
placebo O
was O
given O
to O
participants O
for O
2 O
weeks O
and O
then O
alternated O
for O
another O
2 O
weeks O
. O
[]

RESULTS O
Compared O
with O
systemic O
T1 O
blood O
, O
pericardial O
blood O
contained O
increased O
C4b/c B-outcome ['Physiological-Clinical']
and O
C3b/c B-outcome ['Physiological-Clinical']
, O
and O
increased O
levels O
of O
microparticles B-outcome ['Physiological-Clinical']
with O
bound O
complement O
components O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
subgroup O
identified O
as O
depressed O
was O
entered O
into O
the O
nested O
IDACC O
trial O
, O
which O
tests O
the O
hypothesis O
that O
identifying O
depression O
and O
offering O
an O
evidence-based O
intervention O
to O
general O
practitioners O
, O
incorporating O
multidisciplinary O
telephone O
case O
conferencing O
, O
will O
reduce O
levels O
of O
depression B-outcome ['Life-Impact']
, O
improve O
quality O
of O
life O
, O
and O
reduce O
associated O
economic B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
. O
['Life-Impact', 'Resource-use']

The O
results O
of O
experimental O
and O
clinical O
studies O
support O
the O
hypothesis O
that O
gut-derived O
endotoxins O
might O
be O
of O
relevance O
for O
the O
development O
and O
course O
of O
alcoholic O
liver O
disease O
. O
[]

A O
prospective O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
prophylactic O
intravesical O
instillation O
of O
pirarubicin O
( O
THP O
) O
prior O
to O
transurethral B-outcome ['Physiological-Clinical']
resection I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TUR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
superficial I-outcome ['Physiological-Clinical']
bladder I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Comparative O
dose O
efficacy O
study O
of O
atorvastatin O
versus O
simvastatin O
, O
pravastatin O
, O
lovastatin O
, O
and O
fluvastatin O
in O
patients O
with O
hypercholesterolemia O
( O
the O
CURVES O
study O
) O
The O
objective O
of O
this O
multicenter O
, O
randomized O
, O
open-label O
, O
parallel-group O
, O
8-week O
study O
was O
to O
evaluate O
the O
comparative O
dose O
efficacy O
of O
the O
3-hydroxy-3-methylglutaryl O
coenzyme O
A O
( O
HMG-CoA O
) O
reductase O
inhibitor O
atorvastatin O
10 O
, O
20 O
, O
40 O
, O
and O
80 O
mg O
compared O
with O
simvastatin O
10 O
, O
20 O
, O
and O
40 O
mg O
, O
pravastatin O
10 O
, O
20 O
, O
and O
40 O
mg O
, O
lovastatin O
20 O
, O
40 O
, O
and O
80 O
mg O
, O
and O
fluvastatin O
20 O
and O
40 O
mg. O
Investigators O
enrolled O
534 O
hypercholesterolemic O
patients O
( O
low-density O
lipoprotein O
[ O
LDL O
] O
cholesterol O
> O
or O
= O
160 O
mg/dl O
[ O
4.2 O
mmol/L O
] O
and O
triglycerides O
< O
or O
= O
400 O
mg/dl O
[ O
4.5 O
mmol/L O
] O
) O
. O
[]

RESULTS O
Among O
patients O
not O
taking O
vitamin O
A O
prior O
to O
entry O
, O
those O
in O
the O
DHA O
+ O
A O
group O
had O
a O
slower O
decline O
in O
field B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
and O
electroretinogram B-outcome ['Physiological-Clinical']
amplitude I-outcome ['Physiological-Clinical']
than O
those O
in O
the O
control O
+ O
A O
group O
over O
the O
first O
2 O
years O
( O
P O
=.01 O
and O
P O
=.03 O
, O
respectively O
) O
; O
these O
differences O
were O
not O
observed O
in O
years O
3 O
and O
4 O
of O
follow-up O
or O
among O
patients O
taking O
vitamin O
A O
prior O
to O
entry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
former O
group O
, O
the O
survival B-outcome ['Mortality']
rates O
at O
12 O
and O
24 O
months O
were O
33 O
percent O
and O
10 O
percent O
, O
respectively O
, O
whereas O
they O
were O
50 O
percent O
and O
38 O
percent O
in O
the O
patients O
receiving O
combined O
therapy O
( O
P O
less O
than O
0.001 O
) O
. O
['Mortality']

The O
main O
inclusion O
criteria O
for O
participants O
were O
a O
positive O
dermatophyte O
culture O
and O
at O
least O
25 O
% O
distal O
subungual O
clinical O
involvement O
. O
[]

Treatment O
of O
posterior O
uveitis O
with O
a O
fluocinolone O
acetonide O
implant O
: O
three-year O
clinical O
trial O
results O
. O
[]

No O
correlation O
with O
intellectual B-outcome ['Life-Impact']
ability I-outcome ['Life-Impact']
was O
found O
at O
any O
of O
these O
sites O
. O
['Life-Impact']

We O
studied O
17 O
patients O
with O
AS O
( O
ICD-10 O
; O
14 O
male O
, O
3 O
female O
; O
mean O
age O
16.4 O
years O
, O
mean O
full-scale O
IQ O
97 O
) O
and O
compared O
them O
with O
a O
control O
group O
of O
13 O
patients O
with O
normal-intelligence O
autism O
or O
high-functioning O
autism O
( O
HFA O
) O
( O
ICD-10/DSM-III-R O
; O
12 O
male O
, O
1 O
female O
; O
mean O
age O
15.5 O
years O
, O
mean O
full-scale O
IQ O
81.2 O
) O
. O
[]

METHODS O
We O
present O
1 O
year O
of O
follow-up O
information O
on O
95 O
subjects O
enrolled O
in O
the O
United O
States O
Food O
and O
Drug O
Administration O
Phase O
III O
clinical O
trials O
. O
[]

OBJECTIVE:: O
With O
increasing O
incorporation O
of O
MRI O
in O
radiotherapy, O
we O
investigate O
two O
MRI O
sequences O
for O
prostate O
delineation O
in O
radiographer-led O
image O
guidance. O
[]

Existing O
studies O
suggest O
that O
inclusion O
of O
physical O
activity O
and O
TAG O
levels O
might O
improve O
the O
performance O
of O
the O
VIDSUN O
questionnaire O
. O
[]

MEASUREMENTS O
( O
1 O
) O
Report O
of O
patient O
verified O
by O
partner O
as O
to O
number O
of O
coital B-outcome ['Life-Impact']
episodes I-outcome ['Life-Impact']
per O
month O
; O
( O
2 O
) O
penile-brachial B-outcome ['Physiological-Clinical']
pressure B-outcome ['Physiological-Clinical']
index O
determinations O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2019/01/23 O
06:00 O
[entrez] O
[]

The O
following O
facts O
about O
the O
predictive O
factor O
for O
the O
prognosis O
of O
DU O
complication O
were O
found O
: O
the O
sensitivity B-outcome ['Physiological-Clinical']
of O
83.6 O
% O
, O
the O
specificity O
of O
92.8 O
% O
, O
the O
predictive O
accuracy O
of O
88.7 O
% O
, O
the O
relative O
risk O
of O
the O
predicted O
outcome O
of O
7.5 O
, O
the O
relative O
risk O
of O
a O
different O
outcome O
of O
0.11 O
, O
the O
odds O
ration O
of O
65.4 O
. O
['Physiological-Clinical']

M-mode O
echocardiographic O
measurements O
were O
made O
in O
21 O
patients O
with O
coronary O
artery O
disease O
who O
were O
receiving O
placebo O
, O
acebutolol O
, O
and O
propranolol O
in O
a O
double-blind O
, O
randomized O
, O
crossover O
study O
. O
[]

The O
results O
showed O
that O
, O
compared O
to O
controls O
, O
the O
treated O
children O
with O
ASD O
improved O
in O
their O
conceptual O
ToM O
skills O
, O
but O
their O
elementary O
understanding O
, O
self O
reported O
empathic O
skills O
or O
parent O
reported O
social O
behaviour O
did O
not O
improve O
. O
[]

The O
inconvenience O
of O
this O
parenteral O
regimen O
created O
an O
increased O
need O
for O
oral O
pediatric O
formulations O
for O
the O
treatment O
of O
invasive O
diarrhea O
. O
[]

As O
L-ICI B-outcome ['Physiological-Clinical']
can O
be O
influenced O
by O
this O
type O
of O
drug O
, O
it O
may O
be O
an O
interesting O
parameter O
for O
studies O
of O
motor O
learning O
and O
use-dependent O
plasticity O
. O
['Physiological-Clinical']

Remifentanil O
with O
morphine O
transitional O
analgesia O
shortens O
neurological B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
compared O
to O
fentanyl O
for O
supratentorial O
craniotomy O
. O
['Physiological-Clinical']

However O
, O
a O
modest O
benefit O
can O
not O
be O
excluded O
and O
larger O
randomised O
placebo-controlled O
trials O
with O
longer O
durations O
of O
pentoxifylline B-outcome ['Resource-use']
treatment I-outcome ['Resource-use']
may O
be O
justified O
. O
['Resource-use']

This O
value O
was O
then O
lower O
than O
expected O
in O
group O
2 O
, O
corresponding O
to O
a O
loss O
of O
plasma B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
of O
> O
3 O
mL/kg O
. O
['Physiological-Clinical']

The O
safety O
of O
anti-C. O
difficile O
whey O
protein O
concentrate O
( O
anti-CD O
WPC O
) O
is O
supported O
by O
analytical O
data O
comparing O
the O
composition O
of O
raw O
milk O
from O
immunized O
cows O
versus O
that O
from O
non-immunized O
cows O
, O
and O
the O
composition O
of O
anti-CD O
WPC O
versus O
that O
of O
regular O
whey O
protein O
concentrate O
. O
[]

RESULTS O
The O
intention-to-treat O
analysis O
showed O
a O
survival B-outcome ['Mortality']
rate O
of O
63.6 O
per O
cent O
in O
the O
PC O
group O
and O
65.3 O
per O
cent O
in O
the O
LD O
group O
( O
P O
= O
0.69 O
) O
, O
with O
recurrence B-outcome ['Physiological-Clinical']
rates O
of O
27.8 O
and O
27.9 O
per O
cent O
respectively O
. O
['Mortality', 'Physiological-Clinical']

Half O
received O
i.v O
. O
[]

Central O
venous O
catheter O
self-care O
increased O
patients O
' O
independence B-outcome ['Life-Impact']
from O
health O
professionals O
and O
supported O
perceived O
self-efficacy B-outcome ['Life-Impact']
and O
control O
. O
['Life-Impact', 'Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
and O
compare O
laparoscopic O
treatment O
for O
stage O
I O
endometrial O
cancer O
with O
the O
traditional O
transabdominal O
approach O
. O
[]

This O
study O
was O
designed O
to O
investigate O
the O
validity O
of O
the O
then O
current O
recommendations O
for O
initiation O
of O
therapy O
with O
enalapril O
in O
hypertensive O
patients O
on O
treatment O
with O
a O
diuretic O
. O
[]

In O
study O
2 O
, O
the O
amount O
of O
lansoprazole B-outcome ['Life-Impact']
consumed I-outcome ['Life-Impact']
was O
approximately O
50 O
% O
less O
than O
that O
of O
omeprazole O
, O
and O
this O
translated O
to O
81 O
% O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
with O
lansoprazole O
compared O
with O
only O
9.5 O
% O
for O
omeprazole O
. O
['Life-Impact', 'Life-Impact']

In O
the O
same O
groups O
bacterial B-outcome ['Physiological-Clinical']
cystitis I-outcome ['Physiological-Clinical']
occurred O
in O
17 O
( O
21.8 O
% O
) O
patients O
and O
in O
16 O
( O
18.4 O
% O
) O
patients O
, O
respectively O
. O
['Physiological-Clinical']

METHOD O
The O
cost-effectiveness O
analysis O
was O
part O
of O
a O
randomized-controlled O
trial O
with O
a O
sample O
size O
of O
175 O
, O
of O
which O
89 O
were O
in O
the O
nursing-led O
inpatient O
unit O
arm O
and O
86 O
in O
the O
control O
arm O
. O
['Resource-use']

A O
questionnaire O
was O
completed O
assessing O
interest B-outcome ['Life-Impact']
in O
BRCA1 B-outcome ['Physiological-Clinical']
testing O
and O
knowledge O
on O
breast O
cancer O
genetics O
and O
screening O
. O
['Life-Impact', 'Physiological-Clinical']

Although O
no O
significant O
differences O
were O
found O
in O
the O
incidence O
of O
de O
novo B-outcome ['Physiological-Clinical']
adnexal I-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
, O
the O
lowest O
rate O
was O
found O
in O
the O
fibrin O
gel O
group O
, O
with O
4/32 O
patients O
( O
12.5 O
% O
) O
in O
the O
control O
group O
, O
2/29 O
patients O
( O
6.8 O
% O
) O
in O
the O
fibrin O
gel O
group O
and O
5/30 O
patients O
( O
16.7 O
% O
) O
in O
the O
fibrin O
sheet O
group O
. O
['Physiological-Clinical']

Treatment O
and O
controls O
had O
similar O
routine O
care O
during O
the O
study O
period O
and O
there O
were O
no O
study O
dropouts O
after O
treatment O
had O
started O
. O
[]

Both O
groups O
were O
given O
intravenous O
iron O
gluconate O
( O
125 O
mg O
) O
every O
day O
for O
15 O
days O
. O
[]

Many O
subjects O
dropped O
out O
of O
the O
study O
, O
but O
those O
in O
active O
treatment O
who O
completed O
the O
eight O
week O
trial O
had O
a O
decrease O
in O
methamphetamine B-outcome ['Physiological-Clinical']
craving I-outcome ['Physiological-Clinical']
compared O
to O
the O
placebo O
treatment O
as O
measured O
by O
the O
OCDS O
modified O
for O
use O
in O
this O
population O
. O
['Physiological-Clinical']

As O
interactions O
between O
metaboreceptors O
and O
chemoreceptors O
have O
been O
previously O
observed O
, O
the O
purpose O
of O
this O
study O
was O
to O
isolate O
the O
metaboreflex O
while O
acutely O
stimulating O
or O
inhibiting O
the O
CC O
to O
determine O
whether O
the O
metaboreflex O
increased O
CC O
activity/sensitivity O
. O
[]

The O
median O
survival B-outcome ['Mortality']
was O
138 O
days O
for O
placebo O
and O
160 O
days O
for O
marimastat O
, O
with O
2-year O
survival O
of O
3 O
% O
and O
9 O
% O
respectively O
. O
['Mortality']

Randomized O
clinical O
study O
comparing O
Compeed O
cold O
sore O
patch O
to O
acyclovir O
cream O
5 O
% O
in O
the O
treatment O
of O
herpes O
simplex O
labialis O
. O
[]

The O
study O
was O
designed O
to O
compare O
the O
rate O
and O
extent O
of O
absorption B-outcome ['Physiological-Clinical']
of O
a O
fixed O
dose O
combination O
tablet O
of O
lamivudine O
( O
CAS O
134678-17-4 O
) O
and O
stavudine O
( O
CAS O
3056-17-5 O
) O
with O
the O
concurrent O
administration O
of O
lamivudine O
tablet O
and O
stavudine O
capsule O
in O
24 O
healthy O
volunteers O
under O
fasting O
conditions O
. O
['Physiological-Clinical']

From O
15 O
% O
to O
40 O
% O
of O
these O
events O
occurred O
beyond O
30 O
days O
. O
[]

RESULTS O
Patients O
taking O
pentoxifylline O
had O
less O
pain B-outcome ['Physiological-Clinical']
and O
reported O
smaller O
and O
fewer O
['Physiological-Clinical']

Both O
groups O
underwent O
daily O
supplementation O
of O
either O
3g O
CLA O
or O
3g O
placebo O
for O
30 O
days O
, O
respectively O
, O
and O
performed O
exercise O
on O
a O
bicycle O
ergometer O
3 O
times O
per O
week O
for O
30-40 O
min O
at O
50 O
% O
VO2 O
peak O
workload O
. O
[]

OBJECTIVE O
Transient B-outcome ['Physiological-Clinical']
lower O
esophageal B-outcome ['Physiological-Clinical']
sphincter I-outcome ['Physiological-Clinical']
relaxations B-outcome ['Life-Impact']
( O
TLESRs O
) O
are O
the O
main O
mechanism O
underlying O
gastroesophageal O
reflux O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Patients O
were O
randomly O
assigned O
to O
placebo O
or O
eptifibatide O
as O
an O
adjunct O
to O
stent O
implantation O
( O
1,755 O
with O
CrCl O
> O
or O
=60 O
ml/min O
and O
289 O
with O
CrCl O
< O
60 O
ml/min O
) O
. O
[]

FUNDING O
Biogen O
Idec O
and O
AbbVie O
Biotherapeutics O
Inc O
. O
[]

Twenty O
patients O
were O
treated O
with O
oral O
azithromycin O
, O
250 O
mg O
bd O
for O
two O
days O
followed O
by O
250 O
mg O
od O
for O
eight O
days O
, O
21 O
patients O
were O
given O
phenoxymethylpenicillin O
1 O
million O
IU O
tds O
for O
14 O
days O
and O
23 O
patients O
received O
doxycycline O
, O
100 O
mg O
bd O
for O
14 O
days O
. O
[]

BACKGROUND: O
Exacerbations O
of O
chronic O
obstructive O
pulmonary O
disease O
(COPD) O
are O
associated O
with O
loss O
of O
lung O
function O
and O
poor O
outcomes O
for O
patients. O
[]

In O
Group O
I O
, O
plasma O
lysozyme O
levels O
in O
arterial O
and O
venous O
blood O
samples O
did O
not O
show O
significant O
changes O
during O
the O
surgery O
. O
[]

After O
eight O
chemotherapy O
cycles O
, O
initial O
bulky O
and O
residual O
disease O
is O
irradiated O
. O
[]

AIMS O
Our O
objective O
was O
to O
compare O
the O
efficacy O
and O
safety O
of O
imidafenacin O
over O
fesoterodine O
in O
patients O
with O
overactive O
bladder O
( O
OAB O
) O
. O
[]

The O
toxicity B-outcome ['Adverse-effects']
was O
manageable. O
[['Adverse-effects']]

Thirteen O
GH-deficient O
adults O
( O
4 O
females O
, O
9 O
males O
; O
mean O
( O
SEM O
) O
age O
26.4 O
( O
1.7 O
) O
years O
) O
, O
who O
had O
completed O
4 O
months O
of O
GH O
therapy O
in O
a O
double-blind O
placebo-controlled O
cross-over O
study O
were O
followed O
, O
for O
further O
16.1 O
( O
0.8 O
) O
months O
of O
uninterrupted O
GH O
therapy O
in O
an O
open O
design O
. O
[]

To O
share O
or O
not O
to O
share O
: O
a O
randomized O
trial O
of O
consent O
for O
data O
sharing B-outcome ['Life-Impact']
in O
genome O
research O
. O
['Life-Impact']

A O
significant O
increase O
in O
aortic B-outcome ['Physiological-Clinical']
PWV I-outcome ['Physiological-Clinical']
, O
a O
marker O
of O
aortic B-outcome ['Physiological-Clinical']
stiffness I-outcome ['Physiological-Clinical']
, O
was O
noted O
after O
patients O
switched O
from O
high-flux O
to O
low-flux O
polyamide O
membranes O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Thirty-five O
( O
49 O
% O
) O
of O
72 O
enrolled O
subjects O
were O
classified O
as O
methylphenidate O
responders O
. O
[]

Primary O
outcomes O
were O
safety O
and O
feasibility B-outcome ['Life-Impact']
of O
treatment O
, O
based O
on O
ankle-brachial B-outcome ['Physiological-Clinical']
index O
( O
ABI O
) O
and O
rest B-outcome ['Life-Impact']
pain B-outcome ['Physiological-Clinical']
, O
and O
analysis O
was O
per O
protocol O
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Patients O
were O
assigned O
to O
each O
of O
the O
following O
treatments O
: O
oral O
CoQ O
( O
10 O
) O
( O
100 O
mg O
tid O
) O
, O
CoQ O
( O
10 O
) O
plus O
supervised O
exercise O
training O
( O
ET O
) O
( O
60 O
% O
of O
peak O
VO O
( O
2 O
) O
, O
five O
times O
a O
week O
) O
, O
placebo O
, O
and O
placebo O
plus O
ET O
. O
[]

RESULTS O
Eleven O
( O
65 O
% O
) O
of O
the O
17 O
patients O
who O
completed O
both O
test O
days O
showed O
a O
significant O
global O
worsening O
of O
behavioral O
symptoms O
with O
short-term O
tryptophan O
depletion O
, O
but O
none O
of O
the O
17 O
patients O
showed O
any O
significant O
change O
in O
clinical O
status O
from O
baseline O
after O
sham O
depletion O
( O
P O
= O
.001 O
) O
. O
[]

Operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
and O
fluid B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
were O
significantly O
greater O
in O
group O
A O
than O
in O
group O
B O
( O
23.4 O
+/- O
5.7 O
vs O
16.9 O
+/- O
4.7 O
minutes O
and O
486.4 O
+/- O
170.0 O
vs O
222.1 O
+/- O
104.9 O
mL O
, O
respectively O
) O
. O
['Life-Impact', 'Physiological-Clinical']

OBJECTIVE O
To O
describe O
in O
detail O
the O
resources B-outcome ['Resource-use']
used O
and O
costs B-outcome ['Resource-use']
incurred I-outcome ['Resource-use']
in O
the O
clinical O
management O
of O
patients O
with O
insulin-dependent O
diabetes O
mellitus O
( O
IDDM O
) O
in O
the O
Diabetes O
Control O
and O
Complications O
Trial O
( O
DCCT O
) O
. O
['Resource-use', 'Resource-use']

Although O
the O
intensive O
insulin O
therapy O
group O
had O
more O
glucose B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
performed O
than O
the O
control O
group O
, O
a O
similar O
proportion O
of O
values O
were O
within O
the O
target O
range O
( O
682 O
[ O
42.4 O
% O
] O
of O
1607 O
values O
in O
the O
5- O
to O
7-mmol/L O
range O
; O
250 O
[ O
38.7 O
% O
] O
of O
660 O
values O
in O
the O
8- O
to O
10-mmol/L O
range O
, O
P O
= O
.35 O
) O
. O
['Physiological-Clinical']

However O
, O
the O
improvement O
found O
is O
limited O
to O
a O
circumscribed O
area O
of O
social-communicative O
function O
and O
generalization O
is O
not O
ensured O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
behavioral B-outcome ['Life-Impact']
effects O
of O
four O
doses O
of O
psychostimulant O
medication O
, O
combining O
extended-release O
methylphenidate O
( O
MPH O
) O
in O
the O
morning O
with O
immediate-release O
MPH O
in O
the O
afternoon O
. O
['Life-Impact']

The O
positive O
percent O
of O
coli-form B-outcome ['Physiological-Clinical']
on O
the O
hand O
swabs O
in O
intervention O
group O
(2.00%) O
were O
significantly O
lower O
than O
that O
in O
control O
group O
(9.45%) O
at O
the O
end O
of O
year O
2.The O
intervention O
of O
intensive O
education O
on O
hand O
hygiene O
effectively O
improved O
the O
personal B-outcome ['Life-Impact']
hygiene I-outcome ['Life-Impact']
both O
of O
children O
and O
parents, O
as O
well O
as O
reduced O
the O
incidence O
of O
hand B-outcome ['Physiological-Clinical']
food I-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
We O
suggested O
expanding O
the O
intervention O
measures O
in O
community O
to O
prevent O
HFMD. O
[['Physiological-Clinical'], ['Life-Impact'], ['Physiological-Clinical']]

The O
5-year O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
rates O
were O
72.3 O
% O
for O
the O
CCRT O
arm O
and O
54.2 O
% O
for O
the O
RT-only O
arm O
( O
P O
=.0022 O
) O
. O
['Mortality']

DESIGN O
Phase O
II O
, O
prospective O
, O
randomized O
, O
assessor-blind O
, O
multicenter O
, O
dose-finding O
, O
noninferiority O
study O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
effect O
of O
LOLA O
in O
healthy O
patients O
with O
cirrhosis O
and O
no O
evidence O
of O
clinical O
encephalopathy O
after O
challenging O
the O
central O
nervous O
system O
by O
administration O
of O
oral O
glutamine O
. O
[]

Publication O
date: O
2018/11/08 O
00:00 O
[accepted] O
[]

RESULTS O
FMA B-outcome ['Physiological-Clinical']
total O
scores O
were O
significantly O
higher O
and O
synergistic B-outcome ['Physiological-Clinical']
shoulder B-outcome ['Physiological-Clinical']
abduction B-outcome ['Physiological-Clinical']
during O
reach B-outcome ['Physiological-Clinical']
was O
less O
in O
the O
MT O
+ O
MG O
and O
MT O
groups O
compared O
with O
the O
CT O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
needle O
sensation O
was O
evoked O
and O
the O
subject O
was O
trained O
to O
identify O
the O
characteristic O
needle O
sensation O
. O
[]

Echocardiographic B-outcome ['Physiological-Clinical']
, O
hemodynamic B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
investigate O
whether O
fish O
oil O
affects O
cardiovascular O
risk O
factors O
during O
the O
adolescent O
growth O
spurt O
. O
[]

A O
growing O
literature O
suggests O
that O
the O
self-face O
is O
involved O
in O
processing O
the O
facial O
expressions O
of O
others O
. O
[]

DESIGN O
Randomized O
and O
placebo-controlled O
study O
. O
[]

The O
decrease O
in O
systolic B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
diastolic I-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
significantly O
less O
in O
the O
300-ml O
h-1 O
group O
at O
the O
end O
of O
induction O
and O
immediately O
after O
induction O
( O
P O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical']

BACKGROUND: O
Total O
knee O
arthroplasty O
(TKA) O
is O
a O
surgical O
procedure O
to O
replace O
the O
weight-bearing O
surfaces O
of O
the O
knee O
joint O
to O
relieve O
pain O
and O
disability. O
[]

Moderate O
sodium O
restriction O
, O
angiotensin O
converting O
enzyme O
inhibition O
, O
and O
thiazide O
diuretic O
in O
the O
management O
of O
essential O
hypertension O
. O
[]

Uric O
acid O
levels O
were O
lowered O
with O
high O
doses O
. O
[]

Long-term O
body O
image O
and O
cosmetic O
appearance O
were O
excellent O
in O
both O
groups O
. O
[]

18 O
patients O
received O
placebo O
and O
23 O
ones O
were O
given O
enalapril O
. O
[]

CLINICAL O
TRIAL O
REGISTRATION O
ClinicalTrials.gov O
, O
www.clinicaltrials.gov O
, O
NCT01509313 O
. O
[]

The O
number O
of O
patients O
who O
discontinued B-outcome ['Life-Impact']
treatment O
due O
to O
an O
unsatisfactory O
analgesic B-outcome ['Resource-use']
response O
was O
significantly O
less O
in O
the O
HI2 O
group O
( O
2 O
; O
1.3 O
% O
) O
than O
in O
the O
CA O
group O
( O
12 O
; O
7.5 O
% O
) O
( O
P O
= O
0.008 O
) O
. O
['Life-Impact', 'Resource-use']

Journal-Name:Journal O
of O
drugs O
in O
dermatology O
: O
JDD O
[]

METHODS O
The O
authors O
divided O
60 O
participants O
randomly O
into O
three O
groups O
: O
NovaMin O
powder O
with O
NovaMin-containing O
toothpaste O
( O
group O
1 O
) O
, O
a O
placebo O
powder O
with O
NovaMin-containing O
toothpaste O
( O
group O
2 O
) O
and O
a O
placebo O
powder O
with O
the O
control O
toothpaste O
( O
group O
3 O
) O
. O
[]

Fifty-seven O
patients O
received O
amlodipine O
maleate O
( O
29 O
men O
, O
28 O
women O
; O
mean O
[ O
SD O
] O
age O
, O
49.0 O
[ O
11.4 O
] O
years O
) O
and O
61 O
received O
amlodipine O
besylate O
( O
35 O
men O
, O
26 O
women O
; O
mean O
[ O
SD O
] O
age O
, O
51.6 O
[ O
9.4 O
] O
years O
) O
. O
[]

Thermal O
welding O
versus O
bipolar O
tonsillectomy O
: O
a O
comparative O
study O
. O
[]

RATIONALE O
The O
acute O
effect O
of O
secondhand O
smoke O
( O
SHS O
) O
on O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
the O
duration O
of O
system B-outcome ['Physiological-Clinical']
disruption I-outcome ['Physiological-Clinical']
remain O
unknown O
. O
['Physiological-Clinical', 'Physiological-Clinical']

PURPOSE O
To O
determine O
the O
prophylactic O
properties O
of O
amifostine O
against O
acute O
and O
late O
toxicities O
from O
radiochemotherapy O
in O
patients O
with O
head-and-neck O
cancer O
. O
[]

Results O
showed O
that O
triacylglycerol-rich B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
zeaxanthin I-outcome ['Physiological-Clinical']
peaked O
at O
6 O
h O
post-ingestion O
for O
all O
formulations O
. O
['Physiological-Clinical']

Ro O
15-1788 O
, O
an O
imidazodiazepine O
derivative O
, O
exhibits O
marked O
antagonism O
of O
the O
behavioural O
and O
biochemical O
effects O
of O
the O
benzodiazepines O
in O
animals O
and O
man O
. O
[]

The O
results O
suggest O
the O
need O
for O
improvements O
in O
colonoscopic O
technology O
. O
[]

The O
morbidity O
scores O
( O
infection/infusion O
) O
were O
1.59 O
, O
1.21 O
and O
1.77 O
respectively O
( O
p O
- O
N/S O
) O
. O
[]

METHODS O
Middle-aged O
working O
men O
with O
recent O
LBP O
but O
without O
severe O
disability O
were O
randomly O
allocated O
to O
either O
a O
training O
( O
TG O
, O
n O
= O
52 O
) O
or O
control O
group O
( O
CG O
, O
n O
= O
54 O
) O
. O
[]

METHODS O
In O
this O
study O
, O
88 O
patients O
6-17 O
years O
of O
age O
, O
with O
ADHD O
and O
ASD O
, O
were O
treated O
with O
1.2 O
mg/kg/day O
atomoxetine O
for O
20 O
weeks O
as O
follow-up O
of O
an O
8 O
week O
double-blind O
placebo-controlled O
period O
. O
[]

The O
mean O
decrease O
in O
Hb B-outcome ['Physiological-Clinical']
( O
g/L O
) O
at O
3 O
months O
adjusted O
for O
co-variates O
was O
significantly O
less O
in O
the O
delayed O
clamping O
group O
compared O
to O
the O
early O
clamping O
group O
( O
-1.09 O
, O
95 O
% O
CI-1.58 O
to O
-0.62 O
, O
p O
> O
0.001 O
) O
. O
['Physiological-Clinical']

The O
results O
of O
this O
study O
suggest O
that O
indomethacin O
phonophoresis O
provides O
significant O
pain B-outcome ['Physiological-Clinical']
relieving O
effect O
over O
the O
TMJ O
pain O
. O
['Physiological-Clinical']

The O
hypothesis O
was O
that O
it O
is O
easier O
to O
control O
energy O
intake O
and O
lose O
weight O
if O
snacks O
in O
between O
meals O
are O
omitted O
. O
[]

The O
t80 B-outcome ['Physiological-Clinical']
of O
fentanyl O
was O
longer O
( O
P O
< O
0.05 O
) O
than O
that O
of O
alfentanil O
or O
sufentanil O
, O
and O
there O
was O
a O
linear O
correlation O
between O
the O
t80 B-outcome ['Physiological-Clinical']
of O
the O
opioid O
and O
the O
time B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
tracheal I-outcome ['Life-Impact']
extubation B-outcome ['Resource-use']
( O
r O
= O
0.51 O
; O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use']

Iron O
sulphate O
100 O
mg O
was O
prescribed O
orally O
twice O
a O
day O
. O
[]

The O
spectrum O
and O
frequency O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
with O
esomeprazole O
were O
similar O
to O
those O
with O
placebo O
. O
['Adverse-effects']

In O
elderly O
black O
patients O
, O
terazosin O
, O
1 O
to O
10 O
mg O
daily O
, O
was O
as O
effective O
in O
lowering O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
as O
propranolol O
( O
40 O
to O
120 O
mg O
twice O
daily O
) O
. O
['Physiological-Clinical']

There O
was O
a O
significant O
( O
ANOVA O
) O
drop O
of O
the O
haematocrit B-outcome ['Physiological-Clinical']
value O
only O
in O
the O
control O
group O
, O
and O
end-point O
values O
for O
haematocrit O
and O
haemoglobin O
were O
significantly O
elevated O
in O
the O
400 O
and O
500 O
U/kg O
groups O
compared O
with O
the O
control O
group O
( O
Table O
9 O
) O
. O
['Physiological-Clinical']

However, O
there O
was O
a O
statistically O
significant O
improvement O
in O
child O
and O
parent O
reported O
pain B-outcome ['Physiological-Clinical']
, O
coordination B-outcome ['Life-Impact']
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
in O
both O
groups. O
[['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

The O
average O
time O
of O
observation O
was O
34.5 O
months O
. O
[]

Initial O
parameters O
failed O
to O
distinguish O
the O
first O
two O
groups O
, O
but O
Lennox-Gastaut O
syndrome O
( O
the O
third O
group O
) O
was O
distinct O
from O
both O
groups O
of O
myoclonic O
astatic O
epilepsy O
from O
the O
onset O
. O
[]

Strength O
of O
vital O
force O
in O
classical O
homeopathy O
: O
bio-psycho-social-spiritual O
correlates O
within O
a O
complex O
systems O
context O
. O
[]

Patients O
receiving O
150 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
had O
prolonged O
median O
OS B-outcome ['Mortality']
compared O
with O
those O
in O
the O
100 O
mg/m O
( O
2 O
) O
nab-paclitaxel O
arm O
( O
hazard O
ratio O
, O
0.575 O
; O
P O
= O
.008 O
) O
. O
['Mortality']

OBJECTIVE O
In O
this O
pilot O
study O
, O
we O
determined O
the O
effectiveness O
of O
a O
weighted O
vest O
on O
attention O
to O
task O
for O
second-grade O
general O
education O
students O
with O
difficulty O
attending O
. O
[]

The O
itching B-outcome ['Physiological-Clinical']
and O
burning B-outcome ['Physiological-Clinical']
symptoms O
were O
not O
severe O
and O
can O
be O
explained O
by O
the O
preservative O
benzyl O
alcohol O
present O
in O
the O
CS O
gel O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
sequence O
of O
test O
conditions O
was O
randomized O
and O
double-blind O
. O
[]

CONCLUSIONS O
Students O
taught O
on O
a O
traditional O
course O
have O
a O
higher O
level O
of O
anatomical B-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
than O
those O
taught O
on O
an O
integrated O
course O
. O
['Life-Impact']

The O
duration O
of O
hospital B-outcome ['Resource-use']
stay B-outcome ['Resource-use']
, O
the O
number O
of O
['Resource-use', 'Resource-use']

The O
subjective O
effects O
produced O
by O
mecamylamine O
were O
not O
characteristic O
of O
those O
of O
psychoactive O
drugs O
. O
[]

The O
CSF B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
neopterin I-outcome ['Physiological-Clinical']
decreased O
by O
63 O
% O
( O
from O
29.6 O
to O
12.9 O
nmol/l O
, O
p O
< O
0.01 O
) O
during O
zidovudine O
but O
increased O
by O
15 O
% O
( O
from O
22.6 O
to O
25.9 O
nmol/l O
, O
not O
significant O
during O
didanosine O
treatment O
. O
['Physiological-Clinical']

After O
an O
initial O
health O
examination O
, O
participants O
in O
the O
I O
group O
were O
counselled O
at O
baseline O
and O
at O
5 O
months O
. O
[]

METHODS O
AND O
RESULTS O
To O
compare O
and O
contrast O
the O
relative O
importance O
of O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( O
CRP B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
AND O
OBJECTIVE O
Since O
the O
efficacy O
of O
the O
standard O
triple O
therapies O
for O
Helicobacter O
pylori O
eradication O
has O
decreased O
, O
novel O
antibiotic O
regimens O
have O
been O
introduced O
, O
including O
concomitant O
, O
sequential O
, O
and O
hybrid O
therapies O
. O
[]

On O
multivariate O
analysis O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
=.02 O
) O
, O
event-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( O
P O
=.02 O
) O
, O
and O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
better O
( O
P O
=.06 O
) O
in O
younger O
children O
due O
to O
a O
lower O
relapse B-outcome ['Physiological-Clinical']
rate O
( O
P O
=.02 O
) O
especially O
in O
the O
bone O
marrow O
( O
P O
=.02 O
) O
. O
['Mortality', 'Mortality', 'Mortality', 'Physiological-Clinical']

Improvements O
were O
limited O
to O
the O
recognition O
of O
expressions O
of O
anger O
, O
with O
poor O
maintenance O
of O
these O
skills O
at O
follow-up O
. O
[]

13 O
patients O
in O
each O
group O
had O
gangrene B-outcome ['Physiological-Clinical']
or O
empyema B-outcome ['Physiological-Clinical']
, O
and O
one O
in O
each O
group O
had O
perforation O
of O
the O
gallbladder O
causing O
diffuse O
peritonitis O
. O
['Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE: O
To O
reduce O
the O
inappropriate O
identification O
of O
eye O
drops, O
through O
the O
use O
of O
different O
colors. O
[]

We O
investigated O
the O
relationship O
between O
serum B-outcome ['Physiological-Clinical']
G-CSF I-outcome ['Physiological-Clinical']
levels O
and O
circulating B-outcome ['Physiological-Clinical']
neutrophil I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
and O
the O
pharmacokinetics O
of O
rhG-CSF O
for O
patients O
with O
lung O
cancer O
who O
had O
been O
treated O
with O
myelosuppressive O
chemotherapy O
and O
then O
with O
subcutaneous O
rhG-CSF O
( O
lenograstim O
, O
2 O
micrograms O
per O
kg O
of O
body O
weight O
per O
day O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
outcome O
was O
stroke B-outcome ['Physiological-Clinical']
recurrence O
within O
one-year O
follow-up. O
[['Physiological-Clinical']]

OBJECTIVE O
To O
compare O
growth B-outcome ['Physiological-Clinical']
and O
incidence O
of O
malnutrition B-outcome ['Physiological-Clinical']
in O
infants O
receiving O
long-term O
dietary O
supplementation O
with O
ready-to-use O
fortified O
spread O
( O
FS O
) O
or O
micronutrient-fortified O
maize-soy O
flour O
( O
likuni O
phala O
[ O
LP O
] O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
five-year O
survival B-outcome ['Mortality']
rate O
was O
89.3 O
percent O
for O
those O
assigned O
to O
CABG O
and O
86.3 O
percent O
for O
those O
assigned O
to O
PTCA O
( O
P O
= O
0.19 O
; O
95 O
percent O
confidence O
interval O
of O
the O
difference O
in O
survival O
, O
-0.2 O
percent O
to O
6.0 O
percent O
) O
. O
['Mortality']

Publication O
date: O
2019/02/28 O
06:00 O
[medline] O
[]

In O
group O
A O
, O
both O
ovulation O
and O
pregnancy B-outcome ['Physiological-Clinical']
rate O
were O
much O
lower O
than O
the O
other O
two O
groups O
( O
27.27 O
% O
and O
12.73 O
% O
, O
respectively O
) O
. O
['Physiological-Clinical']

Mean O
followup O
was O
5.96 O
years O
in O
the O
2 O
groups O
. O
[]

METHODS: O
Participants O
were O
randomly O
assigned O
to O
either O
the O
CART O
group O
that O
performed O
combined O
aerobic O
and O
resistance O
exercise O
of O
moderate O
intensity O
[aerobic O
exercise O
50-80% O
of O
HRmax O
(maximum O
heart O
rate) O
and O
resistance O
exercises O
at O
50-80% O
of O
1 O
Repetition O
Maximum O
(RM)], O
5 O
times/week O
for O
4 O
weeks, O
or O
to O
the O
control O
group O
that O
followed O
conventional O
treatment O
without O
any O
supervised O
exercise O
intervention. O
[]

Twelve O
patients O
already O
used O
other O
neuroleptic O
medication O
, O
which O
was O
kept O
unchanged O
during O
the O
trial O
period O
. O
[]

Changes O
in O
morning B-outcome ['Physiological-Clinical']
SBP I-outcome ['Physiological-Clinical']
and O
DBP B-outcome ['Physiological-Clinical']
were O
also O
determined O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Fifty O
patients O
were O
recruited O
in O
the O
school O
's O
Urgent O
Care O
Clinic O
and O
divided O
evenly O
into O
two O
groups O
: O
one O
( O
control O
) O
receiving O
the O
standard O
consent O
, O
with O
the O
second O
receiving O
a O
SmartConsent O
. O
[]

STUDY O
DESIGN O
Thirty O
residents O
in O
general O
surgery O
performed O
2 O
open O
partial O
gastrectomy O
training O
events O
on O
a O
porcine O
model O
. O
[]

These O
findings O
confirm O
that O
pitch B-outcome ['Life-Impact']
processing I-outcome ['Life-Impact']
is O
enhanced O
in O
high-functioning O
autism O
. O
['Life-Impact']

Activity B-outcome ['Life-Impact']
in O
premotor O
regions O
, O
IPL B-outcome ['Physiological-Clinical']
and O
MOTG O
correlated O
positively O
with O
social B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
, O
whereas O
prefrontal O
Mu-sources O
correlated O
negatively O
with O
social B-outcome ['Life-Impact']
competence I-outcome ['Life-Impact']
. O
['Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

BACKGROUND O
Given O
escalating O
rates O
of O
chronic O
disease O
, O
broad-reach O
and O
cost-effective O
interventions O
to O
increase O
physical O
activity O
and O
improve O
dietary O
intake O
are O
needed O
. O
[]

BFST-D O
improved O
individual O
communication O
of O
adolescents O
and O
mothers O
, O
but O
not O
fathers O
. O
[]

Several O
quality O
of O
life O
scores O
improved O
significantly O
in O
the O
study O
group O
after O
6 O
months O
( O
p O
< O
0.05 O
) O
. O
[]

METHODS O
The O
purpose O
of O
this O
study O
was O
to O
test O
the O
effectiveness O
of O
timely O
patient O
feedback O
in O
the O
form O
of O
a O
letter O
providing O
recent O
patient-specific O
symptoms O
, O
medication O
, O
and O
health O
service O
use O
combined O
with O
guideline-based O
recommendations O
for O
changes O
in O
therapy O
on O
improving O
the O
quality O
of O
asthma O
care O
by O
inner-city O
primary O
care O
providers O
and O
on O
resultant O
asthma O
morbidity O
. O
[]

RESULTS O
Tramadol O
and O
placebo O
had O
no O
statistical O
significances O
in O
analgesic B-outcome ['Resource-use']
properties O
, O
assessed O
by O
the O
means O
of O
pain B-outcome ['Physiological-Clinical']
rating O
at O
the O
different O
time O
intervals O
. O
['Resource-use', 'Physiological-Clinical']

CONCLUSION O
MDD O
patients O
were O
able O
to O
utilize B-outcome ['Life-Impact']
predictive I-outcome ['Life-Impact']
context I-outcome ['Life-Impact']
in O
order O
to O
facilitate O
processing O
of O
deterministic O
targets O
, O
however O
, O
this O
ability B-outcome ['Life-Impact']
was O
limited O
compared O
to O
controls O
, O
as O
demonstrated O
by O
context-dependent O
P3b O
deficits O
. O
['Life-Impact', 'Life-Impact']

as O
found O
in O
the O
fresh O
wild O
amla O
fruit) O
in O
patients O
with O
dyslipidemia. O
[]

Response O
rate O
was O
81 O
% O
( O
95 O
% O
CI O
, O
76 O
% O
to O
86 O
% O
; O
CR B-outcome ['Physiological-Clinical']
, O
22 O
% O
; O
PR O
, O
59 O
% O
) O
. O
['Physiological-Clinical']

The O
systemic B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
local I-outcome ['Life-Impact']
tolerability I-outcome ['Life-Impact']
of O
the O
drug O
was O
good O
. O
['Life-Impact']

Journal-Name:The O
British O
journal O
of O
radiology O
[]

CONCLUSIONS O
The O
fast-titration O
regimen O
had O
a O
similar O
adverse B-outcome ['Adverse-effects']
event O
['Adverse-effects']

CONCLUSIONS O
Targeting O
to O
remission O
with O
tight O
clinical O
controls O
results O
in O
low O
radiologic B-outcome ['Physiological-Clinical']
progression I-outcome ['Physiological-Clinical']
in O
most O
RA O
patients O
. O
['Physiological-Clinical']

Patient-provider O
communication O
in O
the O
intervention O
group O
was O
characterized O
as O
being O
more O
interested B-outcome ['Life-Impact']
, O
friendly B-outcome ['Life-Impact']
, O
responsive B-outcome ['Life-Impact']
, O
interactive B-outcome ['Life-Impact']
, O
and O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

METHODS O
Participants O
were O
pregnant O
women O
( O
N=56 O
) O
, O
with O
past O
histories O
of O
MDD/PPMD O
but O
not O
depressed O
in O
their O
current O
pregnancy O
. O
[]

SIB O
produced O
wide O
variation O
and O
unacceptably O
high O
TV B-outcome ['Physiological-Clinical']
and O
MV B-outcome ['Physiological-Clinical']
in O
experienced O
hands O
. O
['Physiological-Clinical', 'Physiological-Clinical']

BACKGROUND O
There O
are O
patients O
with O
stage O
I-III O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
who O
are O
not O
suitable O
for O
curative O
radical O
chemoradiation O
therapy O
. O
[]

Greater O
proclination B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
and Seperator ['Physiological-Clinical', 'Physiological-Clinical']
more X ['Physiological-Clinical', 'Physiological-Clinical']
protrusion B-outcome ['Physiological-Clinical', 'Physiological-Clinical']
of I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
mandibular I-outcome ['Physiological-Clinical', 'Physiological-Clinical']
incisors E3-outcome ['Physiological-Clinical', 'Physiological-Clinical']
were O
found O
in O
the O
IA O
group. O
[['Physiological-Clinical', 'Physiological-Clinical']]

The O
effect O
of O
month-long O
naltrexone O
( O
NTX O
) O
treatment O
at O
a O
daily O
oral O
dose O
of O
0.5 O
mg/kg/day O
was O
contrasted O
with O
placebo O
( O
PLC O
) O
in O
a O
double-blind O
study O
with O
conjoint O
clinical O
and O
biochemical O
evaluations O
of O
therapeutic O
effects O
. O
[]

Children O
received O
2 O
doses O
of O
placebo O
or O
porcine O
secretin O
, O
6 O
weeks O
apart O
. O
[]

The O
primary O
endpoint O
was O
the O
number O
of O
new B-outcome ['Physiological-Clinical']
active I-outcome ['Physiological-Clinical']
MRI-evident I-outcome ['Physiological-Clinical']
lesions I-outcome ['Physiological-Clinical']
over O
24 O
weeks O
of O
treatment O
. O
['Physiological-Clinical']

Logistic O
regression O
results O
indicated O
an O
11.2 O
times O
higher O
odds O
for O
re-enrollment O
of O
the O
intervention O
group O
than O
the O
control O
group O
( O
p O
< O
.001 O
) O
. O
[]

Eighty O
cats O
were O
randomly O
allocated O
so O
that O
there O
were O
20 O
cats O
in O
four O
different O
treatment O
groups O
. O
[]

Echocardiographic O
evaluation O
of O
children O
with O
systemic O
ventricular O
dysfunction O
treated O
with O
carvedilol O
. O
[]

There O
was O
a O
significant O
dose O
related O
decrease O
in O
the O
fractional O
recovery O
of O
3-MX O
and O
1-MU O
( O
p O
< O
0.001 O
) O
and O
a O
dose O
related O
increase O
in O
fractional B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
DMU I-outcome ['Physiological-Clinical']
and O
unchanged O
theophylline O
( O
p O
< O
0.01 O
and O
p O
< O
0.001 O
respectively O
) O
. O
['Physiological-Clinical']

Infants O
nursed O
with O
a O
postural O
support O
roll O
either O
with O
or O
without O
a O
postural O
support O
nappy O
demonstrated O
improved O
shoulder B-outcome ['Physiological-Clinical']
posture I-outcome ['Physiological-Clinical']
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

METHODS O
AND O
RESULTS O
This O
study O
was O
a O
prospective O
, O
randomized O
, O
paired O
comparison O
of O
two O
shock O
configurations O
on O
atrial O
DFTs O
in O
33 O
patients O
. O
[]

The O
postoperative B-outcome ['Resource-use']
hospital I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
significantly O
shorter O
in O
the O
LC O
than O
the O
OC O
group O
( O
median O
4 O
[ O
IQR O
2-5 O
] O
vs O
6 O
[ O
5-8 O
] O
days O
; O
p=0.0063 O
) O
. O
['Resource-use']

Removal O
of O
hypertrophied O
anal O
papillae O
and O
fibrous O
anal O
polyps O
increases O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
after O
anal O
fissure O
surgery O
. O
['Life-Impact']

A O
clinical O
trial O
of O
glutathione O
supplementation O
in O
autism O
spectrum O
disorders O
. O
[]

Intervention O
was O
unopposed O
micronized O
17beta-estradiol O
versus O
placebo O
. O
[]

Signal-detection B-outcome ['Physiological-Clinical']
analyses O
confirm O
the O
similarity O
of O
the O
animals O
' O
and O
humans O
' O
performances O
. O
['Physiological-Clinical']

METHODS O
Forty O
adult O
American O
Society O
of O
Anaesthesiologists O
( O
ASA O
) O
grade O
1-111 O
patients O
, O
aged O
between O
40-65 O
years O
undergoing O
surgery O
under O
regional O
anaesthesia O
( O
sub-arachnoid O
block O
) O
were O
included O
. O
[]

According O
to O
Choi O
, O
both O
regimens O
( O
chemotherapy O
or O
immunotherapy O
antibody O
) O
revealed O
similar O
results O
to O
the O
Hans O
algorithm O
on O
5 O
years O
OS O
as O
well O
as O
3 O
year O
EFS O
when O
comparing O
GCB O
versus O
ABC O
or O
non-GCB O
subgroups O
. O
[]

Phenobarbital O
compared O
with O
phenytoin O
for O
the O
treatment O
of O
neonatal O
seizures O
. O
[]

Furthermore O
, O
three O
parents O
in O
the O
local O
services O
group O
commenced O
intensive O
, O
home-based O
behavioural O
intervention O
during O
the O
course O
of O
the O
study O
. O
[]

Comparison O
of O
gonadotropin-releasing O
hormone O
agonists O
and O
antagonists O
in O
assisted O
reproduction O
cycles O
of O
polycystic O
ovarian O
syndrome O
patients O
. O
[]

When O
the O
patient O
left O
the O
postanesthesia O
care O
unit, O
all O
had O
sore B-outcome ['Physiological-Clinical']
throat I-outcome ['Physiological-Clinical']
and O
26/15/25 O
patients O
in O
VDT/VST/DT O
group O
had O
hoarseness B-outcome ['Physiological-Clinical']
. O
All O
had O
good O
outcomes B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the O
surgical O
operations O
.We O
found O
the O
ETView O
tube O
to O
be O
helpful B-outcome ['Life-Impact']
in O
the O
endotracheal O
intubation O
and O
continuous O
surveillance O
of O
tube O
position O
in O
patients O
with O
video-assisted O
thoracoscopic O
lobectomy. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

CONCLUSION O
These O
findings O
suggest O
that O
a O
Longmire-Interposition O
with O
or O
without O
a O
pouch O
for O
reconstruction O
after O
total O
gastrectomy O
is O
not O
connected O
with O
a O
higher O
morbidity B-outcome ['Physiological-Clinical']
or O
mortality B-outcome ['Mortality']
in O
comparison O
to O
a O
Roux-en-Y-reconstruction O
. O
['Physiological-Clinical', 'Mortality']

BACKGROUND O
The O
primary O
objective O
of O
this O
study O
was O
to O
investigate O
the O
behavioral O
and O
biochemical O
responses O
to O
acute O
tryptophan O
depletion O
in O
drug-free O
adult O
patients O
with O
autistic O
disorder O
. O
[]

A O
high O
number O
of O
cells B-outcome ['Physiological-Clinical']
was O
required O
for O
significant O
improvements O
in O
the O
primary O
end O
points O
. O
['Physiological-Clinical']

METHODS O
One O
hundred O
forty-two O
pregnant O
, O
predominantly O
Hispanic O
women O
were O
assigned O
to O
a O
peer-led O
smoking O
cessation O
program O
or O
to O
usual O
care O
. O
[]

STUDY O
DESIGN O
A O
randomized O
, O
controlled O
trial O
in O
the O
setting O
of O
a O
neurotological O
clinic O
in O
Thailand O
. O
[]

Six O
of O
the O
patients O
were O
also O
studied O
with O
0.1 O
mM/kg O
gadopentetate O
dimeglumine O
. O
[]

The O
model O
provided O
reasonably O
good O
estimates O
for O
both O
AUC O
and O
Cmax B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Sixty-nine O
patients O
were O
randomized O
to O
received O
24-hour O
intravenous O
infusions O
of O
levosimendan O
( O
n O
= O
23 O
) O
, O
dobutamine O
( O
n O
= O
23 O
) O
, O
or O
placebo O
( O
n O
= O
23 O
) O
. O
[]

STUDY O
DESIGN O
A O
randomized O
, O
single-blinded O
study O
was O
designed O
. O
[]

Studies O
have O
shown O
that O
insulin O
resistance O
is O
associated O
with O
cognitive O
impairment O
. O
[]

Fifty-two O
patients O
undergoing O
coronary O
artery O
bypass O
on O
cardiopulmonary O
bypass O
were O
divided O
randomly O
into O
3 O
groups O
: O
the O
first O
group O
received O
100 O
microg O
x O
kg O
( O
-1 O
) O
x O
min O
( O
-1 O
) O
propofol O
, O
the O
other O
groups O
received O
one O
minimum O
alveolar O
concentration O
of O
sevoflurane O
or O
isoflurane O
for O
anesthesia O
maintenance O
. O
[]

Axillary B-outcome ['Physiological-Clinical']
metastases I-outcome ['Physiological-Clinical']
were O
found O
in O
16 O
% O
of O
the O
patients O
. O
['Physiological-Clinical']

The O
CPRS-R-DSM-IV-ADHD O
subscale O
was O
significant O
for O
the O
PDD O
subgroup O
( O
p O
= O
0.005 O
, O
Cohen O
d O
= O
0.97 O
) O
and O
marginally O
significant O
for O
the O
entire O
DD O
sample O
( O
p O
= O
0.08 O
, O
Cohen O
d O
= O
0.50 O
) O
. O
['Life-Impact']

BACKGROUND O
Long-term O
data O
comparing O
cemented O
and O
noncemented O
single-implant O
restorations O
has O
not O
been O
reported O
. O
[]

Including O
a O
'no O
active O
intervention O
' O
arm O
in O
surgical O
trials O
is O
possible O
: O
evidence O
from O
the O
CLasP O
randomised O
trial O
. O
[]

METHODS O
Four O
hundred O
patients O
with O
chronic O
stable O
angina O
pectoris O
and O
a O
positive O
treadmill O
exercise O
test O
were O
randomized O
to O
receive O
either O
modified O
release O
dipyridamole O
( O
200 O
mg O
b.i.d O
. O
[]

METHODS/DESIGN O
The O
study O
is O
a O
randomized O
, O
waitlist O
controlled O
, O
single-blinded O
trial O
. O
[]

RESULTS O
The O
total O
effective O
rate O
was O
86.7 O
% O
in O
the O
EA O
plus O
behavior O
therapy O
group O
which O
was O
better O
than O
56.7 O
% O
of O
the O
behavior O
therapy O
group O
, O
and O
had O
significant O
enhancement O
in O
sensation O
, O
association O
, O
body O
, O
and O
ability B-outcome ['Life-Impact']
of O
self-care B-outcome ['Life-Impact']
( O
P O
< O
0.05 O
) O
and O
was O
better O
than O
the O
behavior O
therapy O
group O
in O
sensation B-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact', 'Life-Impact']

In O
patients O
with O
H/A O
, O
pain O
was O
reported O
as O
absent O
or O
mild O
in O
56 O
% O
of O
patients O
at O
the O
starting O
dosage O
of O
25/2500 O
mg/d O
; O
an O
additional O
15 O
% O
of O
the O
patients O
responded O
to O
the O
double O
dosage O
; O
the O
remaining O
29 O
% O
of O
patients O
did O
not O
experience O
any O
pain O
relief O
. O
[]

Thus O
, O
the O
use O
of O
random O
SD O
platelet O
transfusions O
postponed O
alloimmunization O
. O
[]

In O
part O
B, O
patients O
without O
recent O
attacks O
were O
randomly O
assigned O
to O
receive O
once-monthly O
injections O
of O
one O
of O
two O
doses O
of O
givosiran O
(0.35 O
or O
1.0 O
mg O
per O
kilogram) O
or O
placebo O
(total O
of O
two O
injections O
28 O
days O
apart). O
[]

CONCLUSION O
A O
combination O
of O
CRM O
and O
VR O
improves O
BPPV B-outcome ['Physiological-Clinical']
in O
the O
elderly O
. O
['Physiological-Clinical']

The O
?TBS O
values O
were O
analyzed O
using O
one-way O
analysis O
of O
variance O
( O
ANOVA O
) O
and O
the O
Tukey O
test O
( O
p=0.05 O
) O
. O
[]

RESULTS O
Retapamulin O
was O
as O
effective O
as O
cephalexin O
( O
clinical O
success O
rates O
at O
follow-up O
: O
85.9 O
% O
and O
89.7 O
% O
, O
respectively O
) O
. O
[]

Development O
, O
description O
, O
and O
acceptability O
of O
a O
small-group O
, O
behavioral O
intervention O
to O
prevent O
HIV O
and O
hepatitis O
C O
virus O
infections O
among O
young O
adult O
injection O
drug O
users O
. O
[]

These O
findings O
argue O
against O
the O
idea O
that O
elevated O
levels O
of O
total O
factor O
[]

The O
largest O
effect O
was O
in O
the O
detection O
of O
calcification B-outcome ['Physiological-Clinical']
( O
52 O
% O
vs. O
63 O
% O
at O
16:1 O
compression O
vs. O
original O
images O
, O
p O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Symptoms O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
were O
assessed O
( O
Social O
Responsiveness O
Scale-Parent O
( O
SRS-P O
) O
; O
coded O
in-session O
behavior O
) O
in O
typically-developing O
, O
anxiety-disordered O
children O
( O
N O
= O
50 O
) O
treated O
with O
cognitive-behavioral O
therapy O
( O
CBT O
) O
. O
[]

It O
was O
possible O
to O
differentiate O
between O
: O
( O
1 O
) O
three O
concentrations O
of O
tretinoin O
in O
a O
commercial O
cream O
product O
line O
; O
( O
2 O
) O
two O
concentrations O
of O
tretinoin O
in O
a O
commercial O
gel O
product O
line O
; O
( O
3 O
) O
different O
vehicles O
( O
gel O
vs. O
cream O
) O
containing O
the O
same O
concentration O
of O
tretinoin O
, O
and O
( O
4 O
) O
tretinoin O
and O
adapalene O
at O
the O
same O
concentration O
. O
[]

RESULTS O
Dexamethasone O
produced O
a O
significant O
23-mm O
improvement O
on O
the O
100-mm O
patient O
visual O
analog O
scale O
ratings O
, O
compared O
with O
14 O
mm O
for O
placebo O
at O
2 O
days O
and O
24 O
mm O
compared O
with O
19 O
mm O
at O
1 O
month O
. O
[]

Participants O
redeemed O
only O
39% O
(SD O
43%) O
of O
their O
earned O
points. O
[]

Yi O
xue O
ban O
= O
Journal O
of O
Central O
South O
University. O
[]

DISCUSSION: O
Halitosis O
treatment O
is O
a O
topic O
that O
still O
needs O
attention. O
[]

BACKGROUND O
Diabetes O
mellitus O
, O
as O
well O
as O
subsequent O
ocular O
complications O
such O
as O
cystoid O
macular O
edema O
( O
CME O
) O
, O
are O
of O
fundametal O
socio-economic O
relevance O
. O
[]

Histologic B-outcome ['Physiological-Clinical']
conversion I-outcome ['Physiological-Clinical']
in O
the O
non-Hodgkin O
's O
lymphomas O
. O
['Physiological-Clinical']

Pain O
ratings O
were O
recorded O
immediately O
after O
perineorrhaphy O
, O
30 O
minutes O
, O
and O
1 O
, O
2 O
, O
6 O
, O
12 O
and O
24 O
hours O
after O
first O
dose O
on O
a O
10-cm O
visual O
analogue O
scale O
. O
['Physiological-Clinical']

The O
average O
number O
of O
days B-outcome ['Physiological-Clinical']
without I-outcome ['Physiological-Clinical']
fever I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
was O
lower O
in O
group O
2 O
patients O
than O
in O
group O
1 O
patients O
( O
mean+/-SD O
: O
3.85+/-1.98 O
for O
group O
1 O
vs. O
2.78+/-1.03 O
for O
group O
2 O
, O
P=0.044 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Twenty-four O
healthy O
males O
( O
age O
, O
35-48 O
years O
) O
participated O
in O
the O
study O
. O
[]

Thereafter O
no O
further O
significant O
improvement O
between O
the O
two O
different O
treatments O
over O
time O
could O
be O
obtained O
. O
[]

Declamping O
caused O
a O
more O
marked B-outcome ['Physiological-Clinical']
increase O
of O
paCO2 B-outcome ['Physiological-Clinical']
and O
a O
greater O
fall O
of O
pH B-outcome ['Physiological-Clinical']
in O
the O
NA O
group O
as O
compared O
to O
the O
epidural O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Avatar O
assistant O
: O
improving O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
in O
students O
with O
an O
ASD O
through O
a O
computer-based O
intervention O
. O
['Life-Impact']

Anhedonia B-outcome ['Life-Impact']
put O
individuals O
at O
risk O
of O
quitting O
the O
weight O
loss O
program O
( O
bivariate O
analysis O
OR O
3.1 O
, O
95 O
% O
CI O
0.8-11.6 O
, O
p=0.091 O
, O
multivariate O
analysis O
OR O
6.5 O
, O
95 O
% O
CI O
1.1-38.2 O
, O
p=0.038 O
) O
. O
['Life-Impact']

Energy O
given O
was O
correlated O
( O
p O
< O
0.05 O
) O
with O
the O
reduction O
of O
thyroid B-outcome ['Physiological-Clinical']
nodule I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Peak O
current O
was O
32 O
% O
higher O
with O
an O
active O
can O
( O
P O
< O
0.01 O
) O
, O
whereas O
shock B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
was O
18 O
% O
lower O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Participants, O
the O
study O
team O
administering O
treatment, O
and O
investigators O
analysing O
outcomes O
(who O
were O
independent O
of O
the O
study O
team O
and O
had O
no O
further O
involvement) O
were O
masked O
to O
treatment O
groups. O
[]

All O
subjects O
were O
followed O
up O
for O
a O
period O
of O
four O
weeks O
. O
[]

Similarly O
, O
post-operative O
increments O
in O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
ammonia I-outcome ['Physiological-Clinical']
, O
creatinine B-outcome ['Physiological-Clinical']
and O
3-methylhistidine B-outcome ['Physiological-Clinical']
were O
not O
altered O
by O
addition O
of O
insulin O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

NT-proBNP B-outcome ['Physiological-Clinical']
was O
higher O
in O
patients O
with O
more O
severe O
symptoms O
and O
older O
patients O
but O
not O
in O
women O
, O
although O
differences O
in O
NT-proBNP O
may O
have O
been O
confounded O
by O
differences O
in O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
Study O
patients O
consisted O
of O
197 O
consecutive O
patients O
with O
primary O
open-angle O
glaucoma O
who O
were O
randomly O
assigned O
to O
receive O
either O
no O
adjunctive O
mitomycin O
C O
( O
101 O
eyes O
of O
101 O
patients O
) O
or O
to O
receive O
adjunctive O
subconjunctival O
mitomycin O
C O
( O
96 O
eyes O
of O
96 O
patients O
) O
during O
the O
primary O
glaucoma O
triple O
procedure O
. O
[]

The O
source O
of O
this O
eye-position O
information O
, O
particularly O
during O
monocular O
viewing O
, O
is O
a O
matter O
of O
debate O
. O
[]

Ropivacaine O
had O
a O
mean O
onset B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
of O
4.5 O
minutes O
( O
range O
, O
3.5 O
to O
5.5 O
minutes O
) O
. O
['Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
whether O
the O
decision B-outcome ['Life-Impact']
to O
give O
thrombolysis O
was O
correct O
. O
['Life-Impact']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS O
Overall O
, O
9 O
( O
69 O
% O
) O
of O
13 O
patients O
noted O
subjective O
improvement O
after O
BTX-A O
treatment O
. O
[]

We O
conclude O
that O
the O
routine O
use O
of O
cophenylcaine O
for O
nasal O
preparation O
is O
not O
justified O
before O
flexible O
nasendoscopy O
. O
[]

BACKGROUND O
The O
Western O
Ontario O
and O
McMaster O
Universities O
( O
WOMAC O
) O
Osteoarthritis O
Index O
is O
a O
previously O
described O
self-administered O
questionnaire O
covering O
three O
domains O
: O
pain B-outcome ['Physiological-Clinical']
, O
stiffness B-outcome ['Physiological-Clinical']
and O
function B-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

All O
three O
indicators O
of O
CHW O
functioning O
(as O
measured O
by O
reports O
submitted O
from O
CHWs) O
improved O
more O
in O
the O
intervention O
area O
relative O
to O
the O
comparison O
area, O
with O
2 O
out O
of O
3 O
measures O
of O
improvement O
reaching O
statistical O
significance. O
[]

Statistics O
are O
mean O
+/- O
standard O
deviation O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
The O
albumin O
diffusion O
space O
, O
the O
colloid O
oncotic O
pressure O
, O
the O
plasma B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
and O
the O
electrical B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
were O
measured O
before O
( O
T O
= O
10 O
mins O
) O
and O
after O
( O
T O
= O
60 O
, O
120 O
, O
and O
240 O
mins O
) O
hemodilution O
. O
['Physiological-Clinical', 'Physiological-Clinical']

To O
test O
whether O
the O
leukotriene O
antagonist O
ONO-1078 O
( O
pranlukast O
) O
prevents O
asthma O
exacerbations O
during O
reduction O
of O
high-dose O
inhaled O
corticosteroid O
, O
we O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
in O
79 O
asthma O
patients O
requiring O
high O
doses O
( O
1,500 O
microg/d O
or O
more O
) O
of O
inhaled O
beclomethasone O
dipropionate O
( O
BDI O
) O
for O
clinical O
control O
( O
duration O
of O
asthma O
, O
11.0 O
+/- O
3.1 O
yr O
; O
duration O
of O
BDI O
treatment O
, O
0.5 O
+/- O
0.3 O
yr O
; O
FEV1 O
percentage O
of O
predicted O
, O
80.7 O
+/- O
2.0 O
% O
) O
. O
[]

METHODS O
Prospective O
analysis O
was O
employed O
with O
the O
setup O
at O
Alexandria O
IVF/ICSI O
center O
. O
[]

The O
aim O
of O
this O
work O
was O
to O
measure O
the O
color B-outcome ['Physiological-Clinical']
changes I-outcome ['Physiological-Clinical']
occurring O
after O
the O
use O
of O
a O
Gantrez-NNP O
combination O
on O
enamel O
tooth O
blocks O
. O
['Physiological-Clinical']

METHODS: O
We O
performed O
a O
multicenter, O
open-label, O
randomized, O
controlled O
trial O
involving O
patients O
18 O
to O
75 O
years O
of O
age O
with O
resectable O
cancer O
of O
the O
middle O
or O
lower O
third O
of O
the O
esophagus. O
[]

Our O
objective O
was O
to O
determine O
the O
impact O
of O
carbohydrate O
and/or O
protein O
ingestion O
before O
and O
after O
exercise O
on O
ribosomal O
protein O
S6 O
kinase O
( O
S6K1 O
) O
and O
S6 O
phosphorylation O
status O
in O
human O
skeletal O
muscle O
tissue O
. O
[]

1 O
RTX O
course O
. O
[]

CONCLUSIONS O
This O
study O
did O
not O
meet O
the O
prespecified O
benchmark O
of O
35 O
% O
6-month O
PFS O
rate O
; O
both O
combination O
schedules O
of O
cetuximab O
plus O
paclitaxel/carboplatin O
were O
feasible O
and O
equivalent O
for O
treating O
advanced O
NSCLC O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
with O
completely O
resected O
( O
stage O
IB O
, O
II O
, O
or O
IIIA O
) O
NSCLC O
stratified O
by O
stage O
, O
histology O
, O
sex O
, O
postoperative O
radiotherapy O
, O
and O
chemotherapy O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
receive O
gefitinib O
250 O
mg O
per O
day O
or O
placebo O
for O
2 O
years O
. O
[]

PATIENTS O
Endocrinologically O
normal O
women O
with O
a O
medical O
indication O
for O
IVF O
or O
intracytoplasmic O
sperm O
injection O
, O
or O
healthy O
volunteers O
. O
[]

Rectal B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
was O
significantly O
less O
in O
the O
patients O
who O
received O
anesthesia O
. O
['Physiological-Clinical']

The O
patients O
were O
randomly O
assigned O
to O
the O
control O
( O
levamlodipine O
besylate O
2.5 O
mg/d O
plus O
benazepril O
10 O
mg/d O
, O
n=20 O
) O
or O
probucol O
group O
( O
levamlodipine O
besylate O
2.5 O
mg/d O
plus O
benazepril O
10 O
mg/d O
plus O
probucol O
500 O
mg/d O
, O
n=20 O
) O
. O
[]

We O
compared O
the O
safety O
and O
feasibility B-outcome ['Life-Impact']
of O
early O
and O
late O
delivery O
of O
stem O
cells O
with O
combined O
therapy O
approaches O
. O
['Life-Impact']

The O
sample O
size O
was O
22 O
. O
[]

We O
believe O
that O
the O
interactivity O
, O
dialogic O
feedback O
and O
integration O
with O
the O
curriculum O
offered O
by O
the O
e-learning O
module O
contributed O
to O
its O
impact O
. O
[]

METHODS O
Psychiatric B-outcome ['Physiological-Clinical']
diagnostic O
assessments O
were O
based O
on O
the O
Structured O
Clinical O
Interview O
for O
DSMIV B-outcome ['Physiological-Clinical']
disorders O
( O
SCID-I O
) O
conducted O
by O
a O
clinical O
psychiatrist O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
lungs O
were O
ventilated O
to O
normocapnia O
. O
[]

CONCLUSION O
Tension-free O
repair O
was O
superior O
to O
the O
non-mesh O
Shouldice O
technique O
. O
[]

Based O
primarily O
on O
the O
beneficial O
effect O
of O
gabapentin O
on O
acquired O
pendular O
nystagmus O
( O
APN O
) O
, O
a O
GABAergic O
mechanism O
in O
controlling O
nystagmus O
has O
been O
hypothesised O
. O
[]

Colorectal O
carcinoma O
is O
one O
of O
the O
most O
common O
malignancies O
in O
the O
world O
, O
and O
its O
incidence O
has O
increased O
in O
recent O
years O
. O
[]

The O
maxilla O
moves O
slightly O
downward O
in O
SARME O
. O
[]

PURPOSE O
To O
study O
the O
impact O
of O
clinical O
predisposing O
factors O
on O
rectal O
normal O
tissue O
complication O
probability O
modeling O
using O
the O
updated O
results O
of O
the O
Dutch O
prostate O
dose-escalation O
trial O
. O
[]

Acute B-outcome ['Adverse-effects']
reactions I-outcome ['Adverse-effects']
in O
the O
bladder O
and O
bowel O
were O
significantly O
worse O
after O
photon O
therapy O
. O
['Adverse-effects']

Journal O
ID: O
101090633 O
[]

A O
six-month O
crossover O
chemoprevention O
clinical O
trial O
of O
tea O
in O
smokers O
and O
non-smokers O
: O
methodological O
issues O
in O
a O
feasibility O
study O
. O
[]

Forty-two O
percent O
of O
cisplatin O
patients O
completed O
the O
3 O
cycles O
of O
adjuvant B-outcome ['Resource-use']
therapy I-outcome ['Resource-use']
compared O
to O
70 O
% O
in O
the O
carboplatin O
group O
. O
['Resource-use']

All O
patients O
were O
sufficiently O
ill O
to O
require O
hospitalization O
although O
none O
needed O
ventilatory O
support O
; O
the O
presence O
of O
pneumonia O
was O
excluded O
. O
[]

Effects O
of O
two O
combined O
hormonal O
contraceptives O
with O
the O
same O
composition O
and O
different O
doses O
on O
female O
sexual O
function O
and O
plasma O
androgen O
levels O
. O
[]

Phenytoin O
or O
placebo O
was O
added O
to O
their O
current O
therapy O
in O
a O
double-blind O
cross-over O
design O
for O
6 O
months O
in O
each O
phase O
. O
[]

In O
the O
six O
months O
following O
interferon O
therapy O
, O
only O
31 O
% O
of O
interferon O
and O
27 O
% O
of O
placebo O
recipients O
remained O
free B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
recurrences I-outcome ['Physiological-Clinical']
( O
p O
= O
0.99 O
) O
. O
['Physiological-Clinical']

SETTING O
Southeast O
region O
of O
Sweden O
. O
[]

In O
this O
study O
, O
33 O
patients O
were O
randomly O
assigned O
to O
receive O
desflurane O
( O
D O
) O
or O
isoflurane O
( O
I O
) O
for O
acoustic O
neuroma O
surgery O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
monocyte I-outcome ['Physiological-Clinical']
chemoattractant I-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
and O
urinary B-outcome ['Physiological-Clinical']
albumin-to-creatinine I-outcome ['Physiological-Clinical']
ratio O
and O
monocyte B-outcome ['Physiological-Clinical']
chemoattractant B-outcome ['Physiological-Clinical']
protein-1 I-outcome ['Physiological-Clinical']
were O
measured O
at O
baseline O
and O
16 O
wk O
after O
administration O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
double-blind O
study O
. O
[]

After O
an O
anesthetic O
induction, O
bolus O
of O
rocuronium O
0.1 O
mg/kg O
was O
injected O
when O
it O
was O
needed O
(for O
patient O
involuntary B-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
or O
at O
the O
request O
of O
the O
surgeon) O
in O
group O
B, O
and O
5 O
mcg/kg/min O
of O
rocuronium O
were O
infused O
in O
group O
I O
study O
participants. O
[['Physiological-Clinical']]

Compared O
to O
the O
students O
in O
the O
control O
group O
, O
the O
TeachTown O
: O
Basics O
students O
showed O
more O
improvement O
overall B-outcome ['Life-Impact']
on I-outcome ['Life-Impact']
language I-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
cognitive I-outcome ['Life-Impact']
outcome O
measures O
. O
['Life-Impact']

RESULTS O
The O
odds O
of O
parents O
reporting O
care B-outcome ['Life-Impact']
consistent I-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
that I-outcome ['Life-Impact']
in I-outcome ['Life-Impact']
a I-outcome ['Life-Impact']
medical I-outcome ['Life-Impact']
home I-outcome ['Life-Impact']
were O
less O
likely O
for O
children O
with O
autism O
( O
odds O
ratio O
, O
0.45 O
; O
95 O
% O
confidence O
interval O
, O
0.30-0.66 O
) O
and O
more O
likely O
for O
children O
with O
asthma O
( O
odds O
ratio O
, O
1.17 O
; O
95 O
% O
confidence O
interval O
, O
1.06-1.30 O
) O
compared O
with O
children O
with O
other O
special O
health O
care O
needs O
( O
1 O
[ O
reference O
] O
) O
. O
['Life-Impact']

In O
group O
I O
, O
all O
thrombi O
were O
mobile O
and O
5-13 O
mm O
in O
diameter O
; O
in O
group O
II O
, O
all O
thrombi O
but O
three O
were O
mobile O
and O
3-18 O
mm O
in O
diameter O
. O
[]

In O
the O
sivelestat O
group O
, O
the O
duration O
of O
artificial B-outcome ['Resource-use']
ventilation I-outcome ['Resource-use']
, O
pulmonary O
oxygenation O
ability O
, O
and O
the O
blood B-outcome ['Physiological-Clinical']
PMN-E B-outcome ['Physiological-Clinical']
, O
SP-D B-outcome ['Physiological-Clinical']
, O
TNF-alpha B-outcome ['Physiological-Clinical']
and O
IL-8 B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
decreased O
significantly O
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
is O
evidence O
to O
suggest O
accelerated O
bone B-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
following O
estrogen O
cessation O
. O
['Physiological-Clinical']

Steers O
were O
given O
ad O
libitum O
access O
to O
high-concentrate O
diets O
( O
13 O
% O
CP O
) O
containing O
71 O
% O
whole O
shelled O
corn O
, O
10 O
% O
corn O
silage O
, O
4 O
% O
condensed O
distillers O
solubles O
, O
and O
15 O
% O
protein O
supplements O
( O
DM O
basis O
) O
. O
[]

Title: O
Hybrid O
Minimally O
Invasive O
Esophagectomy O
for O
Esophageal O
Cancer. O
[]

Wound B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
and O
general B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
were O
more O
frequent O
in O
the O
control O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
St O
Vincent O
's O
Hospital O
, O
Melbourne O
, O
Victoria O
( O
a O
tertiary O
referral O
, O
university O
teaching O
hospital O
) O
, O
1 O
October O
1997 O
to O
30 O
November O
1998 O
. O
[]

Cytology O
provided O
useful O
additional O
information O
with O
the O
Menghini O
technique O
. O
[]

With O
respect O
to O
quality O
of O
life O
, O
after O
correcting O
for O
baseline O
imbalances O
, O
there O
were O
no O
significant O
differences O
between O
treatments O
for O
any O
scale O
, O
except O
diarrhea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Exploratory O
analyses O
suggested O
a O
survival B-outcome ['Mortality']
advantage O
for O
ASC O
plus O
vinorelbine O
compared O
with O
ASC O
alone O
( O
HR O
0.80 O
[ O
0.63-1.02 O
] O
; O
p=0.08 O
) O
, O
with O
a O
median O
survival B-outcome ['Mortality']
of O
9.5 O
months O
. O
['Mortality', 'Mortality']

CONCLUSIONS O
The O
five-item O
CYBOCS-PDD O
is O
reliable O
, O
distinct O
from O
other O
measures O
of O
repetitive O
behavior O
, O
and O
sensitive O
to O
change O
. O
[]

[ O
Case-controll O
study O
on O
the O
synergistic B-outcome ['Adverse-effects']
effects O
of O
electroacupuncture O
on O
knee O
osteoarthritis O
after O
arthroscopic O
debridement O
] O
. O
['Adverse-effects']

CONCLUSIONS O
The O
results O
revealed O
that O
the O
efficacy O
and O
side O
effects O
of O
mitoxantrone O
were O
similar O
to O
those O
of O
doxorubicin O
. O
[]

The O
time B-outcome ['Life-Impact']
interval I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
anesthesia I-outcome ['Life-Impact']
start I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
surgery I-outcome ['Life-Impact']
start I-outcome ['Life-Impact']
was O
greater O
in O
group O
T O
than O
group O
I O
( O
48 O
vs O
35 O
mins O
, O
P O
< O
0.001 O
) O
. O
['Life-Impact']

Paired O
contrast O
agent O
injections O
( O
10 O
ml O
dextrose O
in O
water/0.25 O
ml O
air O
) O
were O
administered O
from O
an O
upper O
extremity O
vein O
and O
femoral O
vein O
in O
each O
patient O
during O
spontaneous O
respiration O
, O
cough O
and O
Valsalva O
maneuvers O
. O
[]

Twenty-five O
deaths B-outcome ['Mortality']
were O
not O
due O
to O
bleeding O
but O
were O
closely O
related O
to O
cirrhosis O
. O
['Mortality']

Primary O
capsulectomy O
, O
anterior O
vitrectomy O
, O
lensectomy O
, O
and O
posterior O
chamber O
lens O
implantation O
in O
children O
: O
limbal O
versus O
pars O
plana O
. O
[]

Among O
the O
patients O
that O
responded O
to O
combined O
therapy O
, O
nine O
of O
them O
had O
a O
complete O
response O
, O
four O
a O
partial O
response O
, O
and O
two O
a O
minor O
response O
. O
[]

The O
principle O
symptoms O
were O
fatigue O
, O
breathlessness O
and O
chest O
pain O
. O
[]

Because O
individuals O
with O
autism O
experience O
reduced O
preparatory O
activity O
prior O
to O
a O
voluntary O
movement O
, O
the O
present O
study O
sought O
to O
determine O
whether O
these O
anticipatory O
biases O
are O
exhibited O
by O
persons O
with O
autism O
. O
[]

CONTRAST O
protocol O
consisted O
of O
alternating O
heavy-light O
resistance O
( O
15-50 O
% O
body O
mass O
) O
with O
soccer-specific O
drills O
( O
small-sided O
games O
or O
technical O
skills O
) O
. O
[]

Correlational O
studies O
have O
revealed O
a O
positive O
relationship O
between O
parent O
verbal O
responsiveness O
and O
language O
outcomes O
in O
children O
with O
autism O
. O
[]

Baseline O
QOL B-outcome ['Life-Impact']
scores O
indicated O
significant O
differences O
between O
patients O
with O
CRS O
and O
published O
norms O
in O
6/8 O
subscale O
parameters O
( O
role O
physical O
, O
bodily B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
general B-outcome ['Physiological-Clinical']
health I-outcome ['Physiological-Clinical']
, O
social B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
, O
vitality B-outcome ['Physiological-Clinical']
, O
and O
mental O
health O
) O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Previously O
reported O
equations O
typically O
overestimated O
the O
subjects O
' O
peak O
oxygen B-outcome ['Physiological-Clinical']
uptake I-outcome ['Physiological-Clinical']
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
To O
determine O
the O
effectiveness O
of O
around-the-clock O
( O
ATC O
) O
analgesic O
administration O
, O
with O
or O
without O
nurse O
coaching O
, O
compared O
with O
standard O
care O
with O
as O
needed O
( O
PRN O
) O
dosing O
in O
children O
undergoing O
outpatient O
tonsillectomy O
. O
[]

Aerobic O
pathogens O
were O
frequently O
isolated O
along O
with O
anaerobes O
from O
the O
infectious O
sites O
in O
this O
series O
; O
their O
susceptibility O
or O
resistance O
to O
clindamycin O
or O
cefoxitin O
did O
not O
influence O
the O
therapeutic O
response O
. O
[]

Expenditure O
of O
resources O
on O
waiting O
times O
without O
regard O
to O
clinical O
outcomes O
is O
likely O
to O
be O
wasteful O
and O
additional O
resources O
should O
be O
directed O
at O
achieving O
the O
greatest O
clinical O
benefit O
. O
[]

On O
the O
basis O
of O
these O
results O
, O
it O
seems O
that O
ginger O
has O
the O
potential O
to O
decrease O
eicosanoid O
levels O
, O
perhaps O
by O
inhibiting O
their O
synthesis O
from O
arachidonic O
acid O
. O
[]

Changes O
in O
symptomatology B-outcome ['Physiological-Clinical']
, O
exercise B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
, O
and O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
were O
assessed O
serially O
during O
the O
two-month O
treatment O
period O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

CONCLUSIONS O
Mortality B-outcome ['Mortality']
rates O
at O
6 O
months O
follow-up O
are O
not O
affected O
by O
intensive O
glucose O
control O
in O
patients O
with O
severe O
TBI O
. O
['Mortality']

CONCLUSION O
Both O
study O
groups O
were O
effective O
in O
the O
prevention O
of O
postcoronary B-outcome ['Physiological-Clinical']
bypass I-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
fibrillation I-outcome ['Physiological-Clinical']
with O
respect O
to O
control O
( O
P O
< O
0.01 O
in O
Group O
1 O
and O
P O
< O
0.001 O
in O
Group O
2 O
) O
. O
['Physiological-Clinical']

Randomised O
, O
double O
blind O
, O
placebo O
controlled O
study O
of O
fluticasone O
propionate O
in O
patients O
with O
moderate O
to O
severe O
chronic O
obstructive O
pulmonary O
disease O
: O
the O
ISOLDE O
trial O
. O
[]

However O
, O
during O
testing O
after O
a O
delay O
, O
response O
times O
were O
slower O
and O
proportion O
of O
trials O
retrieved O
was O
lower O
for O
short O
lag O
items O
than O
for O
long O
lag O
items O
. O
[]

The O
Beck O
Depression O
Inventory O
( O
BDI O
) O
, O
the O
Hamilton O
Depression O
Rating O
Scale O
( O
HDRS O
) O
and O
a O
synoptic O
table O
were O
used O
to O
score O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Adjuvant O
L-arginine O
treatment O
for O
in-vitro O
fertilization O
in O
poor O
responder O
patients O
. O
[]

Electrocardiograms O
for O
signal O
averaging O
were O
recorded O
from O
electrodes O
left O
in O
a O
constant O
location O
. O
[]

The O
predominant O
failure O
mode O
was O
adhesive O
. O
[]

TPI O
group O
received O
TPIs O
with O
2 O
mL O
of O
0.2% O
ropivacaine, O
and O
EMLA O
group O
received O
an O
occlusive O
dressing O
with O
EMLA O
cream O
2 O
g O
on O
both O
shoulders. O
[]

Antenatal O
dexamethasone O
treatment O
was O
successful O
in O
reducing O
the O
incidence O
and O
severity O
of O
experimental B-outcome ['Resource-use']
HMD I-outcome ['Resource-use']
in O
this O
animal O
model O
; O
the O
beneficial O
effects O
of O
treatment O
were O
associated O
with O
accelerated O
maturation O
of O
fetal B-outcome ['Physiological-Clinical']
pulmonary I-outcome ['Physiological-Clinical']
functions I-outcome ['Physiological-Clinical']
, O
including O
, O
but O
not O
limited O
to O
, O
synthetic B-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
SAM I-outcome ['Physiological-Clinical']
phospholipid I-outcome ['Physiological-Clinical']
. O
['Resource-use', 'Physiological-Clinical', 'Physiological-Clinical']

After O
4 O
days O
, O
the O
DR O
curve O
of O
the O
NO-treated O
patients O
was O
left O
shifted O
with O
a O
peak O
response O
at O
1 O
ppm O
. O
[]

Cognitive-behavioural O
stress O
management O
with O
HIV-positive O
homosexual O
men O
: O
mechanisms O
of O
sustained O
reductions O
in O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

Nevertheless O
, O
the O
use O
of O
stentless O
bioprostheses O
leads O
to O
a O
significant O
enhancement O
, O
which O
may O
result O
in O
a O
reduction O
of O
the O
cardiac O
risk O
profile O
for O
the O
patient O
. O
[]

INTERVENTION O
( O
S O
) O
An O
ice O
bag O
was O
secured O
to O
the O
lateral O
ankle O
joint O
for O
20 O
minutes O
. O
[]

In O
the O
Sedation O
group O
, O
the O
average O
pain B-outcome ['Physiological-Clinical']
intensity O
score O
was O
0.4 O
( O
0.8 O
) O
. O
['Physiological-Clinical']

Histological O
alterations O
characteristic O
of O
chronic O
rejection O
were O
expressed O
as O
chronic B-outcome ['Resource-use']
allograft I-outcome ['Resource-use']
damage B-outcome ['Physiological-Clinical']
index O
. O
['Resource-use', 'Physiological-Clinical']

The O
dosage O
of O
CC O
was O
fixed O
at O
3.0 O
g/day O
for O
the O
12-week O
study O
. O
[]

SD O
calculated O
GFR O
at O
year O
5 O
was O
55.9 O
? O
[]

Downstaging O
for O
stages O
I O
+ O
II O
did O
not O
occur O
. O
[]

In O
LA O
, O
there O
was O
no O
difference O
in O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
between O
the O
normal O
and O
overweight O
patients O
. O
['Life-Impact']

Effects O
of O
nicotine O
on O
regional B-outcome ['Physiological-Clinical']
cerebral I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
metabolism I-outcome ['Physiological-Clinical']
in O
awake O
resting O
tobacco O
smokers O
. O
['Physiological-Clinical']

Relief O
of O
pain B-outcome ['Physiological-Clinical']
by O
infusion O
of O
morphine O
after O
operation O
: O
does O
tolerance O
develop O
? O
['Physiological-Clinical']

Yet O
, O
sleep O
withdrawal O
even O
if O
only O
partial O
, O
has O
a O
negative O
influence O
on O
performance O
, O
particularly O
when O
the O
type O
of O
exercise O
requires O
good O
psychomotor O
performance O
The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
whether O
the O
intake O
of O
a O
hypnotic O
drug O
would O
have O
negative O
effects O
on O
physical O
performance O
capacity O
. O
[]

Improving O
emotion B-outcome ['Life-Impact']
regulation I-outcome ['Life-Impact']
with O
CBT O
in O
young O
children O
with O
high O
functioning O
autism O
spectrum O
disorders O
: O
a O
pilot O
study O
. O
['Life-Impact']

Change O
from O
baseline O
in O
the O
levels O
of O
high-sensitivity B-outcome ['Physiological-Clinical']
C-reactive I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
, O
CD40 B-outcome ['Physiological-Clinical']
ligand I-outcome ['Physiological-Clinical']
, O
P-selectin B-outcome ['Physiological-Clinical']
, O
and O
N-terminal B-outcome ['Physiological-Clinical']
pro-brain I-outcome ['Physiological-Clinical']
natriuretic I-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
at O
6 O
weeks O
was O
assessed O
to O
evaluate O
each O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Saccade O
accuracy O
is O
1 O
component O
of O
metrics O
, O
which O
to O
function O
optimally O
requires O
several O
cortical O
brain O
structures O
as O
well O
as O
an O
intact O
cerebellum O
and O
brain-stem O
. O
[]

RESULTS O
Thirty-six O
patients O
received O
a O
TKI O
after O
everolimus O
: O
sunitinib O
in O
17 O
patients O
, O
sorafenib O
in O
15 O
, O
and O
dovitinib O
( O
TKI258 O
) O
in O
4 O
. O
[]

This O
study O
was O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
BBOS O
1.5 O
% O
for O
reducing O
ocular O
itching O
associated O
with O
AC O
in O
subjects O
enrolled O
in O
a O
natural O
exposure O
trial O
. O
[]

METHODS O
In O
a O
randomized O
population-based O
screening O
study O
( O
Rotterdam O
section O
of O
the O
European O
Randomized O
Study O
of O
Screening O
for O
Prostate O
Cancer O
) O
, O
in O
which O
10,865 O
men O
have O
been O
screened O
, O
the O
biopsy O
results O
of O
1202 O
men O
with O
PSA O
levels O
of O
4 O
ng/mL O
or O
more O
were O
evaluated O
. O
[]

The O
percentage O
of O
patients O
achieving O
serum B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
6.0 O
mg/dL O
or O
less O
after O
8 O
weeks O
was O
82.0 O
% O
for O
the O
febuxostat O
group O
and O
70.0 O
% O
for O
the O
allopurinol O
group O
( O
P O
= O
0.019 O
, O
logistic O
regression O
analysis O
) O
. O
['Physiological-Clinical']

Preoperative O
and O
postoperative B-outcome ['Physiological-Clinical']
International I-outcome ['Physiological-Clinical']
Prostate I-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Score O
( O
IPSS B-outcome ['Physiological-Clinical']
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Journal-Name:Medicine O
[]

Inhibition O
of O
bone B-outcome ['Physiological-Clinical']
marrow I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
is O
sometimes O
observed O
with O
radiotherapy O
. O
['Physiological-Clinical']

Twenty-eight O
newly O
diagnosed O
patients O
with O
small O
cell O
lung O
cancer O
were O
randomized O
to O
receive O
either O
high-dose O
or O
standard-dose O
cyclophosphamide O
, O
vincristine O
, O
and O
semustine O
in O
a O
trial O
where O
the O
dose O
of O
induction O
chemotherapy O
was O
the O
sole O
treatment O
variable O
. O
[]

BACKGROUND O
A O
proof-of-concept O
study O
suggested O
that O
combination O
therapy O
with O
commercial O
azelastine O
hydrochloride O
nasal O
spray O
and O
fluticasone O
propionate O
nasal O
spray O
significantly O
improved O
nasal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
seasonal I-outcome ['Physiological-Clinical']
allergic I-outcome ['Physiological-Clinical']
rhinitis I-outcome ['Physiological-Clinical']
compared O
with O
either O
agent O
alone O
. O
['Physiological-Clinical']

BACKGROUND O
This O
study O
examines O
socio-demographic O
determinants O
of O
participation O
in O
a O
population-based O
randomized O
controlled O
trial O
that O
proved O
that O
oral O
visual O
inspection O
was O
effective O
in O
reducing O
oral B-outcome ['Mortality']
cancer I-outcome ['Mortality']
mortality I-outcome ['Mortality']
in O
high-risk O
individuals O
in O
India O
. O
['Mortality']

The O
incidence O
of O
nausea B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
was O
higher O
in O
the O
tramadol O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Because O
mailings O
did O
not O
influence O
participation O
in O
[]

OBJECTIVE O
The O
effectiveness O
of O
influenza O
vaccination O
in O
preventing O
illness O
is O
lower O
in O
the O
elderly O
; O
this O
is O
why O
the O
ability O
of O
Lactobacillus O
plantarum O
CECT O
7315/7316 O
to O
stimulate O
the O
response O
to O
influenza B-outcome ['Physiological-Clinical']
vaccination I-outcome ['Physiological-Clinical']
in O
elderly O
was O
evaluated O
. O
['Physiological-Clinical']

CONCLUSION O
Combinative O
assessment O
of O
MSCT O
and O
SAA O
could O
improve O
the O
accuracy O
of O
preoperative O
staging O
, O
and O
thus O
provide O
higher O
predictive O
coincidence O
rate O
of O
operative O
procedures O
. O
[]

Our O
aim O
was O
to O
evaluate O
blood O
loss O
and O
early B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
outcomes I-outcome ['Physiological-Clinical']
in O
patients O
undergoing O
minimally O
invasive O
TKA O
using O
custom-fit O
magnetic O
resonance O
imaging O
( O
MRI O
) O
-based O
pin O
guides O
. O
['Physiological-Clinical']

The O
absorption B-outcome ['Physiological-Clinical']
rate O
constant O
after O
treatment O
at O
01.00 O
hours O
was O
less O
than O
at O
the O
other O
times O
of O
administration O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical']

Journal-Name:Medicine O
[]

RESULTS O
Four O
patients O
receiving O
exercise O
and O
three O
receiving O
flexibility O
treatment O
dropped O
out O
before O
completion O
. O
[]

Cough B-outcome ['Physiological-Clinical']
was O
more O
often O
reported O
with O
lisinopril O
and O
headache B-outcome ['Physiological-Clinical']
, O
sweating B-outcome ['Physiological-Clinical']
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Good O
compliance B-outcome ['Life-Impact']
did O
not O
affect O
the O
results O
. O
['Life-Impact']

The O
intervention O
effect O
was O
greater O
among O
Medicaid-insured O
children O
and O
for O
broad-spectrum O
agents O
. O
[]

Title: O
Comparison O
of O
fit O
factors O
among O
healthcare O
providers O
working O
in O
the O
Emergency O
Department O
Center O
before O
and O
after O
training O
with O
three O
types O
of O
N95 O
and O
higher O
filter O
respirators. O
[]

Title: O
Denosumab O
effects O
on O
serum O
levels O
of O
the O
bone O
morphogenetic O
proteins O
antagonist O
noggin B-outcome ['Physiological-Clinical']
in O
patients O
with O
transfusion-dependent O
thalassemia O
and O
osteoporosis. O
[['Physiological-Clinical']]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
LD O
( O
50 O
) O
for O
acute O
blood O
loss O
in O
mallard O
ducks O
( O
Anas O
platyrhynchos O
) O
, O
compare O
the O
mortality O
rate O
among O
3 O
fluid O
resuscitation O
groups O
, O
and O
determine O
the O
time O
required O
for O
a O
regenerative O
RBC O
response O
. O
[]

024 O
liter O
. O
[]

CONCLUSION O
Topotecan O
continues O
to O
demonstrate O
comparable O
efficacy O
and O
[]

The O
main O
acupoints O
included O
Sishen O
Xue O
, O
Dingshen O
Sanxue O
( O
3 O
points O
for O
mental O
tranquilization O
) O
, O
Nao O
Sanxue O
( O
3 O
points O
for O
the O
function O
of O
brain O
) O
, O
Shou O
Zhisanxue O
( O
3 O
points O
for O
mental O
activities O
on O
hand O
) O
and O
Zozhi O
Sonxue O
( O
3 O
points O
for O
mental O
activities O
on O
foot O
) O
. O
[]

Endurance O
training O
has O
little O
effect O
on O
active O
muscle O
free B-outcome ['Physiological-Clinical']
fatty I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
lipoprotein B-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
, O
or O
triglyceride B-outcome ['Physiological-Clinical']
net O
balances O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Performance O
on O
the O
timing O
task O
was O
analysed O
measuring O
the O
absolute O
value O
of O
timing O
error O
, O
the O
coefficient O
of O
variability O
and O
the O
percentage O
of O
anticipation O
responses O
. O
[]

The O
cardiovascular B-outcome ['Physiological-Clinical']
condition I-outcome ['Physiological-Clinical']
improved O
significantly O
and O
similarly O
in O
the O
two O
groups O
. O
['Physiological-Clinical']

At O
6 O
months O
follow-up O
, O
tape O
group O
patients O
reported O
positive O
attitudes B-outcome ['Life-Impact']
to O
the O
audiotape O
and O
were O
shown O
to O
recall B-outcome ['Life-Impact']
significantly O
more O
information O
about O
their O
illness B-outcome ['Physiological-Clinical']
than O
did O
controls O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

BACKGROUND O
Older O
adult O
cancer O
survivors O
are O
at O
greater O
risk O
of O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
and O
other O
comorbidities O
that O
can O
be O
prevented O
through O
improved O
diet O
and O
weight O
management O
. O
['Physiological-Clinical']

Title: O
Tafenoquine O
versus O
Primaquine O
to O
Prevent O
Relapse B-outcome ['Physiological-Clinical']
of O
Plasmodium O
vivax O
Malaria. O
[['Physiological-Clinical']]

Health-related B-outcome ['Life-Impact']
QoL I-outcome ['Life-Impact']
was O
assessed O
at O
entry O
and O
after O
every O
cycle O
by O
the O
EORTC-QLQ-C30 O
and O
LC13 O
questionnaires O
, O
toxicity B-outcome ['Adverse-effects']
by O
the O
NCI-NCCN O
CTC O
vs O
2 O
, O
and O
intent-to-treat O
objective B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
by O
the O
Recist O
criteria O
. O
['Life-Impact', 'Adverse-effects', 'Physiological-Clinical']

Of O
147 O
FEC O
( O
75 O
) O
infusions O
, O
4.1 O
% O
were O
delayed O
, O
while O
9.8 O
% O
of O
143 O
FEC O
( O
90 O
) O
infusions O
were O
delayed O
. O
[]

Injecting O
a O
long O
acting O
steroid O
is O
a O
common O
practice O
to O
alleviate O
the O
symptoms O
of O
osteoarthritic O
knee. O
[]

Retapamulin O
was O
well O
tolerated B-outcome ['Life-Impact']
and O
the O
topical O
formulation O
was O
preferred O
over O
the O
oral O
drug O
. O
['Life-Impact']

Residual O
urine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
was O
significantly O
decreased O
in O
groups O
L O
, O
M O
and O
H O
after O
instillation O
of O
saline O
into O
the O
bladder O
( O
p O
less O
than O
0.01 O
) O
but O
not O
in O
group O
P. O
The O
maximum O
and O
average O
flow B-outcome ['Physiological-Clinical']
rates O
were O
significantly O
increased O
in O
groups O
L O
, O
M O
and O
H O
( O
p O
less O
than O
0.01 O
) O
but O
not O
in O
group O
P. O
Average O
flow B-outcome ['Physiological-Clinical']
rate O
showed O
significant O
differences O
between O
groups O
M O
or O
H O
versus O
group O
P. O
Neither O
orthostatic B-outcome ['Physiological-Clinical']
hypotension I-outcome ['Physiological-Clinical']
nor O
a O
decrease O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
was O
noted O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Dietetic O
or O
nutrition O
assistants O
are O
being O
introduced O
in O
units O
across O
the O
UK O
. O
[]

On O
the O
AVP O
+ O
ANF O
study O
day O
, O
UNaV B-outcome ['Physiological-Clinical']
increased O
( O
+64 O
% O
) O
as O
with O
P B-outcome ['Physiological-Clinical']
+ I-outcome ['Physiological-Clinical']
ANF I-outcome ['Physiological-Clinical']
, O
but O
V B-outcome ['Physiological-Clinical']
( O
-44 O
% O
) O
and O
CH2O B-outcome ['Physiological-Clinical']
( O
-52 O
% O
) O
continued O
to O
decrease O
below O
baseline O
levels O
; O
analysis O
of O
variance O
showed O
this O
antidiuresis O
reflected O
the O
prevalent O
effect O
of O
AVP O
rather O
than O
any O
specific O
interaction O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Furthermore O
, O
significant O
improvements O
were O
observed O
in O
CARS O
score O
( O
P O
= O
0.04 O
) O
in O
raw O
CM O
group O
only O
. O
[]

MAIN O
OUTCOME O
MEASURE O
Insulin B-outcome ['Physiological-Clinical']
sensitivity I-outcome ['Physiological-Clinical']
( O
rate O
of O
glucose B-outcome ['Physiological-Clinical']
infusion I-outcome ['Physiological-Clinical']
per O
kg O
fat O
free O
body O
mass O
and O
minute O
) O
, O
['Physiological-Clinical', 'Physiological-Clinical']

Postoperative O
pain O
perception O
was O
graded O
using O
the O
modified O
McGill O
pain O
intensity O
scale O
at O
30 O
minutes O
postoperatively O
, O
at O
discharge O
from O
the O
recovery O
room O
, O
and O
the O
next O
morning O
by O
telephone O
interview O
. O
[]

Journal-Name:JAMA O
[]

Study O
results O
do O
not O
support O
the O
hypothesis O
that O
acustimulation O
bands O
are O
efficacious O
as O
an O
adjunct O
to O
pharmacological O
antiemetics O
for O
control O
of O
chemotherapy-related B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
in O
female O
breast O
cancer O
patients O
. O
['Physiological-Clinical']

BACKGROUND O
Home O
based O
medical O
care O
is O
a O
popular O
alternative O
to O
standard O
hospital O
care O
but O
there O
is O
uncertainty O
about O
its O
cost-effectiveness O
. O
['Resource-use']

In O
the O
Primary O
Angioplasty O
in O
Myocardial O
Infarction O
trial O
, O
395 O
patients O
with O
acute O
myocardial O
infarction O
( O
AMI O
) O
were O
prospectively O
randomized O
to O
tissue O
plasminogen O
activator O
( O
tPA O
) O
or O
primary O
percutaneous O
transluminal O
coronary O
angioplasty O
( O
PTCA O
) O
. O
[]

OBJECTIVE O
Autosomal O
dominant O
polycystic O
kidney O
disease O
( O
ADPKD O
) O
is O
progressive O
, O
resulting O
in O
end-stage O
kidney O
failure O
in O
most O
patients O
. O
[]

[ O
Effects O
of O
small O
needle-knife O
comprehensive O
therapy O
on O
pain O
and O
lumbar O
flexion O
range O
in O
the O
chronic O
nonspecific O
low O
back O
pain O
patient O
] O
. O
[]

One O
month O
after O
surgery O
, O
group O
1 O
patients O
( O
n O
= O
97 O
) O
started O
treatment O
with O
intranasal O
furosemide O
, O
group O
2 O
( O
n O
= O
40 O
) O
received O
no O
therapeutic O
treatment O
, O
and O
group O
3 O
( O
n O
= O
33 O
) O
were O
treated O
with O
mometasone O
. O
[]

A O
multivariate O
model O
showed O
a O
significant O
regression O
in O
histopathology B-outcome ['Physiological-Clinical']
score O
as O
a O
function O
of O
the O
square O
of O
H B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
negative O
time O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
clinic O
that O
provided O
initial O
medical O
evaluation O
, O
methadone O
medication O
, O
and O
AIDS O
education O
, O
but O
did O
not O
include O
formal O
drug O
abuse O
counseling O
or O
other O
social O
support O
services O
was O
established O
in O
New O
York O
City O
. O
[]

ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
[]

Initial O
mean O
doses O
of O
CSA O
and O
AZA O
were O
4.2 O
mg/kg O
and O
1.7 O
mg/kg O
respectively O
. O
[]

These O
results O
demonstrate O
the O
effectiveness O
of O
laser O
therapy O
in O
tendonitis O
of O
the O
shoulder O
. O
[]

We O
propose O
a O
pragmatic O
approach O
to O
the O
correction O
or O
amelioration O
of O
venous O
hypertension O
resulting O
from O
hydrodynamic O
and O
hydrostatic O
venous O
reflux O
. O
[]

The O
nasopharyngeal O
temperature O
was O
maintained O
at O
33.0-34.5 O
centigrade O
and O
the O
rectal O
temperature O
was O
maintained O
at O
34.5-35.0 O
centigrade. O
[]

The O
main O
outcome O
measures O
included O
TKR O
recommendation O
, O
implicit O
racial O
preference O
, O
and O
medical O
cooperativeness O
stereotypes O
measured O
with O
implicit O
association O
tests O
. O
[]

Ten O
variables O
were O
independently O
associated O
with O
1-year O
mortality O
: O
five O
used O
in-hospital O
data O
( O
[]

These O
findings O
reveal O
statistically O
significant O
relationships O
of O
low O
to O
moderate O
strength O
among O
potential B-outcome ['Physiological-Clinical']
quantitative I-outcome ['Physiological-Clinical']
spasticity I-outcome ['Physiological-Clinical']
measures O
, O
a O
traditional B-outcome ['Physiological-Clinical']
qualitative I-outcome ['Physiological-Clinical']
spasticity I-outcome ['Physiological-Clinical']
scale O
and O
a O
simple B-outcome ['Physiological-Clinical']
measure I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
voluntary I-outcome ['Physiological-Clinical']
ankle I-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
Despite O
the O
fact O
that O
the O
combination O
of O
anxiolytics O
and O
analgesics O
as O
compared O
with O
analgesics O
alone O
reduced O
anxiety O
and O
the O
requirement O
of O
Morphine O
in O
the O
prehospital O
setting O
of O
acute O
coronary O
syndrome O
, O
this O
strategy O
did O
not O
reduce O
patients O
' O
estimation O
of O
pain O
( O
primary O
endpoint O
) O
. O
[]

Studies O
on O
leptin B-outcome ['Physiological-Clinical']
and O
leptin B-outcome ['Physiological-Clinical']
receptor I-outcome ['Physiological-Clinical']
gene I-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
in O
myometrium O
and O
uterine O
myomas O
of O
gnRH O
analogue-treated O
women O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Reproducibility O
of O
exercise O
performance O
was O
verified O
during O
a O
3 O
week O
run-in O
placebo O
washout O
period O
. O
[]

In O
conclusion O
, O
acute O
RAO O
after O
transradial O
catheterization O
can O
be O
recanalized O
by O
early O
1-hour O
homolateral O
ulnar O
artery O
compression O
. O
[]

RESULTS O
Forty-seven O
patients O
( O
51 O
% O
) O
were O
treated O
with O
fibrin O
glue O
and O
46 O
( O
49 O
% O
) O
were O
not O
. O
[]

Effects O
of O
misoprostol B-outcome ['Physiological-Clinical']
on O
human O
circulation O
. O
['Physiological-Clinical']

C-telopeptide B-outcome ['Physiological-Clinical']
( O
A O
: O
40.7 O
% O
; O
B O
: O
34.1 O
% O
and O
C O
: O
38.5 O
% O
) O
; O
hydroxyproline B-outcome ['Resource-use']
( O
A O
: O
31.1 O
% O
; O
B O
: O
25.3 O
% O
and O
C O
: O
31.5 O
% O
) O
and O
osteocalcin B-outcome ['Physiological-Clinical']
( O
A O
: O
27.0 O
% O
; O
B O
: O
25.4 O
% O
and O
C O
: O
25.1 O
% O
) O
decreased O
similarly O
in O
the O
three O
groups O
. O
['Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

6-mercaptopurine O
should O
remain O
the O
thiopurine O
of O
choice O
for O
continuing O
therapy O
of O
childhood O
lymphoblastic O
leukaemia O
. O
[]

Both O
regimens O
remain O
as O
reasonable O
treatment O
options O
. O
[]

Conversely O
, O
plasma B-outcome ['Physiological-Clinical']
potassium I-outcome ['Physiological-Clinical']
increased O
and O
blood B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Accordingly O
, O
220 O
inpatients O
( O
26 O
% O
chronic O
active O
hepatitis O
, O
68 O
% O
cirrhosis O
, O
6 O
% O
primary O
biliary O
cirrhosis O
) O
with O
stable O
( O
1 O
month O
or O
more O
) O
at O
least O
twofold O
increases O
in O
serum B-outcome ['Physiological-Clinical']
total O
and O
conjugated B-outcome ['Physiological-Clinical']
bilirubin I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
alkaline I-outcome ['Physiological-Clinical']
phosphatase I-outcome ['Physiological-Clinical']
volunteered O
for O
the O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Topical O
selamectin O
was O
found O
to O
be O
40.7-63.3 O
% O
effective O
( O
based O
on O
egg B-outcome ['Physiological-Clinical']
per O
gram O
method O
) O
in O
eliminating B-outcome ['Physiological-Clinical']
S. O
muris B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
total O
study O
period O
will O
be O
9 O
weeks O
. O
[]

RESULTS O
The O
increase O
in O
the O
proportion O
of O
total O
urinary B-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
excreted O
as O
DMA O
in O
the O
folic O
acid O
group O
( O
72 O
% O
before O
and O
79 O
% O
after O
supplementation O
) O
was O
significantly O
( O
P O
< O
0.0001 O
) O
greater O
than O
that O
in O
the O
placebo O
group O
, O
as O
was O
the O
reduction O
in O
the O
proportions O
of O
total O
urinary B-outcome ['Physiological-Clinical']
arsenic I-outcome ['Physiological-Clinical']
excreted I-outcome ['Physiological-Clinical']
as O
MMA O
( O
13 O
% O
and O
10 O
% O
, O
respectively O
; O
P O
< O
0.0001 O
) O
and O
as O
InAs O
( O
15 O
% O
and O
11 O
% O
, O
respectively O
; O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

FINDINGS O
From O
June O
, O
2005 O
, O
to O
August O
, O
2008 O
, O
882 O
women O
were O
enrolled O
, O
824 O
of O
whom O
were O
randomised O
and O
gave O
birth O
to O
805 O
singleton O
or O
first O
, O
liveborn O
infants O
. O
[]

The O
absorbable O
clips O
seem O
to O
be O
as O
effective O
as O
metal O
clips O
in O
providing O
hemostasis B-outcome ['Physiological-Clinical']
in O
cystic O
artery O
and O
in O
cystic O
duct O
ligation O
. O
['Physiological-Clinical']

Side O
effects O
, O
mainly O
diarrhea B-outcome ['Physiological-Clinical']
, O
occurred O
in O
15 O
percent O
of O
the O
patients O
given O
antibiotics O
. O
['Physiological-Clinical']

The O
most O
reliable O
combination O
of O
predictive O
factors O
was O
a O
negative O
anti-human B-outcome ['Physiological-Clinical']
immunodeficiency I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
with O
either O
a O
positive O
history O
of O
acute B-outcome ['Physiological-Clinical']
icteric I-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
and O
AST O
greater O
than O
45 O
IU O
per O
liter O
or O
no O
history O
of O
acute O
icteric O
hepatitis O
and O
AST O
greater O
than O
85 O
IU O
per O
liter O
, O
which O
predicted O
response O
in O
77 O
% O
with O
a O
specificity O
of O
79 O
% O
( O
p O
less O
than O
0.001 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
main O
outcome O
measures O
were O
HIV-RNA B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
, O
and O
blood B-outcome ['Physiological-Clinical']
chemistry I-outcome ['Physiological-Clinical']
profiles O
prior O
to O
the O
treatment O
and O
then O
every O
4 O
weeks O
for O
24 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Physiologic O
modeling O
of O
the O
intravenous B-outcome ['Resource-use']
glucose I-outcome ['Resource-use']
tolerance O
test O
in O
type O
2 O
diabetes O
: O
a O
new O
approach O
to O
the O
insulin O
compartment O
. O
['Resource-use']

In O
a O
recent O
clinical O
trial O
, O
postmenopausal O
estrogen-progestin O
therapy O
was O
shown O
to O
increase O
the O
risk O
of O
early B-outcome ['Physiological-Clinical']
cardiovascular I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
among O
women O
with O
a O
history O
of O
coronary O
heart O
disease O
( O
CHD O
) O
. O
['Physiological-Clinical']

In O
the O
BL O
, O
NO2 B-outcome ['Physiological-Clinical']
exposure I-outcome ['Physiological-Clinical']
caused O
increases O
in O
polymorphonuclear B-outcome ['Physiological-Clinical']
neutrophils I-outcome ['Physiological-Clinical']
( O
PMNs B-outcome ['Physiological-Clinical']
) O
, O
interleukin B-outcome ['Physiological-Clinical']
6 I-outcome ['Physiological-Clinical']
( O
IL-6 B-outcome ['Physiological-Clinical']
) O
, O
IL-8 B-outcome ['Physiological-Clinical']
, O
alpha1-antitrypsin B-outcome ['Physiological-Clinical']
, O
and O
tissue B-outcome ['Physiological-Clinical']
plasminogen I-outcome ['Physiological-Clinical']
activator I-outcome ['Physiological-Clinical']
, O
and O
decreases O
in O
epithelial B-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
standard O
surgical O
procedure O
was O
a O
limited O
lymphadenectomy O
( O
D1 O
) O
with O
staging O
biopsy O
of O
the O
para-aortic O
lymph O
nodes O
. O
[]

Femoral O
vein O
delivery O
of O
contrast O
medium O
enhances O
transthoracic B-outcome ['Physiological-Clinical']
echocardiographic I-outcome ['Physiological-Clinical']
detection I-outcome ['Physiological-Clinical']
of O
patent B-outcome ['Physiological-Clinical']
foramen I-outcome ['Physiological-Clinical']
ovale I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Patients O
were O
randomly O
divided O
in O
two O
groups O
: O
In O
group O
1 O
( O
n O
= O
41 O
) O
postmenopausal O
women O
received O
oral O
risedronate O
( O
35 O
mg/week O
) O
, O
calcium O
( O
1,000 O
mg/day O
) O
, O
and O
vitamin O
D O
( O
400 O
IU/day O
) O
for O
12 O
months O
. O
[]

[ O
Effect O
on O
pressure O
after O
instillation O
of O
a O
drop O
of O
depot-pilocarpine O
. O
[]

METHODS O
Sixty-one O
mother-infant O
pairs O
were O
included O
, O
special O
emphasis O
being O
placed O
on O
the O
maternal O
allergic O
status O
. O
[]

METHODS O
A O
limited O
montage O
sleep O
study O
was O
recorded O
from O
2300 O
to O
0700 O
h O
during O
each O
admission O
. O
[]

This O
web-based O
intervention O
will O
be O
evaluated O
in O
a O
2-year O
cluster O
randomised O
controlled O
trial O
( O
c-RCT O
) O
with O
three O
study O
arms O
. O
[]

RESULTS O
The O
antihypertensive O
effect O
of O
captopril O
and O
atenolol O
was O
not O
influenced O
by O
concurrent O
administration O
of O
pravastatin O
. O
[]

METHODS O
Patients O
with O
refractory O
AF O
underwent O
AV O
node O
ablation O
and O
were O
randomized O
( O
2:2:1 O
) O
to O
BiV O
pacing O
with O
CLS O
, O
BiV O
pacing O
with O
accelerometer O
, O
or O
right O
ventricular O
( O
RV O
) O
pacing O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
prevalence O
and O
correlates O
of O
different O
indicators O
of O
psychological O
distress O
among O
13-14 O
year O
old O
low O
caste O
girls O
in O
rural, O
south O
India. O
[]

The O
impact O
of O
allergy O
on O
patient O
's O
quality O
of O
life O
is O
substantial O
. O
[]

RESULTS O
The O
two O
groups O
were O
well O
matched O
for O
age O
, O
weight O
, O
and O
other O
factors O
, O
which O
could O
predispose O
to O
the O
development O
of O
deep B-outcome ['Physiological-Clinical']
venous I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
DVT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
haemorrhage B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
a O
survival O
analysis O
, O
the O
difference O
between O
the O
two O
response O
curves O
was O
significant O
by O
the O
log-rank O
test O
( O
P O
= O
0.04 O
) O
, O
with O
the O
no O
incentive O
group O
having O
a O
shorter O
time O
to O
response O
than O
the O
incentive O
group O
. O
[]

The O
primary O
aim O
was O
to O
test O
whether O
treatment O
with O
LMWH O
, O
started O
within O
30 O
h O
of O
stroke O
onset O
, O
is O
superior O
to O
aspirin O
for O
the O
prevention O
of O
recurrent B-outcome ['Physiological-Clinical']
stroke I-outcome ['Physiological-Clinical']
during O
the O
first O
14 O
days O
. O
['Physiological-Clinical']

Lumbar B-outcome ['Physiological-Clinical']
spine I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
was O
measured O
by O
dual-energy O
X-ray O
absorptiometry O
, O
and O
trabecular B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
at O
the O
distal O
radius O
, O
cortical B-outcome ['Physiological-Clinical']
bone I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
, O
and O
relative B-outcome ['Physiological-Clinical']
cortical I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
at O
the O
radial O
diaphysis O
by O
peripheral O
computed O
tomography O
before O
the O
beginning O
of O
the O
study O
and O
at O
the O
4th O
, O
8th O
, O
and O
12th O
month O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Recovery B-outcome ['Physiological-Clinical']
after O
prolonged O
anaesthesia O
for O
acoustic O
neuroma O
surgery O
: O
desflurane O
versus O
isoflurane O
. O
['Physiological-Clinical']

POPULATION O
A O
total O
of O
9025 O
women O
were O
screened O
in O
early O
pregnancy O
. O
[]

When O
patients O
were O
reviewed O
four O
months O
after O
treatment O
, O
only O
4 O
of O
44 O
patients O
( O
9 O
% O
) O
who O
used O
a O
dilator O
had O
not O
been O
improved O
and O
required O
additional O
therapy O
, O
compared O
with O
15 O
of O
42 O
patients O
( O
36 O
% O
) O
who O
had O
anal O
stretch O
alone O
( O
P O
less O
than O
0.02 O
) O
. O
[]

Other O
studies O
have O
demonstrated O
that O
LAIV-induced O
immunity O
is O
also O
partially O
explained O
by O
T-cell O
immunity O
, O
serum O
antibody O
responses O
, O
and O
innate O
immunity O
, O
consistent O
with O
the O
multi-faceted O
nature O
of O
immunity O
induced O
by O
wild-type O
influenza O
infection O
and O
other O
live O
virus O
vaccines O
. O
[]

Among O
patients O
who O
received O
sorafenib, O
the O
most O
frequently O
reported O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
grade O
1 O
or O
2 O
events O
of O
rash B-outcome ['Physiological-Clinical']
(73%), O
fatigue B-outcome ['Physiological-Clinical']
(67%), O
hypertension B-outcome ['Physiological-Clinical']
(55%), O
and O
diarrhea B-outcome ['Physiological-Clinical']
(51%). O
[['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

In O
total O
, O
one O
or O
two O
migraine O
attacks O
were O
treated O
in O
268 O
and O
235 O
patients O
, O
respectively O
. O
[]

A O
total O
of O
14 O
patients O
developed O
wound B-outcome ['Physiological-Clinical']
sepsis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

METHODS O
In O
this O
open O
, O
multicentre O
, O
randomised O
, O
controlled O
study O
, O
eligible O
patients O
with O
periarthritis O
of O
the O
shoulder O
were O
randomised O
to O
receive O
either O
oxaprozin O
1200 O
mg O
once O
daily O
( O
n O
= O
49 O
) O
or O
diclofenac O
50 O
mg O
three O
times O
daily O
( O
n O
= O
47 O
) O
. O
[]

on O
retention O
on O
treatment O
over O
1 O
year O
. O
[]

In O
74 O
out O
of O
95 O
patients O
( O
78 O
% O
) O
the O
diagnosis O
was O
placed O
with O
Jumbo O
forcep O
while O
the O
smaller O
forcep O
was O
diagnostic O
in O
62 O
out O
of O
95 O
patients O
( O
65 O
% O
) O
. O
[]

METHODS O
In O
a O
randomized O
, O
double-blind O
, O
four-arm O
study O
with O
placebo O
run-in O
phase O
conducted O
at O
travel O
clinics O
in O
Switzerland O
, O
Germany O
, O
and O
Israel O
, O
we O
compared O
moods O
and O
feelings O
in O
chemoprophylaxis O
users O
( O
n= O
547 O
) O
by O
administering O
the O
standardized O
Profile O
of O
Mood O
States O
( O
POMS O
) O
questionnaire O
. O
[]

Treatments O
were O
administered O
4 O
times O
at O
weekly O
intervals O
. O
[]

The O
study O
design O
is O
feasible O
, O
and O
minor O
improvements O
will O
help O
to O
minimize O
the O
potential O
bias O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
incremental O
cost-effectiveness O
ratios O
( O
ICERs O
) O
of O
two O
brief O
cognitive-behavioral O
therapy O
( O
CBT O
) O
-based O
interventions O
and O
a O
pharmacological O
treatment O
, O
compared O
with O
usual O
care O
, O
initiated O
in O
the O
emergency O
department O
( O
ED O
) O
for O
individuals O
with O
panic B-outcome ['Physiological-Clinical']
disorder I-outcome ['Physiological-Clinical']
( O
PD O
) O
with O
a O
chief O
complaint O
of O
noncardiac O
chest O
pain O
. O
['Resource-use', 'Physiological-Clinical']

Journal-Name:Upsala O
journal O
of O
medical O
sciences O
[]

Persistent B-outcome ['Physiological-Clinical']
bronchial I-outcome ['Physiological-Clinical']
narrowing I-outcome ['Physiological-Clinical']
was O
observed O
in O
patients O
who O
became O
disease-free O
2-yr O
survivors O
. O
['Physiological-Clinical']

RESULTS O
Of O
the O
121 O
patients O
who O
participated O
, O
59 O
received O
C/A O
and O
62 O
received O
H/A O
. O
[]

The O
response O
rate O
to O
the O
two O
treatments O
was O
approximately O
the O
same O
, O
being O
69 O
% O
and O
75 O
% O
after O
terazosin O
and O
enalapril O
, O
respectively O
. O
[]

Every O
other O
boy O
in O
each O
diagnostic O
group O
was O
randomly O
allocated O
to O
receive O
either O
( O
a O
) O
a O
special O
education O
program O
( O
clinical O
index O
group O
) O
or O
( O
b O
) O
follow-up O
without O
the O
special O
education O
program O
( O
clinical O
comparison O
group O
) O
. O
[]

Sixty O
children O
participated O
from O
56 O
classrooms O
in O
30 O
schools O
. O
[]

METHOD O
We O
recorded O
EEG O
in O
15 O
MDD O
patients O
and O
14 O
age-matched O
controls O
. O
[]

Shock O
success O
was O
defined O
as O
return O
of O
sinus B-outcome ['Physiological-Clinical']
rhythm I-outcome ['Physiological-Clinical']
for O
> O
/=30 O
seconds O
. O
['Physiological-Clinical']

Levels O
of O
complement B-outcome ['Physiological-Clinical']
factor O
C3a B-outcome ['Physiological-Clinical']
( O
851 O
( O
791-959 O
) O
ng/ml O
[ O
median O
with O
quartiles O
] O
in O
group O
C O
, O
497 O
( O
476-573 O
) O
ng/ml O
in O
group O
HC O
, O
p O
< O
0.001 O
) O
, O
Terminal B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

QoL B-outcome ['Life-Impact']
improved O
in O
the O
study O
group O
and O
deteriorated O
in O
the O
control O
one O
. O
['Life-Impact']

When O
corrected O
for O
differences O
in O
blood O
glucose O
control O
it O
appeared O
that O
in O
three O
out O
of O
nine O
patients O
glomerular B-outcome ['Physiological-Clinical']
filtration I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
had O
not O
completely O
returned O
to O
the O
reference O
range O
of O
the O
placebo O
group O
. O
['Physiological-Clinical']

A O
comparison O
of O
the O
effectiveness O
and O
patient O
tolerance O
of O
oral O
sodium O
phosphate O
, O
castor O
oil O
, O
and O
standard O
electrolyte O
lavage O
for O
colonoscopy O
or O
sigmoidoscopy O
preparation O
. O
[]

Increasing O
the O
reach O
of O
health B-outcome ['Physiological-Clinical']
sponsorship O
: O
using O
a O
sponsorship O
kit O
to O
promote O
health O
. O
['Physiological-Clinical']

There O
were O
no O
serious B-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
reported O
. O
['Adverse-effects']

Results O
indicated O
that O
the O
hypnosis O
sessions O
predicted O
significantly O
impaired B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
. O
['Life-Impact']

However O
, O
the O
TMP O
test O
group O
( O
425 O
children O
) O
had O
significantly O
higher O
caries B-outcome ['Physiological-Clinical']
increments I-outcome ['Physiological-Clinical']
than O
the O
MFP O
control O
group O
. O
['Physiological-Clinical']

The O
principal O
results O
on O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
show O
neither O
order B-outcome ['Physiological-Clinical']
x O
treatment O
interaction B-outcome ['Life-Impact']
, O
nor O
order O
effect O
but O
a O
significant O
treatment O
effect O
( O
p O
< O
0.01 O
) O
: O
amisulpride O
increases O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
whereas O
bromocriptine B-outcome ['Resource-use']
decreases O
according O
to O
the O
usual O
data O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Resource-use']

Histologic B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
and O
chronicity B-outcome ['Physiological-Clinical']
indexes I-outcome ['Physiological-Clinical']
were O
determined O
in O
renal O
biopsies O
performed O
at O
trial O
entry O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
A O
multicenter O
, O
randomized O
, O
open-label O
, O
parallel O
group O
trial O
was O
conducted O
. O
[]

Changing O
the O
threshold-age O
to O
60 O
years O
, O
67 O
% O
of O
the O
study O
population O
would O
receive O
a O
boost O
and O
the O
5-year O
local B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
would O
be O
reduced O
to O
4.4 O
% O
. O
['Physiological-Clinical']

Do O
ACE O
inhibitors O
improve O
the O
response O
to O
exercise B-outcome ['Life-Impact']
training I-outcome ['Life-Impact']
in O
functionally O
impaired O
older O
adults O
? O
['Life-Impact']

Estrone O
decreased O
in O
55.56 O
% O
of O
women O
in O
the O
experimental O
group O
compared O
with O
42.86 O
% O
in O
the O
placebo O
group O
. O
[]

In O
the O
modified O
localization O
group, O
all O
32 O
patients O
succeeded O
in O
the O
localization B-outcome ['Life-Impact']
, O
and O
the O
success B-outcome ['Life-Impact']
rate O
was O
100%. O
[['Life-Impact'], ['Life-Impact']]

Captopril O
12.5 O
mg O
decreased O
subjective O
activity B-outcome ['Life-Impact']
compared O
with O
placebo O
. O
['Life-Impact']

Effects O
of O
losartan O
and O
enalapril O
on O
high-sensitivity O
C-reactive O
protein O
and O
total O
antioxidant O
in O
renal O
transplant O
recipients O
with O
Renin-Angiotensin O
system O
polymorphisms O
. O
[]

Four O
patients O
died O
without O
further O
therapy O
for O
HCL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
Both O
citalopram O
and O
reboxetine O
showed O
good O
safety O
and O
tolerability B-outcome ['Life-Impact']
. O
['Life-Impact']

Part O
B O
included O
20 O
asymptomatic O
porphobilinogen O
deaminase-deficient O
subjects O
and O
20 O
healthy O
subjects O
. O
[]

The O
primary O
study O
end O
point O
was O
the O
proportion O
of O
DNA B-outcome ['Physiological-Clinical']
aneuploid I-outcome ['Physiological-Clinical']
histograms I-outcome ['Physiological-Clinical']
after O
12 O
months O
. O
['Physiological-Clinical']

RESULTS O
Patients O
from O
TEMPO O
and O
RADIUS O
II O
who O
received O
etanercept O
monotherapy O
showed O
similar O
CDAI O
remission O
rates O
( O
39 O
% O
and O
35 O
% O
, O
respectively O
, O
at O
3 O
years O
) O
. O
[]

Supplementation O
lasted O
for O
14 O
days O
during O
months O
4 O
and O
8 O
. O
[]

The O
increase O
in O
protein B-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
during O
nutrition O
was O
comparable O
in O
the O
2 O
groups O
( O
P=.07 O
) O
. O
['Physiological-Clinical']

LA O
also O
abolished O
some O
of O
the O
negative O
effects O
that O
overweight O
had O
on O
operating B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
, O
and O
sick B-outcome ['Life-Impact']
leave I-outcome ['Life-Impact']
with O
the O
open O
technique O
. O
['Life-Impact', 'Resource-use', 'Life-Impact']

METHODS: O
In O
this O
24-week, O
randomized, O
double-blind, O
placebo-controlled O
phase O
3 O
study, O
225 O
patients, O
142 O
of O
which O
were O
East O
Asian O
(63.4%), O
were O
enrolled: O
Japan O
(n O
= O
114), O
South O
Korea O
(n O
= O
20), O
Taiwan O
(n O
= O
8), O
the O
Czech O
Republic O
(n O
= O
42), O
and O
Poland O
(n O
= O
40). O
[]

ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
[]

BACKGROUND O
Nightblindness O
affects O
16-52 O
% O
of O
pregnant O
women O
in O
areas O
of O
Nepal O
and O
in O
some O
cases O
persists O
after O
vitamin O
A O
treatment O
. O
[]

METHOD O
Twenty-six O
children O
diagnosed O
with O
autism O
at O
age O
2 O
were O
re-assessed O
at O
ages O
3 O
and O
7 O
years O
. O
[]

RESULTS O
Between O
1 O
and O
3 O
years O
, O
there O
were O
infrequent O
additional O
clinical O
events O
that O
were O
equally O
distributed O
between O
the O
SES O
and O
the O
BMS O
group O
. O
[]

Including O
results O
obtained O
by O
second-look O
laparotomy O
, O
we O
did O
not O
observe O
a O
statistically O
significant O
difference O
in O
response O
rates O
in O
the O
two O
treatment O
groups O
. O
[]

RESULTS O
Both O
treatments O
increased O
HDL-cholesterol B-outcome ['Physiological-Clinical']
, O
but O
decreased O
LDL-cholesterol B-outcome ['Physiological-Clinical']
by O
a O
comparable O
extent O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Church-based O
programs O
may O
be O
more O
effective O
if O
they O
are O
spiritually O
based O
in O
nature O
. O
[]

Results O
indicate O
that O
VRE O
was O
superior O
to O
WL O
on O
all O
measures O
, O
including O
willingness B-outcome ['Life-Impact']
to O
fly O
on O
the O
posttreatment O
flight O
( O
76 O
% O
for O
VRE O
and O
SE O
; O
20 O
% O
for O
WL O
) O
. O
['Life-Impact']

PATIENTS O
AND O
METHODS O
90 O
patients O
( O
96 O
hips O
) O
scheduled O
for O
THA O
were O
stratified O
in O
three O
groups O
according O
to O
the O
method O
of O
fixation O
of O
the O
acetabular O
component O
: O
acrylic O
bone O
cement O
with O
fluoride O
( O
Cemex-F O
) O
, O
porous-coated O
press-fit O
cup O
with O
ceramic O
coating O
( O
Trilogy O
, O
uncemented O
) O
and O
acrylic O
cement O
with O
gentamicin O
( O
Palacos O
) O
. O
[]

None O
of O
the O
neonates O
developed O
respiratory B-outcome ['Physiological-Clinical']
depression I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Title: O
Effect O
of O
Magnetic O
Resonance O
Imaging O
vs O
Conventional O
Treat-to-Target O
Strategies O
on O
Disease B-outcome ['Physiological-Clinical']
Activity I-outcome ['Physiological-Clinical']
Remission I-outcome ['Physiological-Clinical']
and O
Radiographic B-outcome ['Physiological-Clinical']
Progression I-outcome ['Physiological-Clinical']
in O
Rheumatoid O
Arthritis: O
The O
IMAGINE-RA O
Randomized O
Clinical O
Trial. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Butorphanol O
and O
meperidine O
compared O
in O
patients O
with O
acute O
ureteral O
colic O
. O
[]

Just O
after O
delivery O
, O
2.5 O
mg O
droperidol O
was O
given O
intravenously O
to O
groups O
2 O
and O
5 O
, O
and O
5 O
mg O
was O
given O
to O
groups O
3 O
and O
6 O
. O
[]

An O
additional O
examination O
was O
performed O
at O
34 O
weeks O
if O
the O
fetal O
weight O
in O
the O
32nd O
week O
was O
estimated O
to O
be O
less O
than O
95 O
% O
of O
the O
expected O
mean O
weight O
. O
[]

Of O
36 O
patients O
who O
completed O
treatment O
, O
16 O
( O
44.4 O
% O
) O
experienced O
true O
withdrawal B-outcome ['Life-Impact']
phenomena I-outcome ['Life-Impact']
on O
reducing O
their O
drugs O
, O
but O
8 O
other O
patients O
had O
pseudo-withdrawal B-outcome ['Life-Impact']
reactions I-outcome ['Life-Impact']
at O
a O
time O
when O
their O
drug O
treatment O
was O
unchanged O
. O
['Life-Impact', 'Life-Impact']

The O
study O
enrolled O
263 O
healthy O
smokers O
( O
M O
( O
age O
) O
= O
49 O
years O
) O
who O
smoked O
a O
mean O
of O
24 O
cigarettes/day O
, O
with O
a O
mean O
of O
31 O
pack-years O
. O
[]

The O
insertion B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
scope I-outcome ['Life-Impact']
was O
easier O
via O
the O
oral O
route O
, O
as O
reflected O
in O
a O
shorter O
examination B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
mean O
165 O
vs. O
210 O
seconds O
, O
p O
= O
0.017 O
) O
and O
patients O
' O
tolerance O
for O
the O
scope O
insertion B-outcome ['Physiological-Clinical']
( O
mean O
score O
: O
8 O
for O
oral O
vs. O
4 O
for O
nasal O
route O
; O
p O
= O
0.03 O
) O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical']

CONCLUSIONS O
The O
Sacred O
Heart O
Halo O
and O
Vantage O
baskets O
resulted O
in O
the O
most O
expeditious B-outcome ['Physiological-Clinical']
stone I-outcome ['Physiological-Clinical']
extraction I-outcome ['Physiological-Clinical']
, O
especially O
for O
2 O
to O
5 O
mm O
calculi O
while O
the O
Microvasive O
Zerotip O
was O
optimal O
for O
8 O
mm O
calculi O
. O
['Physiological-Clinical']

The O
CCR B-outcome ['Physiological-Clinical']
rates O
in O
Regimen O
A O
and O
B O
were O
75.1 O
% O
+/- O
5.8 O
% O
( O
mean O
+/- O
1 O
SE O
) O
and O
49.7 O
% O
+/- O
7.3 O
% O
( O
P O
less O
than O
0.01 O
) O
at O
4 O
years O
, O
and O
72.1 O
% O
+/- O
6.3 O
% O
and O
49.7 O
% O
+/- O
7.3 O
% O
( O
P O
less O
than O
0.05 O
) O
at O
5 O
years O
, O
respectively O
. O
['Physiological-Clinical']

Efficacy O
of O
second O
versus O
third O
generation O
oral O
contraceptives O
in O
the O
treatment O
of O
hirsutism O
. O
[]

METHODS O
The O
ROCAS O
study O
is O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
evaluating O
the O
effects O
of O
simvastatin O
20 O
mg O
daily O
upon O
progression O
of O
asymptomatic O
middle O
cerebral O
artery O
stenosis O
among O
stroke-free O
individuals O
over O
2 O
years O
. O
[]

The O
women O
were O
separated O
into O
those O
who O
were O
given O
2,500 O
IU O
enoxaparin O
once O
daily O
and O
SH O
in O
a O
dose O
of O
5,000 O
IU O
three O
times O
daily O
. O
[]

Post-laparoscopic O
cholecystectomy O
pain O
: O
effects O
of O
intraperitoneal O
local O
anesthetics O
on O
pain O
control O
-- O
a O
randomized O
prospective O
double-blinded O
placebo-controlled O
trial O
. O
[]

BACKGROUND O
Screening O
for O
cervical O
cancer O
based O
on O
testing O
for O
human O
papillomavirus O
( O
HPV O
) O
increases O
the O
sensitivity O
of O
detection O
of O
high-grade O
( O
grade O
2 O
or O
3 O
) O
cervical O
intraepithelial O
neoplasia O
, O
but O
whether O
this O
gain O
represents O
overdiagnosis O
or O
protection O
against O
future O
high-grade O
cervical O
epithelial O
neoplasia O
or O
cervical O
cancer O
is O
unknown O
. O
[]

OG O
cost B-outcome ['Resource-use']
$ O
1675 O
and O
PEG O
$ O
979 O
to O
perform O
. O
['Resource-use']

RESULTS O
The O
pooled O
database O
included O
538 O
patients O
. O
[]

METHODS O
Five O
hundred O
seventy-seven O
women O
were O
screened O
for O
MPC O
. O
[]

This O
post O
hoc O
analysis O
of O
the O
Treating O
to O
New O
Targets O
( O
TNT O
) O
trial O
examined O
whether O
the O
observed O
decrease O
in O
HF O
hospitalizations O
with O
high- O
compared O
to O
low-dose O
atorvastatin O
could O
be O
related O
to O
improvements O
in O
kidney O
function O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
assess O
the O
role O
of O
tissue O
factor O
and O
serum-induced O
cell O
invasion O
in O
patients O
with O
advanced B-outcome ['Physiological-Clinical']
pancreatic I-outcome ['Physiological-Clinical']
cancer B-outcome ['Physiological-Clinical']
( O
APC O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
impact O
on O
guideline O
adherence O
and O
resource O
utilization O
was O
evaluated O
during O
the O
12-month O
period O
before O
and O
after O
implementation O
. O
[]

A O
number O
was O
assigned O
to O
each O
eye O
drop, O
and O
the O
volunteer O
was O
asked O
to O
identify O
it O
by O
color. O
[]

Changes O
in O
RBC B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
were O
not O
consistently O
paralleled O
by O
changes O
in O
Hb O
. O
['Physiological-Clinical']

The O
animal O
used O
for O
these O
studies O
was O
the O
greyhound O
, O
which O
has O
thin O
skin O
, O
angular O
conformation O
, O
limited O
body O
fat O
and O
is O
predisposed O
to O
pressure O
ulcers O
similar O
to O
those O
occurring O
in O
humans O
. O
[]

METHOD O
21 O
patients O
( O
age O
0-2 O
months O
) O
and O
40 O
healthy O
infants O
( O
age O
0-2 O
months O
) O
were O
investigated O
. O
[]

Statistically O
significant O
differences O
between O
oral O
vaccine O
and O
placebo O
were O
not O
found O
in O
the O
clinical O
or O
the O
immunological O
variables O
tested O
. O
[]

One O
hundred O
and O
seventeen O
patients O
formed O
the O
usual O
care O
( O
UC O
) O
group O
. O
[]

We O
undertook O
a O
randomised O
comparison O
of O
the O
safety O
and O
outcome O
of O
LC O
and O
open O
cholecystectomy O
( O
OC O
) O
in O
patients O
with O
acute O
cholecystitis O
. O
[]

Social O
competence O
and O
social O
skills O
training O
and O
intervention O
for O
children O
with O
Autism O
Spectrum O
Disorders O
. O
[]

Group O
I O
consisted O
of O
15 O
patients O
with O
Forrest O
IB O
and O
Group O
II O
consisted O
of O
30 O
patients O
with O
Forrest O
II O
. O
[]

Journal O
ID: O
101249598 O
[]

Effect O
of O
esomeprazole O
triple O
therapy O
on O
eradication B-outcome ['Physiological-Clinical']
rates O
of I-outcome ['Physiological-Clinical']
Helicobacter I-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
, O
['Physiological-Clinical']

Although O
the O
intervention O
successfully O
altered O
several O
hypothesised O
mediating O
constructs O
it O
did O
not O
translate O
into O
long-term O
behaviour O
change. O
[]

Pain O
following O
traumatic O
injuries O
is O
common O
, O
can O
impair O
injury O
recovery O
and O
is O
often O
inadequately O
treated O
. O
[]

RESULTS O
Seventeen O
of O
20 O
( O
85 O
% O
) O
women O
in O
the O
control O
group O
developed O
preeclampsia B-outcome ['Physiological-Clinical']
, O
whereas O
9 O
of O
20 O
( O
45 O
% O
) O
in O
the O
treatment O
group O
developed O
preeclampsia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

These O
findings O
suggest O
that O
over-selectivity B-outcome ['Life-Impact']
is O
not O
simply O
due O
to O
a O
failure O
to O
attend O
to O
all O
of O
the O
stimuli O
presented O
. O
['Life-Impact']

Randomized O
clinical O
trial O
of O
behavioral O
intervention O
and O
nutrition O
education O
to O
improve O
caloric O
intake O
and O
weight O
in O
children O
with O
cystic O
fibrosis O
. O
[]

RESULTS O
By O
examining O
outcome O
measures O
-- O
including O
satisfaction O
with O
care B-outcome ['Life-Impact']
arrangements I-outcome ['Life-Impact']
, O
consumers O
' O
perceptions B-outcome ['Life-Impact']
of O
paid O
caregivers B-outcome ['Life-Impact']
' O
attitudes B-outcome ['Life-Impact']
, O
unmet O
needs O
, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
satisfaction B-outcome ['Life-Impact']
with O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Adverse-effects', 'Life-Impact']

1 O
. O
[]

The O
most O
important O
predictor O
of O
non-attendance O
for O
the O
second O
surveillance O
test O
was O
late O
attendance O
for O
the O
first O
test O
( O
OR O
= O
9.65 O
; O
95 O
% O
CI O
, O
6.60-16.62 O
) O
. O
[]

Blastocysts O
were O
stored O
in O
LN? O
for O
at O
least O
1 O
month O
. O
[]

The O
pharmacokinetic B-outcome ['Physiological-Clinical']
profile O
of O
bilastine O
was O
investigated O
using O
a O
simultaneous O
analysis O
of O
all O
concentration-time O
data O
by O
means O
of O
nonlinear O
mixed-effects O
modelling O
population O
pharmacokinetic O
software O
NONMEM O
version O
6.1 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
the O
case O
of O
the O
right O
colon O
, O
changes O
in O
transit B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
also O
were O
significant O
between O
groups O
. O
['Life-Impact']

Excluding O
hospital B-outcome ['Mortality']
deaths I-outcome ['Mortality']
, O
patients O
with O
leakage B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
anastomotic I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
, O
and O
those O
who O
received O
radiation O
therapy O
to O
histologically O
infiltrated O
resection O
margin O
, O
anastomotic B-outcome ['Physiological-Clinical']
stricture I-outcome ['Physiological-Clinical']
was O
found O
in O
5 O
( O
9.1 O
% O
) O
of O
55 O
patients O
in O
the O
hand-sewn O
group O
and O
20 O
( O
40 O
% O
) O
of O
50 O
in O
the O
stapler O
group O
( O
p O
= O
0.0003 O
) O
. O
['Mortality', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
In O
a O
double-blind O
, O
cross-over O
study O
, O
60 O
breast O
cancer O
patients O
experiencing O
HF O
were O
randomized O
to O
8 O
weeks O
venlafaxine O
followed O
by O
2 O
weeks O
wash-out O
, O
and O
8 O
weeks O
clonidine O
or O
vice O
versa O
. O
[]

The O
responses O
of O
renal O
haemodynamic O
and O
natriuretic O
indices O
to O
the O
oral O
prostaglandin O
synthetase O
inhibitor O
indomethacin O
( O
200 O
mg O
) O
, O
to O
infused O
angiotensin O
II O
( O
1 O
ng O
min-1 O
kg-1 O
) O
and O
to O
the O
combination O
of O
the O
two O
were O
studies O
in O
placebo-controlled O
fashion O
in O
eight O
normal O
male O
subjects O
both O
prior O
to O
and O
following O
administration O
of O
intravenous O
frusemide O
( O
20 O
mg O
) O
. O
[]

They O
were O
randomly O
divided O
into O
3 O
groups O
of O
20 O
cases O
each O
with O
nephrostomy O
tube O
( O
NT O
) O
and O
temporary O
ureteral O
catheter O
( O
TU O
) O
in O
group O
A O
, O
only O
TU O
in O
group O
B O
and O
only O
indwelling O
ureteral O
catheter O
( O
IU O
) O
in O
group O
C. O
Mean O
age O
of O
cases O
were O
43.2 O
( O
25-70 O
) O
, O
40.1 O
( O
25-73 O
) O
, O
and O
44 O
( O
25-70 O
) O
years O
in O
groups O
A O
, O
B O
and O
C O
, O
respectively O
( O
P O
= O
0.6 O
) O
. O
[]

RESULTS O
The O
satisfaction B-outcome ['Life-Impact']
rate O
was O
significantly O
higher O
in O
the O
thermal O
destruction O
group O
. O
['Life-Impact']

Journal-Name:The O
heart O
surgery O
forum O
[]

The O
study O
population O
was O
broken O
down O
into O
five O
age O
groups O
as O
follows O
: O
less O
than O
50 O
years O
( O
group O
one O
) O
, O
50 O
to O
64 O
years O
( O
group O
two O
) O
, O
65 O
to O
74 O
years O
( O
group O
three O
) O
, O
75 O
to O
84 O
years O
( O
group O
four O
) O
, O
and O
85 O
or O
older O
( O
group O
five O
) O
. O
[]

PURPOSE O
To O
determine O
if O
the O
accuracy O
of O
the O
baseline O
prediction O
model O
for O
the O
development O
of O
primary O
open-angle O
glaucoma O
( O
POAG O
) O
in O
patients O
with O
ocular O
hypertension O
can O
be O
improved O
by O
correcting O
intraocular O
pressure O
( O
IOP O
) O
for O
central O
corneal O
thickness O
( O
CCT O
) O
. O
[]

Within-subject O
analyses O
examined O
the O
association O
between O
the O
presence O
of O
IEDs O
and O
changes O
in O
attention-deficit/hyperactivity B-outcome ['Life-Impact']
disorder I-outcome ['Life-Impact']
( I-outcome ['Life-Impact']
ADHD I-outcome ['Life-Impact']
) I-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
. O
['Life-Impact']

During O
the O
48-hour O
observation O
period O
, O
3 O
( O
7 O
% O
) O
of O
46 O
patients O
given O
phenytoin O
and O
3 O
( O
5 O
% O
) O
of O
56 O
patients O
given O
placebo O
experienced O
a O
posttraumatic B-outcome ['Physiological-Clinical']
seizure I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

A O
randomized O
comparison O
of O
the O
Endeavor O
zotarolimus-eluting O
stent O
versus O
the O
TAXUS O
paclitaxel-eluting O
stent O
in O
de O
novo O
native O
coronary O
lesions O
12-month O
outcomes O
from O
the O
ENDEAVOR O
IV O
trial O
. O
[]

The O
standard O
donation O
brochure O
had O
an O
intermediate O
effect O
. O
[]

Effectiveness O
of O
sensory O
integration O
interventions O
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
pilot O
study O
. O
[]

In O
vivo O
effect O
of O
clarithromycin O
on O
multiple O
cytochrome O
P450s O
. O
[]

Autism B-outcome ['Life-Impact']
Diagnostic I-outcome ['Life-Impact']
Observation I-outcome ['Life-Impact']
Schedule O
( O
ADOS O
) O
and O
the O
Gilliam O
Autism O
Rating O
Scale O
( O
GARS O
) O
were O
used O
to O
assess O
core B-outcome ['Life-Impact']
autism B-outcome ['Life-Impact']
behaviours B-outcome ['Life-Impact']
, O
Vineland O
Adaptive O
Behaviour O
Scales O
( O
VABS O
) O
to O
ascertain O
developmental O
level O
, O
and O
Attention-Deficit O
Hyperactivity O
Disorder O
- O
IV O
scale O
( O
ADHD-IV O
) O
to O
determine O
inattention O
and O
hyperactivity O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

However O
, O
acute B-outcome ['Adverse-effects']
toxicities I-outcome ['Adverse-effects']
were O
more O
frequent O
in O
the O
40-Gy O
arm O
. O
['Adverse-effects']

Journal-Name:Medicine O
[]

This O
might O
partly O
account O
for O
the O
lack O
of O
significance O
of O
some O
of O
the O
parameters O
under O
study O
. O
[]

Sequential O
pre-operative/post-operative O
treatment O
with O
anastrozole O
resulted O
in O
lower O
recurrence B-outcome ['Physiological-Clinical']
and O
death B-outcome ['Mortality']
rates O
, O
compared O
with O
tamoxifen O
. O
['Physiological-Clinical', 'Mortality']

Single-dose O
and O
multi-dose O
clindamycin O
therapy O
fails O
to O
demonstrate O
efficacy O
in O
preventing O
infectious O
and O
inflammatory O
complications O
in O
third O
molar O
surgery O
. O
[]

Gonadotropin-releasing O
hormone O
agonist O
in O
the O
treatment O
of O
premenstrual O
symptoms O
with O
and O
without O
ongoing O
dysphoria O
: O
a O
controlled O
study O
. O
[]

METHODS O
We O
conducted O
a O
controlled O
, O
community-level O
, O
cluster-randomized O
trial O
in O
16 O
nonoverlapping O
Massachusetts O
communities O
, O
studied O
from O
1998 O
to O
2003 O
. O
[]

Depression B-outcome ['Life-Impact']
, O
functioning B-outcome ['Life-Impact']
, O
perceived B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
care I-outcome ['Life-Impact']
, O
utilization B-outcome ['Life-Impact']
, O
and O
costs B-outcome ['Resource-use']
were O
secondary O
outcomes O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Resource-use']

Dronedarone O
treatment O
significantly O
reduced O
the O
risk O
of O
first O
CV O
hospitalization B-outcome ['Resource-use']
( O
P O
< O
0.0001 O
vs. O
placebo O
) O
, O
while O
the O
risk O
of O
first O
non-CV B-outcome ['Resource-use']
hospitalization I-outcome ['Resource-use']
was O
similar O
in O
both O
groups O
( O
P O
= O
0.77 O
) O
. O
['Resource-use', 'Resource-use']

AIM O
To O
investigate O
the O
sustained O
effect O
on O
quality O
of O
life O
during O
the O
grass O
pollen O
season O
1 O
year O
after O
3 O
years O
of O
treatment O
with O
the O
SQ-standardized O
grass O
allergy O
immunotherapy O
tablet O
( O
AIT O
) O
, O
Graza O
( O
Phleum O
pratense O
75,000 O
SQ-T/2800 O
BAU O
; O
ALK O
, O
Denmark O
) O
. O
[]

INTERVENTIONS O
Subjects O
received O
either O
intravenous O
fructose-1,6-diphosphate O
125 O
mg/kg O
or O
normal O
saline O
1.3 O
ml/kg O
every O
12 O
hours O
over O
10 O
minutes O
for O
four O
consecutive O
doses O
. O
[]

The O
antibody O
was O
tested O
by O
neutralization O
test O
. O
[]

Significantly O
lower O
( O
p O
< O
0.02 O
) O
plasma O
beta-glucuronidase O
levels O
were O
found O
in O
arterial O
blood O
samples O
in O
Group O
I O
compared O
to O
Group O
II O
( O
5.59 O
? O
[]

Topical O
adrenaline O
in O
the O
control O
of O
intraoperative B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
in O
adenoidectomy O
: O
a O
randomised O
, O
controlled O
trial O
. O
['Physiological-Clinical']

Imagined O
movements O
imparted O
a O
further O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
, O
but O
only O
if O
they O
followed O
hand O
laterality O
recognition O
. O
['Physiological-Clinical', 'Life-Impact']

Smokeless O
tobacco O
was O
provided O
for O
7 O
weeks O
( O
or O
up O
to O
12 O
) O
, O
combined O
with O
eight O
group O
support O
visits O
provided O
by O
nurses O
. O
[]

Likewise O
, O
19.5 O
% O
of O
children O
in O
the O
IT O
methotrexate O
group O
had O
a O
Processing B-outcome ['Life-Impact']
Speed I-outcome ['Life-Impact']
Index O
score O
in O
the O
below-average O
range O
compared O
with O
6.9 O
% O
in O
the O
triple O
IT O
therapy O
group O
( O
P O
= O
.02 O
) O
. O
['Life-Impact']

Efficacy O
was O
evaluated O
using O
standard B-outcome ['Life-Impact']
psychiatric I-outcome ['Life-Impact']
rating I-outcome ['Life-Impact']
scales O
, O
and O
patients O
were O
monitored O
for O
safety O
. O
['Life-Impact']

In O
a O
radiological O
examination O
, O
no O
leak O
of O
contrast O
medium O
under O
the O
tourniquet O
cuff O
( O
300 O
mmHg O
) O
was O
detected O
. O
[]

The O
development B-outcome ['Life-Impact']
for O
the O
group O
of O
children O
on O
diet O
was O
significantly O
better O
than O
for O
the O
controls O
. O
['Life-Impact']

METHODS O
Eight O
hundred O
sixty-one O
patients O
with O
severe O
traumatic O
brain O
injury O
who O
were O
admitted O
to O
86 O
centers O
were O
included O
in O
a O
multicenter O
, O
placebo-controlled O
, O
Phase O
III O
trial O
. O
[]

PATIENTS O
40 O
ASA O
status O
I O
and O
II O
patients O
scheduled O
for O
elective O
surgery O
. O
[]

Enalapril O
in O
single O
doses O
of O
10 O
and O
20 O
mg O
was O
given O
to O
13 O
hypertensive O
patients O
on O
treatment O
with O
bendrofluazide O
5 O
mg O
daily O
in O
a O
randomised O
, O
crossover O
, O
placebo O
controlled O
study O
. O
[]

In O
the O
therapy O
group O
, O
52 O
% O
of O
all O
specimens O
were O
sterile O
, O
in O
the O
control O
group O
only O
25 O
% O
. O
[]

CONCLUSION O
Early O
acupuncture O
can O
improve O
the O
limb O
motor O
function O
in O
the O
severe O
head O
injury O
patients O
. O
[]

The O
addition O
of O
blood O
was O
significantly O
more O
effective O
in O
reducing O
pain B-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
than O
the O
addition O
of O
saline O
( O
p O
< O
0.001 O
) O
, O
but O
was O
not O
significantly O
more O
effective O
than O
the O
addition O
of O
lignocaine O
. O
['Physiological-Clinical']

In O
summary O
, O
excluding O
glucose O
from O
a O
short-term O
feeding O
protocol O
does O
not O
diminish O
the O
protein-sparing B-outcome ['Physiological-Clinical']
effect O
of O
amino O
acids O
and O
avoids O
hyperglycemia B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Further O
improvements O
can O
be O
achieved O
with O
dose-dense O
regimens O
, O
but O
densification O
of O
fluorouracil/epirubicin/cyclophosphamide O
( O
FEC O
) O
has O
proved O
difficult O
, O
with O
FEC O
( O
60 O
) O
providing O
little O
benefit O
over O
standard O
chemotherapy O
and O
FEC O
( O
100 O
) O
associated O
with O
toxicity O
. O
[]

RESULTS O
In O
the O
ER+ O
( O
Estrogen O
Receptor O
? O
[]

Elevated O
scores O
were O
associated O
with O
being O
younger O
, O
female O
, O
divorced O
or O
separated O
, O
not O
employed O
, O
living O
alone O
, O
having O
a O
lower O
level O
of O
education O
, O
and O
having O
poorer O
health O
and O
quality O
of O
life O
. O
[]

Long-term O
effects O
of O
ezetimibe-plus-statin O
therapy O
on O
low-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
levels O
as O
compared O
with O
double-dose O
statin O
therapy O
in O
patients O
with O
coronary O
artery O
disease O
. O
['Physiological-Clinical']

CONCLUSIONS O
Local O
warming O
facilitates O
the O
insertion O
of O
peripheral B-outcome ['Resource-use']
venous I-outcome ['Resource-use']
cannulas I-outcome ['Resource-use']
, O
reducing O
both O
time B-outcome ['Life-Impact']
and I-outcome ['Life-Impact']
number I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
attempts I-outcome ['Life-Impact']
required I-outcome ['Life-Impact']
. O
['Resource-use', 'Life-Impact']

Forty O
unpremedicated O
female O
patients O
aged O
18-59 O
, O
scheduled O
for O
minor O
gynecological O
procedures O
, O
were O
randomly O
assigned O
to O
four O
groups O
. O
[]

Thyroid O
stimulating O
antibodies O
: O
an O
aid O
to O
the O
strategy O
of O
treatment O
of O
Graves O
' O
disease O
? O
[]

Crossover O
was O
also O
comparable O
, O
with O
1 O
occurring O
in O
the O
IBMC O
group O
, O
compared O
with O
3 O
in O
the O
PMMC O
group O
. O
[]

Patients O
were O
removed O
from O
study O
if O
LVEF O
declined O
20 O
or O
more O
EF O
units O
from O
baseline O
to O
a O
final O
value O
of O
greater O
than O
or O
equal O
to O
50 O
% O
, O
or O
by O
10 O
or O
more O
units O
to O
a O
final O
value O
of O
less O
than O
50 O
% O
, O
or O
onset O
of O
clinical O
congestive O
heart O
failure O
( O
CHF O
) O
. O
[]

Influence O
of O
sentinel O
lymph O
node O
tumor O
burden O
on O
survival O
in O
melanoma O
. O
[]

This O
study O
evaluated O
clinical O
and O
radiographic O
twelve-month O
outcomes O
of O
root O
canal O
treatments O
(CT) O
with O
smear O
layer O
removal, O
performed O
in O
primary O
teeth, O
using O
two O
different O
root O
canal O
filling O
materials. O
[]

CONCLUSIONS: O
This O
retrospective O
analysis O
found O
that O
better O
BCVA, O
greater O
total O
macular O
volume, O
and O
presence O
of O
subretinal O
fluid O
at O
baseline O
were O
associated O
with O
more O
rapid O
vision B-outcome ['Physiological-Clinical']
gains. O
[['Physiological-Clinical']]

METHODS O
The O
study O
was O
performed O
on O
16 O
lesions O
, O
either O
superficial O
basal O
cell O
carcinoma O
( O
BCC O
) O
or O
Bowen O
's O
disease O
( O
BD O
) O
. O
[]

AIM O
To O
test O
the O
efficacy O
of O
a O
new O
synbiotic O
formulation O
containing O
Lactobacillus O
paracasei O
B21060 O
, O
arabinogalactan O
and O
xilooligosaccharides O
in O
children O
with O
acute O
diarrhoea O
. O
[]

METHODS O
Sixty-two O
children O
( O
51 O
boys O
and O
11 O
girls O
; O
M O
age O
= O
20 O
months O
; O
SD O
= O
2.6 O
) O
who O
met O
criteria O
for O
autism O
spectrum O
disorders O
( O
ASD O
) O
and O
their O
parents O
participated O
in O
the O
study O
. O
[]

The O
mean O
( O
sd O
) O
end O
tidal O
isoflurane O
concentration O
( O
per O
cent O
) O
needed O
to O
maintain O
a O
light B-outcome ['Resource-use']
surgical I-outcome ['Resource-use']
anaesthesia I-outcome ['Resource-use']
( O
stage O
III O
, O
plane O
2 O
) O
was O
significantly O
lower O
in O
group O
KM O
( O
0.91 O
[ O
0.03 O
] O
) O
than O
in O
groups O
TG O
( O
1.11 O
[ O
0.03 O
] O
) O
and O
KG O
( O
1.14 O
[ O
0.03 O
] O
) O
. O
['Resource-use']

There O
were O
no O
significant O
differences O
in O
clinical B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
or O
in O
frequency O
of O
complications B-outcome ['Adverse-effects']
, O
except O
for O
mild B-outcome ['Physiological-Clinical']
diarrhoea I-outcome ['Physiological-Clinical']
, O
which O
occurred O
in O
16 O
ceftriaxone O
patients O
and O
in O
8 O
in O
the O
other O
group O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical']

The O
treatment O
group O
patients O
received O
a O
preoperative O
NB O
( O
0.25 O
% O
5-8 O
ml O
bupivacaine O
mixed O
with O
20-40 O
mg O
methylprednisolone O
) O
targeting O
the O
supraorbital O
, O
supratrochlear O
, O
auriculotemporal O
, O
and O
posterior O
auricular O
nerves O
. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

Valsartan O
( O
160 O
mg/day O
) O
lowered O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
significantly O
in O
African O
American O
patients O
on O
both O
low O
salt O
( O
-6.4/-4.8 O
mm O
Hg O
: O
P O
< O
.001 O
) O
and O
a O
high O
salt O
diet O
( O
-4.9/-3.8 O
mm O
Hg O
: O
P O
= O
.01 O
) O
. O
['Physiological-Clinical']

METHODS O
Thirty O
patients O
scheduled O
for O
craniotomy O
were O
assigned O
to O
either O
a O
normothermic O
or O
mildly O
hypothermic O
group O
. O
[]

The O
median O
[]

Forty-two O
healthy O
adult O
subjects O
were O
enrolled O
, O
and O
39 O
subjects O
completed O
period O
1 O
. O
[]

However O
, O
positive O
effects O
on O
symptoms B-outcome ['Physiological-Clinical']
, O
knowledge B-outcome ['Life-Impact']
, O
quality O
of O
life O
, O
and O
satisfaction B-outcome ['Life-Impact']
with O
the O
intervention O
were O
found O
in O
both O
the O
short O
and O
the O
long O
version O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Incorporation O
of O
14C-palmitate B-outcome ['Physiological-Clinical']
into I-outcome ['Physiological-Clinical']
lung I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
was O
not O
influenced O
by O
dexamethasone O
, O
but O
a O
significantly O
greater O
portion O
of O
the O
label O
appeared O
in O
the O
DPC O
fraction O
with O
treatment O
. O
['Physiological-Clinical']

Journal-Name:Medicine O
[]

PATIENTS O
AND O
METHODS O
From O
July O
2004 O
to O
April O
2006 O
, O
80 O
patients O
aged O
between O
10 O
and O
15 O
years O
, O
with O
tonsillectomy O
planned O
for O
chronic O
tonsillitis O
, O
were O
included O
in O
the O
study O
. O
[]

Eighteen O
sedentary O
male O
volunteers O
were O
randomly O
divided O
into O
CLA O
and O
Placebo O
( O
PLC O
) O
supplementation O
groups O
. O
[]

Sixty O
and O
59 O
healthy O
young O
adults O
previously O
immunized O
against O
tetanus O
( O
T O
) O
and O
diphtheria O
( O
D O
) O
were O
randomized O
to O
receive O
intramuscularly O
either O
Td O
vaccine O
alone O
( O
group O
1 O
) O
or O
Td O
vaccine O
plus O
500 O
IU O
of O
TIG O
( O
group O
2 O
) O
simultaneously O
. O
[]

This O
study O
evaluated O
Children O
's O
Friendship O
Training O
( O
CFT O
) O
, O
a O
manualized O
parent-assisted O
intervention O
to O
improve O
social O
skills O
among O
second O
to O
fifth O
grade O
children O
with O
autism O
spectrum O
disorders O
. O
[]

Any O
angiographic O
assessment O
of O
thrombolytic O
drug O
efficacy O
should O
take O
these O
variations O
as O
well O
as O
interobserver O
variability O
into O
account O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
the O
percentage O
of O
patients O
with O
steroid B-outcome ['Physiological-Clinical']
sparing I-outcome ['Physiological-Clinical']
, O
defined O
as O
discontinuation O
of O
steroid O
therapy O
without O
a O
disease O
flare O
( O
Crohn O
's O
Disease O
Activity O
Index O
score O
> O
or O
=220 O
points O
) O
at O
week O
36 O
. O
['Physiological-Clinical']

Late O
toxicity B-outcome ['Adverse-effects']
is O
, O
therefore O
, O
important O
. O
['Adverse-effects']

OBJECTIVE O
Stapled O
mucosectomy O
has O
been O
developed O
as O
an O
alternative O
to O
conventional O
haemorrhoidectomy O
for O
the O
elective O
treatment O
of O
haemorrhoids O
, O
but O
has O
not O
been O
assessed O
in O
the O
emergency O
setting O
. O
[]

Is O
successful O
rehabilitation O
of O
complex O
regional O
pain O
syndrome O
due O
to O
sustained O
attention O
to O
the O
affected O
limb O
? O
[]

RA O
patients O
of O
Shen O
deficiency O
and O
cold O
invading O
syndrome O
in O
the O
treatment O
group O
( O
120 O
cases O
) O
were O
treated O
with O
BQZD O
and O
MTX O
( O
10 O
mg/week O
) O
, O
while O
those O
in O
the O
control O
group O
( O
120 O
cases O
) O
were O
treated O
with O
MTX O
( O
10 O
mg/week O
) O
alone O
. O
[]

Participants O
were O
50 O
children O
with O
ASD O
, O
age O
range O
3 O
to O
5 O
years O
, O
who O
had O
previously O
been O
evaluated O
on O
standard O
tests O
of O
language O
and O
level O
of O
functioning O
. O
[]

METHOD O
Caregivers O
( O
n O
= O
77 O
) O
of O
the O
cognitively O
impaired O
living O
at O
home O
were O
randomized O
to O
receive O
nurse O
counseling O
or O
not O
. O
[]

We O
also O
observed O
an O
increase O
in O
intima-media B-outcome ['Physiological-Clinical']
thickness B-outcome ['Physiological-Clinical']
in O
the O
highest O
quintile O
relative O
to O
the O
lowest O
( O
difference O
= O
0.048 O
+/- O
0.025 O
mm O
) O
among O
men O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
the O
syncope O
unit O
and O
standard O
care O
patients O
, O
the O
presumptive B-outcome ['Physiological-Clinical']
diagnosis I-outcome ['Physiological-Clinical']
was O
established O
in O
34 O
( O
67 O
% O
) O
and O
5 O
( O
10 O
% O
) O
patients O
( O
P O
< O
0.001 O
) O
, O
respectively O
, O
hospital B-outcome ['Resource-use']
admission I-outcome ['Resource-use']
was O
required O
for O
22 O
( O
43 O
% O
) O
and O
51 O
( O
98 O
% O
) O
patients O
( O
P O
< O
0.001 O
) O
, O
and O
total O
patient-hospital B-outcome ['Resource-use']
days I-outcome ['Resource-use']
were O
reduced O
from O
140 O
to O
64 O
. O
['Physiological-Clinical', 'Resource-use', 'Resource-use']

An O
analysis O
of O
available O
space O
was O
made O
by O
evaluating O
the O
pre-treatment O
dental O
casts O
of O
all O
patients O
included O
in O
the O
study O
. O
[]

Overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
OS I-outcome ['Mortality']
) I-outcome ['Mortality']
was O
the O
primary O
endpoint O
, O
while O
progression-free O
survival O
( O
PFS O
) O
was O
a O
secondary O
endpoint O
. O
['Mortality']

Routine O
therapies O
for O
COPD O
were O
given O
to O
patients O
in O
the O
control O
group O
, O
while O
15 O
mL O
SI O
was O
given O
to O
those O
in O
the O
treatment O
group O
by O
intravenous O
dripping O
, O
twice O
daily O
for O
total O
14 O
days O
. O
[]

Systolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
was O
168 O
+/- O
18 O
mm O
Hg O
after O
the O
placebo O
phase O
and O
146 O
+/- O
15 O
mm O
Hg O
after O
hydrochlorothiazide O
; O
diastolic O
BP O
was O
103 O
+/- O
6 O
mm O
Hg O
and O
89 O
+/- O
9 O
mm O
Hg O
, O
respectively O
. O
['Physiological-Clinical']

Significant O
treatment O
x O
time O
effects O
were O
found O
for O
postprandial O
glucose B-outcome ['Physiological-Clinical']
(p O
= O
0.004) O
for O
RS O
compared O
to O
placebo, O
with O
a O
trend O
for O
higher O
C-peptide B-outcome ['Physiological-Clinical']
concentrations O
following O
RS. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

In O
group O
A O
, O
endothelium O
dependent O
[ O
( O
12 O
+/- O
5 O
) O
% O
vs O
( O
9 O
+/- O
5 O
) O
% O
, O
t O
= O
2.9 O
, O
P O
< O
0.01 O
] O
and O
independent O
[ O
( O
18 O
+/- O
4 O
) O
% O
vs O
( O
12 O
+/- O
5 O
) O
% O
, O
t O
= O
3.4 O
, O
P O
< O
0.01 O
] O
vasodilatation B-outcome ['Physiological-Clinical']
responses I-outcome ['Physiological-Clinical']
significantly O
increased O
after O
treatment O
, O
no O
significant O
changes O
were O
observed O
in O
group O
B. O
Endothelium O
dependent O
[ O
( O
9 O
+/- O
6 O
) O
% O
, O
t O
= O
2.8 O
, O
P O
< O
0.01 O
] O
and O
independent O
[ O
( O
12 O
+/- O
5 O
) O
% O
, O
t O
= O
3.5 O
, O
P O
< O
0.01 O
] O
['Physiological-Clinical']

No O
difference O
in O
clinical O
outcomes O
could O
be O
demonstrated O
except O
that O
the O
percentage O
of O
patients O
with O
major B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
episodes I-outcome ['Physiological-Clinical']
was O
significantly O
lower O
in O
the O
study O
group O
( O
1.2 O
% O
versus O
5.4 O
% O
, O
p O
= O
0.035 O
) O
. O
['Physiological-Clinical']

MATERIALS O
AND O
METHODS O
A O
total O
of O
118 O
lesions O
in O
lung O
, O
liver O
and O
lymph O
nodes O
were O
selected O
from O
30 O
patients O
enrolled O
in O
early O
phase O
clinical O
trials O
. O
[]

OBJECTIVE O
To O
study O
the O
immunomodulatory O
effect O
of O
the O
histamine O
receptor O
antagonist O
, O
ranitidine O
, O
in O
patients O
admitted O
to O
the O
intensive O
care O
unit O
after O
severe O
head O
injury O
. O
[]

METHODS O
Thirty O
adults O
with O
autistic O
disorder O
completed O
a O
12-week O
double-blind O
, O
placebo-controlled O
trial O
of O
the O
potent O
and O
selective O
serotonin O
uptake O
inhibitor O
fluvoxamine O
maleate O
. O
[]

PURPOSE O
To O
determine O
the O
appropriate O
irradiation O
dose O
after O
four O
cycles O
of O
modern O
combination O
chemotherapy O
in O
nonbulky O
involved O
field O
( O
IF/BF O
) O
and O
noninvolved O
extended-field O
( O
EF/IF O
) O
sites O
in O
patients O
with O
intermediate-stage O
Hodgkin O
's O
disease O
( O
HD O
) O
. O
[]

Cases O
without O
cirrhosis O
and O
with O
APC O
of O
> O
0.25 O
mL/min/kg O
body O
weight O
had O
an O
85 O
% O
chance O
of O
responding B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
interferon I-outcome ['Physiological-Clinical']
; O
this O
was O
unlikely O
a O
simple O
reflection O
of O
histological O
activity O
, O
because O
the O
correlation O
with O
Scheuer O
score O
was O
poor O
in O
this O
subgroup O
( O
r O
= O
-.31 O
, O
P O
< O
.05 O
) O
. O
['Physiological-Clinical']

Journal O
ID: O
101521595 O
[]

VLDL B-outcome ['Physiological-Clinical']
, O
apolipoproteins B-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
, O
CIII B-outcome ['Physiological-Clinical']
, O
and O
E B-outcome ['Physiological-Clinical']
, O
and O
risk O
of O
recurrent B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
in O
the O
Cholesterol O
and O
Recurrent O
Events O
( O
CARE O
) O
trial O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Background O
Very O
little O
research O
has O
been O
done O
to O
simultaneously O
investigate O
the O
effects O
of O
Tai O
Chi O
(TC) O
on O
depression O
and O
heart O
rate O
variability O
(HRV). O
[]

CONCLUSIONS O
Prophylaxis O
with O
isoniazid O
reduces O
the O
risk O
of O
tuberculosis O
in O
persons O
with O
HIV O
infection O
. O
[]

RESULTS O
The O
mean O
ages O
and O
the O
mean O
cyst B-outcome ['Physiological-Clinical']
diameters B-outcome ['Physiological-Clinical']
of O
the O
patients O
for O
each O
group O
were O
not O
significantly O
different O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESPIRE O
( O
Randomized O
Exposure O
Study O
of O
Pollution O
Indoors O
and O
Respiratory O
Effects O
) O
was O
a O
randomized O
trial O
of O
a O
chimney O
woodstove O
that O
reduces O
wood O
smoke O
exposure O
. O
[]

Serum O
for O
rabies O
antibody O
determination O
and O
F O
( O
ab O
' O
) O
2 O
concentration O
was O
collected O
at O
hours O
( O
H O
) O
0 O
, O
6 O
and O
12 O
, O
and O
on O
day O
( O
D O
) O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
12 O
and O
15 O
. O
[]

Kaliuresis B-outcome ['Physiological-Clinical']
was O
similar O
during O
the O
two O
treatment O
periods O
, O
despite O
the O
striking O
differences O
observed O
in O
natriuresis O
. O
['Physiological-Clinical']

METHODS O
We O
studied O
nine O
healthy O
male O
volunteers O
( O
18-40 O
yr O
) O
on O
two O
randomly O
assigned O
treatment O
days O
: O
( O
1 O
) O
control O
and O
( O
2 O
) O
magnesium O
( O
80 O
mg O
kg O
( O
-1 O
) O
followed O
by O
infusion O
at O
2 O
g O
h O
( O
-1 O
) O
) O
. O
[]

RESULTS O
Constitutive B-outcome ['Physiological-Clinical']
proteins I-outcome ['Physiological-Clinical']
such I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
prealbumin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
retinol-binding I-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
levels O
increased O
( O
p O
< O
0.05 O
) O
, O
and O
acute O
phase O
proteins B-outcome ['Physiological-Clinical']
such I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
1-acid I-outcome ['Physiological-Clinical']
glycoprotein I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
C3 I-outcome ['Physiological-Clinical']
complement I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
alpha I-outcome ['Physiological-Clinical']
2-macroglobulin I-outcome ['Physiological-Clinical']
, I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
fibrinogen I-outcome ['Physiological-Clinical']
levels O
significantly O
decreased O
in O
the O
oxandrolone O
group O
compared O
with O
placebo O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

In O
phase O
2 O
, O
the O
alternate O
treatment O
group O
received O
standard O
weight O
placement O
of O
1.5 O
% O
body O
weight O
. O
[]

The O
target O
administration O
period O
was O
5 O
years O
. O
[]

MATERIALS O
AND O
METHODS O
Thirty-three O
edentulous O
patients O
who O
experienced O
difficulties O
when O
using O
hard O
denture O
bases O
because O
of O
changes O
in O
denture-supporting O
tissues O
were O
accepted O
for O
the O
study O
and O
randomly O
received O
Molloplast O
B O
, O
GC O
Reline O
Soft O
, O
Silagum O
Comfort O
, O
or O
Mollosil O
Plus O
relines O
. O
[]

Thirty-five O
patients O
completed O
the O
study O
, O
18 O
received O
regular O
opioids O
plus O
ketamine O
, O
while O
17 O
received O
regular O
opioids O
plus O
placebo O
. O
[]

Effects O
of O
exposure O
to O
thin-ideal O
media O
images O
on O
body B-outcome ['Life-Impact']
dissatisfaction I-outcome ['Life-Impact']
: O
testing O
the O
inclusion O
of O
a O
disclaimer O
versus O
warning O
label O
. O
['Life-Impact']

Ten O
subjects O
served O
as O
controls O
and O
received O
symptomatic O
treatments O
. O
[]

Immediately O
restored O
, O
single-tapered O
implants O
in O
the O
anterior O
maxilla O
: O
prosthodontic O
and O
aesthetic O
outcomes O
after O
1 O
year O
. O
[]

The O
absolute O
difference O
of O
aortic B-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
between O
ultrasound O
and O
CT O
was O
< O
5 O
mm O
in O
88 O
% O
of O
patients O
. O
['Physiological-Clinical']

SETTING O
Intensive O
care O
unit O
of O
a O
tertiary O
care O
hospital O
. O
[]

Younger O
participants O
, O
aged O
< O
34 O
years O
, O
reported O
more O
confusion B-outcome ['Life-Impact']
( O
p= O
.013 O
) O
at O
T2 O
than O
at O
T1 O
and O
T4 O
. O
['Life-Impact']

SUBJECTS O
One O
hundred O
and O
five O
obese O
[ O
Body O
Mass O
Index O
( O
BMI O
) O
> O
or O
= O
30 O
] O
patients O
participated O
in O
the O
study O
. O
[]

Pace B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
was O
the O
only O
significant O
difference O
between O
the O
2 O
groups O
. O
['Physiological-Clinical']

At O
the O
end O
of O
4-week O
follow-up, O
there O
were O
also O
no O
significant O
differences O
regarding O
the O
post-voiding B-outcome ['Physiological-Clinical']
residual I-outcome ['Physiological-Clinical']
urine I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(PV-VRU) I-outcome ['Physiological-Clinical']
(P O
= O
.42), O
voided B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
(P O
= O
.71), O
maximum B-outcome ['Physiological-Clinical']
urinary I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate O
(Qmax) O
(P O
= O
.24), O
and O
Barthel O
Index O
(BI) O
scores O
(P O
= O
.75) O
between O
2 O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

We O
conducted O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
to O
examine O
the O
efficacy O
of O
prophylactic O
ondansetron O
on O
post-operative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
( O
PONV B-outcome ['Physiological-Clinical']
) O
during O
opioid O
patient-controlled O
analgesia O
( O
PCA O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Mean O
esophageal B-outcome ['Resource-use']
and I-outcome ['Resource-use']
duodenal I-outcome ['Resource-use']
endoscopy I-outcome ['Resource-use']
scores O
were O
similar O
in O
the O
2 O
groups O
at O
Days O
8 O
and O
15 O
. O
['Resource-use']

RESULTS O
After O
the O
program O
, O
the O
mean O
rank O
of O
the O
perceived B-outcome ['Life-Impact']
self-efficacy I-outcome ['Life-Impact']
for O
the O
self-management B-outcome ['Life-Impact']
strategies I-outcome ['Life-Impact']
was O
statistically O
different O
between O
the O
two O
groups O
( O
p O
= O
0.023 O
) O
. O
['Life-Impact', 'Life-Impact']

In O
a O
randomized O
, O
controlled O
study O
, O
610 O
patients O
undergoing O
coronary O
artery O
bypass O
grafting O
were O
assigned O
either O
to O
a O
fish O
oil O
group O
, O
receiving O
4 O
g/day O
of O
fish O
oil O
concentrate O
, O
or O
to O
a O
control O
group O
. O
[]

Effects O
occurred O
in O
regions O
that O
may O
be O
behaviorally O
relevant O
to O
mood O
and O
anxiety O
disorders O
. O
[]

The O
results O
had O
revealed O
that O
adolescents O
with O
ASDs O
were O
less O
sensitive O
than O
controls O
to O
the O
misalignment O
of O
face O
parts O
and O
it O
was O
concluded O
their O
face O
processing O
was O
less O
holistic O
. O
[]

Smaller O
improvements O
were O
seen O
in O
high-density B-outcome ['Physiological-Clinical']
lipoprotein I-outcome ['Physiological-Clinical']
cholesterol I-outcome ['Physiological-Clinical']
and O
triglyceride B-outcome ['Physiological-Clinical']
levels O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Myocardial O
extracellular O
volume O
by O
cardiac O
magnetic O
resonance O
imaging O
in O
patients O
treated O
with O
anthracycline-based O
chemotherapy O
. O
[]

Healthy O
first-time O
mothers O
delivering O
in O
the O
capital O
Beirut O
between O
March O
and O
July O
2009 O
, O
were O
interviewed O
at O
1-3 O
days O
and O
8-12 O
weeks O
post O
delivery O
. O
[]

Tamoxifen O
was O
studied O
in O
176 O
patients O
with O
T1-2N0M0 O
tumors O
. O
[]

CONCLUSION O
The O
results O
show O
that O
memory B-outcome ['Life-Impact']
, O
attention B-outcome ['Life-Impact']
, O
and O
tracking B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
are O
unaffected O
after O
acute O
and O
subchronic O
administration O
of O
levocetirizine O
( O
5 O
mg O
) O
, O
whereas O
diphenhydramine O
( O
50 O
mg O
) O
significantly O
affected O
divided B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
and O
tracking B-outcome ['Life-Impact']
after O
acute O
administration O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Publication O
Type: O
Journal O
Article O
[]

The O
LIT O
did O
not O
seem O
to O
have O
important O
effects O
on O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
CCR I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
SPACE O
trial O
compared O
risk O
and O
effectiveness O
of O
stent-supported O
angioplasty O
( O
CAS O
) O
vs O
carotid O
endarterectomy O
( O
CEA O
) O
using O
a O
noninferiority O
design O
in O
patients O
with O
symptomatic O
stenoses O
. O
[]

We O
hypothesized O
that O
participants O
randomized O
to O
an O
intervention O
condition O
would O
report O
improvements O
in O
relaxation B-outcome ['Life-Impact']
, O
awareness B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
tension I-outcome ['Life-Impact']
, O
getting B-outcome ['Life-Impact']
needs I-outcome ['Life-Impact']
met I-outcome ['Life-Impact']
and O
coping B-outcome ['Life-Impact']
confidence I-outcome ['Life-Impact']
compared O
with O
those O
receiving O
UCO O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Emotion O
regulation O
strategies O
that O
promote O
learning O
: O
reappraisal O
enhances O
children B-outcome ['Physiological-Clinical']
's O
memory B-outcome ['Life-Impact']
for I-outcome ['Life-Impact']
educational I-outcome ['Life-Impact']
information I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Life-Impact']

BACKGROUND O
AND O
PURPOSE O
Prolonged O
wakefulness O
impairs O
sustained O
vigilant B-outcome ['Life-Impact']
attention I-outcome ['Life-Impact']
, O
measured O
with O
the O
psychomotor B-outcome ['Life-Impact']
vigilance I-outcome ['Life-Impact']
task O
( O
PVT O
) O
, O
and O
induces O
a O
compensatory O
increase O
in O
sleep O
intensity O
in O
recovery O
sleep O
, O
quantified O
by O
slow-wave B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
SWA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
the O
sleep B-outcome ['Physiological-Clinical']
electroencephalogram I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
EEG I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
R317573 O
appears O
to O
produce O
acute O
dose-dependent O
changes O
in O
rCMglu O
. O
[]

MATERIALS O
AND O
METHODS O
This O
investigation O
was O
designed O
as O
a O
randomized O
, O
prospective O
, O
single-blinded O
controlled O
study O
. O
[]

A O
total O
of O
1161 O
subjects O
were O
randomized O
to O
OCT O
and O
1163 O
to O
placebo O
; O
over O
80 O
% O
returned O
for O
a O
repeat O
13C-urea O
breath O
test O
on O
at O
least O
one O
occasion O
. O
[]

Significantly O
higher O
dietary O
intakes O
of O
folate O
( O
P O
= O
0.035 O
) O
, O
non-starch O
polysaccharides O
( O
P O
= O
0.001 O
) O
, O
vitamin O
C O
( O
P O
= O
0.0001 O
) O
and O
carotenoids O
( O
P O
= O
0.0001 O
) O
were O
observed O
in O
both O
intervention O
groups O
compared O
with O
CT O
, O
which O
were O
broadly O
supported O
by O
nutrient O
biomarker O
analysis O
. O
[]

But O
EA O
seems O
to O
have O
little O
influence O
on O
the O
stress O
reaction O
to O
major O
abdominal O
surgery O
. O
[]

At O
baseline O
, O
DTCs O
were O
detected O
in O
26 O
of O
60 O
patients O
in O
the O
zoledronic O
acid O
group O
and O
28 O
of O
58 O
patients O
in O
the O
control O
group O
. O
[]

Patients O
in O
the O
routine O
chemotherapy O
group O
(n O
= O
30, O
RC O
group) O
received O
cisplatin O
infusion O
within O
1 O
h O
and O
5-FU O
infusion O
for O
about O
24 O
h. O
The O
dose O
in O
the O
RC O
group O
was O
the O
same O
as O
that O
in O
the O
CC O
group. O
[]

Few O
controlled O
clinical O
trials O
of O
psychological O
interventions O
for O
cancer B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
relief O
exist O
in O
spite O
of O
frequent O
support O
for O
their O
importance O
as O
adjuncts O
to O
medical O
treatment O
. O
['Physiological-Clinical']

Use O
of O
granulocyte-macrophage O
colony-stimulating O
factor O
and O
erythropoietin O
in O
combination O
after O
autologous O
marrow O
transplantation O
. O
[]

Esomeprazole O
was O
associated O
with O
a O
significantly O
shorter O
mean O
time O
to O
first O
( O
6-7 O
days O
) O
and O
sustained O
( O
12-17 O
days O
) O
resolution B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
compared O
with O
placebo O
( O
first O
, O
10-12 O
days O
; O
sustained O
, O
21-22 O
days O
; O
P O
< O
or O
= O
0.008 O
) O
. O
['Physiological-Clinical']

BACKGROUND: O
Bisphosphonates O
prevent O
fractures O
in O
patients O
with O
osteoporosis, O
but O
their O
efficacy O
in O
women O
with O
osteopenia O
is O
unknown. O
[]

Initial O
results O
of O
the O
Italian O
PROSIT O
study O
. O
[]

Plasma O
levels O
of O
IL-5 O
increased O
after O
allergen O
challenge O
( O
8.7 O
+/- O
2.9 O
to O
14.5 O
+/- O
3.9 O
pg/mL O
, O
P O
= O
0.001 O
) O
, O
and O
the O
increase O
in O
plasma O
IL-5 O
was O
positively O
correlated O
with O
the O
rise O
in O
sputum B-outcome ['Physiological-Clinical']
ECP I-outcome ['Physiological-Clinical']
in O
a O
subgroup O
of O
'responders O
' O
( O
n O
= O
12 O
, O
r O
= O
0.71 O
, O
P O
= O
0.01 O
) O
. O
['Physiological-Clinical']

Successfully O
detoxified O
patients O
were O
referred O
to O
ongoing O
drug O
treatment O
. O
[]

Publication O
Type: O
Multicenter O
Study O
[]

CONCLUSIONS O
Although O
the O
main O
findings O
were O
similar O
to O
those O
from O
other O
brief-intervention O
studies O
in O
Western O
cultures O
, O
findings O
here O
also O
suggest O
that O
intervention O
may O
have O
differential O
benefits O
for O
specific O
subgroups O
of O
patients O
in O
the O
ED O
, O
an O
area O
of O
research O
that O
may O
warrant O
additional O
study O
of O
brief O
intervention O
in O
the O
ED O
setting O
. O
[]

RESULTS O
The O
trial O
was O
completed O
by O
71 O
% O
and O
77 O
% O
of O
the O
patients O
from O
the O
STG O
and O
the O
CG O
, O
respectively O
. O
[]

This O
is O
the O
first O
placebo-controlled O
trial O
of O
olanzapine O
in O
the O
treatment O
of O
children O
and O
adolescents O
with O
PDD O
. O
[]

DESIGN O
randomized O
controlled O
trial O
. O
[]

The O
latter O
two O
groups O
were O
rendered O
diabetic O
by O
i.p O
. O
[]

OBJECTIVE O
Plasmakinetic O
vaporesection O
of O
the O
prostate O
( O
PKVP O
) O
using O
normal O
saline O
irrigation O
has O
the O
theoretical O
advantage O
of O
avoiding O
transurethral O
resection O
syndrome O
and O
minimizing O
blood O
loss O
. O
[]

Group O
A O
was O
restored O
with O
prefabricated O
glass-fiber O
posts O
and O
Artglass O
polymer O
core O
; O
group O
B O
with O
prefabricated O
glass-fiber O
posts O
and O
Charisma O
composite O
resin O
core O
; O
and O
group O
C O
with O
prefabricated O
glass-fiber O
posts O
and O
AB O
composite O
resin O
core O
. O
[]

MATERIALS O
AND O
METHODS O
A O
total O
of O
198 O
English-speaking O
women O
, O
with O
no O
personal O
or O
family O
history O
of O
breast O
cancer O
, O
were O
recruited O
and O
randomized O
to O
four O
groups O
when O
they O
presented O
to O
the O
clinic O
for O
a O
screening O
mammogram O
. O
[]

Supplementary O
motor O
area O
activity O
may O
be O
abnormal O
in O
Parkinson O
's O
disease O
since O
its O
major O
input O
from O
the O
basal O
ganglia O
is O
disrupted O
. O
[]

The O
aim O
of O
the O
present O
study O
protocol O
is O
to O
introduce O
a O
theory-based O
approach O
to O
diagnose O
implementation O
difficulties O
of O
TUPAC O
counselling O
guidelines O
among O
dental O
providers O
. O
[]

RESULTS O
Ninety O
seven O
per O
cent O
of O
subjects O
were O
H B-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
positive O
at O
baseline O
, O
and O
53 O
% O
were O
positive O
at O
12 O
years O
. O
['Physiological-Clinical']

[ O
Plasma O
separation O
combined O
with O
CVVHF O
in O
septic O
and O
SIRS O
patients O
] O
. O
[]

Apparent B-outcome ['Physiological-Clinical']
nitrogen I-outcome ['Physiological-Clinical']
balance I-outcome ['Physiological-Clinical']
was O
positive O
pre-operatively O
and O
became O
less O
so O
post-operatively O
whether O
insulin O
was O
given O
or O
not O
. O
['Physiological-Clinical']

A O
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
the O
individual O
effectiveness O
of O
three O
types O
of O
conservative O
therapy O
in O
the O
treatment O
of O
plantar O
fasciitis O
. O
[]

Autism O
is O
a O
neurodevelopmental O
disorder O
characterized O
by O
dysfunction O
in O
three O
core O
behavioral O
domains O
: O
repetitive B-outcome ['Life-Impact']
behaviors I-outcome ['Life-Impact']
, O
social O
deficits O
, O
and O
language O
abnormalities O
. O
['Life-Impact']

The O
results O
demonstrate O
a O
feasible O
and O
non-threatening O
way O
to O
provide O
women O
with O
important O
personalized O
information O
about O
breast B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical']

This O
study O
evaluated O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
( O
HBOT O
) O
. O
[]

INTERVENTIONS O
AND O
MAIN O
OUTCOME O
MEASURES O
Psychological B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
was O
assessed O
with O
General B-outcome ['Life-Impact']
Health I-outcome ['Life-Impact']
Questionnaire-12 O
( O
GHQ-12 O
) O
, O
Thyroid B-outcome ['Physiological-Clinical']
Symptom I-outcome ['Physiological-Clinical']
Questionnaire O
, O
and O
Hospital O
Anxiety B-outcome ['Life-Impact']
and O
Depression B-outcome ['Life-Impact']
Scale O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

The O
technique O
of O
dual O
isotopes O
of O
stable O
calcium O
was O
used O
with O
a O
calcium O
carrier O
to O
measure O
calcium O
absorption O
at O
baseline O
and O
after O
8 O
wk O
. O
[]

Little O
evidence O
has O
been O
published O
for O
the O
nondiabetic O
population O
. O
[]

OBJECTIVE O
We O
sought O
to O
study O
the O
effect O
of O
probiotic O
and O
prebiotic O
supplementation O
in O
preventing O
allergies O
. O
[]

Pentoxifylline O
therapy O
was O
particularly O
useful O
in O
restoring O
the O
PBPI O
in O
men O
with O
the O
pelvic O
steal O
syndrome O
; O
six O
of O
seven O
such O
subjects O
improved O
into O
the O
normal O
range O
. O
[]

By O
February O
1998 O
, O
haematoxylin O
and O
eosin O
stained O
sections O
from O
155 O
RP O
specimens O
had O
been O
received O
and O
evaluated O
by O
the O
reviewing O
pathologist O
( O
RM O
) O
. O
[]

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual B-outcome ['Life-Impact']
function I-outcome ['Life-Impact']
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O
['Life-Impact']

They O
provide O
supportive O
evidence O
that O
tailored O
intervention O
programs O
should O
be O
developed O
to O
support O
the O
screening O
and O
completion O
of O
treatment O
of O
foreign-born O
adolescents O
. O
[]

Treatment O
sites O
( O
n O
= O
10 O
) O
received O
a O
periodontal O
formulation O
of O
minocycline O
hydrochloride O
, O
placebo O
sites O
( O
5 O
) O
received O
ointment O
without O
minocycline O
, O
and O
control O
sites O
( O
5 O
) O
did O
not O
receive O
ointment O
. O
[]

At O
the O
end O
of O
treatment O
86 O
% O
of O
patients O
in O
the O
CHOP O
arm O
had O
responded O
with O
58 O
% O
in O
CR O
. O
[]

However O
, O
the O
age O
of O
the O
subjects O
was O
found O
to O
be O
an O
intervening O
variable O
: O
The O
older O
subjects O
of O
both O
groups O
demonstrated O
a O
gradual O
but O
not O
significant O
decline O
in O
hypertonus O
, O
whereas O
the O
younger O
adults O
demonstrated O
a O
significant O
decline O
in O
hypertonus O
over O
a O
6-week O
period O
. O
[]

Effects O
of O
a O
single O
intravenous O
dose O
of O
aspirin O
( O
600 O
mg O
) O
on O
bradykinin-stimulated O
prostaglandin O
( O
PG O
) O
and O
on O
thromboxane O
( O
TX O
) O
biosynthesis O
were O
determined O
in O
nine O
healthy O
male O
volunteers O
. O
[]

The O
6-month O
angiographic O
follow-up O
showed O
a O
mean O
minimal B-outcome ['Physiological-Clinical']
luminal I-outcome ['Physiological-Clinical']
diameter I-outcome ['Physiological-Clinical']
of O
1.57 O
+/- O
0.74 O
mm O
in O
the O
conventional O
group O
versus O
1.93 O
+/- O
0.85 O
mm O
in O
the O
stented O
group O
( O
P O
=.009 O
) O
and O
a O
mean O
diameter B-outcome ['Physiological-Clinical']
stenosis I-outcome ['Physiological-Clinical']
of O
44.7 O
% O
+/- O
25.0 O
% O
versus O
35.5 O
% O
+/- O
26.5 O
% O
( O
P O
=.036 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
is O
increasing O
interest O
in O
the O
use O
of O
gluten- O
and O
casein-free O
diets O
for O
children O
with O
autism O
spectrum O
disorders O
( O
ASDs O
) O
. O
[]

Under O
OT O
activation B-outcome ['Life-Impact']
differences O
between O
genotypes O
were O
more O
evident O
( O
though O
not O
statistically O
significantly O
increased O
) O
and O
RT O
were O
accelerated O
in O
homozygotic O
risk O
allele O
carriers O
. O
['Life-Impact']

So O
we O
tried O
tobramycin/dexamethasone O
eye O
drops O
as O
a O
replacement. O
[]

Although O
support O
persons O
and O
smokers O
can O
be O
engaged O
in O
this O
type O
of O
outreach O
program O
, O
refinements O
in O
the O
intervention O
approach O
are O
needed O
to O
improve O
the O
smoking B-outcome ['Life-Impact']
outcomes O
. O
['Life-Impact']

In O
the O
second O
phase O
, O
the O
adult O
either O
imitated O
the O
child O
or O
was O
contingently O
responsive O
to O
the O
child O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
miss O
rate O
of O
colonoscopy O
by O
same O
day O
back-to-back O
colonoscopy O
. O
[]

A O
prospective O
, O
double-blind O
study O
of O
392 O
patients O
randomized O
into O
four O
groups O
was O
performed O
to O
establish O
whether O
diagnostic O
intravenous O
urograms O
could O
be O
obtained O
with O
a O
lower O
dose O
of O
iodine O
when O
using O
the O
dimeric O
, O
non-ionic O
contrast O
medium O
iodixanol O
compared O
with O
the O
monomeric O
, O
non-ionic O
iohexol O
. O
[]

Anesthesia O
induction O
and O
perioperative O
management O
followed O
the O
same O
protocols O
in O
the O
two O
groups O
, O
and O
in O
UTI O
group O
, O
patients O
received O
5000 O
U/kg O
UTI O
while O
those O
in O
the O
control O
group O
were O
given O
the O
same O
volume O
of O
saline O
. O
[]

SETTING O
8 O
university O
hospitals O
. O
[]

She O
reviewed O
the O
subject O
's O
answers O
to O
the O
questionnaire O
items O
correcting O
and/or O
clarifying O
them O
. O
[]

RESULTS O
Pediatricians O
in O
the O
intervention O
group O
, O
compared O
with O
those O
in O
the O
control O
group O
, O
demonstrated O
significantly O
higher O
rates O
of O
many O
American O
Academy O
of O
Pediatrics-recommended O
ADHD O
care O
practices O
, O
including O
collection O
of O
parent O
( O
Cohen O
's O
d O
= O
0.69 O
) O
and O
teacher O
( O
d O
= O
0.68 O
) O
rating O
scales O
for O
assessment O
of O
children O
with O
ADHD O
, O
use O
of O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental B-outcome ['Life-Impact']
Disorders I-outcome ['Life-Impact']
, O
Fourth O
Edition O
, O
criteria O
( O
d O
= O
0.85 O
) O
, O
and O
use O
of O
teacher O
rating O
scales O
to O
monitor O
treatment O
responses O
( O
d O
= O
1.01 O
) O
. O
['Life-Impact']

Treatment O
for O
head O
and O
neck O
cancer O
precipitates O
a O
myriad O
of O
distressing O
symptoms O
. O
[]

In O
this O
study O
, O
a O
group O
of O
30 O
senior O
medical O
students O
were O
randomly O
assigned O
to O
one O
of O
four O
different O
training O
groups O
: O
none O
, O
error O
only O
, O
correct O
only O
, O
and O
error+correct O
. O
[]

The O
physical O
activity O
intervention O
will O
consist O
of O
a O
number O
of O
strategies O
including O
: O
delivering O
structured O
fundamental O
movement O
skill O
activities O
, O
increasing O
physical O
activity O
opportunities O
, O
increasing O
staff O
role O
modelling O
, O
providing O
children O
with O
a O
physical O
activity O
promoting O
indoor O
and O
outdoor O
environment O
and O
limiting O
children O
's O
small O
screen O
recreation O
and O
sedentary O
behaviours O
. O
[]

The O
observed O
behavioural O
effects O
of O
methadone O
were O
decreased O
licking B-outcome ['Life-Impact']
and O
swallowing B-outcome ['Life-Impact']
and O
an O
increase O
in O
whining B-outcome ['Life-Impact']
after O
SC O
administration O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
receiving O
panitumumab O
in O
combination O
with O
bevacizumab O
and O
chemotherapy O
experienced O
a O
higher O
incidence O
of O
death B-outcome ['Mortality']
( O
9 O
% O
versus O
4 O
% O
) O
and O
a O
higher O
risk O
for O
grade O
3 O
and O
4 O
toxicities B-outcome ['Adverse-effects']
than O
patients O
receiving O
bevacizumab O
and O
chemotherapy O
alone O
. O
['Mortality', 'Adverse-effects']

Furthermore O
, O
measures O
to O
further O
increase O
the O
proportion O
of O
ursodeoxycholic O
acid O
in O
circulating O
bile O
acids O
should O
be O
explored O
. O
[]

A O
surveillance O
system O
, O
including O
CCD O
cameras O
and O
pulse O
oximeters O
, O
will O
be O
set O
up O
to O
evaluate O
the O
intervention O
. O
[]

CONCLUSIONS: O
We O
have O
developed O
an O
automated, O
accurate, O
and O
precise O
assay O
for O
the O
determination O
of O
belatacept O
serum O
concentrations. O
[]

Likely O
due O
to O
greater O
beverage O
osmolality O
(81 O
+/- O
1.4 O
vs. O
11 O
+/- O
0.7 O
mOsmol/kg), O
thirst B-outcome ['Physiological-Clinical']
sensation I-outcome ['Physiological-Clinical']
remained O
12% O
higher O
with O
MW O
(p O
< O
0.05). O
[['Physiological-Clinical']]

Patients O
were O
assessed O
for O
response O
to O
treatment O
( O
defined O
as O
a O
platelet O
count O
of O
50,000-400,000 O
per O
?L O
) O
weekly O
during O
the O
first O
6 O
weeks O
and O
at O
least O
once O
every O
4 O
weeks O
thereafter O
; O
the O
primary O
endpoint O
was O
the O
odds O
of O
response B-outcome ['Physiological-Clinical']
to O
eltrombopag O
versus O
placebo O
. O
['Physiological-Clinical']

Atropine O
and O
glycopyrrolate O
induced O
a O
significant O
increase O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
a O
simultaneous O
decrease O
in O
pressure B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
quotient I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
PRQ I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
while O
scopolamine O
caused O
a O
significant O
decrease O
in O
heart B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
with O
a O
simultaneous O
increase O
in O
PRQ B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
the O
number O
of O
wet B-outcome ['Physiological-Clinical']
nights I-outcome ['Physiological-Clinical']
and O
urodynamic B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
did O
not O
change O
significantly O
in O
group O
2 O
. O
['Physiological-Clinical', 'Physiological-Clinical']

29 O
GN O
patients O
with O
normal O
renal O
function O
( O
17 O
membranoproliferative O
GN O
, O
12 O
IgA O
GN O
) O
were O
randomly O
assigned O
to O
receive O
100 O
mg/day O
of O
diclofenac O
or O
placebo O
for O
at O
least O
2 O
months O
. O
[]

Effect O
of O
inhaled O
heparin O
on O
adenosine-induced O
bronchial O
hyperreactivity O
. O
[]

Through O
primary O
and O
secondary O
review O
with O
preset O
inclusion O
criteria O
, O
two O
independent O
judges O
identified O
27 O
randomized O
controlled O
trials O
, O
of O
which O
13 O
met O
inclusion O
criteria O
. O
[]

CONCLUSION O
When O
an O
appropriate O
drug O
combination O
is O
used O
, O
diabetic O
patients O
can O
achieve O
mydriasis B-outcome ['Physiological-Clinical']
as O
satisfactory O
as O
non-diabetic O
patients O
, O
allowing O
adequate O
fundus O
examination O
and/or O
retinopathy O
treatment O
. O
['Physiological-Clinical']

Perceptual O
wind-up O
in O
the O
human O
oesophagus O
is O
enhanced O
by O
central O
sensitisation O
. O
[]

Elective O
testicular O
biopsy O
was O
performed O
on O
235 O
( O
89.4 O
% O
) O
boys O
. O
[]

The O
median O
change O
from O
baseline O
in O
the O
percent O
of O
predicted O
forced B-outcome ['Physiological-Clinical']
expiratory I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
in O
1 O
second O
was O
8.7 O
% O
( O
range O
, O
2.3 O
to O
31.3 O
; O
P=0.008 O
for O
the O
within-subject O
comparison O
, O
P=0.56 O
vs. O
placebo O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
effect O
of O
exercise O
training O
and O
dietary O
macronutrient O
composition O
on O
24 O
h B-outcome ['Physiological-Clinical']
substrate I-outcome ['Physiological-Clinical']
oxidation I-outcome ['Physiological-Clinical']
in O
male O
, O
obese O
subjects O
. O
['Physiological-Clinical']

Measurements O
from O
Doppler O
sonography O
had O
lower O
reproducibility O
and O
sensitivity B-outcome ['Physiological-Clinical']
compared O
with O
the O
other O
applied O
methods O
. O
['Physiological-Clinical']

CONCLUSIONS O
To O
our O
knowledge O
, O
this O
is O
the O
first O
prospective O
randomized O
study O
comparing O
the O
three O
methods O
of O
chalazia O
treatment O
. O
[]

METHODS O
Patients O
with O
stage O
II/III O
LARC O
received O
capecitabine O
1250 O
mg/m O
( O
2 O
) O
twice O
daily O
for O
2 O
weeks O
followed O
by O
intravenous O
cetuximab O
400 O
mg/m O
( O
2 O
) O
at O
week O
3 O
, O
then O
weekly O
intravenous O
250 O
mg/m O
( O
2 O
) O
cetuximab O
plus O
CRT O
including O
capecitabine O
825 O
mg/m O
( O
2 O
) O
twice O
daily O
( O
including O
weekends O
during O
radiotherapy O
) O
with O
radiotherapy O
of O
45 O
Gy O
( O
25 O
x O
1.8 O
Gy O
) O
, O
5 O
days O
a O
week O
for O
5 O
weeks O
. O
[]

Both O
eye O
gaze O
and O
arrow O
pointing O
distractors O
resulted O
in O
overt B-outcome ['Life-Impact']
cueing I-outcome ['Life-Impact']
effects I-outcome ['Life-Impact']
, O
both O
in O
terms O
of O
increased O
saccadic B-outcome ['Life-Impact']
reaction I-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
, O
and O
in O
proportions O
of O
saccades B-outcome ['Life-Impact']
executed I-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
cued I-outcome ['Life-Impact']
direction I-outcome ['Life-Impact']
instead O
of O
to I-outcome ['Life-Impact']
the I-outcome ['Life-Impact']
target B-outcome ['Life-Impact']
, O
for O
both O
participant O
groups O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

OBJECTIVE O
Our O
purpose O
was O
to O
study O
the O
effect O
of O
hematinic O
supplementation O
on O
the O
maternal B-outcome ['Physiological-Clinical']
erythropoietin I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
during O
singleton O
pregnancy O
. O
['Physiological-Clinical']

It O
is O
estimated O
that O
for O
bladder B-outcome ['Physiological-Clinical']
morbidity I-outcome ['Physiological-Clinical']
the O
RBE B-outcome ['Physiological-Clinical']
value I-outcome ['Physiological-Clinical']
, O
for O
photon O
dose O
fractions O
of O
2.75 O
Gy O
, O
is O
less O
than O
3.3 O
for O
early O
reactions O
and O
equal O
to O
3.4 O
for O
late O
effects O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
data O
were O
registered O
in O
an O
Excel O
spreadsheet O
and O
analysed O
with O
SAS O
. O
[]

Basal B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
TCr I-outcome ['Physiological-Clinical']
content O
was O
lower O
( O
P O
< O
0.05 O
) O
in O
VEG O
compared O
with O
NVEG O
. O
['Physiological-Clinical']

MAIN O
OUTCOME O
MEASURES O
Primary O
efficacy O
endpoints O
were O
intra-individual O
differences O
( O
test-reference O
) O
in O
mean O
Hb O
levels O
and O
mean O
weekly O
dose/kg O
of O
body O
weight O
. O
[]

Follow-up O
angiography O
was O
scheduled O
after O
clipping O
and O
3 O
and O
12 O
months O
after O
endovascular O
treatment O
. O
[]

The O
etiology O
of O
this O
pathophysiological O
problem O
is O
multifactorial O
, O
and O
patient O
positioning O
may O
be O
a O
contributing O
factor O
. O
[]

Blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
hypertensive O
patients O
was O
lowered O
by O
bed O
rest O
only O
, O
or O
by O
oxprenolol O
or O
methyldopa O
, O
but O
remained O
elevated O
. O
['Physiological-Clinical']

Thus O
, O
adolescents O
with O
impairments O
in O
these O
skills O
are O
at O
risk O
for O
a O
variety O
of O
negative O
outcomes O
. O
[]

These O
design O
considerations O
include O
the O
definition O
of O
inclusion O
criteria O
that O
are O
relevant O
to O
clinical O
practice O
and O
matching O
study O
design O
to O
the O
goal O
of O
evaluating O
short- O
and O
long-term O
effects O
. O
[]

Objective: O
To O
evaluate O
the O
intervention O
effects O
of O
peer O
support O
education O
mode O
for O
type B-outcome ['Physiological-Clinical']
2 I-outcome ['Physiological-Clinical']
diabetes I-outcome ['Physiological-Clinical']
control I-outcome ['Physiological-Clinical']
in O
rural O
residents. O
[['Physiological-Clinical']]

However O
, O
serum B-outcome ['Physiological-Clinical']
rhG-CSF I-outcome ['Physiological-Clinical']
levels O
can O
not O
be O
maintained O
throughout O
the O
course O
of O
rhG-CSF O
therapy O
. O
['Physiological-Clinical']

PsycINFO O
Database O
Record O
(c) O
2018 O
APA, O
all O
rights O
reserved). O
[]

The O
findings O
do O
not O
support O
routine O
ultrasonography O
in O
the O
third O
trimester O
for O
low O
risk O
pregnancies. O
[]

However O
, O
because O
cryotherapy O
is O
not O
100 O
% O
effective O
, O
follow-up O
is O
needed O
after O
treatment O
to O
detect O
post-treatment O
failures O
. O
[]

did O
not O
achieve O
statistically O
significant O
increases O
( O
P O
= O
0.25 O
) O
. O
[]

Furthermore O
, O
the O
combination O
of O
the O
two O
drugs O
was O
shown O
to O
enhance O
the O
antihypertensive B-outcome ['Resource-use']
effect O
of O
the O
two O
compounds O
alone O
. O
['Resource-use']

No O
significant O
main O
effect O
of O
[]

SETTING O
An O
oral O
medicine O
specialist O
referral O
center O
in O
Manchester O
. O
[]

A O
randomised O
double-blind O
placebo-controlled O
study O
was O
designed O
to O
evaluate O
the O
effects O
of O
a O
semisynthetic O
macrolide O
antibiotic O
, O
clarithromycin O
, O
on O
bronchial B-outcome ['Physiological-Clinical']
hyperresponsiveness I-outcome ['Physiological-Clinical']
to O
methacholine O
in O
patients O
with O
a O
diagnosis O
of O
asthma O
. O
['Physiological-Clinical']

Health B-outcome ['Physiological-Clinical']
advice I-outcome ['Physiological-Clinical']
was O
given O
to O
76 O
% O
of O
905 O
participants O
following O
health O
checks O
. O
['Physiological-Clinical']

The O
ID O
Group O
, O
following O
OK-432 O
injection O
, O
had O
a O
4.8 O
% O
incidence O
of O
fever B-outcome ['Physiological-Clinical']
and O
a O
52.4 O
% O
incidence O
of O
local B-outcome ['Physiological-Clinical']
abscess I-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
at O
the O
injection O
site O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
outcome O
was O
between-group O
change O
in O
6-minute O
walk O
distance O
from O
baseline O
to O
20 O
weeks O
. O
[]

Assessments O
were O
repeated O
after O
prolonged O
treatment O
with O
PUFA O
( O
2 O
g/die O
, O
n O
= O
15 O
) O
or O
placebo O
( O
n O
= O
10 O
) O
. O
[]

After O
1-week O
washout O
period O
47 O
patients O
were O
randomized O
to O
ketazolam O
15 O
mg O
, O
and O
45 O
to O
placebo O
for O
15 O
days O
( O
first O
period O
) O
. O
[]

Coagulation O
factor O
concentrate O
in O
the O
treatment O
of O
the O
haemorrhagic B-outcome ['Physiological-Clinical']
diathesis I-outcome ['Physiological-Clinical']
of O
fulminant O
hepatic O
failure O
. O
['Physiological-Clinical']

Anti-emetic B-outcome ['Resource-use']
efficacy O
of O
prophylactic O
granisetron O
compared O
with O
perphenazine O
for O
the O
prevention O
of O
post-operative B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
in O
children O
. O
['Resource-use', 'Physiological-Clinical']

On O
a O
different O
day O
, O
in O
all O
subjects O
we O
determined O
intraarterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
, O
EKG B-outcome ['Physiological-Clinical']
and O
muscle B-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( O
MSNA B-outcome ['Physiological-Clinical']
) O
both O
supine O
and O
during O
upright O
tilt O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Twenty O
children O
with O
autism O
( O
mean O
age O
, O
5 O
years O
) O
were O
recruited O
for O
the O
study O
from O
a O
school O
for O
children O
with O
autism O
. O
[]

METHODS O
This O
multicentre O
, O
clinical O
trial O
was O
an O
investigation O
to O
compare O
the O
antiallergic O
efficacy O
, O
local O
tolerance O
and O
safety O
of O
Antazolin/Tetryzolin O
eye O
drops O
and O
Levocabastine O
eye O
drops O
. O
[]

TPM O
is O
an O
effective O
and O
generally O
well-tolerated B-outcome ['Life-Impact']
migraine O
prophylactic O
( O
preventive O
) O
therapy O
for O
adults O
, O
as O
demonstrated O
in O
several O
randomized O
, O
double-blind O
, O
placebo-controlled O
trials O
. O
['Life-Impact']

RESULTS O
The O
five-year O
actuarial O
rates O
of O
cancer B-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
at O
any O
site O
and O
of O
distant O
metastases O
in O
the O
radiotherapy-first O
group O
and O
the O
chemotherapy-first O
group O
were O
38 O
percent O
and O
31 O
percent O
( O
P O
= O
0.17 O
) O
and O
36 O
percent O
and O
25 O
percent O
( O
P O
= O
0.05 O
) O
, O
respectively O
. O
['Physiological-Clinical']

Patients O
with O
pretreatment O
EBV O
( O
+ O
) O
plasma O
( O
n O
= O
54 O
) O
had O
inferior O
failure-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
FFS I-outcome ['Mortality']
) I-outcome ['Mortality']
compared O
with O
those O
with O
pretreatment O
EBV O
( O
- O
) O
plasma O
( O
n O
= O
274 O
) O
, O
log-rank O
P O
= O
.009 O
. O
['Mortality']

16 O
patients O
with O
relapsing O
non-Hodgkin O
's O
malignant O
lymphomas O
considered O
as O
clinical O
stage O
I O
or O
II O
were O
treated O
by O
an O
association O
of O
chemo O
+ O
radiotherapy O
and O
thereafter O
by O
maintenance O
BCG O
therapy O
. O
[]

t O
( O
max O
) O
was O
significantly O
prolonged O
when O
cephalexin O
was O
administered O
with O
ranitidine O
or O
omeprazole O
. O
[]

Effect O
of O
ranitidine O
and O
amoxicillin O
plus O
metronidazole O
on O
the O
eradication O
of O
Helicobacter O
pylori O
and O
the O
recurrence O
of O
duodenal O
ulcer O
. O
[]

Parents O
in O
both O
intervention O
and O
control O
groups O
received O
health O
and O
safety O
counseling O
during O
home O
visits O
on O
the O
same O
schedule O
. O
[]

A O
significant O
decrease O
in O
number O
of O
tender B-outcome ['Physiological-Clinical']
sites I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
masticatory I-outcome ['Physiological-Clinical']
muscles I-outcome ['Physiological-Clinical']
was O
found O
in O
group O
T O
at O
the O
follow-ups O
. O
['Physiological-Clinical']

BACKGROUND: O
This O
randomized O
controlled O
trial O
evaluated O
the O
effectiveness O
of O
nerve O
electrical O
stimulation O
(NES) O
for O
the O
treatment O
of O
chemotherapy-induced O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
(CINV) O
in O
patients O
with O
advanced O
gastric O
cancer O
(AGC). O
[['Physiological-Clinical'], ['Physiological-Clinical']]

Clonidine O
( O
2.5 O
or O
5.0 O
microg/kg O
) O
was O
administered O
orally O
90 O
min O
before O
the O
induction O
of O
anesthesia O
in O
the O
Clonidine O
groups O
. O
[]

RESULTS O
Twenty O
seven O
families O
guessed O
their O
child O
's O
group O
assignment O
correctly O
and O
27 O
guessed O
incorrectly O
. O
[]

MEASUREMENTS O
AND O
MAIN O
RESULTS O
Operative O
parameters O
( O
operative B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
, O
fluid B-outcome ['Physiological-Clinical']
absorption I-outcome ['Physiological-Clinical']
, O
complications B-outcome ['Adverse-effects']
, O
need O
for O
second B-outcome ['Physiological-Clinical']
intervention I-outcome ['Physiological-Clinical']
) O
and O
reproductive O
outcome O
parameters O
( O
pregnancy B-outcome ['Physiological-Clinical']
, O
abortion B-outcome ['Mortality']
, O
term B-outcome ['Physiological-Clinical']
and O
preterm B-outcome ['Physiological-Clinical']
delivery I-outcome ['Physiological-Clinical']
, O
modality O
of O
delivery B-outcome ['Physiological-Clinical']
, O
cervical B-outcome ['Physiological-Clinical']
cerclage I-outcome ['Physiological-Clinical']
) O
were O
measured O
. O
['Life-Impact', 'Physiological-Clinical', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Adenocarcinoma O
of O
the O
gastrointestinal O
tract O
remains O
a O
major O
challenge O
to O
tumor O
biologists O
and O
clinical O
oncologists O
because O
it O
is O
generally O
resistant O
to O
chemotherapy O
and O
radiation O
therapy O
, O
yet O
common O
enough O
to O
represent O
a O
vital O
public O
health O
concern O
in O
America O
. O
[]

In O
a O
randomized O
study O
of O
patients O
undergoing O
Caesarean O
section O
, O
either O
enflurane O
( O
mean O
0.24 O
MAC-h O
) O
or O
halothane O
( O
mean O
0.23 O
MAC-h O
) O
and O
50 O
% O
nitrous O
oxide O
in O
oxygen O
were O
administered O
to O
women O
( O
n O
= O
12 O
) O
with O
severe O
pre-eclampsia-eclampsia O
and O
to O
16 O
healthy O
pregnant O
patients O
with O
normal O
renal O
and O
hepatic O
function O
. O
[]

6 O
. O
[]

Dehydration O
impairs O
physiological O
function O
and O
physical O
performance, O
thus O
understanding O
effective O
rehydration O
strategies O
is O
paramount. O
[]

CONCLUSIONS O
Continuous O
subcutaneous O
insulin O
infusion O
improves O
glycemic O
control O
and O
some O
aspects O
of O
health-related O
quality O
of O
life O
in O
patients O
with O
a O
history O
of O
long-term O
poor O
glycemic O
control O
. O
[]

An O
important O
part O
of O
the O
mechanism O
of O
DVT O
prophylaxis O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
is O
reduced O
venous O
stasis O
with O
increased O
velocity O
of O
venous O
return O
. O
[]

DESIGN O
Prospective O
, O
comparative O
, O
open-label O
clinical O
trial O
. O
[]

Diabetic O
nephropathy O
patients O
were O
treated O
with O
either O
B6 O
( O
N.=12 O
) O
( O
250 O
mg/day O
) O
or O
B1+B6 O
( O
N.=15 O
) O
( O
250 O
mg/day O
, O
each O
) O
for O
five O
months O
. O
[]

The O
total O
number O
of O
patients O
with O
adverse B-outcome ['Adverse-effects']
experiences I-outcome ['Adverse-effects']
were O
10 O
( O
45.5 O
% O
) O
, O
14 O
( O
33.3 O
% O
) O
and O
11 O
( O
25 O
% O
) O
in O
groups O
1,2 O
and O
3 O
, O
respectively O
. O
['Adverse-effects']

Patients O
were O
given O
the O
drugs O
intravenously O
for O
a O
minimum O
of O
three O
days O
followed O
by O
oral O
preparations O
for O
the O
next O
seven O
to O
ten O
days O
. O
[]

The O
mRNA B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
was O
measured O
at O
baseline O
and O
12 O
weeks O
by O
TaqMan(R) O
Low O
Density O
Array. O
[['Physiological-Clinical']]

Subjects O
with O
a O
negative O
history O
for O
HZ O
were O
randomized O
1:1 O
to O
receive O
one O
dose O
of O
either O
formulation O
. O
[]

Body O
mass O
index O
, O
fasting B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
electrolyte I-outcome ['Physiological-Clinical']
pattern I-outcome ['Physiological-Clinical']
, O
uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
, O
white B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
count I-outcome ['Physiological-Clinical']
, O
lipid B-outcome ['Physiological-Clinical']
profile I-outcome ['Physiological-Clinical']
as O
well O
as O
hepatic B-outcome ['Physiological-Clinical']
and O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
parameters O
remained O
unaltered O
throughout O
the O
observation O
period O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Excluded O
were O
partially-erupted O
teeth O
and O
surfaces O
with O
caries O
or O
restorations O
that O
had O
to O
be O
measured O
. O
[]

After O
a O
10-min O
rest, O
they O
exercised O
to O
a O
Trec O
of O
39.5 O
degrees O
C. O
Subsequently, O
they O
underwent O
CWI O
(9.99 O
+/- O
0.03 O
degrees O
C) O
until O
Trec O
reached O
38 O
degrees O
C. O
On O
control O
(CON) O
days, O
the O
same O
procedures O
occurred O
without O
the O
15-min O
PC O
intervention. O
[]

Preliminary O
evidence O
suggests O
that O
patients' O
beliefs O
and O
perceptions O
may O
influence O
their O
prognosis. O
[]

Although O
aging O
is O
associated O
with O
multiple O
abnormalities O
in O
immune O
function O
, O
the O
effect O
of O
aging O
on O
the O
production O
of O
proinflammatory B-outcome ['Physiological-Clinical']
cytokines O
has O
not O
been O
well O
studied O
under O
conditions O
of O
clinical O
stress O
. O
['Physiological-Clinical']

Familial O
adenomatous O
polyposis O
( O
FAP O
) O
strikes O
young O
people O
and O
, O
untreated O
, O
confers O
virtually O
a O
100 O
% O
risk O
of O
colorectal O
cancer O
and O
early O
death O
. O
[]

This O
effect O
was O
reversible O
among O
patients O
who O
returned O
from O
bicarbonate O
to O
lactate O
fluid O
. O
[]

Two O
wound O
infections O
occurred O
in O
the O
metronidazole O
group O
( O
5 O
% O
) O
and O
in O
both O
cases O
the O
organisms O
recovered O
were O
staphylococci O
of O
presumed B-outcome ['Physiological-Clinical']
skin I-outcome ['Physiological-Clinical']
origin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Clinical B-outcome ['Physiological-Clinical']
pharmacology I-outcome ['Physiological-Clinical']
of O
methadone O
in O
dogs O
. O
['Physiological-Clinical']

RESULTS O
Of O
the O
118 O
patients O
27 O
( O
23 O
% O
) O
had O
a O
negative O
repeat O
sextant O
biopsy O
. O
[]

By O
week O
8, O
HP/TAZ O
lotion O
achieved O
a O
63.5% O
reduction O
in O
mean O
IGAxBSA O
composite O
score O
(P<0.001 O
versus O
TAZ O
and O
vehicle), O
that O
was O
sustained O
four O
weeks O
posttreatment O
(P<0.001 O
versus O
TAZ O
and O
vehicle O
and O
P=0.003 O
versus O
HP). O
[]

Parents O
were O
also O
asked O
a O
series O
of O
questions O
to O
gather O
information O
about O
the O
pamphlet O
and O
its O
usefulness O
. O
[]

BACKGROUND O
Pneumocystis O
carinii O
pneumonia O
( O
PCP O
) O
continues O
to O
be O
the O
most O
common O
index O
diagnosis O
in O
the O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
, O
but O
it O
is O
not O
clear O
which O
of O
several O
available O
agents O
is O
the O
most O
effective O
in O
preventing O
a O
recurrence O
of O
PCP O
. O
[]

Sub-Tenon O
's O
anesthesia O
involved O
direct O
transconjunctival O
infiltration O
of O
the O
same O
local O
anesthetic O
directly O
into O
the O
sub-Tenon O
's O
space O
, O
in O
the O
inferior-nasal O
quadrant O
, O
using O
a O
blunt O
23-gauge O
cannula O
. O
[]

RESULTS O
The O
RV O
pacing O
contributed O
to O
significant O
increase O
in O
left B-outcome ['Physiological-Clinical']
atrial I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
LV B-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
end-systolic I-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
, O
and O
LV B-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
compared O
to O
BiV O
pacing O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Interventricular B-outcome ['Physiological-Clinical']
dyssynchrony I-outcome ['Physiological-Clinical']
significantly O
decreased O
with O
BiV O
compared O
with O
RV O
pacing O
. O
['Physiological-Clinical']

A O
neuropsychological O
battery O
including O
the O
Digit O
Span O
subtest O
from O
the O
Wechsler O
Adult O
Intelligence O
Scale-III O
( O
WAIS-III O
) O
, O
the O
verbal O
fluency O
test O
, O
the O
Hopkins O
Verbal O
Learning O
Test O
( O
HVLT O
) O
, O
the O
Trail-Making O
Test O
( O
TMT O
) O
and O
the O
Wisconsin O
Card O
Sorting O
Test O
( O
WCST O
) O
was O
administered O
at O
baseline O
and O
week O
eight O
. O
[]

METHODS: O
In O
this O
mixed-methods O
pilot O
trial, O
participants O
with O
quiescent O
or O
mildly-active O
CD O
were O
randomly O
assigned O
1:1:1 O
to O
HIIT, O
MICT O
or O
usual O
care O
control, O
and O
followed O
up O
for O
6 O
months. O
[]

PRL-8-53 O
: O
enhanced O
learning B-outcome ['Life-Impact']
and O
subsequent O
retention B-outcome ['Life-Impact']
in O
humans O
as O
a O
result O
of O
low O
oral O
doses O
of O
new O
psychotropic O
agent O
. O
['Life-Impact', 'Life-Impact']

Canadian O
HIV O
Trials O
Network O
Protocol O
010 O
Study O
Group O
. O
[]

Duration O
of O
granulocytopenia B-outcome ['Physiological-Clinical']
was O
reduced O
in O
the O
G-CSF O
group O
, O
but O
thrombocytopenia B-outcome ['Physiological-Clinical']
was O
prolonged O
, O
and O
the O
number O
of O
['Physiological-Clinical', 'Physiological-Clinical']

Gabapentin O
might O
also O
reduce O
postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

On O
all O
measures O
group O
variability O
in O
scores O
increased O
with O
age O
. O
[]

Cervico-vaginal O
lavage O
was O
collected O
to O
measure O
the O
concentrations O
of O
IL-1? O
, O
TNF? O
and O
IL-6 O
by O
ELISA O
. O
[]

To O
achieve O
the O
accrual O
goal O
of O
140 O
subjects O
in O
this O
single O
institution O
study O
, O
the O
Wisconsin O
Cancer B-outcome ['Physiological-Clinical']
Reporting O
System O
( O
WCRS O
) O
, O
a O
population-based O
cancer O
registry O
, O
was O
used O
. O
['Physiological-Clinical']

C-terminal B-outcome ['Physiological-Clinical']
FGF23 I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
in O
stored O
plasma O
samples O
. O
['Physiological-Clinical']

Septicemia B-outcome ['Physiological-Clinical']
occurred O
in O
15.5 O
percent O
of O
the O
immune O
globulin O
recipients O
and O
17.2 O
percent O
of O
the O
controls O
. O
['Physiological-Clinical']

L(- O
1); O
betaA2: O
9.2 O
+/- O
1.1 O
mmol. O
[]

CONCLUSION O
Aerosolized O
tobramycin O
was O
well O
tolerated O
in O
ventilated O
patients O
with O
documented O
nosocomial O
pneumonia O
. O
[]

CONCLUSIONS O
Regular O
intake O
of O
lime O
juice O
may O
be O
of O
great O
therapeutic O
and O
nutritional O
relevance O
in O
children O
with O
SCA O
. O
[]

Funded O
by O
the O
Department O
of O
Veterans O
Affairs O
Cooperative O
Studies O
Program; O
ClinicalTrials.gov O
number, O
NCT01265550.). O
[]

No O
significant O
decrease O
in O
total O
respiratory B-outcome ['Physiological-Clinical']
resistance I-outcome ['Physiological-Clinical']
at I-outcome ['Physiological-Clinical']
8 I-outcome ['Physiological-Clinical']
Hz I-outcome ['Physiological-Clinical']
( O
Rrs B-outcome ['Physiological-Clinical']
[ I-outcome ['Physiological-Clinical']
8 I-outcome ['Physiological-Clinical']
] I-outcome ['Physiological-Clinical']
) O
was O
observed O
after O
ipratropium O
, O
whereas O
Rrs O
( O
8 O
) O
decreased O
significantly O
20 O
min O
after O
fenoterol O
and O
40 O
min O
after O
the O
combination O
regimen O
( O
p O
less O
than O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Treatments O
were O
compared O
after O
2 O
weeks O
( O
strip O
use O
) O
and O
12 O
weeks O
( O
dentifrice O
use O
) O
using O
analysis O
of O
covariance O
. O
[]

Effects O
of O
early O
enteral O
feeding O
on O
fecal B-outcome ['Physiological-Clinical']
elastase I-outcome ['Physiological-Clinical']
1 I-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
secretin I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Atenolol O
was O
shown O
to O
be O
an O
effective O
anti-anginal O
agent O
when O
given O
once O
daily O
, O
and O
there O
were O
no O
major O
differences O
between O
the O
doses O
studied O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
C-peptide I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
counter-regulatory B-outcome ['Physiological-Clinical']
hormones I-outcome ['Physiological-Clinical']
were O
also O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
contrast O
, O
aortic O
cross-clamping O
during O
isoflurane O
anesthesia O
was O
not O
associated O
with O
renal B-outcome ['Physiological-Clinical']
hemodynamic I-outcome ['Physiological-Clinical']
impairment I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Effects O
of O
statins O
on O
progression O
of O
subclinical B-outcome ['Physiological-Clinical']
brain I-outcome ['Physiological-Clinical']
infarct I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
increase O
in O
hilliness O
, O
measured O
by O
the O
GFP O
, O
was O
significant O
. O
[]

METHODS O
Type O
2 O
diabetic O
patients O
( O
N.=57 O
) O
were O
divided O
into O
two O
groups O
as O
with O
nephropathy O
( O
N.=27 O
) O
and O
without O
nephropathy O
( O
N.=30 O
) O
. O
[]

The O
intensity O
of O
pain B-outcome ['Physiological-Clinical']
was O
scored O
based O
on O
10-point O
VAS O
before O
and O
after O
treatment O
for O
up O
to O
24 O
h O
postoperatively O
. O
['Physiological-Clinical']

They O
will O
be O
randomized O
in O
a O
2:2:1 O
ratio O
to O
receive O
12 O
weekly O
yoga O
classes O
, O
12 O
weekly O
conventional O
therapeutic O
exercise O
classes O
of O
comparable O
physical O
exertion O
, O
or O
a O
self-care O
book O
. O
[]

Blood O
was O
drawn O
before O
treatment O
of O
patients O
with O
newly O
diagnosed O
hypothyroidism O
and O
when O
euthyroidism O
was O
achieved O
. O
[]

Human O
subjects O
performed O
either O
10 O
wk O
of O
training O
with O
an O
acute O
exercise O
bout O
before O
and O
after O
the O
training O
period O
, O
or O
a O
low-glycogen O
vs. O
normal-glycogen O
acute O
exercise O
trial O
. O
[]

METHODS O
This O
was O
a O
prospective O
randomized O
study O
. O
[]

Naproxen O
enhanced O
the O
anti-aggregatory B-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
of O
aspirin O
after O
24 O
h O
( O
CT B-outcome ['Physiological-Clinical']
rising O
from O
104+/-16 O
s O
at O
baseline O
to O
212+/-69 O
s O
at O
24 O
h O
, O
P O
< O
0.001 O
) O
, O
which O
was O
not O
seen O
with O
any O
other O
drug O
combination O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
These O
results O
suggest O
that O
preoperative O
hemodilution O
using O
4 O
% O
albumin O
on O
a O
1:1 O
volume O
basis O
for O
blood O
substitution O
during O
a O
prolonged O
surgical O
procedure O
with O
reduced O
blood O
losses O
enhances O
the O
extravasation O
rate O
of O
albumin O
and O
fluid O
to O
the O
interstitial O
tissues O
, O
impeding O
the O
maintenance O
of O
isovolemia O
. O
[]

The O
effect O
lasted O
for O
the O
entire O
period O
of O
drug O
administration O
and O
in O
50 O
% O
of O
patients O
a O
normal O
platelet O
aggregation O
was O
maintained O
until O
the O
fourth O
day O
after O
discontinuation O
of O
the O
drug O
. O
[]

Inhaled O
fluticasone O
reduces O
sputum B-outcome ['Physiological-Clinical']
inflammatory I-outcome ['Physiological-Clinical']
indices I-outcome ['Physiological-Clinical']
in O
severe O
bronchiectasis O
. O
['Physiological-Clinical']

Health-related B-outcome ['Life-Impact']
quality I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
healthcare B-outcome ['Resource-use']
resource I-outcome ['Resource-use']
utilization I-outcome ['Resource-use']
, O
and O
days B-outcome ['Life-Impact']
missed I-outcome ['Life-Impact']
from I-outcome ['Life-Impact']
work I-outcome ['Life-Impact']
or O
school B-outcome ['Life-Impact']
were O
also O
reported O
. O
['Life-Impact', 'Resource-use', 'Life-Impact', 'Life-Impact']

After O
total O
mastectomy O
and O
axillary O
node O
sampling O
, O
high-risk O
patients O
were O
randomized O
to O
adjuvant O
therapy O
. O
[]

PMID: O
31615781 O
[]

Journal O
ID: O
100968547 O
[]

At O
follow-up O
, O
the O
CBT O
group O
tended O
to O
be O
more O
likely O
to O
have O
experienced O
3 O
months O
of O
seizure B-outcome ['Physiological-Clinical']
freedom I-outcome ['Physiological-Clinical']
( O
odds O
ratio O
3.125 O
, O
p O
= O
0.086 O
) O
. O
['Physiological-Clinical']

Primary O
outcome O
was O
severity O
of O
autism B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
( O
a O
total O
score O
of O
social B-outcome ['Life-Impact']
communication B-outcome ['Life-Impact']
algorithm O
items O
from O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Patients O
aged O
12 O
to O
17 O
years O
received O
rizatriptan O
5 O
mg O
( O
n O
= O
149 O
) O
or O
placebo O
( O
n O
= O
147 O
) O
for O
a O
moderate O
or O
severe O
headache O
and O
for O
up O
to O
two O
recurrences O
. O
[]

In O
a O
secondary O
analysis O
, O
outcome O
variables O
were O
compared O
with O
the O
nonrandomized O
patients O
without O
previous O
statin O
therapy O
( O
n O
= O
126 O
) O
. O
[]

This O
study O
's O
purpose O
was O
to O
determine O
whether O
using O
chlorhexidine O
gluconate O
( O
CHG O
) O
in O
a O
prophylactic O
perirectal O
skin-care O
regimen O
decreases O
perirectal O
infections O
and O
whether O
it O
produces O
more O
skin O
irritation O
than O
a O
nonmedicated O
skin O
cleanser O
. O
[]

CONCLUSIONS O
This O
low O
0.3 O
% O
rate O
is O
in O
agreement O
with O
recent O
studies O
that O
focus O
on O
thromboembolic B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

BACKGROUND O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
performance B-outcome ['Life-Impact']
of O
a O
new O
cuff B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
release O
valve O
( O
CPRV O
) O
, O
in O
which O
the O
release O
pressure O
can O
be O
adjusted O
from O
10 O
to O
25 O
cmH2O O
, O
particularly O
intended O
to O
control O
pressure O
in O
paediatric O
cuffed O
tracheal O
tubes O
and O
to O
avoid O
cuff O
hyperinflation O
caused O
by O
N2O O
diffusion O
. O
['Life-Impact', 'Physiological-Clinical']

There O
was O
no O
significant O
difference O
in O
the O
severity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
on O
the O
above O
3 O
dosages O
, O
and O
no O
difference O
in O
the O
duration O
of O
infection-free B-outcome ['Physiological-Clinical']
intervals I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

They O
were O
assigned O
randomly O
to O
active O
warming O
or O
passive O
insulation O
on O
day O
1 O
and O
given O
alternative O
treatment O
during O
the O
subsequent O
visit O
. O
[]

This O
effect O
was O
more O
marked O
if O
the O
epidural O
catheter O
was O
sited O
in O
the O
thoracic O
rather O
than O
the O
lumbar O
area O
. O
[]

Different O
underlying O
mechanisms O
have O
been O
proposed O
, O
and O
allogeneic O
leucocytes O
in O
transfused O
blood O
have O
been O
suggested O
to O
contribute O
to O
this O
phenomenon O
. O
[]

DESIGN O
Prospective O
study O
. O
[]

OBJECTIVE O
The O
potential O
of O
probiotics O
to O
control O
allergic B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
at O
an O
early O
age O
was O
assessed O
in O
a O
randomized O
double-blind O
placebo-controlled O
study O
. O
['Physiological-Clinical']

Patients O
who O
were O
nonadherent O
to O
medication O
regimens O
were O
more O
likely O
to O
relapse B-outcome ['Life-Impact']
. O
['Life-Impact']

Data O
from O
this O
study O
indicate O
that O
consumption O
of O
medium-and O
long-chain O
triglycerides O
can O
reduce O
body B-outcome ['Physiological-Clinical']
weight I-outcome ['Physiological-Clinical']
and O
body B-outcome ['Physiological-Clinical']
['Physiological-Clinical', 'Physiological-Clinical']

Patient O
information O
, O
shared O
care O
and O
decision-making O
are O
recognised O
as O
beneficial O
to O
chronic O
disease O
management O
. O
[]

METHODS O
Some O
280 O
men O
with O
a O
primary O
hernia O
were O
randomized O
prospectively O
to O
undergo O
Shouldice O
, O
tension-free O
Lichtenstein O
or O
laparoscopic O
TAPP O
repair O
. O
[]

METHODS: O
We O
randomly O
assigned O
female O
healthcare O
workers O
with O
recurrent O
non-specific O
LBP O
to O
one O
of O
four O
study-arms: O
Combined O
neuromuscular O
exercise O
and O
back O
care O
counseling; O
Exercise; O
Counseling; O
and O
no O
intervention O
Control. O
[]

The O
addition O
of O
tamoxifen O
to O
epirubicin O
resulted O
in O
a O
suppression O
of O
a O
key O
angiogenic B-outcome ['Physiological-Clinical']
pathway O
. O
['Physiological-Clinical']

At O
a O
median O
follow-up O
of O
35 O
months O
, O
11 O
invasive O
breast O
cancers O
were O
detected O
in O
those O
given O
exemestane O
and O
in O
32 O
of O
those O
given O
placebo O
, O
with O
a O
65 O
% O
relative O
reduction O
in O
the O
annual O
incidence O
of O
invasive B-outcome ['Physiological-Clinical']
breast I-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
( O
0.19 O
% O
vs. O
0.55 O
% O
; O
hazard O
ratio O
, O
0.35 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.18 O
to O
0.70 O
; O
P=0.002 O
) O
. O
['Physiological-Clinical']

Patients O
who O
received O
naloxone O
( O
n O
= O
58 O
) O
showed O
significant O
increases O
in O
mean O
scores O
on O
all O
three O
rating O
scales O
, O
but O
this O
was O
due O
primarily O
to O
increases O
observed O
in O
a O
minority O
of O
patients O
. O
[]

CONCLUSION O
The O
combination O
of O
gemcitabine O
and O
tipifarnib O
has O
an O
acceptable O
toxicity O
profile O
but O
does O
not O
prolong O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
in O
advanced O
pancreatic O
cancer O
compared O
with O
single-agent O
gemcitabine O
. O
['Mortality']

In O
study O
I O
, O
MEG-X B-outcome ['Physiological-Clinical']
formation I-outcome ['Physiological-Clinical']
rate O
was O
dose-independent O
in O
patients O
with O
severely O
impaired O
liver O
function O
. O
['Physiological-Clinical']

plus O
omeprazole O
40 O
mg O
q.d.s. O
, O
or O
dirithromycin O
500 O
mg O
q.d.s O
. O
[]

Dis O
. O
[]

These O
children O
were O
randomly O
divided O
into O
two O
groups O
: O
Therapy O
Group O
( O
TG O
) O
- O
composed O
by O
six O
subjects O
receiving O
both O
direct O
and O
indirect O
intervention O
; O
and O
Orientation O
Group O
( O
OG O
) O
- O
constituted O
by O
five O
subjects O
receiving O
exclusively O
indirect O
intervention O
. O
[]

To O
determine O
whether O
antioxidants O
can O
influence O
human O
susceptibility O
to O
ozone O
( O
O O
( O
3 O
) O
) O
-induced O
changes O
in O
lung B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
airway B-outcome ['Physiological-Clinical']
inflammation I-outcome ['Physiological-Clinical']
, O
we O
placed O
31 O
healthy O
nonsmoking O
adults O
( O
18 O
to O
35 O
yr O
old O
) O
on O
a O
diet O
low O
in O
ascorbate O
for O
3 O
wk O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Evaluation O
of O
masking O
study O
participants O
to O
intravitreal O
injections O
in O
a O
randomized O
clinical O
trial O
. O
[]

RESULTS O
Although O
the O
decision O
aid O
had O
no O
significant O
effect O
on O
postdecisional O
regret O
or O
actual O
genetic O
testing O
decision O
, O
the O
trial O
results O
demonstrated O
that O
participants O
who O
received O
the O
decision O
aid O
had O
significantly O
lower O
levels O
of O
decisional B-outcome ['Life-Impact']
conflict I-outcome ['Life-Impact']
( O
ie O
, O
uncertainty B-outcome ['Life-Impact']
) O
regarding O
genetic B-outcome ['Physiological-Clinical']
testing I-outcome ['Physiological-Clinical']
( O
chi-square O
( O
1 O
) O
= O
8.97 O
; O
P O
= O
.003 O
) O
and O
were O
more O
likely O
to O
be O
classified O
as O
having O
made O
an O
informed B-outcome ['Life-Impact']
choice I-outcome ['Life-Impact']
concerning O
genetic O
testing O
( O
chi-square O
( O
1 O
) O
= O
4.37 O
; O
P O
= O
.037 O
) O
than O
participants O
who O
received O
a O
control O
pamphlet O
. O
['Life-Impact', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact']

By O
the O
end O
of O
the O
study O
the O
mean O
levodopa O
SR O
dosage O
was O
190 O
mg/d O
and O
the O
mean O
ropinirole O
dosage O
was O
1.45 O
mg/d O
. O
[]

Insight B-outcome ['Physiological-Clinical']
was O
clinically O
significantly O
improved O
( O
risk O
ratio=1.15 O
, O
95 O
% O
CI O
1.01-1.31 O
) O
. O
['Physiological-Clinical']

A O
parallel O
set O
of O
analyses O
was O
conducted O
on O
partners O
' O
depression B-outcome ['Life-Impact']
and O
anxiety B-outcome ['Life-Impact']
data O
. O
['Life-Impact', 'Life-Impact']

Blacks O
, O
Hispanics O
and O
( O
non-Hispanic O
) O
whites O
were O
all O
more O
highly O
educated O
, O
less O
likely O
to O
currently B-outcome ['Life-Impact']
smoke I-outcome ['Life-Impact']
and O
more O
likely O
to O
get O
regular B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
than O
their O
counterparts O
in O
the O
general O
population O
. O
['Life-Impact', 'Life-Impact']

Study O
patients O
were O
randomized O
to O
the O
two O
treatment O
arms O
, O
Er O
: O
YAG O
( O
3.8 O
J/cm O
( O
2 O
) O
, O
30 O
% O
pattern O
overlap O
, O
0 O
% O
interpulse O
overlap O
, O
15 O
microm O
per O
pass O
with O
no O
coagulation O
) O
and O
IPL O
( O
560-nm O
filter O
, O
30 O
J/cm O
( O
2 O
) O
, O
2.4/4.0-ms O
pulse O
with O
10-ms O
delay O
) O
, O
each O
receiving O
three O
sequential O
treatments O
spaced O
1 O
month O
apart O
. O
[]

AIM O
To O
compare O
the O
immediate O
restoration O
of O
single O
implants O
in O
the O
esthetic O
zones O
performed O
on O
implants O
placed O
immediately O
after O
tooth O
extraction O
or O
8 O
weeks O
later O
( O
immediate O
replacement O
vs. O
immediate O
restoration O
) O
. O
[]

In O
the O
whole O
group O
and O
in O
groups O
A O
and O
B O
considered O
individually O
, O
responses O
to O
D O
and O
P O
did O
not O
differ O
. O
[]

However O
, O
to O
our O
knowledge O
, O
there O
have O
been O
no O
studies O
using O
all O
these O
measures O
together O
as O
an O
adjuvant O
antidepressant O
strategy O
. O
[]

Recent O
work O
suggests O
, O
however O
, O
that O
the O
use O
of O
lithium O
with O
early O
morning O
sleep O
deprivation O
sustains O
this O
rapid O
antidepressant B-outcome ['Resource-use']
effect O
and O
makes O
it O
clinically O
useful O
. O
['Resource-use']

PURPOSE O
Blockage O
of O
long-term O
indwelling O
catheters O
with O
mineral O
deposit O
is O
an O
ongoing O
management O
issue O
, O
but O
evidence O
on O
optimal O
management O
is O
lacking O
. O
[]

INTERVENTIONS O
Subjects O
received O
riluzole O
( O
titrated O
to O
50 O
or O
100 O
mg/day O
based O
on O
bodyweight O
) O
or O
placebo O
in O
addition O
to O
risperidone O
( O
titrated O
up O
to O
2 O
or O
3 O
mg/day O
based O
on O
bodyweight O
) O
for O
10 O
weeks O
. O
[]

RESULTS O
Baseline O
mean O
+/- O
SEM O
values O
after O
washout O
prior O
to O
each O
randomized O
treatment O
comparing O
levocetirizine O
vs O
placebo O
were O
not O
significantly O
different O
for O
prechallenge O
FEV1 B-outcome ['Physiological-Clinical']
( O
% O
predicted O
) O
83 O
+/- O
4 O
vs O
82 O
+/- O
4 O
, O
or O
AMP B-outcome ['Physiological-Clinical']
PC20 I-outcome ['Physiological-Clinical']
( O
mg O
ml O
( O
-1 O
) O
) O
45 O
+/- O
24 O
vs O
45 O
+/- O
22 O
, O
respectively O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Our O
results O
show O
that O
deep B-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
thrombosis I-outcome ['Physiological-Clinical']
during O
the O
first O
week O
after O
hip O
replacement O
surgery O
can O
not O
be O
discovered O
by O
clinical O
diagnostics O
. O
['Physiological-Clinical']

Low O
grade O
lymphomas O
( O
16 O
patients O
) O
received O
a O
cyclophosphamide O
, O
vincristine O
, O
prednisone O
association O
. O
[]

Efficacy O
of O
a O
barrier O
cream O
and O
its O
vehicle O
as O
protective O
measures O
against O
occupational B-outcome ['Physiological-Clinical']
irritant I-outcome ['Physiological-Clinical']
contact I-outcome ['Physiological-Clinical']
dermatitis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

RESULTS O
All O
cases O
studied O
met O
full O
Autism O
Diagnostic O
Interview O
( O
ADI O
) O
criteria O
for O
classical O
autism O
. O
[]

The O
primary O
and O
secondary O
outcome O
results O
were O
similar O
in O
the O
two O
aspirin O
strata O
. O
[]

It O
is O
concluded O
that O
the O
immunity B-outcome ['Physiological-Clinical']
is O
disturbed O
in O
patients O
with O
laryngo-pharyngeal O
cancer O
, O
but O
that O
this O
disturbance O
does O
not O
clearly O
correlate O
with O
the O
clinical O
state O
of O
the O
disease O
. O
['Physiological-Clinical']

Patients O
with O
CSF+/Mass O
had O
a O
nominally O
higher O
treatment O
failure B-outcome ['Physiological-Clinical']
rate O
compared O
with O
patients O
with O
CNS- O
after O
adjusting O
for O
marrow O
status O
and O
lactate O
dehydrogenase O
( O
LDH O
) O
diagnosis O
, O
with O
a O
relative O
failure O
rate O
( O
RFR O
) O
of O
1.52 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.88 O
to O
2.6 O
; O
P O
=.15 O
) O
. O
['Physiological-Clinical']

OBJECTIVES O
In O
aromatherapy O
, O
lavender O
aroma O
is O
reputed O
to O
assist O
with O
relaxation O
. O
[]

Patients O
completed O
a O
questionnaire O
before O
and O
1 O
year O
after O
surgery O
to O
evaluate O
symptoms O
, O
function O
, O
and O
overall O
satisfaction O
. O
[]

STUDY O
DESIGN O
AND O
METHODS O
In O
a O
randomized O
, O
controlled O
trial O
, O
477 O
women O
with O
anemia O
, O
iron O
deficiency O
, O
and O
heavy O
uterine O
bleeding O
were O
assigned O
to O
receive O
either O
IV O
ferric O
carboxymaltose O
( O
< O
or=1000 O
mg O
over O
15 O
min O
, O
repeated O
weekly O
to O
achieve O
a O
total O
calculated O
replacement O
dose O
) O
or O
325 O
mg O
of O
ferrous O
sulfate O
( O
65 O
mg O
elemental O
iron O
) O
prescribed O
orally O
thrice O
daily O
for O
6 O
weeks O
. O
[]

A O
similar O
comparison O
during O
trial O
2 O
revealed O
a O
1.8 O
+/- O
0.3 O
mmol.l-1 O
increase O
in O
lactate B-outcome ['Physiological-Clinical']
, O
signifying O
a O
workload O
above O
LSS O
and O
therefore O
confirming O
trial O
1 O
as O
the O
maximum O
LSS O
( O
MLSS O
) O
. O
['Physiological-Clinical']

The O
updated O
survival O
analysis O
showed O
similar O
results O
. O
[]

The O
aim O
of O
the O
present O
study O
was O
to O
test O
whether O
a O
higher O
dose O
of O
G-CSF O
( O
10 O
micro O
g/kg/day O
) O
would O
reduce O
these O
complications B-outcome ['Adverse-effects']
. O
['Adverse-effects']

INTRODUCTION O
Increased O
reliance O
on O
bulbospinal O
motor O
systems O
has O
been O
implicated O
in O
individuals O
with O
chronic O
stroke O
during O
maximum O
voluntary O
arm O
joint O
torque O
generation O
. O
[]

RESEARCH O
DESIGN O
AND O
METHODS O
We O
studied O
83 O
of O
86 O
individuals O
> O
or=25 O
years O
of O
age O
with O
type O
1 O
diabetes O
who O
used O
CGM O
as O
part O
of O
a O
6-month O
randomized O
clinical O
trial O
in O
a O
subsequent O
6-month O
extension O
study O
. O
[]

If O
we O
shifted O
the O
target O
blood O
pressure O
from O
below O
140/90 O
to O
below O
130/85 O
for O
drug-treated O
subjects O
under O
60 O
( O
n O
= O
278 O
) O
the O
number O
of O
inadequately B-outcome ['Life-Impact']
treated I-outcome ['Life-Impact']
subjects O
increased O
by O
34 O
( O
12.2 O
% O
of O
278 O
) O
; O
14 O
in O
the O
low-risk O
group O
, O
15 O
in O
the O
medium-risk O
group O
, O
and O
only O
five O
in O
the O
high- O
or O
very-high-risk O
groups O
. O
['Life-Impact']

823 O
N O
, O
ES O
= O
0.21 O
) O
. O
[]

At O
these O
time O
points: O
T(0)(the O
day O
before O
operation), O
T(1)(immediate O
before O
anesthesia O
induction), O
T(2)(1 O
h O
after O
emergence), O
T(3)(24 O
h O
after O
operation), O
T(4)(3 O
d O
after O
operation), O
T(5)(7 O
d O
after O
operation), O
T(6)(one O
month O
after O
operation), O
T(7)(3 O
months O
after O
operation) O
and O
T(8)(6 O
month O
after O
operation) O
, O
venous O
blood O
samples O
of O
patients O
were O
collected O
for O
detection O
of O
epinephrine B-outcome ['Physiological-Clinical']
, O
norepinephrine B-outcome ['Physiological-Clinical']
and O
corticosterone B-outcome ['Physiological-Clinical']
. O
The O
pain B-outcome ['Physiological-Clinical']
visual O
analogue O
scale(VSA) O
was O
used O
to O
assess O
pain B-outcome ['Physiological-Clinical']
levels O
in O
patients O
at O
T(2), O
T(3), O
T(4), O
T(5), O
T(6), O
T(7), O
T(8). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

2 O
. O
[]

We O
performed O
a O
randomized O
trial O
comparing O
the O
use O
of O
quantitative O
DNAemia O
versus O
positive O
antigenemia O
for O
starting O
preemptive O
antihuman O
cytomegalovirus O
( O
HCMV O
) O
therapy O
in O
hematopoietic O
stem-cell O
transplantation O
( O
HSCT O
) O
recipients O
. O
[]

Publication O
date: O
2019/01/31 O
00:00 O
[accepted] O
[]

Prediction O
linear O
equations O
for O
the O
main O
variables O
of O
clinical O
interest O
were O
established O
by O
backward O
stepwise O
regression O
analysis O
including O
: O
sex O
, O
age O
, O
knee O
extensor O
peak O
torque O
, O
bone-free O
lean O
leg O
mass O
, O
total O
and O
lean O
body O
mass O
, O
height O
, O
and O
physical O
activity O
scores O
. O
[]

CEE O
0.625 O
mg O
was O
also O
administered O
once O
daily O
as O
open O
labelled O
tablets O
to O
all O
subjects O
throughout O
the O
study O
. O
[]

RESULTS O
Bleeding B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
gums I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
probing I-outcome ['Physiological-Clinical']
( O
BOP B-outcome ['Physiological-Clinical']
) O
and O
pocket B-outcome ['Physiological-Clinical']
depth I-outcome ['Physiological-Clinical']
( O
PD B-outcome ['Physiological-Clinical']
) O
improved O
at O
the O
treatment O
site O
and O
were O
maintained O
for O
13 O
weeks O
after O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
comparative O
study O
of O
the O
pharmacokinetics B-outcome ['Physiological-Clinical']
of O
ibuprofen O
arginate O
versus O
dexibuprofen O
in O
healthy O
volunteers O
. O
['Physiological-Clinical']

3 O
) O
After O
treatment O
, O
the O
onsets O
of O
refractory B-outcome ['Physiological-Clinical']
angina I-outcome ['Physiological-Clinical']
pectoris I-outcome ['Physiological-Clinical']
were O
reduced O
more O
significantly O
in O
the O
diltiazem O
group O
than O
in O
nitroglycerin O
group O
[ O
4 O
( O
3.8 O
% O
) O
vs O
13 O
( O
11.9 O
% O
) O
, O
RR O
0.32 O
( O
95 O
% O
CI O
0.11 O
- O
0.96 O
) O
, O
P O
< O
0.05 O
] O
. O
( O
['Physiological-Clinical']

The O
training O
group O
performed O
exercises O
every O
day O
: O
on O
bicycle O
ergometer O
during O
30 O
minutes O
( O
5 O
times O
a O
week O
) O
, O
overall-conditioning O
exercises O
for O
30 O
minutes O
daily O
and O
30 O
to O
60 O
minutes O
of O
walking O
each O
day O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Relapse-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
; O
number O
of O
N.S O
. O
['Mortality']

Main O
outcome O
measures O
, O
derived O
actigraphically O
, O
were O
sleep O
latency O
, O
total O
sleep O
time O
, O
wake O
after O
sleep O
onset O
and O
number O
of O
awakenings O
. O
[]

In O
the O
placebo O
, O
vitamin O
A O
, O
and O
beta O
carotene O
groups O
the O
rates O
of O
stillbirth O
and O
infant O
mortality O
were O
47.9 O
( O
95 O
% O
CI O
, O
44.3-51.5 O
) O
, O
45.6 O
( O
95 O
% O
CI O
, O
42.1-49.2 O
) O
, O
and O
51.8 O
( O
95 O
% O
CI O
, O
48.0-55.6 O
) O
per O
1000 O
births O
and O
68.1 O
( O
95 O
% O
CI O
, O
63.7-72.5 O
) O
, O
65.0 O
( O
95 O
% O
CI O
, O
60.7-69.4 O
) O
, O
and O
69.8 O
( O
95 O
% O
CI O
, O
65.4-72.3 O
) O
per O
1000 O
live O
births O
, O
respectively O
. O
[]

This O
economic B-outcome ['Resource-use']
evaluation O
also O
considered O
relative O
efficacies O
of O
the O
approaches O
using O
the O
primary O
outcome O
variable O
of O
symptomatic O
, O
sustained B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
tachyarrhythmia I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
( O
including O
sudden B-outcome ['Mortality']
death I-outcome ['Mortality']
) O
. O
['Resource-use', 'Physiological-Clinical', 'Mortality']

As O
a O
group O
, O
the O
patients O
displayed O
greater O
UFC B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
and O
lower B-outcome ['Physiological-Clinical']
ACTH I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
than O
the O
controls O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Although O
the O
results O
presented O
within O
do O
not O
include O
factors O
of O
study O
and O
study-by-treatment O
interaction O
, O
analyses O
were O
performed O
to O
confirm O
that O
the O
results O
were O
consistent O
across O
the O
2 O
identical O
, O
double-blind O
, O
randomized O
studies O
and O
within O
each O
treatment O
group O
across O
studies O
to O
justify O
pooling O
the O
data O
from O
both O
studies O
. O
[]

No O
women O
given O
metformin O
spontaneously B-outcome ['Physiological-Clinical']
['Physiological-Clinical']

This O
suggests O
that O
autistic O
patients O
had O
significantly O
greater O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
to O
sumatriptan O
than O
normal O
controls O
, O
independent O
of O
placebo O
effects O
. O
['Physiological-Clinical']

Injury B-outcome ['Physiological-Clinical']
and O
illness B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
in O
the O
Certified O
Safe O
Farm O
study O
. O
['Physiological-Clinical', 'Resource-use']

While O
the O
study O
did O
not O
yield O
definitive O
data O
about O
the O
relative O
engagement O
potential O
of O
ESM O
alternatives O
, O
it O
does O
provide O
a O
foundation O
for O
future O
research O
, O
including O
guidance O
related O
to O
participant O
profiles O
, O
stimulus O
characteristics O
, O
and O
data O
coding O
challenges O
. O
[]

The O
relative O
risk O
( O
RR B-outcome ['Physiological-Clinical']
) O
of O
developing O
PIPN O
was O
significantly O
higher O
in O
controls O
than O
in O
vitamin O
E O
group O
patients O
( O
RR=0.3 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
=0.1-0.9 O
) O
. O
['Physiological-Clinical']

However O
, O
the O
noninvasive O
approach O
generated O
higher O
follow-up O
hospital B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
( O
$ O
9,204 O
+/- O
9,217 O
) O
than O
the O
invasive O
approach O
( O
$ O
3,784 O
+/- O
4,944 O
) O
( O
P O
= O
0.01 O
) O
. O
['Resource-use']

This O
study O
compared O
two O
formats O
of O
a O
social O
story O
targeting O
the O
improvement O
of O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
during O
game O
play O
using O
a O
pretest O
posttest O
repeated O
measures O
randomized O
control O
group O
design O
. O
['Life-Impact']

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
efficacy O
of O
controlled-release O
( O
CR O
) O
melatonin O
in O
the O
treatment O
of O
delayed O
sleep O
phase O
syndrome O
and O
impaired O
sleep O
maintenance O
of O
children O
with O
neurodevelopmental O
disabilities O
including O
autistic O
spectrum O
disorders O
. O
[]

Journal-Name:National O
Bureau O
of O
Economic O
Research O
bulletin O
on O
aging O
and O
health O
[]

Itching B-outcome ['Physiological-Clinical']
was O
depressed O
by O
38 O
% O
following O
betamethasone O
( O
P O
< O
0.05 O
) O
and O
by O
18 O
% O
following O
methylprednisolone O
( O
P=0.07 O
) O
compared O
with O
placebo O
. O
['Physiological-Clinical']

Evidence O
from O
three O
systematic O
reviews O
demonstrates O
that O
sterile O
water O
injections O
( O
SWI O
) O
provide O
statistically O
and O
clinically O
significant O
pain B-outcome ['Physiological-Clinical']
relief I-outcome ['Physiological-Clinical']
in O
women O
experiencing O
continuous O
lower O
back O
pain O
during O
labour O
. O
['Physiological-Clinical']

METHODS O
201 O
patients O
with O
clinically O
definite O
multiple O
sclerosis O
were O
studied O
. O
[]

OBJECTIVE O
To O
conduct O
a O
randomized O
, O
controlled O
trial O
to O
evaluate O
the O
efficacy O
of O
the O
Early O
Start O
Denver O
Model O
( O
ESDM O
) O
, O
a O
comprehensive O
developmental O
behavioral O
intervention O
, O
for O
improving O
outcomes O
of O
toddlers O
diagnosed O
with O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Ranitidine O
premedication O
reduces O
gastric O
volume O
, O
increases O
gastric O
pH O
, O
and O
may O
reduce O
GER B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

BACKGROUND O
Because O
of O
the O
widespread O
existence O
of O
Neisseria O
gonorrhoeae O
resistant O
to O
penicillin O
or O
tetracycline O
, O
ceftriaxone O
is O
now O
recommended O
for O
the O
treatment O
of O
gonorrhea B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

High O
density O
lipoprotein O
cholesterol O
was O
lower O
in O
the O
intervention O
group O
( O
p O
< O
0.05 O
) O
. O
[]

The O
mean O
age O
of O
randomised O
children O
was O
24 O
months O
and O
mean O
blood O
lead O
level O
26 O
micrograms/dL O
. O
[]

BACKGROUND O
The O
short-term O
effects O
of O
denopamine O
, O
an O
orally O
available O
beta-stimulant O
, O
on O
exercise O
capacity O
were O
studied O
in O
patients O
with O
chronic O
heart O
failure O
. O
[]

BACKGROUND O
The O
Chronic O
Respiratory O
Questionnaire O
( O
CRQ O
) O
and O
the O
St O
George O
's O
Respiratory O
Questionnaire O
( O
SGRQ O
) O
are O
the O
two O
most O
widely O
used O
quality O
of O
life O
questionnaires O
in O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O
[]

Based O
on O
these O
criteria O
, O
ototoxicity B-outcome ['Physiological-Clinical']
was O
seen O
in O
5/27 O
( O
18.5 O
% O
) O
patients O
treated O
with O
G-C O
and O
2/19 O
( O
10.5 O
% O
) O
patients O
treated O
with O
N-C O
. O
['Physiological-Clinical']

However O
, O
this O
difference O
was O
not O
statistically O
significant O
( O
p=0.78 O
) O
. O
[]

Because O
the O
mechanism O
of O
action O
for O
ipilimumab O
is O
thought O
to O
be O
HLA O
independent O
, O
most O
trials O
enrolled O
patients O
without O
regard O
to O
HLA O
subtype O
. O
[]

A O
double-blind O
comparative O
study O
of O
ofloxacin O
otic O
drops O
versus O
neomycin-polymyxin O
B-hydrocortisone O
otic O
drops O
in O
the O
medical O
treatment O
of O
chronic O
suppurative O
otitis O
media O
. O
[]

The O
activated B-outcome ['Physiological-Clinical']
clotting I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
measured O
at O
the O
end O
of O
the O
procedure O
. O
['Physiological-Clinical']

Four O
parameters O
were O
followed O
: O
serum-specific O
IgE O
against O
antigen O
E O
, O
total O
blocking O
antibody O
against O
antigen O
E O
, O
local O
and O
systemic O
reactions O
to O
injection O
therapy O
, O
and O
symptom O
score O
indices O
. O
[]

RESULTS O
In O
the O
trimethoprim-sulfamethoxazole O
group O
( O
n O
= O
154 O
) O
there O
were O
14 O
recurrences B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
PCP I-outcome ['Physiological-Clinical']
, O
as O
compared O
with O
36 O
recurrences O
( O
including O
1 O
extrapulmonary O
recurrence O
) O
in O
the O
aerosolized-pentamidine O
group O
( O
n O
= O
156 O
) O
. O
['Physiological-Clinical']

Journal-Name:Nutrients O
[]

RESULTS O
We O
found O
a O
significant O
decrease O
in O
pulmonary O
function O
, O
an O
increased O
use O
of O
salbutamol O
and O
the O
development O
of O
a O
late O
asthmatic O
response O
and O
bronchial O
hyperresponsiveness O
, O
as O
well O
as O
a O
significant O
induction O
of O
eNO O
, O
eosinophils O
, O
and O
Th-2 O
cytokines O
. O
[]

END O
POINTS: O
Primary O
end O
point O
was O
MACE B-outcome ['Physiological-Clinical', 'Mortality']
at O
1 O
year O
and O
secondary O
end O
points O
at O
the O
end O
of O
1 O
year O
were O
cardiac B-outcome ['Mortality']
death I-outcome ['Mortality']
, O
urgent O
target O
lesion B-outcome ['Resource-use']
revascularization I-outcome ['Resource-use']
, O
acute B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
syndrome I-outcome ['Physiological-Clinical']
, O
stroke B-outcome ['Physiological-Clinical']
and O
in-stent B-outcome ['Physiological-Clinical']
re-stenosis I-outcome ['Physiological-Clinical']
. O
RESULTS: O
204 O
patients O
were O
enrolled O
between O
January O
2013 O
to O
July O
2014, O
91 O
in O
the O
polymer-free O
group O
and O
113 O
in O
the O
biodegradable O
polymer O
group. O
[['Physiological-Clinical', 'Mortality'], ['Mortality'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

morphine O
was O
more O
effective O
for O
treatment O
of O
pain B-outcome ['Physiological-Clinical']
after O
laparoscopic O
cholecystectomy O
. O
['Physiological-Clinical']

METHOD O
Randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
design O
. O
[]

Loss O
of O
lean B-outcome ['Physiological-Clinical']
body I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
was O
not O
spared O
in O
the O
HPLC O
group O
. O
['Physiological-Clinical']

Intention-to-treat O
eradication O
rates O
were O
88.2 O
% O
( O
95 O
% O
CI O
80.9-93.0 O
% O
) O
vs. O
79.1 O
% O
( O
95 O
% O
CI O
71.1-85.4 O
% O
) O
, O
p O
= O
0.029 O
, O
respectively O
. O
[]

CONCLUSIONS O
Remission O
by O
year O
3 O
in O
etanercept-treated O
( O
with O
and O
without O
methotrexate O
) O
patients O
with O
RA O
occurred O
in O
?35 O
% O
of O
patients O
in O
both O
an O
RCT O
( O
TEMPO O
) O
and O
a O
clinical O
practice O
setting O
( O
RADIUS O
II O
) O
, O
and O
more O
frequently O
in O
those O
with O
lower O
baseline O
disease O
severity O
. O
[]

Multivariate O
statistical O
models O
adjusting O
for O
these O
factors O
confirmed O
the O
statistically O
significant O
RFS B-outcome ['Mortality']
benefit O
of O
HDI O
versus O
Obs O
but O
did O
not O
demonstrate O
a O
significant O
OS B-outcome ['Mortality']
benefit O
in O
the O
pooled O
populations O
. O
['Mortality', 'Mortality']

The O
incidence O
of O
postinjection B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
temporary B-outcome ['Physiological-Clinical']
numbness/paresthesia I-outcome ['Physiological-Clinical']
, O
and O
incisive B-outcome ['Physiological-Clinical']
papilla I-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
or O
soreness B-outcome ['Physiological-Clinical']
would O
indicate O
that O
some O
pain O
and O
problems O
occur O
with O
the O
P-ASA O
technique O
, O
regardless O
of O
whether O
2 O
% O
lidocaine O
with O
1:100,000 O
epinephrine O
or O
3 O
% O
mepivacaine O
is O
used O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
, O
the O
texture O
, O
depth O
, O
and O
color O
of O
the O
root-surface O
lesions O
were O
monitored O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Publication O
date: O
2018/12/20 O
06:00 O
[entrez] O
[]

A O
two-filter O
model O
for O
frequency O
discrimination B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Public O
and O
private O
heart O
rate O
feedback O
in O
social O
phobia O
: O
a O
manipulation O
of O
anxiety B-outcome ['Life-Impact']
visibility I-outcome ['Life-Impact']
. O
['Life-Impact']

METHODS O
Fifty O
ASA O
I-II O
patients O
were O
included O
in O
the O
randomized O
double O
blind O
study O
. O
[]

Needles O
on O
the O
4 O
extremities O
were O
withdrawn O
first O
after O
30 O
minutes O
, O
needles O
on O
head O
were O
remained O
during O
behavior O
training O
. O
[]

The O
experimental O
acupuncture O
treatment O
consisted O
of O
specific O
acupuncture O
body O
points O
related O
to O
menopausal B-outcome ['Physiological-Clinical']
symptoms I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Many O
patients O
with O
venous O
thromboembolism O
are O
being O
treated O
with O
low O
molecular O
weight O
heparin O
for O
extended O
periods O
of O
time O
. O
[]

Change O
from O
baseline O
in O
the O
vitality B-outcome ['Physiological-Clinical']
subscale O
of O
the O
SF-36 O
was O
7.3-7.8 O
in O
the O
placebo O
and O
the O
750-mg/day O
arm O
, O
versus O
10.5-14.6 O
in O
the O
1,000- O
and O
2,000-mg/day O
arms O
. O
['Physiological-Clinical']

SETTING O
Seven O
trials O
from O
Mexico O
, O
Haiti O
, O
the O
United O
States O
, O
Zambia O
, O
Uganda O
and O
Kenya O
. O
[]

Median O
random O
assignment O
to O
balloon B-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
was O
82 O
( O
55 O
, O
100 O
) O
minutes O
, O
and O
median O
random O
assignment O
to O
needle B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
was O
15 O
( O
10 O
, O
26 O
) O
minutes O
( O
P O
< O
.0001 O
) O
. O
['Physiological-Clinical', 'Life-Impact']

Are O
PRO O
discharge O
screens O
associated O
with O
postdischarge O
adverse O
outcomes O
? O
[]

The O
score O
of O
childhood O
autism O
rating O
scale O
( O
CARS O
) O
and O
clinical B-outcome ['Physiological-Clinical']
efficacy O
in O
both O
groups O
were O
observed O
before O
and O
after O
treatment O
. O
['Physiological-Clinical']

Rabeprazole-based O
short-term O
triple O
therapy O
may O
be O
applicable O
in O
CYP2C19 O
PMs O
for O
H. O
pylori O
eradication O
. O
[]

We O
used O
mixed O
linear O
modeling O
of O
log-transformed O
swim O
time O
to O
quantify O
effects O
on O
performance B-outcome ['Life-Impact']
in O
training O
versus O
competition O
, O
in O
morning O
versus O
evening O
swims O
, O
and O
with O
use O
of O
caffeine O
. O
['Life-Impact']

RESULTS O
Preoperative O
characteristics O
and O
risk O
factors O
( O
EuroSCORE O
: O
group O
1 O
= O
7.9 O
vs O
group O
2 O
= O
8.1 O
) O
, O
number O
of O
grafted B-outcome ['Physiological-Clinical']
coronary I-outcome ['Physiological-Clinical']
vessels I-outcome ['Physiological-Clinical']
( O
group O
1 O
= O
2.4 O
vs O
group O
2 O
= O
2.5 O
) O
, O
aortic B-outcome ['Physiological-Clinical']
crossclamping I-outcome ['Physiological-Clinical']
time I-outcome ['Physiological-Clinical']
( O
group O
1 O
= O
37 O
+/- O
7 O
minutes O
vs O
group O
2 O
= O
38 O
+/- O
7 O
minutes O
) O
, O
ventilation B-outcome ['Life-Impact']
time I-outcome ['Life-Impact']
( O
group O
1 O
= O
22 O
+/- O
12 O
hours O
vs O
group O
2 O
= O
23 O
+/- O
11 O
hours O
) O
, O
intensive B-outcome ['Resource-use']
care I-outcome ['Resource-use']
unit I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
( O
group O
1 O
= O
39 O
+/- O
10 O
hours O
vs O
group O
2 O
= O
40 O
+/- O
9 O
hours O
) O
, O
and O
hospital B-outcome ['Mortality']
mortality I-outcome ['Mortality']
( O
group O
1 O
= O
3.8 O
% O
vs O
group O
2 O
= O
5 O
% O
) O
were O
comparable O
between O
the O
groups O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact', 'Resource-use', 'Mortality']

This O
study O
evaluated O
whether O
a O
single O
dose O
of O
intranasal O
oxytocin O
acutely O
improves O
social O
cognitive O
functioning O
in O
schizophrenia O
. O
[]

In O
the O
multiple-dose O
studies O
, O
127 O
healthy O
subjects O
received O
bilastine O
10 O
, O
20 O
, O
40 O
, O
50 O
, O
80 O
, O
100 O
, O
140 O
or O
200 O
mg/day O
as O
multiple O
doses O
during O
a O
4- O
, O
7- O
or O
14-day O
period O
. O
[]

Information O
about O
pupils B-outcome ['Physiological-Clinical']
' O
smoking B-outcome ['Life-Impact']
status B-outcome ['Life-Impact']
and O
other O
factors O
related O
to O
smoking O
will O
be O
obtained O
using O
a O
web-based O
questionnaire O
. O
['Physiological-Clinical', 'Life-Impact', 'Life-Impact']

In O
addition, O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
were O
also O
assessed O
during O
the O
period O
of O
this O
study. O
[['Adverse-effects']]

After O
10 O
weeks O
standard O
hypolipidemic O
diet O
and O
hydrochlorothiazide O
( O
25 O
mg O
od O
) O
therapy O
, O
30 O
patients O
whose O
cholesterol B-outcome ['Physiological-Clinical']
levels O
were O
still O
greater O
than O
or O
equal O
to O
250 O
mg/100 O
ml O
and O
whose O
diastolic B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure O
was O
less O
than O
95 O
mmHg O
were O
randomized O
to O
one O
of O
the O
following O
treatments O
: O
simvastatin O
, O
20 O
mg O
od O
, O
gemfibrozil O
, O
600 O
mg O
bid O
or O
placebo O
, O
while O
continuing O
dietetic O
and O
diuretic O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Randomized O
trial O
of O
angiotensin O
II-receptor O
blocker O
vs. O
dihydropiridine O
calcium O
channel O
blocker O
in O
the O
treatment O
of O
paroxysmal O
atrial O
fibrillation O
with O
hypertension O
( O
J-RHYTHM O
II O
study O
) O
. O
[]

Embolization O
results O
were O
evaluated O
by O
a O
central O
laboratory O
. O
[]

METHODS O
Two O
groups O
of O
21 O
males O
with O
moderate O
and O
heavy O
recreational O
use O
of O
MDMA O
, O
respectively O
, O
and O
a O
control O
group O
of O
20 O
males O
without O
use O
of O
MDMA O
were O
compared O
. O
[]

This O
demonstrated O
that O
fever B-outcome ['Physiological-Clinical']
continued O
to O
be O
significantly O
associated O
with O
most O
outcome O
measures O
, O
even O
when O
infection B-outcome ['Physiological-Clinical']
was O
added O
to O
the O
model O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
presentation O
of O
the O
research O
design O
includes O
discussions O
of O
data O
collection O
and O
patient O
sampling O
methods O
; O
the O
measurement O
of O
patient O
outcomes O
, O
including O
measures O
of O
health B-outcome ['Resource-use']
care I-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
utilization B-outcome ['Life-Impact']
, O
patient B-outcome ['Physiological-Clinical']
functional I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
and O
quality O
of O
life O
. O
['Resource-use', 'Life-Impact', 'Physiological-Clinical']

It O
has O
been O
shown O
that O
phenytoin O
has O
no O
effect O
on O
the O
absorption O
of O
this O
folate B-outcome ['Physiological-Clinical']
polyglutamate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

CONCLUSIONS O
Transhiatal O
esophagectomy O
is O
a O
safe O
and O
fast O
procedure O
. O
[]

Effects O
of O
cognitive-behavioral O
therapy O
on O
anxiety O
in O
children O
with O
autism O
spectrum O
disorders O
: O
a O
randomized O
controlled O
trial O
. O
[]

CONCLUSION O
Liposome-entrapped O
D. O
Pteronyssinus O
vaccination O
: O
( O
i O
) O
protects O
mild O
asthma O
patients O
from O
the O
worsening O
of O
asthma O
due O
to O
sustained O
mite O
exposure O
; O
and O
( O
ii O
) O
reduces O
the O
functional O
and O
inflammatory O
changes O
induced O
by O
allergen O
bronchial O
provocation O
. O
[]

These O
findings O
can O
help O
to O
determine O
an O
effective O
hypoxic O
exercise O
regimen O
to O
minimize O
immune O
dysfunction O
by O
retarding O
T-lymphocyte O
senescence O
. O
[]

No O
eyes B-outcome ['Physiological-Clinical']
lost I-outcome ['Physiological-Clinical']
> O
or O
=1 O
line O
of O
BCVA B-outcome ['Physiological-Clinical']
; O
in O
the O
ZAR O
group O
, O
2 O
eyes O
gained O
1 O
line O
and O
6 O
eyes O
gained O
> O
or O
=2 O
lines O
; O
in O
the O
Planoscan O
group O
, O
3 O
eyes O
gained O
1 O
line O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Is O
altered O
central O
pain O
processing O
related O
to O
disease O
stage O
in O
chronic O
pancreatitis O
patients O
with O
pain O
? O
[]

The O
patients O
were O
followed O
up O
for O
6 O
months. O
[]

Acute O
prolactin O
and O
oxytocin O
responses O
and O
milk B-outcome ['Physiological-Clinical']
yield I-outcome ['Physiological-Clinical']
to O
infant O
suckling O
and O
artificial B-outcome ['Resource-use']
methods I-outcome ['Resource-use']
of I-outcome ['Resource-use']
expression I-outcome ['Resource-use']
in O
lactating O
women O
. O
['Physiological-Clinical', 'Resource-use']

CONCLUSIONS O
Proton O
pump O
inhibitors O
and O
roxithromycin O
do O
not O
alter O
the O
systemic O
bioavailability O
of O
each O
other O
. O
[]

Indeed O
, O
42 O
% O
of O
the O
enriched O
group O
and O
only O
7 O
% O
of O
the O
control O
group O
had O
what O
we O
considered O
to O
be O
a O
clinically O
significant O
improvement O
of O
5 O
points O
on O
that O
scale O
. O
[]

Complications O
associated O
with O
rectal O
lesions O
may O
be O
severe O
enough O
to O
cause O
life-threatening O
septicemia O
. O
[]

Therefore, O
a O
novel O
system O
for O
patient O
classification O
(category O
14) O
was O
developed O
in O
the O
present O
study O
based O
on O
these O
two O
indices O
to O
assist O
in O
predicting O
the O
prognosis O
and O
therapeutic O
response. O
[]

Subjects O
in O
group O
A O
underwent O
BF O
once O
a O
week O
for O
a O
total O
of O
four O
sessions O
. O
[]

Although O
there O
are O
studies O
confirming O
ergogenic O
effects O
of O
caffeine O
(CAF) O
on O
different O
physical O
and O
mental O
abilities, O
much O
controversy O
remains O
about O
its O
influence O
on O
power. O
[]

The O
effect O
was O
assessed O
using O
PANSS O
, O
CGI O
, O
MADRS O
and O
neuropsychological O
tests O
. O
[]

Serum B-outcome ['Physiological-Clinical']
IgG I-outcome ['Physiological-Clinical']
anti-IgG I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
were O
determined O
after O
dithiothreitol O
treatment O
. O
['Physiological-Clinical']

Interestingly, O
the O
main O
determinant O
of O
vitamin O
D O
at O
baseline O
was O
the O
waist O
circumference. O
[]

0.4 O
vs O
3.8 O
? O
[]

MATERIAL O
AND O
METHODS O
A O
total O
of O
1195 O
patients O
in O
the O
LIFE-study O
had O
diabetes O
at O
the O
time O
of O
the O
randomisation O
. O
[]

The O
primary O
efficacy O
endpoint O
was O
percentage O
reduction O
in O
direct B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
LDL-C. O
Ezetimibe O
reduced O
direct B-outcome ['Physiological-Clinical']
LDL-C I-outcome ['Physiological-Clinical']
by O
a O
mean O
of O
17.7 O
% O
from O
baseline O
to O
endpoint O
, O
compared O
with O
an O
increase O
of O
0.8 O
% O
with O
placebo O
( O
P O
< O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Both O
techniques O
created O
the O
same O
level O
of O
epithelial B-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increase O
and O
variation, O
with O
a O
significantly O
higher O
mid-peripheral B-outcome ['Physiological-Clinical']
epithelial I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
increase. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

1 O
. O
[]

A O
blinded O
, O
four-treatment O
crossover O
study O
in O
16 O
normal O
adult O
male O
volunteers O
compared O
plasma O
concentrations O
and O
urinary B-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
of O
digoxin B-outcome ['Resource-use']
, O
measured O
by O
radioimmunoassay O
, O
after O
oral O
administration O
of O
soft O
gelatin O
capsule O
formulations O
of O
digoxin O
. O
['Physiological-Clinical', 'Resource-use']

We O
expect O
long-term B-outcome ['Life-Impact']
implant I-outcome ['Life-Impact']
survival I-outcome ['Life-Impact']
to O
be O
better O
with O
the O
TM O
tibial O
component O
. O
['Life-Impact']

Two O
subjects O
had O
severe O
adverse O
events O
requiring O
prednisolone O
to O
cope O
with O
nocturnal O
asthma O
symptoms O
. O
[]

There O
was O
no O
significant O
difference O
in O
adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
between O
the O
2 O
groups O
. O
['Adverse-effects']

Including O
additionally O
3 O
patients O
on O
placebo O
and O
1 O
patient O
on O
valproate O
who O
felt O
they O
had O
suffered O
a O
migraine B-outcome ['Physiological-Clinical']
attack B-outcome ['Physiological-Clinical']
, O
but O
who O
had O
as O
associated O
symptoms O
only O
photophobia B-outcome ['Physiological-Clinical']
or O
phonophobia B-outcome ['Physiological-Clinical']
, O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
induced B-outcome ['Resource-use']
migraine B-outcome ['Physiological-Clinical']
after O
valproate O
was O
seen O
( O
P O
= O
0.031 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Resource-use', 'Physiological-Clinical']

However O
, O
while O
TD O
children O
showed O
activation O
of O
this O
system O
during O
both O
self- O
and O
other-processing O
, O
children O
with O
ASD O
only O
recruited O
this O
system O
while O
viewing O
images O
containing O
mostly O
their O
own O
face O
. O
[]

Effects O
of O
tryptophan O
depletion O
in O
drug-free O
adults O
with O
autistic O
disorder O
. O
[]

ASD O
families O
received O
more O
hours O
of O
conventional B-outcome ['Resource-use']
services I-outcome ['Resource-use']
compared O
with O
DD O
families O
( O
17.8 O
vs O
11 O
; O
p O
< O
.001 O
) O
. O
['Resource-use']

Inclusion O
criteria O
were O
one O
or O
more O
relapses O
in O
the O
year O
before O
entry O
and O
at O
least O
one O
gadolinium B-outcome ['Physiological-Clinical']
enhancing I-outcome ['Physiological-Clinical']
( O
GdE B-outcome ['Physiological-Clinical']
) O
lesion B-outcome ['Physiological-Clinical']
on O
screening O
MRI O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Of O
the O
66 O
patients O
enrolled O
, O
9 O
were O
observed O
for O
one O
month O
or O
less O
; O
7 O
were O
followed O
for O
two O
months O
; O
only O
50 O
patients O
were O
followed O
for O
more O
than O
2 O
months O
and O
could O
be O
adequately O
evaluated O
. O
[]

Effect O
of O
clinical O
context O
on O
simulator-based O
assessment O
of O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
taking O
- O
a O
pilot O
randomized O
study O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
investigate O
the O
impact O
of O
coagulative O
parameters O
on O
different O
anticoagulation B-outcome ['Physiological-Clinical']
systems O
in O
molecular O
adsorbent O
recirculating O
system O
( O
MARS O
) O
in O
subjects O
with O
liver O
failure O
, O
and O
to O
evaluate O
the O
safety O
of O
different O
anticoagulation B-outcome ['Physiological-Clinical']
methods O
. O
['Physiological-Clinical', 'Physiological-Clinical']

After O
24 O
weeks O
treatment O
, O
simvastatin O
induced O
a O
37 O
% O
reduction O
in O
cholesterol B-outcome ['Physiological-Clinical']
plasma O
levels O
, O
a O
9 O
% O
increase O
of O
HDL B-outcome ['Physiological-Clinical']
and O
a O
16 O
% O
reduction O
of O
LDL B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Events B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
anaemia I-outcome ['Physiological-Clinical']
, O
abdominal B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
jaundice B-outcome ['Physiological-Clinical']
and O
weight O
loss B-outcome ['Physiological-Clinical']
were O
more O
common O
in O
the O
placebo O
arm O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Results O
combining O
the O
P-values O
of O
both O
studies O
indicate O
that O
the O
relative O
risk O
of O
having O
persistent O
disease O
was O
2.9 O
times O
greater O
for O
patients O
who O
received O
chemotherapy O
. O
[]

Dose-response O
relationship O
of O
complementary O
radiotherapy O
following O
four O
cycles O
of O
combination O
chemotherapy O
in O
intermediate-stage O
Hodgkin O
's O
disease O
. O
[]

Compared O
to O
the O
non-screened O
, O
a O
higher O
proportion O
of O
screened B-outcome ['Resource-use']
individuals O
were O
women O
( O
OR=4.51 O
; O
CI O
: O
4.28-4.75 O
) O
, O
lived O
in O
better O
housing O
( O
OR=1.35 O
; O
CI O
: O
1.25-1.41 O
) O
, O
had O
television/radio O
( O
OR=1.50 O
; O
CI O
: O
1.43-1.58 O
) O
and O
were O
tobacco O
and O
alcohol O
users O
( O
OR=2.75 O
; O
CI O
: O
2.57-2.95 O
) O
. O
['Resource-use']

The O
study O
was O
focused O
on O
aseptic O
sternal O
complications O
, O
namely O
bone B-outcome ['Physiological-Clinical']
dehiscence I-outcome ['Physiological-Clinical']
and O
superficial B-outcome ['Physiological-Clinical']
wound I-outcome ['Physiological-Clinical']
instability I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Journal O
ID: O
2985213R O
[]

These O
results O
suggest O
that O
treatment O
and O
follow-up O
to O
prevent O
recolonisation O
in O
pregnant O
women O
with O
group-B O
streptococci O
in O
the O
urine O
may O
reduce O
the O
frequency O
of O
preterm B-outcome ['Physiological-Clinical']
labour I-outcome ['Physiological-Clinical']
in O
these O
patients O
. O
['Physiological-Clinical']

Further O
studies O
are O
needed O
to O
assess O
the O
optimal O
treatment O
strategy O
for O
hypertension O
in O
the O
elderly O
. O
[]

METHODS O
We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
clinical O
trial O
at O
three O
primary O
care O
centers O
in O
North O
Carolina O
. O
[]

A O
randomised O
clinical O
trial O
. O
[]

At O
each O
test O
session O
subjects O
completed O
visual O
analog O
scales O
and O
knee B-outcome ['Physiological-Clinical']
girth I-outcome ['Physiological-Clinical']
was O
measured O
. O
['Physiological-Clinical']

The O
induction O
time B-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
measured I-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
onset I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
loss I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
eyelash I-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
was O
shortest O
in O
the O
case O
of O
thiopental O
; O
while O
a O
lower O
frequency O
of O
apnea B-outcome ['Physiological-Clinical']
, O
lesser O
suppression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
circulation I-outcome ['Physiological-Clinical']
, O
and O
lack O
of O
venous B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
were O
points O
favoring O
midazolam O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

P3 O
maxima O
elicited O
by O
rare O
non-targets O
were O
recorded O
more O
rostrally O
after O
fenfluramine O
treatment O
. O
[]

OBJECTIVE O
To O
examine O
the O
predictive O
validity O
of O
symptom B-outcome ['Life-Impact']
severity I-outcome ['Life-Impact']
, O
cognitive B-outcome ['Life-Impact']
and O
language B-outcome ['Life-Impact']
measures O
taken O
at O
ages O
2 O
and O
3 O
years O
to O
outcome O
at O
age O
7 O
in O
a O
sample O
of O
children O
diagnosed O
with O
autism O
at O
age O
2 O
. O
['Life-Impact', 'Life-Impact']

BACKGROUND O
Although O
chlorhexidine-based O
solutions O
and O
alcohol-based O
povidone-iodine O
have O
been O
shown O
to O
be O
more O
efficient O
than O
aqueous O
povidone-iodine O
for O
skin O
disinfection O
at O
catheter O
insertion O
sites O
, O
their O
abilities O
to O
reduce O
catheter-related B-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
have O
never O
been O
compared O
. O
['Physiological-Clinical']

Patients O
showing O
evidence O
of O
impairment O
were O
randomly O
assigned O
to O
one O
of O
two O
training O
groups O
: O
individualized O
PC-supported O
training O
or O
neuropsychological O
group O
therapy O
. O
[]

Effect O
of O
a O
ferrule O
and O
increased O
clinical O
crown O
length O
on O
the O
in O
vitro O
fracture O
resistance O
of O
premolars O
restored O
using O
two O
dowel-and-core O
systems O
. O
[]

CONCLUSIONS O
In O
WRIST O
, O
not O
only O
was O
( O
192 O
) O
Ir O
therapy O
effective O
in O
reducing O
restenosis O
, O
but O
it O
also O
reduced O
the O
lesion O
length O
of O
treatment O
failures O
by O
50 O
% O
, O
and O
it O
was O
not O
associated O
with O
edge O
proliferation O
. O
[]

on O
day O
1 O
or O
the O
same O
chemotherapy O
, O
plus O
GM-CSF O
10 O
micrograms O
kg-1 O
s.c. O
starting O
from O
day O
4 O
, O
repeated O
as O
soon O
as O
haematopoietic O
recovery O
from O
nadir O
occurred O
. O
[]

Concentric O
( O
maximal O
EMG O
activity O
during O
extension O
) O
and O
eccentric O
( O
maximal O
EMG O
activity O
during O
flexion O
) O
ratios O
were O
also O
used O
in O
the O
analyses O
. O
[]

METHODS O
Twenty O
adult O
severely O
burned O
patients O
with O
sepsis O
were O
studied O
. O
[]

No O
patient O
received O
antibiotics O
at O
the O
time O
of O
surgery O
or O
prior O
to O
the O
first O
positive O
blood O
culture O
, O
yet O
B. O
fragilis O
was O
the O
single O
organism O
isolated O
from O
blood O
and O
abscesses O
in O
these O
patients O
. O
[]

We O
studied O
94 O
patients O
( O
mean O
age O
, O
35.6 O
+/- O
11.2 O
years O
) O
with O
moderate O
to O
severe O
acute O
asthma O
. O
[]

The O
first O
consisted O
of O
a O
brochure O
, O
which O
provided O
answers O
to O
the O
questionnaire O
items O
and O
addressed O
the O
issues O
in O
more O
depth O
. O
[]

MATERIALS O
AND O
METHODS O
In O
a O
prospective O
, O
randomized O
clinical O
trial O
involving O
patients O
with O
dysfunctional O
, O
stenotic O
hemodialysis O
arteriovenous O
fistulas O
( O
AVFs O
) O
, O
patients O
were O
randomized O
to O
receive O
CBA O
or O
HPBA O
if O
conventional O
PTA O
had O
suboptimal O
results O
( O
ie O
, O
residual O
stenosis O
> O
30 O
% O
) O
. O
[]

Patients O
with O
clinical O
stage O
I-II O
gastric O
cancer O
with O
a O
body O
mass O
index O
of O
25 O
and O
over, O
who O
undergo O
laparoscopic O
subtotal O
gastrectomy O
will O
be O
eligible O
for O
trial O
inclusion. O
[]

Although O
the O
incidence O
of O
myelosuppression B-outcome ['Physiological-Clinical']
and O
alopecia B-outcome ['Physiological-Clinical']
was O
significantly O
higher O
in O
group O
B O
, O
neuropathy B-outcome ['Physiological-Clinical']
was O
significantly O
more O
frequent O
in O
group O
A O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
patients O
were O
24 O
children O
undergoing O
tonsillectomy O
and O
adenoidectomy O
. O
[]

Secondary O
end O
points O
were O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
, O
overall O
survival B-outcome ['Mortality']
( O
OS B-outcome ['Mortality']
) O
, O
and O
safety O
. O
['Mortality', 'Mortality', 'Mortality']

[ O
Encephalopathy O
therapeutic O
tongue O
acupoint O
apparatus O
( O
ETTAA O
) O
for O
42 O
cases O
of O
autism O
] O
. O
[]

Time B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
preoperative I-outcome ['Physiological-Clinical']
neurological I-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
is O
faster O
and O
morphine O
provides O
some O
transitional B-outcome ['Resource-use']
analgesia I-outcome ['Resource-use']
without O
compromising O
the O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
recovery I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Resource-use', 'Life-Impact']

OBJECTIVE O
Most O
children O
with O
autism O
rely O
on O
schools O
as O
their O
primary O
source O
of O
intervention O
, O
yet O
research O
has O
suggested O
that O
teachers O
rarely O
use O
evidence-based O
practices O
. O
[]

The O
ability O
to O
discriminate O
between O
subjects O
with O
different O
levels O
of O
FEV B-outcome ['Physiological-Clinical']
( O
1 O
) O
was O
somewhat O
better O
for O
the O
SGRQ O
. O
['Physiological-Clinical']

Atrial O
natriuretic O
factor O
( O
ANF O
) O
has O
an O
inhibitory O
effect O
on O
angiotensin B-outcome ['Physiological-Clinical']
II I-outcome ['Physiological-Clinical']
and O
ACTH B-outcome ['Physiological-Clinical']
stimulated I-outcome ['Physiological-Clinical']
aldosterone I-outcome ['Physiological-Clinical']
secretion I-outcome ['Physiological-Clinical']
in O
man O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Integral O
part O
of O
the O
study O
was O
the O
monitoring O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
the O
treatment O
. O
['Adverse-effects']

OBJECTIVES O
To O
compare O
the O
efficacy O
and O
safety O
of O
fondaparinux O
in O
conjunction O
with O
intermittent O
pneumatic O
compression O
vs. O
intermittent O
pneumatic O
compression O
alone O
in O
this O
context O
. O
[]

All O
patients O
that O
were O
operated O
returned O
to O
full B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
. O
However, O
median O
duration B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
operation I-outcome ['Life-Impact']
was O
longer O
and O
lasted O
1 O
hour O
and O
55 O
minutes. O
[['Life-Impact'], ['Life-Impact']]

METHODS O
We O
conducted O
a O
prospective O
randomized O
clinical O
trial O
in O
126 O
patients O
scheduled O
for O
cardiac O
catheterization O
in O
a O
teaching O
hospital O
. O
[]

Journal-Name:Journal O
of O
the O
International O
Society O
of O
Sports O
Nutrition O
[]

Our O
data O
suggest O
that O
therapeutic O
doses O
of O
glucocorticoids O
induce O
obesity O
mostly O
by O
increasing O
energy B-outcome ['Life-Impact']
intake I-outcome ['Life-Impact']
, O
an O
effect O
which O
may O
be O
related O
to O
the O
ability O
of O
glucocorticoids O
to O
act O
directly O
or O
indirectly O
on O
the O
central O
regulation O
of O
appetite O
. O
['Life-Impact']

On O
subjective O
preference O
measures O
, O
parents O
and O
children O
favored O
the O
weighted O
blanket O
. O
[]

RESULTS O
The O
duration O
of O
hypoxemia B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
transcutaneous I-outcome ['Physiological-Clinical']
partial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
of O
O2 B-outcome ['Physiological-Clinical']
< O
6.6 O
kPa O
( O
< O
50 O
mm O
Hg O
) O
and/or O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
oxygen I-outcome ['Physiological-Clinical']
saturation B-outcome ['Physiological-Clinical']
< O
80 O
% O
) O
during O
treatment O
procedures O
was O
significantly O
longer O
in O
the O
saline O
group O
( O
mean O
82 O
vs O
36 O
seconds O
, O
P O
= O
.001 O
) O
and O
distress O
quantified O
by O
a O
novel O
behavioral O
scoring O
method O
was O
much O
higher O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
. O
[]

Prolonged O
infusion O
of O
low-dose O
gemcitabine O
and O
cisplatin O
( O
GC O
) O
proved O
to O
be O
an O
effective O
treatment O
for O
patients O
with O
advanced O
bladder O
cancer O
. O
[]

A O
significantly O
higher O
level O
of O
anxiety B-outcome ['Life-Impact']
was O
found O
in O
the O
experimental O
group O
on O
admission O
, O
but O
this O
difference O
became O
nonsignificant O
when O
baseline O
level O
and O
length O
of O
waiting O
time O
were O
entered O
as O
covariates O
. O
['Life-Impact']

A O
delay O
in O
initiating O
RTX O
treatment O
may O
result O
in O
increased O
PJD O
. O
[]

The O
current O
study O
will O
investigate O
the O
efficacy O
of O
group-based O
CBT O
for O
adults O
with O
ASD O
. O
[]

Attempts O
have O
also O
been O
made O
to O
remove O
proinflammatory O
cytokines O
, O
eicosanoides O
, O
and O
coagulative O
factors O
from O
the O
circulation O
in O
the O
human O
body O
. O
[]

RESULTS O
The O
ESDM O
group O
exhibited O
greater O
improvements O
in O
autism B-outcome ['Life-Impact']
symptoms B-outcome ['Life-Impact']
, O
['Life-Impact', 'Life-Impact']

The O
most O
consistent O
data O
with O
respect O
to O
micronutrient O
antioxidants O
and O
atherosclerosis O
appear O
to O
relate O
to O
alpha-tocopherol O
( O
AT O
) O
, O
the O
predominant O
lipid-soluble O
antioxidant O
in O
LDL O
. O
[]

All O
trainees O
performed O
their O
first O
ten O
individual O
colonoscopies O
described O
in O
detail O
in O
a O
separate O
protocol O
. O
[]

The O
value O
for O
the O
area O
under O
the O
concentration-time B-outcome ['Physiological-Clinical']
curve O
of O
rhG-CSF B-outcome ['Physiological-Clinical']
on O
the O
day O
of O
neutrophilia O
was O
lower O
than O
that O
on O
the O
day O
of O
neutropenia O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

treatment O
interaction O
was O
observed O
for O
Irritability O
( O
F O
( O
1.658 O
, O
63.021 O
) O
= O
13.580 O
, O
P O
< O
0.001 O
) O
, O
Lethargy/Social O
Withdrawal O
( O
F O
( O
1.948 O
, O
74.032 O
) O
= O
16.811 O
, O
P O
< O
0.001 O
) O
, O
and O
Stereotypic O
Behavior O
( O
F O
( O
1.742 O
, O
66.198 O
) O
= O
12.104 O
, O
P O
< O
0.001 O
) O
, O
but O
not O
for O
Hyperactivity/Noncompliance O
( O
F O
( O
2.564 O
, O
97.424 O
) O
= O
1.469 O
, O
P O
= O
0.232 O
) O
, O
and O
Inappropriate O
Speech O
subscales O
( O
F O
( O
1.607 O
, O
61.075 O
) O
= O
0.173 O
, O
P O
= O
0.794 O
) O
. O
[]

Importance: O
Multimodal O
postoperative O
analgesia O
is O
widely O
used O
but O
lacks O
evidence O
of O
benefit. O
[]

Despite O
numerous O
publications O
and O
clinical O
trials O
, O
the O
results O
of O
treatment O
of O
recalcitrant O
chronic O
plantar O
fasciitis O
with O
extracorporeal O
shockwave O
therapy O
( O
ESWT O
) O
still O
remain O
equivocal O
as O
to O
whether O
or O
not O
this O
treatment O
provides O
relief B-outcome ['Physiological-Clinical']
from O
the O
pain B-outcome ['Physiological-Clinical']
associated O
with O
this O
condition O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O
[]

Those O
factors O
include O
being O
of O
African-American O
race O
, O
having O
a O
preoperative O
intraocular O
pressure O
of O
20 O
mm O
Hg O
or O
more O
on O
maximum O
tolerated O
medications O
, O
and O
being O
on O
two O
or O
more O
medications O
preoperatively O
. O
[]

In O
aspirin-treated O
platelets O
, O
the O
aggregation O
capacity B-outcome ['Life-Impact']
induced O
by O
adenosine O
diphosphate O
was O
inhibited O
before O
the O
operation O
( O
p O
< O
0.05 O
) O
and O
showed O
substantial O
recovery O
during O
the O
operation O
( O
p O
< O
0.05 O
) O
. O
['Life-Impact']

V O
diagnosis O
of O
severe O
mental O
illness O
from O
psychiatric O
disability O
from O
10 O
supported O
housing O
facilities O
and O
41 O
of O
their O
caregivers O
participated O
in O
this O
12-month O
study O
during O
2005-2006 O
in O
Sweden O
. O
[]

RESULTS: O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
ejection I-outcome ['Physiological-Clinical']
fraction I-outcome ['Physiological-Clinical']
(LVEF) I-outcome ['Physiological-Clinical']
decreased O
from O
62+/-5% O
at O
baseline O
to O
58+/-7% O
at O
6-months O
(p=0.002) O
in O
patients O
assigned O
to O
placebo O
but O
no O
statistically O
significant O
changes O
were O
observed O
in O
any O
of O
the O
3 O
carvedilol O
groups. O
[['Physiological-Clinical']]

RESULTS O
Evaluation O
of O
all O
patients O
included O
global B-outcome ['Physiological-Clinical']
clinical I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
nephrotoxicity B-outcome ['Physiological-Clinical']
, O
as O
well O
as O
the O
economic B-outcome ['Resource-use']
costs I-outcome ['Resource-use']
and O
effectiveness O
derived O
from O
the O
vancomycin O
monitoring O
program O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Resource-use']

Despite O
an O
observed O
association O
between O
colonic O
inflammation O
and O
grade O
2 O
or O
higher O
diarrhea O
, O
no O
baseline O
biomarkers O
could O
reliably O
predict O
development O
of O
gastrointestinal O
toxicity O
. O
[]

Development O
of O
an O
adaptive O
low-pass O
filtered O
speech O
test O
for O
the O
identification O
of O
auditory B-outcome ['Physiological-Clinical']
processing I-outcome ['Physiological-Clinical']
disorders I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

for O
16 O
and O
12 O
wk O
separated O
by O
a O
6-month O
interval O
[ O
756 O
million O
units O
] O
) O
. O
[]

CONCLUSION O
Plasma O
endotoxin O
and O
cytokines O
( O
TNF-alpha O
, O
IL-1 O
beta O
, O
IL-6 O
and O
IL-8 O
) O
can O
be O
removed O
effectively O
with O
CRRT O
in O
severely O
burned O
patients O
with O
sepsis O
. O
[]

The O
hydration O
status O
was O
assessed O
with O
USG O
and O
body O
mass O
measures O
and O
urine O
volume O
collections O
. O
[]

At O
an O
individual O
initial O
visit O
the O
12 O
volunteers O
were O
introduced O
to O
the O
needle O
sensation O
by O
having O
a O
needle O
inserted O
into O
the O
point O
LI O
11 O
. O
[]

Monitoring O
with O
the O
bispectral O
index O
in O
those O
aged O
from O
1 O
to O
3 O
years O
revealed O
use O
of O
lower O
doses O
of O
midazolam O
, O
at O
2.09 O
mg O
per O
kg O
per O
hr O
, O
with O
standard O
deviation O
of O
0.36 O
, O
and O
similarly O
lowers O
doses O
of O
ketamine O
, O
at O
2.07 O
mg O
per O
kg O
per O
hr O
, O
with O
standard O
deviation O
of O
0.22 O
, O
the O
values O
in O
those O
not O
monitored O
being O
2.93 O
, O
with O
standard O
deviation O
of O
0.45 O
, O
and O
2.96 O
with O
standard O
deviation O
of O
0.51 O
respectively O
, O
these O
difference O
being O
statistically O
significant O
( O
p O
= O
0.001 O
and O
p O
= O
0.04 O
, O
respectively O
) O
. O
[]

Secondary O
outcomes O
were O
as O
follows O
: O
severity O
of O
immediate B-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
, O
as O
graded O
by O
a O
3-point O
scale O
from O
1 O
( O
no O
bleeding O
) O
to O
3 O
( O
injection O
or O
['Physiological-Clinical']

RESULTS O
Preoperative O
variables O
were O
the O
same O
in O
both O
groups O
. O
[]

We O
have O
measured O
serum B-outcome ['Physiological-Clinical']
prolactin I-outcome ['Physiological-Clinical']
levels O
during O
pyridoxine O
administration O
in O
two O
groups O
of O
hyperprolactinaemic O
subjects O
. O
['Physiological-Clinical']

Plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
, O
serum B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
, O
C B-outcome ['Physiological-Clinical']
peptide I-outcome ['Physiological-Clinical']
and O
lipids B-outcome ['Physiological-Clinical']
were O
measured O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Eighty-five O
ASA O
grade O
I O
or O
II O
patients O
( O
aged O
60-89 O
yr O
) O
for O
elective O
total O
hip O
replacement O
were O
randomized O
to O
receive O
500 O
mL O
crystalloid O
solution O
( O
Hartmanns O
, O
n O
= O
29 O
) O
, O
500 O
mL O
colloid O
( O
Haemaccel O
, O
n O
= O
28 O
) O
, O
or O
no O
prehydration O
( O
n O
= O
28 O
) O
over O
10 O
min O
prior O
to O
spinal O
anesthesia O
. O
[]

[ O
Radiotherapy O
for O
choroidal O
neovascularization O
in O
age-related O
macular O
degeneration O
. O
[]

Late-onset O
sepsis B-outcome ['Physiological-Clinical']
occurred O
in O
414 O
of O
1389 O
infants O
(29.8%) O
in O
the O
faster-increment O
group O
and O
434 O
of O
1397 O
(31.1%) O
in O
the O
slower-increment O
group O
(adjusted O
risk O
ratio, O
0.96; O
95% O
CI, O
0.86 O
to O
1.07). O
[['Physiological-Clinical']]

Videos O
representing O
movements O
were O
shown O
in O
full O
before O
experimental O
trials O
; O
the O
actual O
tasks O
consisted O
of O
watching O
the O
same O
videos O
, O
but O
interrupted O
after O
a O
variable O
interval O
( O
'pre-dark O
' O
) O
from O
its O
onset O
by O
a O
dark O
interval O
of O
variable O
duration O
. O
[]

We O
performed O
a O
subset O
analysis O
of O
73 O
patients O
who O
underwent O
pancreatectomy. O
[]

resected O
prostate O
was O
calculated O
( O
2.65 O
versus O
4.65 O
gm O
. O
[]

Complications B-outcome ['Adverse-effects']
, O
for O
both O
groups O
were O
similar O
with O
30% O
in O
proposed O
drainage O
and O
25% O
in O
traditional O
approach O
(p=0.723). O
[['Adverse-effects']]

Eighty-seven O
were O
enrolled O
and O
randomized O
. O
[]

OBJECTIVES O
Conventional O
neuroleptics O
ameliorate O
symptoms O
in O
children O
with O
autistic O
disorder O
; O
however O
, O
they O
are O
known O
to O
cause O
dyskinesias O
. O
[]

Checklist O
ratings O
did O
not O
show O
significant O
changes O
. O
[]

CONCLUSIONS O
A O
prepackaged O
low O
residue O
one-day O
diet O
provided O
cleansing B-outcome ['Physiological-Clinical']
efficacy O
similar O
to O
that O
of O
a O
clear O
liquid O
diet O
and O
offered O
the O
benefit O
of O
improved O
tolerability B-outcome ['Life-Impact']
compared O
to O
the O
conventional O
PEG O
4L O
regimen O
. O
['Physiological-Clinical', 'Life-Impact']

Patients O
performed O
under O
general O
anesthesia O
( O
n O
= O
35 O
) O
were O
separated O
as O
a O
nasogastric O
tube O
for O
visualization O
of O
the O
esophagus O
was O
used O
. O
[]

Conclusion O
We O
demonstrated O
the O
feasibility B-outcome ['Life-Impact']
and O
acceptability B-outcome ['Life-Impact']
of O
the O
use O
of O
a O
robotic O
walking O
aid O
from O
the O
perspective O
of O
both O
older O
individuals O
and O
physiotherapists. O
[['Life-Impact'], ['Life-Impact']]

METHODS: O
A O
single-blind O
randomized O
controlled O
trial O
was O
performed. O
[]

Effect O
of O
postural O
supports O
on O
neuromotor B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
in O
very O
preterm O
infants O
to O
term O
equivalent O
age O
. O
['Physiological-Clinical']

RESULTS O
Over O
half O
of O
the O
carers O
reported O
some O
MH B-outcome ['Physiological-Clinical']
problems I-outcome ['Physiological-Clinical']
and O
a O
minority O
( O
5.4 O
% O
) O
were O
experiencing O
considerable O
difficulties O
. O
['Physiological-Clinical']

Trandolapril O
2 O
mg O
once O
daily O
is O
an O
effective O
antihypertensive O
agent O
, O
comparable O
to O
HCTZ O
. O
[]

RESULTS O
A O
smoker O
was O
present O
in O
37.5 O
% O
of O
homes O
. O
[]

plus O
omeprazole O
20 O
mg O
b.d. O
, O
dirithromycin O
1000 O
mg O
q.d.s O
. O
[]

METHODS O
This O
23-day O
, O
prospective O
, O
double-blind O
, O
randomized O
, O
parallel-group O
study O
was O
conducted O
at O
3 O
Colombian O
centers O
: O
University O
Libre O
, O
Social O
Security O
Institute O
, O
and O
General O
Hospital O
of O
Medell?n O
, O
Cali O
, O
Colombia O
. O
[]

All O
three O
regimens O
were O
well O
tolerated B-outcome ['Life-Impact']
. O
['Life-Impact']

Again O
chronic O
renal O
failure O
patients O
showed O
PRL B-outcome ['Physiological-Clinical']
plasma I-outcome ['Physiological-Clinical']
values I-outcome ['Physiological-Clinical']
abnormally O
elevated O
till O
the O
end O
of O
the O
test O
. O
['Physiological-Clinical']

Active O
treatment O
produced O
similar O
relative O
risk O
reductions O
for O
the O
primary O
outcome O
, O
major B-outcome ['Physiological-Clinical']
macrovascular I-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
, O
death B-outcome ['Mortality']
and O
renal B-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
across O
age O
groups O
( O
all O
P O
heterogeneity O
> O
0.3 O
) O
. O
['Physiological-Clinical', 'Mortality', 'Physiological-Clinical']

There O
were O
no O
significant O
differences O
between O
treatment O
arms O
for O
time O
to O
onset O
of O
neuropathy O
( O
P O
= O
0.58 O
) O
, O
for O
chemotherapy O
dose O
reductions O
due O
to O
neuropathy O
( O
P O
= O
0.21 O
) O
, O
or O
for O
secondary O
endpoints O
derived O
from O
patient-reported O
neuropathy O
symptom O
assessments O
. O
[]

The O
sample O
consisted O
of O
182 O
prenatal O
Vietnamese O
women O
. O
[]

Metabolism O
of O
enflurane O
resulted O
in O
plasma B-outcome ['Physiological-Clinical']
inorganic I-outcome ['Physiological-Clinical']
fluoride I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
( O
max O
15 O
mumol O
litre O
-1 O
) O
which O
were O
well O
below O
the O
toxic O
value O
. O
['Physiological-Clinical']

The O
intervention O
period O
was O
from O
April O
1 O
to O
July O
31, O
2011 O
and O
April O
1 O
to O
July O
31, O
2012. O
[]

RESULTS O
No O
significant O
differences O
were O
found O
between O
study O
arms O
at O
3 O
months O
in O
number O
of O
male B-outcome ['Life-Impact']
partners I-outcome ['Life-Impact']
, O
number O
of O
unprotected B-outcome ['Life-Impact']
anal B-outcome ['Life-Impact']
intercourse I-outcome ['Life-Impact']
partners I-outcome ['Life-Impact']
, O
proportion O
reporting O
unprotected B-outcome ['Life-Impact']
sex I-outcome ['Life-Impact']
, O
number O
of O
acts B-outcome ['Life-Impact']
protected O
by O
condoms B-outcome ['Life-Impact']
, O
self-efficacy B-outcome ['Life-Impact']
, O
condom B-outcome ['Life-Impact']
attitudes I-outcome ['Life-Impact']
, O
condom B-outcome ['Life-Impact']
intentions I-outcome ['Life-Impact']
, O
social B-outcome ['Life-Impact']
isolation I-outcome ['Life-Impact']
and O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

RESULTS O
The O
cumulative O
probability O
of O
cure O
was O
significantly O
( O
P O
< O
0.001 O
) O
different O
in O
children O
receiving O
GB O
for O
both O
acute O
[ O
hazard O
ratio O
( O
HR O
) O
= O
0.63 O
( O
95 O
% O
CI O
: O
0.56-0.67 O
) O
] O
and O
prolonged O
diarrhoea O
[ O
HR O
= O
0.38 O
( O
95 O
% O
CI O
: O
0.26-0.59 O
) O
] O
. O
[]

Effects O
of O
10 O
Hz O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rTMS O
) O
on O
clinical O
global O
impression O
in O
chronic O
schizophrenia O
. O
[]

hsCRP O
measurement O
should O
be O
performed O
early O
after O
presentation O
and O
index O
diagnosis-specific O
cutpoints O
should O
be O
used O
. O
[]

At O
baseline O
and O
12-month O
follow-up, O
ocular O
exams O
for O
trachoma B-outcome ['Physiological-Clinical']
, O
ocular O
swabs O
for O
detection O
of O
chlamydial B-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
, O
and O
finger O
prick O
blood O
for O
analysis O
of O
anti-chlamydial B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
were O
taken. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

TSB B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
at O
regular O
intervals O
. O
['Physiological-Clinical']

Effect O
of O
systemic O
nitric O
oxide O
synthase O
inhibition O
on O
postexercise O
hypotension O
in O
humans O
. O
[]

Topical O
capsaicin O
has O
been O
found O
to O
be O
efficacious O
in O
several O
types O
of O
neuropathic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

The O
injection O
regimen O
was O
changed O
in O
every O
patient O
every O
two O
months O
, O
from O
36 O
U/kg O
once O
to O
18 O
U/kg O
twice O
and O
12 O
U/kg O
three O
times O
, O
intravenously O
. O
[]

Induced O
sputum B-outcome ['Physiological-Clinical']
differential I-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
counts I-outcome ['Physiological-Clinical']
were O
obtained O
at O
baseline O
and O
at O
five O
further O
visits O
. O
['Physiological-Clinical']

Title: O
Study O
on O
the O
safety O
of O
Polygala O
tenuifolia O
Willdenow O
root O
extract O
powder O
(BT-11) O
in O
young O
person O
aged O
from O
9 O
to O
19 O
years O
old. O
[]

In O
contrast O
, O
lathosterol/TC O
unchanged O
and O
campesterol/TC O
increased O
, O
increasing O
campesterol/lathosterol O
ratio O
for O
52 O
weeks O
in O
double-dose O
statin O
. O
[]

Nonfasting B-outcome ['Physiological-Clinical']
serum I-outcome ['Physiological-Clinical']
lipid I-outcome ['Physiological-Clinical']
and O
lipoproteins B-outcome ['Physiological-Clinical']
and O
plasma B-outcome ['Physiological-Clinical']
tHcy I-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
cysteine I-outcome ['Physiological-Clinical']
levels O
were O
measured O
in O
the O
children O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

EEG- O
and O
SC-biofeedback O
sessions O
were O
similar O
and O
participants O
were O
blinded O
to O
the O
type O
of O
feedback O
they O
received O
. O
[]

Students O
will O
be O
randomised O
to O
four O
groups O
, O
completing O
the O
four O
VP O
topics O
in O
the O
same O
order O
, O
but O
with O
each O
group O
exposed O
to O
a O
different O
VP O
design O
sequentially O
. O
[]

OBJECTIVE O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
inhaled O
fluticasone O
propionate O
powder O
in O
patients O
with O
moderate O
asthma O
previously O
treated O
with O
an O
inhaled O
corticosteroid O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Magnetic O
resonance O
angiography O
for O
monitoring O
prophylactic O
endoscopic O
treatment O
of O
high O
risk O
esophageal O
varices O
. O
[]

n O
= O
77 O
) O
received O
therapy O
with O
dressing O
changes O
every O
48 O
hours O
. O
[]

RESULTS: O
After O
4-week O
treatment, O
the O
patients O
undergoing O
verum O
TENS O
showed O
statistically O
efficacy O
of O
symptoms B-outcome ['Physiological-Clinical']
relief, O
as O
measured O
by O
the O
scales O
of O
Tinnitus B-outcome ['Physiological-Clinical']
Severity I-outcome ['Physiological-Clinical']
Scale O
(TSS) O
(P O
< O
.01), O
Tinnitus B-outcome ['Physiological-Clinical']
Questionnaire O
(TQ) O
(P O
< O
.01), O
and O
Tinnitus B-outcome ['Physiological-Clinical']
Handicap I-outcome ['Physiological-Clinical']
Inventory O
(THI)], O
(P O
< O
.01), O
and O
improvement O
of O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
, O
as O
assessed O
by O
the O
SF-12 O
(P O
< O
.01), O
compared O
with O
patients O
receiving O
sham O
TENS. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Life-Impact']]

During O
phase O
2 O
, O
a O
4-day O
double-blind O
challenge O
period O
, O
subjects O
wore O
active O
and O
placebo O
systems O
concurrently O
. O
[]

Journal O
ID: O
101213729 O
[]

Therefore O
, O
a O
proved O
contact O
allergen O
was O
shown O
to O
be O
required O
for O
therapeutic O
success O
. O
[]

Therefore O
, O
we O
conclude O
that O
4-week O
H-AT O
intervention O
reduced O
senescent O
T-lymphocyte O
subsets O
with O
increasing O
IFN-? O
level O
in O
blood O
, O
which O
responses O
are O
accompanied O
by O
depressed O
oxidative O
stress O
and O
pro-inflammatory O
cytokine O
production O
. O
[]

METHODS O
A O
total O
of O
34 O
children O
( O
6-18 O
years O
) O
with O
allergic O
asthma O
were O
assigned O
to O
cluster O
( O
n O
= O
22 O
) O
or O
classic O
SIT O
( O
n O
= O
12 O
) O
. O
[]

UNLABELLED O
The O
purpose O
of O
this O
randomized O
crossover O
trial O
was O
to O
determine O
the O
effects O
on O
autonomic O
responses O
in O
preterm O
infants O
of O
longer O
Kangaroo O
Care O
( O
30 O
minutes O
, O
KC30 O
) O
and O
shorter O
KC O
( O
15 O
minutes O
, O
KC15 O
) O
before O
and O
throughout O
heel O
stick O
compared O
with O
incubator O
care O
( O
IC O
) O
. O
[]

Patients O
randomized O
to O
CDDP/FU O
also O
received O
CDDP O
20 O
mg/m2 O
intravenous O
( O
IV O
) O
bolus O
on O
days O
1 O
to O
5 O
of O
each O
cycle O
. O
[]

Four O
different O
doses O
of O
recombinant O
human O
porphobilinogen O
deaminase O
were O
studied O
( O
0.5 O
, O
1 O
, O
2 O
and O
4 O
mg/kg O
bodyweight O
) O
. O
[]

and O
salbutamol O
200 O
microg O
p.r.n O
. O
[]

Bismuth O
subsalicylate O
in O
the O
treatment O
of O
gastritis O
due O
to O
Campylobacter O
pylori O
. O
[]

Objective: O
To O
assess O
whether O
EEG-guided O
anesthetic O
administration O
decreases O
the O
incidence O
of O
postoperative O
delirium B-outcome ['Physiological-Clinical', 'Life-Impact']
. O
Design, O
Setting, O
and O
Participants: O
Randomized O
clinical O
trial O
of O
1232 O
adults O
aged O
60 O
years O
and O
older O
undergoing O
major O
surgery O
and O
receiving O
general O
anesthesia O
at O
Barnes-Jewish O
Hospital O
in O
St O
Louis. O
[['Physiological-Clinical', 'Life-Impact']]

The O
effectiveness O
of O
omeprazole O
, O
clarithromycin O
and O
tinidazole O
in O
eradicating B-outcome ['Physiological-Clinical']
Helicobacter I-outcome ['Physiological-Clinical']
pylori I-outcome ['Physiological-Clinical']
in O
a O
community O
screen O
and O
treat O
programme O
. O
['Physiological-Clinical']

Basal B-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
and O
vascular B-outcome ['Physiological-Clinical']
conductance I-outcome ['Physiological-Clinical']
increased O
by O
55-60 O
% O
after O
strength O
training O
( O
both O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

More O
recently O
, O
magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
been O
proposed O
as O
an O
equivalent O
method O
, O
but O
this O
has O
not O
yet O
been O
fully O
validated O
. O
[]

The O
analgesic B-outcome ['Resource-use']
effect O
of O
1,2,6-IP3 O
was O
evaluated O
in O
a O
double-blind O
, O
randomized O
study O
in O
24 O
patients O
undergoing O
cholecystectomy O
. O
['Resource-use']

RESULTS O
The O
FEV1 B-outcome ['Physiological-Clinical']
, O
FVC B-outcome ['Physiological-Clinical']
, O
FEV1/FVC B-outcome ['Physiological-Clinical']
( O
% O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Patients O
most O
likely O
to O
improve O
with O
treatment O
tended O
to O
be O
younger O
and O
nonobese O
and O
have O
the O
greatest O
limitations O
initially O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
dopexamine O
, O
an O
inodilator O
drug O
, O
on O
hemodynamic O
and O
splanchnic O
perfusion O
with O
measurement O
of O
gastric O
intramucosal O
pH O
, O
by O
the O
method O
of O
gastric O
tonometry O
, O
during O
abdominal O
aneurysm O
resection O
. O
[]

The O
minimal O
bleeding O
event O
rate O
is O
higher O
than O
reported O
but O
does O
not O
seem O
to O
affect O
adherence O
to O
treatment O
. O
[]

Changes O
in O
motor O
cortex O
excitability O
associated O
with O
temporal O
repetitive O
transcranial O
magnetic O
stimulation O
in O
tinnitus O
: O
hints O
for O
cross-modal O
plasticity O
? O
[]

Additionally O
at O
6 O
week O
review O
the O
time O
to O
return O
to O
work O
was O
recorded O
and O
an O
endoanal B-outcome ['Resource-use']
ultrasound I-outcome ['Resource-use']
was O
carried O
out O
. O
['Resource-use']

Risk O
of O
infection O
after O
penetrating O
abdominal O
trauma O
. O
[]

The O
median O
ventilation O
time O
( O
14 O
hours O
versus O
13 O
hours O
) O
, O
median O
catecholamine O
dose O
, O
frequency O
of O
dialysis-dependent O
acute B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
( O
28 O
% O
versus O
18 O
% O
) O
, O
cardiac O
indices O
, O
and O
frequency O
of O
a O
low O
cardiac O
output O
syndrome O
( O
26 O
% O
versus O
25 O
% O
) O
did O
not O
significantly O
differ O
between O
groups O
. O
['Physiological-Clinical']

CONCLUSIONS O
Cognitive O
functioning O
in O
MS O
is O
independent O
of O
fatigue O
. O
[]

OBJECTIVE O
To O
address O
the O
hypothesis O
that O
multiphasic O
oral O
contraceptives O
( O
OCs O
) O
increase O
rather O
than O
decrease O
the O
risk O
of O
functional B-outcome ['Physiological-Clinical']
ovarian I-outcome ['Physiological-Clinical']
cysts I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
significant O
difference O
in O
excretion O
of O
PGE-M O
between O
the O
sexes O
was O
observed O
in O
the O
pre-pubertal O
age-grou O
( O
male O
: O
2.9 O
+/- O
0.8 O
mug/24 O
hours O
, O
n=5 O
; O
female O
: O
3.1 O
+/- O
0.9 O
mug/24 O
hours O
, O
n=5 O
) O
or O
in O
the O
age-group O
of O
45-80 O
years O
( O
male O
: O
9.3 O
+/- O
1.1 O
mug/24 O
hours O
, O
n=21 O
; O
female O
: O
7.3 O
+/- O
0.9 O
mug/24 O
hours O
, O
n=12 O
) O
. O
[]

RESULTS O
Disability B-outcome ['Life-Impact']
, O
depression B-outcome ['Life-Impact']
, O
and O
visual O
analog O
scale O
scores O
decreased O
significantly O
after O
both O
treatments O
. O
['Life-Impact', 'Life-Impact']

It O
may O
be O
either O
binocular O
eye O
position O
, O
or O
the O
position O
of O
the O
viewing-eye O
only O
, O
that O
is O
crucial O
. O
[]

An O
open O
, O
randomized O
study O
evaluated O
the O
immune B-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
safety O
of O
two O
different O
regimens O
of O
diphtheria-tetanus-acellular O
pertussis-hepatitis O
B-inactivated O
poliovirus-Haemophilus O
influenzae O
type O
b O
( O
DTPa-HBV-IPV-Hib O
) O
immunization O
in O
infants O
primed O
at O
birth O
with O
hepatitis O
B O
vaccine O
. O
['Physiological-Clinical']

OBJECTIVE O
Transthoracic B-outcome ['Physiological-Clinical']
impedance I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
TTI I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
a O
factor O
determining O
the O
magnitude O
of O
the O
transmyocardial O
current O
during O
external O
defibrillation O
. O
['Physiological-Clinical']

The O
primary O
outcome O
measure O
was O
cardiovascular B-outcome ['Mortality']
mortality I-outcome ['Mortality']
. O
['Mortality']

The O
use O
of O
sedation O
of O
moderate O
depth O
renders O
cardioversion O
by O
either O
approach O
acceptable O
. O
[]

Estimates O
of O
respiratory O
and O
heart O
rate O
power O
spectra O
and O
linear O
transfer O
functions O
between O
the O
two O
groups O
were O
generated O
by O
Fourier O
analysis O
. O
[]

They O
prepared O
Class O
I O
, O
III O
and O
V O
cavities O
, O
placed O
resin O
restorations O
and O
evaluated O
subjects O
on O
the O
day O
of O
the O
procedure O
and O
30 O
days O
and O
six O
months O
postoperatively O
for O
pulp B-outcome ['Physiological-Clinical']
vitality I-outcome ['Physiological-Clinical']
, O
recurrent B-outcome ['Physiological-Clinical']
caries I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical']
and O
discomfort B-outcome ['Physiological-Clinical']
, O
and O
restoration B-outcome ['Physiological-Clinical']
retention I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

METHODS O
We O
conducted O
a O
double-blind O
, O
placebo-controlled O
trial O
of O
a O
single O
intravenous O
dose O
of O
synthetic O
human O
secretin O
in O
60 O
children O
( O
age O
, O
3 O
to O
14 O
years O
) O
with O
autism O
or O
pervasive O
developmental O
disorder O
. O
[]

This O
is O
possibly O
due O
to O
the O
fact O
that O
either O
subacromial O
tissue O
, O
despite O
of O
chronic O
inflammation O
, O
does O
not O
show O
the O
same O
reagibility O
as O
synovia O
or O
it O
is O
a O
problem O
of O
the O
nearly O
complete O
resection O
of O
the O
subacromial O
bursa O
. O
[]

CONCLUSION O
Omission O
of O
the O
bladder O
flap O
at O
primary O
and O
repeat O
cesarean O
deliveries O
does O
not O
increase O
intraoperative O
or O
postoperative O
complications O
. O
[]

Treatment O
consisted O
of O
a O
16-week O
group O
intervention O
designed O
to O
teach O
appropriate O
social O
behavior O
. O
[]

Vulvar B-outcome ['Physiological-Clinical']
irritation I-outcome ['Physiological-Clinical']
was O
seen O
in O
seven O
of O
these O
10 O
volunteers O
. O
['Physiological-Clinical']

PATIENTS O
Sixty-two O
women O
with O
symptomatic O
uterine O
myomas O
( O
size O
16-20 O
wks O
) O
. O
[]

Induction O
time O
was O
prolonged O
in O
the O
group O
E1 O
compared O
to O
the O
other O
two O
groups O
( O
P O
< O
0.05 O
) O
. O
[]

BACKGROUND: O
Medical O
researchers O
have O
been O
reluctant O
to O
use O
neuromuscular O
blocking O
drugs O
(NMBD) O
during O
the O
use O
of O
intraoperative O
motor O
evoked O
potential O
(MEP) O
monitoring O
despite O
the O
possibility O
of O
patient O
movement. O
[]

Moreover O
, O
the O
increased O
level O
of O
HMGB1 O
exhibited O
in O
a O
late O
stage O
of O
CCI O
was O
inhibited O
by O
exogenous O
overexpression O
of O
hIL-10 O
in O
the O
CCI O
model O
. O
[]

For O
all O
secondary O
efficacy O
parameter O
results O
were O
similar O
. O
- O
[]

RESULTS O
Between O
April O
2005 O
and O
February O
2006 O
, O
a O
total O
of O
918 O
patients O
were O
enrolled O
. O
[]

A O
high O
proportion O
of O
first-time O
donors O
indicated O
that O
they O
had O
experienced O
a O
reaction O
to O
blood O
donation O
. O
[]

The O
efficacy O
and O
safety O
indices O
were O
evaluated O
at O
the O
baseline O
and O
24 O
weeks O
after O
treatment O
, O
including O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
, O
condition B-outcome ['Physiological-Clinical']
assessment O
, O
Health B-outcome ['Physiological-Clinical']
Assessment O
Questionnaire O
( O
HAQ O
) O
, O
disease B-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
index O
28 O
( O
DAS28 O
) O
, O
laboratory B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
erythrocyte I-outcome ['Physiological-Clinical']
sedimentation B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
ESR I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
and O
C-reactive B-outcome ['Physiological-Clinical']
protein I-outcome ['Physiological-Clinical']
( B-outcome ['Physiological-Clinical']
CRP I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
, O
safety O
indicators O
, O
and O
Chinese O
medical O
syndrome B-outcome ['Physiological-Clinical']
integrals O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

With O
infliximab O
treatment O
, O
SDAI O
and O
CDAI O
remission O
rates O
were O
of O
the O
same O
magnitude O
as O
those O
observed O
with O
tocilizumab O
treatment O
, O
and O
DAS28 O
remission O
rates O
were O
lower O
. O
[]

CONCLUSIONS O
Acupuncture O
of O
CV24 O
is O
an O
easy O
to O
apply O
and O
effective O
method O
to O
reduce O
gag B-outcome ['Physiological-Clinical']
reflex I-outcome ['Physiological-Clinical']
during O
TEE O
. O
['Physiological-Clinical']

The O
geometric O
mean O
titer O
( O
GMT O
) O
values O
ranged O
from O
group O
0.027-0.117 O
IU O
ml O
( O
-1 O
) O
in O
the O
Erig O
group O
and O
from O
0.029 O
to O
0.072 O
IU O
ml O
( O
-1 O
) O
in O
the O
PHT-Erig O
. O
[]

However O
, O
WL O
alone O
did O
not O
alter O
C1 O
and O
C2 O
. O
[]

Ropinirole O
as O
a O
treatment O
of O
restless O
legs O
syndrome O
in O
patients O
on O
chronic O
hemodialysis O
: O
an O
open O
randomized O
crossover O
trial O
versus O
levodopa O
sustained O
release O
. O
[]

Correlational O
analyses O
showed O
that O
attention O
to O
the O
Eye O
area O
of O
unfamiliar O
and O
Self O
Faces O
was O
related O
to O
socio-communicative O
ability O
in O
children O
with O
ASD O
. O
[]

CONCLUSION O
Patients O
who O
experience O
virologic B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
with O
a O
regimen O
of O
lamivudine O
150 O
mg O
BID O
in O
combination O
with O
stavudine/PI O
can O
maintain O
that O
suppression B-outcome ['Physiological-Clinical']
by O
continuing O
their O
regimen O
or O
switching O
to O
lamivudine O
300 O
mg O
QD O
and O
continuing O
the O
other O
components O
. O
['Physiological-Clinical', 'Physiological-Clinical']

In O
all O
, O
90.5 O
% O
of O
parents O
indicated O
that O
they O
would O
definitely O
recommend O
the O
clinical O
trial O
to O
other O
families O
with O
similar O
children O
. O
[]

The O
mean O
[]

Until O
now O
, O
4 O
patients O
in O
the O
Chinese O
herb O
group O
, O
one O
in O
the O
control O
group O
are O
still O
enjoying O
their O
[]

No O
patient O
experienced O
virologic O
failure O
, O
clinical O
disease O
progression O
, O
or O
a O
drug-related B-outcome ['Adverse-effects']
serious I-outcome ['Adverse-effects']
adverse I-outcome ['Adverse-effects']
event I-outcome ['Adverse-effects']
during O
the O
trial O
. O
['Adverse-effects']

Nineteen O
children O
( O
8 O
male O
, O
11 O
female O
) O
with O
a O
median O
age O
5.9 O
years O
( O
range O
2.6-13 O
years O
) O
were O
recruited O
into O
the O
study O
. O
[]

We O
used O
transcranial O
magnetic O
stimulation O
( O
TMS O
) O
to O
evaluate O
the O
effect O
of O
single O
doses O
of O
amantadine O
on O
human O
motor O
cortex B-outcome ['Physiological-Clinical']
excitability O
in O
normal O
subjects O
. O
['Physiological-Clinical']

Acceptability B-outcome ['Life-Impact']
data O
were O
explored O
with O
respect O
to O
whether O
any O
differences O
may O
be O
attributed O
to O
demographics O
and O
symptom O
and O
quality-of-life B-outcome ['Life-Impact']
levels O
, O
such O
as O
depression B-outcome ['Life-Impact']
and O
cognitive O
and O
emotional B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']

Safety O
analysis O
demonstrated O
no O
dose-dependent O
increase O
in O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
, O
and O
no O
drug-related O
increase O
in O
daytime O
somnolence B-outcome ['Physiological-Clinical']
was O
observed O
. O
['Adverse-effects', 'Physiological-Clinical']

RESULTS O
The O
exercise O
class O
group O
improved O
from O
a O
mean O
Constant O
score O
of O
39.8 O
at O
baseline O
to O
71.4 O
at O
6 O
weeks O
and O
88.1 O
at O
1 O
year O
. O
[]

As O
part O
of O
the O
large-scale O
assessment O
of O
sibenadet O
, O
a O
12-month O
safety O
study O
has O
been O
conducted O
. O
[]

We O
found O
that O
, O
with O
comparable O
degrees O
of O
neuromuscular B-outcome ['Physiological-Clinical']
block I-outcome ['Physiological-Clinical']
, O
the O
onset O
time O
of O
succinylcholine O
at O
the O
adductor O
pollicis O
was O
significantly O
shorter O
( O
P O
< O
0.01 O
) O
than O
for O
rocuronium O
0.6 O
mg O
kg-1 O
and O
0.9 O
mg O
kg-1 O
( O
EMG O
, O
80 O
+/- O
39 O
vs O
145 O
+/- O
48 O
s O
and O
99 O
+/- O
31 O
s O
; O
AMG O
, O
90 O
+/- O
39 O
vs O
124 O
+/- O
53 O
s O
and O
106 O
+/- O
38 O
s O
) O
. O
['Physiological-Clinical']

Arm O
A O
was O
started O
at O
the O
26th O
postoperative O
day O
and O
arm O
B O
at O
the O
21st O
day O
on O
average O
. O
[]

Coronary O
arteriography O
was O
performed O
at O
baseline O
and O
at O
15 O
, O
30 O
, O
45 O
, O
60 O
, O
75 O
, O
and O
90 O
minutes O
after O
drug O
infusion O
. O
[]

A O
total O
of O
118 O
subjects O
were O
randomly O
allocated O
to O
receive O
SJW O
300 O
mg O
, O
600 O
mg O
, O
or O
a O
matching O
placebo O
tablet O
3 O
times O
a O
day O
combined O
with O
a O
behavioral O
intervention O
for O
12 O
weeks O
. O
[]

METHODS O
Theories O
of O
behaviour B-outcome ['Life-Impact']
change I-outcome ['Life-Impact']
have O
been O
used O
to O
identify O
key O
theoretical O
domains O
relevant O
to O
the O
behaviours O
of O
healthcare O
providers O
involved O
in O
implementing O
clinical O
guidelines O
. O
['Life-Impact']

RESULTS O
A O
total O
of O
55 O
patients O
completed O
the O
study O
. O
[]

RESULTS O
On O
d O
3 O
, O
C-peptide B-outcome ['Physiological-Clinical']
was O
more O
than O
10-fold O
lower O
( O
P O
< O
0.0001 O
) O
in O
the O
IIT O
group O
than O
in O
the O
CIT O
group O
. O
['Physiological-Clinical']

We O
obtained O
toxicity B-outcome ['Adverse-effects']
data O
using O
an O
adverse-event O
reporting O
system O
, O
with O
follow-up O
questionnaires O
to O
seek O
detailed O
information O
for O
specific O
toxicities O
. O
['Adverse-effects']

The O
CI O
for O
each O
efficacy O
variable O
fell O
within O
the O
predefined O
equivalence O
ranges O
( O
pain O
, O
+/- O
75 O
mm O
; O
physical O
function O
, O
+/- O
255 O
mm O
; O
PGA O
, O
+/- O
20 O
mm O
) O
, O
indicating O
that O
no O
clinically O
relevant O
difference O
was O
found O
between O
the O
2 O
treatment O
arms O
. O
[]

The O
three O
levels O
correspond O
to O
a O
simplified O
hierarchy O
of O
controls O
. O
[]

Subgroup O
analysis O
by O
sex O
, O
age O
, O
and O
body O
mass O
index O
showed O
comparable O
outcomes O
between O
the O
two O
groups O
except O
that O
the O
[]

Probiotics O
prevent O
IgE-associated O
allergy O
until O
age O
5 O
years O
in O
cesarean-delivered O
children O
but O
not O
in O
the O
total O
cohort O
. O
[]

Detailed O
assessment O
of O
drug O
safety O
, O
biochemical B-outcome ['Physiological-Clinical']
and O
haematological B-outcome ['Physiological-Clinical']
parameters I-outcome ['Physiological-Clinical']
, O
and O
efficacy O
was O
made O
at O
these O
dates O
. O
['Physiological-Clinical', 'Physiological-Clinical']

has O
no O
statistically O
significant O
effect O
on O
the O
improvement O
of O
the O
visual B-outcome ['Physiological-Clinical']
acuity I-outcome ['Physiological-Clinical']
and O
the O
fluorescein B-outcome ['Physiological-Clinical']
angiographic I-outcome ['Physiological-Clinical']
findings I-outcome ['Physiological-Clinical']
in O
Behcet O
's O
patients O
with O
CMO O
. O
['Physiological-Clinical', 'Physiological-Clinical']

METHODS O
The O
concentrations O
of O
recombinant B-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
porphobilinogen I-outcome ['Physiological-Clinical']
deaminase B-outcome ['Physiological-Clinical']
and O
titres B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
antibodies I-outcome ['Physiological-Clinical']
against I-outcome ['Physiological-Clinical']
recombinant I-outcome ['Physiological-Clinical']
human I-outcome ['Physiological-Clinical']
porphobilinogen B-outcome ['Physiological-Clinical']
deaminase I-outcome ['Physiological-Clinical']
were O
analysed O
by O
ELISA O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

At O
the O
beginning O
of O
the O
trial O
, O
all O
patients O
were O
also O
randomised O
between O
late O
intensification O
alone O
and O
both O
early O
plus O
late O
blocks O
. O
[]

No O
cases O
in O
the O
other O
two O
groups O
encountered O
this O
problem O
. O
[]

increase O
of O
A O
beta O
40 O
was O
7.0 O
pg/ml O
( O
8.4 O
) O
in O
the O
vitamin O
group O
( O
4.9 O
% O
) O
, O
and O
26.8 O
pg/ml O
( O
7.7 O
) O
( O
18.5 O
% O
) O
in O
the O
placebo O
group O
. O
[]

RESULTS O
The O
mean O
follow-up O
for O
the O
overall O
cohort O
was O
27 O
months O
. O
[]

PATIENTS O
Seven O
healthy O
men O
and O
women O
. O
[]

CONCLUSION O
The O
addition O
of O
vancomycin O
to O
heparin O
CVC O
flush O
solution O
did O
not O
reduce O
bacteremia B-outcome ['Physiological-Clinical']
with O
vancomycin-susceptible O
organisms O
. O
['Physiological-Clinical']

On O
the O
whole O
, O
ofloxacin O
was O
well O
tolerated B-outcome ['Life-Impact']
by O
our O
patients O
. O
['Life-Impact']

Neither O
the O
distribution O
of O
the O
patients O
among O
Lown B-outcome ['Physiological-Clinical']
classification O
nor O
the O
Final O
Score O
of O
the O
Italian O
['Physiological-Clinical']

There O
were O
29 O
cardiac O
deaths O
. O
[]

After O
8 O
weeks O
of O
risperidone O
, O
prolactin B-outcome ['Physiological-Clinical']
increased O
to O
39.0 O
+/- O
19.2 O
ng/ml O
, O
compared O
with O
10.1 O
+/- O
8.8 O
ng/ml O
for O
placebo O
( O
p O
< O
.0001 O
) O
. O
['Physiological-Clinical']

All O
initial O
responders O
remained O
HCV B-outcome ['Physiological-Clinical']
RNA I-outcome ['Physiological-Clinical']
negative O
throughout O
the O
treatment O
period O
. O
['Physiological-Clinical']

Recombinant O
HBV O
vaccine O
induced O
better O
long O
term O
[]

Homeopaths O
and O
the O
conventional O
medical O
provider O
rated O
their O
Clinical B-outcome ['Physiological-Clinical']
Global I-outcome ['Physiological-Clinical']
Impression I-outcome ['Physiological-Clinical']
( O
CGI B-outcome ['Physiological-Clinical']
) O
of O
the O
severity B-outcome ['Physiological-Clinical']
of O
illness B-outcome ['Physiological-Clinical']
( O
1 O
= O
normal O
; O
7 O
= O
among O
the O
most O
extremely O
ill O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Compared O
to O
MIIT O
and O
CG, O
participants O
of O
the O
HIIT O
group O
showed O
significant O
post-intervention O
improvements O
in O
BMI B-outcome ['Physiological-Clinical']
(p=.002 O
and O
p<.001, O
respectively) O
and O
gait B-outcome ['Life-Impact']
speed I-outcome ['Life-Impact']
(p<.001 O
for O
both). O
[['Physiological-Clinical'], ['Life-Impact']]

For O
6 O
% O
coriander O
oil O
in O
unguentum O
leniens O
, O
a O
highly O
significant O
improvement O
of O
the O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
( O
p O
< O
0.0001 O
) O
was O
observed O
during O
the O
entire O
observation O
period O
; O
the O
number O
of O
positive O
fungal B-outcome ['Physiological-Clinical']
cultures I-outcome ['Physiological-Clinical']
also O
tended O
to O
decrease O
( O
p O
= O
0.0654 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

There O
were O
three O
experimental O
conditions O
: O
1 O
) O
tailored O
, O
iterative O
, O
printed O
dietary O
feedback O
( O
TF O
) O
with O
three O
instalments O
mail-delivered O
over O
a O
3-month O
period O
that O
were O
re-tailored O
to O
most O
recent O
assessment O
of O
dietary O
intake O
, O
intention O
to O
change O
and O
assessment O
of O
self-adequacy O
of O
dietary O
intake O
. O
[]

When O
the O
total O
experience O
is O
considered O
( O
clindamycin O
or O
cefoxitin O
with O
and O
without O
gentamicin O
) O
, O
20 O
of O
24 O
patients O
( O
83 O
% O
) O
responded B-outcome ['Physiological-Clinical']
to O
clindamycin O
and O
18 O
of O
22 O
( O
82 O
% O
) O
responded B-outcome ['Physiological-Clinical']
to O
cefoxitin O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Subtotal O
, O
bilateral O
strumectomies O
were O
performed O
according O
to O
Rothmund O
's O
suggestions O
. O
[]

No O
statistically O
significant O
differences O
in O
donepezil B-outcome ['Physiological-Clinical']
pharmacokinetics I-outcome ['Physiological-Clinical']
( O
Cmax O
, O
tmax O
, O
AUC O
( O
0-120 O
) O
, O
AUC O
( O
0-infinity O
) O
or O
t1/2 O
) O
were O
observed O
when O
donepezil O
administered O
alone O
was O
compared O
with O
donepezil O
administered O
in O
combination O
with O
digoxin O
. O
['Physiological-Clinical']

Is O
chronic O
sildenafil O
therapy O
safe O
and O
clinically O
beneficial O
in O
patients O
with O
systolic O
heart O
failure O
? O
[]

Department O
of O
Pharmacy O
Practice, O
Sri O
Adichunchanagiri O
College O
of O
Pharmacy, O
B. O
G. O
Nagara, O
Karnataka, O
India O
- O
rajesh.venkyresearch01@gmail.com. O
[]

Chi-squared O
analyses O
suggested O
educators O
' O
conceptions O
for O
organising O
murmurs O
differed O
significantly O
from O
students O
' O
conceptions O
. O
[]

Long-term O
decrease O
in O
bladder B-outcome ['Physiological-Clinical']
cancer I-outcome ['Physiological-Clinical']
recurrence I-outcome ['Physiological-Clinical']
with O
hexaminolevulinate O
enabled O
fluorescence O
cystoscopy O
. O
['Physiological-Clinical']

The O
160 O
patients O
fulfilled O
the O
study O
requirements. O
[]

Endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
evaluated O
using O
high-resolution O
vascular O
ultrasound O
. O
['Physiological-Clinical']

PATIENTS O
The O
study O
population O
was O
aged O
45 O
to O
85 O
years O
. O
[]

Ten O
patients O
were O
randomly O
assigned O
to O
receive O
4.4 O
mL O
of O
2 O
% O
lidocaine O
with O
1:80,000 O
epinephrine O
as O
a O
local O
anesthetic O
and O
10 O
were O
given O
4.4 O
mL O
of O
3 O
% O
prilocaine O
with O
0.03 O
IU/mL O
felypressin O
. O
[]

Long O
lines O
offer O
practical O
advantages O
over O
short O
lines O
for O
patients O
requiring O
longer O
term O
i.v O
. O
[]

Anti-angiogenic B-outcome ['Physiological-Clinical']
effects O
of O
epigallocatechin-3-gallate O
in O
human O
skin O
. O
['Physiological-Clinical']

A O
placebo-controlled O
trial O
of O
D-cycloserine O
added O
to O
conventional O
neuroleptics O
in O
patients O
with O
schizophrenia O
. O
[]

Patients O
were O
examined O
weekly O
during O
the O
treatment O
period O
and O
then O
at O
monthly O
intervals O
for O
a O
further O
6 O
months O
. O
[]

Black O
tea O
treatment O
was O
associated O
with O
the O
highest O
rates O
of O
dropout B-outcome ['Life-Impact']
among O
smokers O
( O
37 O
% O
) O
, O
but O
was O
associated O
with O
the O
lowest O
rate O
of O
dropout O
among O
non-smokers O
( O
4 O
% O
) O
. O
['Life-Impact']

The O
decrease O
in O
the O
number O
of O
blood B-outcome ['Physiological-Clinical']
eosinophils I-outcome ['Physiological-Clinical']
during O
the O
treatment O
was O
more O
marked O
in O
the O
high O
dose O
budesonide O
group O
( O
P=0.02 O
; O
high O
vs. O
low O
dose O
budesonide O
) O
. O
['Physiological-Clinical']

When O
Skp2 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
and O
p27kip1 B-outcome ['Physiological-Clinical']
expression I-outcome ['Physiological-Clinical']
were O
combined O
, O
patients O
with O
both O
Skp2 O
overexpression O
and O
reduced O
expression B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
p27kip1 I-outcome ['Physiological-Clinical']
revealed O
poorest O
disease-free B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
as O
compared O
to O
the O
other O
cases O
( O
p=0.0017 O
and O
p O
< O
0.0001 O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Mortality']

INTRODUCTION O
The O
aim O
of O
the O
study O
is O
to O
test O
whether O
nizatidine O
delivered O
via O
a O
unique O
bimodal O
pulsatile-controlled O
release O
system O
, O
nizatidine O
controlled O
release O
( O
CR O
) O
, O
accelerates O
gastric B-outcome ['Physiological-Clinical']
emptying I-outcome ['Physiological-Clinical']
in O
patients O
with O
gastroesophageal O
reflux O
disease O
( O
GERD O
) O
. O
['Physiological-Clinical']

PARTICIPANTS O
Hypertensive O
patients O
, O
210 O
females O
and O
160 O
males O
, O
treated O
or O
untreated O
with O
antihypertensive O
drugs O
with O
a O
sitting O
diastolic O
blood O
pressure O
between O
95 O
and O
115 O
mmHg O
and O
a O
serum O
total O
cholesterol O
between O
6.5 O
mmol/l O
( O
7.0 O
for O
those O
age O
60-67 O
years O
) O
and O
9.0 O
mmol/l O
. O
[]

Important O
demographic O
and O
skin O
cancer O
risk O
factor O
differences O
in O
sun O
protective O
behaviors O
and O
stages O
of O
change O
for O
sun O
protection O
were O
found O
, O
especially O
differences O
based O
on O
age O
, O
gender O
, O
and O
degree O
of O
sun O
sensitivity O
. O
[]

Patients O
were O
randomized O
to O
receive O
one O
of O
the O
following O
treatments O
: O
( O
a O
) O
concomitant O
therapy O
: O
omeprazole O
20mg O
, O
amoxicillin O
1g O
, O
clarithromycin O
500 O
mg O
, O
and O
tinidazole O
500 O
mg O
for O
5 O
days O
; O
( O
b O
) O
sequential O
therapy O
: O
omeprazole O
20mg O
and O
amoxicillin O
1g O
for O
5 O
days O
followed O
by O
omeprazole O
20mg O
, O
clarithromycin O
500 O
mg O
, O
and O
tinidazole O
500 O
mg O
for O
5 O
days O
; O
( O
c O
) O
hybrid O
therapy O
: O
omeprazole O
20mg O
, O
and O
amoxicillin O
1g O
for O
7 O
days O
followed O
by O
omeprazole O
20mg O
, O
amoxicillin O
1g O
, O
clarithromycin O
500 O
mg O
, O
and O
tinidazole O
500 O
mg O
, O
for O
7 O
days O
. O
[]

Surgical O
time O
is O
reduced O
. O
[]

Arginine O
vasopressin O
reduced O
V B-outcome ['Physiological-Clinical']
( O
-58 O
% O
) O
and O
CH2O B-outcome ['Physiological-Clinical']
( O
-68 O
% O
) O
but O
did O
not O
alter O
UNaV B-outcome ['Physiological-Clinical']
or O
Ccr B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Conclusion: O
Perioperative O
application O
of O
dexmedetomidine O
can O
effectively O
decrease O
the O
perioperative O
stress B-outcome ['Physiological-Clinical']
response, O
obviously O
cut O
down O
the O
perioperative O
opioid B-outcome ['Resource-use']
consumption I-outcome ['Resource-use']
, O
and O
prevent O
the O
transition O
from O
postoperative O
acute B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
to O
chronic B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
in O
patients O
with O
radical O
resection O
of O
esophageal O
cancer O
under O
combined O
thoracoscope O
and O
laparoscope. O
[['Physiological-Clinical'], ['Resource-use'], ['Physiological-Clinical'], ['Physiological-Clinical']]

Correcting O
for O
body O
height O
decreased O
the O
association O
with O
age O
. O
[]

METHODS O
The O
relationship O
between O
the O
changes O
of O
endogenous O
estrogen O
and O
the O
concentration O
of O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
in O
the O
serum O
of O
Chinese O
women O
was O
investigated O
. O
[]

The O
anti-stigma O
program O
improved O
the O
knowledge O
and O
attitudes O
, O
but O
not O
the O
behavioural O
intentions O
of O
participants O
towards O
their O
peers O
with O
autism O
. O
[]

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
efficacy O
of O
SJW O
for O
smoking B-outcome ['Life-Impact']
cessation I-outcome ['Life-Impact']
. O
['Life-Impact']

Compared O
to O
the O
controls O
, O
more O
women O
in O
the O
intervention O
group O
described O
the O
term O
breast B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
correctly O
and O
recognized O
it O
as O
a O
risk O
factor O
for O
breast O
cancer O
. O
['Physiological-Clinical']

DHA O
supplementation O
increased O
plasma O
glycerophospholipid B-outcome ['Physiological-Clinical']
DHA I-outcome ['Physiological-Clinical']
proportional O
to O
dose O
by O
0.4% O
DHA O
per O
1 O
mg O
intake/kg O
bodyweight. O
[['Physiological-Clinical']]

The O
WAIS-III O
General O
Ability O
Index O
( O
GAI O
; O
Tulsky O
, O
Saklofske O
, O
Wilkins O
, O
& O
Weiss O
, O
2001 O
) O
is O
a O
recently O
developed O
, O
6-subtest O
measure O
of O
global O
intellectual O
functioning O
. O
[]

However O
, O
the O
high O
incidence O
of O
severe O
, O
life-threatening B-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical']

For O
the O
first O
3 O
groups, O
we O
applied O
tape O
to O
the O
shoulder O
and O
scapular O
region. O
[]

Journal O
ID: O
0255562 O
[]

CONCLUSIONS O
The O
reach O
of O
the O
same O
tailored B-outcome ['Life-Impact']
physical I-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
( O
PA O
) O
intervention O
in O
a O
printed O
or O
Web-based O
delivery O
mode O
differed O
between O
sociodemographic O
subgroups O
of O
participants O
over O
50 O
years O
of O
age O
. O
['Life-Impact']

Rectal O
pain O
thresholds O
and O
smooth O
muscle O
tone O
were O
measured O
with O
a O
barostat O
before O
and O
after O
treatment O
in O
18 O
patients O
( O
study O
I O
) O
, O
and O
treatment O
changes O
in O
heart O
rate O
, O
blood O
pressure O
, O
skin O
conductance O
, O
finger O
temperature O
, O
and O
forehead O
electromyographic O
activity O
were O
assessed O
in O
24 O
patients O
( O
study O
II O
) O
. O
[]

Long-term O
antiarrhythmic O
therapy O
is O
not O
considered O
an O
exclusion O
criterion O
. O
[]

Eighteen O
( O
62 O
% O
) O
of O
29 O
patients O
treated O
with O
OK-432 O
had O
a O
fever O
, O
but O
well O
tolerated O
. O
[]

A O
double-blind O
controlled O
trial O
. O
[]

22 O
; O
95 O
% O
CI O
1.02 O
to O
1.45 O
; O
P=0.032 O
) O
independently O
predicted O
worsened O
clinical B-outcome ['Physiological-Clinical']
outcome O
regardless O
of O
the O
treatment O
modality O
. O
['Physiological-Clinical']

That O
looks O
familiar O
: O
attention O
allocation O
to O
familiar O
and O
unfamiliar O
faces O
in O
children O
with O
autism O
spectrum O
disorder O
. O
[]

Data O
were O
collected O
at O
admission O
and O
at O
discharge O
, O
and O
then O
at O
3 O
and O
9 O
months O
after O
discharge O
. O
[]

DESIGN O
Open O
interventional O
crossover O
study O
. O
[]

CONCLUSIONS O
In O
normal-weight O
healthy O
young O
subjects O
, O
modest O
fat O
gain O
results O
in O
impaired O
endothelial B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
, O
even O
in O
the O
absence O
of O
changes O
in O
['Physiological-Clinical']

Therefore O
, O
patients O
with O
the O
risk O
factors O
above O
presented O
should O
routinely O
undergo O
nutritional O
screening O
and/or O
assessment O
in O
order O
to O
be O
able O
to O
early O
diagnose O
or O
prevent O
malnutrition O
and O
its O
correlated O
morbidity O
and O
mortality O
. O
[]

One O
group O
received O
risperidone O
plus O
Ginko O
T.D O
and O
the O
other O
received O
risperidone O
plus O
placebo O
. O
[]

During O
myocardial O
ischemia O
there O
is O
a O
drop O
in O
high-energy B-outcome ['Physiological-Clinical']
phosphates I-outcome ['Physiological-Clinical']
in O
the O
myocardium O
. O
['Physiological-Clinical']

METHOD O
Forty O
children O
between O
the O
ages O
of O
4 O
and O
12 O
years O
with O
a O
DSM O
IV O
clinical O
diagnosis O
of O
autism O
who O
were O
outpatients O
from O
a O
specialty O
clinic O
for O
children O
were O
recruited O
. O
[]

METHODS/DESIGN O
The O
study O
is O
conducted O
as O
a O
randomized O
controlled O
trial O
. O
[]

OBJECTIVE O
Intraoperative O
comfort O
and O
patient B-outcome ['Life-Impact']
satisfaction I-outcome ['Life-Impact']
during O
surgical O
procedures O
under O
regional O
anaesthesia O
can O
be O
improved O
with O
the O
use O
of O
supplemental O
intravenous O
sedation O
. O
['Life-Impact']

INTRODUCTION O
Atrioesophageal O
fistula O
is O
an O
uncommon O
but O
often O
lethal O
complication O
of O
atrial O
fibrillation O
( O
AF O
) O
ablation O
. O
[]

The O
authors O
investigated O
the O
effect O
of O
altering O
central O
cholinergic O
transmission O
, O
by O
physostigmine O
and O
scopolamine O
, O
on O
unconsciousness O
produced O
by O
propofol O
. O
[]

A O
new O
immunomodulating O
agent O
, O
bestatin O
( O
INN O
: O
Ubenimex O
has O
low O
toxicity O
even O
after O
long-term O
oral O
administration O
and O
has O
significant O
modifications O
in O
immunological B-outcome ['Physiological-Clinical']
response O
. O
['Physiological-Clinical']

STATEMENT O
OF O
PROBLEMS O
Postoperative O
cold O
sensitivity O
after O
the O
cementation O
of O
indirect O
restorations O
with O
composite O
cements O
has O
been O
reported O
frequently O
but O
not O
scientifically O
documented O
. O
[]

To O
understand O
better O
the O
ability O
of O
these O
pumps O
to O
assist O
women O
in O
the O
maintenance O
of O
lactation O
, O
the O
current O
study O
was O
undertaken O
to O
evaluate O
their O
effects O
on O
milk O
yield O
and O
prolactin O
and O
oxytocin B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
when O
compared O
to O
natural O
infant O
suckling O
. O
['Physiological-Clinical']

A O
randomized O
controlled O
trial O
of O
acellular O
diphtheria/pertussis/tetanus O
( O
ADPT O
) O
freeze-dried O
and O
liquid O
vaccines O
in O
infants O
was O
conducted O
in O
a O
peri-urban O
community O
( O
Ashaiman O
) O
in O
southern O
Ghana O
. O
[]

Journal O
ID: O
7511141 O
[]

Overall O
differences O
in O
strength B-outcome ['Physiological-Clinical']
were O
consistently O
significant O
between O
the O
study O
groups O
( O
P O
= O
.0025 O
) O
. O
['Physiological-Clinical']

A O
short-term O
cognitive O
group O
treatment O
program O
gives O
substantial O
weight O
reduction O
up O
to O
18 O
months O
from O
the O
end O
of O
treatment O
. O
[]

Evaluation O
of O
an O
aquatics O
programme O
on O
fitness B-outcome ['Physiological-Clinical']
parameters O
of O
individuals O
with O
a O
brain O
injury O
. O
['Physiological-Clinical']

FUNDING: O
UK O
National O
Institute O
for O
Health O
Research O
Health O
Technology O
Assessment O
programme O
(10/57/49). O
[]

A O
controlled O
study O
using O
tetracycline O
. O
[]

Lomefloxacin O
was O
effective O
therapy O
for O
five O
of O
seven O
( O
71 O
% O
) O
patients O
, O
and O
ciprofloxacin O
was O
effective O
therapy O
for O
two O
of O
five O
patients O
( O
40 O
% O
) O
. O
[]

Journal-Name:Medicine O
[]

The O
criteria O
for O
a O
successful O
priming O
session O
were O
a O
patient-assessed O
instantaneous O
total O
nasal B-outcome ['Physiological-Clinical']
symptom I-outcome ['Physiological-Clinical']
score O
of O
at O
least O
6 O
( O
of O
a O
possible O
12 O
) O
and O
a O
nasal B-outcome ['Physiological-Clinical']
congestion I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
rhinorrhea I-outcome ['Physiological-Clinical']
score O
of O
at O
least O
2 O
( O
of O
a O
possible O
3 O
) O
90 O
minutes O
after O
allergen O
exposure O
during O
at O
least O
two O
consecutive O
priming O
sessions O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Shear O
bond O
values O
of O
the O
ceramic O
brackets O
were O
higher O
than O
those O
of O
the O
metal O
brackets O
independent O
of O
HFLCS O
application O
( O
P O
< O
0.001 O
) O
. O
[]

SICI B-outcome ['Physiological-Clinical']
was O
associated O
with O
significant O
changes O
with O
respect O
to O
treatment O
response O
. O
['Physiological-Clinical']

The O
goal O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
these O
two O
pharmacological O
agents O
, O
used O
alone O
or O
in O
combination O
, O
to O
reduce O
postoperative B-outcome ['Physiological-Clinical']
AF I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Quantitative O
image O
quality O
parameters O
and O
figure O
of O
merit O
( O
FOM O
) O
of O
coronary O
artery O
were O
evaluated O
. O
[]

PATIENTS O
Injection O
drug O
users O
( O
IDUs O
) O
seeking O
substance O
abuse O
treatment O
between O
the O
ages O
of O
18 O
and O
50 O
years O
who O
were O
addicted O
to O
opioids O
( O
e.g. O
, O
heroin O
) O
and O
not O
currently O
in O
drug O
treatment O
. O
[]

CONCLUSIONS O
Clindamycin O
vaginal O
cream O
therapy O
was O
associated O
with O
significantly O
prolonged O
gestation O
and O
reduced O
cost O
of O
neonatal O
care O
in O
women O
with O
BV O
. O
[]

Leucine-enriched O
essential O
amino O
acid O
and O
carbohydrate O
ingestion O
following O
resistance O
exercise O
enhances O
mTOR O
signaling O
and O
protein O
synthesis O
in O
human O
muscle O
. O
[]

RESULTS O
Forty O
parent-child O
dyads O
enrolled O
: O
82.5 O
% O
were O
Hispanic O
, O
80 O
% O
had O
a O
girl O
and O
65 O
% O
reported O
income O
? O
[]

The O
equations O
describing O
the O
models O
for O
AUC O
using O
two O
time O
points O
( O
3 O
and O
24h O
) O
and O
Cmax O
for O
the O
training O
data O
set O
of O
30 O
subjects O
were O
AUCpredicted O
= O
11.1 O
C3h O
+ O
121.4 O
C24h O
- O
157 O
( O
r O
= O
0.80 O
) O
Cmax O
( O
predicted O
) O
= O
0.036 O
AUC O
+ O
42.9 O
( O
r O
= O
0.74 O
) O
The O
model O
was O
validated O
on O
64 O
patients O
who O
received O
flunarizine O
orally O
. O
[]

Irritability/aggression O
is O
a O
significant O
comorbid O
symptom O
in O
this O
population O
, O
which O
greatly O
impacts O
burden O
of O
care O
. O
[]

The O
primary O
outcome O
was O
improvement O
in O
dry B-outcome ['Physiological-Clinical']
mouth I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

PATIENTS O
2121/2292 O
patients O
( O
92.5 O
% O
) O
had O
an O
analysable O
dataset O
for O
either O
biomarker O
. O
[]

Patients O
from O
the O
1st O
group O
were O
to O
take O
nicorandil O
2 O
days O
and O
1 O
day O
before O
the O
PCI O
at O
the O
30 O
mg/day O
dose, O
then O
20 O
mg O
orally O
2 O
hours O
just O
before O
PCI, O
and O
one O
more O
time O
6 O
hours O
after O
the O
PCI O
- O
10 O
mg O
nicorandil. O
[]

P B-outcome ['Physiological-Clinical']
wave I-outcome ['Physiological-Clinical']
and O
QRS B-outcome ['Physiological-Clinical']
duration I-outcome ['Physiological-Clinical']
were O
measured O
from O
SAECG O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Publication O
date: O
2018/12/21 O
06:00 O
[entrez] O
[]

INTERVENTION O
Thirty O
patients O
were O
treated O
with O
a O
simple O
shoulder O
sling O
and O
30 O
patients O
with O
ESIN O
within O
3 O
days O
after O
trauma O
. O
[]

2 O
, O
piglets O
were O
weaned O
at O
21 O
d O
of O
age O
and O
then O
had O
free O
access O
to O
diets O
supplemented O
with O
1 O
% O
L-glutamine O
( O
wt O
: O
wt O
) O
or O
isonitrogenous O
L-alanine O
( O
control O
) O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

BACKGROUND O
The O
CoAct O
( O
Cocreating O
Activity O
) O
study O
is O
investigating O
a O
novel O
lifestyle O
intervention O
, O
aimed O
at O
the O
working O
population O
, O
with O
daily O
activity O
monitoring O
and O
distance O
counselling O
via O
telephone O
and O
secure O
web O
messages O
. O
[]

We O
trained O
9 O
persons O
with O
heart O
failure O
to O
mentor O
other O
heart O
failure O
patients O
and O
tested O
the O
effectiveness O
of O
this O
approach O
in O
a O
randomized O
controlled O
clinical O
trial O
. O
[]

Postoperative O
analgesia O
with O
preoperative O
oral O
ibuprofen O
or O
acetaminophen O
in O
children O
undergoing O
myringotomy O
. O
[]

No O
major O
side O
effects O
were O
noted O
in O
any O
of O
the O
groups O
either O
. O
[]

Neither O
enalapril O
alone O
( O
+59 O
+/- O
46 O
mL/min O
, O
P O
= O
0.21 O
) O
nor O
eprosartan O
alone O
( O
+113 O
+/- O
51 O
mL/min O
, O
P O
= O
0.06 O
) O
had O
a O
clear-cut O
significant O
effect O
on O
RPF B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

At O
the O
end O
of O
the O
study O
, O
the O
carotid B-outcome ['Physiological-Clinical']
intima-media I-outcome ['Physiological-Clinical']
thickness I-outcome ['Physiological-Clinical']
decreased O
in O
group O
L O
( O
P O
< O
.01 O
) O
, O
left B-outcome ['Physiological-Clinical']
ventricular I-outcome ['Physiological-Clinical']
mass I-outcome ['Physiological-Clinical']
index I-outcome ['Physiological-Clinical']
in O
groups O
E O
and O
L O
( O
P O
< O
.05 O
and O
P O
< O
.001 O
, O
respectively O
) O
, O
with O
a O
concomitant O
reduction O
in O
cholesterol B-outcome ['Physiological-Clinical']
in O
group O
L O
( O
P O
< O
.03 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
curved O
tip O
was O
directed O
ventrally O
. O
[]

The O
third O
indicator O
, O
training B-outcome ['Life-Impact']
attrition I-outcome ['Life-Impact']
, O
shows O
a O
better O
result O
for O
the O
group O
training O
. O
['Life-Impact']

Statistical O
analysis O
was O
performed O
using O
Fisher O
, O
Spearman O
correlation O
coefficient O
, O
kappa O
, O
Kruskal-Wallis O
and O
Miller O
tests O
( O
P O
< O
0.05 O
) O
. O
[]

CONCLUSION O
Although O
the O
psychoeducational O
intervention O
did O
not O
result O
in O
changes O
in O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
, O
improvements O
in O
adaptive B-outcome ['Life-Impact']
coping I-outcome ['Life-Impact']
and O
indicators O
of O
psychological B-outcome ['Life-Impact']
growth I-outcome ['Life-Impact']
were O
found O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Science O
to O
practice O
in O
underserved O
communities O
: O
the O
effectiveness O
of O
school O
mental O
health O
programming O
. O
[]

Complete B-outcome ['Physiological-Clinical']
ophthalmologic I-outcome ['Physiological-Clinical']
examinations I-outcome ['Physiological-Clinical']
were O
performed O
just O
before O
GLP O
and O
IB O
injection O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
treatment O
. O
['Physiological-Clinical']

Title: O
Long-term O
results O
of O
a O
phase O
II O
study O
of O
hypofractionated O
proton O
therapy O
for O
prostate O
cancer: O
moderate O
versus O
extreme O
hypofractionation. O
[]

There O
was O
a O
significant O
relationship O
between O
failure O
of O
the O
fixation O
and O
varus O
reduction O
( O
p O
= O
0.04 O
) O
as O
well O
as O
screw/neck O
angle O
deviation O
more O
than O
20 O
degrees O
in O
the O
lateral O
projection O
( O
p O
= O
0.005 O
) O
or O
if O
the O
implant O
was O
in O
a O
superior O
or O
posterior O
position O
( O
p O
= O
0.02 O
) O
. O
[]

Title: O
The O
effect O
of O
two O
beta-alanine O
dosing O
strategies O
on O
30-minute O
rowing B-outcome ['Physiological-Clinical']
performance I-outcome ['Physiological-Clinical']
: O
a O
randomized, O
controlled O
trial. O
[['Physiological-Clinical']]

INTRODUCTION O
Randomized O
trials O
have O
demonstrated O
the O
effectiveness O
of O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
( O
DASH O
) O
program O
for O
lowering O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
; O
however O
, O
program O
participation O
has O
been O
limited O
in O
some O
populations O
. O
['Physiological-Clinical']

We O
investigated O
the O
effects O
of O
negative O
pressure O
wound O
therapy O
(NPWT) O
on O
short- O
and O
long-term O
wound O
outcomes O
in O
patients O
undergoing O
pancreatectomy. O
[]

Gabapentin O
but O
not O
vigabatrin O
is O
effective O
in O
the O
treatment O
of O
acquired O
nystagmus O
in O
multiple O
sclerosis O
: O
How O
valid O
is O
the O
GABAergic O
hypothesis O
? O
[]

Durable O
clinical O
responses O
were O
observed O
in O
some O
patients O
for O
7 O
years O
or O
more O
. O
[]

There O
were O
no O
significant O
differences O
between O
the O
three O
groups O
with O
respect O
to O
requirements O
for O
supplemental B-outcome ['Resource-use']
pain I-outcome ['Resource-use']
medications I-outcome ['Resource-use']
in O
the O
recovery O
room O
, O
incidence O
of O
postoperative B-outcome ['Physiological-Clinical']
vomiting I-outcome ['Physiological-Clinical']
, O
or O
length O
of O
time O
spent O
in O
the O
recovery O
room O
. O
['Resource-use', 'Physiological-Clinical']

Publication O
date: O
2019/01/07 O
00:00 O
[accepted] O
[]

A O
limited O
number O
of O
studies O
have O
used O
a O
double O
blind O
approach O
to O
evaluate O
the O
efficacy O
of O
hyperbaric O
oxygen O
therapy O
in O
the O
treatment O
of O
diabetic O
ulcers O
. O
[]

Neutralizing B-outcome ['Physiological-Clinical']
antibody I-outcome ['Physiological-Clinical']
titres I-outcome ['Physiological-Clinical']
were O
lower O
after O
intradermal O
( O
i.d O
. O
) O
['Physiological-Clinical']

Propranolol O
and O
atenolol O
did O
not O
significantly O
influence O
insulin B-outcome ['Physiological-Clinical']
binding I-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
erythrocytes I-outcome ['Physiological-Clinical']
, O
but O
they O
clearly O
reduced O
the O
glucose B-outcome ['Physiological-Clinical']
disappearance I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
KITT I-outcome ['Physiological-Clinical']
was O
compared O
to O
placebo O
( O
p O
= O
0.0036 O
and O
p O
= O
0.0003 O
) O
, O
respectively O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Resting B-outcome ['Physiological-Clinical']
MSA I-outcome ['Physiological-Clinical']
, O
total O
body B-outcome ['Physiological-Clinical']
and O
right B-outcome ['Physiological-Clinical']
renal I-outcome ['Physiological-Clinical']
NE I-outcome ['Physiological-Clinical']
spillover I-outcome ['Physiological-Clinical']
did O
not O
differ O
significantly O
after O
placebo O
and O
metformin O
treatment O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Granisetron O
given O
at O
20 O
or O
40 O
micrograms/kg O
i.v O
. O
[]

OBJECTIVE O
The O
study O
objective O
was O
to O
identify O
factors O
associated O
with O
death O
and O
cardiac O
transplantation O
in O
infants O
undergoing O
the O
Norwood O
procedure O
and O
to O
determine O
differences O
in O
associations O
that O
might O
favor O
the O
modified O
Blalock-Taussig O
shunt O
or O
a O
right O
ventricle-to-pulmonary O
artery O
shunt O
. O
[]

In O
brief O
, O
the O
SPF O
project O
is O
a O
group O
randomized O
trial O
to O
test O
the O
effectiveness O
of O
a O
school O
based O
intervention O
promoting O
sun O
protection O
in O
general O
, O
and O
hat O
use O
in O
particular O
, O
in O
Hillsborough O
County O
Schools O
, O
Florida O
. O
[]

MATERIALS O
AND O
METHODS: O
A O
randomized, O
controlled, O
clinical O
trial O
was O
conducted O
on O
62 O
postmenopausal O
women O
referred O
to O
health O
centers O
of O
Isfahan, O
Iran. O
[]

During O
the O
other O
treatment O
period O
volunteers O
ate O
a O
standard O
supper O
, O
snacks O
, O
breakfast O
and O
lunch O
. O
[]

RESULTS O
Patients O
with O
cirrhosis O
( O
n O
= O
427 O
) O
reported O
lower O
general B-outcome ['Life-Impact']
well-being I-outcome ['Life-Impact']
and O
more O
fatigue B-outcome ['Physiological-Clinical']
( O
P O
< O
0.001 O
) O
than O
patients O
with O
fibrosis O
( O
n O
= O
622 O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Patients O
with O
detectable O
or O
undetectable O
viral O
load O
could O
develop O
HBV B-outcome ['Physiological-Clinical']
reactivation I-outcome ['Physiological-Clinical']
and O
HBsAg B-outcome ['Physiological-Clinical']
reverse I-outcome ['Physiological-Clinical']
seroconversion I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSION O
DST O
is O
effective O
on O
IgAN O
of O
deficiency O
of O
Yin O
with O
damp-heat O
symptom O
. O
[]

BACKGROUND O
Persistent O
infection O
with O
Helicobacter O
pylori O
is O
associated O
with O
the O
recurrence O
of O
duodenal O
ulcer O
. O
[]

Thirty-two O
healthy O
, O
opioid-naive O
adults O
were O
randomized O
to O
MS-sNT O
administered O
with O
240 O
mL O
of O
4 O
% O
, O
20 O
% O
, O
or O
40 O
% O
alcohol O
or O
water O
. O
[]

Conversely O
, O
in O
the O
endurance O
group O
the O
V/M B-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
max I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
was O
not O
altered O
, O
whereas O
the O
['Physiological-Clinical']

CONCLUSIONS O
Women O
at O
highest O
risk O
of O
default O
from O
follow-up O
cytology O
tend O
to O
be O
young O
, O
smoke O
, O
lack O
post-secondary O
education O
, O
and O
have O
defaulted O
from O
a O
previous O
surveillance O
appointment O
. O
[]

Tapered O
, O
roughened-surface O
Southern O
implants O
were O
placed O
using O
a O
standardized O
technique O
, O
and O
implant O
level O
bone O
impressions O
were O
made O
. O
[]

Pharmacokinetics O
of O
naproxen O
after O
oral O
administration O
of O
two O
tablet O
formulations O
in O
healthy O
volunteers O
. O
[]

There O
were O
significant O
improvements O
in O
household O
purchasing B-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
vegetables I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
whole I-outcome ['Life-Impact', 'Life-Impact']
grains S2-outcome ['Life-Impact', 'Life-Impact']
, O
in O
individual O
intakes B-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
refined I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
grains I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
healthy I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
proteins I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
whole-fat I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
dairies I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
legumes I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
100% I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
fruit I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
juices I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
, Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
sweets I-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
snacks S2-outcome ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact']
; O
and O
in O
the O
individual O
frequency O
of O
intake B-outcome ['Life-Impact', 'Life-Impact']
of I-outcome ['Life-Impact', 'Life-Impact']
fruits I-outcome ['Life-Impact', 'Life-Impact']
and Seperator ['Life-Impact', 'Life-Impact']
cold I-outcome ['Life-Impact', 'Life-Impact']
cuts/cured I-outcome ['Life-Impact', 'Life-Impact']
meats S2-outcome ['Life-Impact', 'Life-Impact']
within O
the O
intervention O
group O
(p O
< O
0.05). O
[['Life-Impact', 'Life-Impact'], ['Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact', 'Life-Impact'], ['Life-Impact', 'Life-Impact']]

The O
global B-outcome ['Physiological-Clinical']
incidence O
of O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
was O
45 O
% O
higher O
with O
EC O
, O
though O
not O
significant O
( O
32 O
vs. O
22 O
% O
, O
p O
= O
0.075 O
) O
. O
['Physiological-Clinical', 'Adverse-effects']

The O
two O
groups O
had O
a O
similar O
3-year O
disease-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
progression B-outcome ['Mortality']
free I-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
, O
i.e O
. O
['Mortality', 'Mortality', 'Mortality']

Levosulpiride O
in O
functional O
dyspepsia O
: O
a O
multicentric O
, O
double-blind O
, O
controlled O
trial O
. O
[]

Is O
a O
calculated O
total O
hip O
BMD O
of O
clinical B-outcome ['Physiological-Clinical']
use I-outcome ['Physiological-Clinical']
? O
['Physiological-Clinical']

Reduction O
with O
aspiration O
of O
blood O
. O
[]

METHOD O
Twenty-two O
lower O
extremities O
from O
healthy O
volunteers O
and O
11 O
lower O
extremities O
from O
patients O
with O
class O
4 O
to O
class O
6 O
post-thrombotic O
chronic O
venous O
insufficiency O
were O
studied O
. O
[]

In O
contrast O
, O
they O
chose O
amphetamine O
either O
as O
often O
as O
or O
more O
often O
than O
placebo O
. O
[]

The O
mean O
arterial B-outcome ['Physiological-Clinical']
pressures I-outcome ['Physiological-Clinical']
and O
pulse B-outcome ['Physiological-Clinical']
rates I-outcome ['Physiological-Clinical']
were O
not O
significantly O
different O
in O
each O
group O
throughout O
the O
course O
of O
the O
operation O
. O
['Physiological-Clinical', 'Physiological-Clinical']

RESULTS O
Interaction O
between O
HFLCS O
and O
bracket O
type O
was O
not O
statistically O
significant O
( O
P O
= O
0.15 O
) O
. O
[]

Stage O
of O
change O
appears O
to O
be O
useful O
for O
understanding O
mediators O
of O
health O
promotion O
intervention O
effectiveness O
. O
[]

The O
prolactinemia O
, O
reflecting O
the O
DA O
action O
, O
has O
been O
also O
measured O
. O
[]

In O
a O
prospective O
, O
randomized O
clinical O
trial O
, O
the O
toxicity O
of O
1 O
mg O
of O
amphotericin O
B O
( O
AmB O
) O
per O
kg O
of O
body O
weight O
per O
day O
infused O
in O
5 O
% O
dextrose O
was O
compared O
with O
that O
of O
AmB O
infused O
in O
lipid O
emulsion O
in O
children O
with O
malignant O
disease O
. O
[]

RESULTS O
At O
baseline O
, O
patients O
reported O
greater O
anxiety B-outcome ['Life-Impact']
and O
lower O
QoL B-outcome ['Life-Impact']
than O
healthy O
populations O
. O
['Life-Impact', 'Life-Impact']

In O
this O
group O
, O
the O
mean O
plasma B-outcome ['Physiological-Clinical']
level O
of O
prilocaine O
at O
2 O
minutes O
was O
1.22 O
micrograms/ml O
, O
maximum O
2.12 O
micrograms/ml O
. O
['Physiological-Clinical']

Using O
initial O
assessment O
data O
from O
46 O
clients O
of O
a O
clinical O
psychology O
alcohol O
problems O
service O
( O
30 O
men O
, O
16 O
women O
) O
, O
an O
attempt O
was O
made O
to O
operationalize O
the O
concepts O
of O
dependence O
and O
personal O
persuasion O
using O
a O
variety O
of O
indicators O
of O
each O
. O
[]

5.0 O
) O
, O
( O
50.2 O
? O
[]

The O
HS-60 O
and O
HS-30 O
heifers O
were O
limited-fed O
to O
gain O
0.9 O
kg/d O
, O
and O
the O
LS-30 O
heifers O
had O
ad O
libitum O
access O
to O
the O
diet O
. O
[]

The O
aim O
of O
this O
study O
is O
to O
compare O
the O
efficacy O
and O
safety O
of O
these O
two O
treatment O
alternatives O
. O
[]

Treatment O
consisted O
of O
pelvic O
floor O
exercises O
in O
the O
case O
of O
stress O
incontinence O
and O
bladder O
training O
in O
the O
case O
of O
urge O
incontinence O
. O
[]

Enhanced O
pitch O
sensitivity O
in O
individuals O
with O
autism O
: O
a O
signal O
detection O
analysis O
. O
[]

All O
patients O
tolerated B-outcome ['Life-Impact']
this O
protocol O
of O
the O
therapy O
and O
the O
main O
toxic B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
were O
fever B-outcome ['Physiological-Clinical']
and O
general B-outcome ['Physiological-Clinical']
fatigue I-outcome ['Physiological-Clinical']
. O
['Life-Impact', 'Adverse-effects', 'Physiological-Clinical', 'Physiological-Clinical']

The O
results O
obtained O
with O
the O
three O
Na+ O
modeling O
programs O
were O
similar O
. O
[]

METHODS O
On O
six O
occasions O
, O
1 O
to O
3 O
days O
apart O
within O
15 O
days O
, O
199 O
patients O
with O
elbow O
epicondylitis O
received O
40 O
mA-minutes O
of O
either O
active O
or O
placebo O
treatment O
. O
[]

One O
vaccinee O
in O
the O
DTPa O
HBV-HPV- O
Hib O
group O
failed O
to O
respond O
to O
the O
poliovirus O
type O
1 O
antigen O
. O
[]

Participants O
( O
N O
= O
22 O
) O
performed O
the O
TGMD-2 O
under O
three O
different O
protocols O
( O
traditional O
protocol O
, O
picture O
task O
card O
protocol O
, O
and O
picture O
activity O
schedule O
protocol O
) O
. O
[]

Neuro-ophthalmological O
and O
electro-oculographic O
( O
EOG O
) O
evaluations O
were O
performed O
four O
and O
three O
times O
, O
respectively O
. O
[]

Mean O
hospital B-outcome ['Resource-use']
stay I-outcome ['Resource-use']
was O
1.24 O
days O
( O
0.62 O
) O
and O
2.76 O
days O
( O
1.01 O
) O
( O
P O
< O
.001 O
) O
in O
the O
stapled O
and O
open O
group O
, O
respectively O
. O
['Resource-use']

In O
random O
order O
, O
subjects O
either O
breathed O
room O
air O
, O
hypoxia O
( O
target O
SPo2 O
= O
85 O
% O
) O
, O
or O
hyperoxia O
( O
FiO2 O
= O
1.0 O
) O
during O
the O
PECO O
to O
modulate O
the O
chemoreflex O
. O
[]

Mean O
change O
from O
baseline O
at O
Week O
12 O
in O
CCQ B-outcome ['Physiological-Clinical']
Total O
Score O
was O
significantly O
better O
in O
continuous O
abstainers O
( O
-1.04 O
) O
vs. O
continuous O
smokers O
( O
-0.53 O
; O
P O
< O
0.0001 O
) O
: O
this O
improvement O
was O
sustained O
at O
Weeks O
24 O
and O
52 O
. O
['Physiological-Clinical']

Experiments O
2-5 O
sought O
to O
test O
the O
generality O
of O
this O
effect O
over O
variations O
in O
study O
material O
( O
video O
or O
live O
interaction O
) O
, O
test O
format O
( O
cued- O
or O
free-recall O
) O
and O
information O
modality O
( O
visual O
or O
auditory O
details O
recalled O
) O
. O
[]

From O
the O
registries O
, O
90 O
residents O
, O
aged O
20 O
to O
49 O
years O
old O
, O
were O
randomly O
selected O
to O
represent O
each O
sex O
from O
each O
area O
. O
[]

We O
determined O
counseling O
by O
post-visit O
patient O
interviews O
. O
[]

No O
trial-dependent O
differences O
were O
observed O
in O
the O
Recovery O
period. O
[]

Which O
women O
default O
from O
follow-up O
cervical O
cytology O
tests O
? O
[]

Uric B-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
levels O
were O
significantly O
reduced O
at O
both O
7 O
days O
and O
6 O
weeks O
in O
the O
high-dose O
group O
( O
by O
0.14 O
mmol/L O
at O
6 O
weeks O
, O
P=0.002 O
) O
. O
['Physiological-Clinical']

Lumbar O
epidural O
anesthesia O
with O
20 O
ml O
of O
either O
3 O
% O
2-chloroprocaine O
( O
C O
) O
, O
1.5 O
% O
lidocaine O
( O
L O
) O
, O
or O
1.5 O
% O
mepivacaine O
( O
M O
) O
with O
epinephrine O
was O
studied O
in O
84 O
outpatients O
undergoing O
surgery O
( O
extracorporeal O
shock O
wave O
lithotripsy O
( O
ESWL O
] O
. O
[]

Baseline O
and O
postcatheterization O
serum B-outcome ['Physiological-Clinical']
Cr I-outcome ['Physiological-Clinical']
levels O
were O
analyzed O
in O
a O
longitudinal O
fashion O
, O
allowing O
for O
differences O
in O
the O
time O
between O
blood O
draws O
, O
to O
determine O
the O
different O
critical O
trajectories O
of O
serum O
Cr O
. O
['Physiological-Clinical']

Multivariate O
analysis O
in O
this O
same O
age O
group O
showed O
that O
the O
intervention O
was O
independently O
associated O
with O
a O
reduction O
in O
pain B-outcome ['Physiological-Clinical']
distress I-outcome ['Physiological-Clinical']
as O
perceived O
by O
parents O
based O
on O
the O
mean O
change O
in O
visual O
analog O
scale O
scores O
. O
['Physiological-Clinical']

For O
all O
patients O
, O
baseline O
TEI O
index O
was O
a O
predictor O
of O
worsened B-outcome ['Physiological-Clinical']
outcome I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

After O
practice O
, O
half O
of O
the O
participants O
were O
immediately O
tested O
and O
the O
other O
half O
were O
tested O
after O
a O
7-day O
delay O
. O
[]

After O
the O
induction O
of O
DOMS B-outcome ['Physiological-Clinical']
, O
the O
participants O
were O
randomly O
divided O
into O
an O
experimental O
condition O
( O
HVPC O
) O
or O
a O
placebo O
condition O
. O
['Physiological-Clinical']

All O
patients O
reported O
their O
average O
and O
worst O
pain B-outcome ['Physiological-Clinical']
levels O
at O
baseline O
and O
2 O
and O
3 O
weeks O
after O
the O
start O
of O
the O
intervention O
. O
['Physiological-Clinical']

Effects O
of O
four O
dose O
levels O
of O
MPH O
on O
parent O
and O
teacher O
behavioral B-outcome ['Life-Impact']
ratings O
were O
investigated O
using O
a O
within-subject O
, O
crossover O
, O
placebo-controlled O
design O
. O
['Life-Impact']

From O
November O
1989 O
to O
June O
1990 O
, O
13 O
patients O
received O
aprotinin O
as O
a O
bolus O
of O
0.5 O
Mill O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
accuracy O
of O
pelvic O
radiotherapy O
during O
a O
trial O
of O
blocked O
radiotherapy O
at O
the O
Royal O
Marsden O
Hospital O
, O
UK O
. O
[]

Patients O
with O
dysthymia B-outcome ['Life-Impact']
in O
addition O
to O
major B-outcome ['Life-Impact']
depression I-outcome ['Life-Impact']
also O
showed O
significant O
improvement O
( O
p O
< O
.05 O
) O
when O
treated O
with O
nefazodone O
, O
with O
significant O
differences O
in O
response O
rates O
seen O
as O
early O
as O
week O
2 O
and O
through O
the O
end O
of O
the O
trial O
. O
['Life-Impact', 'Life-Impact']

CONCLUSION O
YXDM O
combined O
with O
BHT O
injection O
had O
better O
effect O
in O
[]

METHODS O
Data O
from O
a O
randomized O
controlled O
trial O
with O
442 O
patients O
with O
low O
back O
pain O
were O
used O
. O
[]

We O
collected O
6484 O
questionnaires, O
including O
3583 O
in O
the O
intervention O
group O
[response O
rate: O
96% O
(3583/3726) O
and O
2901 O
in O
the O
control O
group O
[response O
rate: O
90% O
(2901/3224)]. O
We O
observed O
that O
hand B-outcome ['Life-Impact']
washing I-outcome ['Life-Impact']
habit I-outcome ['Life-Impact']
of O
children O
and O
parent, O
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
hand I-outcome ['Life-Impact']
food I-outcome ['Life-Impact']
mouth I-outcome ['Life-Impact']
disease I-outcome ['Life-Impact']
of O
parents, O
children's O
daily O
cleaning B-outcome ['Life-Impact']
habits I-outcome ['Life-Impact']
scores O
improved O
in O
the O
intervention O
group O
and O
higher O
than O
that O
in O
the O
control O
group O
at O
both O
the O
end O
of O
year O
1 O
(April O
1-July O
31, O
2011)and O
year O
2 O
(April O
1-July O
31, O
2012). O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

RESULTS O
The O
groups O
were O
matched O
in O
regard O
to O
patient O
age O
( O
p O
= O
0.84 O
) O
, O
body O
mass O
index O
( O
p O
= O
0.43 O
) O
, O
American O
Society O
of O
Anesthesiologists O
class O
( O
p O
= O
0.81 O
) O
and O
laterality O
( O
p O
= O
0.12 O
) O
. O
[]

To O
test O
this O
hypothesis O
, O
we O
have O
performed O
the O
corollary O
experiment O
whereby O
the O
action O
of O
endogenous O
GHRH O
has O
been O
antagonized O
. O
[]

Medication O
side O
effects O
were O
mild O
in O
the O
majority O
of O
subjects O
. O
( O
[]

RESULTS: O
Plazomicin O
was O
noninferior O
to O
meropenem O
with O
respect O
to O
the O
primary O
efficacy O
end O
points. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

RESULTS O
No O
significant O
between O
group O
differences O
were O
found O
for O
WOMAC O
pain B-outcome ['Physiological-Clinical']
over O
the O
16-month O
follow-up O
. O
['Physiological-Clinical']

This O
study O
evaluates O
the O
safety O
and O
efficacy O
of O
buspirone O
hydrochloride O
for O
the O
treatment O
of O
a O
patient O
with O
autism O
and O
hyperactivity O
disorder O
and O
determines O
the O
effect O
of O
buspirone O
on O
the O
number O
of O
performance O
tasks O
completed O
by O
the O
patient O
at O
school O
. O
[]

METHODS O
This O
was O
a O
2-day O
, O
double-blind O
, O
double-dummy O
, O
randomized O
, O
parallel-group O
, O
placebo-controlled O
study O
of O
diclofenac-K O
( O
12.5 O
mg O
) O
tablets O
vs O
paracetamol O
( O
500 O
mg O
) O
tablets O
and O
placebo O
in O
patients O
with O
moderate O
or O
severe O
pain O
within O
8 O
hours O
of O
extraction O
of O
impacted O
third O
molars O
. O
[]

Background O
and O
Objectives: O
The O
authors O
sought O
to O
assess O
the O
effect O
of O
the O
use O
of O
a O
new O
crosslinked O
hyaluronan O
(NCH) O
gel O
on O
the O
prevention O
of O
intrauterine B-outcome ['Physiological-Clinical']
adhesions I-outcome ['Physiological-Clinical']
(IUAs) I-outcome ['Physiological-Clinical']
in O
women O
underwent O
curettage O
in O
the O
second O
trimester. O
[['Physiological-Clinical']]

Four O
of O
the O
variants O
used O
the O
continuous O
SWAT O
subscales O
while O
one O
used O
the O
discrete O
SWAT O
subscale O
. O
[]

In O
the O
prosthetic O
bypass O
group O
, O
there O
was O
no O
significant O
difference O
in O
patency B-outcome ['Physiological-Clinical']
rate O
in O
the O
8-mm O
bypass O
subgroup O
, O
but O
there O
was O
a O
significant O
difference O
in O
patency B-outcome ['Physiological-Clinical']
rate O
in O
the O
6-mm O
bypass O
subgroup O
( O
femoral-popliteal O
; O
71.4 O
% O
in O
the O
WASA O
group O
versus O
57.9 O
% O
in O
the O
ASA O
group O
; O
P O
=.02 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Cost B-outcome ['Resource-use']
differences O
for O
the O
period O
preceding O
and O
subsequent O
to O
the O
cessation O
attempt O
were O
assessed O
by O
trial O
participants O
' O
12-month O
sustained O
quit O
status O
. O
['Resource-use']

Low O
efficacy O
of O
mebendazole O
against O
hookworm B-outcome ['Physiological-Clinical']
in O
Vietnam O
: O
two O
randomized O
controlled O
trials O
. O
['Physiological-Clinical']

Acidosis O
was O
defined O
as O
pH O
< O
7.25 O
. O
[]

In O
period O
2 O
: O
ErSr O
urinary B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
output I-outcome ['Physiological-Clinical']
was O
reduced O
by O
81.4 O
( O
SEM O
17.8 O
) O
mmol O
( O
mEq O
) O
/24 O
h O
and O
there O
was O
a O
weight O
loss B-outcome ['Physiological-Clinical']
of O
8.2 O
( O
SEM O
0.7 O
) O
kg O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
toxicity O
( O
particularly O
diarrhoea O
) O
, O
quality O
of O
life O
, O
and O
efficacy O
of O
combination O
chemotherapy O
and O
irinotecan O
in O
these O
patients O
. O
[]

RESULTS O
The O
overall O
frequency O
of O
allelic B-outcome ['Physiological-Clinical']
imbalance B-outcome ['Physiological-Clinical']
was O
79 O
% O
in O
primary O
tumors O
and O
88 O
% O
in O
paired O
metastases O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CONCLUSIONS O
This O
study O
indicates O
the O
effectiveness O
of O
risperidone O
during O
a O
period O
of O
several O
months O
, O
reducing O
disruptive B-outcome ['Life-Impact']
behavior I-outcome ['Life-Impact']
in O
about O
half O
of O
the O
children O
with O
autism O
spectrum O
disorders O
. O
['Life-Impact']

Treatment O
with O
etidronate O
increases O
BMD B-outcome ['Physiological-Clinical']
in O
chronically O
hospitalized O
patients O
poststroke O
, O
and O
may O
prevent O
hip O
fracture O
. O
['Physiological-Clinical']

Evaluation O
of O
the O
effect O
of O
low O
level O
laser O
on O
prevention O
of O
chemotherapy-induced B-outcome ['Physiological-Clinical']
mucositis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

This O
difference O
was O
not O
found O
for O
erythema B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

In O
this O
design O
, O
however O
, O
lithium/early O
morning O
sleep O
deprivation O
was O
no O
faster O
than O
either O
of O
the O
two O
desipramine/sleep O
deprivation O
conditions O
in O
inducing B-outcome ['Physiological-Clinical']
remission I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

All O
three O
treatments O
generally O
yielded O
comparable O
results O
for O
the O
secondary O
efficacy O
variables O
and O
all O
treatments O
were O
well O
[]

In O
Experiment O
1 O
participants O
watched O
a O
video O
, O
before O
a O
cued-recall O
test O
for O
which O
they O
were O
either O
instructed O
to O
close O
their O
eyes O
, O
or O
received O
no-instructions O
. O
[]

A O
sensory O
integration O
therapy O
program O
on O
sensory O
problems O
for O
children O
with O
autism O
. O
[]

OBJECTIVE O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
tetrahydrobiopterin O
( O
BH4 O
) O
reduced O
core O
symptoms O
of O
autism O
spectrum O
disorder O
( O
ASD O
) O
. O
[]

Injections O
areas O
were O
assessed O
for O
the O
presence O
of O
bruising B-outcome ['Physiological-Clinical']
at O
48 O
and O
72 O
hours O
after O
each O
injection O
. O
['Physiological-Clinical']

The O
slope O
of O
the O
regression O
line O
for O
the O
delta O
melanin B-outcome ['Resource-use']
index O
against O
delta O
erythema B-outcome ['Physiological-Clinical']
['Resource-use', 'Physiological-Clinical']

Placebo-controlled O
acute O
dosage O
naltrexone O
study O
in O
young O
autistic O
children O
. O
[]

No O
differences O
in O
power O
emerged O
. O
[]

The O
cumulative O
rate O
of O
HIV O
transmission O
or O
death O
at O
12 O
months O
was O
10?2 O
% O
( O
95 O
% O
CI O
7?6-13?6 O
% O
) O
in O
the O
triple O
antiretroviral O
group O
compared O
with O
16?0 O
% O
( O
12?7-20?0 O
% O
) O
in O
the O
zidovudine O
and O
single-dose O
nevirapine O
group O
( O
p=0?017 O
) O
. O
[]

It O
can O
also O
correlate O
with O
gamma-aminobutyric O
acid O
( O
GABA O
) O
-homocarnosine O
interaction O
, O
with O
possible O
anticonvulsive O
effects O
. O
[]

On O
the O
basis O
of O
traditional O
treatment, O
the O
children O
in O
the O
SBH O
treatment O
group O
were O
given O
SBH O
treatment O
within O
6 O
hours O
after O
birth. O
[]

The O
groups O
were O
comparable O
for O
maternal O
age O
, O
parity O
, O
weight O
and O
supplemental O
iron O
intake O
, O
infant O
s O
birth O
weight O
, O
gestation O
and O
sex O
. O
[]

METHODS O
A O
randomized O
, O
open-labeled O
, O
prospective O
controlled O
trial O
comparing O
sequential O
vs. O
standard O
triple-drug O
therapy O
was O
carried O
out O
at O
Lokmanya O
Tilak O
Municipal O
General O
Hospital O
, O
Mumbai O
. O
[]

The O
need O
for O
an O
additional B-outcome ['Resource-use']
antibiotic I-outcome ['Resource-use']
course O
was O
observed O
in O
8 O
patients O
in O
the O
trimethoprim-sulfamethoxazole O
group O
and O
5 O
patients O
in O
the O
ciprofloxacin O
group O
( O
difference O
, O
2.3 O
% O
; O
95 O
% O
CI O
, O
-5.4 O
to O
10.0 O
; O
P O
= O
.549 O
) O
. O
['Resource-use']

A O
vocabulary B-outcome ['Life-Impact']
difference O
score O
, O
calculated O
using O
the O
MacArthur O
Communicative O
Development O
Inventories O
( O
L. O
Fenson O
et O
al. O
, O
1993 O
) O
, O
was O
used O
as O
the O
outcome O
measure O
of O
spoken O
vocabulary O
6 O
months O
later O
. O
['Life-Impact']

Significant O
differences O
were O
not O
identified O
between O
patients O
with O
similar O
current O
ages O
and O
cerebrovascular O
disease O
risk O
who O
had O
early-onset O
or O
late-onset O
depression O
. O
[]

Cemented O
CeraOne O
and O
porcelain O
fused O
to O
TiAdapt O
abutment O
single-implant O
crown O
restorations O
: O
a O
10-year O
comparative O
follow-up O
study O
. O
[]

One O
hundred O
thirty-two O
other O
patients O
received O
chemotherapy O
and O
RT O
during O
induction O
( O
up-front O
RT O
) O
. O
[]

A O
comparative O
study O
on O
control O
subjects O
and O
depressed O
patients O
. O
[]

Tractography O
was O
conducted O
to O
isolate O
the O
superior O
longitudinal O
fasciculus O
and O
investigate O
whether O
the O
exercise O
intervention O
affected O
WMI O
in O
this O
region O
. O
[]

Journal O
ID: O
2985248R O
[]

RESULTS O
After O
the O
intervention O
period O
, O
the O
diabetes O
specific O
formula O
resulted O
in O
a O
significantly O
lower O
postprandial B-outcome ['Physiological-Clinical']
rise I-outcome ['Physiological-Clinical']
in I-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
0.5 O
hour O
( O
P O
< O
0.05 O
) O
and O
1 O
hour O
( O
P O
< O
0.01 O
) O
; O
significantly O
lower O
peak O
height O
of O
plasma B-outcome ['Physiological-Clinical']
glucose I-outcome ['Physiological-Clinical']
( O
P O
= O
0.05 O
) O
; O
significantly O
lower O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
at O
0.5 O
hour O
( O
P O
< O
0.01 O
) O
, O
1 O
hour O
( O
P O
< O
0.01 O
) O
and O
2 O
hours O
( O
P O
< O
0.01 O
) O
; O
and O
a O
significantly O
lower O
plasma B-outcome ['Physiological-Clinical']
insulin I-outcome ['Physiological-Clinical']
peak I-outcome ['Physiological-Clinical']
compared O
to O
controls O
; O
both O
OGTT O
and O
a O
standard O
test O
meal O
( O
P O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Neuromuscular B-outcome ['Resource-use']
monitoring I-outcome ['Resource-use']
was O
performed O
using O
an O
electromyographic O
( O
EMG O
) O
device O
( O
Datex O
Relaxograph O
) O
. O
['Resource-use']

The O
strongest O
predictor O
of O
lower O
maternal B-outcome ['Life-Impact']
attachment I-outcome ['Life-Impact']
was O
depressive B-outcome ['Life-Impact']
symptoms I-outcome ['Life-Impact']
late O
in O
pregnancy O
; O
pregnancy O
intention O
was O
marginally O
predictive O
of O
attachment B-outcome ['Life-Impact']
, O
with O
lower O
scores O
being O
associated O
with O
unwanted O
pregnancies O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Phosphodiesterase-4 O
inhibitors O
represent O
a O
promising O
new O
class O
of O
substances O
for O
use O
in O
antiinflammatory O
treatment O
of O
this O
disease O
. O
[]

During O
the O
first O
4 O
days O
these O
changes O
were O
significant O
( O
p O
< O
0.05 O
) O
. O
[]

The O
75 O
% O
Awassi O
crosses O
were O
least O
profitable B-outcome ['Life-Impact']
. O
['Life-Impact']

The O
odds O
ratio O
( O
OR O
) O
of O
patients O
with O
wounds O
in O
the O
control O
group O
was O
4.1 O
( O
95 O
% O
CI O
is O
1.884 O
, O
8.964 O
) O
more O
likely O
to O
be O
contaminated O
with O
bacteria O
compared O
with O
wounds O
covered O
with O
occlusive O
ionic O
silver-containing O
dressing O
. O
[]

Our O
purpose O
was O
to O
investigate O
the O
effectiveness O
and O
cost-effectiveness O
of O
three O
intervention-arms O
(combined O
neuromuscular O
exercise O
and O
back O
care O
counselling O
or O
either O
alone) O
compared O
with O
non-treatment. O
[]

Both O
groups O
completed O
+25d O
in O
the O
hot O
condition. O
[]

Relationship O
between O
endogenous O
estrogen O
concentrations O
and O
serum O
cholesteryl O
ester O
transfer O
protein O
concentrations O
in O
Chinese O
women O
. O
[]

We O
investigated O
to O
compare O
the O
effects O
of O
the O
addition O
of O
tamoxifen O
to O
epirubicin O
versus O
epirubicin O
alone O
on O
VEGF O
and O
VEGFR2 O
expression O
in O
breast O
cancer O
patients O
. O
[]

Statistically O
significant O
root B-outcome ['Physiological-Clinical']
coverage I-outcome ['Physiological-Clinical']
percentage O
was O
observed O
at O
one O
year O
post-treatment O
for O
both O
groups O
(p O
< O
0.05). O
[['Physiological-Clinical']]

OBJECTIVE O
The O
renin-angiotensin O
system O
is O
thought O
to O
be O
involved O
in O
the O
progression O
of O
chronic O
renal O
diseases O
of O
both O
diabetic O
and O
non-diabetic O
origin O
. O
[]

The O
hypothesis O
was O
that O
, O
although O
the O
concentration O
of O
bupivacaine O
( O
0.1 O
% O
) O
was O
low O
to O
minimize O
its O
adverse O
effects O
, O
if O
the O
infusion O
rate O
of O
a O
fentanyl/bupivacaine O
solution O
was O
closely O
adjusted O
according O
to O
need O
, O
the O
presence O
bupivacaine O
would O
reduce O
the O
requirement O
for O
epidural O
fentanyl O
. O
[]

PGE1 O
decreased O
systolic B-outcome ['Physiological-Clinical']
arterial I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
approximately O
34 O
% O
from O
pre-administration O
values O
. O
['Physiological-Clinical']

The O
mean O
value O
of O
all O
measured O
hematology B-outcome ['Physiological-Clinical']
variables O
remained O
within O
the O
reference O
values O
in O
all O
study O
subject O
and O
no O
significant O
changes O
were O
observed O
in O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
or O
lipid B-outcome ['Physiological-Clinical']
values. O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

To O
evaluate O
the O
role O
of O
hydroxyurea O
( O
HU O
) O
for O
the O
outcome O
of O
IFN O
therapy O
, O
we O
conducted O
a O
randomized O
trial O
to O
compare O
the O
combination O
of O
IFN O
and O
HU O
vs O
HU O
monotherapy O
( O
CML-study O
II O
) O
. O
[]

The O
objective O
of O
this O
research O
was O
to O
determine O
if O
bioelastic O
matrices O
could O
provide O
controlled B-outcome ['Physiological-Clinical']
release I-outcome ['Physiological-Clinical']
of O
thromboxane O
A2 O
synthetase O
inhibitor O
( O
dazmegrel O
) O
at O
tissue O
concentrations O
sufficient O
for O
inhibition O
of O
thromboxane O
synthesis O
. O
['Physiological-Clinical']

Four O
participants O
( O
9 O
% O
) O
in O
the O
group O
that O
had O
arthroscopic O
cuff O
repair O
alone O
, O
one O
with O
a O
Type-2 O
and O
three O
with O
a O
Type-3 O
acromion O
, O
required O
additional B-outcome ['Resource-use']
surgery I-outcome ['Resource-use']
by O
the O
twenty-four-month O
time O
point O
. O
['Resource-use']

The O
scores O
for O
the O
bispectral O
index O
may O
not O
reflect O
correct O
values O
in O
children O
, O
but O
may O
be O
helpful O
during O
titration O
of O
sedatives O
such O
as O
midazolam O
and O
ketamine O
. O
[]

Clofarabine O
? O
[]

BACKGROUND O
The O
antifibrinolytic O
tranexamic O
acid O
reduces O
surgical O
blood O
loss O
, O
but O
studies O
have O
not O
identified O
an O
optimal O
regimen O
. O
[]

Use O
of O
nerve O
stimulation O
did O
not O
significantly O
alter O
the O
requirements O
for O
analgesia O
although O
there O
was O
a O
reduction O
in O
postoperative B-outcome ['Physiological-Clinical']
nausea I-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
in O
the O
nerve O
stimulation O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Gonorrhea B-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
chlamydial I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
was O
detected O
in O
6 O
% O
of O
intervention O
and O
11 O
% O
of O
control O
participants O
at O
follow-up O
( O
AOR O
= O
2.2 O
; O
95 O
% O
CI O
= O
1.1 O
, O
4.1 O
) O
, O
with O
greatest O
benefits O
seen O
among O
men O
( O
for O
gender O
interaction O
, O
P O
= O
.03 O
) O
. O
['Physiological-Clinical']

n O
= O
755 O
) O
, O
lumiracoxib O
100 O
mg O
b.i.d O
. O
( O
[]

Quantitative O
monitoring O
of O
serum B-outcome ['Physiological-Clinical']
hepatitis I-outcome ['Physiological-Clinical']
B I-outcome ['Physiological-Clinical']
virus I-outcome ['Physiological-Clinical']
DNA I-outcome ['Physiological-Clinical']
and O
blood B-outcome ['Physiological-Clinical']
lymphocyte I-outcome ['Physiological-Clinical']
subsets I-outcome ['Physiological-Clinical']
during O
combined O
prednisolone O
and O
interferon-alpha O
therapy O
in O
patients O
with O
chronic O
hepatitis O
B O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
effect O
of O
oral O
steroids O
with O
and O
without O
vitamin O
D3 O
on O
early O
efficacy O
of O
immunotherapy O
in O
asthmatic O
children O
. O
[]

BACKGROUND O
Allopurinol O
has O
been O
widely O
used O
for O
treatment O
of O
hyperuricemia O
, O
however O
, O
it O
may O
be O
associated O
with O
various O
adverse O
effects O
. O
[]

Serotonergic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
was O
measured O
by O
the O
neuro-endocrine O
response O
to O
a O
placebo-controlled O
, O
crossover O
challenge O
with O
dexfenfluramine O
. O
['Physiological-Clinical']

Carriers O
of O
HBV O
are O
over O
100 O
times O
more O
likely O
to O
develop O
liver O
cancer O
than O
non-carriers O
. O
[]

Treadmill B-outcome ['Life-Impact']
exercise I-outcome ['Life-Impact']
tests O
and O
72-hour O
electrocardiographic B-outcome ['Physiological-Clinical']
recordings O
were O
obtained O
at O
the O
end O
of O
two O
2-week O
treatment O
periods O
with O
sustained-release O
diltiazem O
180 O
mg O
b.i.d O
. O
['Life-Impact', 'Physiological-Clinical']

After O
stratification O
according O
to O
staging O
and O
initial O
treatment O
, O
one-third O
of O
the O
patients O
received O
chemotherapy O
for O
2 O
years O
( O
methotrexate O
400 O
mg O
followed O
by O
citrovorum O
factor O
100 O
mg O
+ O
bleomycin O
60 O
mg/week O
, O
during O
the O
first O
15 O
weeks O
) O
, O
one-third O
of O
the O
patients O
received O
immunotherapy O
with O
weekly O
C. O
parvum O
injections O
during O
2 O
years O
, O
while O
the O
remaining O
third O
did O
not O
receive O
any O
treatment O
. O
[]

Enhancing O
HIV O
medication O
adherence B-outcome ['Life-Impact']
in O
India O
. O
['Life-Impact']

Thus O
a O
study O
of O
phenytoin O
prophylaxis O
was O
undertaken O
and O
is O
herein O
reported O
. O
[]

When O
sex O
was O
considered, O
females O
had O
lower O
urine B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
[UV] I-outcome ['Physiological-Clinical']
, O
elevated O
urine B-outcome ['Physiological-Clinical']
osmolality I-outcome ['Physiological-Clinical']
(UOsm) I-outcome ['Physiological-Clinical']
(p O
< O
0.05), O
trends O
for O
higher O
Delta O
Body B-outcome ['Physiological-Clinical']
Weight I-outcome ['Physiological-Clinical']
[BW] I-outcome ['Physiological-Clinical']
), O
urine B-outcome ['Physiological-Clinical']
specific I-outcome ['Physiological-Clinical']
gravity I-outcome ['Physiological-Clinical']
[USG] I-outcome ['Physiological-Clinical']
, O
but O
similar O
salivary B-outcome ['Physiological-Clinical']
osmolality I-outcome ['Physiological-Clinical']
(SOsm) I-outcome ['Physiological-Clinical']
. O
Analysis O
of O
beverages O
and O
urine O
for O
antioxidant B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(AP) I-outcome ['Physiological-Clinical']
revealed O
a O
four-fold O
greater O
antioxidant B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(AP) I-outcome ['Physiological-Clinical']
in O
MW, O
which O
increased O
peak O
urine O
antioxidant B-outcome ['Physiological-Clinical']
potential I-outcome ['Physiological-Clinical']
(AP) I-outcome ['Physiological-Clinical']
(9.4 O
+/- O
0.7 O
vs. O
7.6 O
+/- O
1.0 O
mmol, O
MW O
vs. O
control, O
p O
< O
0.05). O
[['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Physiological-Clinical']]

BACKGROUND O
As O
the O
proportion O
of O
the O
population O
that O
is O
older O
continues O
to O
rise O
, O
infection O
in O
older O
people O
has O
become O
an O
important O
healthcare O
problem O
. O
[]

We O
evaluated O
in O
a O
randomized O
, O
double-blind O
and O
cross-over O
study O
, O
the O
effects O
of O
a O
DA O
agonist O
( O
bromocriptine O
) O
and O
a O
DA O
antagonist O
( O
amisulpride O
) O
on O
platelet O
5-HT O
in O
infantile O
autism O
. O
[]

induction O
and O
VEGF O
expression O
and O
may O
serve O
as O
a O
potential O
agent O
in O
the O
prevention O
of O
telangiectasias O
. O
[]

Sleep B-outcome ['Physiological-Clinical']
disturbances I-outcome ['Physiological-Clinical']
in O
the O
experimental O
acupuncture O
treatment O
group O
declined O
over O
the O
study O
. O
['Physiological-Clinical']

Seventy-seven O
consecutive O
biopsies O
were O
performed O
by O
a O
single O
operator O
. O
[]

A O
Siemens/CTI O
931/08-12 O
scanner O
with O
the O
capability O
of O
15 O
horizontal O
brain O
slices O
was O
used O
. O
[]

In O
complex O
regional O
pain O
syndrome O
( O
CRPS1 O
) O
initiated O
by O
wrist O
fracture O
, O
a O
motor O
imagery O
program O
( O
MIP O
) O
, O
consisting O
of O
hand O
laterality O
recognition O
followed O
by O
imagined O
movements O
and O
then O
mirror O
movements O
, O
reduces O
pain B-outcome ['Physiological-Clinical']
and O
disability B-outcome ['Life-Impact']
, O
but O
the O
mechanism O
of O
effect O
is O
unclear O
. O
['Physiological-Clinical', 'Life-Impact']

To O
investigate O
the O
applicability B-outcome ['Life-Impact']
and O
effectiveness O
of O
a O
peer-mentored O
exercise O
program O
, O
this O
study O
compared O
the O
retention B-outcome ['Life-Impact']
and O
participation B-outcome ['Life-Impact']
rates O
, O
and O
physical B-outcome ['Physiological-Clinical']
improvements I-outcome ['Physiological-Clinical']
of O
older O
adults O
trained O
by O
peer O
mentors O
( O
PM O
) O
to O
a O
group O
trained O
by O
young O
qualified O
student O
mentors O
( O
SM O
) O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact', 'Physiological-Clinical']

AIMS O
To O
investigate O
the O
impact O
of O
variations O
in O
clinical O
context O
on O
blood O
pressure O
measurement O
in O
a O
simulator-based O
OSCE O
. O
[]

OBJECTIVE: O
To O
investigate O
the O
effects O
of O
aerosol O
inhalation O
on O
respiratory B-outcome ['Physiological-Clinical']
mechanical I-outcome ['Physiological-Clinical']
parameters O
under O
different O
ventilation O
patterns O
and O
ventilator O
parameters O
in O
patients O
on O
mechanical O
ventilation O
and O
simulated O
model O
of O
aqualung O
in O
vitro. O
[['Physiological-Clinical']]

One O
hundred O
children O
with O
ASD O
, O
aged O
7 O
to O
12 O
years O
will O
be O
randomly O
assigned O
to O
an O
intervention O
or O
a O
waiting O
list O
control O
group O
. O
[]

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
of O
meropenem O
, O
a O
new O
carbapenem O
antibiotic O
, O
with O
that O
of O
imipenem O
, O
which O
is O
the O
standard O
prophylactic O
treatment O
in O
patients O
with O
severe O
acute O
pancreatitis O
. O
[]

A O
study O
was O
undertaken O
to O
compare O
directly O
the O
self-administered O
version O
of O
the O
CRQ O
and O
the O
SGRQ O
with O
respect O
to O
feasibility O
, O
internal O
consistency O
, O
validity O
, O
and O
sensitivity O
to O
changes O
resulting O
from O
bronchodilator O
therapy O
. O
[]

We O
examined O
the O
associations O
of O
prediagnostic O
plasma O
levels O
of O
25 O
( O
OH O
) O
D O
and O
1,25 O
( O
OH O
) O
2D O
, O
individually O
and O
jointly O
, O
with O
total O
and O
aggressive O
disease O
, O
and O
explored O
whether O
relations O
between O
vitamin O
D O
metabolites O
and O
prostate O
cancer O
were O
modified O
by O
the O
functional O
VDR O
FokI O
polymorphism O
, O
using O
conditional O
logistic O
regression O
. O
[]

We O
evaluated O
the O
acute O
effects O
of O
decaffeinated O
coffee O
and O
the O
major O
coffee O
components O
chlorogenic O
acid O
and O
trigonelline O
on O
glucose O
tolerance O
. O
[]

In O
the O
healthy O
subjects O
, O
there O
was O
no O
significant O
difference O
in O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
with O
the O
different O
doses O
but O
in O
duodenal O
ulcer O
patients O
a O
tenfold O
increase O
of O
the O
antacid O
dose O
resulted O
in O
a O
doubling O
of O
the O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
action I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

SETTING O
Outpatient O
clinics O
. O
[]

mean O
diastolic O
BP O
( O
DBP O
) O
increased O
in O
both O
study O
groups O
. O
[]

RATIONALE O
AND O
OBJECTIVE O
Depression O
is O
a O
significant O
complication O
of O
stroke O
. O
[]

C B-outcome ['Physiological-Clinical']
parvum I-outcome ['Physiological-Clinical']
was O
eradicated O
from O
stool O
in O
13 O
( O
52 O
% O
) O
of O
25 O
receiving O
nitazoxanide O
and O
three O
( O
14 O
% O
) O
of O
22 O
receiving O
placebo O
( O
38 O
% O
, O
95 O
% O
CI O
14-63 O
; O
p=0.007 O
) O
. O
['Physiological-Clinical']

A O
literature O
search O
( O
MEDLINE O
database O
) O
revealed O
wide O
variations O
in O
IDI O
techniques O
without O
a O
basis O
for O
comparison O
. O
[]

Of O
these O
, O
85 O
patients O
were O
randomized O
to O
the O
treatment O
group O
and O
underwent O
pTBA O
within O
96 O
hours O
after O
subarachnoid O
hemorrhage O
. O
[]

These O
increases O
indicated O
buccal B-outcome ['Physiological-Clinical']
tipping I-outcome ['Physiological-Clinical']
of O
the O
teeth O
. O
['Physiological-Clinical']

No O
patient O
had O
[]

High-functioning O
autism O
( O
HFA O
) O
is O
characterized O
by O
persistent O
impairment O
in O
social O
interaction O
despite O
the O
absence O
of O
mental O
retardation O
. O
[]

After O
restoration O
of O
euthyroidism O
, O
a O
significant O
improvement O
in O
LV B-outcome ['Physiological-Clinical']
systolic I-outcome ['Physiological-Clinical']
and O
diastolic B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
as O
assessed O
with O
2D-STE O
strain O
was O
observed O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
intention-to-treat O
analysis O
showed O
a O
difference O
in O
the O
risk O
of O
definitive O
treatment B-outcome ['Physiological-Clinical']
failure I-outcome ['Physiological-Clinical']
(oral O
group O
vs. O
intravenous O
group) O
of O
-1.4 O
percentage O
points O
(90% O
confidence O
interval O
[CI], O
-4.9 O
to O
2.2; O
95% O
CI, O
-5.6 O
to O
2.9), O
indicating O
noninferiority. O
[['Physiological-Clinical']]

Ongoing O
Telmisartan O
Alone O
and O
in O
Combination O
With O
Ramipril O
Global O
Endpoint O
Trial O
( O
ONTARGET O
) O
: O
implications O
for O
reduced O
cardiovascular B-outcome ['Physiological-Clinical']
risk O
. O
['Physiological-Clinical']

QoL B-outcome ['Life-Impact']
was O
measured O
with O
the O
St O
George O
's O
Respiratory B-outcome ['Physiological-Clinical']
Questionnaire O
( O
SGRQ O
) O
and O
a O
visual O
analogue O
scale O
( O
VAS O
) O
. O
['Life-Impact', 'Physiological-Clinical']

Parametric O
analysis O
revealed O
activity B-outcome ['Life-Impact']
correlating O
with O
temporal O
complexity O
during O
initiate O
in O
bilateral O
supplementary O
and O
pre-supplementary O
motor O
cortex O
( O
SMA O
and O
preSMA O
) O
, O
rostral B-outcome ['Physiological-Clinical']
dorsal I-outcome ['Physiological-Clinical']
premotor I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
PMC O
) O
, O
basal B-outcome ['Physiological-Clinical']
ganglia I-outcome ['Physiological-Clinical']
, O
and O
dorsolateral B-outcome ['Physiological-Clinical']
prefrontal I-outcome ['Physiological-Clinical']
cortex I-outcome ['Physiological-Clinical']
( O
DLPFC O
) O
, O
among O
other O
areas O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

STUDY O
DESIGN O
Adults O
with O
uncomplicated O
acute O
appendicitis O
were O
randomized O
1:1 O
to O
either O
SILS O
or O
3-port O
laparoscopic O
appendectomy O
. O
[]

Surgical O
site O
infection O
(SSI) O
and O
incisional O
hernia O
are O
common O
complications O
after O
major O
pancreatectomy. O
[]

MAIN O
OUTCOME O
MEASURES O
Biochemical B-outcome ['Physiological-Clinical']
[ O
peak-stimulated B-outcome ['Physiological-Clinical']
LH I-outcome ['Physiological-Clinical']
, O
estradiol B-outcome ['Physiological-Clinical']
( O
girls O
) O
, O
and O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Changes O
of O
RPF O
induced O
by O
treatment O
correlated O
with O
the O
L-NMMA O
induced O
decrease O
in O
RPF B-outcome ['Physiological-Clinical']
in O
the O
combination O
( O
r O
= O
0.70 O
, O
P O
< O
0.01 O
) O
and O
eprosartan O
phase O
( O
r O
= O
0.86 O
, O
P O
< O
0.001 O
) O
, O
but O
not O
in O
the O
enalapril O
phase O
( O
r O
= O
-0.44 O
, O
P O
= O
0.10 O
) O
. O
['Physiological-Clinical']

METHODS O
From O
215 O
patients O
admitted O
within O
24 O
hours O
of O
a O
hemispheric O
ischemic O
stroke O
, O
89 O
patients O
on O
chronic O
statin O
treatment O
were O
randomly O
assigned O
either O
to O
statin O
withdrawal O
for O
the O
first O
3 O
days O
after O
admission O
( O
n O
= O
46 O
) O
or O
to O
immediately O
receive O
atorvastatin O
20 O
mg/day O
( O
n O
= O
43 O
) O
. O
[]

RESULTS O
Relative O
to O
children O
in O
the O
wait-list O
group O
, O
program O
participants O
showed O
greater O
improvements O
in O
social B-outcome ['Life-Impact']
skills I-outcome ['Life-Impact']
over O
the O
course O
of O
the O
intervention O
, O
as O
indicated O
by O
parent-report O
measures O
. O
['Life-Impact']

Significant O
treatment O
effects O
were O
found O
for O
five O
of O
seven O
primary O
outcome O
measures O
( O
parent O
ratings O
and O
direct O
child O
measures O
) O
. O
[]

Similarly O
, O
the O
need O
for O
target B-outcome ['Physiological-Clinical']
vessel I-outcome ['Physiological-Clinical']
revascularization I-outcome ['Physiological-Clinical']
was O
reduced O
from O
25.5 O
% O
to O
24.2 O
% O
and O
to O
15.2 O
% O
in O
the O
placebo O
, O
usual-dose O
, O
and O
high-dose O
groups O
, O
respectively O
( O
P=0.08 O
) O
. O
['Physiological-Clinical']

Survival O
curve O
analyses O
revealed O
little O
difference O
between O
these O
groups O
for O
major O
vascular B-outcome ['Physiological-Clinical']
end I-outcome ['Physiological-Clinical']
points I-outcome ['Physiological-Clinical']
, O
total O
mortality B-outcome ['Mortality']
, O
all O
amputations B-outcome ['Resource-use']
, O
or O
myocardial B-outcome ['Physiological-Clinical']
infarctions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Mortality', 'Resource-use', 'Physiological-Clinical']

Brief O
report O
: O
effect O
of O
a O
focused O
imitation O
intervention O
on O
social B-outcome ['Life-Impact']
functioning I-outcome ['Life-Impact']
in O
children O
with O
autism O
. O
['Life-Impact']

METHOD O
Forty O
individuals O
comprised O
the O
simulating O
and O
control O
group O
and O
all O
participants O
were O
randomly O
assigned O
to O
the O
simulating O
and O
control O
groups O
. O
[]

METHODS O
Thirty-one O
patients O
with O
cirrhosis O
receiving O
norfloxacin O
( O
400 O
mg/day O
) O
were O
included O
. O
[]

OUTCOMES O
The O
primary O
outcome O
was O
predialysis O
anti-Xa O
levels O
20 O
to O
24 O
hours O
after O
the O
third O
LMWH O
dose O
( O
therapeutic O
target O
, O
< O
0.2 O
IU/mL O
) O
. O
[]

Seven O
healthy O
subjects O
immersed O
a O
hand O
in O
random O
order O
in O
either O
warm O
water O
or O
in O
cold O
water O
at O
5 O
degrees O
C O
for O
2 O
min O
, O
after O
taking O
orally O
a O
single O
dose O
of O
120 O
mg O
of O
propranolol O
or O
a O
placebo O
in O
a O
double O
blind O
fashion O
. O
[]

Fisher's O
exact O
test O
was O
used O
to O
verify O
the O
differences O
between O
categorical O
variables. O
[]

The O
first O
molar O
, O
first O
premolar O
, O
lateral O
incisor O
, O
and O
contralateral O
canine O
( O
control O
) O
were O
blindly O
tested O
with O
an O
Analytic O
Technology O
pulp O
tester O
at O
3-min O
cycles O
for O
50 O
min O
. O
[]

Due O
to O
the O
sample O
size O
and O
short O
time O
frame O
, O
results O
of O
a O
repeated O
measures O
analysis O
of O
variance O
did O
not O
reach O
significance O
. O
[]

The O
conventional O
methods O
of O
IPC O
use O
low O
pressure O
and O
slow O
inflation O
of O
the O
air O
bladder O
on O
the O
leg O
to O
augment O
venous O
return O
. O
[]

METHODS O
Twenty O
drug-free O
adults O
with O
autistic O
disorder O
( O
16 O
men O
and O
4 O
women O
) O
( O
mean O
[ O
+/- O
SD O
] O
age O
, O
30.5 O
+/- O
8.5 O
years O
) O
underwent O
short-term O
tryptophan O
depletion O
in O
a O
double-blind O
, O
placebo-controlled O
, O
randomized O
crossover O
design O
. O
[]

Nasal O
allergic O
inflammation O
enhances O
bone-marrow O
eosinophil O
production O
, O
mainly O
via O
IL-5 O
, O
and O
rhinitis O
patients O
have O
increased O
airway O
inflammation O
during O
the O
pollen O
season O
. O
[]

Radiographic O
progression O
was O
much O
greater O
in O
patients O
receiving O
MTX O
plus O
placebo O
than O
in O
patients O
receiving O
infliximab O
plus O
MTX O
, O
irrespective O
of O
[]

The O
Sur-Catch O
NT O
was O
significantly O
slower O
for O
2 O
mm O
calculi O
than O
the O
N-Circle O
( O
p O
= O
0.01 O
) O
, O
Dimension O
( O
p O
=.03 O
) O
, O
Halo O
( O
p O
=.0005 O
) O
, O
Vantage O
( O
p O
=.001 O
) O
and O
Zerotip O
( O
p O
=.002 O
) O
. O
[]

BACKGROUND O
AND O
PURPOSE O
A O
low-affinity O
, O
use-dependent O
N-Methyl-D-Aspartate O
( O
NMDA O
) O
antagonist O
AR-R15896AR O
has O
neuroprotective O
properties O
in O
animal O
models O
of O
ischaemic O
stroke O
. O
[]

OBJECTIVE O
The O
standard O
opioid O
treatment O
for O
postoperative O
pain O
can O
be O
associated O
with O
nausea O
, O
vomiting O
, O
and O
constipation O
. O
[]

The O
study O
objective O
was O
to O
compare O
whether O
evidence-based O
narrative O
versus O
traditional O
summary O
improved O
recall O
of O
opioid O
prescribing O
guidelines O
from O
the O
American O
College O
of O
Emergency O
Physicians O
( O
ACEP O
) O
. O
[]

TRIAL O
REGISTRATION: O
ClinicalTrials.gov O
NCT01277302 O
. O
[]

It O
was O
lowered O
after O
drug O
therapy O
in O
the O
two O
groups O
with O
statistical O
difference O
( O
P O
< O
0.05 O
) O
. O
[]

It O
is O
unknown O
whether O
small-molecule O
agents O
confer O
similar O
benefits O
. O
[]

The O
sample O
included O
15 O
children O
aged O
2-16 O
years O
with O
autism O
spectrum O
disorder O
. O
[]

Seventy-six O
healthy O
postmenopausal O
women O
were O
randomly O
assigned O
to O
placebo O
or O
800 O
IU O
( O
20 O
?g O
) O
, O
2000 O
IU O
( O
50 O
?g O
) O
, O
or O
4000 O
IU O
( O
100 O
?g O
) O
vitamin O
D? O
for O
8 O
wk O
. O
[]

Follow-up O
appointments O
were O
made O
for O
intervention O
patients O
to O
attend O
their O
GPs O
. O
[]

ALT B-outcome ['Physiological-Clinical']
values O
decreased O
from O
pre-treatment O
levels O
of O
157.0 O
+/- O
62.6 O
IU/l O
to O
82.5 O
+/- O
46.4 O
IU/l O
( O
P O
< O
0.05 O
) O
, O
and O
GGT O
fell O
from O
141.3 O
+/- O
86.2 O
IU/l O
to O
66.0 O
+/- O
49.5 O
IU/l O
( O
P O
< O
0.001 O
) O
. O
['Physiological-Clinical']

Treatment O
group O
patients O
( O
n O
= O
22 O
) O
were O
administered O
various O
assessments O
of O
complicated O
grief O
indicators O
, O
including O
the O
Impact O
of O
Event O
Scale O
, O
the O
anxiety B-outcome ['Life-Impact']
and O
depression B-outcome ['Life-Impact']
subscales O
of O
the O
Brief O
Symptom B-outcome ['Life-Impact']
Inventory O
, O
and O
the O
SF-12 O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

4 O
cm O
in O
diameter O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
15 O
patients O
were O
treated O
with O
PLA O
, O
using O
a O
multifibre O
system O
connected O
to O
a O
neodymium O
yttrium-aluminium-garnet O
laser O
source O
; O
15 O
patients O
were O
treated O
with O
RFA O
, O
using O
an O
expandable O
needle O
electrode O
. O
[]

Intermittent O
theta-burst O
transcranial O
magnetic O
stimulation O
for O
treatment O
of O
Parkinson B-outcome ['Physiological-Clinical']
disease I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Title: O
[Effects O
of O
rhodiola O
rosea O
on O
oxidative B-outcome ['Physiological-Clinical']
stress I-outcome ['Physiological-Clinical']
and O
negative B-outcome ['Physiological-Clinical']
emotional I-outcome ['Physiological-Clinical']
states I-outcome ['Physiological-Clinical']
in O
patients O
with O
obstructive O
sleep O
apnea]. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

87.3 O
+/- O
7.7 O
kg) O
with O
at O
least O
2 O
years O
of O
experience O
in O
resistance O
training. O
[]

RESULTS O
All O
reinfusion O
sessions O
were O
tolerated B-outcome ['Life-Impact']
well O
by O
all O
patients O
. O
['Life-Impact']

The O
authors O
assessed O
the O
safety O
and O
effectiveness O
of O
atomoxetine O
monotherapy O
compared O
with O
combined O
atomoxetine/fluoxetine O
therapy O
in O
a O
population O
of O
children O
and O
adolescents O
with O
ADHD O
and O
concurrent O
symptoms O
of O
depression O
or O
anxiety O
. O
[]

Several O
studies O
have O
linked O
increased O
intake O
of O
dietary O
fibre O
to O
improvement O
in O
the O
management O
of O
body O
weight. O
[]

The O
study O
showed O
levobunolol O
to O
be O
as O
safe O
and O
effective O
as O
timolol O
in O
the O
long-term O
control O
of O
raised O
[]

RESULTS O
One O
hundred O
twenty-four O
patients O
were O
recruited O
over O
a O
23-month O
period O
. O
[]

Validation O
studies O
are O
needed O
as O
a O
next O
step O
. O
[]

OBJECTIVE O
The O
authors O
rated O
periventricular O
and O
subcortical O
signal O
hyperintensities O
on O
magnetic O
resonance O
imaging O
( O
MRI O
) O
scans O
in O
elderly O
patients O
with O
depression O
and O
in O
normal O
subjects O
with O
similar O
demographic O
features O
to O
examine O
whether O
such O
changes O
discriminate O
patients O
with O
depression O
from O
normal O
subjects O
and O
whether O
they O
are O
associated O
with O
any O
clinical O
variables O
. O
[]

This O
Phase O
II O
study O
has O
been O
undertaken O
to O
establish O
the O
efficacy O
and O
safety O
of O
ebrotidine O
, O
administered O
in O
four O
dosages O
as O
a O
single O
evening O
dose O
versus O
placebo O
in O
the O
treatment O
of O
duodenal O
ulcer O
. O
[]

Outcomes O
were O
evaluated O
at O
baseline O
, O
immediately O
after O
treatment O
, O
at O
10 O
and O
30 O
min O
. O
[]

There O
was O
an O
increase O
in O
peak O
tidal B-outcome ['Physiological-Clinical']
volume I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
VT I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
both O
groups O
but O
this O
did O
not O
lead O
to O
an O
increase O
in O
peak O
ventilation B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

One O
hundred O
twenty-eight O
patients O
were O
treated O
with O
postoperative O
radiotherapy O
with O
50 O
Gy O
in O
25 O
daily O
fractions O
over O
5 O
weeks O
. O
[]

BK O
caused O
cough B-outcome ['Physiological-Clinical']
at O
14.3 O
+/- O
0.7 O
( O
-log O
M O
) O
although O
BK1-7 O
, O
a O
major O
metabolite O
of O
BK O
by O
ACE O
, O
caused O
cough B-outcome ['Physiological-Clinical']
at O
5.7 O
+/- O
0.7 O
( O
-log O
M O
) O
in O
another O
3 O
patients O
with O
cough O
associated O
with O
ACE O
inhibitor O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Women O
( O
8,800 O
) O
, O
aged O
30-62 O
, O
were O
randomly O
selected O
among O
women O
without O
a O
registered O
Pap O
smear O
in O
the O
two O
latest O
screening O
rounds O
. O
[]

RESULTS O
Overall O
, O
the O
most O
frequent O
type O
of O
back O
pain O
experienced O
was O
lumbar B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
( O
36 O
[ O
72.0 O
% O
] O
) O
. O
['Physiological-Clinical']

The O
World O
Health O
Organisation O
(WHO) O
'5 O
Moments O
for O
Hand O
Hygiene' O
poster O
has O
been O
used O
to O
reduce O
hospital-acquired O
infections, O
but O
there O
is O
no O
similar O
tool O
to O
prevent O
community-acquired O
newborn O
infections O
in O
low-resource O
settings. O
[]

There O
was O
no O
significant O
difference O
in O
length B-outcome ['Resource-use']
of I-outcome ['Resource-use']
stay I-outcome ['Resource-use']
between O
2 O
groups O
( O
t=0.474, O
P=0.640). O
[['Resource-use']]

Serum B-outcome ['Physiological-Clinical']
norepinephrine I-outcome ['Physiological-Clinical']
, O
epinephrine B-outcome ['Physiological-Clinical']
, O
dopamine B-outcome ['Physiological-Clinical']
and O
ACTH B-outcome ['Physiological-Clinical']
concentrations I-outcome ['Physiological-Clinical']
were O
measured O
before O
and O
after O
the O
examination O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Male O
and O
female O
Korean O
patients O
aged O
18 O
to O
75 O
years O
having O
uncomplicated O
, O
mild O
to O
moderate O
, O
essential O
hypertension O
( O
sitting O
diastolic O
blood O
pressure O
[ O
SiDBP O
] O
90- O
< O
110 O
mm O
Hg O
) O
and O
receiving O
no O
antihypertensives O
in O
the O
2 O
weeks O
before O
randomization O
were O
eligible O
. O
[]

The O
results O
obtained O
in O
111 O
patients O
do O
not O
support O
any O
consistent O
relationship O
between O
plasma O
level O
of O
haloperidol O
and O
clinical B-outcome ['Physiological-Clinical']
improvement I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Intensive O
treatment O
should O
be O
started O
as O
soon O
as O
is O
safely O
possible O
after O
the O
onset O
of O
type O
1 O
diabetes O
mellitus O
and O
maintained O
thereafter O
, O
aiming O
for O
a O
practicable O
[]

METHODS O
Long-stay O
patients O
with O
schizophrenia O
in O
a O
state O
hospital O
were O
randomly O
assigned O
to O
begin O
open-label O
clozapine O
( O
n O
= O
138 O
) O
or O
to O
continue O
receiving O
conventional O
antipsychotic O
medications O
( O
n O
= O
89 O
) O
. O
[]

Belatacept O
, O
a O
costimulation O
blocker O
, O
may O
preserve O
renal B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
and O
improve O
long-term O
outcomes O
versus O
calcineurin O
inhibitors O
in O
kidney O
transplantation O
. O
['Physiological-Clinical']

INTERVENTIONS O
Twelve O
weeks O
of O
citalopram O
hydrobromide O
( O
10 O
mg/5 O
mL O
) O
or O
placebo O
. O
[]

Nine O
( O
7 O
% O
) O
eltrombopag-treated O
patients O
and O
two O
( O
3 O
% O
) O
in O
the O
placebo O
group O
had O
mild O
increases O
in O
alanine O
aminotransferase O
concentration O
, O
and O
five O
( O
4 O
% O
) O
eltrombopag-treated O
patients O
( O
vs O
none O
allocated O
to O
placebo O
) O
had O
increases O
in O
total O
bilirubin O
. O
[]

= O
0.05 O
] O
, O
progression-free B-outcome ['Mortality']
survival I-outcome ['Mortality']
( I-outcome ['Mortality']
PFS I-outcome ['Mortality']
) I-outcome ['Mortality']
and O
survival O
with O
a O
functional O
larynx O
( O
SFL O
) O
. O
['Mortality']

Publication O
Type: O
Multicenter O
Study O
[]

Outcomes O
were O
measured O
in O
3 O
randomized O
conditions O
(no O
brace, O
forearm O
band, O
or O
elbow O
sleeve). O
[]

Growth O
hormone O
( O
GH O
) O
can O
induce O
an O
accelerated B-outcome ['Physiological-Clinical']
lipolysis I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Coronary B-outcome ['Resource-use']
angiography I-outcome ['Resource-use']
was O
performed O
in O
75 O
% O
of O
the O
90 O
patients O
eligible O
for O
restudy O
. O
['Resource-use']

The O
association O
between O
changes O
in O
the O
QLQ-C30 O
change O
and O
the O
corresponding O
SSQ O
ratings O
were O
determined O
by O
calculation O
of O
mean O
change O
scores O
for O
each O
SSQ O
category O
and O
by O
Spearman O
rank O
correlation O
coefficient O
analysis O
. O
[]

Through O
a O
village-based O
surveillance O
system O
, O
diarrhoeal O
morbidity O
data O
( O
severity O
, O
duration O
, O
compliance O
) O
were O
collected O
for O
14 O
days O
. O
[]

Although O
the O
2 O
therapies O
showed O
comparable O
mean O
effects O
for O
decreasing O
LDL-C B-outcome ['Physiological-Clinical']
, O
similar O
adverse O
reaction O
and O
cost O
, O
each O
therapy O
was O
predominantly O
more O
effective O
in O
some O
patients O
than O
in O
others O
. O
['Physiological-Clinical']

Active O
treatment O
was O
first O
a O
single O
100-mg O
dose O
of O
naltrexone O
hydrochloride O
. O
[]

After O
completion O
, O
the O
oxygenators O
were O
dissected O
and O
examined O
. O
[]

DESIGN: O
A O
parallel O
group O
trial O
with O
follow-up O
METHODS:: O
Thirty O
young O
women O
were O
divided O
into O
2 O
groups: O
experimental O
(n O
= O
15) O
and O
control O
(n O
= O
15). O
[]

Discrimination O
attained O
on O
haloperidol O
was O
retained O
when O
the O
children O
were O
switched O
to O
placebo O
. O
[]

Under O
40 O
mg O
nimodipine O
the O
subgroup O
with O
poor O
alpha-activity B-outcome ['Physiological-Clinical']
showed O
a O
shift B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
left I-outcome ['Physiological-Clinical']
; O
the O
subgroup O
with O
abundant O
alpha-activity B-outcome ['Physiological-Clinical']
to I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
right I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

OBJECTIVE O
To O
compare O
injection O
pain O
of O
a O
HA O
gel O
with O
preincorporated O
lidocaine O
with O
that O
with O
a O
non-lidocaine O
formulation O
. O
[]

The O
paroxetine O
352 O
bipolar O
trial O
: O
A O
study O
in O
medical O
ghostwriting O
. O
[]

During O
phase O
1 O
, O
egg B-outcome ['Physiological-Clinical']
production I-outcome ['Physiological-Clinical']
decreased O
linearly O
( O
P O
< O
0.05 O
) O
and O
feed B-outcome ['Life-Impact']
conversion I-outcome ['Life-Impact']
ratio O
( O
FCR O
) O
tended O
to O
increase O
linearly O
( O
P O
= O
0.057 O
) O
with O
increasing O
choline O
level O
in O
the O
diet O
. O
['Physiological-Clinical', 'Life-Impact']

The O
primary O
endpoints O
were O
HIV-free O
infant O
survival O
at O
6 O
weeks O
and O
12 O
months O
; O
HIV-free O
survival O
at O
12 O
months O
in O
infants O
who O
were O
ever O
breastfed O
; O
AIDS-free O
survival O
in O
mothers O
at O
18 O
months O
; O
and O
serious O
adverse O
events O
in O
mothers O
and O
babies O
. O
[]

Values O
are O
given O
as O
completely O
acceptable O
, O
n O
( O
% O
) O
; O
fairly O
acceptable O
, O
n O
( O
% O
) O
; O
fairly O
unacceptable O
, O
n O
( O
% O
) O
and O
completely O
unacceptable O
, O
n O
( O
% O
) O
. O
( O
[]

BACKGROUND O
Self-esteem O
is O
a O
major O
concern O
in O
mood O
disorders O
. O
[]

BACKGROUND O
Daytime B-outcome ['Physiological-Clinical']
muscle I-outcome ['Physiological-Clinical']
sympathetic I-outcome ['Physiological-Clinical']
nerve I-outcome ['Physiological-Clinical']
activity I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
MSNA I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
is O
elevated O
in O
HF O
patients O
with O
coexisting O
OSA O
. O
['Physiological-Clinical']

Fifty O
percent O
of O
the O
usual-care O
group O
reported O
maintaining B-outcome ['Physiological-Clinical']
or O
increasing O
their O
physical B-outcome ['Life-Impact']
activity I-outcome ['Life-Impact']
to O
a O
moderate-intensity B-outcome ['Physiological-Clinical']
level O
, O
while O
33 O
% O
of O
the O
exercise O
group O
did O
not O
exercise O
at O
the O
prescribed O
levels O
. O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical']

Following O
a O
total O
of O
70 O
cycles O
, O
70 O
% O
of O
r-hFSH/r-hLH O
treated O
patients O
met O
the O
primary O
endpoint O
vs O
88 O
% O
in O
hMG-HP O
group O
( O
p=0.11 O
) O
. O
[]

Women O
's O
responses O
to O
information O
on O
mammographic O
breast O
density O
. O
[]

RESULTS O
No O
statistically O
significant O
difference O
in O
baseline O
characteristics O
between O
randomized O
groups O
was O
found O
. O
[]

Effects O
of O
a O
low-salt O
diet O
and O
of O
acute O
salt O
loading O
on O
blood B-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
and O
intralymphocytic B-outcome ['Physiological-Clinical']
sodium I-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
in O
young O
subjects O
with O
borderline O
hypertension O
. O
['Physiological-Clinical', 'Physiological-Clinical']

The O
primary O
end O
point O
was O
objective O
response O
rate O
( O
ORR O
) O
. O
[]

The O
impact O
of O
glutamine O
substitution O
on O
postoperative O
immunosuppression O
and O
morbidity O
was O
investigated O
in O
patients O
with O
surgical O
interventions O
and O
total O
parenteral O
nutrition O
in O
a O
prospective O
randomized O
trial O
. O
[]

METHODS O
Over O
a O
6-year O
period O
, O
patients O
with O
persistent O
H. O
pylori O
infection O
following O
omeprazole-clarithromycin-amoxicillin O
eradication O
therapy O
were O
randomized O
to O
receive O
omeprazole O
, O
20 O
mg O
twice O
daily O
, O
bismuth O
, O
120 O
mg O
four O
times O
daily O
, O
metronidazole O
, O
500 O
mg O
twice O
daily O
, O
and O
either O
tetracycline O
, O
500 O
mg O
four O
times O
daily O
, O
or O
clarithromycin O
, O
500 O
mg O
twice O
daily O
, O
given O
for O
7 O
days O
. O
[]

PURPOSE O
This O
randomized O
group O
experiment O
compared O
the O
efficacy O
of O
2 O
communication O
interventions O
( O
Responsive O
Education O
and O
Prelinguistic O
Milieu O
Teaching O
[ O
RPMT O
] O
and O
the O
Picture O
Exchange O
Communication O
System O
[ O
PECS O
] O
) O
on O
spoken O
communication O
in O
36 O
preschoolers O
with O
autism O
spectrum O
disorders O
( O
ASD O
) O
. O
[]

PATIENTS O
AND O
METHODS O
Patients O
were O
younger O
than O
55 O
years O
and O
had O
at O
least O
one O
adverse O
prognostic O
factor O
. O
[]

Adult O
patients O
with O
CT-scan O
diagnosed O
uncomplicated O
acute O
appendicitis O
will O
be O
enrolled O
in O
nine O
Finnish O
hospitals. O
[]

Naftidrofuryl O
significantly O
improved O
the O
physiological B-outcome ['Physiological-Clinical']
function I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
the I-outcome ['Physiological-Clinical']
liver I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
as I-outcome ['Physiological-Clinical']
reflected I-outcome ['Physiological-Clinical']
by I-outcome ['Physiological-Clinical']
indocyanine I-outcome ['Physiological-Clinical']
green I-outcome ['Physiological-Clinical']
( O
ICG B-outcome ['Physiological-Clinical']
) O
clearance B-outcome ['Physiological-Clinical']
by O
the O
liver O
( O
t O
= O
2.61 O
; O
p O
less O
than O
or O
equal O
to O
0.02 O
) O
and O
also O
caused O
a O
larger O
fall O
in O
raised O
serum O
levels O
of O
gamma O
glutamyl O
transpeptidase O
( O
GGT O
) O
than O
did O
the O
placebo O
injections O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Venous O
velocities O
were O
monitored O
after O
the O
application O
of O
each O
of O
five O
IPC O
devices O
, O
with O
all O
the O
patients O
in O
the O
supine O
position O
. O
[]

STUDY O
DESIGN O
AND O
METHODS O
Participants O
were O
randomly O
assigned O
to O
read O
one O
of O
three O
brochures O
: O
1 O
) O
a O
new O
brochure O
addressing O
common O
donor O
concerns O
and O
suggesting O
specific O
coping O
strategies O
, O
2 O
) O
a O
standard O
blood O
center O
brochure O
, O
or O
3 O
) O
a O
control O
brochure O
on O
healthy O
eating O
and O
exercise O
. O
[]

The O
level O
of O
significance O
was O
set O
at O
p O
< O
or=0.05 O
. O
[]

Publication O
Type: O
Randomized O
Controlled O
Trial O
[]

Evaluation O
included O
performance B-outcome ['Life-Impact']
times I-outcome ['Life-Impact']
or O
number O
of O
completed O
tasks O
within O
a O
given O
time O
frame O
. O
['Life-Impact']

Group O
B O
(scleral O
group) O
included O
124 O
cases O
(127 O
eyes), O
using O
the O
sclera O
as O
allograft. O
[]

Consolidation O
consisted O
of O
six O
courses O
of O
chemotherapy O
; O
the O
first O
, O
third O
, O
and O
fifth O
courses O
were O
a O
combination O
of O
high-dose O
cytarabine O
, O
etoposide O
, O
and O
dexamethasone O
( O
R3 O
) O
, O
whereas O
the O
second O
, O
fourth O
, O
and O
sixth O
courses O
included O
vincristine O
, O
prednisone O
, O
cyclophosphamide O
, O
doxorubicin O
, O
and O
methotrexate O
( O
COPADM O
) O
. O
[]

SETTING O
Women O
referred O
to O
routine O
ultrasound O
examination O
at O
Aker O
and O
Ullev?l O
Hospitals O
in O
Norway O
. O
[]

Plasma B-outcome ['Physiological-Clinical']
samples I-outcome ['Physiological-Clinical']
were O
obtained O
at O
baseline O
, O
+0.333 O
; O
0.667 O
; O
1.00 O
; O
1.33 O
; O
1.67 O
; O
2.00 O
; O
2.33 O
; O
2.67 O
; O
3.00 O
; O
3.50 O
; O
4.00 O
; O
6.00 O
; O
8.00 O
; O
12.0 O
; O
24.0 O
; O
36.0 O
; O
48.0 O
and O
72.0 O
h O
post-administration O
. O
['Physiological-Clinical']

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
if O
topical O
tetracaine O
reduces O
the O
pain O
of O
intramuscular O
palivizumab O
compared O
to O
placebo O
. O
[]

Eight O
of O
the O
children O
were O
comatose O
. O
[]

In O
patients O
with O
unstable O
angina/non-ST-elevation O
myocardial O
infarction O
( O
STEMI O
) O
, O
hsCRP O
> O
3 O
mg/L O
was O
associated O
with O
increased O
10-month O
mortality B-outcome ['Mortality']
( O
adjHR O
2.3 O
, O
P O
= O
0.002 O
) O
, O
whereas O
in O
STEMI O
a O
relationship O
with O
mortality O
was O
seen O
at O
hsCRP O
> O
10 O
mg/L O
( O
adjHR O
3.0 O
, O
P O
= O
0.008 O
) O
. O
['Mortality']

Serious O
adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
during O
treatment O
due O
to O
psychiatric O
conditions O
were O
associated O
with O
AR-R15896AR O
( O
3 O
vs. O
0 O
) O
. O
['Adverse-effects']

Employing O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
design O
, O
95 O
participants O
were O
assigned O
to O
one O
of O
two O
groups O
and O
administered O
a O
single O
dose O
of O
either O
secretin O
or O
placebo O
. O
[]

The O
objective O
of O
this O
study O
was O
to O
determine O
the O
impact O
of O
a O
multifaceted O
, O
community-wide O
intervention O
on O
overall O
antibiotic O
use O
for O
young O
children O
and O
on O
use O
of O
broad-spectrum O
agents O
. O
[]

The O
deperitonealized O
areas O
( O
N O
= O
205 O
) O
of O
all O
sidewalls O
were O
divided O
into O
three O
groups O
: O
less O
than O
100 O
mm2 O
, O
N O
= O
72 O
; O
100-1000 O
mm2 O
, O
N O
= O
95 O
; O
and O
more O
than O
1000 O
mm2 O
, O
N O
= O
38 O
. O
[]

STUDY O
DESIGN O
A O
prospective O
, O
randomized O
controlled O
trial O
. O
[]

BACKGROUND O
There O
is O
a O
growing O
body O
of O
evidence O
that O
advanced O
glycation O
end O
products O
( O
AGE O
) O
and O
their O
receptor O
( O
RAGE O
) O
system O
are O
implicated O
in O
chronic O
kidney O
disease O
( O
CKD O
) O
. O
[]

9.2 O
ng/ml O
, O
p O
< O
0.001 O
) O
, O
without O
a O
significant O
reduction O
in O
von O
Willebrand O
factor O
levels O
, O
and O
tended O
to O
prolong O
the O
prothrombin O
and O
partial O
thromboplastin O
times O
. O
[]

The O
cumulative B-outcome ['Life-Impact']
dose I-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
morphine I-outcome ['Life-Impact']
by O
PCA O
for O
each O
group O
was O
used O
as O
the O
end-point O
of O
the O
study O
. O
['Life-Impact']

RESULTS O
353 O
children O
with O
positive O
throat O
swabs O
for O
GABHS O
were O
randomised O
to O
amoxicillin O
( O
n O
= O
177 O
) O
or O
penicillin O
V O
( O
n O
= O
176 O
) O
. O
[]

A O
randomized O
double-blind O
clinical O
trial O
of O
griseofulvin O
treatment O
. O
[]

Treatment O
was O
continued O
until O
relapse O
or O
up O
to O
16 O
weeks O
. O
[]

MAIN O
OUTCOME O
MEASURES O
Clinical O
and O
instrumental O
evaluation O
of O
postoperative O
outcomes O
. O
[]

Dust-trapping O
reservoirs O
were O
common O
; O
76.8 O
% O
of O
children O
's O
bedrooms O
had O
carpeting O
. O
[]

The O
lowering O
effect O
of O
reduced O
alcohol O
consumption O
on O
blood O
pressure O
was O
independent O
of O
changes O
in O
salt O
consumption O
, O
which O
were O
estimated O
by O
24-hour O
urine O
collection O
and O
body O
weight O
. O
( O
[]

A O
controlled O
trial O
was O
undertaken O
to O
compare O
the O
efficacy O
of O
transcutaneous O
electrical O
nerve O
stimulation O
( O
TENS O
) O
with O
standard O
intramuscular O
opiate O
analgesia O
in O
the O
management O
of O
postoperative O
pain O
following O
appendicectomy O
. O
[]

We O
found O
that O
early O
treatment O
was O
important O
, O
since O
the O
effect O
on O
duration B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
whoops I-outcome ['Physiological-Clinical']
was O
most O
pronounced O
when O
disease O
duration O
before O
treatment O
was O
less O
than O
or O
equal O
to O
7 O
days O
. O
['Physiological-Clinical']

Little O
is O
known O
about O
the O
effects O
of O
bisphosphonates O
on O
bone O
metastases O
from O
other O
tumors O
and O
in O
particular O
from O
tumors O
for O
which O
no O
effective O
treatment O
is O
available O
. O
[]

Results O
were O
also O
combined O
with O
other O
second-line O
irinotecan O
trials O
. O
[]

Publication O
Type: O
Journal O
Article O
[]

RESULTS O
Qualitative O
assessment O
was O
subtle O
among O
the O
three O
protocols O
. O
[]

TRIAL O
REGISTRATION: O
Brazilian O
Registry O
of O
Clinical O
Trials O
(no. O
[]

It O
was O
shown O
that O
the O
imparting B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
knowledge I-outcome ['Life-Impact']
is O
significantly O
improved O
when O
this O
learning O
system O
is O
employed O
. O
['Life-Impact']

Screen-and-treat O
cervical O
cancer O
prevention O
programs O
based O
on O
high-risk O
human O
papillomavirus O
( O
HPV O
) O
testing O
and O
cryotherapy O
have O
been O
shown O
to O
be O
effective O
in O
resource-limited O
settings O
. O
[]

CONCLUSIONS: O
Training O
on O
wearing O
an O
N95 O
or O
higher O
respirator O
improved O
the O
protection B-outcome ['Life-Impact']
performance O
of O
respirators O
among O
healthcare O
providers O
working O
in O
the O
EMC. O
[['Life-Impact']]

Title: O
Efficacy O
of O
a O
nootropic O
spearmint O
extract O
on O
reactive B-outcome ['Life-Impact']
agility I-outcome ['Life-Impact']
: O
a O
randomized, O
double-blind, O
placebo-controlled, O
parallel O
trial. O
[['Life-Impact']]

Health-promotion O
interventions O
have O
been O
shown O
to O
reduce O
limitation O
from O
secondary O
conditions O
, O
which O
can O
be O
a O
significant O
barrier O
to O
labor O
force O
participation O
among O
people O
with O
disabilities O
. O
[]

On O
the O
other O
hand O
, O
orchiectomy O
has O
few O
, O
if O
any O
, O
complications O
. O
[]

INTERVENTIONS O
The O
patients O
slept O
at O
0 O
degrees O
, O
15 O
degrees O
, O
30 O
degrees O
, O
and O
45 O
degrees O
in O
random O
order O
. O
[]

METHODS O
Two O
hundred O
two O
patients O
with O
PPLs O
and O
positive O
EBUS O
findings O
were O
enrolled O
. O
[]

The O
associations O
between O
any O
2 O
groups O
of O
continuous O
variables O
will O
be O
tested O
using O
the O
t O
test O
or O
the O
Mann-Whitney O
U O
test O
and O
that O
of O
2 O
groups O
of O
categorical O
variables O
with O
chi-square O
or O
Fishers O
exact O
test O
where O
appropriate. O
[]

There O
also O
was O
no O
difference O
in O
INR O
variation O
based O
on O
warfarin O
formulation O
( O
p O
> O
0.69 O
) O
, O
nor O
was O
a O
patient O
and O
warfarin O
interaction O
found O
( O
p O
> O
0.81 O
) O
. O
[]

[ O
Potentiation O
of O
the O
effect O
of O
non-depolarizing O
muscle O
relaxants O
by O
acylaminopenicillins O
. O
[]

METHOD O
Forty-eight O
children O
( O
5 O
years O
to O
16 O
years O
, O
5 O
months O
) O
who O
showed O
behavioral O
improvement O
during O
acute O
treatment O
with O
risperidone O
were O
followed O
for O
6 O
months O
and O
assessed O
with O
the O
Vineland O
Scales O
. O
[]

1998 O
) O
with O
two O
important O
new O
contributions O
. O
[]

With O
the O
control O
group O
it O
continued O
until O
discharge O
( O
usually O
on O
the O
15th O
day O
) O
and O
at O
home O
for O
about O
three O
weeks O
until O
the O
completion O
of O
the O
physiotherapy O
cycle O
. O
[]

and O
oral O
administration O
of O
Yizhi O
Jiannao O
Granules O
; O
the O
Chinese O
herb O
group O
was O
treated O
with O
Yizhi O
Jiannao O
Granules O
, O
and O
the O
western O
medicine O
group O
with O
oral O
administration O
of O
Aricept O
. O
[]

The O
primary O
outcome O
, O
knowledge B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
benefits I-outcome ['Life-Impact']
and O
harms B-outcome ['Adverse-effects']
of I-outcome ['Adverse-effects']
screening I-outcome ['Adverse-effects']
, O
and O
secondary O
outcomes O
, O
['Life-Impact', 'Adverse-effects']

An O
interaction O
between O
age O
and O
treatment O
for O
the O
primary O
endpoints O
( O
p=0.03 O
) O
was O
seen O
. O
[]

The O
effects O
of O
orthotic O
heel O
lifts O
on O
Achilles B-outcome ['Physiological-Clinical']
tendon I-outcome ['Physiological-Clinical']
force I-outcome ['Physiological-Clinical']
and O
strain B-outcome ['Physiological-Clinical']
during O
running O
. O
['Physiological-Clinical', 'Physiological-Clinical']

We O
compared O
outcome O
and O
complications O
of O
three O
simple O
varicocelectomy O
techniques O
. O
[]

Interruption O
of O
treatment O
in O
the O
TOTO O
group O
did O
not O
result O
in O
a O
better O
gain O
in O
height B-outcome ['Physiological-Clinical']
standard I-outcome ['Physiological-Clinical']
deviation O
score O
H-SDSCA B-outcome ['Physiological-Clinical']
when O
compared O
with O
the O
TTOO O
group O
. O
['Physiological-Clinical', 'Physiological-Clinical']

CCR O
was O
seen O
in O
25 O
patients O
of O
whom O
10 O
received O
PUVA O
alone O
( O
CCR O
22 O
% O
) O
and O
15 O
received O
combination O
therapy O
( O
CCR O
31 O
% O
) O
( O
P O
= O
0?45 O
) O
. O
[]

We O
did O
not O
observe O
an O
association O
between O
TP53 B-outcome ['Physiological-Clinical']
tumour I-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
and O
prognosis O
for O
patients O
who O
received O
paclitaxel/cisplatin O
combination O
treatment O
, O
indicating O
that O
the O
effect O
of O
this O
therapy O
is O
not O
influenced O
by O
this O
parameter O
. O
['Physiological-Clinical']

All O
aripiprazole O
doses O
demonstrated O
significantly O
greater O
improvements O
in O
mean O
Clinical B-outcome ['Physiological-Clinical']
Global B-outcome ['Physiological-Clinical']
Impressions-Improvement O
score O
than O
placebo O
at O
week O
8 O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

Group-based O
HIV O
risk O
reduction O
intervention O
for O
adolescent O
girls O
: O
evidence O
of O
feasibility O
and O
efficacy O
. O
[]

PURPOSE/OBJECTIVES O
Through O
a O
randomized O
clinical O
trial O
, O
to O
compare O
patients O
undergoing O
an O
initial O
course O
of O
chemotherapy O
who O
report O
pain B-outcome ['Physiological-Clinical']
and O
fatigue B-outcome ['Physiological-Clinical']
at O
baseline O
and O
who O
are O
receiving O
conventional O
care O
alone O
with O
those O
receiving O
conventional O
care O
plus O
a O
nursing O
intervention O
on O
outcomes O
reported O
at O
20 O
weeks O
. O
['Physiological-Clinical', 'Physiological-Clinical']

When O
the O
group O
of O
healthy O
controls O
was O
included O
in O
the O
analyses O
, O
it O
is O
of O
note O
that O
group-by-time O
interaction O
showed O
a O
significant O
result O
for O
the O
frontal O
lobe O
at O
trend O
level O
( O
F O
( O
3,81 O
) O
=2.686 O
; O
P=0.052 O
) O
. O
[]

METHODS O
Twenty O
patients O
with O
mild O
SDB O
for O
whom O
conservative O
treatment O
failed O
were O
identified O
and O
consecutively O
enrolled O
into O
an O
institutional O
review O
board-approved O
surgical O
protocol O
. O
[]

Treatment O
of O
familial O
hypercholesterolemia O
with O
a O
combination O
of O
bezafibrate O
and O
guar O
. O
[]

CONCLUSION O
Use O
of O
CEE O
results O
in O
a O
modest O
but O
statistically O
significant O
increase O
in O
mammographic B-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
that O
is O
sustained O
over O
at O
least O
a O
2-year O
period O
. O
['Physiological-Clinical']

While O
there O
have O
been O
several O
decision O
aids O
( O
DAs O
) O
developed O
and O
tested O
, O
very O
few O
have O
included O
an O
exercise O
to O
help O
men O
clarify O
their O
values O
and O
preferences B-outcome ['Life-Impact']
about O
PCa O
screening O
. O
['Life-Impact']

CONCLUSION: O
The O
findings O
indicated O
the O
pilates O
exercises O
can O
be O
valuable O
for O
improvement O
of O
CKD O
patients' O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
(QOL) I-outcome ['Life-Impact']
. O
[['Life-Impact']]

Study O
2 O
was O
a O
randomized O
control O
field O
experiment O
that O
assessed O
a O
team-oriented O
training O
. O
[]

METHODS O
Sixty-seven O
English-speaking O
adult O
cancer O
outpatients O
, O
including O
15 O
minorities O
, O
with O
moderate O
pain O
over O
the O
prior O
2 O
weeks O
were O
randomly O
assigned O
to O
the O
experimental O
( O
N O
= O
34 O
) O
or O
control O
group O
( O
N O
= O
33 O
) O
. O
[]

Ambulatory O
activity O
was O
measured O
during O
1 O
week O
with O
a O
StepWatch O
activity O
monitor O
as O
steps O
per O
day O
, O
and O
time O
spent O
at O
medium O
and O
high O
step O
rates O
. O
[]

Complication O
rates O
, O
and O
['Adverse-effects']

Clinical O
data O
and O
biological O
parameters O
were O
detected O
and O
recorded. O
[]

Bifidobacteria B-outcome ['Physiological-Clinical']
were O
analysed O
by O
a O
direct O
PCR O
method O
in O
fecal O
samples O
from O
mothers O
at O
30-35 O
weeks O
of O
gestation O
and O
from O
infants O
at O
1 O
month O
of O
age O
and O
from O
breast-milk O
samples O
1 O
month O
post-partum O
. O
['Physiological-Clinical']

PATIENTS O
AND O
METHODS O
Totally O
25 O
patients O
with O
a O
history O
of O
differentiated O
thyroid O
carcinoma O
on O
long-term O
TSH-suppressive O
levothyroxine O
( O
l-T O
( O
4 O
) O
) O
substitution O
were O
randomized O
to O
persistent O
TSH-suppressive O
l-T O
( O
4 O
) O
substitution O
( O
low-TSH O
group O
) O
or O
restoration O
of O
euthyroidism O
. O
[]

Safety O
was O
assessed O
by O
measuring O
changes O
in O
pulse B-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
, O
blood O
pressure O
, O
and O
electrocardiogram O
( O
ECG O
) O
intervals O
after O
dosing O
with O
study O
drug O
, O
['Physiological-Clinical']

Of O
the O
37 O
patients O
who O
completed O
the O
trial O
16 O
out O
of O
19 O
( O
84 O
% O
) O
of O
the O
patients O
in O
the O
Grenz O
ray O
group O
, O
and O
13 O
out O
of O
18 O
( O
72 O
% O
) O
of O
the O
patients O
in O
the O
combination O
group O
healed B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

No O
difference O
was O
found O
between O
the O
two O
anesthetic O
techniques O
in O
the O
incidence O
of O
nausea O
, O
vomiting O
, O
or O
both O
during O
the O
first O
24 O
hr O
after O
operation O
. O
[]

Examination O
of O
PTK2 O
gene O
expression O
in O
CLL8 O
patients O
yielded O
similar O
results O
. O
[]

Comparison O
between O
the O
central O
effects O
of O
camazepam O
and O
temazepam O
. O
[]

Younger O
children O
had O
more O
severe B-outcome ['Physiological-Clinical']
diarrhea I-outcome ['Physiological-Clinical']
( O
P O
=.002 O
) O
, O
whereas O
older O
children O
had O
worse O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting B-outcome ['Physiological-Clinical']
( O
P O
=.01 O
) O
after O
chemotherapy O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

IFTC O
0702 O
randomized O
phase O
III O
study O
] O
. O
[]

CONCLUSIONS O
These O
results O
indicate O
that O
proteinuria O
is O
reduced O
by O
low O
doses O
of O
losartan O
or O
enalapril O
. O
[]

Adverse B-outcome ['Adverse-effects']
effects I-outcome ['Adverse-effects']
included O
sedation O
and O
fatigue B-outcome ['Physiological-Clinical']
during O
the O
first O
2 O
weeks O
of O
clonidine O
treatment O
. O
['Adverse-effects', 'Physiological-Clinical']

METHODS O
We O
studied O
153 O
anemic O
cancer O
patients O
receiving O
cyclic O
combination O
chemotherapy O
in O
a O
prospective O
multicenter O
, O
double-blind O
, O
placebo-controlled O
trial O
. O
[]

A O
dose-response O
study O
of O
the O
effect O
of O
levobunolol O
on O
ocular B-outcome ['Physiological-Clinical']
hypertension I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Endotoxin B-outcome ['Physiological-Clinical']
concentration I-outcome ['Physiological-Clinical']
was O
also O
determined O
in O
15 O
healthy O
controls O
. O
['Physiological-Clinical']

and O
simultaneously O
an O
infusion O
of O
0.05 O
, O
0.10 O
, O
0.15 O
, O
or O
0.20 O
mg O
propofol/kg O
per O
minute O
was O
started O
. O
[]

No O
statistically O
significant O
difference O
(P O
> O
0.05) O
among O
the O
groups O
was O
found O
regarding O
degree O
or O
duration O
of O
pain B-outcome ['Physiological-Clinical']
. O
There O
was O
no O
statistically O
significant O
difference O
(P O
> O
0.05) O
among O
the O
4(o)C O
and O
2.5(o)C O
groups. O
[['Physiological-Clinical']]

There O
were O
19 O
serious O
bacterial B-outcome ['Physiological-Clinical']
infections I-outcome ['Physiological-Clinical']
in O
the O
trimethoprim-sulfamethoxazole O
group O
and O
38 O
in O
the O
pentamidine O
group O
. O
['Physiological-Clinical']

CONCLUSION O
Addition O
of O
MgSO4 O
to O
conventional O
therapy O
helps O
in O
achieving O
earlier O
improvement O
in O
clinical B-outcome ['Physiological-Clinical']
signs I-outcome ['Physiological-Clinical']
and O
symptoms B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
asthma I-outcome ['Physiological-Clinical']
and O
PEFR B-outcome ['Physiological-Clinical']
in O
patients O
not O
responding O
to O
conventional O
therapy O
alone O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Yohimbine O
in O
neurally O
mediated O
syncope O
. O
[]

STUDY O
DESIGN O
Prospective O
multicenter O
randomized O
controlled O
study O
designed O
to O
assess O
the O
noninferiority O
of O
diet O
versus O
dialysis O
in O
1-year O
mortality O
assessed O
by O
using O
intention-to-treat O
and O
per-protocol O
analysis O
. O
[]

Clinical O
results O
of O
its O
medium-term O
action O
] O
. O
[]

Patients O
were O
given O
a O
250-mL O
bolus O
of O
Voluven O
( O
6 O
% O
hydroxyethyl O
starch O
130/0.4 O
in O
0.9 O
% O
sodium O
chloride O
) O
until O
the O
stroke O
volume O
no O
longer O
increased O
by O
10 O
% O
, O
then O
received O
either O
dopexamine O
( O
0.5 O
?g O
? O
[]

IFN-alpha-2b O
SC O
was O
begun O
on O
week O
4 O
and O
continued O
thrice O
weekly O
at O
5 O
MU/m2 O
for O
2 O
years O
. O
[]

Aftermath O
of O
a O
clinical O
trial O
: O
evaluating O
the O
sustainability O
of O
a O
medical O
device O
intervention O
in O
Ghana O
. O
[]

These O
bleeding O
complications O
were O
severe O
in O
only O
4.5 O
% O
and O
3 O
% O
, O
respectively O
. O
( O
[]

A O
global O
evaluation O
to O
assess O
the O
method O
of O
irrigation O
and O
the O
solutions O
used O
for O
irrigation O
was O
completed O
by O
both O
the O
physician O
blinded O
to O
the O
treatment O
groups O
and O
the O
volunteers O
. O
[]

Two O
of O
three O
control O
subjects O
also O
had O
increased O
erythron B-outcome ['Physiological-Clinical']
iron I-outcome ['Physiological-Clinical']
turnovers I-outcome ['Physiological-Clinical']
, O
which O
in O
one O
case O
was O
related O
to O
increased O
dialysis-associated B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
losses I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

Needle O
excision O
took O
longer B-outcome ['Life-Impact']
to I-outcome ['Life-Impact']
perform I-outcome ['Life-Impact']
( O
median O
treatment O
time O
210 O
vs O
90 O
seconds O
, O
P O
< O
0.0001 O
) O
and O
surgeons O
more O
often O
['Life-Impact']

Clay O
modeling O
might O
be O
a O
useful O
self-help O
tool O
to O
help O
manage O
craving B-outcome ['Life-Impact']
for O
chocolate O
, O
snacks O
and O
other O
foods O
. O
['Life-Impact']

We O
aimed O
to O
study O
the O
radiation B-outcome ['Life-Impact']
exposure I-outcome ['Life-Impact']
reduction O
to O
operators O
with O
the O
use O
of O
RADPAD O
and O
also O
measureradiation O
doses O
in O
different O
angiographic O
projections. O
[['Life-Impact']]

An O
auricular B-outcome ['Physiological-Clinical']
remodeling I-outcome ['Physiological-Clinical']
with O
size O
regression B-outcome ['Physiological-Clinical']
occurred O
in O
those O
patients O
who O
recovered O
from O
sinus O
rhythm O
, O
worthy O
of O
remark O
in O
Group O
II O
( O
-10.8 O
% O
of O
left O
auricular O
volume O
reduction O
in O
Group O
I O
compared O
to O
-21.5 O
% O
in O
Group O
II O
; O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Group O
A O
received O
an O
educational O
leaflet O
with O
general O
information O
about O
osteoporosis O
; O
group O
B O
followed O
current O
practice O
. O
[]

Journal O
ID: O
9812598 O
[]

Forty-six O
patients O
were O
irradiated O
with O
7 O
Gy O
single O
dose O
within O
16-20 O
h O
before O
operation O
. O
[]

Both O
medicaments O
excerted O
an O
identical O
analgetic O
efficiency O
. O
['Physiological-Clinical']

RESULTS O
The O
median O
percentage O
decrease O
in O
the O
size O
of O
the O
epithelial B-outcome ['Physiological-Clinical']
defect I-outcome ['Physiological-Clinical']
was O
significantly O
greater O
in O
the O
cord O
serum O
group O
at O
days O
7 O
, O
14 O
and O
21 O
( O
p O
< O
0.05 O
) O
when O
measured O
in O
terms O
of O
the O
area O
and O
perimeter O
. O
['Physiological-Clinical']

After O
12 O
weeks O
of O
the O
treatment O
we O
observed O
in O
these O
patients O
decreases O
in O
CD3 B-outcome ['Physiological-Clinical']
, O
CD4 B-outcome ['Physiological-Clinical']
, O
CD8 B-outcome ['Physiological-Clinical']
and O
CD16 B-outcome ['Physiological-Clinical']
cell O
numbers O
and O
elevation O
of O
CD4/CD8 B-outcome ['Physiological-Clinical']
ratio I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

A O
carbohydrate O
meal O
attenuates O
the O
forearm O
vasoconstrictor O
response O
to O
lower O
body O
subatmospheric O
pressure O
in O
healthy O
young O
adults O
. O
[]

Title: O
Comparison O
the O
efficacy O
of O
hemorrhage O
control O
of O
Surgiflo O
Haemostatic O
Matrix O
and O
absorbable O
gelatin O
sponge O
in O
posterior O
lumbar O
surgery: O
A O
randomized O
controlled O
study. O
[]

There O
are O
no O
controlled O
studies O
evaluating O
these O
interventions O
as O
adjuncts O
to O
facilitate O
completion O
of O
painful O
procedures O
in O
the O
pediatric O
emergency O
department O
( O
ED O
) O
. O
[]

PARTICIPANTS O
Thirty O
physically O
active O
males O
with O
tight O
hamstrings O
and O
at O
least O
one O
latent O
MTrP O
on O
muscles O
innervated O
by O
the O
lumbosacral O
, O
sciatic O
, O
tibial O
and O
common O
peroneal O
nerves O
. O
[]

CONCLUSIONS O
Video-assisted O
thoracoscopic O
talc O
insufflation O
has O
not O
been O
shown O
to O
be O
a O
superior O
approach O
compared O
with O
talc O
slurry O
in O
our O
study O
. O
[]

The O
radiographs B-outcome ['Physiological-Clinical']
of O
hands O
and O
feet O
were O
analyzed O
by O
using O
the O
Larsen O
score O
at O
baseline O
, O
2 O
, O
5 O
, O
and O
11 O
years O
, O
and O
the O
radiographs O
of O
large O
joints O
, O
at O
11 O
years O
. O
['Physiological-Clinical']

RESULTS O
None O
of O
the O
41 O
patients O
exhibited O
heterozygous B-outcome ['Physiological-Clinical']
or O
homozygous B-outcome ['Physiological-Clinical']
M66I I-outcome ['Physiological-Clinical']
and O
R492W B-outcome ['Physiological-Clinical']
variant I-outcome ['Physiological-Clinical']
alleles I-outcome ['Physiological-Clinical']
, O
or O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

There O
were O
4 O
cases O
with O
possible O
systemic B-outcome ['Physiological-Clinical']
fungal I-outcome ['Physiological-Clinical']
infection I-outcome ['Physiological-Clinical']
in O
the O
itraconazole O
group O
, O
and O
there O
were O
8 O
possible O
and O
3 O
probable O
cases O
in O
the O
fluconazole O
group O
. O
['Physiological-Clinical']

Clonidine O
reduced O
arterial B-outcome ['Physiological-Clinical']
blood I-outcome ['Physiological-Clinical']
pressure I-outcome ['Physiological-Clinical']
from O
125/79 O
+/- O
13/8 O
to O
104/68 O
+/- O
9/7 O
mmHg O
( O
p O
less O
than O
0.01 O
) O
, O
urinary B-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
excretion I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
from O
68 O
( O
31-369 O
) O
to O
46 O
( O
6-200 O
) O
micrograms/min O
( O
median O
and O
range O
) O
( O
p O
less O
than O
0.01 O
) O
, O
and O
fractional B-outcome ['Physiological-Clinical']
clearance I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
albumin I-outcome ['Physiological-Clinical']
in O
all O
patients O
( O
median O
29 O
% O
) O
( O
p O
less O
than O
0.01 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

All O
4 O
positive O
cases O
were O
esthesioneuroblastomas B-outcome ['Physiological-Clinical']
, O
and O
all O
19 O
poorly O
differentiated O
tumors O
were O
negative O
. O
['Physiological-Clinical']

RESULTS O
At O
12 O
weeks O
of O
infant O
age O
, O
the O
intervention O
was O
effective O
in O
almost O
doubling O
the O
rate O
of O
exclusive B-outcome ['Physiological-Clinical']
breastfeeding B-outcome ['Physiological-Clinical']
( O
risk O
ratio O
1.92 O
; O
95 O
% O
CI O
: O
1.59-2.33 O
) O
and O
increasing O
infant O
weight O
and O
length-for-age B-outcome ['Physiological-Clinical']
z-scores I-outcome ['Physiological-Clinical']
( O
weight O
difference O
0.09 O
; O
95 O
% O
CI O
: O
0.00-0.18 O
, O
length O
difference O
0.11 O
; O
95 O
% O
CI O
: O
0.03-0.19 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

In O
addition O
to O
freedom B-outcome ['Physiological-Clinical']
from I-outcome ['Physiological-Clinical']
bleeding I-outcome ['Physiological-Clinical']
and O
no O
lost B-outcome ['Physiological-Clinical']
days I-outcome ['Physiological-Clinical']
from O
work O
, O
there O
was O
increased O
mobility B-outcome ['Life-Impact']
and O
physical B-outcome ['Life-Impact']
capacity I-outcome ['Life-Impact']
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

OBJECTIVE O
Risperidone O
is O
effective O
for O
short-term O
treatment O
of O
aggression O
, O
temper O
outbursts O
, O
and O
self-injurious O
behavior O
in O
children O
with O
autism O
. O
[]

The O
cohort O
was O
followed O
through O
July O
2000 O
for O
development O
of O
breast O
diseases O
, O
and O
the O
breast O
cancer O
cases O
were O
followed O
through O
2001 O
for O
vital O
status O
. O
[]

OBJECTIVES O
To O
test O
the O
hypotheses O
that O
: O
( O
1 O
) O
Lumbar O
spine O
radiography O
in O
primary O
care O
patients O
with O
low O
back O
pain O
is O
not O
associated O
with O
improved O
patient O
outcomes O
, O
including O
pain B-outcome ['Physiological-Clinical']
, O
disability B-outcome ['Life-Impact']
, O
health B-outcome ['Physiological-Clinical']
status I-outcome ['Physiological-Clinical']
, O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
, O
reassurance B-outcome ['Physiological-Clinical']
, O
and O
patient O
satisfaction B-outcome ['Life-Impact']
or O
belief B-outcome ['Life-Impact']
in O
the O
value O
of O
radiography O
. O
( O
['Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Physiological-Clinical', 'Life-Impact', 'Life-Impact']

Each O
participant O
received O
160 O
perturbations O
, O
25 O
% O
of O
which O
were O
combined O
with O
a O
SAS O
. O
[]

SETTING O
Neonatal O
intensive O
care O
unit O
in O
a O
106-bed O
quaternary O
care O
pediatric O
hospital O
. O
[]

SUMMARY O
This O
study O
examined O
whether O
24 O
months O
of O
weight O
training O
exercises O
enhanced O
the O
effectiveness O
of O
risedronate O
, O
calcium O
, O
and O
vitamin O
D O
in O
maintaining O
or O
improving O
bone B-outcome ['Physiological-Clinical']
mineral I-outcome ['Physiological-Clinical']
density I-outcome ['Physiological-Clinical']
( I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
) I-outcome ['Physiological-Clinical']
in O
223 O
postmenopausal O
breast O
cancer O
survivors O
. O
['Physiological-Clinical']

Thirty-two O
immune B-outcome ['Physiological-Clinical']
cell I-outcome ['Physiological-Clinical']
populations I-outcome ['Physiological-Clinical']
were O
characterized O
using O
three-color O
flow O
cytometry O
. O
['Physiological-Clinical']

We O
suggest O
that O
the O
preSMA O
and O
rostral O
dorsal O
PMC O
activities O
during O
initiate O
may O
be O
associated O
with O
selection O
of O
timing O
parameters O
, O
while O
activation O
in O
centromedial O
prefrontal O
cortex O
during O
both O
initiate O
and O
synchronise O
may O
be O
associated O
with O
[]

This O
technique O
requires O
several O
orthogonal O
projections O
. O
[]

The O
therapy O
became O
effective O
after O
six O
weeks O
of O
training O
. O
[]

RESULTS O
The O
lead-in O
that O
described O
the O
highest O
likelihood O
of O
hypertension B-outcome ['Physiological-Clinical']
was O
associated O
with O
significantly O
higher O
reported O
readings O
and O
lower O
accuracy B-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical', 'Physiological-Clinical']

In B-outcome ['Physiological-Clinical']
vitro I-outcome ['Physiological-Clinical']
fertilization I-outcome ['Physiological-Clinical']
(IVF) I-outcome ['Physiological-Clinical']
/ O
intracytoplasmic B-outcome ['Physiological-Clinical']
sperm I-outcome ['Physiological-Clinical']
injection I-outcome ['Physiological-Clinical']
(ICSI) I-outcome ['Physiological-Clinical']
outcomes O
were O
compared O
between O
groups. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

We O
assessed O
the O
effectiveness O
of O
the O
interventions O
on O
intensity B-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
low I-outcome ['Physiological-Clinical']
back I-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
, O
pain B-outcome ['Physiological-Clinical', 'Life-Impact']
interfering I-outcome ['Physiological-Clinical', 'Life-Impact']
with O
work O
and O
fear O
avoidance O
beliefs B-outcome ['Life-Impact']
against O
the O
Control, O
and O
calculated O
the O
incremental O
cost-effectiveness O
ratios O
for O
sickness B-outcome ['Life-Impact']
absence I-outcome ['Life-Impact']
and O
QALY. O
[['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Life-Impact'], ['Life-Impact']]

Family O
education O
for O
people O
with O
schizophrenia O
in O
Beijing O
, O
China O
: O
randomised O
controlled O
trial O
. O
[]

For O
each O
limb O
, O
wounds O
were O
randomly O
assigned O
to O
four O
treatment O
groups O
: O
no O
treatment O
( O
control O
) O
, O
carrier O
( O
Methyl O
Cellulose O
gel O
) O
, O
50 O
ng/wound O
rhTGF-beta O
1 O
in O
carrier O
, O
and O
500 O
ng/wound O
rhTGF-beta O
1 O
in O
carrier O
. O
[]

OBJECTIVES O
We O
examined O
whether O
tomato O
paste O
-- O
rich O
in O
lycopene O
, O
a O
powerful O
antioxidant O
-- O
can O
protect O
human O
skin O
against O
UVR-induced O
effects O
partially O
mediated O
by O
oxidative O
stress O
, O
i.e O
. O
[]

Thus, O
reasons O
for O
engaging O
in O
weight O
loss O
interventions O
needs O
exploring, O
in O
order O
to O
engage O
more O
workplaces O
in O
weight O
loss O
interventions. O
[]

In O
adult O
autistic O
disorders O
, O
severity O
of O
repetitive O
behaviors O
at O
baseline O
, O
as O
measured O
by O
YBOCS-compulsion O
score O
, O
significantly O
positively O
correlated O
with O
both O
peak O
delta O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response I-outcome ['Physiological-Clinical']
and O
area O
under O
the O
curve O
growth B-outcome ['Physiological-Clinical']
hormone I-outcome ['Physiological-Clinical']
response B-outcome ['Physiological-Clinical']
to O
sumatriptan O
. O
['Life-Impact', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Future O
studies O
with O
longer O
treatment O
duration O
and O
larger O
sample O
size O
are O
needed O
to O
further O
explore O
the O
potential O
role O
of O
rosiglitazone O
in O
improving O
cognitive O
function O
in O
patients O
with O
schizophrenia O
. O
[]

SETTING O
Neurologic O
and O
ophthalmologic O
examinations O
at O
13 O
clinical O
sites O
. O
[]

Of O
those O
in O
the O
intervention O
group O
who O
tested, O
64.5% O
chose O
the O
self-test B-outcome ['Life-Impact']
and O
35.5% O
chose O
the O
standard O
provider-administered O
blood-based O
HIV B-outcome ['Life-Impact']
test I-outcome ['Life-Impact']
. O
Although O
the O
intervention O
more O
than O
doubled O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates, O
because O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates O
were O
so O
low O
in O
this O
population O
(by O
design O
as O
we O
selected O
irregular O
testers), O
even O
in O
the O
intervention O
group O
more O
than O
96% O
of O
participants O
did O
not O
test B-outcome ['Life-Impact']
. O
CONCLUSIONS: O
Announcing O
the O
availability O
of O
HIV O
self-testing O
via O
text O
message O
increased O
HIV B-outcome ['Life-Impact']
testing I-outcome ['Life-Impact']
rates O
among O
truckers O
who O
were O
not O
regularly O
accessing O
HIV O
testing. O
[['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact'], ['Life-Impact']]

The O
orientation O
perpendicular O
to O
the O
ventricular O
septum O
greatly O
facilitates O
the O
postoperative B-outcome ['Life-Impact']
feasibility I-outcome ['Life-Impact']
and O
accuracy O
of O
fluoroscopy B-outcome ['Resource-use']
, O
and O
it O
is O
not O
detrimental O
to O
the O
valve O
's O
['Life-Impact', 'Resource-use']

Intention B-outcome ['Life-Impact']
to O
treat O
( O
ITT O
) O
and O
per-protocol O
( O
PP O
) O
analyses O
were O
performed O
, O
and O
risk O
ratios O
( O
RR O
) O
adjusted O
by O
age O
, O
gender O
and O
area O
, O
were O
calculated O
. O
['Life-Impact']

None O
of O
the O
subjects O
withdrew O
from O
the O
study O
. O
[]

Cooperative O
Study O
Group O
of O
Kyushu O
and O
Chugoku O
for O
HCFU O
Adjuvant O
Chemotherapy O
] O
. O
[]

The O
median O
proportion O
of O
utterances B-outcome ['Life-Impact']
with I-outcome ['Life-Impact']
echolalia I-outcome ['Life-Impact']
was O
0.16 O
. O
['Life-Impact']

Randomization O
was O
unbalanced O
1:2 O
in O
favor O
of O
the O
combination O
therapy O
, O
since O
study O
conditions O
were O
identical O
to O
the O
previous O
CML-study O
I O
and O
it O
had O
been O
planned O
in O
advance O
to O
add O
the O
HU O
patients O
of O
study O
I O
( O
n=194 O
) O
to O
the O
HU O
control O
group O
. O
[]

The O
hazard O
ratio O
of O
death B-outcome ['Mortality']
for O
LTA B-outcome ['Physiological-Clinical']
compared O
with O
TH O
was O
1.36 O
( O
0.89-2.08 O
, O
p=0.92 O
) O
. O
['Mortality', 'Physiological-Clinical']

Efficacy O
measures O
, O
overall O
response O
rate O
, O
time-to-progression B-outcome ['Physiological-Clinical']
and O
overall B-outcome ['Mortality']
survival I-outcome ['Mortality']
were O
equivalent O
in O
both O
arms O
. O
['Physiological-Clinical', 'Mortality']

Some O
case O
reports O
mention O
that O
Spironolactone O
, O
a O
mineral O
corticoid O
antagonist O
and O
aldosterone O
antagonist O
, O
reduces O
binging B-outcome ['Life-Impact']
in O
patients O
with O
bulimia O
nervosa O
. O
['Life-Impact']

Participants O
were O
33 O
children O
( O
29 O
boys O
) O
between O
the O
ages O
of O
5 O
and O
13 O
years O
who O
participated O
in O
a O
four-week O
crossover O
trial O
of O
placebo O
and O
increasing O
doses O
of O
methylphenidate O
given O
in O
random O
order O
each O
for O
one O
week O
. O
[]

Somatostatin O
and O
ranitidine O
in O
the O
treatment O
of O
non-variceal O
upper O
gastrointestinal O
bleeding O
: O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
controlled O
study O
. O
[]

Randomized O
comparison O
of O
two O
communication O
interventions O
for O
preschoolers O
with O
autism O
spectrum O
disorders O
. O
[]

The O
FemCap O
is O
a O
new O
silicone O
rubber O
barrier O
contraceptive O
shaped O
like O
a O
sailor O
's O
hat O
, O
with O
a O
dome O
that O
covers O
the O
cervix O
, O
a O
rim O
that O
fits O
into O
the O
fornices O
, O
and O
a O
brim O
that O
conforms O
to O
the O
vaginal O
walls O
around O
the O
cervix O
. O
[]

Intraoperative O
measures O
included O
anesthetic B-outcome ['Life-Impact']
concentration, O
EEG B-outcome ['Physiological-Clinical']
suppression I-outcome ['Physiological-Clinical']
, O
and O
hypotension B-outcome ['Physiological-Clinical']
. O
Adverse B-outcome ['Adverse-effects']
events I-outcome ['Adverse-effects']
included O
undesirable B-outcome ['Physiological-Clinical']
intraoperative I-outcome ['Physiological-Clinical']
movement I-outcome ['Physiological-Clinical']
, O
intraoperative B-outcome ['Physiological-Clinical', 'Life-Impact']
awareness I-outcome ['Physiological-Clinical', 'Life-Impact']
with O
recall O
, O
postoperative O
nausea B-outcome ['Physiological-Clinical']
and O
vomiting O
, O
medical O
complications B-outcome ['Adverse-effects']
, O
and O
death B-outcome ['Mortality']
. O
Results: O
Of O
the O
1232 O
randomized O
patients O
(median O
age, O
69 O
years O
[range, O
60 O
to O
95]; O
563 O
women O
[45.7%]), O
1213 O
(98.5%) O
were O
assessed O
for O
the O
primary O
outcome. O
[['Life-Impact'], ['Physiological-Clinical'], ['Physiological-Clinical'], ['Adverse-effects'], ['Physiological-Clinical'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Adverse-effects'], ['Mortality']]

Variations O
in O
construct O
design O
should O
be O
further O
explored O
to O
enhance O
the O
training O
and O
assessment O
of O
clinical O
competence O
that O
reflects O
the O
unpredictability O
encountered O
in O
daily O
clinical O
practice O
. O
[]

The O
study O
compares O
the O
efficacy O
of O
MCP O
using O
the O
AIMhi O
Stay O
Strong O
App O
with O
two O
control O
groups O
(control O
app O
intervention O
and O
treatment O
as O
usual) O
on O
participant-reported O
psychological B-outcome ['Life-Impact']
distress I-outcome ['Life-Impact']
(the O
primary O
outcome) O
using O
the O
Kessler O
Distress O
Scale O
(K10)]; O
depressive B-outcome ['Physiological-Clinical', 'Life-Impact']
symptoms I-outcome ['Physiological-Clinical', 'Life-Impact']
using O
the O
adapted O
Patient O
Health B-outcome ['Physiological-Clinical']
Questionnaire O
(PHQ-9)]; O
quality B-outcome ['Life-Impact']
of I-outcome ['Life-Impact']
life I-outcome ['Life-Impact']
using O
the O
EuroQoL O
instrument O
( O
EQ5D]) O
and O
adherence B-outcome ['Life-Impact']
to O
dialysis O
treatment O
planning O
through O
file O
audit. O
[['Life-Impact'], ['Physiological-Clinical', 'Life-Impact'], ['Physiological-Clinical'], ['Life-Impact'], ['Life-Impact']]

The O
cumulative O
opioid B-outcome ['Resource-use']
requirement I-outcome ['Resource-use']
was O
significantly O
less O
in O
group O
O O
at O
6, O
12, O
24, O
and O
48 O
hours O
after O
surgery. O
( O
[['Resource-use']]

The O
grade O
of O
Lipiodol O
accumulation O
and O
the O
tumor O
regression O
rate O
were O
determined O
2 O
weeks O
after O
TAI O
by O
computerized O
tomography O
. O
[]

A O
mean O
+/- O
SD O
peak O
serum B-outcome ['Physiological-Clinical']
itraconazole I-outcome ['Physiological-Clinical']
concentration B-outcome ['Physiological-Clinical']
of O
0.90 O
+/- O
0.30 O
micrograms/ml O
was O
observed O
at O
3.0 O
+/- O
0.7 O
hours O
when O
itraconazole O
was O
administered O
alone O
, O
compared O
with O
undetectable O
levels O
in O
all O
patients O
during O
therapy O
with O
ddI O
. O
['Physiological-Clinical', 'Physiological-Clinical']

Compared O
to O
the O
placebo O
group O
, O
the O
olanzapine O
group O
had O
a O
lower O
incidence O
of O
( O
59.2 O
% O
versus O
91.1 O
% O
, O
p O
< O
0.001 O
) O
and O
a O
longer O
time O
to O
( O
46 O
versus O
15 O
days O
, O
p O
< O
0.001 O
) O
symptomatic B-outcome ['Physiological-Clinical']
relapse I-outcome ['Physiological-Clinical']
of O
any O
kind O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
study O
the O
efficacy O
of O
two O
types O
of O
intervention O
to O
stop O
tobacco B-outcome ['Life-Impact']
dependency O
. O
['Life-Impact']

CONCLUSION O
( O
S O
) O
For O
infertile O
women O
, O
basic O
information O
describing O
the O
impact O
of O
smoking O
on O
fertility O
, O
along O
with O
exhaled O
CO O
monitoring O
and O
a O
more O
intensive O
intervention O
were O
both O
highly O
effective O
. O
[]

UNLABELLED O
Reports O
of O
transient O
neurological O
symptoms O
with O
the O
use O
of O
subarachnoid O
lidocaine O
has O
generated O
interest O
in O
alternate O
local O
anesthetics O
of O
intermediate O
duration O
, O
such O
as O
mepivacaine O
. O
[]

CONCLUSION: O
Both O
drugs O
reduced O
menstrual B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
. O
Ginger O
as O
well O
as O
Novafen O
is O
effective O
in O
relieving O
pain B-outcome ['Physiological-Clinical']
in O
girls O
with O
primary O
dysmenorrhea O
. O
[['Physiological-Clinical'], ['Physiological-Clinical']]

By O
8 O
weeks O
, O
average O
6-minute B-outcome ['Life-Impact']
walk I-outcome ['Life-Impact']
distances I-outcome ['Life-Impact']
had O
improved O
by O
13.1 O
% O
and O
WOMAC O
scores O
had O
improved O
by O
55.8 O
% O
over O
baseline O
values O
in O
the O
treatment O
group O
( O
P O
< O
0.05 O
) O
. O
['Life-Impact']

Its O
prevention O
may O
improve O
maternal O
and O
infant O
survival O
. O
[]

Mood O
status O
and O
quality O
of O
life O
were O
assessed O
using O
the O
Profile O
of O
Mood B-outcome ['Life-Impact']
States O
and O
Medical O
Outcomes O
Study O
36-item O
Short-Form O
Health O
Survey O
at O
baseline O
and O
following O
3 O
and O
6 O
months O
of O
treatment O
. O
['Life-Impact']

In O
the O
indomethacin O
group O
, O
dura O
was O
sufficiently O
relaxed O
in O
eight O
of O
nine O
patients O
and O
dura O
was O
opened O
without O
the O
occurrence O
of O
cerebral B-outcome ['Physiological-Clinical']
swelling I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Journal-Name:JSLS O
: O
Journal O
of O
the O
Society O
of O
Laparoendoscopic O
Surgeons O
[]

As O
hydrogen O
gas O
was O
recently O
reported O
to O
activate O
PGC1alpha, O
the O
present O
study O
investigated O
whether O
it O
restores O
exhausted O
CD8+ B-outcome ['Physiological-Clinical']
T I-outcome ['Physiological-Clinical']
cells I-outcome ['Physiological-Clinical']
to O
improve O
prognosis O
in O
patients O
with O
stage O
IV O
colorectal O
cancer. O
[['Physiological-Clinical']]

Twenty O
families O
were O
randomly O
assigned O
to O
the O
treatment O
or O
waitlist O
group O
. O
[]

Patients O
received O
24 O
weeks O
' O
treatment O
with O
oral O
lamotrigine O
100 O
mg O
( O
LTG O
100 O
, O
n O
= O
115 O
) O
or O
200 O
mg O
( O
LTG O
200 O
, O
n O
= O
111 O
) O
or O
carbamazepine O
600 O
mg O
( O
CBZ O
600 O
, O
n O
= O
117 O
) O
. O
[]

Clinical B-outcome ['Physiological-Clinical']
effects O
of O
root O
instrumentation O
using O
conventional O
steel O
or O
non-tooth O
substance O
removing O
plastic O
curettes O
during O
supportive O
periodontal O
therapy O
( O
SPT O
) O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
assess O
post-treatment O
effects O
in O
endometriosis O
patients O
of O
a O
12-month O
course O
of O
GnRH O
agonist O
alone O
or O
with O
one O
of O
three O
add-back O
regimens O
. O
[]

Thus, O
krill O
powder O
has O
a O
lot O
of O
potential O
in O
improving O
lipid O
and O
metabolic O
profile O
and O
reinforcing O
the O
activity O
of O
the O
antioxidant O
system. O
[]

The O
mean O
exercise O
time O
until O
marked O
dyspnea O
decreased O
from O
218.5 O
seconds O
in O
the O
carbon O
monoxide O
control O
period O
to O
146.6 O
seconds O
after O
breathing O
carbon O
monoxide O
( O
P O
less O
than O
0.001 O
) O
. O
[]

On O
continual O
treatment O
there O
were O
21 O
bleedings B-outcome ['Physiological-Clinical']
on O
weekly O
injections O
of O
36 O
U O
factor O
VIII O
per O
kg O
, O
14 O
on O
twice O
weekly O
18 O
U/kg O
and O
none O
on O
12 O
U/kg O
, O
three O
times O
weekly O
. O
['Physiological-Clinical']

RESULTS O
All O
subjects O
showed O
improvements O
in O
affective B-outcome ['Life-Impact']
speech I-outcome ['Life-Impact']
comprehension I-outcome ['Life-Impact']
from O
pre- O
to O
post-infusion O
; O
however O
, O
whereas O
those O
who O
received O
placebo O
first O
tended O
to O
revert O
to O
baseline O
after O
a O
delay O
, O
those O
who O
received O
oxytocin O
first O
retained O
the O
ability O
to O
accurately O
assign O
emotional B-outcome ['Life-Impact']
significance O
to O
speech O
intonation B-outcome ['Life-Impact']
on O
the O
speech O
comprehension O
task O
. O
['Life-Impact', 'Life-Impact', 'Life-Impact']

Screening O
for O
abdominal O
aortic O
aneurysms O
( O
AAAs O
) O
in O
patients O
at O
risk O
will O
become O
more O
cost O
effective O
if O
a O
simple O
, O
inexpensive O
, O
and O
reliable O
ultrasound O
device O
is O
available O
. O
[]

Spinal O
anesthesia O
is O
often O
used O
in O
this O
institution O
, O
as O
well O
as O
many O
others O
, O
for O
this O
procedure O
. O
[]

CONCLUSIONS O
Brief O
, O
daily O
hopping O
exercises O
increased O
femoral B-outcome ['Physiological-Clinical']
neck I-outcome ['Physiological-Clinical']
BMD I-outcome ['Physiological-Clinical']
in O
premenopausal O
women O
but O
less O
frequent O
exercise O
was O
not O
effective O
. O
['Physiological-Clinical']

The O
patients O
were O
randomly O
allocated O
to O
Groups O
L O
( O
n O
= O
51 O
) O
and O
LM O
( O
n O
= O
56 O
) O
using O
the O
closed-envelope O
method O
. O
[]

Patients O
also O
received O
oral O
prednisone O
5 O
mg O
twice O
daily O
. O
[]

Rats O
in O
each O
group O
were O
intrathecally O
delivered O
with O
NS O
, O
LV/control O
, O
or O
recombinant O
vector O
LV/hIL-10 O
in O
a O
total O
volume O
of O
10 O
?l O
. O
[]

More O
interestingly, O
preoperative O
analgesia O
group O
patients O
consumed O
less O
patient-controlled O
analgesia B-outcome ['Resource-use']
compared O
to O
postoperative O
analgesia O
group O
patients O
at O
72 O
hours O
post O
operation. O
[['Resource-use']]

Amonafide O
was O
given O
at O
300 O
mg/m2/day O
i.v O
. O
[]

The O
intensity O
of O
skin B-outcome ['Physiological-Clinical']
erythema I-outcome ['Physiological-Clinical']
was O
evaluated O
once O
per O
week O
by O
non-invasive O
instrumental O
reflectance O
spectrophotometry O
in O
comparison O
with O
a O
visual O
scoring O
system O
. O
['Physiological-Clinical']

PATIENTS O
A O
consecutive O
sample O
of O
93 O
children O
undergoing O
outpatient O
adenoidectomy O
. O
[]

There O
were O
three O
babies O
in O
the O
forceps O
group O
with O
unexplained B-outcome ['Physiological-Clinical']
neonatal I-outcome ['Physiological-Clinical']
convulsions I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

For O
identified O
cases O
, O
rosters O
were O
prepared O
and O
sent O
to O
the O
physician O
with O
a O
cover O
letter O
and O
study O
description O
. O
[]

RESULTS O
The O
total O
effective O
rate O
in O
the O
treatment O
group O
was O
obviously O
higher O
than O
that O
in O
the O
control O
group O
( O
77.1 O
% O
vs. O
54.3 O
% O
, O
P O
< O
0.05 O
) O
. O
[]

One O
day O
after O
chemotherapy O
in O
losartan O
group O
vs. O
amlodipine O
group O
we O
observed O
a O
significant O
difference O
in O
urinary B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
of O
18 O
mg/24 O
h O
vs. O
40 O
mg/24 O
h. O
Thirty O
days O
after O
chemotherapy O
we O
observed O
a O
significant O
difference O
in O
azotemia B-outcome ['Physiological-Clinical']
of O
0.0 O
mg/dl O
vs. O
3.8 O
mg/dl O
( O
p O
< O
0.001 O
) O
, O
serum B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
of O
0.05 O
mg/dl O
vs. O
0.49 O
mg/dl O
( O
p O
< O
0.001 O
) O
, O
urinary B-outcome ['Physiological-Clinical']
uric I-outcome ['Physiological-Clinical']
acid I-outcome ['Physiological-Clinical']
( O
p O
< O
0.001 O
) O
of O
23 O
mg/24 O
h O
vs. O
0.0 O
mg/24 O
h O
, O
GFR O
of O
2 O
ml/min/1.73 O
m O
( O
2 O
) O
vs. O
-8 O
ml/min/1.73 O
m O
( O
2 O
) O
( O
p O
< O
0.05 O
) O
and O
systolic B-outcome ['Physiological-Clinical']
BP I-outcome ['Physiological-Clinical']
( O
SBP O
) O
of O
3.6 O
mmHg O
vs. O
0.8 O
mmHg O
( O
p O
< O
0.05 O
) O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

The O
intervention O
group O
will O
receive O
14 O
training O
sessions O
, O
each O
1 O
hour O
long O
, O
with O
a O
physiotherapist O
over O
6 O
weeks O
and O
will O
be O
encouraged O
to O
practice O
independently O
for O
1 O
hour/day O
to O
give O
a O
total O
of O
56 O
hours O
of O
training O
time O
per O
participant O
. O
[]

The O
results O
did O
not O
show O
any O
differences O
between O
the O
three O
groups O
, O
neither O
in O
physical B-outcome ['Life-Impact']
performance I-outcome ['Life-Impact']
characteristic O
nor O
in O
['Life-Impact']

A O
simple O
test O
of O
blood O
coagulability O
was O
used O
to O
assess O
whether O
an O
adequate O
neutralizing O
dose O
of O
antivenom O
had O
been O
given O
. O
[]

METHODS O
In O
the O
surgery O
setting O
, O
a O
total O
of O
381 O
patients O
were O
randomised O
to O
chemotherapy O
( O
C O
, O
192 O
patients O
) O
or O
no O
chemotherapy O
( O
NoC O
, O
189 O
patients O
) O
. O
[]

RESULTS O
Patients O
with O
high O
serum O
magnesium O
( O
defined O
as O
> O
or O
= O
1.9 O
mEq/liter O
, O
n O
= O
242 O
) O
were O
less O
likely O
to O
survive B-outcome ['Mortality']
than O
were O
patients O
with O
a O
normal O
magnesium O
level O
( O
n O
= O
627 O
) O
( O
p O
< O
0.05 O
, O
risk O
ratio O
= O
1.41 O
) O
. O
['Mortality']

OFC O
and O
rACC O
activation O
to O
the O
misleading O
cue O
were O
also O
associated O
with O
less O
aversive B-outcome ['Physiological-Clinical']
ratings I-outcome ['Physiological-Clinical']
of I-outcome ['Physiological-Clinical']
that I-outcome ['Physiological-Clinical']
taste I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Technological O
advances O
in O
the O
administration O
of O
volatile O
agents O
as O
long-term O
sedatives O
in O
the O
Intensive O
Care O
Unit O
may O
facilitate O
their O
more O
widespread O
use O
. O
[]

OBJECTIVES O
To O
develop O
a O
predictive O
model O
and O
a O
simplified O
score O
for O
use O
on O
day O
7 O
of O
hospitalization O
to O
assess O
whether O
a O
patient O
receiving O
mechanical O
ventilation O
is O
likely O
to O
require O
an O
additional O
25 O
days O
of O
hospitalization O
( O
ie O
, O
would O
qualify O
for O
transfer O
to O
a O
long-term O
care O
hospital O
) O
. O
[]

OBJECTIVE O
A O
heightened O
inflammatory O
response O
occurs O
after O
cardiac O
surgery O
. O
[]

Effect O
of O
antacids O
on O
intragastric B-outcome ['Physiological-Clinical']
pH I-outcome ['Physiological-Clinical']
in O
healthy O
subjects O
and O
duodenal O
ulcer O
patients O
. O
['Physiological-Clinical']

All O
patients O
achieved O
small O
sustainable O
improvements B-outcome ['Physiological-Clinical']
-- I-outcome ['Physiological-Clinical']
9HPT I-outcome ['Physiological-Clinical']
, O
5 O
% O
of O
maximum O
( O
confidence O
interval O
[ O
CI O
] O
= O
3 O
% O
-7 O
% O
) O
; O
JTT B-outcome ['Physiological-Clinical']
, O
5.7 O
% O
( O
CI O
= O
3 O
% O
-8 O
% O
) O
; O
and O
grip B-outcome ['Life-Impact']
strength I-outcome ['Life-Impact']
, O
6 O
% O
( O
CI O
= O
2 O
% O
-10 O
% O
) O
-- O
all O
below O
the O
defined O
clinically O
important O
level O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Life-Impact']

A O
double-blind O
, O
placebo-controlled O
trial O
is O
needed O
to O
confirm O
these O
results O
. O
[]

Baseline O
leptin B-outcome ['Physiological-Clinical']
levels O
( O
mean O
+/- O
SEM O
: O
12.4 O
+/- O
2.1 O
micrograms/L O
) O
were O
independent O
of O
body O
mass O
index O
( O
25 O
+/- O
1 O
kg/m2 O
) O
, O
insulin O
( O
18.6 O
+/- O
2.9 O
microIU/mL O
) O
, O
cortisol O
( O
504 O
+/- O
43 O
mmol/L O
) O
, O
and O
thyroid O
hormones O
( O
T4 O
: O
63 O
+/- O
5 O
nmol/L O
, O
T3 O
: O
0.72 O
+/- O
0.08 O
nmol/L O
) O
but O
correlated O
positively O
with O
circulating O
levels O
of O
IGF-I O
[ O
86 O
+/- O
6 O
micrograms/L O
, O
determination O
coefficient O
( O
R2 O
) O
= O
0.25 O
] O
and O
ALS O
( O
7.2 O
+/- O
0.6 O
mg/L O
, O
R2 O
= O
0.32 O
) O
. O
['Physiological-Clinical']

DESIGN O
A O
longitudinal O
study O
design O
where O
a O
cohort O
was O
followed O
for O
3 O
years O
. O
[]

Standard O
and O
high-pressure B-outcome ['Physiological-Clinical']
, O
rapid-inflation B-outcome ['Physiological-Clinical']
compression I-outcome ['Physiological-Clinical']
significantly O
increased O
the O
popliteal B-outcome ['Physiological-Clinical']
and I-outcome ['Physiological-Clinical']
femoral I-outcome ['Physiological-Clinical']
vein I-outcome ['Physiological-Clinical']
velocities I-outcome ['Physiological-Clinical']
in O
healthy O
and O
post-thrombotic O
subjects O
. O
['Physiological-Clinical', 'Physiological-Clinical', 'Physiological-Clinical']

Pain O
scores O
for O
delivery O
of O
the O
anesthetic O
, O
using O
a O
numerical O
rating O
scale O
, O
produced O
a O
median O
score O
of O
1 O
for O
1-QST O
and O
2 O
for O
the O
retrobulbar O
technique O
. O
[]

Belatacept O
serum O
concentrations O
were O
determined O
at O
several O
time O
points O
between O
belatacept O
infusions. O
[]

Improvement O
in O
lifestyle B-outcome ['Life-Impact']
seemed O
to O
reduce O
the O
need O
for O
supplementary O
treatment O
with O
['Life-Impact']

There O
was O
also O
no O
significant O
difference O
in O
the O
FTI B-outcome ['Physiological-Clinical']
measurements I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

Postoperative B-outcome ['Physiological-Clinical']
pain I-outcome ['Physiological-Clinical']
was O
assessed O
for O
24 O
hr O
using O
an O
objective O
pain B-outcome ['Physiological-Clinical']
score O
. O
['Physiological-Clinical', 'Physiological-Clinical']

For O
example O
, O
in O
the O
early O
phase O
of O
hypertension O
, O
diuretics O
usually O
worsen O
the O
metabolic B-outcome ['Physiological-Clinical']
equilibrium I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

plus O
tobramycin O
3 O
mg/kg O
per O
day O
( O
1.5 O
mg/kg O
b.i.d O
. O
) O
, O
[]

This O
effect O
is O
lost O
after O
4 O
days O
, O
suggesting O
that O
a O
regular O
daily O
co-administration O
of O
NSAID O
does O
not O
have O
an O
influence O
on O
platelet B-outcome ['Physiological-Clinical']
inhibition I-outcome ['Physiological-Clinical']
by O
aspirin O
. O
['Physiological-Clinical']

Here O
, O
we O
further O
report O
that O
low-dose O
cyclophosphamide O
( O
CY O
) O
, O
a O
conventional O
chemotherapy O
drug O
, O
can O
effectively O
prevent O
the O
recurrence O
of O
large B-outcome ['Physiological-Clinical']
CA I-outcome ['Physiological-Clinical']
in O
clinical O
patients O
after O
laser O
therapy O
. O
['Physiological-Clinical']

We O
conducted O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
study O
to O
determine O
if O
intravenous O
aminophylline O
adds O
any O
benefit O
to O
high O
doses O
of O
inhaled O
salbutamol O
in O
patients O
who O
presented O
for O
treatment O
of O
acute O
asthma O
. O
[]

More O
patients O
who O
received O
alvimopan O
achieved O
GI-2 B-outcome ['Physiological-Clinical']
recovery I-outcome ['Physiological-Clinical']
on I-outcome ['Physiological-Clinical']
or I-outcome ['Physiological-Clinical']
before I-outcome ['Physiological-Clinical']
POD I-outcome ['Physiological-Clinical']
5 I-outcome ['Physiological-Clinical']
( O
alvimopan O
, O
80 O
% O
; O
placebo O
, O
66 O
% O
) O
and O
DCO O
written O
before O
POD O
7 O
( O
alvimopan O
, O
87 O
% O
; O
placebo O
, O
72 O
% O
) O
, O
with O
corresponding O
NNTs O
equal O
to O
7 O
. O
['Physiological-Clinical']

METHODS O
This O
was O
a O
randomized O
controlled O
trial O
conducted O
between O
December O
2008 O
and O
April O
2011 O
to O
improve O
CRC O
screening O
in O
16 O
rural O
family O
physician O
offices O
. O
[]

Major B-outcome ['Physiological-Clinical']
adverse I-outcome ['Physiological-Clinical']
cardiac I-outcome ['Physiological-Clinical']
events I-outcome ['Physiological-Clinical']
were O
noted O
in O
10 O
% O
of O
the O
SES O
group O
versus O
34 O
% O
in O
the O
BMS O
group O
( O
P O
< O
.001 O
) O
. O
['Physiological-Clinical']

BACKGROUND O
There O
is O
a O
paucity O
of O
randomized O
trials O
regarding O
diagnostic O
testing O
in O
women O
with O
suspected O
coronary O
artery O
disease O
( O
CAD O
) O
. O
[]

Grade O
3 O
systemic B-outcome ['Adverse-effects']
solicited I-outcome ['Adverse-effects']
AE I-outcome ['Adverse-effects']
occurred O
in O
5.4% O
and O
2.9% O
of O
the O
participants O
in O
the O
Havrix O
group O
after O
the O
1st O
and O
2nd O
doses, O
respectively. O
[['Adverse-effects']]

Participants O
in O
the O
control O
group O
were O
each O
given O
a O
manual O
toothbrush O
and O
dental O
floss O
. O
[]

The O
baseline O
characteristics O
was O
comparable O
between O
the O
two O
groups O
. O
[]

Both O
eyes O
of O
each O
volunteer O
were O
irrigated O
simultaneously O
for O
15 O
minutes O
, O
with O
additional O
discomfort B-outcome ['Physiological-Clinical']
scores O
being O
recorded O
every O
5 O
minutes O
using O
the O
same O
100-mm O
, O
unnumbered O
analog O
discomfort B-outcome ['Physiological-Clinical']
scale O
. O
['Physiological-Clinical', 'Physiological-Clinical']

22.3 O
ng/L O
; O
CRP O
: O
35.0 O
? O
[]

Although O
soluble O
tumor O
necrosis O
factor-alpha O
receptor O
II O
concentrations O
at O
baseline O
and O
24 O
weeks O
were O
at O
least O
marginally O
associated O
with O
subsequent O
changes O
in O
BMD B-outcome ['Physiological-Clinical']
( O
P O
= O
0.06 O
and O
P O
= O
0.028 O
, O
respectively O
) O
, O
these O
associations O
were O
no O
longer O
significant O
after O
adjustment O
for O
CD4 O
T O
cell O
count O
. O
['Physiological-Clinical']

In O
a O
randomized O
, O
double-blinded O
study O
, O
a O
newly-introduced O
barrier O
cream O
and O
its O
moisturizing O
vehicle O
were O
compared O
regarding O
their O
skin O
compatibility O
, O
efficacy O
and O
resulting O
acceptance O
. O
[]

Interdigestive B-outcome ['Physiological-Clinical']
fundus I-outcome ['Physiological-Clinical']
motility I-outcome ['Physiological-Clinical']
was O
recorded O
by O
barostat O
( O
maximum O
capacity O
of O
intragastric O
bag O
1200 O
ml O
) O
during O
basal O
and O
peptide O
periods O
of O
60 O
minutes O
each O
. O
['Physiological-Clinical']

There O
was O
no O
difference O
between O
the O
two O
groups O
with O
respect O
to O
changes O
in O
peak O
expiratory B-outcome ['Physiological-Clinical']
flow I-outcome ['Physiological-Clinical']
rate I-outcome ['Physiological-Clinical']
. O
['Physiological-Clinical']

AIM O
To O
assess O
the O
efficacy O
and O
safety O
of O
esomeprazole O
in O
patients O
with O
frequent B-outcome ['Physiological-Clinical']
heartburn I-outcome ['Physiological-Clinical']
for O
> O
or O
= O
6 O
months O
and O
no O
evidence O
of O
erosive O
oesophagitis O
on O
endoscopy O
. O
['Physiological-Clinical']

The O
GMC O
after O
3 O
doses O
revaccination O
with O
four O
kinds O
of O
HepB O
, O
included O
5 O
microg O
HepB-Y O
, O
10 O
microg O
HepB-Y O
, O
l0 O
microg O
HepB-CHO O
, O
10 O
microg O
HepB-HY O
were O
168.8 O
mJU/ml O
, O
174.7 O
mIU/ml O
, O
184.9 O
mIU/ml O
, O
182.9 O
mIU/ml O
respectively O
. O
[]

Furthermore O
, O
24-h O
proteinuria B-outcome ['Physiological-Clinical']
was O
reduced O
by O
23 O
% O
( O
mean O
95 O
% O
CI O
; O
2?44 O
) O
by O
treatment O
with O
aliskiren O
( O
150 O
mg O
) O
, O
by O
36 O
% O
( O
95 O
% O
CI O
, O
17?55 O
; O
P O
< O
0.001 O
) O
with O
aliskiren O
( O
300 O
mg O
) O
, O
by O
7.1 O
% O
( O
95 O
% O
CI O
, O
11?26 O
) O
with O
perindopril O
( O
5 O
mg O
) O
and O
by O
25 O
% O
( O
95 O
% O
CI O
, O
11?39 O
; O
P O
< O
0.05 O
) O
with O
perindopril O
( O
10 O
mg O
) O
, O
compared O
to O
placebo O
. O
['Physiological-Clinical']

This O
24 O
% O
drop O
in O
emergency B-outcome ['Resource-use']
department I-outcome ['Resource-use']
visits I-outcome ['Resource-use']
resulted O
in O
an O
intervention O
that O
was O
cost O
saving O
in O
its O
first O
year O
. O
['Resource-use']

However O
, O
it O
is O
unlikely O
this O
plays O
a O
major O
role O
in O
the O
mechanism O
by O
which O
iTFA O
increase O
the O
risk O
of O
CVD O
. O
[]

Venographic O
assessment O
of O
clot B-outcome ['Physiological-Clinical']
size O
evolution O
between O
day O
0 O
and O
day O
10 O
showed O
a O
statistically O
significant O
superiority O
( O
P O
< O
.002 O
) O
of O
enoxaparin O
over O
the O
reference O
treatment O
with O
UFH O
. O
['Physiological-Clinical']

However O
, O
more O
research O
is O
needed O
to O
determine O
the O
cost-efficacy O
of O
more O
labor-intensive O
approaches O
to O
registry O
accrual O
. O
[]

In O
particular O
, O
the O
clinical O
results O
of O
endotoxin O
removal O
with O
polymyxin O
B O
immobilized O
fiber O
are O
summarized O
in O
this O
article O
. O
[]

Urine B-outcome ['Physiological-Clinical']
samples O
were O
collected O
before O
and O
after O
14 O
d O
of O
supplementation O
with O
300 O
microg O
( O
1.2 O
micromol O
) O
biotin/d O
or O
placebo O
. O
['Physiological-Clinical']

OBJECTIVE O
To O
evaluate O
the O
urinary B-outcome ['Physiological-Clinical']
and O
sexual B-outcome ['Physiological-Clinical']
consequences I-outcome ['Physiological-Clinical']
of O
vaginal O
delivery O
compared O
with O
Caesarean O
section O
. O
['Physiological-Clinical', 'Physiological-Clinical']

MATERIAL O
AND O
METHOD O
Forty-four O
subjects O
, O
aged O
35 O
to O
59-year-old O
, O
with O
hypertension O
in O
Nakhon O
Pathom O
Province O
, O
Thailand O
, O
were O
randomly O
allocated O
to O
either O
an O
experimental O
group O
( O
n O
= O
22 O
) O
or O
a O
control O
group O
( O
n O
= O
20 O
) O
. O
[]

Thirty-six O
healthy O
patients O
were O
randomized O
to O
participate O
in O
a O
crossover O
trial O
of O
either O
Lightwand O
or O
GlideScope O
to O
Macintosh O
laryngoscopy O
, O
with O
in-line O
stabilization O
. O
[]

